

COVID-19 Immunogenicity Analysis Report
mock Study

USG COVID-19 Response Biostatistics Team

March 30, 2021

Contents

| | | |
|----------|---|------------|
| 1 | Tabular Description of Immunogenicity Data | 15 |
| 2 | Graphical Description of Immunogenicity Data | 413 |
| 2.1 | Pairs plots of antibody markers for overall per-protocol cohort | 413 |
| 2.2 | RCDF plots of antibody markers for overall per-protocol cohort | 430 |
| 2.3 | Scatter plots of antibody markers versus age for overall per-protocol cohort | 442 |
| 2.4 | Box plots of antibody markers for overall per-protocol cohort | 446 |
| 2.5 | Spaghetti plots of antibody markers over time for the overall per-protocol cohort | 462 |
| 2.6 | RCDF plots of antibody markers by demographics for per-protocol cohort | 464 |
| 2.7 | Boxplots of antibody markers by demographics for per-protocol cohort | 536 |

List of Tables

| | | |
|------|--|----|
| 1.1 | Table 1. Demographic and Clinical Characteristics at Baseline in the Baseline SARS-CoV-2 Negative Per-Protocol Cohort | 15 |
| 1.2 | Table 2. Demographic and Clinical Characteristics at Baseline in the Baseline SARS-CoV-2 Positive Per-Protocol Cohort | 17 |
| 1.3 | Table 3a. Percentage of responders, and participants with concentrations $\geq 2 \times LLOD$ or $\geq 4 \times LLOD$ for binding antibody markers by All participants | 18 |
| 1.4 | Table 3b. Percentage of responders, and participants with concentrations $\geq 2 \times LLOD$ or $\geq 4 \times LLOD$ for binding antibody markers by Age | 20 |
| 1.5 | Table 3c. Percentage of responders, and participants with concentrations $\geq 2 \times LLOD$ or $\geq 4 \times LLOD$ for binding antibody markers by Risk for Severe Covid-19 | 24 |
| 1.6 | Table 3d. Percentage of responders, and participants with concentrations $\geq 2 \times LLOD$ or $\geq 4 \times LLOD$ for binding antibody markers by Age, Risk for Severe Covid-19 | 28 |
| 1.7 | Table 3e. Percentage of responders, and participants with concentrations $\geq 2 \times LLOD$ or $\geq 4 \times LLOD$ for binding antibody markers by Sex | 37 |
| 1.8 | Table 3f. Percentage of responders, and participants with concentrations $\geq 2 \times LLOD$ or $\geq 4 \times LLOD$ for binding antibody markers by Age, sex | 41 |
| 1.9 | Table 3g. Percentage of responders, and participants with concentrations $\geq 2 \times LLOD$ or $\geq 4 \times LLOD$ for binding antibody markers by Hispanic or Latino ethnicity | 49 |
| 1.10 | Table 3h. Percentage of responders, and participants with concentrations $\geq 2 \times LLOD$ or $\geq 4 \times LLOD$ for binding antibody markers by Race | 56 |
| 1.11 | Table 3i. Percentage of responders, and participants with concentrations $\geq 2 \times LLOD$ or $\geq 4 \times LLOD$ for binding antibody markers by Underrepresented minority status | 74 |
| 1.12 | Table 3j. Percentage of responders, and participants with concentrations $\geq 2 \times LLOD$ or $\geq 4 \times LLOD$ for binding antibody markers by Age, Underrepresented minority status | 79 |
| 1.13 | Table 4a. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by All participants | 90 |
| 1.14 | Table 4b. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Age | 91 |
| 1.15 | Table 4c. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Risk for Severe Covid-19 | 93 |
| 1.16 | Table 4d. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Age, Risk for Severe Covid-19 | 95 |

| | |
|---|-----|
| 1.17 Table 4e. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Sex | 98 |
| 1.18 Table 4f. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Age, sex | 100 |
| 1.19 Table 4g. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Hispanic or Latino ethnicity | 103 |
| 1.20 Table 4h. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Race | 106 |
| 1.21 Table 4i. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Underrepresented minority status | 112 |
| 1.22 Table 4j. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Age, Underrepresented minority status | 114 |
| 1.23 Table 5a. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by All participants | 118 |
| 1.24 Table 5b. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Age | 122 |
| 1.25 Table 5c. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Risk for Severe Covid-19 | 130 |
| 1.26 Table 5d. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Age, Risk for Severe Covid-19 | 138 |
| 1.27 Table 5e. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Sex | 154 |
| 1.28 Table 5f. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Age, sex | 162 |
| 1.29 Table 5g. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Hispanic or Latino ethnicity | 178 |
| 1.30 Table 5h. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Race | 190 |
| 1.31 Table 5i. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Underrepresented minority status | 222 |
| 1.32 Table 5j. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Age, Underrepresented minority status | 230 |
| 1.33 Table 6a. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by All participants | 246 |
| 1.34 Table 6b. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Age | 249 |
| 1.35 Table 6c. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Risk for Severe Covid-19 | 255 |
| 1.36 Table 6d. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Age, Risk for Severe Covid-19 | 261 |
| 1.37 Table 6e. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Sex | 275 |
| 1.38 Table 6f. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Age, sex | 281 |

| | |
|---|-----|
| 1.39 Table 6g. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Hispanic or Latino ethnicity | 294 |
| 1.40 Table 6h. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Race | 305 |
| 1.41 Table 6i. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Underrepresented minority status . . | 335 |
| 1.42 Table 6j. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Age, Underrepresented minority status | 342 |
| 1.43 Table 7. The ratios of GMTs/GMCs between groups | 360 |
| 1.44 Table 8a. Differences in the responder rates, 2FRs, 4FRs between the vaccine arm and the placebo arm by All participants | 407 |
| 1.45 Table 9. Antibody levels in the baseline SARS-CoV-2 negative per-protocol cohort (vaccine vs. placebo) | 409 |
| 1.46 Table 10. Antibody levels in the baseline SARS-CoV-2 positive per-protocol cohort (vaccine vs. placebo) | 410 |
| 1.47 Table 11. Antibody levels in the per-protocol cohort (vaccine recipients) | 411 |
| 1.48 Table 12. Antibody levels in the per-protocol cohort (placebo recipients) | 412 |

List of Figures

| | | |
|------|--|-----|
| 2.1 | Pair plots of D29 Ab markers: baseline negative vaccine arm | 414 |
| 2.2 | Pair plots of D57 Ab markers: baseline negative vaccine arm | 415 |
| 2.3 | Pair plots of D29 fold-rise over D1 Ab markers: baseline negative vaccine arm | 416 |
| 2.4 | Pair plots of D57 fold-rise over D1 Ab markers: baseline negative vaccine arm | 417 |
| 2.5 | Pair plots of D1, D29 and D57 Binding Antibody to Spike: baseline negative vaccine arm . . | 418 |
| 2.6 | Pair plots of D1, D29 and D57 Binding Antibody to RBD: baseline negative vaccine arm . . | 419 |
| 2.7 | Pair plots of D1, D29 and D57 PsV Neutralization 50% Titer: baseline negative vaccine arm | 420 |
| 2.8 | Pair plots of D1, D29 and D57 PsV Neutralization 80% Titer: Baseline negative vaccine arm | 421 |
| 2.9 | Pair plots of D29 Ab markers: baseline negative vaccine arm | 422 |
| 2.10 | Pair plots of D57 Ab markers: baseline negative vaccine arm | 423 |
| 2.11 | Pair plots of D29 fold-rise over D1 Ab markers: baseline negative vaccine arm | 424 |
| 2.12 | Pair plots of D57 fold-rise over D1 Ab markers: baseline negative vaccine arm | 425 |
| 2.13 | Pair plots of D1, D29 and D57 Binding Antibody to Spike: baseline negative vaccine arm . . | 426 |
| 2.14 | Pair plots of D1, D29 and D57 Binding Antibody to RBD: baseline negative vaccine arm . . | 427 |
| 2.15 | Pair plots of D1, D29 and D57 PsV Neutralization 50% Titer: baseline negative vaccine arm | 428 |
| 2.16 | Pair plots of D1, D29 and D57 PsV Neutralization 80% Titer: Baseline negative vaccine arm | 429 |
| 2.17 | RCDF plots for D29 Ab markers: by baseline status x randomization arm | 430 |
| 2.18 | RCDF plots for D57 Ab markers: by baseline status x randomization arm | 431 |
| 2.19 | RCDF plots for D29 fold-rise over D1 Ab markers: by baseline status x randomization arm . | 432 |
| 2.20 | RCDF plots for D57 fold-rise over D1 Ab markers: by baseline status x randomization arm . | 433 |
| 2.21 | RCDF plots for D29 Ab markers: by baseline status for the vaccine arm | 434 |
| 2.22 | RCDF plots for D57 Ab markers: by baseline status for the vaccine arm | 435 |
| 2.23 | RCDF plots for D29 over D1 fold-rise Ab markers: by baseline status for the vaccine arm . | 436 |
| 2.24 | RCDF plots for D57 fold-rise over D1 Ab markers: by baseline status for the vaccine arm . | 437 |
| 2.25 | RCDF plots for D29 Ab markers: baseline negative vaccine arm | 438 |
| 2.26 | RCDF plots for D57 Ab markers: baseline negative vaccine arm | 439 |
| 2.27 | RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm | 440 |
| 2.28 | RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm | 441 |

| | |
|---|-----|
| 2.29 Scatter plots for D29 Ab markers vs. age: baseline negative vaccine arm | 442 |
| 2.30 Scatter plots for D57 Ab markers vs. age: baseline negative vaccine arm | 443 |
| 2.31 Scatter plots for D29 Ab markers vs. age: baseline positive vaccine arm | 444 |
| 2.32 Scatter plots for D57 Ab markers vs. age: baseline positive vaccine arm | 445 |
| 2.33 Boxplots of D29 Ab markers: baseline negative vaccine + placebo arms | 446 |
| 2.34 Boxplots of D57 Ab markers: baseline negative vaccine + placebo arms | 447 |
| 2.35 Boxplots of D29 fold-rise over D1 Ab markers: baseline negative vaccine + placebo arms | 448 |
| 2.36 Boxplots of D57 fold-rise over D1 Ab markers: baseline negative vaccine + placebo arms | 449 |
| 2.37 Boxplots of D29 Ab markers: baseline positive vaccine + placebo arms | 450 |
| 2.38 Boxplots of D57 Ab markers: baseline positive vaccine + placebo arms | 451 |
| 2.39 Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine + placebo arms | 452 |
| 2.40 Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine + placebo arms | 453 |
| 2.41 Boxplots of D29 Ab markers: baseline positive + negative vaccine arm | 454 |
| 2.42 Boxplots of D57 Ab markers: baseline positive + negative vaccine arm | 455 |
| 2.43 Boxplots of D29 fold-rise over D1 Ab markers: baseline positive + negative vaccine arm | 456 |
| 2.44 Boxplots of D57 fold-rise over D1 Ab markers: baseline positive + negative vaccine arm | 457 |
| 2.45 Boxplots of D29 Ab markers: baseline positive + negative placebo arm | 458 |
| 2.46 Boxplots of D57 Ab markers: baseline positive + negative placebo arm | 459 |
| 2.47 Boxplots of D29 fold-rise over D1 Ab markers: baseline positive + negative placebo arm | 460 |
| 2.48 Boxplots of D57 fold-rise over D1 Ab markers: baseline positive + negative placebo arm | 461 |
| 2.49 Spaghetti plots of Ab markers over time: baseline negative vaccine + placebo arm | 462 |
| 2.50 Spaghetti plots of Ab markers over time: baseline positive vaccine + placebo arm | 463 |
| 2.51 RCDF plots for D29 Ab markers: baseline negative vaccine arm by age groups. | 464 |
| 2.52 RCDF plots for D57 Ab markers: baseline negative vaccine arm by age groups. | 465 |
| 2.53 RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by age groups. | 466 |
| 2.54 RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by age groups. | 467 |
| 2.55 RCDF plots for D29 Ab markers: baseline negative vaccine arm by high-risk condition. | 468 |
| 2.56 RCDF plots for D57 Ab markers: baseline negative vaccine arm by high-risk condition. | 469 |
| 2.57 RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by high-risk condition. | 470 |
| 2.58 RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by high-risk condition. | 471 |
| 2.59 RCDF plots for D29 Ab markers: baseline negative vaccine arm by age and high-risk condition. | 472 |
| 2.60 RCDF plots for D57 Ab markers: baseline negative vaccine arm by age and high-risk condition. | 473 |
| 2.61 RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and high-risk condition. | 474 |
| 2.62 RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and high-risk condition. | 475 |

| | |
|---|-----|
| 2.63 RCDF plots for D29 Ab markers: baseline negative vaccine arm by sex assigned at birth. | 476 |
| 2.64 RCDF plots for D57 Ab markers: baseline negative vaccine arm by sex assigned at birth. | 477 |
| 2.65 RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by sex assigned at birth. | 478 |
| 2.66 RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by sex assigned at birth. | 479 |
| 2.67 RCDF plots for D29 Ab markers: baseline negative vaccine arm by age and sex assigned at birth. | 480 |
| 2.68 RCDF plots for D57 Ab markers: baseline negative vaccine arm by age and sex assigned at birth. | 481 |
| 2.69 RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and sex assigned at birth. | 482 |
| 2.70 RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and sex at birth. | 483 |
| 2.71 RCDF plots for D29 Ab markers: baseline negative vaccine arm by ethnicity. | 484 |
| 2.72 RCDF plots for D57 Ab markers: baseline negative vaccine arm by ethnicity. | 485 |
| 2.73 RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by ethnicity. . | 486 |
| 2.74 RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by ethnicity. . | 487 |
| 2.75 RCDF plots for D29 Ab markers: baseline negative vaccine arm by race. | 488 |
| 2.76 RCDF plots for D57 Ab markers: baseline negative vaccine arm by race. | 489 |
| 2.77 RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by race. . . | 490 |
| 2.78 RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by race. . . | 491 |
| 2.79 RCDF plots for D29 Ab markers: baseline negative vaccine arm by dichotomous classification of race and ethnic group. | 492 |
| 2.80 RCDF plots for D57 Ab markers: baseline negative vaccine arm by dichotomous classification of race and ethnic group. | 493 |
| 2.81 RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by dichotomous classification of race and ethnic group. | 494 |
| 2.82 RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by dichotomous classification of race and ethnic group. | 495 |
| 2.83 RCDF plots for D29 Ab markers: baseline negative vaccine arm by age and dichotomous classification of race and ethnic group. | 496 |
| 2.84 RCDF plots for D57 Ab markers: baseline negative vaccine arm by age and dichotomous classification of race and ethnic group. | 497 |
| 2.85 RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and dichotomous classification of race and ethnic group. | 498 |
| 2.86 RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and dichotomous classification of race and ethnic group. | 499 |
| 2.87 RCDF plots for D29 Ab markers: baseline positive vaccine arm by age groups. | 500 |
| 2.88 RCDF plots for D57 Ab markers: baseline positive vaccine arm by age groups. | 501 |
| 2.89 RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age groups. | 502 |

| | |
|---|-----|
| 2.90 RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age groups. | 503 |
| 2.91 RCDF plots for D29 Ab markers: baseline positive vaccine arm by high-risk condition. | 504 |
| 2.92 RCDF plots for D57 Ab markers: baseline positive vaccine arm by high-risk condition. | 505 |
| 2.93 RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by high-risk condition. | 506 |
| 2.94 RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by high-risk condition. | 507 |
| 2.95 RCDF plots for D29 Ab markers: baseline positive vaccine arm by age and high-risk condition. | 508 |
| 2.96 RCDF plots for D57 Ab markers: baseline positive vaccine arm by age and high-risk condition. | 509 |
| 2.97 RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and high-risk condition. | 510 |
| 2.98 RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and high-risk condition. | 511 |
| 2.99 RCDF plots for D29 Ab markers: baseline positive vaccine arm by sex assigned at birth. | 512 |
| 2.100RCDF plots for D57 Ab markers: baseline positive vaccine arm by sex assigned at birth. | 513 |
| 2.101RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by sex assigned at birth. | 514 |
| 2.102RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by sex assigned at birth. | 515 |
| 2.103RCDF plots for D29 Ab markers: baseline positive vaccine arm by age and sex assigned at birth. | 516 |
| 2.104RCDF plots for D57 Ab markers: baseline positive vaccine arm by age and sex assigned at birth. | 517 |
| 2.105RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and sex assigned at birth. | 518 |
| 2.106RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and sex assigned at birth. | 519 |
| 2.107RCDF plots for D29 Ab markers: baseline positive vaccine arm by ethnicity. | 520 |
| 2.108RCDF plots for D57 Ab markers: baseline positive vaccine arm by ethnicity. | 521 |
| 2.109RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by ethnicity. | 522 |
| 2.110RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by ethnicity. | 523 |
| 2.111RCDF plots for D29 Ab markers: baseline positive vaccine arm by race. | 524 |
| 2.112RCDF plots for D57 Ab markers: baseline positive vaccine arm by race. | 525 |
| 2.113RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by race. | 526 |
| 2.114RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by race. | 527 |
| 2.115RCDF plots for D29 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group. | 528 |
| 2.116RCDF plots for D57 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group. | 529 |
| 2.117RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group. | 530 |

| | |
|---|-----|
| 2.118RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group. | 531 |
| 2.119RCDF plots for D29 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group. | 532 |
| 2.120RCDF plots for D57 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group. | 533 |
| 2.121RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group. | 534 |
| 2.122RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group. | 535 |
| 2.123Boxplots of D29 Ab markers: Baseline negative vaccine arm by age group. | 536 |
| 2.124Boxplots of D57 Ab markers: Baseline negative vaccine arm by age group. | 537 |
| 2.125Boxplots of D29 fold-rise over D1 Ab markers: Baseline negative vaccine arm by age and sex assigned at birth. | 538 |
| 2.126Boxplots of D57 fold-rise over D1 Ab markers: Baseline negative vaccine arm by age and sex assigned at birth. | 539 |
| 2.127Boxplots of D29 fold-rise over D1 Ab markers: Baseline negative vaccine arm by ethnicity. . . | 540 |
| 2.128Boxplots of D57 fold-rise over D1 Ab markers: Baseline negative vaccine arm by ethnicity. . . | 541 |
| 2.129Boxplots of D29 fold-rise over D1 Ab markers: Baseline negative vaccine arm by race. . . . | 542 |
| 2.130Boxplots of D57 fold-rise over D1 Ab markers: Baseline negative vaccine arm by race. . . . | 543 |
| 2.131Boxplots of D29 fold-rise over D1 Ab markers: Baseline negative vaccine arm by dichotomous classification of race and ethnic group. | 544 |
| 2.132Boxplots of D57 fold-rise over D1 Ab markers: Baseline negative vaccine arm by dichotomous classification of race and ethnic group. | 545 |
| 2.133Boxplots of D29 fold-rise over D1 Ab markers: Baseline negative vaccine arm by age and dichotomous classification of race and ethnic group. | 546 |
| 2.134Boxplots of D57 fold-rise over D1 Ab markers: Baseline negative vaccine arm by age and dichotomous classification of race and ethnic group. | 547 |
| 2.135Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age group. . | 549 |
| 2.136Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age group. . | 550 |
| 2.137Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by high-risk condition. | 551 |
| 2.138Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by high-risk condition. | 552 |
| 2.139Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and high-risk condition. | 553 |
| 2.140Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and high-risk condition. | 554 |
| 2.141Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by sex assigned at birth. | 555 |
| 2.142Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by sex assigned at birth. | 556 |

| | |
|--|-----|
| 2.143Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and sex assigned at birth. | 557 |
| 2.144Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and sex assigned at birth. | 558 |
| 2.145Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by ethnicity. . . | 559 |
| 2.146Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by ethnicity. . . | 560 |
| 2.147Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by race. | 561 |
| 2.148Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by race. | 562 |
| 2.149Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group. | 563 |
| 2.150Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group. | 564 |
| 2.151Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group. | 565 |
| 2.152Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group. | 566 |

MOT

Chapter 1

Tabular Description of Immunogenicity Data

Table 1. Demographic and Clinical Characteristics at Baseline in the Baseline SARS-CoV-2 Negative Per-Protocol Cohort

| Characteristics | Vaccine (N = 914) | Placebo (N = 163) | Total (N = 1077) |
|---|----------------------|----------------------|---------------------|
| Age | | | |
| Age < 65 | 432 (47.3%) | 80 (49.1%) | 512 (47.5%) |
| Age ≥ 65 | 482 (52.7%) | 83 (50.9%) | 565 (52.5%) |
| Mean (Range) | 58.6 (18.0, 85.0) | 59.0 (18.0, 85.0) | 58.7 (18.0, 85.0) |
| BMI | | | |
| Mean ± SD | 30.1 ± 7.0 | 29.6 ± 7.2 | 30.0 ± 7.0 |
| Sex | | | |
| Female | 519 (56.8%) | 87 (53.4%) | 606 (56.3%) |
| Male | 395 (43.2%) | 76 (46.6%) | 471 (43.7%) |
| Race | | | |
| White Non-Hispanic | 362 (43.8%) | 67 (44.7%) | 429 (43.9%) |
| Black or African American | 195 (23.6%) | 39 (26.0%) | 234 (24.0%) |
| Asian | 67 (8.1%) | 12 (8.0%) | 79 (8.1%) |
| American Indian or Alaska Native | 13 (1.6%) | 5 (3.3%) | 18 (1.8%) |
| Native Hawaiian or Other Pacific Islander | 17 (2.1%) | 1 (0.7%) | 18 (1.8%) |
| Multiracial | 52 (6.3%) | 8 (5.3%) | 60 (6.1%) |
| Other | 34 (4.1%) | 4 (2.7%) | 38 (3.9%) |
| Not reported and unknown | 87 (10.5%) | 14 (9.3%) | 101 (10.3%) |
| Communities of Color | 420 (53.7%) | 73 (52.1%) | 493 (53.5%) |
| Hispanic or Latino ethnicity | | | |
| Hispanic or Latino | 136 (14.9%) | 20 (12.3%) | 156 (14.5%) |
| Not Hispanic or Latino | 690 (75.5%) | 130 (79.8%) | 820 (76.1%) |
| Not reported and unknown | 88 (9.6%) | 13 (8.0%) | 101 (9.4%) |
| Risk for Severe Covid-19 | | | |
| At-risk | 469 (51.3%) | 84 (51.5%) | 553 (51.3%) |
| Not at-risk | 445 (48.7%) | 79 (48.5%) | 524 (48.7%) |
| Age, Risk for Severe Covid-19 | | | |
| Age < 65 At-risk | 214 (23.4%) | 40 (24.5%) | 254 (23.6%) |

(continued)

| Characteristics | Vaccine (N = 914) | Placebo (N = 163) | Total (N = 1077) |
|----------------------|----------------------|----------------------|---------------------|
| Age < 65 Not at-risk | 218 (23.9%) | 40 (24.5%) | 258 (24.0%) |
| Age \geq 65 | 482 (52.7%) | 83 (50.9%) | 565 (52.5%) |

This table summarizes the random subcohort, which was randomly sampled from the per-protocol cohort, and excludes individuals with a COVID failure event < 7 days post Day 57. The sampling was stratified by 24 strata defined by enrollment characteristics: Assigned treatment arm \times Baseline SARS-CoV-2 naïve vs. non-naïve status (defined by serostatus and NAAT testing) \times Randomization strata (Age < 65 and at-risk, Age < 65 and not at-risk, Age \geq 65) \times Communities of color (Yes/No) defined by White Non-Hispanic vs. all others (following the primary COVE trial paper).

MOCH

Table 2. Demographic and Clinical Characteristics at Baseline in the Baseline SARS-CoV-2 Positive Per-Protocol Cohort

| Characteristics | Vaccine (N = 274) | Placebo (N = 270) | Total (N = 544) |
|---|----------------------|----------------------|--------------------|
| Age | | | |
| Age < 65 | 146 (53.3%) | 147 (54.4%) | 293 (53.9%) |
| Age ≥ 65 | 128 (46.7%) | 123 (45.6%) | 251 (46.1%) |
| Mean (Range) | 56.0 (18.0, 85.0) | 55.8 (18.0, 85.0) | 55.9 (18.0, 85.0) |
| BMI | | | |
| Mean ± SD | 30.7 ± 6.8 | 30.1 ± 7.2 | 30.4 ± 7.0 |
| Sex | | | |
| Female | 153 (55.8%) | 155 (57.4%) | 308 (56.6%) |
| Male | 121 (44.2%) | 115 (42.6%) | 236 (43.4%) |
| Race | | | |
| White Non-Hispanic | 125 (49.8%) | 121 (49.0%) | 246 (49.4%) |
| Black or African American | 52 (20.7%) | 60 (24.3%) | 112 (22.5%) |
| Asian | 24 (9.6%) | 13 (5.3%) | 37 (7.4%) |
| American Indian or Alaska Native | 6 (2.4%) | 4 (1.6%) | 10 (2.0%) |
| Native Hawaiian or Other Pacific Islander | 5 (2.0%) | 1 (0.4%) | 6 (1.2%) |
| Multiracial | 12 (4.8%) | 19 (7.7%) | 31 (6.2%) |
| Other | 7 (2.8%) | 5 (2.0%) | 12 (2.4%) |
| Not reported and unknown | 20 (8.0%) | 24 (9.7%) | 44 (8.8%) |
| Communities of Color | 120 (49.0%) | 111 (47.8%) | 231 (48.4%) |
| Hispanic or Latino ethnicity | | | |
| Hispanic or Latino | 35 (12.8%) | 38 (14.1%) | 73 (13.4%) |
| Not Hispanic or Latino | 217 (79.2%) | 214 (79.3%) | 431 (79.2%) |
| Not reported and unknown | 22 (8.0%) | 18 (6.7%) | 40 (7.4%) |
| Risk for Severe Covid-19 | | | |
| At-risk | 125 (45.6%) | 123 (45.6%) | 248 (45.6%) |
| Not at-risk | 149 (54.4%) | 147 (54.4%) | 296 (54.4%) |
| Age, Risk for Severe Covid-19 | | | |
| Age < 65 At-risk | 73 (26.6%) | 75 (27.8%) | 148 (27.2%) |
| Age < 65 Not at-risk | 73 (26.6%) | 72 (26.7%) | 145 (26.7%) |
| Age ≥ 65 | 128 (46.7%) | 123 (45.6%) | 251 (46.1%) |

This table summarizes the random subcohort, which was randomly sampled from the per-protocol cohort, and excludes individuals with a COVID failure event < 7 days post Day 57. The sampling was stratified by 24 strata defined by enrollment characteristics: Assigned treatment arm × Baseline SARS-CoV-2 naïve vs. non-naïve status (defined by serostatus and NAAT testing) × Randomization strata (Age < 65 and at-risk, Age < 65 and not at-risk, Age ≥ 65) × Communities of color (Yes/No) defined by White Non-Hispanic vs. all others (following the primary COVE trial paper).

Table 3a. Percentage of responders, and participants with concentrations $\geq 2 \times \text{LLOD}$ or $\geq 4 \times \text{LLOD}$ for binding antibody markers by All participants

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % Greater than $2 \times \text{LLOD}$ | % Greater than $4 \times \text{LLOD}$ |
|-------------------------|--------|---------|---------------------|------------------------|-----|--|--|--|
| All participants | | | | | | | | |
| | Day 29 | Vaccine | Negative | Anti N IgG (IU/ml) | 914 | 13295/13295 = 100.0% (100.0%, 100.0%) | 13268.1/13295 = 99.8% (98.6%, 100.0%) | 13268.1/13295 = 99.8% (98.6%, 100.0%) |
| | Day 29 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 914 | 13295/13295 = 100.0% (100.0%, 100.0%) | 13295/13295 = 100.0% (100.0%, 100.0%) | 13295/13295 = 100.0% (100.0%, 100.0%) |
| | Day 29 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 914 | 13295/13295 = 100.0% (100.0%, 100.0%) | 13295/13295 = 100.0% (100.0%, 100.0%) | 13295/13295 = 100.0% (100.0%, 100.0%) |
| | Day 29 | Vaccine | Positive | Anti N IgG (IU/ml) | 274 | 1432/1432 = 100.0% (100.0%, 100.0%) | 1432/1432 = 100.0% (100.0%, 100.0%) | 1432/1432 = 100.0% (100.0%, 100.0%) |
| | Day 29 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 274 | 1432/1432 = 100.0% (100.0%, 100.0%) | 1432/1432 = 100.0% (100.0%, 100.0%) | 1432/1432 = 100.0% (100.0%, 100.0%) |
| | Day 29 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 274 | 1432/1432 = 100.0% (100.0%, 100.0%) | 1432/1432 = 100.0% (100.0%, 100.0%) | 1432/1432 = 100.0% (100.0%, 100.0%) |
| | Day 29 | Placebo | Negative | Anti N IgG (IU/ml) | 163 | 0/13359 = 0.0% (0.0%, 0.0%) | 0/13359 = 0.0% (0.0%, 0.0%) | 0/13359 = 0.0% (0.0%, 0.0%) |
| | Day 29 | Placebo | Negative | Anti RBD IgG (IU/ml) | 163 | 0/13359 = 0.0% (0.0%, 0.0%) | 0/13359 = 0.0% (0.0%, 0.0%) | 0/13359 = 0.0% (0.0%, 0.0%) |
| | Day 29 | Placebo | Negative | Anti Spike IgG (IU/ml) | 163 | 0/13359 = 0.0% (0.0%, 0.0%) | 0/13359 = 0.0% (0.0%, 0.0%) | 0/13359 = 0.0% (0.0%, 0.0%) |
| | Day 29 | Placebo | Positive | Anti N IgG (IU/ml) | 270 | 1357/1357 = 100.0% (100.0%, 100.0%) | 1357/1357 = 100.0% (100.0%, 100.0%) | 1354.5/1357 = 99.8% (98.7%, 100.0%) |
| | Day 29 | Placebo | Positive | Anti RBD IgG (IU/ml) | 270 | 1357/1357 = 100.0% (100.0%, 100.0%) | 1357/1357 = 100.0% (100.0%, 100.0%) | 1357/1357 = 100.0% (100.0%, 100.0%) |
| | Day 29 | Placebo | Positive | Anti Spike IgG (IU/ml) | 270 | 1357/1357 = 100.0% (100.0%, 100.0%) | 1357/1357 = 100.0% (100.0%, 100.0%) | 1357/1357 = 100.0% (100.0%, 100.0%) |
| | Day 57 | Vaccine | Negative | Anti N IgG (IU/ml) | 914 | 13295/13295 = 100.0% (100.0%, 100.0%) | 13295/13295 = 100.0% (100.0%, 100.0%) | 13295/13295 = 100.0% (100.0%, 100.0%) |
| | Day 57 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 914 | 13295/13295 = 100.0% (100.0%, 100.0%) | 13295/13295 = 100.0% (100.0%, 100.0%) | 13295/13295 = 100.0% (100.0%, 100.0%) |
| | Day 57 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 914 | 13295/13295 = 100.0% (100.0%, 100.0%) | 13295/13295 = 100.0% (100.0%, 100.0%) | 13295/13295 = 100.0% (100.0%, 100.0%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % Greater than 2 × LLOD | % Greater than 4 × LLOD |
|-------|--------|---------|---------------------|------------------------|-----|--|--|--|
| | Day 57 | Vaccine | Positive | Anti N IgG (IU/ml) | 274 | 1432/1432 = 100.0% (100.0%, 100.0%) | 1432/1432 = 100.0% (100.0%, 100.0%) | 1432/1432 = 100.0% (100.0%, 100.0%) |
| | Day 57 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 274 | 1432/1432 = 100.0% (100.0%, 100.0%) | 1432/1432 = 100.0% (100.0%, 100.0%) | 1432/1432 = 100.0% (100.0%, 100.0%) |
| | Day 57 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 274 | 1432/1432 = 100.0% (100.0%, 100.0%) | 1432/1432 = 100.0% (100.0%, 100.0%) | 1432/1432 = 100.0% (100.0%, 100.0%) |
| | Day 57 | Placebo | Negative | Anti N IgG (IU/ml) | 163 | 0/13359 = 0.0% (0.0%, 0.0%) | 0/13359 = 0.0% (0.0%, 0.0%) | 0/13359 = 0.0% (0.0%, 0.0%) |
| | Day 57 | Placebo | Negative | Anti RBD IgG (IU/ml) | 163 | 76.3/13359 = 0.6% (0.1%, 4.0%) | 0/13359 = 0.0% (0.0%, 0.0%) | 0/13359 = 0.0% (0.0%, 0.0%) |
| | Day 57 | Placebo | Negative | Anti Spike IgG (IU/ml) | 163 | 0/13359 = 0.0% (0.0%, 0.0%) | 0/13359 = 0.0% (0.0%, 0.0%) | 0/13359 = 0.0% (0.0%, 0.0%) |
| | Day 57 | Placebo | Positive | Anti N IgG (IU/ml) | 270 | 1357/1357 = 100.0% (100.0%, 100.0%) | 1357/1357 = 100.0% (100.0%, 100.0%) | 1357/1357 = 100.0% (100.0%, 100.0%) |
| | Day 57 | Placebo | Positive | Anti RBD IgG (IU/ml) | 270 | 1357/1357 = 100.0% (100.0%, 100.0%) | 1357/1357 = 100.0% (100.0%, 100.0%) | 1357/1357 = 100.0% (100.0%, 100.0%) |
| | Day 57 | Placebo | Positive | Anti Spike IgG (IU/ml) | 270 | 1357/1357 = 100.0% (100.0%, 100.0%) | 1357/1357 = 100.0% (100.0%, 100.0%) | 1357/1357 = 100.0% (100.0%, 100.0%) |

Binding Antibody Responders are defined as participants who had baseline values below the LLOD with detectable antibody concentration above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in antibody concentration. Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 3b. Percentage of responders, and participants with concentrations $\geq 2 \times \text{LLOD}$ or $\geq 4 \times \text{LLOD}$ for binding antibody markers by Age

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % Greater than $2 \times \text{LLOD}$ | % Greater than $4 \times \text{LLOD}$ |
|------------|--------|---------|---------------------|------------------------|-----|--|--|--|
| Age | | | | | | | | |
| Age < 65 | Day 29 | Vaccine | Negative | Anti N IgG (IU/ml) | 432 | 10518/10518 = 100.0% (100.0%, 100.0%) | 10491.1/10518 = 99.7% (98.2%, 100.0%) | 10491.1/10518 = 99.7% (98.2%, 100.0%) |
| Age < 65 | Day 29 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 432 | 10518/10518 = 100.0% (100.0%, 100.0%) | 10518/10518 = 100.0% (100.0%, 100.0%) | 10518/10518 = 100.0% (100.0%, 100.0%) |
| Age < 65 | Day 29 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 432 | 10518/10518 = 100.0% (100.0%, 100.0%) | 10518/10518 = 100.0% (100.0%, 100.0%) | 10518/10518 = 100.0% (100.0%, 100.0%) |
| Age < 65 | Day 29 | Vaccine | Positive | Anti N IgG (IU/ml) | 146 | 1145/1145 = 100.0% (100.0%, 100.0%) | 1145/1145 = 100.0% (100.0%, 100.0%) | 1145/1145 = 100.0% (100.0%, 100.0%) |
| Age < 65 | Day 29 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 146 | 1145/1145 = 100.0% (100.0%, 100.0%) | 1145/1145 = 100.0% (100.0%, 100.0%) | 1145/1145 = 100.0% (100.0%, 100.0%) |
| Age < 65 | Day 29 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 146 | 1145/1145 = 100.0% (100.0%, 100.0%) | 1145/1145 = 100.0% (100.0%, 100.0%) | 1145/1145 = 100.0% (100.0%, 100.0%) |
| Age < 65 | Day 29 | Placebo | Negative | Anti N IgG (IU/ml) | 80 | 0/10234 = 0.0% (0.0%, 0.0%) | 0/10234 = 0.0% (0.0%, 0.0%) | 0/10234 = 0.0% (0.0%, 0.0%) |
| Age < 65 | Day 29 | Placebo | Negative | Anti RBD IgG (IU/ml) | 80 | 0/10234 = 0.0% (0.0%, 0.0%) | 0/10234 = 0.0% (0.0%, 0.0%) | 0/10234 = 0.0% (0.0%, 0.0%) |
| Age < 65 | Day 29 | Placebo | Negative | Anti Spike IgG (IU/ml) | 80 | 0/10234 = 0.0% (0.0%, 0.0%) | 0/10234 = 0.0% (0.0%, 0.0%) | 0/10234 = 0.0% (0.0%, 0.0%) |
| Age < 65 | Day 29 | Placebo | Positive | Anti N IgG (IU/ml) | 147 | 1098/1098 = 100.0% (100.0%, 100.0%) | 1098/1098 = 100.0% (100.0%, 100.0%) | 1095.5/1098 = 99.8% (98.4%, 100.0%) |
| Age < 65 | Day 29 | Placebo | Positive | Anti RBD IgG (IU/ml) | 147 | 1098/1098 = 100.0% (100.0%, 100.0%) | 1098/1098 = 100.0% (100.0%, 100.0%) | 1098/1098 = 100.0% (100.0%, 100.0%) |
| Age < 65 | Day 29 | Placebo | Positive | Anti Spike IgG (IU/ml) | 147 | 1098/1098 = 100.0% (100.0%, 100.0%) | 1098/1098 = 100.0% (100.0%, 100.0%) | 1098/1098 = 100.0% (100.0%, 100.0%) |
| Age < 65 | Day 57 | Vaccine | Negative | Anti N IgG (IU/ml) | 432 | 10518/10518 = 100.0% (100.0%, 100.0%) | 10518/10518 = 100.0% (100.0%, 100.0%) | 10518/10518 = 100.0% (100.0%, 100.0%) |
| Age < 65 | Day 57 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 432 | 10518/10518 = 100.0% (100.0%, 100.0%) | 10518/10518 = 100.0% (100.0%, 100.0%) | 10518/10518 = 100.0% (100.0%, 100.0%) |
| Age < 65 | Day 57 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 432 | 10518/10518 = 100.0% (100.0%, 100.0%) | 10518/10518 = 100.0% (100.0%, 100.0%) | 10518/10518 = 100.0% (100.0%, 100.0%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % Greater than 2 × LLOD | % Greater than 4 × LLOD |
|----------|--------|---------|---------------------|------------------------|-----|--|--|--|
| Age < 65 | Day 57 | Vaccine | Positive | Anti N IgG (IU/ml) | 146 | 1145/1145 = 100.0% (100.0%, 100.0%) | 1145/1145 = 100.0% (100.0%, 100.0%) | 1145/1145 = 100.0% (100.0%, 100.0%) |
| Age < 65 | Day 57 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 146 | 1145/1145 = 100.0% (100.0%, 100.0%) | 1145/1145 = 100.0% (100.0%, 100.0%) | 1145/1145 = 100.0% (100.0%, 100.0%) |
| Age < 65 | Day 57 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 146 | 1145/1145 = 100.0% (100.0%, 100.0%) | 1145/1145 = 100.0% (100.0%, 100.0%) | 1145/1145 = 100.0% (100.0%, 100.0%) |
| Age < 65 | Day 57 | Placebo | Negative | Anti N IgG (IU/ml) | 80 | 0/10234 = 0.0% (0.0%, 0.0%) | 0/10234 = 0.0% (0.0%, 0.0%) | 0/10234 = 0.0% (0.0%, 0.0%) |
| Age < 65 | Day 57 | Placebo | Negative | Anti RBD IgG (IU/ml) | 80 | 76.3/10234 = 0.7% (0.1%, 5.3%) | 0/10234 = 0.0% (0.0%, 0.0%) | 0/10234 = 0.0% (0.0%, 0.0%) |
| Age < 65 | Day 57 | Placebo | Negative | Anti Spike IgG (IU/ml) | 80 | 0/10234 = 0.0% (0.0%, 0.0%) | 0/10234 = 0.0% (0.0%, 0.0%) | 0/10234 = 0.0% (0.0%, 0.0%) |
| Age < 65 | Day 57 | Placebo | Positive | Anti N IgG (IU/ml) | 147 | 1098/1098 = 100.0% (100.0%, 100.0%) | 1098/1098 = 100.0% (100.0%, 100.0%) | 1098/1098 = 100.0% (100.0%, 100.0%) |
| Age < 65 | Day 57 | Placebo | Positive | Anti RBD IgG (IU/ml) | 147 | 1098/1098 = 100.0% (100.0%, 100.0%) | 1098/1098 = 100.0% (100.0%, 100.0%) | 1098/1098 = 100.0% (100.0%, 100.0%) |
| Age < 65 | Day 57 | Placebo | Positive | Anti Spike IgG (IU/ml) | 147 | 1098/1098 = 100.0% (100.0%, 100.0%) | 1098/1098 = 100.0% (100.0%, 100.0%) | 1098/1098 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 | Day 29 | Vaccine | Negative | Anti N IgG (IU/ml) | 482 | 2777/2777 = 100.0% (100.0%, 100.0%) | 2777/2777 = 100.0% (100.0%, 100.0%) | 2777/2777 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 | Day 29 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 482 | 2777/2777 = 100.0% (100.0%, 100.0%) | 2777/2777 = 100.0% (100.0%, 100.0%) | 2777/2777 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 | Day 29 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 482 | 2777/2777 = 100.0% (100.0%, 100.0%) | 2777/2777 = 100.0% (100.0%, 100.0%) | 2777/2777 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 | Day 29 | Vaccine | Positive | Anti N IgG (IU/ml) | 128 | 287/287 = 100.0% (100.0%, 100.0%) | 287/287 = 100.0% (100.0%, 100.0%) | 287/287 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 | Day 29 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 128 | 287/287 = 100.0% (100.0%, 100.0%) | 287/287 = 100.0% (100.0%, 100.0%) | 287/287 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 | Day 29 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 128 | 287/287 = 100.0% (100.0%, 100.0%) | 287/287 = 100.0% (100.0%, 100.0%) | 287/287 = 100.0% (100.0%, 100.0%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % Greater than 2 × LLOD | % Greater than 4 × LLOD |
|----------|--------|---------|---------------------|------------------------|-----|--|--|--|
| Age ≥ 65 | Day 29 | Placebo | Negative | Anti N IgG (IU/ml) | 83 | 0/3125 = 0.0% (0.0%, 0.0%) | 0/3125 = 0.0% (0.0%, 0.0%) | 0/3125 = 0.0% (0.0%, 0.0%) |
| Age ≥ 65 | Day 29 | Placebo | Negative | Anti RBD IgG (IU/ml) | 83 | 0/3125 = 0.0% (0.0%, 0.0%) | 0/3125 = 0.0% (0.0%, 0.0%) | 0/3125 = 0.0% (0.0%, 0.0%) |
| Age ≥ 65 | Day 29 | Placebo | Negative | Anti Spike IgG (IU/ml) | 83 | 0/3125 = 0.0% (0.0%, 0.0%) | 0/3125 = 0.0% (0.0%, 0.0%) | 0/3125 = 0.0% (0.0%, 0.0%) |
| Age ≥ 65 | Day 29 | Placebo | Positive | Anti N IgG (IU/ml) | 123 | 259/259 = 100.0% (100.0%, 100.0%) | 259/259 = 100.0% (100.0%, 100.0%) | 259/259 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 | Day 29 | Placebo | Positive | Anti RBD IgG (IU/ml) | 123 | 259/259 = 100.0% (100.0%, 100.0%) | 259/259 = 100.0% (100.0%, 100.0%) | 259/259 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 | Day 29 | Placebo | Positive | Anti Spike IgG (IU/ml) | 123 | 259/259 = 100.0% (100.0%, 100.0%) | 259/259 = 100.0% (100.0%, 100.0%) | 259/259 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 | Day 57 | Vaccine | Negative | Anti N IgG (IU/ml) | 482 | 2777/2777 = 100.0% (100.0%, 100.0%) | 2777/2777 = 100.0% (100.0%, 100.0%) | 2777/2777 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 | Day 57 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 482 | 2777/2777 = 100.0% (100.0%, 100.0%) | 2777/2777 = 100.0% (100.0%, 100.0%) | 2777/2777 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 | Day 57 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 482 | 2777/2777 = 100.0% (100.0%, 100.0%) | 2777/2777 = 100.0% (100.0%, 100.0%) | 2777/2777 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 | Day 57 | Vaccine | Positive | Anti N IgG (IU/ml) | 128 | 287/287 = 100.0% (100.0%, 100.0%) | 287/287 = 100.0% (100.0%, 100.0%) | 287/287 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 | Day 57 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 128 | 287/287 = 100.0% (100.0%, 100.0%) | 287/287 = 100.0% (100.0%, 100.0%) | 287/287 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 | Day 57 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 128 | 287/287 = 100.0% (100.0%, 100.0%) | 287/287 = 100.0% (100.0%, 100.0%) | 287/287 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 | Day 57 | Placebo | Negative | Anti N IgG (IU/ml) | 83 | 0/3125 = 0.0% (0.0%, 0.0%) | 0/3125 = 0.0% (0.0%, 0.0%) | 0/3125 = 0.0% (0.0%, 0.0%) |
| Age ≥ 65 | Day 57 | Placebo | Negative | Anti RBD IgG (IU/ml) | 83 | 0/3125 = 0.0% (0.0%, 0.0%) | 0/3125 = 0.0% (0.0%, 0.0%) | 0/3125 = 0.0% (0.0%, 0.0%) |
| Age ≥ 65 | Day 57 | Placebo | Negative | Anti Spike IgG (IU/ml) | 83 | 0/3125 = 0.0% (0.0%, 0.0%) | 0/3125 = 0.0% (0.0%, 0.0%) | 0/3125 = 0.0% (0.0%, 0.0%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % Greater than 2 × LLOD | % Greater than 4 × LLOD |
|----------|--------|---------|---------------------|------------------------|-----|--------------------------------------|--------------------------------------|--------------------------------------|
| Age ≥ 65 | Day 57 | Placebo | Positive | Anti N IgG (IU/ml) | 123 | 259/259 = 100.0% (100.0%, 100.0%) | 259/259 = 100.0% (100.0%, 100.0%) | 259/259 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 | Day 57 | Placebo | Positive | Anti RBD IgG (IU/ml) | 123 | 259/259 = 100.0% (100.0%, 100.0%) | 259/259 = 100.0% (100.0%, 100.0%) | 259/259 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 | Day 57 | Placebo | Positive | Anti Spike IgG (IU/ml) | 123 | 259/259 = 100.0% (100.0%, 100.0%) | 259/259 = 100.0% (100.0%, 100.0%) | 259/259 = 100.0% (100.0%, 100.0%) |

Binding Antibody Responders are defined as participants who had baseline values below the LLOD with detectable antibody concentration above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in antibody concentration.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 3c. Percentage of responders, and participants with concentrations $\geq 2 \times \text{LLOD}$ or $\geq 4 \times \text{LLOD}$ for binding antibody markers by Risk for Severe Covid-19

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % Greater than $2 \times \text{LLOD}$ | % Greater than $4 \times \text{LLOD}$ |
|---------------------------------|--------|---------|---------------------|------------------------|-----|--|--|--|
| Risk for Severe Covid-19 | | | | | | | | |
| At-risk | Day 29 | Vaccine | Negative | Anti N IgG (IU/ml) | 469 | 3736.6/3736.6 = 100.0% (100.0%, 100.0%) | 3736.6/3736.6 = 100.0% (100.0%, 100.0%) | 3736.6/3736.6 = 100.0% (100.0%, 100.0%) |
| At-risk | Day 29 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 469 | 3736.6/3736.6 = 100.0% (100.0%, 100.0%) | 3736.6/3736.6 = 100.0% (100.0%, 100.0%) | 3736.6/3736.6 = 100.0% (100.0%, 100.0%) |
| At-risk | Day 29 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 469 | 3736.6/3736.6 = 100.0% (100.0%, 100.0%) | 3736.6/3736.6 = 100.0% (100.0%, 100.0%) | 3736.6/3736.6 = 100.0% (100.0%, 100.0%) |
| At-risk | Day 29 | Vaccine | Positive | Anti N IgG (IU/ml) | 125 | 368.8/368.8 = 100.0% (100.0%, 100.0%) | 368.8/368.8 = 100.0% (100.0%, 100.0%) | 368.8/368.8 = 100.0% (100.0%, 100.0%) |
| At-risk | Day 29 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 125 | 368.8/368.8 = 100.0% (100.0%, 100.0%) | 368.8/368.8 = 100.0% (100.0%, 100.0%) | 368.8/368.8 = 100.0% (100.0%, 100.0%) |
| At-risk | Day 29 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 125 | 368.8/368.8 = 100.0% (100.0%, 100.0%) | 368.8/368.8 = 100.0% (100.0%, 100.0%) | 368.8/368.8 = 100.0% (100.0%, 100.0%) |
| At-risk | Day 29 | Placebo | Negative | Anti N IgG (IU/ml) | 84 | 0/4096.4 = 0.0% (0.0%, 0.0%) | 0/4096.4 = 0.0% (0.0%, 0.0%) | 0/4096.4 = 0.0% (0.0%, 0.0%) |
| At-risk | Day 29 | Placebo | Negative | Anti RBD IgG (IU/ml) | 84 | 0/4096.4 = 0.0% (0.0%, 0.0%) | 0/4096.4 = 0.0% (0.0%, 0.0%) | 0/4096.4 = 0.0% (0.0%, 0.0%) |
| At-risk | Day 29 | Placebo | Negative | Anti Spike IgG (IU/ml) | 84 | 0/4096.4 = 0.0% (0.0%, 0.0%) | 0/4096.4 = 0.0% (0.0%, 0.0%) | 0/4096.4 = 0.0% (0.0%, 0.0%) |
| At-risk | Day 29 | Placebo | Positive | Anti N IgG (IU/ml) | 123 | 331.2/331.2 = 100.0% (100.0%, 100.0%) | 331.2/331.2 = 100.0% (100.0%, 100.0%) | 328.8/331.2 = 99.3% (94.8%, 99.9%) |
| At-risk | Day 29 | Placebo | Positive | Anti RBD IgG (IU/ml) | 123 | 331.2/331.2 = 100.0% (100.0%, 100.0%) | 331.2/331.2 = 100.0% (100.0%, 100.0%) | 331.2/331.2 = 100.0% (100.0%, 100.0%) |
| At-risk | Day 29 | Placebo | Positive | Anti Spike IgG (IU/ml) | 123 | 331.2/331.2 = 100.0% (100.0%, 100.0%) | 331.2/331.2 = 100.0% (100.0%, 100.0%) | 331.2/331.2 = 100.0% (100.0%, 100.0%) |
| At-risk | Day 57 | Vaccine | Negative | Anti N IgG (IU/ml) | 469 | 3736.6/3736.6 = 100.0% (100.0%, 100.0%) | 3736.6/3736.6 = 100.0% (100.0%, 100.0%) | 3736.6/3736.6 = 100.0% (100.0%, 100.0%) |
| At-risk | Day 57 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 469 | 3736.6/3736.6 = 100.0% (100.0%, 100.0%) | 3736.6/3736.6 = 100.0% (100.0%, 100.0%) | 3736.6/3736.6 = 100.0% (100.0%, 100.0%) |
| At-risk | Day 57 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 469 | 3736.6/3736.6 = 100.0% (100.0%, 100.0%) | 3736.6/3736.6 = 100.0% (100.0%, 100.0%) | 3736.6/3736.6 = 100.0% (100.0%, 100.0%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % Greater than 2 × LLOD | % Greater than 4 × LLOD |
|-------------|--------|---------|---------------------|------------------------|-----|--|--|--|
| At-risk | Day 57 | Vaccine | Positive | Anti N IgG (IU/ml) | 125 | 368.8/368.8 = 100.0% (100.0%, 100.0%) | 368.8/368.8 = 100.0% (100.0%, 100.0%) | 368.8/368.8 = 100.0% (100.0%, 100.0%) |
| At-risk | Day 57 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 125 | 368.8/368.8 = 100.0% (100.0%, 100.0%) | 368.8/368.8 = 100.0% (100.0%, 100.0%) | 368.8/368.8 = 100.0% (100.0%, 100.0%) |
| At-risk | Day 57 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 125 | 368.8/368.8 = 100.0% (100.0%, 100.0%) | 368.8/368.8 = 100.0% (100.0%, 100.0%) | 368.8/368.8 = 100.0% (100.0%, 100.0%) |
| At-risk | Day 57 | Placebo | Negative | Anti N IgG (IU/ml) | 84 | 0/4096.4 = 0.0% (0.0%, 0.0%) | 0/4096.4 = 0.0% (0.0%, 0.0%) | 0/4096.4 = 0.0% (0.0%, 0.0%) |
| At-risk | Day 57 | Placebo | Negative | Anti RBD IgG (IU/ml) | 84 | 76.3/4096.4 = 1.9% (0.2%, 12.6%) | 0/4096.4 = 0.0% (0.0%, 0.0%) | 0/4096.4 = 0.0% (0.0%, 0.0%) |
| At-risk | Day 57 | Placebo | Negative | Anti Spike IgG (IU/ml) | 84 | 0/4096.4 = 0.0% (0.0%, 0.0%) | 0/4096.4 = 0.0% (0.0%, 0.0%) | 0/4096.4 = 0.0% (0.0%, 0.0%) |
| At-risk | Day 57 | Placebo | Positive | Anti N IgG (IU/ml) | 123 | 331.2/331.2 = 100.0% (100.0%, 100.0%) | 331.2/331.2 = 100.0% (100.0%, 100.0%) | 331.2/331.2 = 100.0% (100.0%, 100.0%) |
| At-risk | Day 57 | Placebo | Positive | Anti RBD IgG (IU/ml) | 123 | 331.2/331.2 = 100.0% (100.0%, 100.0%) | 331.2/331.2 = 100.0% (100.0%, 100.0%) | 331.2/331.2 = 100.0% (100.0%, 100.0%) |
| At-risk | Day 57 | Placebo | Positive | Anti Spike IgG (IU/ml) | 123 | 331.2/331.2 = 100.0% (100.0%, 100.0%) | 331.2/331.2 = 100.0% (100.0%, 100.0%) | 331.2/331.2 = 100.0% (100.0%, 100.0%) |
| Not at-risk | Day 29 | Vaccine | Negative | Anti N IgG (IU/ml) | 445 | 9558.4/9558.4 = 100.0% (100.0%, 100.0%) | 9531.4/9558.4 = 99.7% (98.0%, 100.0%) | 9531.4/9558.4 = 99.7% (98.0%, 100.0%) |
| Not at-risk | Day 29 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 445 | 9558.4/9558.4 = 100.0% (100.0%, 100.0%) | 9558.4/9558.4 = 100.0% (100.0%, 100.0%) | 9558.4/9558.4 = 100.0% (100.0%, 100.0%) |
| Not at-risk | Day 29 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 445 | 9558.4/9558.4 = 100.0% (100.0%, 100.0%) | 9558.4/9558.4 = 100.0% (100.0%, 100.0%) | 9558.4/9558.4 = 100.0% (100.0%, 100.0%) |
| Not at-risk | Day 29 | Vaccine | Positive | Anti N IgG (IU/ml) | 149 | 1063.2/1063.2 = 100.0% (100.0%, 100.0%) | 1063.2/1063.2 = 100.0% (100.0%, 100.0%) | 1063.2/1063.2 = 100.0% (100.0%, 100.0%) |
| Not at-risk | Day 29 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 149 | 1063.2/1063.2 = 100.0% (100.0%, 100.0%) | 1063.2/1063.2 = 100.0% (100.0%, 100.0%) | 1063.2/1063.2 = 100.0% (100.0%, 100.0%) |
| Not at-risk | Day 29 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 149 | 1063.2/1063.2 = 100.0% (100.0%, 100.0%) | 1063.2/1063.2 = 100.0% (100.0%, 100.0%) | 1063.2/1063.2 = 100.0% (100.0%, 100.0%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % Greater than 2 × LLOD | % Greater than 4 × LLOD |
|-------------|--------|---------|---------------------|------------------------|-----|--|--|--|
| Not at-risk | Day 29 | Placebo | Negative | Anti N IgG (IU/ml) | 79 | 0/9262.6 = 0.0% (0.0%, 0.0%) | 0/9262.6 = 0.0% (0.0%, 0.0%) | 0/9262.6 = 0.0% (0.0%, 0.0%) |
| Not at-risk | Day 29 | Placebo | Negative | Anti RBD IgG (IU/ml) | 79 | 0/9262.6 = 0.0% (0.0%, 0.0%) | 0/9262.6 = 0.0% (0.0%, 0.0%) | 0/9262.6 = 0.0% (0.0%, 0.0%) |
| Not at-risk | Day 29 | Placebo | Negative | Anti Spike IgG (IU/ml) | 79 | 0/9262.6 = 0.0% (0.0%, 0.0%) | 0/9262.6 = 0.0% (0.0%, 0.0%) | 0/9262.6 = 0.0% (0.0%, 0.0%) |
| Not at-risk | Day 29 | Placebo | Positive | Anti N IgG (IU/ml) | 147 | 1025.8/1025.8 = 100.0% (100.0%, 100.0%) | 1025.8/1025.8 = 100.0% (100.0%, 100.0%) | 1025.8/1025.8 = 100.0% (100.0%, 100.0%) |
| Not at-risk | Day 29 | Placebo | Positive | Anti RBD IgG (IU/ml) | 147 | 1025.8/1025.8 = 100.0% (100.0%, 100.0%) | 1025.8/1025.8 = 100.0% (100.0%, 100.0%) | 1025.8/1025.8 = 100.0% (100.0%, 100.0%) |
| Not at-risk | Day 29 | Placebo | Positive | Anti Spike IgG (IU/ml) | 147 | 1025.8/1025.8 = 100.0% (100.0%, 100.0%) | 1025.8/1025.8 = 100.0% (100.0%, 100.0%) | 1025.8/1025.8 = 100.0% (100.0%, 100.0%) |
| Not at-risk | Day 57 | Vaccine | Negative | Anti N IgG (IU/ml) | 445 | 9558.4/9558.4 = 100.0% (100.0%, 100.0%) | 9558.4/9558.4 = 100.0% (100.0%, 100.0%) | 9558.4/9558.4 = 100.0% (100.0%, 100.0%) |
| Not at-risk | Day 57 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 445 | 9558.4/9558.4 = 100.0% (100.0%, 100.0%) | 9558.4/9558.4 = 100.0% (100.0%, 100.0%) | 9558.4/9558.4 = 100.0% (100.0%, 100.0%) |
| Not at-risk | Day 57 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 445 | 9558.4/9558.4 = 100.0% (100.0%, 100.0%) | 9558.4/9558.4 = 100.0% (100.0%, 100.0%) | 9558.4/9558.4 = 100.0% (100.0%, 100.0%) |
| Not at-risk | Day 57 | Vaccine | Positive | Anti N IgG (IU/ml) | 149 | 1063.2/1063.2 = 100.0% (100.0%, 100.0%) | 1063.2/1063.2 = 100.0% (100.0%, 100.0%) | 1063.2/1063.2 = 100.0% (100.0%, 100.0%) |
| Not at-risk | Day 57 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 149 | 1063.2/1063.2 = 100.0% (100.0%, 100.0%) | 1063.2/1063.2 = 100.0% (100.0%, 100.0%) | 1063.2/1063.2 = 100.0% (100.0%, 100.0%) |
| Not at-risk | Day 57 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 149 | 1063.2/1063.2 = 100.0% (100.0%, 100.0%) | 1063.2/1063.2 = 100.0% (100.0%, 100.0%) | 1063.2/1063.2 = 100.0% (100.0%, 100.0%) |
| Not at-risk | Day 57 | Placebo | Negative | Anti N IgG (IU/ml) | 79 | 0/9262.6 = 0.0% (0.0%, 0.0%) | 0/9262.6 = 0.0% (0.0%, 0.0%) | 0/9262.6 = 0.0% (0.0%, 0.0%) |
| Not at-risk | Day 57 | Placebo | Negative | Anti RBD IgG (IU/ml) | 79 | 0/9262.6 = 0.0% (0.0%, 0.0%) | 0/9262.6 = 0.0% (0.0%, 0.0%) | 0/9262.6 = 0.0% (0.0%, 0.0%) |
| Not at-risk | Day 57 | Placebo | Negative | Anti Spike IgG (IU/ml) | 79 | 0/9262.6 = 0.0% (0.0%, 0.0%) | 0/9262.6 = 0.0% (0.0%, 0.0%) | 0/9262.6 = 0.0% (0.0%, 0.0%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % Greater than 2 × LLOD | % Greater than 4 × LLOD |
|-------------|--------|---------|---------------------|------------------------|-----|--|--|--|
| Not at-risk | Day 57 | Placebo | Positive | Anti N IgG (IU/ml) | 147 | 1025.8/1025.8 = 100.0% (100.0%, 100.0%) | 1025.8/1025.8 = 100.0% (100.0%, 100.0%) | 1025.8/1025.8 = 100.0% (100.0%, 100.0%) |
| Not at-risk | Day 57 | Placebo | Positive | Anti RBD IgG (IU/ml) | 147 | 1025.8/1025.8 = 100.0% (100.0%, 100.0%) | 1025.8/1025.8 = 100.0% (100.0%, 100.0%) | 1025.8/1025.8 = 100.0% (100.0%, 100.0%) |
| Not at-risk | Day 57 | Placebo | Positive | Anti Spike IgG (IU/ml) | 147 | 1025.8/1025.8 = 100.0% (100.0%, 100.0%) | 1025.8/1025.8 = 100.0% (100.0%, 100.0%) | 1025.8/1025.8 = 100.0% (100.0%, 100.0%) |

Binding Antibody Responders are defined as participants who had baseline values below the LLOD with detectable antibody concentration above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in antibody concentration.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 3d. Percentage of responders, and participants with concentrations $\geq 2 \times \text{LLOD}$ or $\geq 4 \times \text{LLOD}$ for binding antibody markers by Age, Risk for Severe Covid-19

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % Greater than $2 \times \text{LLOD}$ | % Greater than $4 \times \text{LLOD}$ |
|--------------------------------------|--------|---------|---------------------|------------------------|-----|--|--|--|
| Age, Risk for Severe Covid-19 | | | | | | | | |
| Age < 65 At-risk | Day 29 | Vaccine | Negative | Anti N IgG (IU/ml) | 214 | 2279/2279 = 100.0% (100.0%, 100.0%) | 2279/2279 = 100.0% (100.0%, 100.0%) | 2279/2279 = 100.0% (100.0%, 100.0%) |
| Age < 65 At-risk | Day 29 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 214 | 2279/2279 = 100.0% (100.0%, 100.0%) | 2279/2279 = 100.0% (100.0%, 100.0%) | 2279/2279 = 100.0% (100.0%, 100.0%) |
| Age < 65 At-risk | Day 29 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 214 | 2279/2279 = 100.0% (100.0%, 100.0%) | 2279/2279 = 100.0% (100.0%, 100.0%) | 2279/2279 = 100.0% (100.0%, 100.0%) |
| Age < 65 At-risk | Day 29 | Vaccine | Positive | Anti N IgG (IU/ml) | 73 | 248/248 = 100.0% (100.0%, 100.0%) | 248/248 = 100.0% (100.0%, 100.0%) | 248/248 = 100.0% (100.0%, 100.0%) |
| Age < 65 At-risk | Day 29 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 73 | 248/248 = 100.0% (100.0%, 100.0%) | 248/248 = 100.0% (100.0%, 100.0%) | 248/248 = 100.0% (100.0%, 100.0%) |
| Age < 65 At-risk | Day 29 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 73 | 248/248 = 100.0% (100.0%, 100.0%) | 248/248 = 100.0% (100.0%, 100.0%) | 248/248 = 100.0% (100.0%, 100.0%) |
| Age < 65 At-risk | Day 29 | Placebo | Negative | Anti N IgG (IU/ml) | 40 | 0/2454 = 0.0% (0.0%, 0.0%) | 0/2454 = 0.0% (0.0%, 0.0%) | 0/2454 = 0.0% (0.0%, 0.0%) |
| Age < 65 At-risk | Day 29 | Placebo | Negative | Anti RBD IgG (IU/ml) | 40 | 0/2454 = 0.0% (0.0%, 0.0%) | 0/2454 = 0.0% (0.0%, 0.0%) | 0/2454 = 0.0% (0.0%, 0.0%) |
| Age < 65 At-risk | Day 29 | Placebo | Negative | Anti Spike IgG (IU/ml) | 40 | 0/2454 = 0.0% (0.0%, 0.0%) | 0/2454 = 0.0% (0.0%, 0.0%) | 0/2454 = 0.0% (0.0%, 0.0%) |
| Age < 65 At-risk | Day 29 | Placebo | Positive | Anti N IgG (IU/ml) | 75 | 226/226 = 100.0% (100.0%, 100.0%) | 226/226 = 100.0% (100.0%, 100.0%) | 223.5/226 = 98.9% (92.3%, 99.9%) |
| Age < 65 At-risk | Day 29 | Placebo | Positive | Anti RBD IgG (IU/ml) | 75 | 226/226 = 100.0% (100.0%, 100.0%) | 226/226 = 100.0% (100.0%, 100.0%) | 226/226 = 100.0% (100.0%, 100.0%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % Greater than 2 × LLOD | % Greater than 4 × LLOD |
|------------------|--------|---------|---------------------|------------------------|-----|--|--|--|
| Age < 65 At-risk | Day 29 | Placebo | Positive | Anti Spike IgG (IU/ml) | 75 | 226/226 = 100.0% (100.0%, 100.0%) | 226/226 = 100.0% (100.0%, 100.0%) | 226/226 = 100.0% (100.0%, 100.0%) |
| Age < 65 At-risk | Day 57 | Vaccine | Negative | Anti N IgG (IU/ml) | 214 | 2279/2279 = 100.0% (100.0%, 100.0%) | 2279/2279 = 100.0% (100.0%, 100.0%) | 2279/2279 = 100.0% (100.0%, 100.0%) |
| Age < 65 At-risk | Day 57 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 214 | 2279/2279 = 100.0% (100.0%, 100.0%) | 2279/2279 = 100.0% (100.0%, 100.0%) | 2279/2279 = 100.0% (100.0%, 100.0%) |
| Age < 65 At-risk | Day 57 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 214 | 2279/2279 = 100.0% (100.0%, 100.0%) | 2279/2279 = 100.0% (100.0%, 100.0%) | 2279/2279 = 100.0% (100.0%, 100.0%) |
| Age < 65 At-risk | Day 57 | Vaccine | Positive | Anti N IgG (IU/ml) | 73 | 248/248 = 100.0% (100.0%, 100.0%) | 248/248 = 100.0% (100.0%, 100.0%) | 248/248 = 100.0% (100.0%, 100.0%) |
| Age < 65 At-risk | Day 57 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 73 | 248/248 = 100.0% (100.0%, 100.0%) | 248/248 = 100.0% (100.0%, 100.0%) | 248/248 = 100.0% (100.0%, 100.0%) |
| Age < 65 At-risk | Day 57 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 73 | 248/248 = 100.0% (100.0%, 100.0%) | 248/248 = 100.0% (100.0%, 100.0%) | 248/248 = 100.0% (100.0%, 100.0%) |
| Age < 65 At-risk | Day 57 | Placebo | Negative | Anti N IgG (IU/ml) | 40 | 0/2454 = 0.0% (0.0%, 0.0%) | 0/2454 = 0.0% (0.0%, 0.0%) | 0/2454 = 0.0% (0.0%, 0.0%) |
| Age < 65 At-risk | Day 57 | Placebo | Negative | Anti RBD IgG (IU/ml) | 40 | 76.3/2454 = 3.1% (0.4%, 20.6%) | 0/2454 = 0.0% (0.0%, 0.0%) | 0/2454 = 0.0% (0.0%, 0.0%) |
| Age < 65 At-risk | Day 57 | Placebo | Negative | Anti Spike IgG (IU/ml) | 40 | 0/2454 = 0.0% (0.0%, 0.0%) | 0/2454 = 0.0% (0.0%, 0.0%) | 0/2454 = 0.0% (0.0%, 0.0%) |
| Age < 65 At-risk | Day 57 | Placebo | Positive | Anti N IgG (IU/ml) | 75 | 226/226 = 100.0% (100.0%, 100.0%) | 226/226 = 100.0% (100.0%, 100.0%) | 226/226 = 100.0% (100.0%, 100.0%) |
| Age < 65 At-risk | Day 57 | Placebo | Positive | Anti RBD IgG (IU/ml) | 75 | 226/226 = 100.0% (100.0%, 100.0%) | 226/226 = 100.0% (100.0%, 100.0%) | 226/226 = 100.0% (100.0%, 100.0%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % Greater than 2 × LLOD | % Greater than 4 × LLOD |
|----------------------|--------|---------|---------------------|------------------------|-----|--|--|--|
| Age < 65 At-risk | Day 57 | Placebo | Positive | Anti Spike IgG (IU/ml) | 75 | 226/226 = 100.0% (100.0%, 100.0%) | 226/226 = 100.0% (100.0%, 100.0%) | 226/226 = 100.0% (100.0%, 100.0%) |
| Age < 65 Not at-risk | Day 29 | Vaccine | Negative | Anti N IgG (IU/ml) | 218 | 8239/8239 = 100.0% (100.0%, 100.0%) | 8212.1/8239 = 99.7% (97.7%, 100.0%) | 8212.1/8239 = 99.7% (97.7%, 100.0%) |
| Age < 65 Not at-risk | Day 29 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 218 | 8239/8239 = 100.0% (100.0%, 100.0%) | 8239/8239 = 100.0% (100.0%, 100.0%) | 8239/8239 = 100.0% (100.0%, 100.0%) |
| Age < 65 Not at-risk | Day 29 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 218 | 8239/8239 = 100.0% (100.0%, 100.0%) | 8239/8239 = 100.0% (100.0%, 100.0%) | 8239/8239 = 100.0% (100.0%, 100.0%) |
| Age < 65 Not at-risk | Day 29 | Vaccine | Positive | Anti N IgG (IU/ml) | 73 | 897/897 = 100.0% (100.0%, 100.0%) | 897/897 = 100.0% (100.0%, 100.0%) | 897/897 = 100.0% (100.0%, 100.0%) |
| Age < 65 Not at-risk | Day 29 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 73 | 897/897 = 100.0% (100.0%, 100.0%) | 897/897 = 100.0% (100.0%, 100.0%) | 897/897 = 100.0% (100.0%, 100.0%) |
| Age < 65 Not at-risk | Day 29 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 73 | 897/897 = 100.0% (100.0%, 100.0%) | 897/897 = 100.0% (100.0%, 100.0%) | 897/897 = 100.0% (100.0%, 100.0%) |
| Age < 65 Not at-risk | Day 29 | Placebo | Negative | Anti N IgG (IU/ml) | 40 | 0/7780 = 0.0% (0.0%, 0.0%) | 0/7780 = 0.0% (0.0%, 0.0%) | 0/7780 = 0.0% (0.0%, 0.0%) |
| Age < 65 Not at-risk | Day 29 | Placebo | Negative | Anti RBD IgG (IU/ml) | 40 | 0/7780 = 0.0% (0.0%, 0.0%) | 0/7780 = 0.0% (0.0%, 0.0%) | 0/7780 = 0.0% (0.0%, 0.0%) |
| Age < 65 Not at-risk | Day 29 | Placebo | Negative | Anti Spike IgG (IU/ml) | 40 | 0/7780 = 0.0% (0.0%, 0.0%) | 0/7780 = 0.0% (0.0%, 0.0%) | 0/7780 = 0.0% (0.0%, 0.0%) |
| Age < 65 Not at-risk | Day 29 | Placebo | Positive | Anti N IgG (IU/ml) | 72 | 872/872 = 100.0% (100.0%, 100.0%) | 872/872 = 100.0% (100.0%, 100.0%) | 872/872 = 100.0% (100.0%, 100.0%) |
| Age < 65 Not at-risk | Day 29 | Placebo | Positive | Anti RBD IgG (IU/ml) | 72 | 872/872 = 100.0% (100.0%, 100.0%) | 872/872 = 100.0% (100.0%, 100.0%) | 872/872 = 100.0% (100.0%, 100.0%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % Greater than 2 × LLOD | % Greater than 4 × LLOD |
|----------------------|--------|---------|---------------------|------------------------|-----|-------------------------------------|-------------------------------------|-------------------------------------|
| Age < 65 Not at-risk | Day 29 | Placebo | Positive | Anti Spike IgG (IU/ml) | 72 | 872/872 = 100.0% (100.0%, 100.0%) | 872/872 = 100.0% (100.0%, 100.0%) | 872/872 = 100.0% (100.0%, 100.0%) |
| Age < 65 Not at-risk | Day 57 | Vaccine | Negative | Anti N IgG (IU/ml) | 218 | 8239/8239 = 100.0% (100.0%, 100.0%) | 8239/8239 = 100.0% (100.0%, 100.0%) | 8239/8239 = 100.0% (100.0%, 100.0%) |
| Age < 65 Not at-risk | Day 57 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 218 | 8239/8239 = 100.0% (100.0%, 100.0%) | 8239/8239 = 100.0% (100.0%, 100.0%) | 8239/8239 = 100.0% (100.0%, 100.0%) |
| Age < 65 Not at-risk | Day 57 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 218 | 8239/8239 = 100.0% (100.0%, 100.0%) | 8239/8239 = 100.0% (100.0%, 100.0%) | 8239/8239 = 100.0% (100.0%, 100.0%) |
| Age < 65 Not at-risk | Day 57 | Vaccine | Positive | Anti N IgG (IU/ml) | 73 | 897/897 = 100.0% (100.0%, 100.0%) | 897/897 = 100.0% (100.0%, 100.0%) | 897/897 = 100.0% (100.0%, 100.0%) |
| Age < 65 Not at-risk | Day 57 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 73 | 897/897 = 100.0% (100.0%, 100.0%) | 897/897 = 100.0% (100.0%, 100.0%) | 897/897 = 100.0% (100.0%, 100.0%) |
| Age < 65 Not at-risk | Day 57 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 73 | 897/897 = 100.0% (100.0%, 100.0%) | 897/897 = 100.0% (100.0%, 100.0%) | 897/897 = 100.0% (100.0%, 100.0%) |
| Age < 65 Not at-risk | Day 57 | Placebo | Negative | Anti N IgG (IU/ml) | 40 | 0/7780 = 0.0% (0.0%, 0.0%) | 0/7780 = 0.0% (0.0%, 0.0%) | 0/7780 = 0.0% (0.0%, 0.0%) |
| Age < 65 Not at-risk | Day 57 | Placebo | Negative | Anti RBD IgG (IU/ml) | 40 | 0/7780 = 0.0% (0.0%, 0.0%) | 0/7780 = 0.0% (0.0%, 0.0%) | 0/7780 = 0.0% (0.0%, 0.0%) |
| Age < 65 Not at-risk | Day 57 | Placebo | Negative | Anti Spike IgG (IU/ml) | 40 | 0/7780 = 0.0% (0.0%, 0.0%) | 0/7780 = 0.0% (0.0%, 0.0%) | 0/7780 = 0.0% (0.0%, 0.0%) |
| Age < 65 Not at-risk | Day 57 | Placebo | Positive | Anti N IgG (IU/ml) | 72 | 872/872 = 100.0% (100.0%, 100.0%) | 872/872 = 100.0% (100.0%, 100.0%) | 872/872 = 100.0% (100.0%, 100.0%) |
| Age < 65 Not at-risk | Day 57 | Placebo | Positive | Anti RBD IgG (IU/ml) | 72 | 872/872 = 100.0% (100.0%, 100.0%) | 872/872 = 100.0% (100.0%, 100.0%) | 872/872 = 100.0% (100.0%, 100.0%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % Greater than 2 × LLOD | % Greater than 4 × LLOD |
|----------------------|--------|---------|---------------------|------------------------|-----|--|--|--|
| Age < 65 Not at-risk | Day 57 | Placebo | Positive | Anti Spike IgG (IU/ml) | 72 | 872/872 = 100.0% (100.0%, 100.0%) | 872/872 = 100.0% (100.0%, 100.0%) | 872/872 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 At-risk | Day 29 | Vaccine | Negative | Anti N IgG (IU/ml) | 255 | 1457.6/1457.6 = 100.0% (100.0%, 100.0%) | 1457.6/1457.6 = 100.0% (100.0%, 100.0%) | 1457.6/1457.6 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 At-risk | Day 29 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 255 | 1457.6/1457.6 = 100.0% (100.0%, 100.0%) | 1457.6/1457.6 = 100.0% (100.0%, 100.0%) | 1457.6/1457.6 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 At-risk | Day 29 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 255 | 1457.6/1457.6 = 100.0% (100.0%, 100.0%) | 1457.6/1457.6 = 100.0% (100.0%, 100.0%) | 1457.6/1457.6 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 At-risk | Day 29 | Vaccine | Positive | Anti N IgG (IU/ml) | 52 | 120.8/120.8 = 100.0% (100.0%, 100.0%) | 120.8/120.8 = 100.0% (100.0%, 100.0%) | 120.8/120.8 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 At-risk | Day 29 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 52 | 120.8/120.8 = 100.0% (100.0%, 100.0%) | 120.8/120.8 = 100.0% (100.0%, 100.0%) | 120.8/120.8 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 At-risk | Day 29 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 52 | 120.8/120.8 = 100.0% (100.0%, 100.0%) | 120.8/120.8 = 100.0% (100.0%, 100.0%) | 120.8/120.8 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 At-risk | Day 29 | Placebo | Negative | Anti N IgG (IU/ml) | 44 | 0/1642.4 = 0.0% (0.0%, 0.0%) | 0/1642.4 = 0.0% (0.0%, 0.0%) | 0/1642.4 = 0.0% (0.0%, 0.0%) |
| Age ≥ 65 At-risk | Day 29 | Placebo | Negative | Anti RBD IgG (IU/ml) | 44 | 0/1642.4 = 0.0% (0.0%, 0.0%) | 0/1642.4 = 0.0% (0.0%, 0.0%) | 0/1642.4 = 0.0% (0.0%, 0.0%) |
| Age ≥ 65 At-risk | Day 29 | Placebo | Negative | Anti Spike IgG (IU/ml) | 44 | 0/1642.4 = 0.0% (0.0%, 0.0%) | 0/1642.4 = 0.0% (0.0%, 0.0%) | 0/1642.4 = 0.0% (0.0%, 0.0%) |
| Age ≥ 65 At-risk | Day 29 | Placebo | Positive | Anti N IgG (IU/ml) | 48 | 105.2/105.2 = 100.0% (100.0%, 100.0%) | 105.2/105.2 = 100.0% (100.0%, 100.0%) | 105.2/105.2 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 At-risk | Day 29 | Placebo | Positive | Anti RBD IgG (IU/ml) | 48 | 105.2/105.2 = 100.0% (100.0%, 100.0%) | 105.2/105.2 = 100.0% (100.0%, 100.0%) | 105.2/105.2 = 100.0% (100.0%, 100.0%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % Greater than 2 × LLOD | % Greater than 4 × LLOD |
|------------------|--------|---------|---------------------|------------------------|-----|--|--|--|
| Age ≥ 65 At-risk | Day 29 | Placebo | Positive | Anti Spike IgG (IU/ml) | 48 | 105.2/105.2 = 100.0% (100.0%, 100.0%) | 105.2/105.2 = 100.0% (100.0%, 100.0%) | 105.2/105.2 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 At-risk | Day 57 | Vaccine | Negative | Anti N IgG (IU/ml) | 255 | 1457.6/1457.6 = 100.0% (100.0%, 100.0%) | 1457.6/1457.6 = 100.0% (100.0%, 100.0%) | 1457.6/1457.6 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 At-risk | Day 57 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 255 | 1457.6/1457.6 = 100.0% (100.0%, 100.0%) | 1457.6/1457.6 = 100.0% (100.0%, 100.0%) | 1457.6/1457.6 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 At-risk | Day 57 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 255 | 1457.6/1457.6 = 100.0% (100.0%, 100.0%) | 1457.6/1457.6 = 100.0% (100.0%, 100.0%) | 1457.6/1457.6 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 At-risk | Day 57 | Vaccine | Positive | Anti N IgG (IU/ml) | 52 | 120.8/120.8 = 100.0% (100.0%, 100.0%) | 120.8/120.8 = 100.0% (100.0%, 100.0%) | 120.8/120.8 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 At-risk | Day 57 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 52 | 120.8/120.8 = 100.0% (100.0%, 100.0%) | 120.8/120.8 = 100.0% (100.0%, 100.0%) | 120.8/120.8 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 At-risk | Day 57 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 52 | 120.8/120.8 = 100.0% (100.0%, 100.0%) | 120.8/120.8 = 100.0% (100.0%, 100.0%) | 120.8/120.8 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 At-risk | Day 57 | Placebo | Negative | Anti N IgG (IU/ml) | 44 | 0/1642.4 = 0.0% (0.0%, 0.0%) | 0/1642.4 = 0.0% (0.0%, 0.0%) | 0/1642.4 = 0.0% (0.0%, 0.0%) |
| Age ≥ 65 At-risk | Day 57 | Placebo | Negative | Anti RBD IgG (IU/ml) | 44 | 0/1642.4 = 0.0% (0.0%, 0.0%) | 0/1642.4 = 0.0% (0.0%, 0.0%) | 0/1642.4 = 0.0% (0.0%, 0.0%) |
| Age ≥ 65 At-risk | Day 57 | Placebo | Negative | Anti Spike IgG (IU/ml) | 44 | 0/1642.4 = 0.0% (0.0%, 0.0%) | 0/1642.4 = 0.0% (0.0%, 0.0%) | 0/1642.4 = 0.0% (0.0%, 0.0%) |
| Age ≥ 65 At-risk | Day 57 | Placebo | Positive | Anti N IgG (IU/ml) | 48 | 105.2/105.2 = 100.0% (100.0%, 100.0%) | 105.2/105.2 = 100.0% (100.0%, 100.0%) | 105.2/105.2 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 At-risk | Day 57 | Placebo | Positive | Anti RBD IgG (IU/ml) | 48 | 105.2/105.2 = 100.0% (100.0%, 100.0%) | 105.2/105.2 = 100.0% (100.0%, 100.0%) | 105.2/105.2 = 100.0% (100.0%, 100.0%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % Greater than 2 × LLOD | % Greater than 4 × LLOD |
|----------------------|--------|---------|---------------------|------------------------|-----|--|--|--|
| Age ≥ 65 At-risk | Day 57 | Placebo | Positive | Anti Spike IgG (IU/ml) | 48 | 105.2/105.2 = 100.0% (100.0%, 100.0%) | 105.2/105.2 = 100.0% (100.0%, 100.0%) | 105.2/105.2 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 Not at-risk | Day 29 | Vaccine | Negative | Anti N IgG (IU/ml) | 227 | 1319.4/1319.4 = 100.0% (100.0%, 100.0%) | 1319.4/1319.4 = 100.0% (100.0%, 100.0%) | 1319.4/1319.4 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 Not at-risk | Day 29 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 227 | 1319.4/1319.4 = 100.0% (100.0%, 100.0%) | 1319.4/1319.4 = 100.0% (100.0%, 100.0%) | 1319.4/1319.4 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 Not at-risk | Day 29 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 227 | 1319.4/1319.4 = 100.0% (100.0%, 100.0%) | 1319.4/1319.4 = 100.0% (100.0%, 100.0%) | 1319.4/1319.4 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 Not at-risk | Day 29 | Vaccine | Positive | Anti N IgG (IU/ml) | 76 | 166.2/166.2 = 100.0% (100.0%, 100.0%) | 166.2/166.2 = 100.0% (100.0%, 100.0%) | 166.2/166.2 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 Not at-risk | Day 29 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 76 | 166.2/166.2 = 100.0% (100.0%, 100.0%) | 166.2/166.2 = 100.0% (100.0%, 100.0%) | 166.2/166.2 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 Not at-risk | Day 29 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 76 | 166.2/166.2 = 100.0% (100.0%, 100.0%) | 166.2/166.2 = 100.0% (100.0%, 100.0%) | 166.2/166.2 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 Not at-risk | Day 29 | Placebo | Negative | Anti N IgG (IU/ml) | 39 | 0/1482.6 = 0.0% (0.0%, 0.0%) | 0/1482.6 = 0.0% (0.0%, 0.0%) | 0/1482.6 = 0.0% (0.0%, 0.0%) |
| Age ≥ 65 Not at-risk | Day 29 | Placebo | Negative | Anti RBD IgG (IU/ml) | 39 | 0/1482.6 = 0.0% (0.0%, 0.0%) | 0/1482.6 = 0.0% (0.0%, 0.0%) | 0/1482.6 = 0.0% (0.0%, 0.0%) |
| Age ≥ 65 Not at-risk | Day 29 | Placebo | Negative | Anti Spike IgG (IU/ml) | 39 | 0/1482.6 = 0.0% (0.0%, 0.0%) | 0/1482.6 = 0.0% (0.0%, 0.0%) | 0/1482.6 = 0.0% (0.0%, 0.0%) |
| Age ≥ 65 Not at-risk | Day 29 | Placebo | Positive | Anti N IgG (IU/ml) | 75 | 153.8/153.8 = 100.0% (100.0%, 100.0%) | 153.8/153.8 = 100.0% (100.0%, 100.0%) | 153.8/153.8 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 Not at-risk | Day 29 | Placebo | Positive | Anti RBD IgG (IU/ml) | 75 | 153.8/153.8 = 100.0% (100.0%, 100.0%) | 153.8/153.8 = 100.0% (100.0%, 100.0%) | 153.8/153.8 = 100.0% (100.0%, 100.0%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % Greater than 2 × LLOD | % Greater than 4 × LLOD |
|----------------------|--------|---------|---------------------|------------------------|-----|---|---|---|
| Age ≥ 65 Not at-risk | Day 29 | Placebo | Positive | Anti Spike IgG (IU/ml) | 75 | 153.8/153.8 = 100.0% (100.0%, 100.0%) | 153.8/153.8 = 100.0% (100.0%, 100.0%) | 153.8/153.8 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 Not at-risk | Day 57 | Vaccine | Negative | Anti N IgG (IU/ml) | 227 | 1319.4/1319.4 = 100.0% (100.0%, 100.0%) | 1319.4/1319.4 = 100.0% (100.0%, 100.0%) | 1319.4/1319.4 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 Not at-risk | Day 57 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 227 | 1319.4/1319.4 = 100.0% (100.0%, 100.0%) | 1319.4/1319.4 = 100.0% (100.0%, 100.0%) | 1319.4/1319.4 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 Not at-risk | Day 57 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 227 | 1319.4/1319.4 = 100.0% (100.0%, 100.0%) | 1319.4/1319.4 = 100.0% (100.0%, 100.0%) | 1319.4/1319.4 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 Not at-risk | Day 57 | Vaccine | Positive | Anti N IgG (IU/ml) | 76 | 166.2/166.2 = 100.0% (100.0%, 100.0%) | 166.2/166.2 = 100.0% (100.0%, 100.0%) | 166.2/166.2 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 Not at-risk | Day 57 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 76 | 166.2/166.2 = 100.0% (100.0%, 100.0%) | 166.2/166.2 = 100.0% (100.0%, 100.0%) | 166.2/166.2 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 Not at-risk | Day 57 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 76 | 166.2/166.2 = 100.0% (100.0%, 100.0%) | 166.2/166.2 = 100.0% (100.0%, 100.0%) | 166.2/166.2 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 Not at-risk | Day 57 | Placebo | Negative | Anti N IgG (IU/ml) | 39 | 0/1482.6 = 0.0% (0.0%, 0.0%) | 0/1482.6 = 0.0% (0.0%, 0.0%) | 0/1482.6 = 0.0% (0.0%, 0.0%) |
| Age ≥ 65 Not at-risk | Day 57 | Placebo | Negative | Anti RBD IgG (IU/ml) | 39 | 0/1482.6 = 0.0% (0.0%, 0.0%) | 0/1482.6 = 0.0% (0.0%, 0.0%) | 0/1482.6 = 0.0% (0.0%, 0.0%) |
| Age ≥ 65 Not at-risk | Day 57 | Placebo | Negative | Anti Spike IgG (IU/ml) | 39 | 0/1482.6 = 0.0% (0.0%, 0.0%) | 0/1482.6 = 0.0% (0.0%, 0.0%) | 0/1482.6 = 0.0% (0.0%, 0.0%) |
| Age ≥ 65 Not at-risk | Day 57 | Placebo | Positive | Anti N IgG (IU/ml) | 75 | 153.8/153.8 = 100.0% (100.0%, 100.0%) | 153.8/153.8 = 100.0% (100.0%, 100.0%) | 153.8/153.8 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 Not at-risk | Day 57 | Placebo | Positive | Anti RBD IgG (IU/ml) | 75 | 153.8/153.8 = 100.0% (100.0%, 100.0%) | 153.8/153.8 = 100.0% (100.0%, 100.0%) | 153.8/153.8 = 100.0% (100.0%, 100.0%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % Greater than 2 × LLOD | % Greater than 4 × LLOD |
|----------------------|--------|---------|---------------------|------------------------|----|--|--|--|
| Age ≥ 65 Not at-risk | Day 57 | Placebo | Positive | Anti Spike IgG (IU/ml) | 75 | 153.8/153.8 = 100.0% (100.0%, 100.0%) | 153.8/153.8 = 100.0% (100.0%, 100.0%) | 153.8/153.8 = 100.0% (100.0%, 100.0%) |

Binding Antibody Responders are defined as participants who had baseline values below the LLOD with detectable antibody concentration above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in antibody concentration.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 3e. Percentage of responders, and participants with concentrations $\geq 2 \times \text{LLOD}$ or $\geq 4 \times \text{LLOD}$ for binding antibody markers by Sex

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % Greater than $2 \times \text{LLOD}$ | % Greater than $4 \times \text{LLOD}$ |
|------------|--------|---------|---------------------|------------------------|-----|--|--|--|
| Sex | | | | | | | | |
| Male | Day 29 | Vaccine | Negative | Anti N IgG (IU/ml) | 395 | 5298.6/5298.6 = 100.0% (100.0%, 100.0%) | 5298.6/5298.6 = 100.0% (100.0%, 100.0%) | 5298.6/5298.6 = 100.0% (100.0%, 100.0%) |
| Male | Day 29 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 395 | 5298.6/5298.6 = 100.0% (100.0%, 100.0%) | 5298.6/5298.6 = 100.0% (100.0%, 100.0%) | 5298.6/5298.6 = 100.0% (100.0%, 100.0%) |
| Male | Day 29 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 395 | 5298.6/5298.6 = 100.0% (100.0%, 100.0%) | 5298.6/5298.6 = 100.0% (100.0%, 100.0%) | 5298.6/5298.6 = 100.0% (100.0%, 100.0%) |
| Male | Day 29 | Vaccine | Positive | Anti N IgG (IU/ml) | 121 | 564.7/564.7 = 100.0% (100.0%, 100.0%) | 564.7/564.7 = 100.0% (100.0%, 100.0%) | 564.7/564.7 = 100.0% (100.0%, 100.0%) |
| Male | Day 29 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 121 | 564.7/564.7 = 100.0% (100.0%, 100.0%) | 564.7/564.7 = 100.0% (100.0%, 100.0%) | 564.7/564.7 = 100.0% (100.0%, 100.0%) |
| Male | Day 29 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 121 | 564.7/564.7 = 100.0% (100.0%, 100.0%) | 564.7/564.7 = 100.0% (100.0%, 100.0%) | 564.7/564.7 = 100.0% (100.0%, 100.0%) |
| Male | Day 29 | Placebo | Negative | Anti N IgG (IU/ml) | 76 | 0/4771.7 = 0.0% (0.0%, 0.0%) | 0/4771.7 = 0.0% (0.0%, 0.0%) | 0/4771.7 = 0.0% (0.0%, 0.0%) |
| Male | Day 29 | Placebo | Negative | Anti RBD IgG (IU/ml) | 76 | 0/4771.7 = 0.0% (0.0%, 0.0%) | 0/4771.7 = 0.0% (0.0%, 0.0%) | 0/4771.7 = 0.0% (0.0%, 0.0%) |
| Male | Day 29 | Placebo | Negative | Anti Spike IgG (IU/ml) | 76 | 0/4771.7 = 0.0% (0.0%, 0.0%) | 0/4771.7 = 0.0% (0.0%, 0.0%) | 0/4771.7 = 0.0% (0.0%, 0.0%) |
| Male | Day 29 | Placebo | Positive | Anti N IgG (IU/ml) | 115 | 529.2/529.2 = 100.0% (100.0%, 100.0%) | 529.2/529.2 = 100.0% (100.0%, 100.0%) | 526.8/529.2 = 99.5% (96.7%, 99.9%) |
| Male | Day 29 | Placebo | Positive | Anti RBD IgG (IU/ml) | 115 | 529.2/529.2 = 100.0% (100.0%, 100.0%) | 529.2/529.2 = 100.0% (100.0%, 100.0%) | 529.2/529.2 = 100.0% (100.0%, 100.0%) |
| Male | Day 29 | Placebo | Positive | Anti Spike IgG (IU/ml) | 115 | 529.2/529.2 = 100.0% (100.0%, 100.0%) | 529.2/529.2 = 100.0% (100.0%, 100.0%) | 529.2/529.2 = 100.0% (100.0%, 100.0%) |
| Male | Day 57 | Vaccine | Negative | Anti N IgG (IU/ml) | 395 | 5298.6/5298.6 = 100.0% (100.0%, 100.0%) | 5298.6/5298.6 = 100.0% (100.0%, 100.0%) | 5298.6/5298.6 = 100.0% (100.0%, 100.0%) |
| Male | Day 57 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 395 | 5298.6/5298.6 = 100.0% (100.0%, 100.0%) | 5298.6/5298.6 = 100.0% (100.0%, 100.0%) | 5298.6/5298.6 = 100.0% (100.0%, 100.0%) |
| Male | Day 57 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 395 | 5298.6/5298.6 = 100.0% (100.0%, 100.0%) | 5298.6/5298.6 = 100.0% (100.0%, 100.0%) | 5298.6/5298.6 = 100.0% (100.0%, 100.0%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % Greater than 2 × LLOD | % Greater than 4 × LLOD |
|--------|--------|---------|---------------------|------------------------|-----|--|--|--|
| Male | Day 57 | Vaccine | Positive | Anti N IgG (IU/ml) | 121 | 564.7/564.7 = 100.0% (100.0%, 100.0%) | 564.7/564.7 = 100.0% (100.0%, 100.0%) | 564.7/564.7 = 100.0% (100.0%, 100.0%) |
| Male | Day 57 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 121 | 564.7/564.7 = 100.0% (100.0%, 100.0%) | 564.7/564.7 = 100.0% (100.0%, 100.0%) | 564.7/564.7 = 100.0% (100.0%, 100.0%) |
| Male | Day 57 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 121 | 564.7/564.7 = 100.0% (100.0%, 100.0%) | 564.7/564.7 = 100.0% (100.0%, 100.0%) | 564.7/564.7 = 100.0% (100.0%, 100.0%) |
| Male | Day 57 | Placebo | Negative | Anti N IgG (IU/ml) | 76 | 0/4771.7 = 0.0% (0.0%, 0.0%) | 0/4771.7 = 0.0% (0.0%, 0.0%) | 0/4771.7 = 0.0% (0.0%, 0.0%) |
| Male | Day 57 | Placebo | Negative | Anti RBD IgG (IU/ml) | 76 | 76.3/4771.7 = 1.6% (0.2%, 11.0%) | 0/4771.7 = 0.0% (0.0%, 0.0%) | 0/4771.7 = 0.0% (0.0%, 0.0%) |
| Male | Day 57 | Placebo | Negative | Anti Spike IgG (IU/ml) | 76 | 0/4771.7 = 0.0% (0.0%, 0.0%) | 0/4771.7 = 0.0% (0.0%, 0.0%) | 0/4771.7 = 0.0% (0.0%, 0.0%) |
| Male | Day 57 | Placebo | Positive | Anti N IgG (IU/ml) | 115 | 529.2/529.2 = 100.0% (100.0%, 100.0%) | 529.2/529.2 = 100.0% (100.0%, 100.0%) | 529.2/529.2 = 100.0% (100.0%, 100.0%) |
| Male | Day 57 | Placebo | Positive | Anti RBD IgG (IU/ml) | 115 | 529.2/529.2 = 100.0% (100.0%, 100.0%) | 529.2/529.2 = 100.0% (100.0%, 100.0%) | 529.2/529.2 = 100.0% (100.0%, 100.0%) |
| Male | Day 57 | Placebo | Positive | Anti Spike IgG (IU/ml) | 115 | 529.2/529.2 = 100.0% (100.0%, 100.0%) | 529.2/529.2 = 100.0% (100.0%, 100.0%) | 529.2/529.2 = 100.0% (100.0%, 100.0%) |
| Female | Day 29 | Vaccine | Negative | Anti N IgG (IU/ml) | 519 | 7996.4/7996.4 = 100.0% (100.0%, 100.0%) | 7969.4/7996.4 = 99.7% (97.6%, 100.0%) | 7969.4/7996.4 = 99.7% (97.6%, 100.0%) |
| Female | Day 29 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 519 | 7996.4/7996.4 = 100.0% (100.0%, 100.0%) | 7996.4/7996.4 = 100.0% (100.0%, 100.0%) | 7996.4/7996.4 = 100.0% (100.0%, 100.0%) |
| Female | Day 29 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 519 | 7996.4/7996.4 = 100.0% (100.0%, 100.0%) | 7996.4/7996.4 = 100.0% (100.0%, 100.0%) | 7996.4/7996.4 = 100.0% (100.0%, 100.0%) |
| Female | Day 29 | Vaccine | Positive | Anti N IgG (IU/ml) | 153 | 867.3/867.3 = 100.0% (100.0%, 100.0%) | 867.3/867.3 = 100.0% (100.0%, 100.0%) | 867.3/867.3 = 100.0% (100.0%, 100.0%) |
| Female | Day 29 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 153 | 867.3/867.3 = 100.0% (100.0%, 100.0%) | 867.3/867.3 = 100.0% (100.0%, 100.0%) | 867.3/867.3 = 100.0% (100.0%, 100.0%) |
| Female | Day 29 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 153 | 867.3/867.3 = 100.0% (100.0%, 100.0%) | 867.3/867.3 = 100.0% (100.0%, 100.0%) | 867.3/867.3 = 100.0% (100.0%, 100.0%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % Greater than 2 × LLOD | % Greater than 4 × LLOD |
|--------|--------|---------|---------------------|------------------------|-----|--|--|--|
| Female | Day 29 | Placebo | Negative | Anti N IgG (IU/ml) | 87 | 0/8587.3 = 0.0% (0.0%, 0.0%) | 0/8587.3 = 0.0% (0.0%, 0.0%) | 0/8587.3 = 0.0% (0.0%, 0.0%) |
| Female | Day 29 | Placebo | Negative | Anti RBD IgG (IU/ml) | 87 | 0/8587.3 = 0.0% (0.0%, 0.0%) | 0/8587.3 = 0.0% (0.0%, 0.0%) | 0/8587.3 = 0.0% (0.0%, 0.0%) |
| Female | Day 29 | Placebo | Negative | Anti Spike IgG (IU/ml) | 87 | 0/8587.3 = 0.0% (0.0%, 0.0%) | 0/8587.3 = 0.0% (0.0%, 0.0%) | 0/8587.3 = 0.0% (0.0%, 0.0%) |
| Female | Day 29 | Placebo | Positive | Anti N IgG (IU/ml) | 155 | 827.8/827.8 = 100.0% (100.0%, 100.0%) | 827.8/827.8 = 100.0% (100.0%, 100.0%) | 827.8/827.8 = 100.0% (100.0%, 100.0%) |
| Female | Day 29 | Placebo | Positive | Anti RBD IgG (IU/ml) | 155 | 827.8/827.8 = 100.0% (100.0%, 100.0%) | 827.8/827.8 = 100.0% (100.0%, 100.0%) | 827.8/827.8 = 100.0% (100.0%, 100.0%) |
| Female | Day 29 | Placebo | Positive | Anti Spike IgG (IU/ml) | 155 | 827.8/827.8 = 100.0% (100.0%, 100.0%) | 827.8/827.8 = 100.0% (100.0%, 100.0%) | 827.8/827.8 = 100.0% (100.0%, 100.0%) |
| Female | Day 57 | Vaccine | Negative | Anti N IgG (IU/ml) | 519 | 7996.4/7996.4 = 100.0% (100.0%, 100.0%) | 7996.4/7996.4 = 100.0% (100.0%, 100.0%) | 7996.4/7996.4 = 100.0% (100.0%, 100.0%) |
| Female | Day 57 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 519 | 7996.4/7996.4 = 100.0% (100.0%, 100.0%) | 7996.4/7996.4 = 100.0% (100.0%, 100.0%) | 7996.4/7996.4 = 100.0% (100.0%, 100.0%) |
| Female | Day 57 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 519 | 7996.4/7996.4 = 100.0% (100.0%, 100.0%) | 7996.4/7996.4 = 100.0% (100.0%, 100.0%) | 7996.4/7996.4 = 100.0% (100.0%, 100.0%) |
| Female | Day 57 | Vaccine | Positive | Anti N IgG (IU/ml) | 153 | 867.3/867.3 = 100.0% (100.0%, 100.0%) | 867.3/867.3 = 100.0% (100.0%, 100.0%) | 867.3/867.3 = 100.0% (100.0%, 100.0%) |
| Female | Day 57 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 153 | 867.3/867.3 = 100.0% (100.0%, 100.0%) | 867.3/867.3 = 100.0% (100.0%, 100.0%) | 867.3/867.3 = 100.0% (100.0%, 100.0%) |
| Female | Day 57 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 153 | 867.3/867.3 = 100.0% (100.0%, 100.0%) | 867.3/867.3 = 100.0% (100.0%, 100.0%) | 867.3/867.3 = 100.0% (100.0%, 100.0%) |
| Female | Day 57 | Placebo | Negative | Anti N IgG (IU/ml) | 87 | 0/8587.3 = 0.0% (0.0%, 0.0%) | 0/8587.3 = 0.0% (0.0%, 0.0%) | 0/8587.3 = 0.0% (0.0%, 0.0%) |
| Female | Day 57 | Placebo | Negative | Anti RBD IgG (IU/ml) | 87 | 0/8587.3 = 0.0% (0.0%, 0.0%) | 0/8587.3 = 0.0% (0.0%, 0.0%) | 0/8587.3 = 0.0% (0.0%, 0.0%) |
| Female | Day 57 | Placebo | Negative | Anti Spike IgG (IU/ml) | 87 | 0/8587.3 = 0.0% (0.0%, 0.0%) | 0/8587.3 = 0.0% (0.0%, 0.0%) | 0/8587.3 = 0.0% (0.0%, 0.0%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % Greater than 2 × LLOD | % Greater than 4 × LLOD |
|--------|--------|---------|---------------------|------------------------|-----|--|--|--|
| Female | Day 57 | Placebo | Positive | Anti N IgG (IU/ml) | 155 | 827.8/827.8 = 100.0% (100.0%, 100.0%) | 827.8/827.8 = 100.0% (100.0%, 100.0%) | 827.8/827.8 = 100.0% (100.0%, 100.0%) |
| Female | Day 57 | Placebo | Positive | Anti RBD IgG (IU/ml) | 155 | 827.8/827.8 = 100.0% (100.0%, 100.0%) | 827.8/827.8 = 100.0% (100.0%, 100.0%) | 827.8/827.8 = 100.0% (100.0%, 100.0%) |
| Female | Day 57 | Placebo | Positive | Anti Spike IgG (IU/ml) | 155 | 827.8/827.8 = 100.0% (100.0%, 100.0%) | 827.8/827.8 = 100.0% (100.0%, 100.0%) | 827.8/827.8 = 100.0% (100.0%, 100.0%) |

Binding Antibody Responders are defined as participants who had baseline values below the LLOD with detectable antibody concentration above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in antibody concentration.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 3f. Percentage of responders, and participants with concentrations $\geq 2 \times \text{LLOD}$ or $\geq 4 \times \text{LLOD}$ for binding antibody markers by Age, sex

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % Greater than $2 \times \text{LLOD}$ | % Greater than $4 \times \text{LLOD}$ |
|-----------------|--------|---------|---------------------|------------------------|-----|--|--|--|
| Age, sex | | | | | | | | |
| Age < 65 Female | Day 29 | Vaccine | Negative | Anti N IgG (IU/ml) | 269 | 6524.4/6524.4 = 100.0% (100.0%, 100.0%) | 6497.4/6524.4 = 99.6% (97.1%, 99.9%) | 6497.4/6524.4 = 99.6% (97.1%, 99.9%) |
| Age < 65 Female | Day 29 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 269 | 6524.4/6524.4 = 100.0% (100.0%, 100.0%) | 6524.4/6524.4 = 100.0% (100.0%, 100.0%) | 6524.4/6524.4 = 100.0% (100.0%, 100.0%) |
| Age < 65 Female | Day 29 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 269 | 6524.4/6524.4 = 100.0% (100.0%, 100.0%) | 6524.4/6524.4 = 100.0% (100.0%, 100.0%) | 6524.4/6524.4 = 100.0% (100.0%, 100.0%) |
| Age < 65 Female | Day 29 | Vaccine | Positive | Anti N IgG (IU/ml) | 79 | 701.8/701.8 = 100.0% (100.0%, 100.0%) | 701.8/701.8 = 100.0% (100.0%, 100.0%) | 701.8/701.8 = 100.0% (100.0%, 100.0%) |
| Age < 65 Female | Day 29 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 79 | 701.8/701.8 = 100.0% (100.0%, 100.0%) | 701.8/701.8 = 100.0% (100.0%, 100.0%) | 701.8/701.8 = 100.0% (100.0%, 100.0%) |
| Age < 65 Female | Day 29 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 79 | 701.8/701.8 = 100.0% (100.0%, 100.0%) | 701.8/701.8 = 100.0% (100.0%, 100.0%) | 701.8/701.8 = 100.0% (100.0%, 100.0%) |
| Age < 65 Female | Day 29 | Placebo | Negative | Anti N IgG (IU/ml) | 52 | 0/7188.8 = 0.0% (0.0%, 0.0%) | 0/7188.8 = 0.0% (0.0%, 0.0%) | 0/7188.8 = 0.0% (0.0%, 0.0%) |
| Age < 65 Female | Day 29 | Placebo | Negative | Anti RBD IgG (IU/ml) | 52 | 0/7188.8 = 0.0% (0.0%, 0.0%) | 0/7188.8 = 0.0% (0.0%, 0.0%) | 0/7188.8 = 0.0% (0.0%, 0.0%) |
| Age < 65 Female | Day 29 | Placebo | Negative | Anti Spike IgG (IU/ml) | 52 | 0/7188.8 = 0.0% (0.0%, 0.0%) | 0/7188.8 = 0.0% (0.0%, 0.0%) | 0/7188.8 = 0.0% (0.0%, 0.0%) |
| Age < 65 Female | Day 29 | Placebo | Positive | Anti N IgG (IU/ml) | 83 | 673.1/673.1 = 100.0% (100.0%, 100.0%) | 673.1/673.1 = 100.0% (100.0%, 100.0%) | 673.1/673.1 = 100.0% (100.0%, 100.0%) |
| Age < 65 Female | Day 29 | Placebo | Positive | Anti RBD IgG (IU/ml) | 83 | 673.1/673.1 = 100.0% (100.0%, 100.0%) | 673.1/673.1 = 100.0% (100.0%, 100.0%) | 673.1/673.1 = 100.0% (100.0%, 100.0%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % Greater than 2 × LLOD | % Greater than 4 × LLOD |
|-----------------|--------|---------|---------------------|------------------------|-----|---|---|---|
| Age < 65 Female | Day 29 | Placebo | Positive | Anti Spike IgG (IU/ml) | 83 | 673.1/673.1 = 100.0% (100.0%, 100.0%) | 673.1/673.1 = 100.0% (100.0%, 100.0%) | 673.1/673.1 = 100.0% (100.0%, 100.0%) |
| Age < 65 Female | Day 57 | Vaccine | Negative | Anti N IgG (IU/ml) | 269 | 6524.4/6524.4 = 100.0% (100.0%, 100.0%) | 6524.4/6524.4 = 100.0% (100.0%, 100.0%) | 6524.4/6524.4 = 100.0% (100.0%, 100.0%) |
| Age < 65 Female | Day 57 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 269 | 6524.4/6524.4 = 100.0% (100.0%, 100.0%) | 6524.4/6524.4 = 100.0% (100.0%, 100.0%) | 6524.4/6524.4 = 100.0% (100.0%, 100.0%) |
| Age < 65 Female | Day 57 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 269 | 6524.4/6524.4 = 100.0% (100.0%, 100.0%) | 6524.4/6524.4 = 100.0% (100.0%, 100.0%) | 6524.4/6524.4 = 100.0% (100.0%, 100.0%) |
| Age < 65 Female | Day 57 | Vaccine | Positive | Anti N IgG (IU/ml) | 79 | 701.8/701.8 = 100.0% (100.0%, 100.0%) | 701.8/701.8 = 100.0% (100.0%, 100.0%) | 701.8/701.8 = 100.0% (100.0%, 100.0%) |
| Age < 65 Female | Day 57 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 79 | 701.8/701.8 = 100.0% (100.0%, 100.0%) | 701.8/701.8 = 100.0% (100.0%, 100.0%) | 701.8/701.8 = 100.0% (100.0%, 100.0%) |
| Age < 65 Female | Day 57 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 79 | 701.8/701.8 = 100.0% (100.0%, 100.0%) | 701.8/701.8 = 100.0% (100.0%, 100.0%) | 701.8/701.8 = 100.0% (100.0%, 100.0%) |
| Age < 65 Female | Day 57 | Placebo | Negative | Anti N IgG (IU/ml) | 52 | 0/7188.8 = 0.0% (0.0%, 0.0%) | 0/7188.8 = 0.0% (0.0%, 0.0%) | 0/7188.8 = 0.0% (0.0%, 0.0%) |
| Age < 65 Female | Day 57 | Placebo | Negative | Anti RBD IgG (IU/ml) | 52 | 0/7188.8 = 0.0% (0.0%, 0.0%) | 0/7188.8 = 0.0% (0.0%, 0.0%) | 0/7188.8 = 0.0% (0.0%, 0.0%) |
| Age < 65 Female | Day 57 | Placebo | Negative | Anti Spike IgG (IU/ml) | 52 | 0/7188.8 = 0.0% (0.0%, 0.0%) | 0/7188.8 = 0.0% (0.0%, 0.0%) | 0/7188.8 = 0.0% (0.0%, 0.0%) |
| Age < 65 Female | Day 57 | Placebo | Positive | Anti N IgG (IU/ml) | 83 | 673.1/673.1 = 100.0% (100.0%, 100.0%) | 673.1/673.1 = 100.0% (100.0%, 100.0%) | 673.1/673.1 = 100.0% (100.0%, 100.0%) |
| Age < 65 Female | Day 57 | Placebo | Positive | Anti RBD IgG (IU/ml) | 83 | 673.1/673.1 = 100.0% (100.0%, 100.0%) | 673.1/673.1 = 100.0% (100.0%, 100.0%) | 673.1/673.1 = 100.0% (100.0%, 100.0%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % Greater than 2 × LLOD | % Greater than 4 × LLOD |
|-----------------|--------|---------|---------------------|------------------------|-----|--|--|--|
| Age < 65 Female | Day 57 | Placebo | Positive | Anti Spike IgG (IU/ml) | 83 | 673.1/673.1 = 100.0% (100.0%, 100.0%) | 673.1/673.1 = 100.0% (100.0%, 100.0%) | 673.1/673.1 = 100.0% (100.0%, 100.0%) |
| Age < 65 Male | Day 29 | Vaccine | Negative | Anti N IgG (IU/ml) | 163 | 3993.6/3993.6 = 100.0% (100.0%, 100.0%) | 3993.6/3993.6 = 100.0% (100.0%, 100.0%) | 3993.6/3993.6 = 100.0% (100.0%, 100.0%) |
| Age < 65 Male | Day 29 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 163 | 3993.6/3993.6 = 100.0% (100.0%, 100.0%) | 3993.6/3993.6 = 100.0% (100.0%, 100.0%) | 3993.6/3993.6 = 100.0% (100.0%, 100.0%) |
| Age < 65 Male | Day 29 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 163 | 3993.6/3993.6 = 100.0% (100.0%, 100.0%) | 3993.6/3993.6 = 100.0% (100.0%, 100.0%) | 3993.6/3993.6 = 100.0% (100.0%, 100.0%) |
| Age < 65 Male | Day 29 | Vaccine | Positive | Anti N IgG (IU/ml) | 67 | 443.2/443.2 = 100.0% (100.0%, 100.0%) | 443.2/443.2 = 100.0% (100.0%, 100.0%) | 443.2/443.2 = 100.0% (100.0%, 100.0%) |
| Age < 65 Male | Day 29 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 67 | 443.2/443.2 = 100.0% (100.0%, 100.0%) | 443.2/443.2 = 100.0% (100.0%, 100.0%) | 443.2/443.2 = 100.0% (100.0%, 100.0%) |
| Age < 65 Male | Day 29 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 67 | 443.2/443.2 = 100.0% (100.0%, 100.0%) | 443.2/443.2 = 100.0% (100.0%, 100.0%) | 443.2/443.2 = 100.0% (100.0%, 100.0%) |
| Age < 65 Male | Day 29 | Placebo | Negative | Anti N IgG (IU/ml) | 28 | 0/3045.2 = 0.0% (0.0%, 0.0%) | 0/3045.2 = 0.0% (0.0%, 0.0%) | 0/3045.2 = 0.0% (0.0%, 0.0%) |
| Age < 65 Male | Day 29 | Placebo | Negative | Anti RBD IgG (IU/ml) | 28 | 0/3045.2 = 0.0% (0.0%, 0.0%) | 0/3045.2 = 0.0% (0.0%, 0.0%) | 0/3045.2 = 0.0% (0.0%, 0.0%) |
| Age < 65 Male | Day 29 | Placebo | Negative | Anti Spike IgG (IU/ml) | 28 | 0/3045.2 = 0.0% (0.0%, 0.0%) | 0/3045.2 = 0.0% (0.0%, 0.0%) | 0/3045.2 = 0.0% (0.0%, 0.0%) |
| Age < 65 Male | Day 29 | Placebo | Positive | Anti N IgG (IU/ml) | 64 | 424.9/424.9 = 100.0% (100.0%, 100.0%) | 424.9/424.9 = 100.0% (100.0%, 100.0%) | 422.4/424.9 = 99.4% (95.8%, 99.9%) |
| Age < 65 Male | Day 29 | Placebo | Positive | Anti RBD IgG (IU/ml) | 64 | 424.9/424.9 = 100.0% (100.0%, 100.0%) | 424.9/424.9 = 100.0% (100.0%, 100.0%) | 424.9/424.9 = 100.0% (100.0%, 100.0%) |
| Age < 65 Male | Day 29 | Placebo | Positive | Anti Spike IgG (IU/ml) | 64 | 424.9/424.9 = 100.0% (100.0%, 100.0%) | 424.9/424.9 = 100.0% (100.0%, 100.0%) | 424.9/424.9 = 100.0% (100.0%, 100.0%) |
| Age < 65 Male | Day 57 | Vaccine | Negative | Anti N IgG (IU/ml) | 163 | 3993.6/3993.6 = 100.0% (100.0%, 100.0%) | 3993.6/3993.6 = 100.0% (100.0%, 100.0%) | 3993.6/3993.6 = 100.0% (100.0%, 100.0%) |
| Age < 65 Male | Day 57 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 163 | 3993.6/3993.6 = 100.0% (100.0%, 100.0%) | 3993.6/3993.6 = 100.0% (100.0%, 100.0%) | 3993.6/3993.6 = 100.0% (100.0%, 100.0%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % Greater than 2 × LLOD | % Greater than 4 × LLOD |
|---------------|--------|---------|---------------------|------------------------|-----|--|--|--|
| Age < 65 Male | Day 57 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 163 | 3993.6/3993.6 = 100.0% (100.0%, 100.0%) | 3993.6/3993.6 = 100.0% (100.0%, 100.0%) | 3993.6/3993.6 = 100.0% (100.0%, 100.0%) |
| Age < 65 Male | Day 57 | Vaccine | Positive | Anti N IgG (IU/ml) | 67 | 443.2/443.2 = 100.0% (100.0%, 100.0%) | 443.2/443.2 = 100.0% (100.0%, 100.0%) | 443.2/443.2 = 100.0% (100.0%, 100.0%) |
| Age < 65 Male | Day 57 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 67 | 443.2/443.2 = 100.0% (100.0%, 100.0%) | 443.2/443.2 = 100.0% (100.0%, 100.0%) | 443.2/443.2 = 100.0% (100.0%, 100.0%) |
| Age < 65 Male | Day 57 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 67 | 443.2/443.2 = 100.0% (100.0%, 100.0%) | 443.2/443.2 = 100.0% (100.0%, 100.0%) | 443.2/443.2 = 100.0% (100.0%, 100.0%) |
| Age < 65 Male | Day 57 | Placebo | Negative | Anti N IgG (IU/ml) | 28 | 0/3045.2 = 0.0% (0.0%, 0.0%) | 0/3045.2 = 0.0% (0.0%, 0.0%) | 0/3045.2 = 0.0% (0.0%, 0.0%) |
| Age < 65 Male | Day 57 | Placebo | Negative | Anti RBD IgG (IU/ml) | 28 | 76.3/3045.2 = 2.5% (0.3%, 17.6%) | 0/3045.2 = 0.0% (0.0%, 0.0%) | 0/3045.2 = 0.0% (0.0%, 0.0%) |
| Age < 65 Male | Day 57 | Placebo | Negative | Anti Spike IgG (IU/ml) | 28 | 0/3045.2 = 0.0% (0.0%, 0.0%) | 0/3045.2 = 0.0% (0.0%, 0.0%) | 0/3045.2 = 0.0% (0.0%, 0.0%) |
| Age < 65 Male | Day 57 | Placebo | Positive | Anti N IgG (IU/ml) | 64 | 424.9/424.9 = 100.0% (100.0%, 100.0%) | 424.9/424.9 = 100.0% (100.0%, 100.0%) | 424.9/424.9 = 100.0% (100.0%, 100.0%) |
| Age < 65 Male | Day 57 | Placebo | Positive | Anti RBD IgG (IU/ml) | 64 | 424.9/424.9 = 100.0% (100.0%, 100.0%) | 424.9/424.9 = 100.0% (100.0%, 100.0%) | 424.9/424.9 = 100.0% (100.0%, 100.0%) |
| Age < 65 Male | Day 57 | Placebo | Positive | Anti Spike IgG (IU/ml) | 64 | 424.9/424.9 = 100.0% (100.0%, 100.0%) | 424.9/424.9 = 100.0% (100.0%, 100.0%) | 424.9/424.9 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 Male | Day 29 | Vaccine | Negative | Anti N IgG (IU/ml) | 232 | 1305/1305 = 100.0% (100.0%, 100.0%) | 1305/1305 = 100.0% (100.0%, 100.0%) | 1305/1305 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 Male | Day 29 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 232 | 1305/1305 = 100.0% (100.0%, 100.0%) | 1305/1305 = 100.0% (100.0%, 100.0%) | 1305/1305 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 Male | Day 29 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 232 | 1305/1305 = 100.0% (100.0%, 100.0%) | 1305/1305 = 100.0% (100.0%, 100.0%) | 1305/1305 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 Male | Day 29 | Vaccine | Positive | Anti N IgG (IU/ml) | 54 | 121.5/121.5 = 100.0% (100.0%, 100.0%) | 121.5/121.5 = 100.0% (100.0%, 100.0%) | 121.5/121.5 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 Male | Day 29 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 54 | 121.5/121.5 = 100.0% (100.0%, 100.0%) | 121.5/121.5 = 100.0% (100.0%, 100.0%) | 121.5/121.5 = 100.0% (100.0%, 100.0%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % Greater than 2 × LLOD | % Greater than 4 × LLOD |
|---------------|--------|---------|---------------------|------------------------|-----|--|--|--|
| Age ≥ 65 Male | Day 29 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 54 | 121.5/121.5 = 100.0% (100.0%, 100.0%) | 121.5/121.5 = 100.0% (100.0%, 100.0%) | 121.5/121.5 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 Male | Day 29 | Placebo | Negative | Anti N IgG (IU/ml) | 48 | 0/1726.6 = 0.0% (0.0%, 0.0%) | 0/1726.6 = 0.0% (0.0%, 0.0%) | 0/1726.6 = 0.0% (0.0%, 0.0%) |
| Age ≥ 65 Male | Day 29 | Placebo | Negative | Anti RBD IgG (IU/ml) | 48 | 0/1726.6 = 0.0% (0.0%, 0.0%) | 0/1726.6 = 0.0% (0.0%, 0.0%) | 0/1726.6 = 0.0% (0.0%, 0.0%) |
| Age ≥ 65 Male | Day 29 | Placebo | Negative | Anti Spike IgG (IU/ml) | 48 | 0/1726.6 = 0.0% (0.0%, 0.0%) | 0/1726.6 = 0.0% (0.0%, 0.0%) | 0/1726.6 = 0.0% (0.0%, 0.0%) |
| Age ≥ 65 Male | Day 29 | Placebo | Positive | Anti N IgG (IU/ml) | 51 | 104.4/104.4 = 100.0% (100.0%, 100.0%) | 104.4/104.4 = 100.0% (100.0%, 100.0%) | 104.4/104.4 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 Male | Day 29 | Placebo | Positive | Anti RBD IgG (IU/ml) | 51 | 104.4/104.4 = 100.0% (100.0%, 100.0%) | 104.4/104.4 = 100.0% (100.0%, 100.0%) | 104.4/104.4 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 Male | Day 29 | Placebo | Positive | Anti Spike IgG (IU/ml) | 51 | 104.4/104.4 = 100.0% (100.0%, 100.0%) | 104.4/104.4 = 100.0% (100.0%, 100.0%) | 104.4/104.4 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 Male | Day 57 | Vaccine | Negative | Anti N IgG (IU/ml) | 232 | 1305/1305 = 100.0% (100.0%, 100.0%) | 1305/1305 = 100.0% (100.0%, 100.0%) | 1305/1305 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 Male | Day 57 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 232 | 1305/1305 = 100.0% (100.0%, 100.0%) | 1305/1305 = 100.0% (100.0%, 100.0%) | 1305/1305 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 Male | Day 57 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 232 | 1305/1305 = 100.0% (100.0%, 100.0%) | 1305/1305 = 100.0% (100.0%, 100.0%) | 1305/1305 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 Male | Day 57 | Vaccine | Positive | Anti N IgG (IU/ml) | 54 | 121.5/121.5 = 100.0% (100.0%, 100.0%) | 121.5/121.5 = 100.0% (100.0%, 100.0%) | 121.5/121.5 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 Male | Day 57 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 54 | 121.5/121.5 = 100.0% (100.0%, 100.0%) | 121.5/121.5 = 100.0% (100.0%, 100.0%) | 121.5/121.5 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 Male | Day 57 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 54 | 121.5/121.5 = 100.0% (100.0%, 100.0%) | 121.5/121.5 = 100.0% (100.0%, 100.0%) | 121.5/121.5 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 Male | Day 57 | Placebo | Negative | Anti N IgG (IU/ml) | 48 | 0/1726.6 = 0.0% (0.0%, 0.0%) | 0/1726.6 = 0.0% (0.0%, 0.0%) | 0/1726.6 = 0.0% (0.0%, 0.0%) |
| Age ≥ 65 Male | Day 57 | Placebo | Negative | Anti RBD IgG (IU/ml) | 48 | 0/1726.6 = 0.0% (0.0%, 0.0%) | 0/1726.6 = 0.0% (0.0%, 0.0%) | 0/1726.6 = 0.0% (0.0%, 0.0%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % Greater than 2 × LLOD | % Greater than 4 × LLOD |
|-----------------|--------|---------|---------------------|------------------------|-----|--|--|--|
| Age ≥ 65 Male | Day 57 | Placebo | Negative | Anti Spike IgG (IU/ml) | 48 | 0/1726.6 = 0.0% (0.0%, 0.0%) | 0/1726.6 = 0.0% (0.0%, 0.0%) | 0/1726.6 = 0.0% (0.0%, 0.0%) |
| Age ≥ 65 Male | Day 57 | Placebo | Positive | Anti N IgG (IU/ml) | 51 | 104.4/104.4 = 100.0% (100.0%, 100.0%) | 104.4/104.4 = 100.0% (100.0%, 100.0%) | 104.4/104.4 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 Male | Day 57 | Placebo | Positive | Anti RBD IgG (IU/ml) | 51 | 104.4/104.4 = 100.0% (100.0%, 100.0%) | 104.4/104.4 = 100.0% (100.0%, 100.0%) | 104.4/104.4 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 Male | Day 57 | Placebo | Positive | Anti Spike IgG (IU/ml) | 51 | 104.4/104.4 = 100.0% (100.0%, 100.0%) | 104.4/104.4 = 100.0% (100.0%, 100.0%) | 104.4/104.4 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 Female | Day 29 | Vaccine | Negative | Anti N IgG (IU/ml) | 250 | 1472/1472 = 100.0% (100.0%, 100.0%) | 1472/1472 = 100.0% (100.0%, 100.0%) | 1472/1472 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 Female | Day 29 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 250 | 1472/1472 = 100.0% (100.0%, 100.0%) | 1472/1472 = 100.0% (100.0%, 100.0%) | 1472/1472 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 Female | Day 29 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 250 | 1472/1472 = 100.0% (100.0%, 100.0%) | 1472/1472 = 100.0% (100.0%, 100.0%) | 1472/1472 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 Female | Day 29 | Vaccine | Positive | Anti N IgG (IU/ml) | 74 | 165.5/165.5 = 100.0% (100.0%, 100.0%) | 165.5/165.5 = 100.0% (100.0%, 100.0%) | 165.5/165.5 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 Female | Day 29 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 74 | 165.5/165.5 = 100.0% (100.0%, 100.0%) | 165.5/165.5 = 100.0% (100.0%, 100.0%) | 165.5/165.5 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 Female | Day 29 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 74 | 165.5/165.5 = 100.0% (100.0%, 100.0%) | 165.5/165.5 = 100.0% (100.0%, 100.0%) | 165.5/165.5 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 Female | Day 29 | Placebo | Negative | Anti N IgG (IU/ml) | 35 | 0/1398.4 = 0.0% (0.0%, 0.0%) | 0/1398.4 = 0.0% (0.0%, 0.0%) | 0/1398.4 = 0.0% (0.0%, 0.0%) |
| Age ≥ 65 Female | Day 29 | Placebo | Negative | Anti RBD IgG (IU/ml) | 35 | 0/1398.4 = 0.0% (0.0%, 0.0%) | 0/1398.4 = 0.0% (0.0%, 0.0%) | 0/1398.4 = 0.0% (0.0%, 0.0%) |
| Age ≥ 65 Female | Day 29 | Placebo | Negative | Anti Spike IgG (IU/ml) | 35 | 0/1398.4 = 0.0% (0.0%, 0.0%) | 0/1398.4 = 0.0% (0.0%, 0.0%) | 0/1398.4 = 0.0% (0.0%, 0.0%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % Greater than 2 × LLOD | % Greater than 4 × LLOD |
|-----------------|--------|---------|---------------------|------------------------|-----|--|--|--|
| Age ≥ 65 Female | Day 29 | Placebo | Positive | Anti N IgG (IU/ml) | 72 | 154.6/154.6 = 100.0% (100.0%, 100.0%) | 154.6/154.6 = 100.0% (100.0%, 100.0%) | 154.6/154.6 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 Female | Day 29 | Placebo | Positive | Anti RBD IgG (IU/ml) | 72 | 154.6/154.6 = 100.0% (100.0%, 100.0%) | 154.6/154.6 = 100.0% (100.0%, 100.0%) | 154.6/154.6 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 Female | Day 29 | Placebo | Positive | Anti Spike IgG (IU/ml) | 72 | 154.6/154.6 = 100.0% (100.0%, 100.0%) | 154.6/154.6 = 100.0% (100.0%, 100.0%) | 154.6/154.6 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 Female | Day 57 | Vaccine | Negative | Anti N IgG (IU/ml) | 250 | 1472/1472 = 100.0% (100.0%, 100.0%) | 1472/1472 = 100.0% (100.0%, 100.0%) | 1472/1472 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 Female | Day 57 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 250 | 1472/1472 = 100.0% (100.0%, 100.0%) | 1472/1472 = 100.0% (100.0%, 100.0%) | 1472/1472 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 Female | Day 57 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 250 | 1472/1472 = 100.0% (100.0%, 100.0%) | 1472/1472 = 100.0% (100.0%, 100.0%) | 1472/1472 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 Female | Day 57 | Vaccine | Positive | Anti N IgG (IU/ml) | 74 | 165.5/165.5 = 100.0% (100.0%, 100.0%) | 165.5/165.5 = 100.0% (100.0%, 100.0%) | 165.5/165.5 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 Female | Day 57 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 74 | 165.5/165.5 = 100.0% (100.0%, 100.0%) | 165.5/165.5 = 100.0% (100.0%, 100.0%) | 165.5/165.5 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 Female | Day 57 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 74 | 165.5/165.5 = 100.0% (100.0%, 100.0%) | 165.5/165.5 = 100.0% (100.0%, 100.0%) | 165.5/165.5 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 Female | Day 57 | Placebo | Negative | Anti N IgG (IU/ml) | 35 | 0/1398.4 = 0.0% (0.0%, 0.0%) | 0/1398.4 = 0.0% (0.0%, 0.0%) | 0/1398.4 = 0.0% (0.0%, 0.0%) |
| Age ≥ 65 Female | Day 57 | Placebo | Negative | Anti RBD IgG (IU/ml) | 35 | 0/1398.4 = 0.0% (0.0%, 0.0%) | 0/1398.4 = 0.0% (0.0%, 0.0%) | 0/1398.4 = 0.0% (0.0%, 0.0%) |
| Age ≥ 65 Female | Day 57 | Placebo | Negative | Anti Spike IgG (IU/ml) | 35 | 0/1398.4 = 0.0% (0.0%, 0.0%) | 0/1398.4 = 0.0% (0.0%, 0.0%) | 0/1398.4 = 0.0% (0.0%, 0.0%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % Greater than 2 × LLOD | % Greater than 4 × LLOD |
|-----------------|--------|---------|---------------------|------------------------|----|--|--|--|
| Age ≥ 65 Female | Day 57 | Placebo | Positive | Anti N IgG (IU/ml) | 72 | 154.6/154.6 = 100.0% (100.0%, 100.0%) | 154.6/154.6 = 100.0% (100.0%, 100.0%) | 154.6/154.6 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 Female | Day 57 | Placebo | Positive | Anti RBD IgG (IU/ml) | 72 | 154.6/154.6 = 100.0% (100.0%, 100.0%) | 154.6/154.6 = 100.0% (100.0%, 100.0%) | 154.6/154.6 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 Female | Day 57 | Placebo | Positive | Anti Spike IgG (IU/ml) | 72 | 154.6/154.6 = 100.0% (100.0%, 100.0%) | 154.6/154.6 = 100.0% (100.0%, 100.0%) | 154.6/154.6 = 100.0% (100.0%, 100.0%) |

Binding Antibody Responders are defined as participants who had baseline values below the LLOD with detectable antibody concentration above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in antibody concentration.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 3g. Percentage of responders, and participants with concentrations $\geq 2 \times LLOD$ or $\geq 4 \times LLOD$ for binding antibody markers by Hispanic or Latino ethnicity

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % Greater than $2 \times LLOD$ | % Greater than $4 \times LLOD$ |
|-------------------------------------|--------|---------|---------------------|------------------------|-----|--|--|--|
| Hispanic or Latino ethnicity | | | | | | | | |
| Hispanic or Latino | Day 29 | Vaccine | Negative | Anti N IgG (IU/ml) | 136 | 1363.4/1363.4 = 100.0% (100.0%, 100.0%) | 1363.4/1363.4 = 100.0% (100.0%, 100.0%) | 1363.4/1363.4 = 100.0% (100.0%, 100.0%) |
| Hispanic or Latino | Day 29 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 136 | 1363.4/1363.4 = 100.0% (100.0%, 100.0%) | 1363.4/1363.4 = 100.0% (100.0%, 100.0%) | 1363.4/1363.4 = 100.0% (100.0%, 100.0%) |
| Hispanic or Latino | Day 29 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 136 | 1363.4/1363.4 = 100.0% (100.0%, 100.0%) | 1363.4/1363.4 = 100.0% (100.0%, 100.0%) | 1363.4/1363.4 = 100.0% (100.0%, 100.0%) |
| Hispanic or Latino | Day 29 | Vaccine | Positive | Anti N IgG (IU/ml) | 35 | 145.7/145.7 = 100.0% (100.0%, 100.0%) | 145.7/145.7 = 100.0% (100.0%, 100.0%) | 145.7/145.7 = 100.0% (100.0%, 100.0%) |
| Hispanic or Latino | Day 29 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 35 | 145.7/145.7 = 100.0% (100.0%, 100.0%) | 145.7/145.7 = 100.0% (100.0%, 100.0%) | 145.7/145.7 = 100.0% (100.0%, 100.0%) |
| Hispanic or Latino | Day 29 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 35 | 145.7/145.7 = 100.0% (100.0%, 100.0%) | 145.7/145.7 = 100.0% (100.0%, 100.0%) | 145.7/145.7 = 100.0% (100.0%, 100.0%) |
| Hispanic or Latino | Day 29 | Placebo | Negative | Anti N IgG (IU/ml) | 20 | 0/1237.6 = 0.0% (0.0%, 0.0%) | 0/1237.6 = 0.0% (0.0%, 0.0%) | 0/1237.6 = 0.0% (0.0%, 0.0%) |
| Hispanic or Latino | Day 29 | Placebo | Negative | Anti RBD IgG (IU/ml) | 20 | 0/1237.6 = 0.0% (0.0%, 0.0%) | 0/1237.6 = 0.0% (0.0%, 0.0%) | 0/1237.6 = 0.0% (0.0%, 0.0%) |
| Hispanic or Latino | Day 29 | Placebo | Negative | Anti Spike IgG (IU/ml) | 20 | 0/1237.6 = 0.0% (0.0%, 0.0%) | 0/1237.6 = 0.0% (0.0%, 0.0%) | 0/1237.6 = 0.0% (0.0%, 0.0%) |
| Hispanic or Latino | Day 29 | Placebo | Positive | Anti N IgG (IU/ml) | 38 | 133.7/133.7 = 100.0% (100.0%, 100.0%) | 133.7/133.7 = 100.0% (100.0%, 100.0%) | 133.7/133.7 = 100.0% (100.0%, 100.0%) |
| Hispanic or Latino | Day 29 | Placebo | Positive | Anti RBD IgG (IU/ml) | 38 | 133.7/133.7 = 100.0% (100.0%, 100.0%) | 133.7/133.7 = 100.0% (100.0%, 100.0%) | 133.7/133.7 = 100.0% (100.0%, 100.0%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % Greater than 2 × LLOD | % Greater than 4 × LLOD |
|--------------------|--------|---------|---------------------|------------------------|-----|--|--|--|
| Hispanic or Latino | Day 29 | Placebo | Positive | Anti Spike IgG (IU/ml) | 38 | 133.7/133.7 = 100.0% (100.0%, 100.0%) | 133.7/133.7 = 100.0% (100.0%, 100.0%) | 133.7/133.7 = 100.0% (100.0%, 100.0%) |
| Hispanic or Latino | Day 57 | Vaccine | Negative | Anti N IgG (IU/ml) | 136 | 1363.4/1363.4 = 100.0% (100.0%, 100.0%) | 1363.4/1363.4 = 100.0% (100.0%, 100.0%) | 1363.4/1363.4 = 100.0% (100.0%, 100.0%) |
| Hispanic or Latino | Day 57 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 136 | 1363.4/1363.4 = 100.0% (100.0%, 100.0%) | 1363.4/1363.4 = 100.0% (100.0%, 100.0%) | 1363.4/1363.4 = 100.0% (100.0%, 100.0%) |
| Hispanic or Latino | Day 57 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 136 | 1363.4/1363.4 = 100.0% (100.0%, 100.0%) | 1363.4/1363.4 = 100.0% (100.0%, 100.0%) | 1363.4/1363.4 = 100.0% (100.0%, 100.0%) |
| Hispanic or Latino | Day 57 | Vaccine | Positive | Anti N IgG (IU/ml) | 35 | 145.7/145.7 = 100.0% (100.0%, 100.0%) | 145.7/145.7 = 100.0% (100.0%, 100.0%) | 145.7/145.7 = 100.0% (100.0%, 100.0%) |
| Hispanic or Latino | Day 57 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 35 | 145.7/145.7 = 100.0% (100.0%, 100.0%) | 145.7/145.7 = 100.0% (100.0%, 100.0%) | 145.7/145.7 = 100.0% (100.0%, 100.0%) |
| Hispanic or Latino | Day 57 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 35 | 145.7/145.7 = 100.0% (100.0%, 100.0%) | 145.7/145.7 = 100.0% (100.0%, 100.0%) | 145.7/145.7 = 100.0% (100.0%, 100.0%) |
| Hispanic or Latino | Day 57 | Placebo | Negative | Anti N IgG (IU/ml) | 20 | 0/1237.6 = 0.0% (0.0%, 0.0%) | 0/1237.6 = 0.0% (0.0%, 0.0%) | 0/1237.6 = 0.0% (0.0%, 0.0%) |
| Hispanic or Latino | Day 57 | Placebo | Negative | Anti RBD IgG (IU/ml) | 20 | 0/1237.6 = 0.0% (0.0%, 0.0%) | 0/1237.6 = 0.0% (0.0%, 0.0%) | 0/1237.6 = 0.0% (0.0%, 0.0%) |
| Hispanic or Latino | Day 57 | Placebo | Negative | Anti Spike IgG (IU/ml) | 20 | 0/1237.6 = 0.0% (0.0%, 0.0%) | 0/1237.6 = 0.0% (0.0%, 0.0%) | 0/1237.6 = 0.0% (0.0%, 0.0%) |
| Hispanic or Latino | Day 57 | Placebo | Positive | Anti N IgG (IU/ml) | 38 | 133.7/133.7 = 100.0% (100.0%, 100.0%) | 133.7/133.7 = 100.0% (100.0%, 100.0%) | 133.7/133.7 = 100.0% (100.0%, 100.0%) |
| Hispanic or Latino | Day 57 | Placebo | Positive | Anti RBD IgG (IU/ml) | 38 | 133.7/133.7 = 100.0% (100.0%, 100.0%) | 133.7/133.7 = 100.0% (100.0%, 100.0%) | 133.7/133.7 = 100.0% (100.0%, 100.0%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % Greater than 2 × LLOD | % Greater than 4 × LLOD |
|------------------------|--------|---------|---------------------|------------------------|-----|--|--|--|
| Hispanic or Latino | Day 57 | Placebo | Positive | Anti Spike IgG (IU/ml) | 38 | 133.7/133.7 = 100.0% (100.0%, 100.0%) | 133.7/133.7 = 100.0% (100.0%, 100.0%) | 133.7/133.7 = 100.0% (100.0%, 100.0%) |
| Not Hispanic or Latino | Day 29 | Vaccine | Negative | Anti N IgG (IU/ml) | 690 | 10481.2/10481.2 = 100.0% (100.0%, 100.0%) | 10454.2/10481.2 = 99.7% (98.2%, 100.0%) | 10454.2/10481.2 = 99.7% (98.2%, 100.0%) |
| Not Hispanic or Latino | Day 29 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 690 | 10481.2/10481.2 = 100.0% (100.0%, 100.0%) | 10481.2/10481.2 = 100.0% (100.0%, 100.0%) | 10481.2/10481.2 = 100.0% (100.0%, 100.0%) |
| Not Hispanic or Latino | Day 29 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 690 | 10481.2/10481.2 = 100.0% (100.0%, 100.0%) | 10481.2/10481.2 = 100.0% (100.0%, 100.0%) | 10481.2/10481.2 = 100.0% (100.0%, 100.0%) |
| Not Hispanic or Latino | Day 29 | Vaccine | Positive | Anti N IgG (IU/ml) | 217 | 1162.3/1162.3 = 100.0% (100.0%, 100.0%) | 1162.3/1162.3 = 100.0% (100.0%, 100.0%) | 1162.3/1162.3 = 100.0% (100.0%, 100.0%) |
| Not Hispanic or Latino | Day 29 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 217 | 1162.3/1162.3 = 100.0% (100.0%, 100.0%) | 1162.3/1162.3 = 100.0% (100.0%, 100.0%) | 1162.3/1162.3 = 100.0% (100.0%, 100.0%) |
| Not Hispanic or Latino | Day 29 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 217 | 1162.3/1162.3 = 100.0% (100.0%, 100.0%) | 1162.3/1162.3 = 100.0% (100.0%, 100.0%) | 1162.3/1162.3 = 100.0% (100.0%, 100.0%) |
| Not Hispanic or Latino | Day 29 | Placebo | Negative | Anti N IgG (IU/ml) | 130 | 0/10828.8 = 0.0% (0.0%, 0.0%) | 0/10828.8 = 0.0% (0.0%, 0.0%) | 0/10828.8 = 0.0% (0.0%, 0.0%) |
| Not Hispanic or Latino | Day 29 | Placebo | Negative | Anti RBD IgG (IU/ml) | 130 | 0/10828.8 = 0.0% (0.0%, 0.0%) | 0/10828.8 = 0.0% (0.0%, 0.0%) | 0/10828.8 = 0.0% (0.0%, 0.0%) |
| Not Hispanic or Latino | Day 29 | Placebo | Negative | Anti Spike IgG (IU/ml) | 130 | 0/10828.8 = 0.0% (0.0%, 0.0%) | 0/10828.8 = 0.0% (0.0%, 0.0%) | 0/10828.8 = 0.0% (0.0%, 0.0%) |
| Not Hispanic or Latino | Day 29 | Placebo | Positive | Anti N IgG (IU/ml) | 214 | 1121.8/1121.8 = 100.0% (100.0%, 100.0%) | 1121.8/1121.8 = 100.0% (100.0%, 100.0%) | 1119.3/1121.8 = 99.8% (98.4%, 100.0%) |
| Not Hispanic or Latino | Day 29 | Placebo | Positive | Anti RBD IgG (IU/ml) | 214 | 1121.8/1121.8 = 100.0% (100.0%, 100.0%) | 1121.8/1121.8 = 100.0% (100.0%, 100.0%) | 1121.8/1121.8 = 100.0% (100.0%, 100.0%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % Greater than 2 × LLOD | % Greater than 4 × LLOD |
|------------------------|--------|---------|---------------------|------------------------|-----|--|--|--|
| Not Hispanic or Latino | Day 29 | Placebo | Positive | Anti Spike IgG (IU/ml) | 214 | 1121.8/1121.8 = 100.0% (100.0%, 100.0%) | 1121.8/1121.8 = 100.0% (100.0%, 100.0%) | 1121.8/1121.8 = 100.0% (100.0%, 100.0%) |
| Not Hispanic or Latino | Day 57 | Vaccine | Negative | Anti N IgG (IU/ml) | 690 | 10481.2/10481.2 = 100.0% (100.0%, 100.0%) | 10481.2/10481.2 = 100.0% (100.0%, 100.0%) | 10481.2/10481.2 = 100.0% (100.0%, 100.0%) |
| Not Hispanic or Latino | Day 57 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 690 | 10481.2/10481.2 = 100.0% (100.0%, 100.0%) | 10481.2/10481.2 = 100.0% (100.0%, 100.0%) | 10481.2/10481.2 = 100.0% (100.0%, 100.0%) |
| Not Hispanic or Latino | Day 57 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 690 | 10481.2/10481.2 = 100.0% (100.0%, 100.0%) | 10481.2/10481.2 = 100.0% (100.0%, 100.0%) | 10481.2/10481.2 = 100.0% (100.0%, 100.0%) |
| Not Hispanic or Latino | Day 57 | Vaccine | Positive | Anti N IgG (IU/ml) | 217 | 1162.3/1162.3 = 100.0% (100.0%, 100.0%) | 1162.3/1162.3 = 100.0% (100.0%, 100.0%) | 1162.3/1162.3 = 100.0% (100.0%, 100.0%) |
| Not Hispanic or Latino | Day 57 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 217 | 1162.3/1162.3 = 100.0% (100.0%, 100.0%) | 1162.3/1162.3 = 100.0% (100.0%, 100.0%) | 1162.3/1162.3 = 100.0% (100.0%, 100.0%) |
| Not Hispanic or Latino | Day 57 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 217 | 1162.3/1162.3 = 100.0% (100.0%, 100.0%) | 1162.3/1162.3 = 100.0% (100.0%, 100.0%) | 1162.3/1162.3 = 100.0% (100.0%, 100.0%) |
| Not Hispanic or Latino | Day 57 | Placebo | Negative | Anti N IgG (IU/ml) | 130 | 0/10828.8 = 0.0% (0.0%, 0.0%) | 0/10828.8 = 0.0% (0.0%, 0.0%) | 0/10828.8 = 0.0% (0.0%, 0.0%) |
| Not Hispanic or Latino | Day 57 | Placebo | Negative | Anti RBD IgG (IU/ml) | 130 | 76.3/10828.8 = 0.7% (0.1%, 4.9%) | 0/10828.8 = 0.0% (0.0%, 0.0%) | 0/10828.8 = 0.0% (0.0%, 0.0%) |
| Not Hispanic or Latino | Day 57 | Placebo | Negative | Anti Spike IgG (IU/ml) | 130 | 0/10828.8 = 0.0% (0.0%, 0.0%) | 0/10828.8 = 0.0% (0.0%, 0.0%) | 0/10828.8 = 0.0% (0.0%, 0.0%) |
| Not Hispanic or Latino | Day 57 | Placebo | Positive | Anti N IgG (IU/ml) | 214 | 1121.8/1121.8 = 100.0% (100.0%, 100.0%) | 1121.8/1121.8 = 100.0% (100.0%, 100.0%) | 1121.8/1121.8 = 100.0% (100.0%, 100.0%) |
| Not Hispanic or Latino | Day 57 | Placebo | Positive | Anti RBD IgG (IU/ml) | 214 | 1121.8/1121.8 = 100.0% (100.0%, 100.0%) | 1121.8/1121.8 = 100.0% (100.0%, 100.0%) | 1121.8/1121.8 = 100.0% (100.0%, 100.0%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % Greater than 2 × LLOD | % Greater than 4 × LLOD |
|--------------------------|--------|---------|---------------------|------------------------|-----|--|--|--|
| Not Hispanic or Latino | Day 57 | Placebo | Positive | Anti Spike IgG (IU/ml) | 214 | 1121.8/1121.8 = 100.0% (100.0%, 100.0%) | 1121.8/1121.8 = 100.0% (100.0%, 100.0%) | 1121.8/1121.8 = 100.0% (100.0%, 100.0%) |
| Not reported and unknown | Day 29 | Vaccine | Negative | Anti N IgG (IU/ml) | 88 | 1450.4/1450.4 = 100.0% (100.0%, 100.0%) | 1450.4/1450.4 = 100.0% (100.0%, 100.0%) | 1450.4/1450.4 = 100.0% (100.0%, 100.0%) |
| Not reported and unknown | Day 29 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 88 | 1450.4/1450.4 = 100.0% (100.0%, 100.0%) | 1450.4/1450.4 = 100.0% (100.0%, 100.0%) | 1450.4/1450.4 = 100.0% (100.0%, 100.0%) |
| Not reported and unknown | Day 29 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 88 | 1450.4/1450.4 = 100.0% (100.0%, 100.0%) | 1450.4/1450.4 = 100.0% (100.0%, 100.0%) | 1450.4/1450.4 = 100.0% (100.0%, 100.0%) |
| Not reported and unknown | Day 29 | Vaccine | Positive | Anti N IgG (IU/ml) | 22 | 124/124 = 100.0% (100.0%, 100.0%) | 124/124 = 100.0% (100.0%, 100.0%) | 124/124 = 100.0% (100.0%, 100.0%) |
| Not reported and unknown | Day 29 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 22 | 124/124 = 100.0% (100.0%, 100.0%) | 124/124 = 100.0% (100.0%, 100.0%) | 124/124 = 100.0% (100.0%, 100.0%) |
| Not reported and unknown | Day 29 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 22 | 124/124 = 100.0% (100.0%, 100.0%) | 124/124 = 100.0% (100.0%, 100.0%) | 124/124 = 100.0% (100.0%, 100.0%) |
| Not reported and unknown | Day 29 | Placebo | Negative | Anti N IgG (IU/ml) | 13 | 0/1292.7 = 0.0% (0.0%, 0.0%) | 0/1292.7 = 0.0% (0.0%, 0.0%) | 0/1292.7 = 0.0% (0.0%, 0.0%) |
| Not reported and unknown | Day 29 | Placebo | Negative | Anti RBD IgG (IU/ml) | 13 | 0/1292.7 = 0.0% (0.0%, 0.0%) | 0/1292.7 = 0.0% (0.0%, 0.0%) | 0/1292.7 = 0.0% (0.0%, 0.0%) |
| Not reported and unknown | Day 29 | Placebo | Negative | Anti Spike IgG (IU/ml) | 13 | 0/1292.7 = 0.0% (0.0%, 0.0%) | 0/1292.7 = 0.0% (0.0%, 0.0%) | 0/1292.7 = 0.0% (0.0%, 0.0%) |
| Not reported and unknown | Day 29 | Placebo | Positive | Anti N IgG (IU/ml) | 18 | 101.5/101.5 = 100.0% (100.0%, 100.0%) | 101.5/101.5 = 100.0% (100.0%, 100.0%) | 101.5/101.5 = 100.0% (100.0%, 100.0%) |
| Not reported and unknown | Day 29 | Placebo | Positive | Anti RBD IgG (IU/ml) | 18 | 101.5/101.5 = 100.0% (100.0%, 100.0%) | 101.5/101.5 = 100.0% (100.0%, 100.0%) | 101.5/101.5 = 100.0% (100.0%, 100.0%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % Greater than 2 × LLOD | % Greater than 4 × LLOD |
|--------------------------|--------|---------|---------------------|------------------------|----|--|--|--|
| Not reported and unknown | Day 29 | Placebo | Positive | Anti Spike IgG (IU/ml) | 18 | 101.5/101.5 = 100.0% (100.0%, 100.0%) | 101.5/101.5 = 100.0% (100.0%, 100.0%) | 101.5/101.5 = 100.0% (100.0%, 100.0%) |
| Not reported and unknown | Day 57 | Vaccine | Negative | Anti N IgG (IU/ml) | 88 | 1450.4/1450.4 = 100.0% (100.0%, 100.0%) | 1450.4/1450.4 = 100.0% (100.0%, 100.0%) | 1450.4/1450.4 = 100.0% (100.0%, 100.0%) |
| Not reported and unknown | Day 57 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 88 | 1450.4/1450.4 = 100.0% (100.0%, 100.0%) | 1450.4/1450.4 = 100.0% (100.0%, 100.0%) | 1450.4/1450.4 = 100.0% (100.0%, 100.0%) |
| Not reported and unknown | Day 57 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 88 | 1450.4/1450.4 = 100.0% (100.0%, 100.0%) | 1450.4/1450.4 = 100.0% (100.0%, 100.0%) | 1450.4/1450.4 = 100.0% (100.0%, 100.0%) |
| Not reported and unknown | Day 57 | Vaccine | Positive | Anti N IgG (IU/ml) | 22 | 124/124 = 100.0% (100.0%, 100.0%) | 124/124 = 100.0% (100.0%, 100.0%) | 124/124 = 100.0% (100.0%, 100.0%) |
| Not reported and unknown | Day 57 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 22 | 124/124 = 100.0% (100.0%, 100.0%) | 124/124 = 100.0% (100.0%, 100.0%) | 124/124 = 100.0% (100.0%, 100.0%) |
| Not reported and unknown | Day 57 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 22 | 124/124 = 100.0% (100.0%, 100.0%) | 124/124 = 100.0% (100.0%, 100.0%) | 124/124 = 100.0% (100.0%, 100.0%) |
| Not reported and unknown | Day 57 | Placebo | Negative | Anti N IgG (IU/ml) | 13 | 0/1292.7 = 0.0% (0.0%, 0.0%) | 0/1292.7 = 0.0% (0.0%, 0.0%) | 0/1292.7 = 0.0% (0.0%, 0.0%) |
| Not reported and unknown | Day 57 | Placebo | Negative | Anti RBD IgG (IU/ml) | 13 | 0/1292.7 = 0.0% (0.0%, 0.0%) | 0/1292.7 = 0.0% (0.0%, 0.0%) | 0/1292.7 = 0.0% (0.0%, 0.0%) |
| Not reported and unknown | Day 57 | Placebo | Negative | Anti Spike IgG (IU/ml) | 13 | 0/1292.7 = 0.0% (0.0%, 0.0%) | 0/1292.7 = 0.0% (0.0%, 0.0%) | 0/1292.7 = 0.0% (0.0%, 0.0%) |
| Not reported and unknown | Day 57 | Placebo | Positive | Anti N IgG (IU/ml) | 18 | 101.5/101.5 = 100.0% (100.0%, 100.0%) | 101.5/101.5 = 100.0% (100.0%, 100.0%) | 101.5/101.5 = 100.0% (100.0%, 100.0%) |
| Not reported and unknown | Day 57 | Placebo | Positive | Anti RBD IgG (IU/ml) | 18 | 101.5/101.5 = 100.0% (100.0%, 100.0%) | 101.5/101.5 = 100.0% (100.0%, 100.0%) | 101.5/101.5 = 100.0% (100.0%, 100.0%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % Greater than 2 × LLOD | % Greater than 4 × LLOD |
|--------------------------|--------|---------|---------------------|------------------------|----|--|--|--|
| Not reported and unknown | Day 57 | Placebo | Positive | Anti Spike IgG (IU/ml) | 18 | 101.5/101.5 = 100.0% (100.0%, 100.0%) | 101.5/101.5 = 100.0% (100.0%, 100.0%) | 101.5/101.5 = 100.0% (100.0%, 100.0%) |

Binding Antibody Responders are defined as participants who had baseline values below the LLOD with detectable antibody concentration above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in antibody concentration.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.



Table 3h. Percentage of responders, and participants with concentrations $\geq 2 \times \text{LLOD}$ or $\geq 4 \times \text{LLOD}$ for binding antibody markers by Race

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % Greater than $2 \times \text{LLOD}$ | % Greater than $4 \times \text{LLOD}$ |
|--------------------|--------|---------|---------------------|------------------------|-----|--|--|--|
| Race | | | | | | | | |
| White Non-Hispanic | Day 29 | Vaccine | Negative | Anti N IgG (IU/ml) | 362 | 6597/6597 = 100.0% (100.0%, 100.0%) | 6597/6597 = 100.0% (100.0%, 100.0%) | 6597/6597 = 100.0% (100.0%, 100.0%) |
| White Non-Hispanic | Day 29 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 362 | 6597/6597 = 100.0% (100.0%, 100.0%) | 6597/6597 = 100.0% (100.0%, 100.0%) | 6597/6597 = 100.0% (100.0%, 100.0%) |
| White Non-Hispanic | Day 29 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 362 | 6597/6597 = 100.0% (100.0%, 100.0%) | 6597/6597 = 100.0% (100.0%, 100.0%) | 6597/6597 = 100.0% (100.0%, 100.0%) |
| White Non-Hispanic | Day 29 | Vaccine | Positive | Anti N IgG (IU/ml) | 125 | 773.8/773.8 = 100.0% (100.0%, 100.0%) | 773.8/773.8 = 100.0% (100.0%, 100.0%) | 773.8/773.8 = 100.0% (100.0%, 100.0%) |
| White Non-Hispanic | Day 29 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 125 | 773.8/773.8 = 100.0% (100.0%, 100.0%) | 773.8/773.8 = 100.0% (100.0%, 100.0%) | 773.8/773.8 = 100.0% (100.0%, 100.0%) |
| White Non-Hispanic | Day 29 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 125 | 773.8/773.8 = 100.0% (100.0%, 100.0%) | 773.8/773.8 = 100.0% (100.0%, 100.0%) | 773.8/773.8 = 100.0% (100.0%, 100.0%) |
| White Non-Hispanic | Day 29 | Placebo | Negative | Anti N IgG (IU/ml) | 67 | 0/6586.8 = 0.0% (0.0%, 0.0%) | 0/6586.8 = 0.0% (0.0%, 0.0%) | 0/6586.8 = 0.0% (0.0%, 0.0%) |
| White Non-Hispanic | Day 29 | Placebo | Negative | Anti RBD IgG (IU/ml) | 67 | 0/6586.8 = 0.0% (0.0%, 0.0%) | 0/6586.8 = 0.0% (0.0%, 0.0%) | 0/6586.8 = 0.0% (0.0%, 0.0%) |
| White Non-Hispanic | Day 29 | Placebo | Negative | Anti Spike IgG (IU/ml) | 67 | 0/6586.8 = 0.0% (0.0%, 0.0%) | 0/6586.8 = 0.0% (0.0%, 0.0%) | 0/6586.8 = 0.0% (0.0%, 0.0%) |
| White Non-Hispanic | Day 29 | Placebo | Positive | Anti N IgG (IU/ml) | 121 | 666.4/666.4 = 100.0% (100.0%, 100.0%) | 666.4/666.4 = 100.0% (100.0%, 100.0%) | 666.4/666.4 = 100.0% (100.0%, 100.0%) |
| White Non-Hispanic | Day 29 | Placebo | Positive | Anti RBD IgG (IU/ml) | 121 | 666.4/666.4 = 100.0% (100.0%, 100.0%) | 666.4/666.4 = 100.0% (100.0%, 100.0%) | 666.4/666.4 = 100.0% (100.0%, 100.0%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % Greater than 2 × LLOD | % Greater than 4 × LLOD |
|--------------------|--------|---------|---------------------|------------------------|-----|--|--|--|
| White Non-Hispanic | Day 29 | Placebo | Positive | Anti Spike IgG (IU/ml) | 121 | 666.4/666.4 = 100.0% (100.0%, 100.0%) | 666.4/666.4 = 100.0% (100.0%, 100.0%) | 666.4/666.4 = 100.0% (100.0%, 100.0%) |
| White Non-Hispanic | Day 57 | Vaccine | Negative | Anti N IgG (IU/ml) | 362 | 6597/6597 = 100.0% (100.0%, 100.0%) | 6597/6597 = 100.0% (100.0%, 100.0%) | 6597/6597 = 100.0% (100.0%, 100.0%) |
| White Non-Hispanic | Day 57 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 362 | 6597/6597 = 100.0% (100.0%, 100.0%) | 6597/6597 = 100.0% (100.0%, 100.0%) | 6597/6597 = 100.0% (100.0%, 100.0%) |
| White Non-Hispanic | Day 57 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 362 | 6597/6597 = 100.0% (100.0%, 100.0%) | 6597/6597 = 100.0% (100.0%, 100.0%) | 6597/6597 = 100.0% (100.0%, 100.0%) |
| White Non-Hispanic | Day 57 | Vaccine | Positive | Anti N IgG (IU/ml) | 125 | 773.8/773.8 = 100.0% (100.0%, 100.0%) | 773.8/773.8 = 100.0% (100.0%, 100.0%) | 773.8/773.8 = 100.0% (100.0%, 100.0%) |
| White Non-Hispanic | Day 57 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 125 | 773.8/773.8 = 100.0% (100.0%, 100.0%) | 773.8/773.8 = 100.0% (100.0%, 100.0%) | 773.8/773.8 = 100.0% (100.0%, 100.0%) |
| White Non-Hispanic | Day 57 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 125 | 773.8/773.8 = 100.0% (100.0%, 100.0%) | 773.8/773.8 = 100.0% (100.0%, 100.0%) | 773.8/773.8 = 100.0% (100.0%, 100.0%) |
| White Non-Hispanic | Day 57 | Placebo | Negative | Anti N IgG (IU/ml) | 67 | 0/6586.8 = 0.0% (0.0%, 0.0%) | 0/6586.8 = 0.0% (0.0%, 0.0%) | 0/6586.8 = 0.0% (0.0%, 0.0%) |
| White Non-Hispanic | Day 57 | Placebo | Negative | Anti RBD IgG (IU/ml) | 67 | 76.3/6586.8 = 1.2% (0.2%, 8.1%) | 0/6586.8 = 0.0% (0.0%, 0.0%) | 0/6586.8 = 0.0% (0.0%, 0.0%) |
| White Non-Hispanic | Day 57 | Placebo | Negative | Anti Spike IgG (IU/ml) | 67 | 0/6586.8 = 0.0% (0.0%, 0.0%) | 0/6586.8 = 0.0% (0.0%, 0.0%) | 0/6586.8 = 0.0% (0.0%, 0.0%) |
| White Non-Hispanic | Day 57 | Placebo | Positive | Anti N IgG (IU/ml) | 121 | 666.4/666.4 = 100.0% (100.0%, 100.0%) | 666.4/666.4 = 100.0% (100.0%, 100.0%) | 666.4/666.4 = 100.0% (100.0%, 100.0%) |
| White Non-Hispanic | Day 57 | Placebo | Positive | Anti RBD IgG (IU/ml) | 121 | 666.4/666.4 = 100.0% (100.0%, 100.0%) | 666.4/666.4 = 100.0% (100.0%, 100.0%) | 666.4/666.4 = 100.0% (100.0%, 100.0%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % Greater than 2 × LLOD | % Greater than 4 × LLOD |
|---------------------------|--------|---------|---------------------|------------------------|-----|--|--|--|
| White Non-Hispanic | Day 57 | Placebo | Positive | Anti Spike IgG (IU/ml) | 121 | 666.4/666.4 = 100.0% (100.0%, 100.0%) | 666.4/666.4 = 100.0% (100.0%, 100.0%) | 666.4/666.4 = 100.0% (100.0%, 100.0%) |
| Black or African American | Day 29 | Vaccine | Negative | Anti N IgG (IU/ml) | 195 | 2012.2/2012.2 = 100.0% (100.0%, 100.0%) | 1985.2/2012.2 = 98.7% (90.9%, 99.8%) | 1985.2/2012.2 = 98.7% (90.9%, 99.8%) |
| Black or African American | Day 29 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 195 | 2012.2/2012.2 = 100.0% (100.0%, 100.0%) | 2012.2/2012.2 = 100.0% (100.0%, 100.0%) | 2012.2/2012.2 = 100.0% (100.0%, 100.0%) |
| Black or African American | Day 29 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 195 | 2012.2/2012.2 = 100.0% (100.0%, 100.0%) | 2012.2/2012.2 = 100.0% (100.0%, 100.0%) | 2012.2/2012.2 = 100.0% (100.0%, 100.0%) |
| Black or African American | Day 29 | Vaccine | Positive | Anti N IgG (IU/ml) | 52 | 195.6/195.6 = 100.0% (100.0%, 100.0%) | 195.6/195.6 = 100.0% (100.0%, 100.0%) | 195.6/195.6 = 100.0% (100.0%, 100.0%) |
| Black or African American | Day 29 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 52 | 195.6/195.6 = 100.0% (100.0%, 100.0%) | 195.6/195.6 = 100.0% (100.0%, 100.0%) | 195.6/195.6 = 100.0% (100.0%, 100.0%) |
| Black or African American | Day 29 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 52 | 195.6/195.6 = 100.0% (100.0%, 100.0%) | 195.6/195.6 = 100.0% (100.0%, 100.0%) | 195.6/195.6 = 100.0% (100.0%, 100.0%) |
| Black or African American | Day 29 | Placebo | Negative | Anti N IgG (IU/ml) | 39 | 0/2311.6 = 0.0% (0.0%, 0.0%) | 0/2311.6 = 0.0% (0.0%, 0.0%) | 0/2311.6 = 0.0% (0.0%, 0.0%) |
| Black or African American | Day 29 | Placebo | Negative | Anti RBD IgG (IU/ml) | 39 | 0/2311.6 = 0.0% (0.0%, 0.0%) | 0/2311.6 = 0.0% (0.0%, 0.0%) | 0/2311.6 = 0.0% (0.0%, 0.0%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % Greater than 2 × LLOD | % Greater than 4 × LLOD |
|---------------------------|--------|---------|---------------------|------------------------|-----|--|--|--|
| Black or African American | Day 29 | Placebo | Negative | Anti Spike IgG (IU/ml) | 39 | 0/2311.6 = 0.0% (0.0%, 0.0%) | 0/2311.6 = 0.0% (0.0%, 0.0%) | 0/2311.6 = 0.0% (0.0%, 0.0%) |
| Black or African American | Day 29 | Placebo | Positive | Anti N IgG (IU/ml) | 60 | 265.1/265.1 = 100.0% (100.0%, 100.0%) | 265.1/265.1 = 100.0% (100.0%, 100.0%) | 262.6/265.1 = 99.1% (93.4%, 99.9%) |
| Black or African American | Day 29 | Placebo | Positive | Anti RBD IgG (IU/ml) | 60 | 265.1/265.1 = 100.0% (100.0%, 100.0%) | 265.1/265.1 = 100.0% (100.0%, 100.0%) | 265.1/265.1 = 100.0% (100.0%, 100.0%) |
| Black or African American | Day 29 | Placebo | Positive | Anti Spike IgG (IU/ml) | 60 | 265.1/265.1 = 100.0% (100.0%, 100.0%) | 265.1/265.1 = 100.0% (100.0%, 100.0%) | 265.1/265.1 = 100.0% (100.0%, 100.0%) |
| Black or African American | Day 57 | Vaccine | Negative | Anti N IgG (IU/ml) | 195 | 2012.2/2012.2 = 100.0% (100.0%, 100.0%) | 2012.2/2012.2 = 100.0% (100.0%, 100.0%) | 2012.2/2012.2 = 100.0% (100.0%, 100.0%) |
| Black or African American | Day 57 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 195 | 2012.2/2012.2 = 100.0% (100.0%, 100.0%) | 2012.2/2012.2 = 100.0% (100.0%, 100.0%) | 2012.2/2012.2 = 100.0% (100.0%, 100.0%) |
| Black or African American | Day 57 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 195 | 2012.2/2012.2 = 100.0% (100.0%, 100.0%) | 2012.2/2012.2 = 100.0% (100.0%, 100.0%) | 2012.2/2012.2 = 100.0% (100.0%, 100.0%) |
| Black or African American | Day 57 | Vaccine | Positive | Anti N IgG (IU/ml) | 52 | 195.6/195.6 = 100.0% (100.0%, 100.0%) | 195.6/195.6 = 100.0% (100.0%, 100.0%) | 195.6/195.6 = 100.0% (100.0%, 100.0%) |
| Black or African American | Day 57 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 52 | 195.6/195.6 = 100.0% (100.0%, 100.0%) | 195.6/195.6 = 100.0% (100.0%, 100.0%) | 195.6/195.6 = 100.0% (100.0%, 100.0%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % Greater than 2 × LLOD | % Greater than 4 × LLOD |
|---------------------------|--------|---------|---------------------|------------------------|----|--|--|--|
| Black or African American | Day 57 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 52 | 195.6/195.6 = 100.0% (100.0%, 100.0%) | 195.6/195.6 = 100.0% (100.0%, 100.0%) | 195.6/195.6 = 100.0% (100.0%, 100.0%) |
| Black or African American | Day 57 | Placebo | Negative | Anti N IgG (IU/ml) | 39 | 0/2311.6 = 0.0% (0.0%, 0.0%) | 0/2311.6 = 0.0% (0.0%, 0.0%) | 0/2311.6 = 0.0% (0.0%, 0.0%) |
| Black or African American | Day 57 | Placebo | Negative | Anti RBD IgG (IU/ml) | 39 | 0/2311.6 = 0.0% (0.0%, 0.0%) | 0/2311.6 = 0.0% (0.0%, 0.0%) | 0/2311.6 = 0.0% (0.0%, 0.0%) |
| Black or African American | Day 57 | Placebo | Negative | Anti Spike IgG (IU/ml) | 39 | 0/2311.6 = 0.0% (0.0%, 0.0%) | 0/2311.6 = 0.0% (0.0%, 0.0%) | 0/2311.6 = 0.0% (0.0%, 0.0%) |
| Black or African American | Day 57 | Placebo | Positive | Anti N IgG (IU/ml) | 60 | 265.1/265.1 = 100.0% (100.0%, 100.0%) | 265.1/265.1 = 100.0% (100.0%, 100.0%) | 265.1/265.1 = 100.0% (100.0%, 100.0%) |
| Black or African American | Day 57 | Placebo | Positive | Anti RBD IgG (IU/ml) | 60 | 265.1/265.1 = 100.0% (100.0%, 100.0%) | 265.1/265.1 = 100.0% (100.0%, 100.0%) | 265.1/265.1 = 100.0% (100.0%, 100.0%) |
| Black or African American | Day 57 | Placebo | Positive | Anti Spike IgG (IU/ml) | 60 | 265.1/265.1 = 100.0% (100.0%, 100.0%) | 265.1/265.1 = 100.0% (100.0%, 100.0%) | 265.1/265.1 = 100.0% (100.0%, 100.0%) |
| Asian | Day 29 | Vaccine | Negative | Anti N IgG (IU/ml) | 67 | 673.6/673.6 = 100.0% (100.0%, 100.0%) | 673.6/673.6 = 100.0% (100.0%, 100.0%) | 673.6/673.6 = 100.0% (100.0%, 100.0%) |
| Asian | Day 29 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 67 | 673.6/673.6 = 100.0% (100.0%, 100.0%) | 673.6/673.6 = 100.0% (100.0%, 100.0%) | 673.6/673.6 = 100.0% (100.0%, 100.0%) |
| Asian | Day 29 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 67 | 673.6/673.6 = 100.0% (100.0%, 100.0%) | 673.6/673.6 = 100.0% (100.0%, 100.0%) | 673.6/673.6 = 100.0% (100.0%, 100.0%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % Greater than 2 × LLOD | % Greater than 4 × LLOD |
|-------|--------|---------|---------------------|------------------------|----|--|--|--|
| Asian | Day 29 | Vaccine | Positive | Anti N IgG (IU/ml) | 24 | 81.1/81.1 = 100.0% (100.0%, 100.0%) | 81.1/81.1 = 100.0% (100.0%, 100.0%) | 81.1/81.1 = 100.0% (100.0%, 100.0%) |
| Asian | Day 29 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 24 | 81.1/81.1 = 100.0% (100.0%, 100.0%) | 81.1/81.1 = 100.0% (100.0%, 100.0%) | 81.1/81.1 = 100.0% (100.0%, 100.0%) |
| Asian | Day 29 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 24 | 81.1/81.1 = 100.0% (100.0%, 100.0%) | 81.1/81.1 = 100.0% (100.0%, 100.0%) | 81.1/81.1 = 100.0% (100.0%, 100.0%) |
| Asian | Day 29 | Placebo | Negative | Anti N IgG (IU/ml) | 12 | 0/609.1 = 0.0% (0.0%, 0.0%) | 0/609.1 = 0.0% (0.0%, 0.0%) | 0/609.1 = 0.0% (0.0%, 0.0%) |
| Asian | Day 29 | Placebo | Negative | Anti RBD IgG (IU/ml) | 12 | 0/609.1 = 0.0% (0.0%, 0.0%) | 0/609.1 = 0.0% (0.0%, 0.0%) | 0/609.1 = 0.0% (0.0%, 0.0%) |
| Asian | Day 29 | Placebo | Negative | Anti Spike IgG (IU/ml) | 12 | 0/609.1 = 0.0% (0.0%, 0.0%) | 0/609.1 = 0.0% (0.0%, 0.0%) | 0/609.1 = 0.0% (0.0%, 0.0%) |
| Asian | Day 29 | Placebo | Positive | Anti N IgG (IU/ml) | 13 | 48.4/48.4 = 100.0% (100.0%, 100.0%) | 48.4/48.4 = 100.0% (100.0%, 100.0%) | 48.4/48.4 = 100.0% (100.0%, 100.0%) |
| Asian | Day 29 | Placebo | Positive | Anti RBD IgG (IU/ml) | 13 | 48.4/48.4 = 100.0% (100.0%, 100.0%) | 48.4/48.4 = 100.0% (100.0%, 100.0%) | 48.4/48.4 = 100.0% (100.0%, 100.0%) |
| Asian | Day 29 | Placebo | Positive | Anti Spike IgG (IU/ml) | 13 | 48.4/48.4 = 100.0% (100.0%, 100.0%) | 48.4/48.4 = 100.0% (100.0%, 100.0%) | 48.4/48.4 = 100.0% (100.0%, 100.0%) |
| Asian | Day 57 | Vaccine | Negative | Anti N IgG (IU/ml) | 67 | 673.6/673.6 = 100.0% (100.0%, 100.0%) | 673.6/673.6 = 100.0% (100.0%, 100.0%) | 673.6/673.6 = 100.0% (100.0%, 100.0%) |
| Asian | Day 57 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 67 | 673.6/673.6 = 100.0% (100.0%, 100.0%) | 673.6/673.6 = 100.0% (100.0%, 100.0%) | 673.6/673.6 = 100.0% (100.0%, 100.0%) |
| Asian | Day 57 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 67 | 673.6/673.6 = 100.0% (100.0%, 100.0%) | 673.6/673.6 = 100.0% (100.0%, 100.0%) | 673.6/673.6 = 100.0% (100.0%, 100.0%) |
| Asian | Day 57 | Vaccine | Positive | Anti N IgG (IU/ml) | 24 | 81.1/81.1 = 100.0% (100.0%, 100.0%) | 81.1/81.1 = 100.0% (100.0%, 100.0%) | 81.1/81.1 = 100.0% (100.0%, 100.0%) |
| Asian | Day 57 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 24 | 81.1/81.1 = 100.0% (100.0%, 100.0%) | 81.1/81.1 = 100.0% (100.0%, 100.0%) | 81.1/81.1 = 100.0% (100.0%, 100.0%) |
| Asian | Day 57 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 24 | 81.1/81.1 = 100.0% (100.0%, 100.0%) | 81.1/81.1 = 100.0% (100.0%, 100.0%) | 81.1/81.1 = 100.0% (100.0%, 100.0%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % Greater than 2 × LLOD | % Greater than 4 × LLOD |
|----------------------------------|--------|---------|---------------------|------------------------|----|--|--|--|
| Asian | Day 57 | Placebo | Negative | Anti N IgG (IU/ml) | 12 | 0/609.1 = 0.0% (0.0%, 0.0%) | 0/609.1 = 0.0% (0.0%, 0.0%) | 0/609.1 = 0.0% (0.0%, 0.0%) |
| Asian | Day 57 | Placebo | Negative | Anti RBD IgG (IU/ml) | 12 | 0/609.1 = 0.0% (0.0%, 0.0%) | 0/609.1 = 0.0% (0.0%, 0.0%) | 0/609.1 = 0.0% (0.0%, 0.0%) |
| Asian | Day 57 | Placebo | Negative | Anti Spike IgG (IU/ml) | 12 | 0/609.1 = 0.0% (0.0%, 0.0%) | 0/609.1 = 0.0% (0.0%, 0.0%) | 0/609.1 = 0.0% (0.0%, 0.0%) |
| Asian | Day 57 | Placebo | Positive | Anti N IgG (IU/ml) | 13 | 48.4/48.4 = 100.0% (100.0%, 100.0%) | 48.4/48.4 = 100.0% (100.0%, 100.0%) | 48.4/48.4 = 100.0% (100.0%, 100.0%) |
| Asian | Day 57 | Placebo | Positive | Anti RBD IgG (IU/ml) | 13 | 48.4/48.4 = 100.0% (100.0%, 100.0%) | 48.4/48.4 = 100.0% (100.0%, 100.0%) | 48.4/48.4 = 100.0% (100.0%, 100.0%) |
| Asian | Day 57 | Placebo | Positive | Anti Spike IgG (IU/ml) | 13 | 48.4/48.4 = 100.0% (100.0%, 100.0%) | 48.4/48.4 = 100.0% (100.0%, 100.0%) | 48.4/48.4 = 100.0% (100.0%, 100.0%) |
| American Indian or Alaska Native | Day 29 | Vaccine | Negative | Anti N IgG (IU/ml) | 13 | 151.4/151.4 = 100.0% (100.0%, 100.0%) | 151.4/151.4 = 100.0% (100.0%, 100.0%) | 151.4/151.4 = 100.0% (100.0%, 100.0%) |
| American Indian or Alaska Native | Day 29 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 13 | 151.4/151.4 = 100.0% (100.0%, 100.0%) | 151.4/151.4 = 100.0% (100.0%, 100.0%) | 151.4/151.4 = 100.0% (100.0%, 100.0%) |
| American Indian or Alaska Native | Day 29 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 13 | 151.4/151.4 = 100.0% (100.0%, 100.0%) | 151.4/151.4 = 100.0% (100.0%, 100.0%) | 151.4/151.4 = 100.0% (100.0%, 100.0%) |
| American Indian or Alaska Native | Day 29 | Vaccine | Positive | Anti N IgG (IU/ml) | 6 | 31.1/31.1 = 100.0% (100.0%, 100.0%) | 31.1/31.1 = 100.0% (100.0%, 100.0%) | 31.1/31.1 = 100.0% (100.0%, 100.0%) |
| American Indian or Alaska Native | Day 29 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 6 | 31.1/31.1 = 100.0% (100.0%, 100.0%) | 31.1/31.1 = 100.0% (100.0%, 100.0%) | 31.1/31.1 = 100.0% (100.0%, 100.0%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % Greater than 2 × LLOD | % Greater than 4 × LLOD |
|----------------------------------|--------|---------|---------------------|------------------------|----|--|--|--|
| American Indian or Alaska Native | Day 29 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 6 | 31.1/31.1 = 100.0% (100.0%, 100.0%) | 31.1/31.1 = 100.0% (100.0%, 100.0%) | 31.1/31.1 = 100.0% (100.0%, 100.0%) |
| American Indian or Alaska Native | Day 29 | Placebo | Negative | Anti N IgG (IU/ml) | 5 | 0/247.2 = 0.0% (0.0%, 0.0%) | 0/247.2 = 0.0% (0.0%, 0.0%) | 0/247.2 = 0.0% (0.0%, 0.0%) |
| American Indian or Alaska Native | Day 29 | Placebo | Negative | Anti RBD IgG (IU/ml) | 5 | 0/247.2 = 0.0% (0.0%, 0.0%) | 0/247.2 = 0.0% (0.0%, 0.0%) | 0/247.2 = 0.0% (0.0%, 0.0%) |
| American Indian or Alaska Native | Day 29 | Placebo | Negative | Anti Spike IgG (IU/ml) | 5 | 0/247.2 = 0.0% (0.0%, 0.0%) | 0/247.2 = 0.0% (0.0%, 0.0%) | 0/247.2 = 0.0% (0.0%, 0.0%) |
| American Indian or Alaska Native | Day 29 | Placebo | Positive | Anti N IgG (IU/ml) | 4 | 15.3/15.3 = 100.0% | 15.3/15.3 = 100.0% | 15.3/15.3 = 100.0% |
| American Indian or Alaska Native | Day 29 | Placebo | Positive | Anti RBD IgG (IU/ml) | 4 | 15.3/15.3 = 100.0% | 15.3/15.3 = 100.0% | 15.3/15.3 = 100.0% |
| American Indian or Alaska Native | Day 29 | Placebo | Positive | Anti Spike IgG (IU/ml) | 4 | 15.3/15.3 = 100.0% | 15.3/15.3 = 100.0% | 15.3/15.3 = 100.0% |
| American Indian or Alaska Native | Day 57 | Vaccine | Negative | Anti N IgG (IU/ml) | 13 | 151.4/151.4 = 100.0% (100.0%, 100.0%) | 151.4/151.4 = 100.0% (100.0%, 100.0%) | 151.4/151.4 = 100.0% (100.0%, 100.0%) |
| American Indian or Alaska Native | Day 57 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 13 | 151.4/151.4 = 100.0% (100.0%, 100.0%) | 151.4/151.4 = 100.0% (100.0%, 100.0%) | 151.4/151.4 = 100.0% (100.0%, 100.0%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % Greater than 2 × LLOD | % Greater than 4 × LLOD |
|----------------------------------|--------|---------|---------------------|------------------------|----|--|--|--|
| American Indian or Alaska Native | Day 57 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 13 | 151.4/151.4 = 100.0% (100.0%, 100.0%) | 151.4/151.4 = 100.0% (100.0%, 100.0%) | 151.4/151.4 = 100.0% (100.0%, 100.0%) |
| American Indian or Alaska Native | Day 57 | Vaccine | Positive | Anti N IgG (IU/ml) | 6 | 31.1/31.1 = 100.0% (100.0%, 100.0%) | 31.1/31.1 = 100.0% (100.0%, 100.0%) | 31.1/31.1 = 100.0% (100.0%, 100.0%) |
| American Indian or Alaska Native | Day 57 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 6 | 31.1/31.1 = 100.0% (100.0%, 100.0%) | 31.1/31.1 = 100.0% (100.0%, 100.0%) | 31.1/31.1 = 100.0% (100.0%, 100.0%) |
| American Indian or Alaska Native | Day 57 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 6 | 31.1/31.1 = 100.0% (100.0%, 100.0%) | 31.1/31.1 = 100.0% (100.0%, 100.0%) | 31.1/31.1 = 100.0% (100.0%, 100.0%) |
| American Indian or Alaska Native | Day 57 | Placebo | Negative | Anti N IgG (IU/ml) | 5 | 0/247.2 = 0.0% (0.0%, 0.0%) | 0/247.2 = 0.0% (0.0%, 0.0%) | 0/247.2 = 0.0% (0.0%, 0.0%) |
| American Indian or Alaska Native | Day 57 | Placebo | Negative | Anti RBD IgG (IU/ml) | 5 | 0/247.2 = 0.0% (0.0%, 0.0%) | 0/247.2 = 0.0% (0.0%, 0.0%) | 0/247.2 = 0.0% (0.0%, 0.0%) |
| American Indian or Alaska Native | Day 57 | Placebo | Negative | Anti Spike IgG (IU/ml) | 5 | 0/247.2 = 0.0% (0.0%, 0.0%) | 0/247.2 = 0.0% (0.0%, 0.0%) | 0/247.2 = 0.0% (0.0%, 0.0%) |
| American Indian or Alaska Native | Day 57 | Placebo | Positive | Anti N IgG (IU/ml) | 4 | 15.3/15.3 = 100.0% | 15.3/15.3 = 100.0% | 15.3/15.3 = 100.0% |
| American Indian or Alaska Native | Day 57 | Placebo | Positive | Anti RBD IgG (IU/ml) | 4 | 15.3/15.3 = 100.0% | 15.3/15.3 = 100.0% | 15.3/15.3 = 100.0% |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % Greater than 2 × LLOD | % Greater than 4 × LLOD |
|---|--------|---------|---------------------|------------------------|----|--|--|--|
| American Indian or Alaska Native | Day 57 | Placebo | Positive | Anti Spike IgG (IU/ml) | 4 | 15.3/15.3 = 100.0% | 15.3/15.3 = 100.0% | 15.3/15.3 = 100.0% |
| Native Hawaiian or Other Pacific Islander | Day 29 | Vaccine | Negative | Anti N IgG (IU/ml) | 17 | 98.2/98.2 = 100.0% (100.0%, 100.0%) | 98.2/98.2 = 100.0% (100.0%, 100.0%) | 98.2/98.2 = 100.0% (100.0%, 100.0%) |
| Native Hawaiian or Other Pacific Islander | Day 29 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 17 | 98.2/98.2 = 100.0% (100.0%, 100.0%) | 98.2/98.2 = 100.0% (100.0%, 100.0%) | 98.2/98.2 = 100.0% (100.0%, 100.0%) |
| Native Hawaiian or Other Pacific Islander | Day 29 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 17 | 98.2/98.2 = 100.0% (100.0%, 100.0%) | 98.2/98.2 = 100.0% (100.0%, 100.0%) | 98.2/98.2 = 100.0% (100.0%, 100.0%) |
| Native Hawaiian or Other Pacific Islander | Day 29 | Vaccine | Negative | Anti N IgG (IU/ml) | 5 | 23/23 = 100.0% (100.0%, 100.0%) | 23/23 = 100.0% (100.0%, 100.0%) | 23/23 = 100.0% (100.0%, 100.0%) |
| Native Hawaiian or Other Pacific Islander | Day 29 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 5 | 23/23 = 100.0% (100.0%, 100.0%) | 23/23 = 100.0% (100.0%, 100.0%) | 23/23 = 100.0% (100.0%, 100.0%) |
| Native Hawaiian or Other Pacific Islander | Day 29 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 5 | 23/23 = 100.0% (100.0%, 100.0%) | 23/23 = 100.0% (100.0%, 100.0%) | 23/23 = 100.0% (100.0%, 100.0%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % Greater than 2 × LLOD | % Greater than 4 × LLOD |
|---|--------|---------|---------------------|------------------------|----|--|--|--|
| Native Hawaiian or Other Pacific Islander | Day 29 | Placebo | Negative | Anti N IgG (IU/ml) | 1 | 0/28.8 = 0.0% | 0/28.8 = 0.0% | 0/28.8 = 0.0% |
| Native Hawaiian or Other Pacific Islander | Day 29 | Placebo | Negative | Anti RBD IgG (IU/ml) | 1 | 0/28.8 = 0.0% | 0/28.8 = 0.0% | 0/28.8 = 0.0% |
| Native Hawaiian or Other Pacific Islander | Day 29 | Placebo | Negative | Anti Spike IgG (IU/ml) | 1 | 0/28.8 = 0.0% | 0/28.8 = 0.0% | 0/28.8 = 0.0% |
| Native Hawaiian or Other Pacific Islander | Day 29 | Placebo | Positive | Anti N IgG (IU/ml) | 1 | 2.5/2.5 = 100.0% | 2.5/2.5 = 100.0% | 2.5/2.5 = 100.0% |
| Native Hawaiian or Other Pacific Islander | Day 29 | Placebo | Positive | Anti RBD IgG (IU/ml) | 1 | 2.5/2.5 = 100.0% | 2.5/2.5 = 100.0% | 2.5/2.5 = 100.0% |
| Native Hawaiian or Other Pacific Islander | Day 29 | Placebo | Positive | Anti Spike IgG (IU/ml) | 1 | 2.5/2.5 = 100.0% | 2.5/2.5 = 100.0% | 2.5/2.5 = 100.0% |
| Native Hawaiian or Other Pacific Islander | Day 57 | Vaccine | Negative | Anti N IgG (IU/ml) | 17 | 98.2/98.2 = 100.0% (100.0%, 100.0%) | 98.2/98.2 = 100.0% (100.0%, 100.0%) | 98.2/98.2 = 100.0% (100.0%, 100.0%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % Greater than 2 × LLOD | % Greater than 4 × LLOD |
|---|--------|---------|---------------------|------------------------|----|--|--|--|
| Native Hawaiian or Other Pacific Islander | Day 57 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 17 | 98.2/98.2 = 100.0% (100.0%, 100.0%) | 98.2/98.2 = 100.0% (100.0%, 100.0%) | 98.2/98.2 = 100.0% (100.0%, 100.0%) |
| Native Hawaiian or Other Pacific Islander | Day 57 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 17 | 98.2/98.2 = 100.0% (100.0%, 100.0%) | 98.2/98.2 = 100.0% (100.0%, 100.0%) | 98.2/98.2 = 100.0% (100.0%, 100.0%) |
| Native Hawaiian or Other Pacific Islander | Day 57 | Vaccine | Positive | Anti N IgG (IU/ml) | 5 | 23/23 = 100.0% (100.0%, 100.0%) | 23/23 = 100.0% (100.0%, 100.0%) | 23/23 = 100.0% (100.0%, 100.0%) |
| Native Hawaiian or Other Pacific Islander | Day 57 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 5 | 23/23 = 100.0% (100.0%, 100.0%) | 23/23 = 100.0% (100.0%, 100.0%) | 23/23 = 100.0% (100.0%, 100.0%) |
| Native Hawaiian or Other Pacific Islander | Day 57 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 5 | 23/23 = 100.0% (100.0%, 100.0%) | 23/23 = 100.0% (100.0%, 100.0%) | 23/23 = 100.0% (100.0%, 100.0%) |
| Native Hawaiian or Other Pacific Islander | Day 57 | Placebo | Negative | Anti N IgG (IU/ml) | 1 | 0/28.8 = 0.0% | 0/28.8 = 0.0% | 0/28.8 = 0.0% |
| Native Hawaiian or Other Pacific Islander | Day 57 | Placebo | Negative | Anti RBD IgG (IU/ml) | 1 | 0/28.8 = 0.0% | 0/28.8 = 0.0% | 0/28.8 = 0.0% |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % Greater than 2 × LLOD | % Greater than 4 × LLOD |
|---|--------|---------|---------------------|------------------------|----|--|--|--|
| Native Hawaiian or Other Pacific Islander | Day 57 | Placebo | Negative | Anti Spike IgG (IU/ml) | 1 | 0/28.8 = 0.0% | 0/28.8 = 0.0% | 0/28.8 = 0.0% |
| Native Hawaiian or Other Pacific Islander | Day 57 | Placebo | Positive | Anti N IgG (IU/ml) | 1 | 2.5/2.5 = 100.0% | 2.5/2.5 = 100.0% | 2.5/2.5 = 100.0% |
| Native Hawaiian or Other Pacific Islander | Day 57 | Placebo | Positive | Anti RBD IgG (IU/ml) | 1 | 2.5/2.5 = 100.0% | 2.5/2.5 = 100.0% | 2.5/2.5 = 100.0% |
| Native Hawaiian or Other Pacific Islander | Day 57 | Placebo | Positive | Anti Spike IgG (IU/ml) | 1 | 2.5/2.5 = 100.0% | 2.5/2.5 = 100.0% | 2.5/2.5 = 100.0% |
| Multiracial | Day 29 | Vaccine | Negative | Anti N IgG (IU/ml) | 52 | 498.5/498.5 = 100.0% (100.0%, 100.0%) | 498.5/498.5 = 100.0% (100.0%, 100.0%) | 498.5/498.5 = 100.0% (100.0%, 100.0%) |
| Multiracial | Day 29 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 52 | 498.5/498.5 = 100.0% (100.0%, 100.0%) | 498.5/498.5 = 100.0% (100.0%, 100.0%) | 498.5/498.5 = 100.0% (100.0%, 100.0%) |
| Multiracial | Day 29 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 52 | 498.5/498.5 = 100.0% (100.0%, 100.0%) | 498.5/498.5 = 100.0% (100.0%, 100.0%) | 498.5/498.5 = 100.0% (100.0%, 100.0%) |
| Multiracial | Day 29 | Vaccine | Positive | Anti N IgG (IU/ml) | 12 | 56.4/56.4 = 100.0% (100.0%, 100.0%) | 56.4/56.4 = 100.0% (100.0%, 100.0%) | 56.4/56.4 = 100.0% (100.0%, 100.0%) |
| Multiracial | Day 29 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 12 | 56.4/56.4 = 100.0% (100.0%, 100.0%) | 56.4/56.4 = 100.0% (100.0%, 100.0%) | 56.4/56.4 = 100.0% (100.0%, 100.0%) |
| Multiracial | Day 29 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 12 | 56.4/56.4 = 100.0% (100.0%, 100.0%) | 56.4/56.4 = 100.0% (100.0%, 100.0%) | 56.4/56.4 = 100.0% (100.0%, 100.0%) |
| Multiracial | Day 29 | Placebo | Negative | Anti N IgG (IU/ml) | 8 | 0/554 = 0.0% (0.0%, 0.0%) | 0/554 = 0.0% (0.0%, 0.0%) | 0/554 = 0.0% (0.0%, 0.0%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % Greater than 2 × LLOD | % Greater than 4 × LLOD |
|-------------|--------|---------|---------------------|------------------------|----|--|--|--|
| Multiracial | Day 29 | Placebo | Negative | Anti RBD IgG (IU/ml) | 8 | 0/554 = 0.0% (0.0%, 0.0%) | 0/554 = 0.0% (0.0%, 0.0%) | 0/554 = 0.0% (0.0%, 0.0%) |
| Multiracial | Day 29 | Placebo | Negative | Anti Spike IgG (IU/ml) | 8 | 0/554 = 0.0% (0.0%, 0.0%) | 0/554 = 0.0% (0.0%, 0.0%) | 0/554 = 0.0% (0.0%, 0.0%) |
| Multiracial | Day 29 | Placebo | Positive | Anti N IgG (IU/ml) | 19 | 61.4/61.4 = 100.0% (100.0%, 100.0%) | 61.4/61.4 = 100.0% (100.0%, 100.0%) | 61.4/61.4 = 100.0% (100.0%, 100.0%) |
| Multiracial | Day 29 | Placebo | Positive | Anti RBD IgG (IU/ml) | 19 | 61.4/61.4 = 100.0% (100.0%, 100.0%) | 61.4/61.4 = 100.0% (100.0%, 100.0%) | 61.4/61.4 = 100.0% (100.0%, 100.0%) |
| Multiracial | Day 29 | Placebo | Positive | Anti Spike IgG (IU/ml) | 19 | 61.4/61.4 = 100.0% (100.0%, 100.0%) | 61.4/61.4 = 100.0% (100.0%, 100.0%) | 61.4/61.4 = 100.0% (100.0%, 100.0%) |
| Multiracial | Day 57 | Vaccine | Negative | Anti N IgG (IU/ml) | 52 | 498.5/498.5 = 100.0% (100.0%, 100.0%) | 498.5/498.5 = 100.0% (100.0%, 100.0%) | 498.5/498.5 = 100.0% (100.0%, 100.0%) |
| Multiracial | Day 57 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 52 | 498.5/498.5 = 100.0% (100.0%, 100.0%) | 498.5/498.5 = 100.0% (100.0%, 100.0%) | 498.5/498.5 = 100.0% (100.0%, 100.0%) |
| Multiracial | Day 57 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 52 | 498.5/498.5 = 100.0% (100.0%, 100.0%) | 498.5/498.5 = 100.0% (100.0%, 100.0%) | 498.5/498.5 = 100.0% (100.0%, 100.0%) |
| Multiracial | Day 57 | Vaccine | Positive | Anti N IgG (IU/ml) | 12 | 56.4/56.4 = 100.0% (100.0%, 100.0%) | 56.4/56.4 = 100.0% (100.0%, 100.0%) | 56.4/56.4 = 100.0% (100.0%, 100.0%) |
| Multiracial | Day 57 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 12 | 56.4/56.4 = 100.0% (100.0%, 100.0%) | 56.4/56.4 = 100.0% (100.0%, 100.0%) | 56.4/56.4 = 100.0% (100.0%, 100.0%) |
| Multiracial | Day 57 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 12 | 56.4/56.4 = 100.0% (100.0%, 100.0%) | 56.4/56.4 = 100.0% (100.0%, 100.0%) | 56.4/56.4 = 100.0% (100.0%, 100.0%) |
| Multiracial | Day 57 | Placebo | Negative | Anti N IgG (IU/ml) | 8 | 0/554 = 0.0% (0.0%, 0.0%) | 0/554 = 0.0% (0.0%, 0.0%) | 0/554 = 0.0% (0.0%, 0.0%) |
| Multiracial | Day 57 | Placebo | Negative | Anti RBD IgG (IU/ml) | 8 | 0/554 = 0.0% (0.0%, 0.0%) | 0/554 = 0.0% (0.0%, 0.0%) | 0/554 = 0.0% (0.0%, 0.0%) |
| Multiracial | Day 57 | Placebo | Negative | Anti Spike IgG (IU/ml) | 8 | 0/554 = 0.0% (0.0%, 0.0%) | 0/554 = 0.0% (0.0%, 0.0%) | 0/554 = 0.0% (0.0%, 0.0%) |
| Multiracial | Day 57 | Placebo | Positive | Anti N IgG (IU/ml) | 19 | 61.4/61.4 = 100.0% (100.0%, 100.0%) | 61.4/61.4 = 100.0% (100.0%, 100.0%) | 61.4/61.4 = 100.0% (100.0%, 100.0%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % Greater than 2 × LLOD | % Greater than 4 × LLOD |
|-------------|--------|---------|---------------------|------------------------|----|--|--|--|
| Multiracial | Day 57 | Placebo | Positive | Anti RBD IgG (IU/ml) | 19 | 61.4/61.4 = 100.0% (100.0%, 100.0%) | 61.4/61.4 = 100.0% (100.0%, 100.0%) | 61.4/61.4 = 100.0% (100.0%, 100.0%) |
| Multiracial | Day 57 | Placebo | Positive | Anti Spike IgG (IU/ml) | 19 | 61.4/61.4 = 100.0% (100.0%, 100.0%) | 61.4/61.4 = 100.0% (100.0%, 100.0%) | 61.4/61.4 = 100.0% (100.0%, 100.0%) |
| Other | Day 29 | Vaccine | Negative | Anti N IgG (IU/ml) | 34 | 469.2/469.2 = 100.0% (100.0%, 100.0%) | 469.2/469.2 = 100.0% (100.0%, 100.0%) | 469.2/469.2 = 100.0% (100.0%, 100.0%) |
| Other | Day 29 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 34 | 469.2/469.2 = 100.0% (100.0%, 100.0%) | 469.2/469.2 = 100.0% (100.0%, 100.0%) | 469.2/469.2 = 100.0% (100.0%, 100.0%) |
| Other | Day 29 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 34 | 469.2/469.2 = 100.0% (100.0%, 100.0%) | 469.2/469.2 = 100.0% (100.0%, 100.0%) | 469.2/469.2 = 100.0% (100.0%, 100.0%) |
| Other | Day 29 | Vaccine | Positive | Anti N IgG (IU/ml) | 7 | 13.8/13.8 = 100.0% (100.0%, 100.0%) | 13.8/13.8 = 100.0% (100.0%, 100.0%) | 13.8/13.8 = 100.0% (100.0%, 100.0%) |
| Other | Day 29 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 7 | 13.8/13.8 = 100.0% (100.0%, 100.0%) | 13.8/13.8 = 100.0% (100.0%, 100.0%) | 13.8/13.8 = 100.0% (100.0%, 100.0%) |
| Other | Day 29 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 7 | 13.8/13.8 = 100.0% (100.0%, 100.0%) | 13.8/13.8 = 100.0% (100.0%, 100.0%) | 13.8/13.8 = 100.0% (100.0%, 100.0%) |
| Other | Day 29 | Placebo | Negative | Anti N IgG (IU/ml) | 4 | 0/232.6 = 0.0% | 0/232.6 = 0.0% | 0/232.6 = 0.0% |
| Other | Day 29 | Placebo | Negative | Anti RBD IgG (IU/ml) | 4 | 0/232.6 = 0.0% | 0/232.6 = 0.0% | 0/232.6 = 0.0% |
| Other | Day 29 | Placebo | Negative | Anti Spike IgG (IU/ml) | 4 | 0/232.6 = 0.0% | 0/232.6 = 0.0% | 0/232.6 = 0.0% |
| Other | Day 29 | Placebo | Positive | Anti N IgG (IU/ml) | 5 | 24.1/24.1 = 100.0% (100.0%, 100.0%) | 24.1/24.1 = 100.0% (100.0%, 100.0%) | 24.1/24.1 = 100.0% (100.0%, 100.0%) |
| Other | Day 29 | Placebo | Positive | Anti RBD IgG (IU/ml) | 5 | 24.1/24.1 = 100.0% (100.0%, 100.0%) | 24.1/24.1 = 100.0% (100.0%, 100.0%) | 24.1/24.1 = 100.0% (100.0%, 100.0%) |
| Other | Day 29 | Placebo | Positive | Anti Spike IgG (IU/ml) | 5 | 24.1/24.1 = 100.0% (100.0%, 100.0%) | 24.1/24.1 = 100.0% (100.0%, 100.0%) | 24.1/24.1 = 100.0% (100.0%, 100.0%) |
| Other | Day 57 | Vaccine | Negative | Anti N IgG (IU/ml) | 34 | 469.2/469.2 = 100.0% (100.0%, 100.0%) | 469.2/469.2 = 100.0% (100.0%, 100.0%) | 469.2/469.2 = 100.0% (100.0%, 100.0%) |
| Other | Day 57 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 34 | 469.2/469.2 = 100.0% (100.0%, 100.0%) | 469.2/469.2 = 100.0% (100.0%, 100.0%) | 469.2/469.2 = 100.0% (100.0%, 100.0%) |
| Other | Day 57 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 34 | 469.2/469.2 = 100.0% (100.0%, 100.0%) | 469.2/469.2 = 100.0% (100.0%, 100.0%) | 469.2/469.2 = 100.0% (100.0%, 100.0%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % Greater than 2 × LLOD | % Greater than 4 × LLOD |
|--------------------------|--------|---------|---------------------|------------------------|----|--|--|--|
| Other | Day 57 | Vaccine | Positive | Anti N IgG (IU/ml) | 7 | 13.8/13.8 = 100.0% (100.0%, 100.0%) | 13.8/13.8 = 100.0% (100.0%, 100.0%) | 13.8/13.8 = 100.0% (100.0%, 100.0%) |
| Other | Day 57 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 7 | 13.8/13.8 = 100.0% (100.0%, 100.0%) | 13.8/13.8 = 100.0% (100.0%, 100.0%) | 13.8/13.8 = 100.0% (100.0%, 100.0%) |
| Other | Day 57 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 7 | 13.8/13.8 = 100.0% (100.0%, 100.0%) | 13.8/13.8 = 100.0% (100.0%, 100.0%) | 13.8/13.8 = 100.0% (100.0%, 100.0%) |
| Other | Day 57 | Placebo | Negative | Anti N IgG (IU/ml) | 4 | 0/232.6 = 0.0% | 0/232.6 = 0.0% | 0/232.6 = 0.0% |
| Other | Day 57 | Placebo | Negative | Anti RBD IgG (IU/ml) | 4 | 0/232.6 = 0.0% | 0/232.6 = 0.0% | 0/232.6 = 0.0% |
| Other | Day 57 | Placebo | Negative | Anti Spike IgG (IU/ml) | 4 | 0/232.6 = 0.0% | 0/232.6 = 0.0% | 0/232.6 = 0.0% |
| Other | Day 57 | Placebo | Positive | Anti N IgG (IU/ml) | 5 | 24.1/24.1 = 100.0% (100.0%, 100.0%) | 24.1/24.1 = 100.0% (100.0%, 100.0%) | 24.1/24.1 = 100.0% (100.0%, 100.0%) |
| Other | Day 57 | Placebo | Positive | Anti RBD IgG (IU/ml) | 5 | 24.1/24.1 = 100.0% (100.0%, 100.0%) | 24.1/24.1 = 100.0% (100.0%, 100.0%) | 24.1/24.1 = 100.0% (100.0%, 100.0%) |
| Other | Day 57 | Placebo | Positive | Anti Spike IgG (IU/ml) | 5 | 24.1/24.1 = 100.0% (100.0%, 100.0%) | 24.1/24.1 = 100.0% (100.0%, 100.0%) | 24.1/24.1 = 100.0% (100.0%, 100.0%) |
| Not reported and unknown | Day 29 | Vaccine | Negative | Anti N IgG (IU/ml) | 87 | 1413.2/1413.2 = 100.0% (100.0%, 100.0%) | 1413.2/1413.2 = 100.0% (100.0%, 100.0%) | 1413.2/1413.2 = 100.0% (100.0%, 100.0%) |
| Not reported and unknown | Day 29 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 87 | 1413.2/1413.2 = 100.0% (100.0%, 100.0%) | 1413.2/1413.2 = 100.0% (100.0%, 100.0%) | 1413.2/1413.2 = 100.0% (100.0%, 100.0%) |
| Not reported and unknown | Day 29 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 87 | 1413.2/1413.2 = 100.0% (100.0%, 100.0%) | 1413.2/1413.2 = 100.0% (100.0%, 100.0%) | 1413.2/1413.2 = 100.0% (100.0%, 100.0%) |
| Not reported and unknown | Day 29 | Vaccine | Positive | Anti N IgG (IU/ml) | 20 | 155/155 = 100.0% (100.0%, 100.0%) | 155/155 = 100.0% (100.0%, 100.0%) | 155/155 = 100.0% (100.0%, 100.0%) |
| Not reported and unknown | Day 29 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 20 | 155/155 = 100.0% (100.0%, 100.0%) | 155/155 = 100.0% (100.0%, 100.0%) | 155/155 = 100.0% (100.0%, 100.0%) |
| Not reported and unknown | Day 29 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 20 | 155/155 = 100.0% (100.0%, 100.0%) | 155/155 = 100.0% (100.0%, 100.0%) | 155/155 = 100.0% (100.0%, 100.0%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % Greater than 2 × LLOD | % Greater than 4 × LLOD |
|--------------------------|--------|---------|---------------------|------------------------|----|--|--|--|
| Not reported and unknown | Day 29 | Placebo | Negative | Anti N IgG (IU/ml) | 14 | 0/1337.6 = 0.0% (0.0%, 0.0%) | 0/1337.6 = 0.0% (0.0%, 0.0%) | 0/1337.6 = 0.0% (0.0%, 0.0%) |
| Not reported and unknown | Day 29 | Placebo | Negative | Anti RBD IgG (IU/ml) | 14 | 0/1337.6 = 0.0% (0.0%, 0.0%) | 0/1337.6 = 0.0% (0.0%, 0.0%) | 0/1337.6 = 0.0% (0.0%, 0.0%) |
| Not reported and unknown | Day 29 | Placebo | Negative | Anti Spike IgG (IU/ml) | 14 | 0/1337.6 = 0.0% (0.0%, 0.0%) | 0/1337.6 = 0.0% (0.0%, 0.0%) | 0/1337.6 = 0.0% (0.0%, 0.0%) |
| Not reported and unknown | Day 29 | Placebo | Positive | Anti N IgG (IU/ml) | 24 | 165.4/165.4 = 100.0% (100.0%, 100.0%) | 165.4/165.4 = 100.0% (100.0%, 100.0%) | 165.4/165.4 = 100.0% (100.0%, 100.0%) |
| Not reported and unknown | Day 29 | Placebo | Positive | Anti RBD IgG (IU/ml) | 24 | 165.4/165.4 = 100.0% (100.0%, 100.0%) | 165.4/165.4 = 100.0% (100.0%, 100.0%) | 165.4/165.4 = 100.0% (100.0%, 100.0%) |
| Not reported and unknown | Day 29 | Placebo | Positive | Anti Spike IgG (IU/ml) | 24 | 165.4/165.4 = 100.0% (100.0%, 100.0%) | 165.4/165.4 = 100.0% (100.0%, 100.0%) | 165.4/165.4 = 100.0% (100.0%, 100.0%) |
| Not reported and unknown | Day 57 | Vaccine | Negative | Anti N IgG (IU/ml) | 87 | 1413.2/1413.2 = 100.0% (100.0%, 100.0%) | 1413.2/1413.2 = 100.0% (100.0%, 100.0%) | 1413.2/1413.2 = 100.0% (100.0%, 100.0%) |
| Not reported and unknown | Day 57 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 87 | 1413.2/1413.2 = 100.0% (100.0%, 100.0%) | 1413.2/1413.2 = 100.0% (100.0%, 100.0%) | 1413.2/1413.2 = 100.0% (100.0%, 100.0%) |
| Not reported and unknown | Day 57 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 87 | 1413.2/1413.2 = 100.0% (100.0%, 100.0%) | 1413.2/1413.2 = 100.0% (100.0%, 100.0%) | 1413.2/1413.2 = 100.0% (100.0%, 100.0%) |
| Not reported and unknown | Day 57 | Vaccine | Positive | Anti N IgG (IU/ml) | 20 | 155/155 = 100.0% (100.0%, 100.0%) | 155/155 = 100.0% (100.0%, 100.0%) | 155/155 = 100.0% (100.0%, 100.0%) |
| Not reported and unknown | Day 57 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 20 | 155/155 = 100.0% (100.0%, 100.0%) | 155/155 = 100.0% (100.0%, 100.0%) | 155/155 = 100.0% (100.0%, 100.0%) |
| Not reported and unknown | Day 57 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 20 | 155/155 = 100.0% (100.0%, 100.0%) | 155/155 = 100.0% (100.0%, 100.0%) | 155/155 = 100.0% (100.0%, 100.0%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % Greater than 2 × LLOD | % Greater than 4 × LLOD |
|--------------------------|--------|---------|---------------------|------------------------|----|--|--|--|
| Not reported and unknown | Day 57 | Placebo | Negative | Anti N IgG (IU/ml) | 14 | 0/1337.6 = 0.0% (0.0%, 0.0%) | 0/1337.6 = 0.0% (0.0%, 0.0%) | 0/1337.6 = 0.0% (0.0%, 0.0%) |
| Not reported and unknown | Day 57 | Placebo | Negative | Anti RBD IgG (IU/ml) | 14 | 0/1337.6 = 0.0% (0.0%, 0.0%) | 0/1337.6 = 0.0% (0.0%, 0.0%) | 0/1337.6 = 0.0% (0.0%, 0.0%) |
| Not reported and unknown | Day 57 | Placebo | Negative | Anti Spike IgG (IU/ml) | 14 | 0/1337.6 = 0.0% (0.0%, 0.0%) | 0/1337.6 = 0.0% (0.0%, 0.0%) | 0/1337.6 = 0.0% (0.0%, 0.0%) |
| Not reported and unknown | Day 57 | Placebo | Positive | Anti N IgG (IU/ml) | 24 | 165.4/165.4 = 100.0% (100.0%, 100.0%) | 165.4/165.4 = 100.0% (100.0%, 100.0%) | 165.4/165.4 = 100.0% (100.0%, 100.0%) |
| Not reported and unknown | Day 57 | Placebo | Positive | Anti RBD IgG (IU/ml) | 24 | 165.4/165.4 = 100.0% (100.0%, 100.0%) | 165.4/165.4 = 100.0% (100.0%, 100.0%) | 165.4/165.4 = 100.0% (100.0%, 100.0%) |
| Not reported and unknown | Day 57 | Placebo | Positive | Anti Spike IgG (IU/ml) | 24 | 165.4/165.4 = 100.0% (100.0%, 100.0%) | 165.4/165.4 = 100.0% (100.0%, 100.0%) | 165.4/165.4 = 100.0% (100.0%, 100.0%) |

Binding Antibody Responders are defined as participants who had baseline values below the LLOD with detectable antibody concentration above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in antibody concentration.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 3i. Percentage of responders, and participants with concentrations $\geq 2 \times \text{LLOD}$ or $\geq 4 \times \text{LLOD}$ for binding antibody markers by Underrepresented minority status

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % Greater than $2 \times \text{LLOD}$ | % Greater than $4 \times \text{LLOD}$ |
|---|--------|---------|---------------------|------------------------|-----|--|--|--|
| Underrepresented minority status | | | | | | | | |
| Communities of Color | Day 29 | Vaccine | Negative | Anti N IgG (IU/ml) | 420 | 4289/4289 = 100.0% (100.0%, 100.0%) | 4262.1/4289 = 99.4% (95.6%, 99.9%) | 4262.1/4289 = 99.4% (95.6%, 99.9%) |
| Communities of Color | Day 29 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 420 | 4289/4289 = 100.0% (100.0%, 100.0%) | 4289/4289 = 100.0% | 4289/4289 = 100.0% (100.0%, 100.0%) |
| Communities of Color | Day 29 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 420 | 4289/4289 = 100.0% (100.0%, 100.0%) | 4289/4289 = 100.0% (100.0%, 100.0%) | 4289/4289 = 100.0% (100.0%, 100.0%) |
| Communities of Color | Day 29 | Vaccine | Positive | Anti N IgG (IU/ml) | 120 | 462/462 = 100.0% (100.0%, 100.0%) | 462/462 = 100.0% (100.0%, 100.0%) | 462/462 = 100.0% (100.0%, 100.0%) |
| Communities of Color | Day 29 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 120 | 462/462 = 100.0% (100.0%, 100.0%) | 462/462 = 100.0% (100.0%, 100.0%) | 462/462 = 100.0% (100.0%, 100.0%) |
| Communities of Color | Day 29 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 120 | 462/462 = 100.0% (100.0%, 100.0%) | 462/462 = 100.0% (100.0%, 100.0%) | 462/462 = 100.0% (100.0%, 100.0%) |
| Communities of Color | Day 29 | Placebo | Negative | Anti N IgG (IU/ml) | 73 | 0/4319 = 0.0% (0.0%, 0.0%) | 0/4319 = 0.0% (0.0%, 0.0%) | 0/4319 = 0.0% (0.0%, 0.0%) |
| Communities of Color | Day 29 | Placebo | Negative | Anti RBD IgG (IU/ml) | 73 | 0/4319 = 0.0% (0.0%, 0.0%) | 0/4319 = 0.0% (0.0%, 0.0%) | 0/4319 = 0.0% (0.0%, 0.0%) |
| Communities of Color | Day 29 | Placebo | Negative | Anti Spike IgG (IU/ml) | 73 | 0/4319 = 0.0% (0.0%, 0.0%) | 0/4319 = 0.0% (0.0%, 0.0%) | 0/4319 = 0.0% (0.0%, 0.0%) |
| Communities of Color | Day 29 | Placebo | Positive | Anti N IgG (IU/ml) | 111 | 439/439 = 100.0% (100.0%, 100.0%) | 439/439 = 100.0% (100.0%, 100.0%) | 436.5/439 = 99.4% (96.0%, 99.9%) |
| Communities of Color | Day 29 | Placebo | Positive | Anti RBD IgG (IU/ml) | 111 | 439/439 = 100.0% (100.0%, 100.0%) | 439/439 = 100.0% (100.0%, 100.0%) | 439/439 = 100.0% (100.0%, 100.0%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % Greater than 2 × LLOD | % Greater than 4 × LLOD |
|----------------------|--------|---------|---------------------|------------------------|-----|--|--|--|
| Communities of Color | Day 29 | Placebo | Positive | Anti Spike IgG (IU/ml) | 111 | 439/439 = 100.0% (100.0%, 100.0%) | 439/439 = 100.0% (100.0%, 100.0%) | 439/439 = 100.0% (100.0%, 100.0%) |
| Communities of Color | Day 57 | Vaccine | Negative | Anti N IgG (IU/ml) | 420 | 4289/4289 = 100.0% (100.0%, 100.0%) | 4289/4289 = 100.0% (100.0%, 100.0%) | 4289/4289 = 100.0% (100.0%, 100.0%) |
| Communities of Color | Day 57 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 420 | 4289/4289 = 100.0% (100.0%, 100.0%) | 4289/4289 = 100.0% (100.0%, 100.0%) | 4289/4289 = 100.0% (100.0%, 100.0%) |
| Communities of Color | Day 57 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 420 | 4289/4289 = 100.0% (100.0%, 100.0%) | 4289/4289 = 100.0% (100.0%, 100.0%) | 4289/4289 = 100.0% (100.0%, 100.0%) |
| Communities of Color | Day 57 | Vaccine | Positive | Anti N IgG (IU/ml) | 120 | 462/462 = 100.0% (100.0%, 100.0%) | 462/462 = 100.0% (100.0%, 100.0%) | 462/462 = 100.0% (100.0%, 100.0%) |
| Communities of Color | Day 57 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 120 | 462/462 = 100.0% (100.0%, 100.0%) | 462/462 = 100.0% (100.0%, 100.0%) | 462/462 = 100.0% (100.0%, 100.0%) |
| Communities of Color | Day 57 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 120 | 462/462 = 100.0% (100.0%, 100.0%) | 462/462 = 100.0% (100.0%, 100.0%) | 462/462 = 100.0% (100.0%, 100.0%) |
| Communities of Color | Day 57 | Placebo | Negative | Anti N IgG (IU/ml) | 73 | 0/4319 = 0.0% (0.0%, 0.0%) | 0/4319 = 0.0% (0.0%, 0.0%) | 0/4319 = 0.0% (0.0%, 0.0%) |
| Communities of Color | Day 57 | Placebo | Negative | Anti RBD IgG (IU/ml) | 73 | 0/4319 = 0.0% (0.0%, 0.0%) | 0/4319 = 0.0% (0.0%, 0.0%) | 0/4319 = 0.0% (0.0%, 0.0%) |
| Communities of Color | Day 57 | Placebo | Negative | Anti Spike IgG (IU/ml) | 73 | 0/4319 = 0.0% (0.0%, 0.0%) | 0/4319 = 0.0% (0.0%, 0.0%) | 0/4319 = 0.0% (0.0%, 0.0%) |
| Communities of Color | Day 57 | Placebo | Positive | Anti N IgG (IU/ml) | 111 | 439/439 = 100.0% (100.0%, 100.0%) | 439/439 = 100.0% (100.0%, 100.0%) | 439/439 = 100.0% (100.0%, 100.0%) |
| Communities of Color | Day 57 | Placebo | Positive | Anti RBD IgG (IU/ml) | 111 | 439/439 = 100.0% (100.0%, 100.0%) | 439/439 = 100.0% (100.0%, 100.0%) | 439/439 = 100.0% (100.0%, 100.0%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % Greater than 2 × LLOD | % Greater than 4 × LLOD |
|----------------------|--------|---------|---------------------|------------------------|-----|--|--|--|
| Communities of Color | Day 57 | Placebo | Positive | Anti Spike IgG (IU/ml) | 111 | 439/439 = 100.0% (100.0%, 100.0%) | 439/439 = 100.0% (100.0%, 100.0%) | 439/439 = 100.0% (100.0%, 100.0%) |
| White Non-Hispanic | Day 29 | Vaccine | Negative | Anti N IgG (IU/ml) | 362 | 6597/6597 = 100.0% (100.0%, 100.0%) | 6597/6597 = 100.0% (100.0%, 100.0%) | 6597/6597 = 100.0% (100.0%, 100.0%) |
| White Non-Hispanic | Day 29 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 362 | 6597/6597 = 100.0% (100.0%, 100.0%) | 6597/6597 = 100.0% (100.0%, 100.0%) | 6597/6597 = 100.0% (100.0%, 100.0%) |
| White Non-Hispanic | Day 29 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 362 | 6597/6597 = 100.0% (100.0%, 100.0%) | 6597/6597 = 100.0% (100.0%, 100.0%) | 6597/6597 = 100.0% (100.0%, 100.0%) |
| White Non-Hispanic | Day 29 | Vaccine | Positive | Anti N IgG (IU/ml) | 125 | 773.8/773.8 = 100.0% (100.0%, 100.0%) | 773.8/773.8 = 100.0% (100.0%, 100.0%) | 773.8/773.8 = 100.0% (100.0%, 100.0%) |
| White Non-Hispanic | Day 29 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 125 | 773.8/773.8 = 100.0% (100.0%, 100.0%) | 773.8/773.8 = 100.0% (100.0%, 100.0%) | 773.8/773.8 = 100.0% (100.0%, 100.0%) |
| White Non-Hispanic | Day 29 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 125 | 773.8/773.8 = 100.0% (100.0%, 100.0%) | 773.8/773.8 = 100.0% (100.0%, 100.0%) | 773.8/773.8 = 100.0% (100.0%, 100.0%) |
| White Non-Hispanic | Day 29 | Placebo | Negative | Anti N IgG (IU/ml) | 67 | 0/6586.8 = 0.0% (0.0%, 0.0%) | 0/6586.8 = 0.0% (0.0%, 0.0%) | 0/6586.8 = 0.0% (0.0%, 0.0%) |
| White Non-Hispanic | Day 29 | Placebo | Negative | Anti RBD IgG (IU/ml) | 67 | 0/6586.8 = 0.0% (0.0%, 0.0%) | 0/6586.8 = 0.0% (0.0%, 0.0%) | 0/6586.8 = 0.0% (0.0%, 0.0%) |
| White Non-Hispanic | Day 29 | Placebo | Negative | Anti Spike IgG (IU/ml) | 67 | 0/6586.8 = 0.0% (0.0%, 0.0%) | 0/6586.8 = 0.0% (0.0%, 0.0%) | 0/6586.8 = 0.0% (0.0%, 0.0%) |
| White Non-Hispanic | Day 29 | Placebo | Positive | Anti N IgG (IU/ml) | 121 | 666.4/666.4 = 100.0% (100.0%, 100.0%) | 666.4/666.4 = 100.0% (100.0%, 100.0%) | 666.4/666.4 = 100.0% (100.0%, 100.0%) |
| White Non-Hispanic | Day 29 | Placebo | Positive | Anti RBD IgG (IU/ml) | 121 | 666.4/666.4 = 100.0% (100.0%, 100.0%) | 666.4/666.4 = 100.0% (100.0%, 100.0%) | 666.4/666.4 = 100.0% (100.0%, 100.0%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % Greater than 2 × LLOD | % Greater than 4 × LLOD |
|--------------------|--------|---------|---------------------|------------------------|-----|--|--|--|
| White Non-Hispanic | Day 29 | Placebo | Positive | Anti Spike IgG (IU/ml) | 121 | 666.4/666.4 = 100.0% (100.0%, 100.0%) | 666.4/666.4 = 100.0% (100.0%, 100.0%) | 666.4/666.4 = 100.0% (100.0%, 100.0%) |
| White Non-Hispanic | Day 57 | Vaccine | Negative | Anti N IgG (IU/ml) | 362 | 6597/6597 = 100.0% (100.0%, 100.0%) | 6597/6597 = 100.0% (100.0%, 100.0%) | 6597/6597 = 100.0% (100.0%, 100.0%) |
| White Non-Hispanic | Day 57 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 362 | 6597/6597 = 100.0% (100.0%, 100.0%) | 6597/6597 = 100.0% (100.0%, 100.0%) | 6597/6597 = 100.0% (100.0%, 100.0%) |
| White Non-Hispanic | Day 57 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 362 | 6597/6597 = 100.0% (100.0%, 100.0%) | 6597/6597 = 100.0% (100.0%, 100.0%) | 6597/6597 = 100.0% (100.0%, 100.0%) |
| White Non-Hispanic | Day 57 | Vaccine | Positive | Anti N IgG (IU/ml) | 125 | 773.8/773.8 = 100.0% (100.0%, 100.0%) | 773.8/773.8 = 100.0% (100.0%, 100.0%) | 773.8/773.8 = 100.0% (100.0%, 100.0%) |
| White Non-Hispanic | Day 57 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 125 | 773.8/773.8 = 100.0% (100.0%, 100.0%) | 773.8/773.8 = 100.0% (100.0%, 100.0%) | 773.8/773.8 = 100.0% (100.0%, 100.0%) |
| White Non-Hispanic | Day 57 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 125 | 773.8/773.8 = 100.0% (100.0%, 100.0%) | 773.8/773.8 = 100.0% (100.0%, 100.0%) | 773.8/773.8 = 100.0% (100.0%, 100.0%) |
| White Non-Hispanic | Day 57 | Placebo | Negative | Anti N IgG (IU/ml) | 67 | 0/6586.8 = 0.0% (0.0%, 0.0%) | 0/6586.8 = 0.0% (0.0%, 0.0%) | 0/6586.8 = 0.0% (0.0%, 0.0%) |
| White Non-Hispanic | Day 57 | Placebo | Negative | Anti RBD IgG (IU/ml) | 67 | 76.3/6586.8 = 1.2% (0.2%, 8.1%) | 0/6586.8 = 0.0% (0.0%, 0.0%) | 0/6586.8 = 0.0% (0.0%, 0.0%) |
| White Non-Hispanic | Day 57 | Placebo | Negative | Anti Spike IgG (IU/ml) | 67 | 0/6586.8 = 0.0% (0.0%, 0.0%) | 0/6586.8 = 0.0% (0.0%, 0.0%) | 0/6586.8 = 0.0% (0.0%, 0.0%) |
| White Non-Hispanic | Day 57 | Placebo | Positive | Anti N IgG (IU/ml) | 121 | 666.4/666.4 = 100.0% (100.0%, 100.0%) | 666.4/666.4 = 100.0% (100.0%, 100.0%) | 666.4/666.4 = 100.0% (100.0%, 100.0%) |
| White Non-Hispanic | Day 57 | Placebo | Positive | Anti RBD IgG (IU/ml) | 121 | 666.4/666.4 = 100.0% (100.0%, 100.0%) | 666.4/666.4 = 100.0% (100.0%, 100.0%) | 666.4/666.4 = 100.0% (100.0%, 100.0%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % Greater than 2 × LLOD | % Greater than 4 × LLOD |
|--------------------|--------|---------|---------------------|------------------------|-----|--|--|--|
| White Non-Hispanic | Day 57 | Placebo | Positive | Anti Spike IgG (IU/ml) | 121 | 666.4/666.4 = 100.0% (100.0%, 100.0%) | 666.4/666.4 = 100.0% (100.0%, 100.0%) | 666.4/666.4 = 100.0% (100.0%, 100.0%) |

Binding Antibody Responders are defined as participants who had baseline values below the LLOD with detectable antibody concentration above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in antibody concentration.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 3j. Percentage of responders, and participants with concentrations $\geq 2 \times \text{LLOD}$ or $\geq 4 \times \text{LLOD}$ for binding antibody markers by Age, Underrepresented minority status

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % Greater than $2 \times \text{LLOD}$ | % Greater than $4 \times \text{LLOD}$ |
|--|--------|---------|---------------------|------------------------|-----|--|--|--|
| Age, Underrepresented minority status | | | | | | | | |
| Age < 65 Communities of Color | Day 29 | Vaccine | Negative | Anti N IgG (IU/ml) | 192 | 3386/3386 = 100.0% (100.0%, 100.0%) | 3359.1/3386 = 99.2% (94.5%, 99.9%) | 3359.1/3386 = 99.2% (94.5%, 99.9%) |
| Age < 65 Communities of Color | Day 29 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 192 | 3386/3386 = 100.0% (100.0%, 100.0%) | 3386/3386 = 100.0% (100.0%, 100.0%) | 3386/3386 = 100.0% (100.0%, 100.0%) |
| Age < 65 Communities of Color | Day 29 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 192 | 3386/3386 = 100.0% (100.0%, 100.0%) | 3386/3386 = 100.0% (100.0%, 100.0%) | 3386/3386 = 100.0% (100.0%, 100.0%) |
| Age < 65 Communities of Color | Day 29 | Vaccine | Positive | Anti N IgG (IU/ml) | 69 | 375/375 = 100.0% (100.0%, 100.0%) | 375/375 = 100.0% (100.0%, 100.0%) | 375/375 = 100.0% (100.0%, 100.0%) |
| Age < 65 Communities of Color | Day 29 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 69 | 375/375 = 100.0% (100.0%, 100.0%) | 375/375 = 100.0% (100.0%, 100.0%) | 375/375 = 100.0% (100.0%, 100.0%) |
| Age < 65 Communities of Color | Day 29 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 69 | 375/375 = 100.0% (100.0%, 100.0%) | 375/375 = 100.0% (100.0%, 100.0%) | 375/375 = 100.0% (100.0%, 100.0%) |
| Age < 65 Communities of Color | Day 29 | Placebo | Negative | Anti N IgG (IU/ml) | 37 | 0/3281 = 0.0% (0.0%, 0.0%) | 0/3281 = 0.0% (0.0%, 0.0%) | 0/3281 = 0.0% (0.0%, 0.0%) |
| Age < 65 Communities of Color | Day 29 | Placebo | Negative | Anti RBD IgG (IU/ml) | 37 | 0/3281 = 0.0% (0.0%, 0.0%) | 0/3281 = 0.0% (0.0%, 0.0%) | 0/3281 = 0.0% (0.0%, 0.0%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % Greater than 2 × LLOD | % Greater than 4 × LLOD |
|-------------------------------|--------|---------|---------------------|------------------------|-----|--|--|--|
| Age < 65 Communities of Color | Day 29 | Placebo | Negative | Anti Spike IgG (IU/ml) | 37 | 0/3281 = 0.0% (0.0%, 0.0%) | 0/3281 = 0.0% (0.0%, 0.0%) | 0/3281 = 0.0% (0.0%, 0.0%) |
| Age < 65 Communities of Color | Day 29 | Placebo | Positive | Anti N IgG (IU/ml) | 61 | 361/361 = 100.0% (100.0%, 100.0%) | 361/361 = 100.0% (100.0%, 100.0%) | 358.5/361 = 99.3% (95.1%, 99.9%) |
| Age < 65 Communities of Color | Day 29 | Placebo | Positive | Anti RBD IgG (IU/ml) | 61 | 361/361 = 100.0% (100.0%, 100.0%) | 361/361 = 100.0% (100.0%, 100.0%) | 361/361 = 100.0% (100.0%, 100.0%) |
| Age < 65 Communities of Color | Day 29 | Placebo | Positive | Anti Spike IgG (IU/ml) | 61 | 361/361 = 100.0% (100.0%, 100.0%) | 361/361 = 100.0% (100.0%, 100.0%) | 361/361 = 100.0% (100.0%, 100.0%) |
| Age < 65 Communities of Color | Day 57 | Vaccine | Negative | Anti N IgG (IU/ml) | 192 | 3386/3386 = 100.0% (100.0%, 100.0%) | 3386/3386 = 100.0% (100.0%, 100.0%) | 3386/3386 = 100.0% (100.0%, 100.0%) |
| Age < 65 Communities of Color | Day 57 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 192 | 3386/3386 = 100.0% (100.0%, 100.0%) | 3386/3386 = 100.0% (100.0%, 100.0%) | 3386/3386 = 100.0% (100.0%, 100.0%) |
| Age < 65 Communities of Color | Day 57 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 192 | 3386/3386 = 100.0% (100.0%, 100.0%) | 3386/3386 = 100.0% (100.0%, 100.0%) | 3386/3386 = 100.0% (100.0%, 100.0%) |
| Age < 65 Communities of Color | Day 57 | Vaccine | Positive | Anti N IgG (IU/ml) | 69 | 375/375 = 100.0% (100.0%, 100.0%) | 375/375 = 100.0% (100.0%, 100.0%) | 375/375 = 100.0% (100.0%, 100.0%) |
| Age < 65 Communities of Color | Day 57 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 69 | 375/375 = 100.0% (100.0%, 100.0%) | 375/375 = 100.0% (100.0%, 100.0%) | 375/375 = 100.0% (100.0%, 100.0%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % Greater than 2 × LLOD | % Greater than 4 × LLOD |
|-------------------------------|--------|---------|---------------------|------------------------|-----|--|--|--|
| Age < 65 Communities of Color | Day 57 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 69 | 375/375 = 100.0% (100.0%, 100.0%) | 375/375 = 100.0% (100.0%, 100.0%) | 375/375 = 100.0% (100.0%, 100.0%) |
| Age < 65 Communities of Color | Day 57 | Placebo | Negative | Anti N IgG (IU/ml) | 37 | 0/3281 = 0.0% (0.0%, 0.0%) | 0/3281 = 0.0% (0.0%, 0.0%) | 0/3281 = 0.0% (0.0%, 0.0%) |
| Age < 65 Communities of Color | Day 57 | Placebo | Negative | Anti RBD IgG (IU/ml) | 37 | 0/3281 = 0.0% (0.0%, 0.0%) | 0/3281 = 0.0% (0.0%, 0.0%) | 0/3281 = 0.0% (0.0%, 0.0%) |
| Age < 65 Communities of Color | Day 57 | Placebo | Negative | Anti Spike IgG (IU/ml) | 37 | 0/3281 = 0.0% (0.0%, 0.0%) | 0/3281 = 0.0% (0.0%, 0.0%) | 0/3281 = 0.0% (0.0%, 0.0%) |
| Age < 65 Communities of Color | Day 57 | Placebo | Positive | Anti N IgG (IU/ml) | 61 | 361/361 = 100.0% (100.0%, 100.0%) | 361/361 = 100.0% (100.0%, 100.0%) | 361/361 = 100.0% (100.0%, 100.0%) |
| Age < 65 Communities of Color | Day 57 | Placebo | Positive | Anti RBD IgG (IU/ml) | 61 | 361/361 = 100.0% (100.0%, 100.0%) | 361/361 = 100.0% (100.0%, 100.0%) | 361/361 = 100.0% (100.0%, 100.0%) |
| Age < 65 Communities of Color | Day 57 | Placebo | Positive | Anti Spike IgG (IU/ml) | 61 | 361/361 = 100.0% (100.0%, 100.0%) | 361/361 = 100.0% (100.0%, 100.0%) | 361/361 = 100.0% (100.0%, 100.0%) |
| Age < 65 White Non-Hispanic | Day 29 | Vaccine | Negative | Anti N IgG (IU/ml) | 175 | 5217.3/5217.3 = 100.0% (100.0%, 100.0%) | 5217.3/5217.3 = 100.0% (100.0%, 100.0%) | 5217.3/5217.3 = 100.0% (100.0%, 100.0%) |
| Age < 65 White Non-Hispanic | Day 29 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 175 | 5217.3/5217.3 = 100.0% (100.0%, 100.0%) | 5217.3/5217.3 = 100.0% (100.0%, 100.0%) | 5217.3/5217.3 = 100.0% (100.0%, 100.0%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % Greater than 2 × LLOD | % Greater than 4 × LLOD |
|-----------------------------------|--------|---------|---------------------|------------------------|-----|--|--|--|
| Age < 65 White Non-Hispanic | Day 29 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 175 | 5217.3/5217.3 = 100.0% (100.0%, 100.0%) | 5217.3/5217.3 = 100.0% (100.0%, 100.0%) | 5217.3/5217.3 = 100.0% (100.0%, 100.0%) |
| Age < 65 White Non-Hispanic | Day 29 | Vaccine | Positive | Anti N IgG (IU/ml) | 59 | 602.4/602.4 = 100.0% (100.0%, 100.0%) | 602.4/602.4 = 100.0% (100.0%, 100.0%) | 602.4/602.4 = 100.0% (100.0%, 100.0%) |
| Age < 65 White Non-Hispanic | Day 29 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 59 | 602.4/602.4 = 100.0% (100.0%, 100.0%) | 602.4/602.4 = 100.0% (100.0%, 100.0%) | 602.4/602.4 = 100.0% (100.0%, 100.0%) |
| Age < 65 White Non-Hispanic | Day 29 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 59 | 602.4/602.4 = 100.0% (100.0%, 100.0%) | 602.4/602.4 = 100.0% (100.0%, 100.0%) | 602.4/602.4 = 100.0% (100.0%, 100.0%) |
| Age < 65 White Non-Hispanic | Day 29 | Placebo | Negative | Anti N IgG (IU/ml) | 31 | 0/4988.2 = 0.0% (0.0%, 0.0%) | 0/4988.2 = 0.0% (0.0%, 0.0%) | 0/4988.2 = 0.0% (0.0%, 0.0%) |
| Age < 65 White Non-Hispanic | Day 29 | Placebo | Negative | Anti RBD IgG (IU/ml) | 31 | 0/4988.2 = 0.0% (0.0%, 0.0%) | 0/4988.2 = 0.0% (0.0%, 0.0%) | 0/4988.2 = 0.0% (0.0%, 0.0%) |
| Age < 65 White Non-Hispanic | Day 29 | Placebo | Negative | Anti Spike IgG (IU/ml) | 31 | 0/4988.2 = 0.0% (0.0%, 0.0%) | 0/4988.2 = 0.0% (0.0%, 0.0%) | 0/4988.2 = 0.0% (0.0%, 0.0%) |
| Age < 65 White Non-Hispanic | Day 29 | Placebo | Positive | Anti N IgG (IU/ml) | 61 | 517.6/517.6 = 100.0% (100.0%, 100.0%) | 517.6/517.6 = 100.0% (100.0%, 100.0%) | 517.6/517.6 = 100.0% (100.0%, 100.0%) |
| Age < 65 White Non-Hispanic | Day 29 | Placebo | Positive | Anti RBD IgG (IU/ml) | 61 | 517.6/517.6 = 100.0% (100.0%, 100.0%) | 517.6/517.6 = 100.0% (100.0%, 100.0%) | 517.6/517.6 = 100.0% (100.0%, 100.0%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % Greater than 2 × LLOD | % Greater than 4 × LLOD |
|-----------------------------------|--------|---------|---------------------|------------------------|-----|--|--|--|
| Age < 65 White Non-Hispanic | Day 29 | Placebo | Positive | Anti Spike IgG (IU/ml) | 61 | 517.6/517.6 = 100.0% (100.0%, 100.0%) | 517.6/517.6 = 100.0% (100.0%, 100.0%) | 517.6/517.6 = 100.0% (100.0%, 100.0%) |
| Age < 65 White Non-Hispanic | Day 57 | Vaccine | Negative | Anti N IgG (IU/ml) | 175 | 5217.3/5217.3 = 100.0% (100.0%, 100.0%) | 5217.3/5217.3 = 100.0% (100.0%, 100.0%) | 5217.3/5217.3 = 100.0% (100.0%, 100.0%) |
| Age < 65 White Non-Hispanic | Day 57 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 175 | 5217.3/5217.3 = 100.0% (100.0%, 100.0%) | 5217.3/5217.3 = 100.0% (100.0%, 100.0%) | 5217.3/5217.3 = 100.0% (100.0%, 100.0%) |
| Age < 65 White Non-Hispanic | Day 57 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 175 | 5217.3/5217.3 = 100.0% (100.0%, 100.0%) | 5217.3/5217.3 = 100.0% (100.0%, 100.0%) | 5217.3/5217.3 = 100.0% (100.0%, 100.0%) |
| Age < 65 White Non-Hispanic | Day 57 | Vaccine | Positive | Anti N IgG (IU/ml) | 59 | 602.4/602.4 = 100.0% (100.0%, 100.0%) | 602.4/602.4 = 100.0% (100.0%, 100.0%) | 602.4/602.4 = 100.0% (100.0%, 100.0%) |
| Age < 65 White Non-Hispanic | Day 57 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 59 | 602.4/602.4 = 100.0% (100.0%, 100.0%) | 602.4/602.4 = 100.0% (100.0%, 100.0%) | 602.4/602.4 = 100.0% (100.0%, 100.0%) |
| Age < 65 White Non-Hispanic | Day 57 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 59 | 602.4/602.4 = 100.0% (100.0%, 100.0%) | 602.4/602.4 = 100.0% (100.0%, 100.0%) | 602.4/602.4 = 100.0% (100.0%, 100.0%) |
| Age < 65 White Non-Hispanic | Day 57 | Placebo | Negative | Anti N IgG (IU/ml) | 31 | 0/4988.2 = 0.0% (0.0%, 0.0%) | 0/4988.2 = 0.0% (0.0%, 0.0%) | 0/4988.2 = 0.0% (0.0%, 0.0%) |
| Age < 65 White Non-Hispanic | Day 57 | Placebo | Negative | Anti RBD IgG (IU/ml) | 31 | 76.3/4988.2 = 1.5% (0.2%, 11.0%) | 0/4988.2 = 0.0% (0.0%, 0.0%) | 0/4988.2 = 0.0% (0.0%, 0.0%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % Greater than 2 × LLOD | % Greater than 4 × LLOD |
|-------------------------------|--------|---------|---------------------|------------------------|-----|--|--|--|
| Age < 65 White Non-Hispanic | Day 57 | Placebo | Negative | Anti Spike IgG (IU/ml) | 31 | 0/4988.2 = 0.0% (0.0%, 0.0%) | 0/4988.2 = 0.0% (0.0%, 0.0%) | 0/4988.2 = 0.0% (0.0%, 0.0%) |
| Age < 65 White Non-Hispanic | Day 57 | Placebo | Positive | Anti N IgG (IU/ml) | 61 | 517.6/517.6 = 100.0% (100.0%, 100.0%) | 517.6/517.6 = 100.0% (100.0%, 100.0%) | 517.6/517.6 = 100.0% (100.0%, 100.0%) |
| Age < 65 White Non-Hispanic | Day 57 | Placebo | Positive | Anti RBD IgG (IU/ml) | 61 | 517.6/517.6 = 100.0% (100.0%, 100.0%) | 517.6/517.6 = 100.0% (100.0%, 100.0%) | 517.6/517.6 = 100.0% (100.0%, 100.0%) |
| Age < 65 White Non-Hispanic | Day 57 | Placebo | Positive | Anti Spike IgG (IU/ml) | 61 | 517.6/517.6 = 100.0% (100.0%, 100.0%) | 517.6/517.6 = 100.0% (100.0%, 100.0%) | 517.6/517.6 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 Communities of Color | Day 29 | Vaccine | Negative | Anti N IgG (IU/ml) | 228 | 903/903 = 100.0% (100.0%, 100.0%) | 903/903 = 100.0% (100.0%, 100.0%) | 903/903 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 Communities of Color | Day 29 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 228 | 903/903 = 100.0% (100.0%, 100.0%) | 903/903 = 100.0% (100.0%, 100.0%) | 903/903 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 Communities of Color | Day 29 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 228 | 903/903 = 100.0% (100.0%, 100.0%) | 903/903 = 100.0% (100.0%, 100.0%) | 903/903 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 Communities of Color | Day 29 | Vaccine | Positive | Anti N IgG (IU/ml) | 51 | 87/87 = 100.0% (100.0%, 100.0%) | 87/87 = 100.0% (100.0%, 100.0%) | 87/87 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 Communities of Color | Day 29 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 51 | 87/87 = 100.0% (100.0%, 100.0%) | 87/87 = 100.0% (100.0%, 100.0%) | 87/87 = 100.0% (100.0%, 100.0%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % Greater than 2 × LLOD | % Greater than 4 × LLOD |
|----------------------------------|--------|---------|---------------------|------------------------|-----|--------------------------------------|--------------------------------------|--------------------------------------|
| Age ≥ 65 Communities of Color | Day 29 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 51 | 87/87 = 100.0% (100.0%, 100.0%) | 87/87 = 100.0% (100.0%, 100.0%) | 87/87 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 Communities of Color | Day 29 | Placebo | Negative | Anti N IgG (IU/ml) | 36 | 0/1038 = 0.0% (0.0%, 0.0%) | 0/1038 = 0.0% (0.0%, 0.0%) | 0/1038 = 0.0% (0.0%, 0.0%) |
| Age ≥ 65 Communities of Color | Day 29 | Placebo | Negative | Anti RBD IgG (IU/ml) | 36 | 0/1038 = 0.0% (0.0%, 0.0%) | 0/1038 = 0.0% (0.0%, 0.0%) | 0/1038 = 0.0% (0.0%, 0.0%) |
| Age ≥ 65 Communities of Color | Day 29 | Placebo | Negative | Anti Spike IgG (IU/ml) | 36 | 0/1038 = 0.0% (0.0%, 0.0%) | 0/1038 = 0.0% (0.0%, 0.0%) | 0/1038 = 0.0% (0.0%, 0.0%) |
| Age ≥ 65 Communities of Color | Day 29 | Placebo | Positive | Anti N IgG (IU/ml) | 50 | 78/78 = 100.0% (100.0%, 100.0%) | 78/78 = 100.0% (100.0%, 100.0%) | 78/78 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 Communities of Color | Day 29 | Placebo | Positive | Anti RBD IgG (IU/ml) | 50 | 78/78 = 100.0% (100.0%, 100.0%) | 78/78 = 100.0% (100.0%, 100.0%) | 78/78 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 Communities of Color | Day 29 | Placebo | Positive | Anti Spike IgG (IU/ml) | 50 | 78/78 = 100.0% (100.0%, 100.0%) | 78/78 = 100.0% (100.0%, 100.0%) | 78/78 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 Communities of Color | Day 57 | Vaccine | Negative | Anti N IgG (IU/ml) | 228 | 903/903 = 100.0% (100.0%, 100.0%) | 903/903 = 100.0% (100.0%, 100.0%) | 903/903 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 Communities of Color | Day 57 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 228 | 903/903 = 100.0% (100.0%, 100.0%) | 903/903 = 100.0% (100.0%, 100.0%) | 903/903 = 100.0% (100.0%, 100.0%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % Greater than 2 × LLOD | % Greater than 4 × LLOD |
|-------------------------------|--------|---------|---------------------|------------------------|-----|-----------------------------------|-----------------------------------|-----------------------------------|
| Age ≥ 65 Communities of Color | Day 57 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 228 | 903/903 = 100.0% (100.0%, 100.0%) | 903/903 = 100.0% (100.0%, 100.0%) | 903/903 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 Communities of Color | Day 57 | Vaccine | Positive | Anti N IgG (IU/ml) | 51 | 87/87 = 100.0% (100.0%, 100.0%) | 87/87 = 100.0% (100.0%, 100.0%) | 87/87 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 Communities of Color | Day 57 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 51 | 87/87 = 100.0% (100.0%, 100.0%) | 87/87 = 100.0% (100.0%, 100.0%) | 87/87 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 Communities of Color | Day 57 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 51 | 87/87 = 100.0% (100.0%, 100.0%) | 87/87 = 100.0% (100.0%, 100.0%) | 87/87 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 Communities of Color | Day 57 | Placebo | Negative | Anti N IgG (IU/ml) | 36 | 0/1038 = 0.0% (0.0%, 0.0%) | 0/1038 = 0.0% (0.0%, 0.0%) | 0/1038 = 0.0% (0.0%, 0.0%) |
| Age ≥ 65 Communities of Color | Day 57 | Placebo | Negative | Anti RBD IgG (IU/ml) | 36 | 0/1038 = 0.0% (0.0%, 0.0%) | 0/1038 = 0.0% (0.0%, 0.0%) | 0/1038 = 0.0% (0.0%, 0.0%) |
| Age ≥ 65 Communities of Color | Day 57 | Placebo | Negative | Anti Spike IgG (IU/ml) | 36 | 0/1038 = 0.0% (0.0%, 0.0%) | 0/1038 = 0.0% (0.0%, 0.0%) | 0/1038 = 0.0% (0.0%, 0.0%) |
| Age ≥ 65 Communities of Color | Day 57 | Placebo | Positive | Anti N IgG (IU/ml) | 50 | 78/78 = 100.0% (100.0%, 100.0%) | 78/78 = 100.0% (100.0%, 100.0%) | 78/78 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 Communities of Color | Day 57 | Placebo | Positive | Anti RBD IgG (IU/ml) | 50 | 78/78 = 100.0% (100.0%, 100.0%) | 78/78 = 100.0% (100.0%, 100.0%) | 78/78 = 100.0% (100.0%, 100.0%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % Greater than 2 × LLOD | % Greater than 4 × LLOD |
|-----------------------------------|--------|---------|---------------------|------------------------|-----|--|--|--|
| Age ≥ 65 Communities of Color | Day 57 | Placebo | Positive | Anti Spike IgG (IU/ml) | 50 | 78/78 = 100.0% (100.0%, 100.0%) | 78/78 = 100.0% (100.0%, 100.0%) | 78/78 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 White Non-Hispanic | Day 29 | Vaccine | Negative | Anti N IgG (IU/ml) | 187 | 1379.7/1379.7 = 100.0% (100.0%, 100.0%) | 1379.7/1379.7 = 100.0% | 1379.7/1379.7 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 White Non-Hispanic | Day 29 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 187 | 1379.7/1379.7 = 100.0% (100.0%, 100.0%) | 1379.7/1379.7 = 100.0% | 1379.7/1379.7 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 White Non-Hispanic | Day 29 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 187 | 1379.7/1379.7 = 100.0% (100.0%, 100.0%) | 1379.7/1379.7 = 100.0% | 1379.7/1379.7 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 White Non-Hispanic | Day 29 | Vaccine | Positive | Anti N IgG (IU/ml) | 66 | 171.4/171.4 = 100.0% (100.0%, 100.0%) | 171.4/171.4 = 100.0% (100.0%, 100.0%) | 171.4/171.4 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 White Non-Hispanic | Day 29 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 66 | 171.4/171.4 = 100.0% (100.0%, 100.0%) | 171.4/171.4 = 100.0% (100.0%, 100.0%) | 171.4/171.4 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 White Non-Hispanic | Day 29 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 66 | 171.4/171.4 = 100.0% (100.0%, 100.0%) | 171.4/171.4 = 100.0% (100.0%, 100.0%) | 171.4/171.4 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 White Non-Hispanic | Day 29 | Placebo | Negative | Anti N IgG (IU/ml) | 36 | 0/1598.6 = 0.0% (0.0%, 0.0%) | 0/1598.6 = 0.0% (0.0%, 0.0%) | 0/1598.6 = 0.0% (0.0%, 0.0%) |
| Age ≥ 65 White Non-Hispanic | Day 29 | Placebo | Negative | Anti RBD IgG (IU/ml) | 36 | 0/1598.6 = 0.0% (0.0%, 0.0%) | 0/1598.6 = 0.0% (0.0%, 0.0%) | 0/1598.6 = 0.0% (0.0%, 0.0%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % Greater than 2 × LLOD | % Greater than 4 × LLOD |
|-----------------------------------|--------|---------|---------------------|------------------------|-----|--|--|--|
| Age ≥ 65 White Non-Hispanic | Day 29 | Placebo | Negative | Anti Spike IgG (IU/ml) | 36 | 0/1598.6 = 0.0% (0.0%, 0.0%) | 0/1598.6 = 0.0% (0.0%, 0.0%) | 0/1598.6 = 0.0% (0.0%, 0.0%) |
| Age ≥ 65 White Non-Hispanic | Day 29 | Placebo | Positive | Anti N IgG (IU/ml) | 60 | 148.8/148.8 = 100.0% (100.0%, 100.0%) | 148.8/148.8 = 100.0% (100.0%, 100.0%) | 148.8/148.8 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 White Non-Hispanic | Day 29 | Placebo | Positive | Anti RBD IgG (IU/ml) | 60 | 148.8/148.8 = 100.0% (100.0%, 100.0%) | 148.8/148.8 = 100.0% (100.0%, 100.0%) | 148.8/148.8 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 White Non-Hispanic | Day 29 | Placebo | Positive | Anti Spike IgG (IU/ml) | 60 | 148.8/148.8 = 100.0% (100.0%, 100.0%) | 148.8/148.8 = 100.0% (100.0%, 100.0%) | 148.8/148.8 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 White Non-Hispanic | Day 57 | Vaccine | Negative | Anti N IgG (IU/ml) | 187 | 1379.7/1379.7 = 100.0% (100.0%, 100.0%) | 1379.7/1379.7 = 100.0% (100.0%, 100.0%) | 1379.7/1379.7 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 White Non-Hispanic | Day 57 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 187 | 1379.7/1379.7 = 100.0% (100.0%, 100.0%) | 1379.7/1379.7 = 100.0% (100.0%, 100.0%) | 1379.7/1379.7 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 White Non-Hispanic | Day 57 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 187 | 1379.7/1379.7 = 100.0% (100.0%, 100.0%) | 1379.7/1379.7 = 100.0% (100.0%, 100.0%) | 1379.7/1379.7 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 White Non-Hispanic | Day 57 | Vaccine | Positive | Anti N IgG (IU/ml) | 66 | 171.4/171.4 = 100.0% (100.0%, 100.0%) | 171.4/171.4 = 100.0% (100.0%, 100.0%) | 171.4/171.4 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 White Non-Hispanic | Day 57 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 66 | 171.4/171.4 = 100.0% (100.0%, 100.0%) | 171.4/171.4 = 100.0% (100.0%, 100.0%) | 171.4/171.4 = 100.0% (100.0%, 100.0%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % Greater than 2 × LLOD | % Greater than 4 × LLOD |
|-----------------------------------|--------|---------|---------------------|------------------------|----|--|--|--|
| Age ≥ 65 White Non-Hispanic | Day 57 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 66 | 171.4/171.4 = 100.0% (100.0%, 100.0%) | 171.4/171.4 = 100.0% (100.0%, 100.0%) | 171.4/171.4 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 White Non-Hispanic | Day 57 | Placebo | Negative | Anti N IgG (IU/ml) | 36 | 0/1598.6 = 0.0% (0.0%, 0.0%) | 0/1598.6 = 0.0% (0.0%, 0.0%) | 0/1598.6 = 0.0% (0.0%, 0.0%) |
| Age ≥ 65 White Non-Hispanic | Day 57 | Placebo | Negative | Anti RBD IgG (IU/ml) | 36 | 0/1598.6 = 0.0% (0.0%, 0.0%) | 0/1598.6 = 0.0% (0.0%, 0.0%) | 0/1598.6 = 0.0% (0.0%, 0.0%) |
| Age ≥ 65 White Non-Hispanic | Day 57 | Placebo | Negative | Anti Spike IgG (IU/ml) | 36 | 0/1598.6 = 0.0% (0.0%, 0.0%) | 0/1598.6 = 0.0% (0.0%, 0.0%) | 0/1598.6 = 0.0% (0.0%, 0.0%) |
| Age ≥ 65 White Non-Hispanic | Day 57 | Placebo | Positive | Anti N IgG (IU/ml) | 60 | 148.8/148.8 = 100.0% (100.0%, 100.0%) | 148.8/148.8 = 100.0% (100.0%, 100.0%) | 148.8/148.8 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 White Non-Hispanic | Day 57 | Placebo | Positive | Anti RBD IgG (IU/ml) | 60 | 148.8/148.8 = 100.0% (100.0%, 100.0%) | 148.8/148.8 = 100.0% (100.0%, 100.0%) | 148.8/148.8 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 White Non-Hispanic | Day 57 | Placebo | Positive | Anti Spike IgG (IU/ml) | 60 | 148.8/148.8 = 100.0% (100.0%, 100.0%) | 148.8/148.8 = 100.0% (100.0%, 100.0%) | 148.8/148.8 = 100.0% (100.0%, 100.0%) |

Binding Antibody Responders are defined as participants who had baseline values below the LLOD with detectable antibody concentration above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in antibody concentration.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 4a. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by All participants

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % 2-Fold Rise | % 4-Fold Rise |
|-------------------------|--------|---------|---------------------|----------------------|-----|---|---|---|
| All participants | | | | | | | | |
| | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID50 | 914 | 11733.1/13295 = 88.3% (84.7%, 91.0%) | 11787.2/13295 = 88.7% (85.2%, 91.4%) | 10870.9/13295 = 81.8% (77.9%, 85.1%) |
| | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID50 | 274 | 1383.1/1432 = 96.6% (91.6%, 98.7%) | 1383.1/1432 = 96.6% (91.6%, 98.7%) | 1287.8/1432 = 89.9% (83.3%, 94.1%) |
| | Day 29 | Placebo | Negative | Pseudovirus-nAb ID50 | 163 | 149.5/13359 = 1.1% (0.3%, 3.8%) | 149.5/13359 = 1.1% (0.3%, 3.8%) | 0/13359 = 0.0% (0.0%, 0.0%) |
| | Day 29 | Placebo | Positive | Pseudovirus-nAb ID50 | 270 | 1139.8/1357 = 84.0% (76.8%, 89.3%) | 1143.2/1357 = 84.2% (77.0%, 89.5%) | 906/1357 = 66.8% (58.6%, 74.0%) |
| | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID50 | 914 | 13159.4/13295 = 99.0% (98.0%, 99.5%) | 13159.4/13295 = 99.0% (98.0%, 99.5%) | 12955/13295 = 97.4% (95.6%, 98.5%) |
| | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID50 | 274 | 1432/1432 = 100.0% (100.0%, 100.0%) | 1432/1432 = 100.0% (100.0%, 100.0%) | 1432/1432 = 100.0% (100.0%, 100.0%) |
| | Day 57 | Placebo | Negative | Pseudovirus-nAb ID50 | 163 | 131.9/13359 = 1.0% (0.3%, 3.0%) | 131.9/13359 = 1.0% (0.3%, 3.0%) | 0/13359 = 0.0% (0.0%, 0.0%) |
| | Day 57 | Placebo | Positive | Pseudovirus-nAb ID50 | 270 | 1301.8/1357 = 95.9% (90.6%, 98.3%) | 1301.8/1357 = 95.9% (90.6%, 98.3%) | 1253.1/1357 = 92.3% (86.0%, 95.9%) |

Neutralization Responders are defined as participants who had baseline values below the lower limit of detection (LLOD) with detectable ID50 neutralization titer above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in ID50.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 4b. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Age

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % 2-Fold Rise | % 4-Fold Rise |
|------------|--------|---------|---------------------|----------------------|-----|--|--|---|
| Age | | | | | | | | |
| Age < 65 | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID50 | 432 | 9050.2/10518 = 86.0% (81.6%, 89.5%) | 9096.9/10518 = 86.5% (82.1%, 89.9%) | 8317.2/10518 = 79.1% (74.2%, 83.2%) |
| Age < 65 | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID50 | 146 | 1103/1145 = 96.3% (89.7%, 98.7%) | 1103/1145 = 96.3% (89.7%, 98.7%) | 1010.3/1145 = 88.2% (80.0%, 93.4%) |
| Age < 65 | Day 29 | Placebo | Negative | Pseudovirus-nAb ID50 | 80 | 76.3/10234 = 0.7% (0.1%, 5.3%) | 76.3/10234 = 0.7% (0.1%, 5.3%) | 0/10234 = 0.0% (0.0%, 0.0%) |
| Age < 65 | Day 29 | Placebo | Positive | Pseudovirus-nAb ID50 | 147 | 896.3/1098 = 81.6% (72.7%, 88.1%) | 899.7/1098 = 81.9% (73.1%, 88.4%) | 682.7/1098 = 62.2% (52.3%, 71.1%) |
| Age < 65 | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID50 | 432 | 10405/10518 = 98.9% (97.6%, 99.5%) | 10405/10518 = 98.9% (97.6%, 99.5%) | 10226.7/10518 = 97.2% (94.8%, 98.5%) |
| Age < 65 | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID50 | 146 | 1145/1145 = 100.0% (100.0%, 100.0%) | 1145/1145 = 100.0% (100.0%, 100.0%) | 1145/1145 = 100.0% (100.0%, 100.0%) |
| Age < 65 | Day 57 | Placebo | Negative | Pseudovirus-nAb ID50 | 80 | 43.1/10234 = 0.4% (0.1%, 3.0%) | 43.1/10234 = 0.4% (0.1%, 3.0%) | 0/10234 = 0.0% (0.0%, 0.0%) |
| Age < 65 | Day 57 | Placebo | Positive | Pseudovirus-nAb ID50 | 147 | 1042.8/1098 = 95.0% (88.4%, 97.9%) | 1042.8/1098 = 95.0% (88.4%, 97.9%) | 995.7/1098 = 90.7% (82.9%, 95.1%) |
| Age ≥ 65 | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID50 | 482 | 2682.9/2777 = 96.6% (94.4%, 98.0%) | 2690.3/2777 = 96.9% (94.8%, 98.2%) | 2553.6/2777 = 92.0% (89.1%, 94.1%) |
| Age ≥ 65 | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID50 | 128 | 280.1/287 = 97.6% (92.6%, 99.3%) | 280.1/287 = 97.6% (92.6%, 99.3%) | 277.5/287 = 96.7% (91.3%, 98.8%) |
| Age ≥ 65 | Day 29 | Placebo | Negative | Pseudovirus-nAb ID50 | 83 | 73.2/3125 = 2.3% (0.5%, 9.5%) | 73.2/3125 = 2.3% (0.5%, 9.5%) | 0/3125 = 0.0% (0.0%, 0.0%) |
| Age ≥ 65 | Day 29 | Placebo | Positive | Pseudovirus-nAb ID50 | 123 | 243.5/259 = 94.0% (87.7%, 97.2%) | 243.5/259 = 94.0% (87.7%, 97.2%) | 223.3/259 = 86.2% (78.6%, 91.4%) |
| Age ≥ 65 | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID50 | 482 | 2754.3/2777 = 99.2% (97.7%, 99.7%) | 2754.3/2777 = 99.2% (97.7%, 99.7%) | 2728.2/2777 = 98.2% (96.4%, 99.1%) |
| Age ≥ 65 | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID50 | 128 | 287/287 = 100.0% (100.0%, 100.0%) | 287/287 = 100.0% (100.0%, 100.0%) | 287/287 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 | Day 57 | Placebo | Negative | Pseudovirus-nAb ID50 | 83 | 88.8/3125 = 2.8% (0.7%, 10.9%) | 88.8/3125 = 2.8% (0.7%, 10.9%) | 0/3125 = 0.0% (0.0%, 0.0%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % 2-Fold Rise | % 4-Fold Rise |
|---------------|--------|---------|---------------------|----------------------|-----|--------------------------------------|--------------------------------------|-------------------------------------|
| Age \geq 65 | Day 57 | Placebo | Positive | Pseudovirus-nAb ID50 | 123 | 259/259 = 100.0% (100.0%, 100.0%) | 259/259 = 100.0% (100.0%, 100.0%) | 257.4/259 = 99.4% (95.7%, 99.9%) |

Neutralization Responders are defined as participants who had baseline values below the lower limit of detection (LLOD) with detectable ID50 neutralization titer above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in ID50.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 4c. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Risk for Severe Covid-19

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % 2-Fold Rise | % 4-Fold Rise |
|---------------------------------|--------|---------|---------------------|----------------------|-----|--|--|--|
| Risk for Severe Covid-19 | | | | | | | | |
| At-risk | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID50 | 469 | 3353.3/3736.6 = 89.7% (86.3%, 92.4%) | 3360.6/3736.6 = 89.9% (86.6%, 92.5%) | 3035.3/3736.6 = 81.2% (77.1%, 84.8%) |
| At-risk | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID50 | 125 | 355.1/368.8 = 96.3% (90.0%, 98.7%) | 355.1/368.8 = 96.3% (90.0%, 98.7%) | 332.9/368.8 = 90.3% (82.5%, 94.8%) |
| At-risk | Day 29 | Placebo | Negative | Pseudovirus-nAb ID50 | 84 | 149.5/4096.4 = 3.6% (1.0%, 12.0%) | 149.5/4096.4 = 3.6% (1.0%, 12.0%) | 0/4096.4 = 0.0% (0.0%, 0.0%) |
| At-risk | Day 29 | Placebo | Positive | Pseudovirus-nAb ID50 | 123 | 284.5/331.2 = 85.9% (78.4%, 91.1%) | 287.9/331.2 = 86.9% (79.6%, 91.9%) | 248.5/331.2 = 75.0% (66.5%, 82.0%) |
| At-risk | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID50 | 469 | 3654.9/3736.6 = 97.8% (95.6%, 98.9%) | 3654.9/3736.6 = 97.8% (95.6%, 98.9%) | 3597.8/3736.6 = 96.3% (93.7%, 97.8%) |
| At-risk | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID50 | 125 | 368.8/368.8 = 100.0% (100.0%, 100.0%) | 368.8/368.8 = 100.0% (100.0%, 100.0%) | 368.8/368.8 = 100.0% (100.0%, 100.0%) |
| At-risk | Day 57 | Placebo | Negative | Pseudovirus-nAb ID50 | 84 | 43.1/4096.4 = 1.1% (0.1%, 7.4%) | 43.1/4096.4 = 1.1% (0.1%, 7.4%) | 0/4096.4 = 0.0% (0.0%, 0.0%) |
| At-risk | Day 57 | Placebo | Positive | Pseudovirus-nAb ID50 | 123 | 322.9/331.2 = 97.5% (92.2%, 99.2%) | 322.9/331.2 = 97.5% (92.2%, 99.2%) | 317/331.2 = 95.7% (89.9%, 98.2%) |
| Not at-risk | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID50 | 445 | 8379.9/9558.4 = 87.7% (82.8%, 91.3%) | 8426.5/9558.4 = 88.2% (83.4%, 91.7%) | 7835.6/9558.4 = 82.0% (76.7%, 86.3%) |
| Not at-risk | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID50 | 149 | 1028/1063.2 = 96.7% (89.2%, 99.0%) | 1028/1063.2 = 96.7% (89.2%, 99.0%) | 954.9/1063.2 = 89.8% (80.7%, 94.9%) |
| Not at-risk | Day 29 | Placebo | Negative | Pseudovirus-nAb ID50 | 79 | 0/9262.6 = 0.0% (0.0%, 0.0%) | 0/9262.6 = 0.0% (0.0%, 0.0%) | 0/9262.6 = 0.0% (0.0%, 0.0%) |
| Not at-risk | Day 29 | Placebo | Positive | Pseudovirus-nAb ID50 | 147 | 855.3/1025.8 = 83.4% (73.8%, 89.9%) | 855.3/1025.8 = 83.4% (73.8%, 89.9%) | 657.5/1025.8 = 64.1% (53.6%, 73.4%) |
| Not at-risk | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID50 | 445 | 9504.5/9558.4 = 99.4% (97.8%, 99.9%) | 9504.5/9558.4 = 99.4% (97.8%, 99.9%) | 9357.2/9558.4 = 97.9% (95.0%, 99.1%) |
| Not at-risk | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID50 | 149 | 1063.2/1063.2 = 100.0% (100.0%, 100.0%) | 1063.2/1063.2 = 100.0% (100.0%, 100.0%) | 1063.2/1063.2 = 100.0% (100.0%, 100.0%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % 2-Fold Rise | % 4-Fold Rise |
|-------------|--------|---------|---------------------|----------------------|-----|--|--|--|
| Not at-risk | Day 57 | Placebo | Negative | Pseudovirus-nAb ID50 | 79 | 88.8/9262.6 = 1.0% (0.2%, 3.7%) | 88.8/9262.6 = 1.0% (0.2%, 3.7%) | 0/9262.6 = 0.0% (0.0%, 0.0%) |
| Not at-risk | Day 57 | Placebo | Positive | Pseudovirus-nAb ID50 | 147 | 978.9/1025.8 = 95.4% (88.1%, 98.3%) | 978.9/1025.8 = 95.4% (88.1%, 98.3%) | 936.2/1025.8 = 91.3% (82.8%, 95.8%) |

Neutralization Responders are defined as participants who had baseline values below the lower limit of detection (LLOD) with detectable ID50 neutralization titer above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in ID50.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 4d. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Age, Risk for Severe Covid-19

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % 2-Fold Rise | % 4-Fold Rise |
|--------------------------------------|--------|---------|---------------------|----------------------|-----|---------------------------------------|---------------------------------------|---------------------------------------|
| Age, Risk for Severe Covid-19 | | | | | | | | |
| Age < 65 At-risk | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID50 | 214 | 1967.1/2279 = 86.3% (81.1%, 90.3%) | 1967.1/2279 = 86.3% (81.1%, 90.3%) | 1729.6/2279 = 75.9% (69.6%, 81.2%) |
| Age < 65 At-risk | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID50 | 73 | 236.9/248 = 95.5% (86.2%, 98.7%) | 236.9/248 = 95.5% (86.2%, 98.7%) | 214.7/248 = 86.6% (75.4%, 93.1%) |
| Age < 65 At-risk | Day 29 | Placebo | Negative | Pseudovirus-nAb ID50 | 40 | 76.3/2454 = 3.1% (0.4%, 20.6%) | 76.3/2454 = 3.1% (0.4%, 20.6%) | 0/2454 = 0.0% (0.0%, 0.0%) |
| Age < 65 At-risk | Day 29 | Placebo | Positive | Pseudovirus-nAb ID50 | 75 | 186.7/226 = 82.6% (72.4%, 89.6%) | 190.1/226 = 84.1% (74.3%, 90.7%) | 160.7/226 = 71.1% (59.9%, 80.2%) |
| Age < 65 At-risk | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID50 | 214 | 2219.9/2279 = 97.4% (93.8%, 98.9%) | 2219.9/2279 = 97.4% (93.8%, 98.9%) | 2181.6/2279 = 95.7% (91.6%, 97.9%) |
| Age < 65 At-risk | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID50 | 73 | 248/248 = 100.0% (100.0%, 100.0%) | 248/248 = 100.0% (100.0%, 100.0%) | 248/248 = 100.0% (100.0%, 100.0%) |
| Age < 65 At-risk | Day 57 | Placebo | Negative | Pseudovirus-nAb ID50 | 40 | 43.1/2454 = 1.8% (0.2%, 12.3%) | 43.1/2454 = 1.8% (0.2%, 12.3%) | 0/2454 = 0.0% (0.0%, 0.0%) |
| Age < 65 At-risk | Day 57 | Placebo | Positive | Pseudovirus-nAb ID50 | 75 | 217.6/226 = 96.3% (88.7%, 98.9%) | 217.6/226 = 96.3% (88.7%, 98.9%) | 211.8/226 = 93.7% (85.3%, 97.4%) |
| Age < 65 Not at-risk | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID50 | 218 | 7083.2/8239 = 86.0% (80.3%, 90.2%) | 7129.8/8239 = 86.5% (81.0%, 90.7%) | 6587.7/8239 = 80.0% (73.8%, 85.0%) |
| Age < 65 Not at-risk | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID50 | 73 | 866.1/897 = 96.6% (86.9%, 99.2%) | 866.1/897 = 96.6% (86.9%, 99.2%) | 795.6/897 = 88.7% (77.8%, 94.6%) |
| Age < 65 Not at-risk | Day 29 | Placebo | Negative | Pseudovirus-nAb ID50 | 40 | 0/7780 = 0.0% (0.0%, 0.0%) | 0/7780 = 0.0% (0.0%, 0.0%) | 0/7780 = 0.0% (0.0%, 0.0%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % 2-Fold Rise | % 4-Fold Rise |
|----------------------|--------|---------|---------------------|----------------------|-----|--|--|--|
| Age < 65 Not at-risk | Day 29 | Placebo | Positive | Pseudovirus-nAb ID50 | 72 | 709.6/872 = 81.4% (70.1%, 89.1%) | 709.6/872 = 81.4% (70.1%, 89.1%) | 522.1/872 = 59.9% (47.7%, 70.9%) |
| Age < 65 Not at-risk | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID50 | 218 | 8185.1/8239 = 99.3% (97.4%, 99.8%) | 8185.1/8239 = 99.3% (97.4%, 99.8%) | 8045.2/8239 = 97.6% (94.3%, 99.1%) |
| Age < 65 Not at-risk | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID50 | 73 | 897/897 = 100.0% (100.0%, 100.0%) | 897/897 = 100.0% (100.0%, 100.0%) | 897/897 = 100.0% (100.0%, 100.0%) |
| Age < 65 Not at-risk | Day 57 | Placebo | Negative | Pseudovirus-nAb ID50 | 40 | 0/7780 = 0.0% (0.0%, 0.0%) | 0/7780 = 0.0% (0.0%, 0.0%) | 0/7780 = 0.0% (0.0%, 0.0%) |
| Age < 65 Not at-risk | Day 57 | Placebo | Positive | Pseudovirus-nAb ID50 | 72 | 825.1/872 = 94.6% (86.0%, 98.1%) | 825.1/872 = 94.6% (86.0%, 98.1%) | 783.9/872 = 89.9% (79.8%, 95.2%) |
| Age ≥ 65 At-risk | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID50 | 255 | 1386.2/1457.6 = 95.1% (91.4%, 97.3%) | 1393.5/1457.6 = 95.6% (92.0%, 97.6%) | 1305.7/1457.6 = 89.6% (85.0%, 92.9%) |
| Age ≥ 65 At-risk | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID50 | 52 | 118.2/120.8 = 97.8% (85.4%, 99.7%) | 118.2/120.8 = 97.8% (85.4%, 99.7%) | 118.2/120.8 = 97.8% (85.4%, 99.7%) |
| Age ≥ 65 At-risk | Day 29 | Placebo | Negative | Pseudovirus-nAb ID50 | 44 | 73.2/1642.4 = 4.5% (1.0%, 17.7%) | 73.2/1642.4 = 4.5% (1.0%, 17.7%) | 0/1642.4 = 0.0% (0.0%, 0.0%) |
| Age ≥ 65 At-risk | Day 29 | Placebo | Positive | Pseudovirus-nAb ID50 | 48 | 97.8/105.2 = 92.9% (79.7%, 97.8%) | 97.8/105.2 = 92.9% (79.7%, 97.8%) | 87.9/105.2 = 83.5% (69.0%, 92.0%) |
| Age ≥ 65 At-risk | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID50 | 255 | 1434.9/1457.6 = 98.4% (95.7%, 99.4%) | 1434.9/1457.6 = 98.4% (95.7%, 99.4%) | 1416.2/1457.6 = 97.2% (94.0%, 98.7%) |
| Age ≥ 65 At-risk | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID50 | 52 | 120.8/120.8 = 100.0% (100.0%, 100.0%) | 120.8/120.8 = 100.0% (100.0%, 100.0%) | 120.8/120.8 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 At-risk | Day 57 | Placebo | Negative | Pseudovirus-nAb ID50 | 44 | 0/1642.4 = 0.0% (0.0%, 0.0%) | 0/1642.4 = 0.0% (0.0%, 0.0%) | 0/1642.4 = 0.0% (0.0%, 0.0%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % 2-Fold Rise | % 4-Fold Rise |
|----------------------|--------|---------|---------------------|----------------------|-----|---|---|---------------------------------------|
| Age ≥ 65 At-risk | Day 57 | Placebo | Positive | Pseudovirus-nAb ID50 | 48 | 105.2/105.2 = 100.0% (100.0%, 100.0%) | 105.2/105.2 = 100.0% (100.0%, 100.0%) | 105.2/105.2 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 Not at-risk | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID50 | 227 | 1296.7/1319.4 = 98.3% (95.3%, 99.4%) | 1296.7/1319.4 = 98.3% (95.3%, 99.4%) | 1247.9/1319.4 = 94.6% (90.5%, 97.0%) |
| Age ≥ 65 Not at-risk | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID50 | 76 | 161.9/166.2 = 97.4% (89.6%, 99.4%) | 161.9/166.2 = 97.4% (89.6%, 99.4%) | 159.3/166.2 = 95.8% (87.3%, 98.7%) |
| Age ≥ 65 Not at-risk | Day 29 | Placebo | Negative | Pseudovirus-nAb ID50 | 39 | 0/1482.6 = 0.0% (0.0%, 0.0%) | 0/1482.6 = 0.0% (0.0%, 0.0%) | 0/1482.6 = 0.0% (0.0%, 0.0%) |
| Age ≥ 65 Not at-risk | Day 29 | Placebo | Positive | Pseudovirus-nAb ID50 | 75 | 145.7/153.8 = 94.7% (86.2%, 98.1%) | 145.7/153.8 = 94.7% (86.2%, 98.1%) | 135.4/153.8 = 88.1% (78.7%, 93.6%) |
| Age ≥ 65 Not at-risk | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID50 | 227 | 1319.4/1319.4 = 100.0% (100.0%, 100.0%) | 1319.4/1319.4 = 100.0% (100.0%, 100.0%) | 1312/1319.4 = 99.4% (96.1%, 99.9%) |
| Age ≥ 65 Not at-risk | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID50 | 76 | 166.2/166.2 = 100.0% (100.0%, 100.0%) | 166.2/166.2 = 100.0% (100.0%, 100.0%) | 166.2/166.2 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 Not at-risk | Day 57 | Placebo | Negative | Pseudovirus-nAb ID50 | 39 | 88.8/1482.6 = 6.0% (1.4%, 22.0%) | 88.8/1482.6 = 6.0% (1.4%, 22.0%) | 0/1482.6 = 0.0% (0.0%, 0.0%) |
| Age ≥ 65 Not at-risk | Day 57 | Placebo | Positive | Pseudovirus-nAb ID50 | 75 | 153.8/153.8 = 100.0% (100.0%, 100.0%) | 153.8/153.8 = 100.0% (100.0%, 100.0%) | 152.2/153.8 = 99.0% (92.9%, 99.9%) |

Neutralization Responders are defined as participants who had baseline values below the lower limit of detection (LLOD) with detectable ID50 neutralization titer above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in ID50.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 4e. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Sex

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % 2-Fold Rise | % 4-Fold Rise |
|------------|--------|---------|---------------------|----------------------|-----|--|--|--|
| Sex | | | | | | | | |
| Male | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID50 | 395 | 4737.9/5298.6 = 89.4% (83.8%, 93.2%) | 4745.3/5298.6 = 89.6% (83.9%, 93.4%) | 4439.5/5298.6 = 83.8% (77.6%, 88.5%) |
| Male | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID50 | 121 | 557.7/564.7 = 98.8% (94.9%, 99.7%) | 557.7/564.7 = 98.8% (94.9%, 99.7%) | 522.3/564.7 = 92.5% (83.1%, 96.9%) |
| Male | Day 29 | Placebo | Negative | Pseudovirus-nAb ID50 | 76 | 105.1/4771.7 = 2.2% (0.5%, 9.9%) | 105.1/4771.7 = 2.2% (0.5%, 9.9%) | 0/4771.7 = 0.0% (0.0%, 0.0%) |
| Male | Day 29 | Placebo | Positive | Pseudovirus-nAb ID50 | 115 | 433.2/529.2 = 81.9% (69.1%, 90.1%) | 433.2/529.2 = 81.9% (69.1%, 90.1%) | 328.3/529.2 = 62.0% (49.2%, 73.4%) |
| Male | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID50 | 395 | 5254.4/5298.6 = 99.2% (97.9%, 99.7%) | 5254.4/5298.6 = 99.2% (97.9%, 99.7%) | 5101.6/5298.6 = 96.3% (91.7%, 98.4%) |
| Male | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID50 | 121 | 564.7/564.7 = 100.0% (100.0%, 100.0%) | 564.7/564.7 = 100.0% (100.0%, 100.0%) | 564.7/564.7 = 100.0% (100.0%, 100.0%) |
| Male | Day 57 | Placebo | Negative | Pseudovirus-nAb ID50 | 76 | 44.4/4771.7 = 0.9% (0.1%, 6.6%) | 44.4/4771.7 = 0.9% (0.1%, 6.6%) | 0/4771.7 = 0.0% (0.0%, 0.0%) |
| Male | Day 57 | Placebo | Positive | Pseudovirus-nAb ID50 | 115 | 517/529.2 = 97.7% (88.9%, 99.6%) | 517/529.2 = 97.7% (88.9%, 99.6%) | 483.7/529.2 = 91.4% (79.2%, 96.7%) |
| Female | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID50 | 519 | 6995.2/7996.4 = 87.5% (82.6%, 91.1%) | 7041.9/7996.4 = 88.1% (83.3%, 91.6%) | 6431.3/7996.4 = 80.4% (75.1%, 84.8%) |
| Female | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID50 | 153 | 825.4/867.3 = 95.2% (86.7%, 98.3%) | 825.4/867.3 = 95.2% (86.7%, 98.3%) | 765.4/867.3 = 88.3% (78.1%, 94.1%) |
| Female | Day 29 | Placebo | Negative | Pseudovirus-nAb ID50 | 87 | 44.4/8587.3 = 0.5% (0.1%, 3.7%) | 44.4/8587.3 = 0.5% (0.1%, 3.7%) | 0/8587.3 = 0.0% (0.0%, 0.0%) |
| Female | Day 29 | Placebo | Positive | Pseudovirus-nAb ID50 | 155 | 706.6/827.8 = 85.4% (75.6%, 91.7%) | 710/827.8 = 85.8% (76.0%, 92.0%) | 577.7/827.8 = 69.8% (58.8%, 78.9%) |
| Female | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID50 | 519 | 7905/7996.4 = 98.9% (97.2%, 99.5%) | 7905/7996.4 = 98.9% (97.2%, 99.5%) | 7853.4/7996.4 = 98.2% (96.6%, 99.1%) |
| Female | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID50 | 153 | 867.3/867.3 = 100.0% (100.0%, 100.0%) | 867.3/867.3 = 100.0% (100.0%, 100.0%) | 867.3/867.3 = 100.0% (100.0%, 100.0%) |
| Female | Day 57 | Placebo | Negative | Pseudovirus-nAb ID50 | 87 | 87.5/8587.3 = 1.0% (0.2%, 4.1%) | 87.5/8587.3 = 1.0% (0.2%, 4.1%) | 0/8587.3 = 0.0% (0.0%, 0.0%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % 2-Fold Rise | % 4-Fold Rise |
|--------|--------|---------|---------------------|----------------------|-----|---------------------------------------|---------------------------------------|---------------------------------------|
| Female | Day 57 | Placebo | Positive | Pseudovirus-nAb ID50 | 155 | 784.7/827.8 = 94.8% (86.4%, 98.1%) | 784.7/827.8 = 94.8% (86.4%, 98.1%) | 769.4/827.8 = 93.0% (84.0%, 97.1%) |

Neutralization Responders are defined as participants who had baseline values below the lower limit of detection (LLOD) with detectable ID50 neutralization titer above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in ID50.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 4f. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Age, sex

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % 2-Fold Rise | % 4-Fold Rise |
|-----------------|--------|---------|---------------------|----------------------|-----|--|--|--|
| Age, sex | | | | | | | | |
| Age < 65 Female | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID50 | 269 | 5560.6/6524.4 = 85.2% (79.3%, 89.7%) | 5607.3/6524.4 = 85.9% (80.1%, 90.3%) | 5076.7/6524.4 = 77.8% (71.3%, 83.2%) |
| Age < 65 Female | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID50 | 79 | 664.2/701.8 = 94.6% (83.7%, 98.4%) | 664.2/701.8 = 94.6% (83.7%, 98.4%) | 606.9/701.8 = 86.5% (73.8%, 93.5%) |
| Age < 65 Female | Day 29 | Placebo | Negative | Pseudovirus-nAb ID50 | 52 | 0/7188.8 = 0.0% (0.0%, 0.0%) | 0/7188.8 = 0.0% (0.0%, 0.0%) | 0/7188.8 = 0.0% (0.0%, 0.0%) |
| Age < 65 Female | Day 29 | Placebo | Positive | Pseudovirus-nAb ID50 | 83 | 561/673.1 = 83.3% (71.3%, 91.0%) | 564.4/673.1 = 83.8% (71.8%, 91.4%) | 437.7/673.1 = 65.0% (51.8%, 76.3%) |
| Age < 65 Female | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID50 | 269 | 6437/6524.4 = 98.7% (96.5%, 99.5%) | 6437/6524.4 = 98.7% (96.5%, 99.5%) | 6411.4/6524.4 = 98.3% (96.2%, 99.2%) |
| Age < 65 Female | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID50 | 79 | 701.8/701.8 = 100.0% (100.0%, 100.0%) | 701.8/701.8 = 100.0% (100.0%, 100.0%) | 701.8/701.8 = 100.0% (100.0%, 100.0%) |
| Age < 65 Female | Day 57 | Placebo | Negative | Pseudovirus-nAb ID50 | 52 | 43.1/7188.8 = 0.6% (0.1%, 4.4%) | 43.1/7188.8 = 0.6% (0.1%, 4.4%) | 0/7188.8 = 0.0% (0.0%, 0.0%) |
| Age < 65 Female | Day 57 | Placebo | Positive | Pseudovirus-nAb ID50 | 83 | 630.1/673.1 = 93.6% (83.3%, 97.7%) | 630.1/673.1 = 93.6% (83.3%, 97.7%) | 616.4/673.1 = 91.6% (80.5%, 96.6%) |
| Age < 65 Male | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID50 | 163 | 3489.6/3993.6 = 87.4% (79.9%, 92.3%) | 3489.6/3993.6 = 87.4% (79.9%, 92.3%) | 3240.5/3993.6 = 81.1% (73.0%, 87.2%) |
| Age < 65 Male | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID50 | 67 | 438.8/443.2 = 99.0% (93.0%, 99.9%) | 438.8/443.2 = 99.0% (93.0%, 99.9%) | 403.4/443.2 = 91.0% (79.0%, 96.5%) |
| Age < 65 Male | Day 29 | Placebo | Negative | Pseudovirus-nAb ID50 | 28 | 76.3/3045.2 = 2.5% (0.3%, 17.6%) | 76.3/3045.2 = 2.5% (0.3%, 17.6%) | 0/3045.2 = 0.0% (0.0%, 0.0%) |
| Age < 65 Male | Day 29 | Placebo | Positive | Pseudovirus-nAb ID50 | 64 | 335.3/424.9 = 78.9% (63.2%, 89.1%) | 335.3/424.9 = 78.9% (63.2%, 89.1%) | 245/424.9 = 57.7% (42.2%, 71.8%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % 2-Fold Rise | % 4-Fold Rise |
|-----------------|--------|---------|---------------------|----------------------|-----|--|--|--|
| Age < 65 Male | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID50 | 163 | 3968.1/3993.6 = 99.4% (97.5%, 99.8%) | 3968.1/3993.6 = 99.4% (97.5%, 99.8%) | 3815.3/3993.6 = 95.5% (89.2%, 98.2%) |
| Age < 65 Male | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID50 | 67 | 443.2/443.2 = 100.0% (100.0%, 100.0%) | 443.2/443.2 = 100.0% (100.0%, 100.0%) | 443.2/443.2 = 100.0% (100.0%, 100.0%) |
| Age < 65 Male | Day 57 | Placebo | Negative | Pseudovirus-nAb ID50 | 28 | 0/3045.2 = 0.0% (0.0%, 0.0%) | 0/3045.2 = 0.0% (0.0%, 0.0%) | 0/3045.2 = 0.0% (0.0%, 0.0%) |
| Age < 65 Male | Day 57 | Placebo | Positive | Pseudovirus-nAb ID50 | 64 | 412.7/424.9 = 97.1% (86.1%, 99.5%) | 412.7/424.9 = 97.1% (86.1%, 99.5%) | 379.3/424.9 = 89.3% (74.3%, 96.0%) |
| Age ≥ 65 Male | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID50 | 232 | 1248.3/1305 = 95.7% (91.9%, 97.7%) | 1255.7/1305 = 96.2% (92.6%, 98.1%) | 1199/1305 = 91.9% (87.3%, 94.9%) |
| Age ≥ 65 Male | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID50 | 54 | 118.9/121.5 = 97.9% (85.5%, 99.7%) | 118.9/121.5 = 97.9% (85.5%, 99.7%) | 118.9/121.5 = 97.9% (85.5%, 99.7%) |
| Age ≥ 65 Male | Day 29 | Placebo | Negative | Pseudovirus-nAb ID50 | 48 | 28.8/1726.6 = 1.7% (0.2%, 11.6%) | 28.8/1726.6 = 1.7% (0.2%, 11.6%) | 0/1726.6 = 0.0% (0.0%, 0.0%) |
| Age ≥ 65 Male | Day 29 | Placebo | Positive | Pseudovirus-nAb ID50 | 51 | 97.9/104.4 = 93.8% (81.3%, 98.1%) | 97.9/104.4 = 93.8% (81.3%, 98.1%) | 83.3/104.4 = 79.8% (65.3%, 89.2%) |
| Age ≥ 65 Male | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID50 | 232 | 1286.3/1305 = 98.6% (95.4%, 99.6%) | 1286.3/1305 = 98.6% (95.4%, 99.6%) | 1286.3/1305 = 98.6% (95.4%, 99.6%) |
| Age ≥ 65 Male | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID50 | 54 | 121.5/121.5 = 100.0% (100.0%, 100.0%) | 121.5/121.5 = 100.0% (100.0%, 100.0%) | 121.5/121.5 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 Male | Day 57 | Placebo | Negative | Pseudovirus-nAb ID50 | 48 | 44.4/1726.6 = 2.6% (0.3%, 17.2%) | 44.4/1726.6 = 2.6% (0.3%, 17.2%) | 0/1726.6 = 0.0% (0.0%, 0.0%) |
| Age ≥ 65 Male | Day 57 | Placebo | Positive | Pseudovirus-nAb ID50 | 51 | 104.4/104.4 = 100.0% (100.0%, 100.0%) | 104.4/104.4 = 100.0% (100.0%, 100.0%) | 104.4/104.4 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 Female | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID50 | 250 | 1434.6/1472 = 97.5% (94.3%, 98.9%) | 1434.6/1472 = 97.5% (94.3%, 98.9%) | 1354.6/1472 = 92.0% (87.8%, 94.9%) |
| Age ≥ 65 Female | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID50 | 74 | 161.2/165.5 = 97.4% (89.5%, 99.4%) | 161.2/165.5 = 97.4% (89.5%, 99.4%) | 158.6/165.5 = 95.8% (87.3%, 98.7%) |
| Age ≥ 65 Female | Day 29 | Placebo | Negative | Pseudovirus-nAb ID50 | 35 | 44.4/1398.4 = 3.2% (0.4%, 21.1%) | 44.4/1398.4 = 3.2% (0.4%, 21.1%) | 0/1398.4 = 0.0% (0.0%, 0.0%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % 2-Fold Rise | % 4-Fold Rise |
|-----------------|--------|---------|---------------------|----------------------|-----|--|--|--|
| Age ≥ 65 Female | Day 29 | Placebo | Positive | Pseudovirus-nAb ID50 | 72 | 145.6/154.6 = 94.2% (84.9%, 97.9%) | 145.6/154.6 = 94.2% (84.9%, 97.9%) | 140/154.6 = 90.6% (80.8%, 95.6%) |
| Age ≥ 65 Female | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID50 | 250 | 1468/1472 = 99.7% (98.1%, 100.0%) | 1468/1472 = 99.7% (98.1%, 100.0%) | 1441.9/1472 = 98.0% (95.0%, 99.2%) |
| Age ≥ 65 Female | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID50 | 74 | 165.5/165.5 = 100.0% (100.0%, 100.0%) | 165.5/165.5 = 100.0% (100.0%, 100.0%) | 165.5/165.5 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 Female | Day 57 | Placebo | Negative | Pseudovirus-nAb ID50 | 35 | 44.4/1398.4 = 3.2% (0.4%, 21.1%) | 44.4/1398.4 = 3.2% (0.4%, 21.1%) | 0/1398.4 = 0.0% (0.0%, 0.0%) |
| Age ≥ 65 Female | Day 57 | Placebo | Positive | Pseudovirus-nAb ID50 | 72 | 154.6/154.6 = 100.0% (100.0%, 100.0%) | 154.6/154.6 = 100.0% (100.0%, 100.0%) | 153.1/154.6 = 99.0% (92.9%, 99.9%) |

Neutralization Responders are defined as participants who had baseline values below the lower limit of detection (LLOD) with detectable ID50 neutralization titer above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in ID50.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 4g. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Hispanic or Latino ethnicity

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % 2-Fold Rise | % 4-Fold Rise |
|-------------------------------------|--------|---------|---------------------|----------------------|-----|--|--|--|
| Hispanic or Latino ethnicity | | | | | | | | |
| Hispanic or Latino | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID50 | 136 | 1226.3/1363.4 = 89.9% (81.7%, 94.7%) | 1226.3/1363.4 = 89.9% (81.7%, 94.7%) | 1109.8/1363.4 = 81.4% (71.0%, 88.7%) |
| Hispanic or Latino | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID50 | 35 | 144/145.7 = 98.8% (91.4%, 99.9%) | 144/145.7 = 98.8% (91.4%, 99.9%) | 141.7/145.7 = 97.2% (88.7%, 99.4%) |
| Hispanic or Latino | Day 29 | Placebo | Negative | Pseudovirus-nAb ID50 | 20 | 28.8/1237.6 = 2.3% (0.3%, 17.1%) | 28.8/1237.6 = 2.3% (0.3%, 17.1%) | 0/1237.6 = 0.0% (0.0%, 0.0%) |
| Hispanic or Latino | Day 29 | Placebo | Positive | Pseudovirus-nAb ID50 | 38 | 125.7/133.7 = 94.0% (84.6%, 97.8%) | 125.7/133.7 = 94.0% (84.6%, 97.8%) | 90/133.7 = 67.3% (42.1%, 85.3%) |
| Hispanic or Latino | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID50 | 136 | 1328.6/1363.4 = 97.4% (88.5%, 99.5%) | 1328.6/1363.4 = 97.4% (88.5%, 99.5%) | 1328.6/1363.4 = 97.4% (88.5%, 99.5%) |
| Hispanic or Latino | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID50 | 35 | 145.7/145.7 = 100.0% (100.0%, 100.0%) | 145.7/145.7 = 100.0% (100.0%, 100.0%) | 145.7/145.7 = 100.0% (100.0%, 100.0%) |
| Hispanic or Latino | Day 57 | Placebo | Negative | Pseudovirus-nAb ID50 | 20 | 0/1237.6 = 0.0% (0.0%, 0.0%) | 0/1237.6 = 0.0% (0.0%, 0.0%) | 0/1237.6 = 0.0% (0.0%, 0.0%) |
| Hispanic or Latino | Day 57 | Placebo | Positive | Pseudovirus-nAb ID50 | 38 | 133.7/133.7 = 100.0% (100.0%, 100.0%) | 133.7/133.7 = 100.0% (100.0%, 100.0%) | 129.7/133.7 = 97.0% (87.6%, 99.3%) |
| Not Hispanic or Latino | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID50 | 690 | 9218.1/10481.2 = 87.9% (83.8%, 91.2%) | 9272.1/10481.2 = 88.5% (84.4%, 91.6%) | 8529.4/10481.2 = 81.4% (76.8%, 85.2%) |
| Not Hispanic or Latino | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID50 | 217 | 1119.5/1162.3 = 96.3% (90.0%, 98.7%) | 1119.5/1162.3 = 96.3% (90.0%, 98.7%) | 1030.9/1162.3 = 88.7% (80.6%, 93.7%) |
| Not Hispanic or Latino | Day 29 | Placebo | Negative | Pseudovirus-nAb ID50 | 130 | 120.7/10828.8 = 1.1% (0.3%, 4.6%) | 120.7/10828.8 = 1.1% (0.3%, 4.6%) | 0/10828.8 = 0.0% (0.0%, 0.0%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % 2-Fold Rise | % 4-Fold Rise |
|--------------------------|--------|---------|---------------------|----------------------|-----|--|--|--|
| Not Hispanic or Latino | Day 29 | Placebo | Positive | Pseudovirus-nAb ID50 | 214 | 941.9/1121.8 = 84.0% (75.7%, 89.8%) | 945.4/1121.8 = 84.3% (76.0%, 90.1%) | 743.9/1121.8 = 66.3% (57.1%, 74.4%) |
| Not Hispanic or Latino | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID50 | 690 | 10380.4/10481.2 = 99.0% (97.9%, 99.6%) | 10380.4/10481.2 = 99.0% (97.9%, 99.6%) | 10269.3/10481.2 = 98.0% (96.3%, 98.9%) |
| Not Hispanic or Latino | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID50 | 217 | 1162.3/1162.3 = 100.0% (100.0%, 100.0%) | 1162.3/1162.3 = 100.0% (100.0%, 100.0%) | 1162.3/1162.3 = 100.0% (100.0%, 100.0%) |
| Not Hispanic or Latino | Day 57 | Placebo | Negative | Pseudovirus-nAb ID50 | 130 | 87.5/10828.8 = 0.8% (0.2%, 3.2%) | 87.5/10828.8 = 0.8% (0.2%, 3.2%) | 0/10828.8 = 0.0% (0.0%, 0.0%) |
| Not Hispanic or Latino | Day 57 | Placebo | Positive | Pseudovirus-nAb ID50 | 214 | 1076.3/1121.8 = 95.9% (89.7%, 98.5%) | 1076.3/1121.8 = 95.9% (89.7%, 98.5%) | 1048.8/1121.8 = 93.5% (86.3%, 97.0%) |
| Not reported and unknown | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID50 | 88 | 1288.7/1450.4 = 88.9% (74.6%, 95.6%) | 1288.7/1450.4 = 88.9% (74.6%, 95.6%) | 1231.7/1450.4 = 84.9% (71.6%, 92.6%) |
| Not reported and unknown | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID50 | 22 | 119.6/124 = 96.5% (75.1%, 99.6%) | 119.6/124 = 96.5% (75.1%, 99.6%) | 115.2/124 = 92.9% (75.0%, 98.3%) |
| Not reported and unknown | Day 29 | Placebo | Negative | Pseudovirus-nAb ID50 | 13 | 0/1292.7 = 0.0% (0.0%, 0.0%) | 0/1292.7 = 0.0% (0.0%, 0.0%) | 0/1292.7 = 0.0% (0.0%, 0.0%) |
| Not reported and unknown | Day 29 | Placebo | Positive | Pseudovirus-nAb ID50 | 18 | 72.2/101.5 = 71.1% (32.1%, 92.8%) | 72.2/101.5 = 71.1% (32.1%, 92.8%) | 72.2/101.5 = 71.1% (32.1%, 92.8%) |
| Not reported and unknown | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID50 | 88 | 1450.4/1450.4 = 100.0% (100.0%, 100.0%) | 1450.4/1450.4 = 100.0% (100.0%, 100.0%) | 1357.1/1450.4 = 93.6% (77.2%, 98.4%) |
| Not reported and unknown | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID50 | 22 | 124/124 = 100.0% (100.0%, 100.0%) | 124/124 = 100.0% (100.0%, 100.0%) | 124/124 = 100.0% (100.0%, 100.0%) |
| Not reported and unknown | Day 57 | Placebo | Negative | Pseudovirus-nAb ID50 | 13 | 44.4/1292.7 = 3.4% (0.3%, 28.0%) | 44.4/1292.7 = 3.4% (0.3%, 28.0%) | 0/1292.7 = 0.0% (0.0%, 0.0%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % 2-Fold Rise | % 4-Fold Rise |
|--------------------------|--------|---------|---------------------|----------------------|----|--------------------------------------|--------------------------------------|--------------------------------------|
| Not reported and unknown | Day 57 | Placebo | Positive | Pseudovirus-nAb ID50 | 18 | 91.8/101.5 = 90.4% (52.1%, 98.8%) | 91.8/101.5 = 90.4% (52.1%, 98.8%) | 74.6/101.5 = 73.5% (32.9%, 94.0%) |

Neutralization Responders are defined as participants who had baseline values below the lower limit of detection (LLOD) with detectable ID50 neutralization titer above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in ID50.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 4h. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Race

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % 2-Fold Rise | % 4-Fold Rise |
|---------------------------|--------|---------|---------------------|----------------------|-----|--|--|--|
| Race | | | | | | | | |
| White Non-Hispanic | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID50 | 362 | 5915.2/6597 = 89.7% (84.2%, 93.4%) | 5922.6/6597 = 89.8% (84.3%, 93.5%) | 5515.3/6597 = 83.6% (77.6%, 88.3%) |
| White Non-Hispanic | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID50 | 125 | 733.3/773.8 = 94.8% (85.2%, 98.3%) | 733.3/773.8 = 94.8% (85.2%, 98.3%) | 671.1/773.8 = 86.7% (75.6%, 93.2%) |
| White Non-Hispanic | Day 29 | Placebo | Negative | Pseudovirus-nAb ID50 | 67 | 44.4/6586.8 = 0.7% (0.1%, 4.8%) | 44.4/6586.8 = 0.7% (0.1%, 4.8%) | 0/6586.8 = 0.0% (0.0%, 0.0%) |
| White Non-Hispanic | Day 29 | Placebo | Positive | Pseudovirus-nAb ID50 | 121 | 546.7/666.4 = 82.0% (70.0%, 90.0%) | 550.2/666.4 = 82.6% (70.5%, 90.4%) | 458.9/666.4 = 68.9% (56.4%, 79.1%) |
| White Non-Hispanic | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID50 | 362 | 6531.1/6597 = 99.0% (97.8%, 99.6%) | 6531.1/6597 = 99.0% (97.8%, 99.6%) | 6436.8/6597 = 97.6% (95.1%, 98.8%) |
| White Non-Hispanic | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID50 | 125 | 773.8/773.8 = 100.0% (100.0%, 100.0%) | 773.8/773.8 = 100.0% (100.0%, 100.0%) | 773.8/773.8 = 100.0% (100.0%, 100.0%) |
| White Non-Hispanic | Day 57 | Placebo | Negative | Pseudovirus-nAb ID50 | 67 | 0/6586.8 = 0.0% (0.0%, 0.0%) | 0/6586.8 = 0.0% (0.0%, 0.0%) | 0/6586.8 = 0.0% (0.0%, 0.0%) |
| White Non-Hispanic | Day 57 | Placebo | Positive | Pseudovirus-nAb ID50 | 121 | 652.7/666.4 = 97.9% (86.3%, 99.7%) | 652.7/666.4 = 97.9% (86.3%, 99.7%) | 625.2/666.4 = 93.8% (82.4%, 98.0%) |
| Black or African American | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID50 | 195 | 1743.5/2012.2 = 86.6% (78.6%, 92.0%) | 1743.5/2012.2 = 86.6% (78.6%, 92.0%) | 1549.3/2012.2 = 77.0% (67.8%, 84.2%) |
| Black or African American | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID50 | 52 | 195.6/195.6 = 100.0% (100.0%, 100.0%) | 195.6/195.6 = 100.0% (100.0%, 100.0%) | 187/195.6 = 95.6% (72.5%, 99.4%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % 2-Fold Rise | % 4-Fold Rise |
|---------------------------|--------|---------|---------------------|----------------------|-----|--|--|--|
| Black or African American | Day 29 | Placebo | Negative | Pseudovirus-nAb ID50 | 39 | 0/2311.6 = 0.0% (0.0%, 0.0%) | 0/2311.6 = 0.0% (0.0%, 0.0%) | 0/2311.6 = 0.0% (0.0%, 0.0%) |
| Black or African American | Day 29 | Placebo | Positive | Pseudovirus-nAb ID50 | 60 | 220.4/265.1 = 83.2% (66.7%, 92.4%) | 220.4/265.1 = 83.2% (66.7%, 92.4%) | 154/265.1 = 58.1% (40.8%, 73.6%) |
| Black or African American | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID50 | 195 | 1977.3/2012.2 = 98.3% (91.8%, 99.7%) | 1977.3/2012.2 = 98.3% (91.8%, 99.7%) | 1977.3/2012.2 = 98.3% (91.8%, 99.7%) |
| Black or African American | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID50 | 52 | 195.6/195.6 = 100.0% (100.0%, 100.0%) | 195.6/195.6 = 100.0% (100.0%, 100.0%) | 195.6/195.6 = 100.0% (100.0%, 100.0%) |
| Black or African American | Day 57 | Placebo | Negative | Pseudovirus-nAb ID50 | 39 | 43.1/2311.6 = 1.9% (0.2%, 13.1%) | 43.1/2311.6 = 1.9% (0.2%, 13.1%) | 0/2311.6 = 0.0% (0.0%, 0.0%) |
| Black or African American | Day 57 | Placebo | Positive | Pseudovirus-nAb ID50 | 60 | 243.2/265.1 = 91.7% (74.1%, 97.7%) | 243.2/265.1 = 91.7% (74.1%, 97.7%) | 241.6/265.1 = 91.1% (74.1%, 97.4%) |
| Asian | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID50 | 67 | 653.8/673.6 = 97.1% (91.8%, 99.0%) | 653.8/673.6 = 97.1% (91.8%, 99.0%) | 630/673.6 = 93.5% (87.7%, 96.7%) |
| Asian | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID50 | 24 | 78.8/81.1 = 97.1% (80.0%, 99.7%) | 78.8/81.1 = 97.1% (80.0%, 99.7%) | 76.5/81.1 = 94.3% (79.4%, 98.6%) |
| Asian | Day 29 | Placebo | Negative | Pseudovirus-nAb ID50 | 12 | 28.8/609.1 = 4.7% (0.5%, 34.8%) | 28.8/609.1 = 4.7% (0.5%, 34.8%) | 0/609.1 = 0.0% (0.0%, 0.0%) |
| Asian | Day 29 | Placebo | Positive | Pseudovirus-nAb ID50 | 13 | 45.9/48.4 = 94.9% (64.0%, 99.5%) | 45.9/48.4 = 94.9% (64.0%, 99.5%) | 31.3/48.4 = 64.6% (19.5%, 93.2%) |
| Asian | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID50 | 67 | 669.7/673.6 = 99.4% (95.8%, 99.9%) | 669.7/673.6 = 99.4% (95.8%, 99.9%) | 665.7/673.6 = 98.8% (95.4%, 99.7%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % 2-Fold Rise | % 4-Fold Rise |
|----------------------------------|--------|---------|---------------------|----------------------|----|--|--|--|
| Asian | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID50 | 24 | 81.1/81.1 = 100.0% (100.0%, 100.0%) | 81.1/81.1 = 100.0% (100.0%, 100.0%) | 81.1/81.1 = 100.0% (100.0%, 100.0%) |
| Asian | Day 57 | Placebo | Negative | Pseudovirus-nAb ID50 | 12 | 0/609.1 = 0.0% (0.0%, 0.0%) | 0/609.1 = 0.0% (0.0%, 0.0%) | 0/609.1 = 0.0% (0.0%, 0.0%) |
| Asian | Day 57 | Placebo | Positive | Pseudovirus-nAb ID50 | 13 | 45.9/48.4 = 94.9% (64.0%, 99.5%) | 45.9/48.4 = 94.9% (64.0%, 99.5%) | 45.9/48.4 = 94.9% (64.0%, 99.5%) |
| American Indian or Alaska Native | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID50 | 13 | 151.4/151.4 = 100.0% (100.0%, 100.0%) | 151.4/151.4 = 100.0% (100.0%, 100.0%) | 139.5/151.4 = 92.1% (65.9%, 98.6%) |
| American Indian or Alaska Native | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID50 | 6 | 31.1/31.1 = 100.0% (100.0%, 100.0%) | 31.1/31.1 = 100.0% (100.0%, 100.0%) | 31.1/31.1 = 100.0% (100.0%, 100.0%) |
| American Indian or Alaska Native | Day 29 | Placebo | Negative | Pseudovirus-nAb ID50 | 5 | 0/247.2 = 0.0% (0.0%, 0.0%) | 0/247.2 = 0.0% (0.0%, 0.0%) | 0/247.2 = 0.0% (0.0%, 0.0%) |
| American Indian or Alaska Native | Day 29 | Placebo | Positive | Pseudovirus-nAb ID50 | 4 | 5.6/15.3 = 36.5% | 5.6/15.3 = 36.5% | 3.1/15.3 = 20.4% |
| American Indian or Alaska Native | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID50 | 13 | 151.4/151.4 = 100.0% (100.0%, 100.0%) | 151.4/151.4 = 100.0% (100.0%, 100.0%) | 151.4/151.4 = 100.0% (100.0%, 100.0%) |
| American Indian or Alaska Native | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID50 | 6 | 31.1/31.1 = 100.0% (100.0%, 100.0%) | 31.1/31.1 = 100.0% (100.0%, 100.0%) | 31.1/31.1 = 100.0% (100.0%, 100.0%) |
| American Indian or Alaska Native | Day 57 | Placebo | Negative | Pseudovirus-nAb ID50 | 5 | 0/247.2 = 0.0% (0.0%, 0.0%) | 0/247.2 = 0.0% (0.0%, 0.0%) | 0/247.2 = 0.0% (0.0%, 0.0%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % 2-Fold Rise | % 4-Fold Rise |
|---|--------|---------|---------------------|----------------------|----|--|--|--|
| American Indian or Alaska Native | Day 57 | Placebo | Positive | Pseudovirus-nAb ID50 | 4 | 15.3/15.3 = 100.0% | 15.3/15.3 = 100.0% | 15.3/15.3 = 100.0% |
| Native Hawaiian or Other Pacific Islander | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID50 | 17 | 98.2/98.2 = 100.0% (100.0%, 100.0%) | 98.2/98.2 = 100.0% (100.0%, 100.0%) | 94.3/98.2 = 96.0% (70.1%, 99.6%) |
| Native Hawaiian or Other Pacific Islander | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID50 | 5 | 23/23 = 100.0% (100.0%, 100.0%) | 23/23 = 100.0% (100.0%, 100.0%) | 23/23 = 100.0% (100.0%, 100.0%) |
| Native Hawaiian or Other Pacific Islander | Day 29 | Placebo | Negative | Pseudovirus-nAb ID50 | 1 | 0/28.8 = 0.0% | 0/28.8 = 0.0% | 0/28.8 = 0.0% |
| Native Hawaiian or Other Pacific Islander | Day 29 | Placebo | Positive | Pseudovirus-nAb ID50 | 1 | 0/2.5 = 0.0% | 0/2.5 = 0.0% | 0/2.5 = 0.0% |
| Native Hawaiian or Other Pacific Islander | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID50 | 17 | 98.2/98.2 = 100.0% (100.0%, 100.0%) | 98.2/98.2 = 100.0% (100.0%, 100.0%) | 98.2/98.2 = 100.0% (100.0%, 100.0%) |
| Native Hawaiian or Other Pacific Islander | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID50 | 5 | 23/23 = 100.0% (100.0%, 100.0%) | 23/23 = 100.0% (100.0%, 100.0%) | 23/23 = 100.0% (100.0%, 100.0%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % 2-Fold Rise | % 4-Fold Rise |
|---|--------|---------|---------------------|----------------------|----|--|--|--|
| Native Hawaiian or Other Pacific Islander | Day 57 | Placebo | Negative | Pseudovirus-nAb ID50 | 1 | 0/28.8 = 0.0% | 0/28.8 = 0.0% | 0/28.8 = 0.0% |
| Native Hawaiian or Other Pacific Islander | Day 57 | Placebo | Positive | Pseudovirus-nAb ID50 | 1 | 2.5/2.5 = 100.0% | 2.5/2.5 = 100.0% | 2.5/2.5 = 100.0% |
| Multiracial | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID50 | 52 | 416.8/498.5 = 83.6% (62.3%, 94.0%) | 416.8/498.5 = 83.6% (62.3%, 94.0%) | 382/498.5 = 76.6% (54.9%, 89.8%) |
| Multiracial | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID50 | 12 | 56.4/56.4 = 100.0% (100.0%, 100.0%) | 56.4/56.4 = 100.0% (100.0%, 100.0%) | 56.4/56.4 = 100.0% (100.0%, 100.0%) |
| Multiracial | Day 29 | Placebo | Negative | Pseudovirus-nAb ID50 | 8 | 0/554 = 0.0% (0.0%, 0.0%) | 0/554 = 0.0% (0.0%, 0.0%) | 0/554 = 0.0% (0.0%, 0.0%) |
| Multiracial | Day 29 | Placebo | Positive | Pseudovirus-nAb ID50 | 19 | 56.5/61.4 = 92.0% (71.7%, 98.1%) | 56.5/61.4 = 92.0% (71.7%, 98.1%) | 45.2/61.4 = 73.6% (30.6%, 94.6%) |
| Multiracial | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID50 | 52 | 494.5/498.5 = 99.2% (94.3%, 99.9%) | 494.5/498.5 = 99.2% (94.3%, 99.9%) | 494.5/498.5 = 99.2% (94.3%, 99.9%) |
| Multiracial | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID50 | 12 | 56.4/56.4 = 100.0% (100.0%, 100.0%) | 56.4/56.4 = 100.0% (100.0%, 100.0%) | 56.4/56.4 = 100.0% (100.0%, 100.0%) |
| Multiracial | Day 57 | Placebo | Negative | Pseudovirus-nAb ID50 | 8 | 0/554 = 0.0% (0.0%, 0.0%) | 0/554 = 0.0% (0.0%, 0.0%) | 0/554 = 0.0% (0.0%, 0.0%) |
| Multiracial | Day 57 | Placebo | Positive | Pseudovirus-nAb ID50 | 19 | 61.4/61.4 = 100.0% (100.0%, 100.0%) | 61.4/61.4 = 100.0% (100.0%, 100.0%) | 58.9/61.4 = 96.0% (72.4%, 99.5%) |
| Other | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID50 | 34 | 426.4/469.2 = 90.9% (68.6%, 97.8%) | 426.4/469.2 = 90.9% (68.6%, 97.8%) | 383.6/469.2 = 81.8% (59.3%, 93.2%) |
| Other | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID50 | 7 | 13.8/13.8 = 100.0% (100.0%, 100.0%) | 13.8/13.8 = 100.0% (100.0%, 100.0%) | 11.5/13.8 = 83.2% (18.4%, 99.1%) |
| Other | Day 29 | Placebo | Negative | Pseudovirus-nAb ID50 | 4 | 0/232.6 = 0.0% | 0/232.6 = 0.0% | 0/232.6 = 0.0% |
| Other | Day 29 | Placebo | Positive | Pseudovirus-nAb ID50 | 5 | 24.1/24.1 = 100.0% (100.0%, 100.0%) | 24.1/24.1 = 100.0% (100.0%, 100.0%) | 22.6/24.1 = 93.5% (32.5%, 99.8%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % 2-Fold Rise | % 4-Fold Rise |
|--------------------------|--------|---------|---------------------|----------------------|----|--|--|--|
| Other | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID50 | 34 | 469.2/469.2 = 100.0% (100.0%, 100.0%) | 469.2/469.2 = 100.0% (100.0%, 100.0%) | 469.2/469.2 = 100.0% (100.0%, 100.0%) |
| Other | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID50 | 7 | 13.8/13.8 = 100.0% (100.0%, 100.0%) | 13.8/13.8 = 100.0% (100.0%, 100.0%) | 13.8/13.8 = 100.0% (100.0%, 100.0%) |
| Other | Day 57 | Placebo | Negative | Pseudovirus-nAb ID50 | 4 | 0/232.6 = 0.0% | 0/232.6 = 0.0% | 0/232.6 = 0.0% |
| Other | Day 57 | Placebo | Positive | Pseudovirus-nAb ID50 | 5 | 24.1/24.1 = 100.0% (100.0%, 100.0%) | 24.1/24.1 = 100.0% (100.0%, 100.0%) | 24.1/24.1 = 100.0% (100.0%, 100.0%) |
| Not reported and unknown | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID50 | 87 | 1107.8/1413.2 = 78.4% (61.9%, 89.0%) | 1154.4/1413.2 = 81.7% (65.2%, 91.4%) | 1014/1413.2 = 71.8% (55.6%, 83.7%) |
| Not reported and unknown | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID50 | 20 | 155/155 = 100.0% (100.0%, 100.0%) | 155/155 = 100.0% (100.0%, 100.0%) | 139.5/155 = 90.0% (45.7%, 99.0%) |
| Not reported and unknown | Day 29 | Placebo | Negative | Pseudovirus-nAb ID50 | 14 | 76.3/1337.6 = 5.7% (0.6%, 38.4%) | 76.3/1337.6 = 5.7% (0.6%, 38.4%) | 0/1337.6 = 0.0% (0.0%, 0.0%) |
| Not reported and unknown | Day 29 | Placebo | Positive | Pseudovirus-nAb ID50 | 24 | 149.2/165.4 = 90.2% (55.7%, 98.5%) | 149.2/165.4 = 90.2% (55.7%, 98.5%) | 103.1/165.4 = 62.3% (33.5%, 84.4%) |
| Not reported and unknown | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID50 | 87 | 1413.2/1413.2 = 100.0% (100.0%, 100.0%) | 1413.2/1413.2 = 100.0% (100.0%, 100.0%) | 1400.5/1413.2 = 99.1% (93.6%, 99.9%) |
| Not reported and unknown | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID50 | 20 | 155/155 = 100.0% (100.0%, 100.0%) | 155/155 = 100.0% (100.0%, 100.0%) | 155/155 = 100.0% (100.0%, 100.0%) |
| Not reported and unknown | Day 57 | Placebo | Negative | Pseudovirus-nAb ID50 | 14 | 44.4/1337.6 = 3.3% (0.4%, 25.1%) | 44.4/1337.6 = 3.3% (0.4%, 25.1%) | 0/1337.6 = 0.0% (0.0%, 0.0%) |
| Not reported and unknown | Day 57 | Placebo | Positive | Pseudovirus-nAb ID50 | 24 | 148.3/165.4 = 89.6% (55.9%, 98.3%) | 148.3/165.4 = 89.6% (55.9%, 98.3%) | 148.3/165.4 = 89.6% (55.9%, 98.3%) |

Neutralization Responders are defined as participants who had baseline values below the lower limit of detection (LLOD) with detectable ID50 neutralization titer above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in ID50.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 4i. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Underrepresented minority status

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % 2-Fold Rise | % 4-Fold Rise |
|---|--------|---------|---------------------|----------------------|-----|---------------------------------------|---------------------------------------|---------------------------------------|
| Underrepresented minority status | | | | | | | | |
| Communities of Color | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID50 | 420 | 3833.3/4289 = 89.4% (84.6%, 92.8%) | 3833.3/4289 = 89.4% (84.6%, 92.8%) | 3490.9/4289 = 81.4% (75.8%, 86.0%) |
| Communities of Color | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID50 | 120 | 458/462 = 99.1% (96.5%, 99.8%) | 458/462 = 99.1% (96.5%, 99.8%) | 444.7/462 = 96.3% (89.1%, 98.8%) |
| Communities of Color | Day 29 | Placebo | Negative | Pseudovirus-nAb ID50 | 73 | 28.8/4319 = 0.7% (0.1%, 4.8%) | 28.8/4319 = 0.7% (0.1%, 4.8%) | 0/4319 = 0.0% (0.0%, 0.0%) |
| Communities of Color | Day 29 | Placebo | Positive | Pseudovirus-nAb ID50 | 111 | 374.8/439 = 85.4% (74.2%, 92.2%) | 374.8/439 = 85.4% (74.2%, 92.2%) | 276.8/439 = 63.1% (50.1%, 74.4%) |
| Communities of Color | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID50 | 420 | 4219.3/4289 = 98.4% (95.2%, 99.5%) | 4219.3/4289 = 98.4% (95.2%, 99.5%) | 4215.3/4289 = 98.3% (95.2%, 99.4%) |
| Communities of Color | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID50 | 120 | 462/462 = 100.0% (100.0%, 100.0%) | 462/462 = 100.0% (100.0%, 100.0%) | 462/462 = 100.0% (100.0%, 100.0%) |
| Communities of Color | Day 57 | Placebo | Negative | Pseudovirus-nAb ID50 | 73 | 43.1/4319 = 1.0% (0.1%, 7.0%) | 43.1/4319 = 1.0% (0.1%, 7.0%) | 0/4319 = 0.0% (0.0%, 0.0%) |
| Communities of Color | Day 57 | Placebo | Positive | Pseudovirus-nAb ID50 | 111 | 414.6/439 = 94.4% (83.7%, 98.3%) | 414.6/439 = 94.4% (83.7%, 98.3%) | 410.6/439 = 93.5% (83.4%, 97.7%) |
| White Non-Hispanic | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID50 | 362 | 5915.2/6597 = 89.7% (84.2%, 93.4%) | 5922.6/6597 = 89.8% (84.3%, 93.5%) | 5515.3/6597 = 83.6% (77.6%, 88.3%) |
| White Non-Hispanic | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID50 | 125 | 733.3/773.8 = 94.8% (85.2%, 98.3%) | 733.3/773.8 = 94.8% (85.2%, 98.3%) | 671.1/773.8 = 86.7% (75.6%, 93.2%) |
| White Non-Hispanic | Day 29 | Placebo | Negative | Pseudovirus-nAb ID50 | 67 | 44.4/6586.8 = 0.7% (0.1%, 4.8%) | 44.4/6586.8 = 0.7% (0.1%, 4.8%) | 0/6586.8 = 0.0% (0.0%, 0.0%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % 2-Fold Rise | % 4-Fold Rise |
|--------------------|--------|---------|---------------------|----------------------|-----|--|--|--|
| White Non-Hispanic | Day 29 | Placebo | Positive | Pseudovirus-nAb ID50 | 121 | 546.7/666.4 = 82.0% (70.0%, 90.0%) | 550.2/666.4 = 82.6% (70.5%, 90.4%) | 458.9/666.4 = 68.9% (56.4%, 79.1%) |
| White Non-Hispanic | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID50 | 362 | 6531.1/6597 = 99.0% (97.8%, 99.6%) | 6531.1/6597 = 99.0% (97.8%, 99.6%) | 6436.8/6597 = 97.6% (95.1%, 98.8%) |
| White Non-Hispanic | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID50 | 125 | 773.8/773.8 = 100.0% (100.0%, 100.0%) | 773.8/773.8 = 100.0% (100.0%, 100.0%) | 773.8/773.8 = 100.0% (100.0%, 100.0%) |
| White Non-Hispanic | Day 57 | Placebo | Negative | Pseudovirus-nAb ID50 | 67 | 0/6586.8 = 0.0% (0.0%, 0.0%) | 0/6586.8 = 0.0% (0.0%, 0.0%) | 0/6586.8 = 0.0% (0.0%, 0.0%) |
| White Non-Hispanic | Day 57 | Placebo | Positive | Pseudovirus-nAb ID50 | 121 | 652.7/666.4 = 97.9% (86.3%, 99.7%) | 652.7/666.4 = 97.9% (86.3%, 99.7%) | 625.2/666.4 = 93.8% (82.4%, 98.0%) |

Neutralization Responders are defined as participants who had baseline values below the lower limit of detection (LLOD) with detectable ID50 neutralization titer above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in ID50.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 4j. Percentage of responders, and participants participants with 2-fold rise, and participants with 4-fold rise for ID50 pseudo-virus neutralization antibody markers by Age, Underrepresented minority status

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % 2-Fold Rise | % 4-Fold Rise |
|--|--------|---------|---------------------|----------------------|-----|------------------------------------|------------------------------------|------------------------------------|
| Age, Underrepresented minority status | | | | | | | | |
| Age < 65 Communities of Color | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID50 | 192 | 2958/3386 = 87.4% (81.4%, 91.6%) | 2958/3386 = 87.4% (81.4%, 91.6%) | 2671.1/3386 = 78.9% (71.8%, 84.6%) |
| Age < 65 Communities of Color | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID50 | 69 | 372.7/375 = 99.4% (95.6%, 99.9%) | 372.7/375 = 99.4% (95.6%, 99.9%) | 359.4/375 = 95.8% (86.7%, 98.8%) |
| Age < 65 Communities of Color | Day 29 | Placebo | Negative | Pseudovirus-nAb ID50 | 37 | 0/3281 = 0.0% (0.0%, 0.0%) | 0/3281 = 0.0% (0.0%, 0.0%) | 0/3281 = 0.0% (0.0%, 0.0%) |
| Age < 65 Communities of Color | Day 29 | Placebo | Positive | Pseudovirus-nAb ID50 | 61 | 299.9/361 = 83.1% (69.5%, 91.4%) | 299.9/361 = 83.1% (69.5%, 91.4%) | 209.7/361 = 58.1% (42.8%, 72.0%) |
| Age < 65 Communities of Color | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID50 | 192 | 3324.2/3386 = 98.2% (93.9%, 99.5%) | 3324.2/3386 = 98.2% (93.9%, 99.5%) | 3324.2/3386 = 98.2% (93.9%, 99.5%) |
| Age < 65 Communities of Color | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID50 | 69 | 375/375 = 100.0% (100.0%, 100.0%) | 375/375 = 100.0% (100.0%, 100.0%) | 375/375 = 100.0% (100.0%, 100.0%) |
| Age < 65 Communities of Color | Day 57 | Placebo | Negative | Pseudovirus-nAb ID50 | 37 | 43.1/3281 = 1.3% (0.2%, 9.4%) | 43.1/3281 = 1.3% (0.2%, 9.4%) | 0/3281 = 0.0% (0.0%, 0.0%) |
| Age < 65 Communities of Color | Day 57 | Placebo | Positive | Pseudovirus-nAb ID50 | 61 | 336.6/361 = 93.2% (80.2%, 97.9%) | 336.6/361 = 93.2% (80.2%, 97.9%) | 334.1/361 = 92.6% (80.0%, 97.5%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % 2-Fold Rise | % 4-Fold Rise |
|-------------------------------------|--------|---------|---------------------|----------------------|-----|--|--|--|
| Age < 65 White Non-Hispanic | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID50 | 175 | 4601.9/5217.3 = 88.2% (81.3%, 92.8%) | 4601.9/5217.3 = 88.2% (81.3%, 92.8%) | 4253.6/5217.3 = 81.5% (73.9%, 87.3%) |
| Age < 65 White Non-Hispanic | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID50 | 59 | 567/602.4 = 94.1% (81.1%, 98.4%) | 567/602.4 = 94.1% (81.1%, 98.4%) | 507.5/602.4 = 84.2% (69.9%, 92.5%) |
| Age < 65 White Non-Hispanic | Day 29 | Placebo | Negative | Pseudovirus-nAb ID50 | 31 | 0/4988.2 = 0.0% (0.0%, 0.0%) | 0/4988.2 = 0.0% (0.0%, 0.0%) | 0/4988.2 = 0.0% (0.0%, 0.0%) |
| Age < 65 White Non-Hispanic | Day 29 | Placebo | Positive | Pseudovirus-nAb ID50 | 61 | 407.9/517.6 = 78.8% (63.4%, 88.9%) | 411.3/517.6 = 79.5% (64.0%, 89.4%) | 332.4/517.6 = 64.2% (48.6%, 77.4%) |
| Age < 65 White Non-Hispanic | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID50 | 175 | 5166.2/5217.3 = 99.0% (97.4%, 99.6%) | 5166.2/5217.3 = 99.0% (97.4%, 99.6%) | 5094/5217.3 = 97.6% (94.3%, 99.0%) |
| Age < 65 White Non-Hispanic | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID50 | 59 | 602.4/602.4 = 100.0% (100.0%, 100.0%) | 602.4/602.4 = 100.0% (100.0%, 100.0%) | 602.4/602.4 = 100.0% (100.0%, 100.0%) |
| Age < 65 White Non-Hispanic | Day 57 | Placebo | Negative | Pseudovirus-nAb ID50 | 31 | 0/4988.2 = 0.0% (0.0%, 0.0%) | 0/4988.2 = 0.0% (0.0%, 0.0%) | 0/4988.2 = 0.0% (0.0%, 0.0%) |
| Age < 65 White Non-Hispanic | Day 57 | Placebo | Positive | Pseudovirus-nAb ID50 | 61 | 503.9/517.6 = 97.3% (82.5%, 99.7%) | 503.9/517.6 = 97.3% (82.5%, 99.7%) | 476.4/517.6 = 92.0% (77.5%, 97.5%) |
| Age ≥ 65 Communities of Color | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID50 | 228 | 875.3/903 = 96.9% (93.7%, 98.5%) | 875.3/903 = 96.9% (93.7%, 98.5%) | 819.8/903 = 90.8% (86.2%, 93.9%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % 2-Fold Rise | % 4-Fold Rise |
|-----------------------------------|--------|---------|---------------------|----------------------|-----|---|---|---|
| Age ≥ 65 Communities of Color | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID50 | 51 | 85.3/87 = 98.0% (86.6%, 99.7%) | 85.3/87 = 98.0% (86.6%, 99.7%) | 85.3/87 = 98.0% (86.6%, 99.7%) |
| Age ≥ 65 Communities of Color | Day 29 | Placebo | Negative | Pseudovirus-nAb ID50 | 36 | 28.8/1038 = 2.8% (0.4%, 18.7%) | 28.8/1038 = 2.8% (0.4%, 18.7%) | 0/1038 = 0.0% (0.0%, 0.0%) |
| Age ≥ 65 Communities of Color | Day 29 | Placebo | Positive | Pseudovirus-nAb ID50 | 50 | 74.9/78 = 96.0% (84.7%, 99.0%) | 74.9/78 = 96.0% (84.7%, 99.0%) | 67.1/78 = 86.0% (72.9%, 93.4%) |
| Age ≥ 65 Communities of Color | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID50 | 228 | 895.1/903 = 99.1% (96.5%, 99.8%) | 895.1/903 = 99.1% (96.5%, 99.8%) | 891.1/903 = 98.7% (96.0%, 99.6%) |
| Age ≥ 65 Communities of Color | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID50 | 51 | 87/87 = 100.0% (100.0%, 100.0%) | 87/87 = 100.0% (100.0%, 100.0%) | 87/87 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 Communities of Color | Day 57 | Placebo | Negative | Pseudovirus-nAb ID50 | 36 | 0/1038 = 0.0% (0.0%, 0.0%) | 0/1038 = 0.0% (0.0%, 0.0%) | 0/1038 = 0.0% (0.0%, 0.0%) |
| Age ≥ 65 Communities of Color | Day 57 | Placebo | Positive | Pseudovirus-nAb ID50 | 50 | 78/78 = 100.0% (100.0%, 100.0%) | 78/78 = 100.0% (100.0%, 100.0%) | 76.4/78 = 98.0% (86.3%, 99.7%) |
| Age ≥ 65 White Non-Hispanic | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID50 | 187 | 1313.3/1379.7 = 95.2% (91.0%, 97.5%) | 1320.7/1379.7 = 95.7% (91.6%, 97.9%) | 1261.6/1379.7 = 91.4% (86.4%, 94.7%) |
| Age ≥ 65 White Non-Hispanic | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID50 | 66 | 166.2/171.4 = 97.0% (88.3%, 99.3%) | 166.2/171.4 = 97.0% (88.3%, 99.3%) | 163.6/171.4 = 95.5% (86.5%, 98.6%) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Responder | % 2-Fold Rise | % 4-Fold Rise |
|-----------------------------------|--------|---------|---------------------|----------------------|-----|--|--|--|
| Age ≥ 65 White Non-Hispanic | Day 29 | Placebo | Negative | Pseudovirus-nAb ID50 | 36 | 44.4/1598.6 = 2.8% (0.4%, 18.7%) | 44.4/1598.6 = 2.8% (0.4%, 18.7%) | 0/1598.6 = 0.0% (0.0%, 0.0%) |
| Age ≥ 65 White Non-Hispanic | Day 29 | Placebo | Positive | Pseudovirus-nAb ID50 | 60 | 138.8/148.8 = 93.3% (83.1%, 97.5%) | 138.8/148.8 = 93.3% (83.1%, 97.5%) | 126.5/148.8 = 85.0% (73.2%, 92.2%) |
| Age ≥ 65 White Non-Hispanic | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID50 | 187 | 1364.9/1379.7 = 98.9% (95.8%, 99.7%) | 1364.9/1379.7 = 98.9% (95.8%, 99.7%) | 1342.8/1379.7 = 97.3% (93.7%, 98.9%) |
| Age ≥ 65 White Non-Hispanic | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID50 | 66 | 171.4/171.4 = 100.0% (100.0%, 100.0%) | 171.4/171.4 = 100.0% (100.0%, 100.0%) | 171.4/171.4 = 100.0% (100.0%, 100.0%) |
| Age ≥ 65 White Non-Hispanic | Day 57 | Placebo | Negative | Pseudovirus-nAb ID50 | 36 | 0/1598.6 = 0.0% (0.0%, 0.0%) | 0/1598.6 = 0.0% (0.0%, 0.0%) | 0/1598.6 = 0.0% (0.0%, 0.0%) |
| Age ≥ 65 White Non-Hispanic | Day 57 | Placebo | Positive | Pseudovirus-nAb ID50 | 60 | 148.8/148.8 = 100.0% (100.0%, 100.0%) | 148.8/148.8 = 100.0% (100.0%, 100.0%) | 148.8/148.8 = 100.0% (100.0%, 100.0%) |

Neutralization Responders are defined as participants who had baseline values below the lower limit of detection (LLOD) with detectable ID50 neutralization titer above the assay LLOD, or as participants with baseline values above the LLOD with a 4-fold increase in ID50.

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 5a. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by All participants

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|-------------------------|-------|---------|---------------------|------------------------|-----|----------------|
| All participants | | | | | | |
| | Day 1 | Vaccine | Negative | Anti N IgG (IU/ml) | 914 | 10 (10, 10) |
| | Day 1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 914 | 10 (10, 10) |
| | Day 1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 914 | 10 (10, 10) |
| | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 914 | 5 (5, 5) |
| | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 914 | 5 (5, 5) |
| | Day 1 | Vaccine | Positive | Anti N IgG (IU/ml) | 274 | 10 (10, 10) |
| | Day 1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 274 | 10 (10, 10) |
| | Day 1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 274 | 10 (10, 10) |
| | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 274 | 5 (5, 5) |
| | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 274 | 5 (5, 5) |
| | Day 1 | Placebo | Negative | Anti N IgG (IU/ml) | 163 | 10 (10, 10) |
| | Day 1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 163 | 10 (10, 11) |
| | Day 1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 163 | 10 (10, 10) |
| | Day 1 | Placebo | Negative | Pseudovirus-nAb ID50 | 163 | 5 (5, 5) |
| | Day 1 | Placebo | Negative | Pseudovirus-nAb ID80 | 163 | 5 (5, 5) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|-------|--------|---------|---------------------|------------------------|-----|-------------------------|
| | Day 1 | Placebo | Positive | Anti N IgG (IU/ml) | 270 | 10 (10, 10) |
| | Day 1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 270 | 10 (10, 10) |
| | Day 1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 270 | 10 (10, 10) |
| | Day 1 | Placebo | Positive | Pseudovirus-nAb ID50 | 270 | 5 (5, 5) |
| | Day 1 | Placebo | Positive | Pseudovirus-nAb ID80 | 270 | 5 (5, 5) |
| | Day 29 | Vaccine | Negative | Anti N IgG (IU/ml) | 914 | 23543 (19945, 27790) |
| | Day 29 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 914 | 22926 (19863, 26460) |
| | Day 29 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 914 | 40963 (36741, 45671) |
| | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID50 | 914 | 106 (91, 125) |
| | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID80 | 914 | 189 (161, 222) |
| | Day 29 | Vaccine | Positive | Anti N IgG (IU/ml) | 274 | 43010 (33140, 55819) |
| | Day 29 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 274 | 36133 (28182, 46328) |
| | Day 29 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 274 | 79981 (65041, 98352) |
| | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID50 | 274 | 186 (142, 243) |
| | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID80 | 274 | 420 (314, 560) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|-------|--------|---------|---------------------|------------------------|-----|-------------------------------|
| | Day 29 | Placebo | Negative | Anti N IgG (IU/ml) | 163 | 10 (10, 10) |
| | Day 29 | Placebo | Negative | Anti RBD IgG (IU/ml) | 163 | 10 (10, 10) |
| | Day 29 | Placebo | Negative | Anti Spike IgG (IU/ml) | 163 | 10 (10, 10) |
| | Day 29 | Placebo | Negative | Pseudovirus-nAb ID50 | 163 | 5 (5, 5) |
| | Day 29 | Placebo | Negative | Pseudovirus-nAb ID80 | 163 | 5 (5, 5) |
| | Day 29 | Placebo | Positive | Anti N IgG (IU/ml) | 270 | 12518 (9458, 16567) |
| | Day 29 | Placebo | Positive | Anti RBD IgG (IU/ml) | 270 | 12861 (10150, 16296) |
| | Day 29 | Placebo | Positive | Anti Spike IgG (IU/ml) | 270 | 18191 (15159, 21829) |
| | Day 29 | Placebo | Positive | Pseudovirus-nAb ID50 | 270 | 51 (40, 66) |
| | Day 29 | Placebo | Positive | Pseudovirus-nAb ID80 | 270 | 129 (98, 169) |
| | Day 57 | Vaccine | Negative | Anti N IgG (IU/ml) | 914 | 325136 (267241, 395574) |
| | Day 57 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 914 | 966160 (823437, 1133621) |
| | Day 57 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 914 | 2087965 (1831068, 2380904) |
| | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID50 | 914 | 1497 (1228, 1825) |
| | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID80 | 914 | 2223 (1809, 2733) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|-------|--------|---------|---------------------|------------------------|-----|-------------------------------|
| | Day 57 | Vaccine | Positive | Anti N IgG (IU/ml) | 274 | 980579 (697583, 1378379) |
| | Day 57 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 274 | 2298869 (1785648, 2959596) |
| | Day 57 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 274 | 5346334 (4339333, 6587023) |
| | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID50 | 274 | 5680 (3863, 8351) |
| | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID80 | 274 | 7837 (5545, 11076) |
| | Day 57 | Placebo | Negative | Anti N IgG (IU/ml) | 163 | 10 (10, 10) |
| | Day 57 | Placebo | Negative | Anti RBD IgG (IU/ml) | 163 | 10 (10, 10) |
| | Day 57 | Placebo | Negative | Anti Spike IgG (IU/ml) | 163 | 10 (10, 10) |
| | Day 57 | Placebo | Negative | Pseudovirus-nAb ID50 | 163 | 5 (5, 5) |
| | Day 57 | Placebo | Negative | Pseudovirus-nAb ID80 | 163 | 5 (5, 5) |
| | Day 57 | Placebo | Positive | Anti N IgG (IU/ml) | 270 | 130008 (92643, 182444) |
| | Day 57 | Placebo | Positive | Anti RBD IgG (IU/ml) | 270 | 382614 (299829, 488256) |
| | Day 57 | Placebo | Positive | Anti Spike IgG (IU/ml) | 270 | 676872 (531354, 862241) |
| | Day 57 | Placebo | Positive | Pseudovirus-nAb ID50 | 270 | 566 (409, 783) |
| | Day 57 | Placebo | Positive | Pseudovirus-nAb ID80 | 270 | 1324 (937, 1870) |

Table 5b. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Age

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|------------|-------|---------|---------------------|------------------------|-----|----------------|
| Age | | | | | | |
| Age < 65 | Day 1 | Vaccine | Negative | Anti N IgG (IU/ml) | 432 | 10 (10, 10) |
| Age < 65 | Day 1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 432 | 10 (10, 10) |
| Age < 65 | Day 1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 432 | 10 (10, 10) |
| Age < 65 | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 432 | 5 (5, 5) |
| Age < 65 | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 432 | 5 (5, 5) |
| Age < 65 | Day 1 | Vaccine | Positive | Anti N IgG (IU/ml) | 146 | 10 (10, 10) |
| Age < 65 | Day 1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 146 | 10 (10, 10) |
| Age < 65 | Day 1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 146 | 10 (10, 10) |
| Age < 65 | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 146 | 5 (5, 5) |
| Age < 65 | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 146 | 5 (5, 5) |
| Age < 65 | Day 1 | Placebo | Negative | Anti N IgG (IU/ml) | 80 | 10 (10, 11) |
| Age < 65 | Day 1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 80 | 10 (10, 11) |
| Age < 65 | Day 1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 80 | 10 (10, 10) |
| Age < 65 | Day 1 | Placebo | Negative | Pseudovirus-nAb ID50 | 80 | 5 (5, 5) |
| Age < 65 | Day 1 | Placebo | Negative | Pseudovirus-nAb ID80 | 80 | 5 (5, 5) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|----------|--------|---------|---------------------|------------------------|-----|-------------------------|
| Age < 65 | Day 1 | Placebo | Positive | Anti N IgG (IU/ml) | 147 | 10 (10, 10) |
| Age < 65 | Day 1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 147 | 10 (10, 10) |
| Age < 65 | Day 1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 147 | 10 (10, 10) |
| Age < 65 | Day 1 | Placebo | Positive | Pseudovirus-nAb ID50 | 147 | 5 (5, 5) |
| Age < 65 | Day 1 | Placebo | Positive | Pseudovirus-nAb ID80 | 147 | 5 (5, 5) |
| Age < 65 | Day 29 | Vaccine | Negative | Anti N IgG (IU/ml) | 432 | 18416 (15002, 22607) |
| Age < 65 | Day 29 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 432 | 17393 (14565, 20770) |
| Age < 65 | Day 29 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 432 | 31397 (27475, 35879) |
| Age < 65 | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID50 | 432 | 85 (69, 103) |
| Age < 65 | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID80 | 432 | 157 (129, 192) |
| Age < 65 | Day 29 | Vaccine | Positive | Anti N IgG (IU/ml) | 146 | 32567 (23744, 44670) |
| Age < 65 | Day 29 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 146 | 24939 (18393, 33814) |
| Age < 65 | Day 29 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 146 | 59400 (46119, 76506) |
| Age < 65 | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID50 | 146 | 144 (104, 198) |
| Age < 65 | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID80 | 146 | 339 (238, 482) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|----------|--------|---------|---------------------|------------------------|-----|-------------------------------|
| Age < 65 | Day 29 | Placebo | Negative | Anti N IgG (IU/ml) | 80 | 10 (10, 10) |
| Age < 65 | Day 29 | Placebo | Negative | Anti RBD IgG (IU/ml) | 80 | 10 (10, 10) |
| Age < 65 | Day 29 | Placebo | Negative | Anti Spike IgG (IU/ml) | 80 | 10 (10, 10) |
| Age < 65 | Day 29 | Placebo | Negative | Pseudovirus-nAb ID50 | 80 | 5 (5, 5) |
| Age < 65 | Day 29 | Placebo | Negative | Pseudovirus-nAb ID80 | 80 | 5 (5, 5) |
| Age < 65 | Day 29 | Placebo | Positive | Anti N IgG (IU/ml) | 147 | 9820 (7012, 13753) |
| Age < 65 | Day 29 | Placebo | Positive | Anti RBD IgG (IU/ml) | 147 | 9737 (7318, 12957) |
| Age < 65 | Day 29 | Placebo | Positive | Anti Spike IgG (IU/ml) | 147 | 13380 (10752, 16650) |
| Age < 65 | Day 29 | Placebo | Positive | Pseudovirus-nAb ID50 | 147 | 40 (29, 54) |
| Age < 65 | Day 29 | Placebo | Positive | Pseudovirus-nAb ID80 | 147 | 106 (76, 147) |
| Age < 65 | Day 57 | Vaccine | Negative | Anti N IgG (IU/ml) | 432 | 253319 (198848, 322710) |
| Age < 65 | Day 57 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 432 | 737116 (604473, 898866) |
| Age < 65 | Day 57 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 432 | 1643373 (1397160, 1932976) |
| Age < 65 | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID50 | 432 | 1136 (890, 1449) |
| Age < 65 | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID80 | 432 | 1750 (1355, 2260) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|----------|--------|---------|---------------------|------------------------|-----|-------------------------------|
| Age < 65 | Day 57 | Vaccine | Positive | Anti N IgG (IU/ml) | 146 | 739998 (487226, 1123907) |
| Age < 65 | Day 57 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 146 | 1708031 (1250384, 2333179) |
| Age < 65 | Day 57 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 146 | 4266733 (3292306, 5529560) |
| Age < 65 | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID50 | 146 | 4061 (2527, 6527) |
| Age < 65 | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID80 | 146 | 6238 (4090, 9513) |
| Age < 65 | Day 57 | Placebo | Negative | Anti N IgG (IU/ml) | 80 | 10 (10, 10) |
| Age < 65 | Day 57 | Placebo | Negative | Anti RBD IgG (IU/ml) | 80 | 10 (10, 10) |
| Age < 65 | Day 57 | Placebo | Negative | Anti Spike IgG (IU/ml) | 80 | 10 (10, 10) |
| Age < 65 | Day 57 | Placebo | Negative | Pseudovirus-nAb ID50 | 80 | 5 (5, 5) |
| Age < 65 | Day 57 | Placebo | Negative | Pseudovirus-nAb ID80 | 80 | 5 (5, 5) |
| Age < 65 | Day 57 | Placebo | Positive | Anti N IgG (IU/ml) | 147 | 93772 (62211, 141344) |
| Age < 65 | Day 57 | Placebo | Positive | Anti RBD IgG (IU/ml) | 147 | 270061 (201183, 362521) |
| Age < 65 | Day 57 | Placebo | Positive | Anti Spike IgG (IU/ml) | 147 | 484596 (361146, 650244) |
| Age < 65 | Day 57 | Placebo | Positive | Pseudovirus-nAb ID50 | 147 | 387 (262, 572) |
| Age < 65 | Day 57 | Placebo | Positive | Pseudovirus-nAb ID80 | 147 | 1009 (665, 1531) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|---------------|-------|---------|---------------------|------------------------|-----|----------------|
| Age \geq 65 | Day 1 | Vaccine | Negative | Anti N IgG (IU/ml) | 482 | 10 (10, 10) |
| Age \geq 65 | Day 1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 482 | 10 (10, 10) |
| Age \geq 65 | Day 1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 482 | 10 (10, 10) |
| Age \geq 65 | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 482 | 5 (5, 5) |
| Age \geq 65 | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 482 | 5 (5, 5) |
| Age \geq 65 | Day 1 | Vaccine | Positive | Anti N IgG (IU/ml) | 128 | 10 (10, 10) |
| Age \geq 65 | Day 1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 128 | 10 (10, 10) |
| Age \geq 65 | Day 1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 128 | 10 (10, 10) |
| Age \geq 65 | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 128 | 5 (5, 5) |
| Age \geq 65 | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 128 | 5 (5, 5) |
| Age \geq 65 | Day 1 | Placebo | Negative | Anti N IgG (IU/ml) | 83 | 10 (10, 10) |
| Age \geq 65 | Day 1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 83 | 10 (10, 10) |
| Age \geq 65 | Day 1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 83 | 10 (10, 10) |
| Age \geq 65 | Day 1 | Placebo | Negative | Pseudovirus-nAb ID50 | 83 | 5 (5, 5) |
| Age \geq 65 | Day 1 | Placebo | Negative | Pseudovirus-nAb ID80 | 83 | 5 (5, 5) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|---------------|--------|---------|---------------------|------------------------|-----|----------------------------|
| Age \geq 65 | Day 1 | Placebo | Positive | Anti N IgG (IU/ml) | 123 | 10 (10, 10) |
| Age \geq 65 | Day 1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 123 | 10 (10, 10) |
| Age \geq 65 | Day 1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 123 | 10 (10, 10) |
| Age \geq 65 | Day 1 | Placebo | Positive | Pseudovirus-nAb ID50 | 123 | 5 (5, 5) |
| Age \geq 65 | Day 1 | Placebo | Positive | Pseudovirus-nAb ID80 | 123 | 5 (5, 5) |
| Age \geq 65 | Day 29 | Vaccine | Negative | Anti N IgG (IU/ml) | 482 | 59687 (50609, 70395) |
| Age \geq 65 | Day 29 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 482 | 65260 (56734, 75068) |
| Age \geq 65 | Day 29 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 482 | 112166 (98902, 127209) |
| Age \geq 65 | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID50 | 482 | 254 (214, 300) |
| Age \geq 65 | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID80 | 482 | 381 (321, 451) |
| Age \geq 65 | Day 29 | Vaccine | Positive | Anti N IgG (IU/ml) | 128 | 130450 (94702, 179694) |
| Age \geq 65 | Day 29 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 128 | 158619 (123545, 203649) |
| Age \geq 65 | Day 29 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 128 | 262073 (211994, 323982) |
| Age \geq 65 | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID50 | 128 | 522 (373, 731) |
| Age \geq 65 | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID80 | 128 | 988 (733, 1331) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|---------------|--------|---------|---------------------|------------------------|-----|-------------------------------|
| Age \geq 65 | Day 29 | Placebo | Negative | Anti N IgG (IU/ml) | 83 | 10 (10, 10) |
| Age \geq 65 | Day 29 | Placebo | Negative | Anti RBD IgG (IU/ml) | 83 | 10 (10, 10) |
| Age \geq 65 | Day 29 | Placebo | Negative | Anti Spike IgG (IU/ml) | 83 | 10 (10, 10) |
| Age \geq 65 | Day 29 | Placebo | Negative | Pseudovirus-nAb ID50 | 83 | 5 (5, 5) |
| Age \geq 65 | Day 29 | Placebo | Negative | Pseudovirus-nAb ID80 | 83 | 5 (5, 5) |
| Age \geq 65 | Day 29 | Placebo | Positive | Anti N IgG (IU/ml) | 123 | 35028 (24879, 49317) |
| Age \geq 65 | Day 29 | Placebo | Positive | Anti RBD IgG (IU/ml) | 123 | 41836 (32047, 54614) |
| Age \geq 65 | Day 29 | Placebo | Positive | Anti Spike IgG (IU/ml) | 123 | 66891 (53117, 84238) |
| Age \geq 65 | Day 29 | Placebo | Positive | Pseudovirus-nAb ID50 | 123 | 156 (112, 216) |
| Age \geq 65 | Day 29 | Placebo | Positive | Pseudovirus-nAb ID80 | 123 | 301 (219, 413) |
| Age \geq 65 | Day 57 | Vaccine | Negative | Anti N IgG (IU/ml) | 482 | 836805 (684275, 1023335) |
| Age \geq 65 | Day 57 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 482 | 2692372 (2329146, 3112243) |
| Age \geq 65 | Day 57 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 482 | 5171042 (4536102, 5894857) |
| Age \geq 65 | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID50 | 482 | 4259 (3414, 5312) |
| Age \geq 65 | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID80 | 482 | 5506 (4535, 6685) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|---------------|--------|---------|---------------------|------------------------|-----|----------------------------------|
| Age \geq 65 | Day 57 | Vaccine | Positive | Anti N IgG (IU/ml) | 128 | 3014476 (2173987, 4179907) |
| Age \geq 65 | Day 57 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 128 | 7520373 (6146909, 9200723) |
| Age \geq 65 | Day 57 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 128 | 13148461 (11661345, 14825221) |
| Age \geq 65 | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID50 | 128 | 21658 (15437, 30385) |
| Age \geq 65 | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID80 | 128 | 19480 (13318, 28494) |
| Age \geq 65 | Day 57 | Placebo | Negative | Anti N IgG (IU/ml) | 83 | 10 (10, 10) |
| Age \geq 65 | Day 57 | Placebo | Negative | Anti RBD IgG (IU/ml) | 83 | 10 (10, 10) |
| Age \geq 65 | Day 57 | Placebo | Negative | Anti Spike IgG (IU/ml) | 83 | 10 (10, 10) |
| Age \geq 65 | Day 57 | Placebo | Negative | Pseudovirus-nAb ID50 | 83 | 5 (5, 5) |
| Age \geq 65 | Day 57 | Placebo | Negative | Pseudovirus-nAb ID80 | 83 | 5 (5, 5) |
| Age \geq 65 | Day 57 | Placebo | Positive | Anti N IgG (IU/ml) | 123 | 519433 (364323, 740581) |
| Age \geq 65 | Day 57 | Placebo | Positive | Anti RBD IgG (IU/ml) | 123 | 1675605 (1276999, 2198632) |
| Age \geq 65 | Day 57 | Placebo | Positive | Anti Spike IgG (IU/ml) | 123 | 2790960 (2209589, 3525298) |
| Age \geq 65 | Day 57 | Placebo | Positive | Pseudovirus-nAb ID50 | 123 | 2827 (1887, 4233) |
| Age \geq 65 | Day 57 | Placebo | Positive | Pseudovirus-nAb ID80 | 123 | 4185 (2859, 6127) |

Table 5c. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Risk for Severe Covid-19

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|---------------------------------|-------|---------|---------------------|------------------------|-----|----------------|
| Risk for Severe Covid-19 | | | | | | |
| At-risk | Day 1 | Vaccine | Negative | Anti N IgG (IU/ml) | 469 | 10 (10, 10) |
| At-risk | Day 1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 469 | 10 (10, 10) |
| At-risk | Day 1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 469 | 10 (10, 10) |
| At-risk | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 469 | 5 (5, 5) |
| At-risk | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 469 | 5 (5, 5) |
| At-risk | Day 1 | Vaccine | Positive | Anti N IgG (IU/ml) | 125 | 10 (10, 10) |
| At-risk | Day 1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 125 | 10 (10, 10) |
| At-risk | Day 1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 125 | 10 (10, 10) |
| At-risk | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 125 | 5 (5, 5) |
| At-risk | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 125 | 5 (5, 5) |
| At-risk | Day 1 | Placebo | Negative | Anti N IgG (IU/ml) | 84 | 10 (10, 10) |
| At-risk | Day 1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 84 | 10 (10, 10) |
| At-risk | Day 1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 84 | 10 (10, 11) |
| At-risk | Day 1 | Placebo | Negative | Pseudovirus-nAb ID50 | 84 | 5 (5, 5) |
| At-risk | Day 1 | Placebo | Negative | Pseudovirus-nAb ID80 | 84 | 5 (5, 5) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|---------|--------|---------|---------------------|------------------------|-----|---------------------------|
| At-risk | Day 1 | Placebo | Positive | Anti N IgG (IU/ml) | 123 | 10 (10, 10) |
| At-risk | Day 1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 123 | 10 (10, 10) |
| At-risk | Day 1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 123 | 10 (10, 10) |
| At-risk | Day 1 | Placebo | Positive | Pseudovirus-nAb ID50 | 123 | 5 (5, 5) |
| At-risk | Day 1 | Placebo | Positive | Pseudovirus-nAb ID80 | 123 | 5 (5, 5) |
| At-risk | Day 29 | Vaccine | Negative | Anti N IgG (IU/ml) | 469 | 23746 (19934, 28287) |
| At-risk | Day 29 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 469 | 26276 (22610, 30535) |
| At-risk | Day 29 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 469 | 45842 (40067, 52448) |
| At-risk | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID50 | 469 | 103 (87, 122) |
| At-risk | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID80 | 469 | 215 (180, 258) |
| At-risk | Day 29 | Vaccine | Positive | Anti N IgG (IU/ml) | 125 | 55180 (40419, 75332) |
| At-risk | Day 29 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 125 | 55528 (43641, 70653) |
| At-risk | Day 29 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 125 | 103862 (82479, 130788) |
| At-risk | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID50 | 125 | 220 (161, 302) |
| At-risk | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID80 | 125 | 443 (318, 617) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|---------|--------|---------|---------------------|------------------------|-----|-------------------------------|
| At-risk | Day 29 | Placebo | Negative | Anti N IgG (IU/ml) | 84 | 10 (10, 10) |
| At-risk | Day 29 | Placebo | Negative | Anti RBD IgG (IU/ml) | 84 | 10 (10, 10) |
| At-risk | Day 29 | Placebo | Negative | Anti Spike IgG (IU/ml) | 84 | 10 (10, 10) |
| At-risk | Day 29 | Placebo | Negative | Pseudovirus-nAb ID50 | 84 | 5 (5, 5) |
| At-risk | Day 29 | Placebo | Negative | Pseudovirus-nAb ID80 | 84 | 5 (5, 5) |
| At-risk | Day 29 | Placebo | Positive | Anti N IgG (IU/ml) | 123 | 16553 (12215, 22429) |
| At-risk | Day 29 | Placebo | Positive | Anti RBD IgG (IU/ml) | 123 | 16713 (12642, 22096) |
| At-risk | Day 29 | Placebo | Positive | Anti Spike IgG (IU/ml) | 123 | 26705 (21285, 33505) |
| At-risk | Day 29 | Placebo | Positive | Pseudovirus-nAb ID50 | 123 | 69 (52, 93) |
| At-risk | Day 29 | Placebo | Positive | Pseudovirus-nAb ID80 | 123 | 180 (133, 243) |
| At-risk | Day 57 | Vaccine | Negative | Anti N IgG (IU/ml) | 469 | 335374 (270080, 416453) |
| At-risk | Day 57 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 469 | 1142597 (961925, 1357205) |
| At-risk | Day 57 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 469 | 2144439 (1840509, 2498559) |
| At-risk | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID50 | 469 | 1796 (1424, 2264) |
| At-risk | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID80 | 469 | 2766 (2265, 3377) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|---------|--------|---------|---------------------|------------------------|-----|-------------------------------|
| At-risk | Day 57 | Vaccine | Positive | Anti N IgG (IU/ml) | 125 | 1327591 (937265, 1880469) |
| At-risk | Day 57 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 125 | 2930270 (2216035, 3874704) |
| At-risk | Day 57 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 125 | 6396516 (5214355, 7846688) |
| At-risk | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID50 | 125 | 6128 (4355, 8625) |
| At-risk | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID80 | 125 | 11182 (7684, 16271) |
| At-risk | Day 57 | Placebo | Negative | Anti N IgG (IU/ml) | 84 | 10 (10, 10) |
| At-risk | Day 57 | Placebo | Negative | Anti RBD IgG (IU/ml) | 84 | 10 (10, 10) |
| At-risk | Day 57 | Placebo | Negative | Anti Spike IgG (IU/ml) | 84 | 10 (10, 10) |
| At-risk | Day 57 | Placebo | Negative | Pseudovirus-nAb ID50 | 84 | 5 (5, 5) |
| At-risk | Day 57 | Placebo | Negative | Pseudovirus-nAb ID80 | 84 | 5 (5, 5) |
| At-risk | Day 57 | Placebo | Positive | Anti N IgG (IU/ml) | 123 | 197242 (138403, 281094) |
| At-risk | Day 57 | Placebo | Positive | Anti RBD IgG (IU/ml) | 123 | 663561 (492320, 894363) |
| At-risk | Day 57 | Placebo | Positive | Anti Spike IgG (IU/ml) | 123 | 1012116 (794913, 1288669) |
| At-risk | Day 57 | Placebo | Positive | Pseudovirus-nAb ID50 | 123 | 931 (651, 1331) |
| At-risk | Day 57 | Placebo | Positive | Pseudovirus-nAb ID80 | 123 | 2086 (1418, 3067) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|-------------|-------|---------|---------------------|------------------------|-----|----------------|
| Not at-risk | Day 1 | Vaccine | Negative | Anti N IgG (IU/ml) | 445 | 10 (10, 10) |
| Not at-risk | Day 1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 445 | 10 (10, 10) |
| Not at-risk | Day 1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 445 | 10 (10, 10) |
| Not at-risk | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 445 | 5 (5, 5) |
| Not at-risk | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 445 | 5 (5, 5) |
| Not at-risk | Day 1 | Vaccine | Positive | Anti N IgG (IU/ml) | 149 | 10 (10, 10) |
| Not at-risk | Day 1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 149 | 10 (10, 10) |
| Not at-risk | Day 1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 149 | 10 (10, 10) |
| Not at-risk | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 149 | 5 (5, 5) |
| Not at-risk | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 149 | 5 (5, 5) |
| Not at-risk | Day 1 | Placebo | Negative | Anti N IgG (IU/ml) | 79 | 10 (10, 11) |
| Not at-risk | Day 1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 79 | 10 (10, 11) |
| Not at-risk | Day 1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 79 | 10 (10, 10) |
| Not at-risk | Day 1 | Placebo | Negative | Pseudovirus-nAb ID50 | 79 | 5 (5, 5) |
| Not at-risk | Day 1 | Placebo | Negative | Pseudovirus-nAb ID80 | 79 | 5 (5, 5) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|-------------|--------|---------|---------------------|------------------------|-----|-------------------------|
| Not at-risk | Day 1 | Placebo | Positive | Anti N IgG (IU/ml) | 147 | 10 (10, 11) |
| Not at-risk | Day 1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 147 | 10 (10, 10) |
| Not at-risk | Day 1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 147 | 10 (10, 10) |
| Not at-risk | Day 1 | Placebo | Positive | Pseudovirus-nAb ID50 | 147 | 5 (5, 5) |
| Not at-risk | Day 1 | Placebo | Positive | Pseudovirus-nAb ID80 | 147 | 5 (5, 5) |
| Not at-risk | Day 29 | Vaccine | Negative | Anti N IgG (IU/ml) | 445 | 23464 (18827, 29244) |
| Not at-risk | Day 29 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 445 | 21736 (17965, 26298) |
| Not at-risk | Day 29 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 445 | 39200 (34023, 45165) |
| Not at-risk | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID50 | 445 | 108 (87, 133) |
| Not at-risk | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID80 | 445 | 180 (145, 223) |
| Not at-risk | Day 29 | Vaccine | Positive | Anti N IgG (IU/ml) | 149 | 39449 (28242, 55103) |
| Not at-risk | Day 29 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 149 | 31130 (22510, 43050) |
| Not at-risk | Day 29 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 149 | 73051 (55946, 95386) |
| Not at-risk | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID50 | 149 | 175 (124, 247) |
| Not at-risk | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID80 | 149 | 412 (284, 597) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|-------------|--------|---------|---------------------|------------------------|-----|-------------------------------|
| Not at-risk | Day 29 | Placebo | Negative | Anti N IgG (IU/ml) | 79 | 10 (10, 10) |
| Not at-risk | Day 29 | Placebo | Negative | Anti RBD IgG (IU/ml) | 79 | 10 (10, 10) |
| Not at-risk | Day 29 | Placebo | Negative | Anti Spike IgG (IU/ml) | 79 | 10 (10, 10) |
| Not at-risk | Day 29 | Placebo | Negative | Pseudovirus-nAb ID50 | 79 | 5 (5, 5) |
| Not at-risk | Day 29 | Placebo | Negative | Pseudovirus-nAb ID80 | 79 | 5 (5, 5) |
| Not at-risk | Day 29 | Placebo | Positive | Anti N IgG (IU/ml) | 147 | 11438 (8001, 16352) |
| Not at-risk | Day 29 | Placebo | Positive | Anti RBD IgG (IU/ml) | 147 | 11818 (8756, 15950) |
| Not at-risk | Day 29 | Placebo | Positive | Anti Spike IgG (IU/ml) | 147 | 16070 (12770, 20222) |
| Not at-risk | Day 29 | Placebo | Positive | Pseudovirus-nAb ID50 | 147 | 47 (34, 64) |
| Not at-risk | Day 29 | Placebo | Positive | Pseudovirus-nAb ID80 | 147 | 116 (82, 164) |
| Not at-risk | Day 57 | Vaccine | Negative | Anti N IgG (IU/ml) | 445 | 321219 (247884, 416250) |
| Not at-risk | Day 57 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 445 | 904842 (732112, 1118324) |
| Not at-risk | Day 57 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 445 | 2066294 (1739231, 2454861) |
| Not at-risk | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID50 | 445 | 1394 (1075, 1808) |
| Not at-risk | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID80 | 445 | 2041 (1549, 2690) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|-------------|--------|---------|---------------------|------------------------|-----|-------------------------------|
| Not at-risk | Day 57 | Vaccine | Positive | Anti N IgG (IU/ml) | 149 | 882754 (567083, 1374143) |
| Not at-risk | Day 57 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 149 | 2113273 (1525010, 2928453) |
| Not at-risk | Day 57 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 149 | 5023873 (3827375, 6594416) |
| Not at-risk | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID50 | 149 | 5532 (3337, 9171) |
| Not at-risk | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID80 | 149 | 6928 (4429, 10838) |
| Not at-risk | Day 57 | Placebo | Negative | Anti N IgG (IU/ml) | 79 | 10 (10, 10) |
| Not at-risk | Day 57 | Placebo | Negative | Anti RBD IgG (IU/ml) | 79 | 10 (10, 10) |
| Not at-risk | Day 57 | Placebo | Negative | Anti Spike IgG (IU/ml) | 79 | 10 (10, 10) |
| Not at-risk | Day 57 | Placebo | Negative | Pseudovirus-nAb ID50 | 79 | 5 (5, 5) |
| Not at-risk | Day 57 | Placebo | Negative | Pseudovirus-nAb ID80 | 79 | 5 (5, 5) |
| Not at-risk | Day 57 | Placebo | Positive | Anti N IgG (IU/ml) | 147 | 113637 (73666, 175296) |
| Not at-risk | Day 57 | Placebo | Positive | Anti RBD IgG (IU/ml) | 147 | 320294 (235413, 435781) |
| Not at-risk | Day 57 | Placebo | Positive | Anti Spike IgG (IU/ml) | 147 | 594413 (435730, 810886) |
| Not at-risk | Day 57 | Placebo | Positive | Pseudovirus-nAb ID50 | 147 | 482 (318, 728) |
| Not at-risk | Day 57 | Placebo | Positive | Pseudovirus-nAb ID80 | 147 | 1143 (737, 1774) |

Table 5d. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Age, Risk for Severe Covid-19

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|--------------------------------------|-------|---------|---------------------|------------------------|-----|----------------|
| Age, Risk for Severe Covid-19 | | | | | | |
| Age < 65 At-risk | Day 1 | Vaccine | Negative | Anti N IgG (IU/ml) | 214 | 10 (10, 10) |
| Age < 65 At-risk | Day 1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 214 | 10 (10, 10) |
| Age < 65 At-risk | Day 1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 214 | 10 (10, 10) |
| Age < 65 At-risk | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 214 | 5 (5, 5) |
| Age < 65 At-risk | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 214 | 5 (5, 5) |
| Age < 65 At-risk | Day 1 | Vaccine | Positive | Anti N IgG (IU/ml) | 73 | 10 (10, 10) |
| Age < 65 At-risk | Day 1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 73 | 10 (10, 10) |
| Age < 65 At-risk | Day 1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 73 | 10 (10, 10) |
| Age < 65 At-risk | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 73 | 5 (5, 5) |
| Age < 65 At-risk | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 73 | 5 (5, 5) |
| Age < 65 At-risk | Day 1 | Placebo | Negative | Anti N IgG (IU/ml) | 40 | 10 (10, 10) |
| Age < 65 At-risk | Day 1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 40 | 10 (10, 10) |
| Age < 65 At-risk | Day 1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 40 | 10 (10, 11) |
| Age < 65 At-risk | Day 1 | Placebo | Negative | Pseudovirus-nAb ID50 | 40 | 5 (5, 5) |
| Age < 65 At-risk | Day 1 | Placebo | Negative | Pseudovirus-nAb ID80 | 40 | 5 (5, 5) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|------------------|--------|---------|---------------------|------------------------|-----|-------------------------|
| Age < 65 At-risk | Day 1 | Placebo | Positive | Anti N IgG (IU/ml) | 75 | 10 (10, 10) |
| Age < 65 At-risk | Day 1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 75 | 10 (10, 10) |
| Age < 65 At-risk | Day 1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 75 | 10 (10, 10) |
| Age < 65 At-risk | Day 1 | Placebo | Positive | Pseudovirus-nAb ID50 | 75 | 5 (5, 5) |
| Age < 65 At-risk | Day 1 | Placebo | Positive | Pseudovirus-nAb ID80 | 75 | 5 (5, 5) |
| Age < 65 At-risk | Day 29 | Vaccine | Negative | Anti N IgG (IU/ml) | 214 | 15066 (11800, 19236) |
| Age < 65 At-risk | Day 29 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 214 | 16530 (13368, 20441) |
| Age < 65 At-risk | Day 29 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 214 | 31028 (25725, 37423) |
| Age < 65 At-risk | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID50 | 214 | 68 (54, 85) |
| Age < 65 At-risk | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID80 | 214 | 159 (123, 204) |
| Age < 65 At-risk | Day 29 | Vaccine | Positive | Anti N IgG (IU/ml) | 73 | 35719 (23749, 53721) |
| Age < 65 At-risk | Day 29 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 73 | 30603 (22501, 41623) |
| Age < 65 At-risk | Day 29 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 73 | 62641 (46271, 84801) |
| Age < 65 At-risk | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID50 | 73 | 142 (95, 213) |
| Age < 65 At-risk | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID80 | 73 | 291 (187, 453) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|------------------|--------|---------|---------------------|------------------------|-----|-------------------------------|
| Age < 65 At-risk | Day 29 | Placebo | Negative | Anti N IgG (IU/ml) | 40 | 10 (10, 10) |
| Age < 65 At-risk | Day 29 | Placebo | Negative | Anti RBD IgG (IU/ml) | 40 | 10 (10, 10) |
| Age < 65 At-risk | Day 29 | Placebo | Negative | Anti Spike IgG (IU/ml) | 40 | 10 (10, 10) |
| Age < 65 At-risk | Day 29 | Placebo | Negative | Pseudovirus-nAb ID50 | 40 | 5 (5, 6) |
| Age < 65 At-risk | Day 29 | Placebo | Negative | Pseudovirus-nAb ID80 | 40 | 5 (5, 5) |
| Age < 65 At-risk | Day 29 | Placebo | Positive | Anti N IgG (IU/ml) | 75 | 11526 (8014, 16577) |
| Age < 65 At-risk | Day 29 | Placebo | Positive | Anti RBD IgG (IU/ml) | 75 | 10221 (7219, 14470) |
| Age < 65 At-risk | Day 29 | Placebo | Positive | Anti Spike IgG (IU/ml) | 75 | 16112 (12299, 21107) |
| Age < 65 At-risk | Day 29 | Placebo | Positive | Pseudovirus-nAb ID50 | 75 | 48 (34, 67) |
| Age < 65 At-risk | Day 29 | Placebo | Positive | Pseudovirus-nAb ID80 | 75 | 127 (87, 186) |
| Age < 65 At-risk | Day 57 | Vaccine | Negative | Anti N IgG (IU/ml) | 214 | 227691 (168852, 307033) |
| Age < 65 At-risk | Day 57 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 214 | 761200 (595277, 973370) |
| Age < 65 At-risk | Day 57 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 214 | 1498825 (1211392, 1854460) |
| Age < 65 At-risk | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID50 | 214 | 1203 (876, 1652) |
| Age < 65 At-risk | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID80 | 214 | 2067 (1571, 2720) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|------------------|--------|---------|---------------------|------------------------|----|-------------------------------|
| Age < 65 At-risk | Day 57 | Vaccine | Positive | Anti N IgG (IU/ml) | 73 | 848831 (532838, 1352218) |
| Age < 65 At-risk | Day 57 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 73 | 1815884 (1228679, 2683724) |
| Age < 65 At-risk | Day 57 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 73 | 4547755 (3405518, 6073108) |
| Age < 65 At-risk | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID50 | 73 | 2953 (1859, 4690) |
| Age < 65 At-risk | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID80 | 73 | 7954 (4852, 13039) |
| Age < 65 At-risk | Day 57 | Placebo | Negative | Anti N IgG (IU/ml) | 40 | 10 (10, 10) |
| Age < 65 At-risk | Day 57 | Placebo | Negative | Anti RBD IgG (IU/ml) | 40 | 10 (10, 11) |
| Age < 65 At-risk | Day 57 | Placebo | Negative | Anti Spike IgG (IU/ml) | 40 | 10 (10, 10) |
| Age < 65 At-risk | Day 57 | Placebo | Negative | Pseudovirus-nAb ID50 | 40 | 5 (5, 5) |
| Age < 65 At-risk | Day 57 | Placebo | Negative | Pseudovirus-nAb ID80 | 40 | 5 (5, 5) |
| Age < 65 At-risk | Day 57 | Placebo | Positive | Anti N IgG (IU/ml) | 75 | 115913 (72906, 184288) |
| Age < 65 At-risk | Day 57 | Placebo | Positive | Anti RBD IgG (IU/ml) | 75 | 417627 (286526, 608715) |
| Age < 65 At-risk | Day 57 | Placebo | Positive | Anti Spike IgG (IU/ml) | 75 | 575539 (423609, 781958) |
| Age < 65 At-risk | Day 57 | Placebo | Positive | Pseudovirus-nAb ID50 | 75 | 502 (325, 776) |
| Age < 65 At-risk | Day 57 | Placebo | Positive | Pseudovirus-nAb ID80 | 75 | 1382 (851, 2245) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|----------------------|-------|---------|---------------------|------------------------|-----|----------------|
| Age < 65 Not at-risk | Day 1 | Vaccine | Negative | Anti N IgG (IU/ml) | 218 | 10 (10, 10) |
| Age < 65 Not at-risk | Day 1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 218 | 10 (10, 10) |
| Age < 65 Not at-risk | Day 1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 218 | 10 (10, 10) |
| Age < 65 Not at-risk | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 218 | 5 (5, 5) |
| Age < 65 Not at-risk | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 218 | 5 (5, 5) |
| Age < 65 Not at-risk | Day 1 | Vaccine | Positive | Anti N IgG (IU/ml) | 73 | 10 (10, 10) |
| Age < 65 Not at-risk | Day 1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 73 | 10 (10, 10) |
| Age < 65 Not at-risk | Day 1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 73 | 10 (10, 10) |
| Age < 65 Not at-risk | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 73 | 5 (5, 5) |
| Age < 65 Not at-risk | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 73 | 5 (5, 5) |
| Age < 65 Not at-risk | Day 1 | Placebo | Negative | Anti N IgG (IU/ml) | 40 | 10 (10, 11) |
| Age < 65 Not at-risk | Day 1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 40 | 10 (10, 11) |
| Age < 65 Not at-risk | Day 1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 40 | 10 (10, 10) |
| Age < 65 Not at-risk | Day 1 | Placebo | Negative | Pseudovirus-nAb ID50 | 40 | 5 (5, 5) |
| Age < 65 Not at-risk | Day 1 | Placebo | Negative | Pseudovirus-nAb ID80 | 40 | 5 (5, 6) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|----------------------|--------|---------|---------------------|------------------------|-----|-------------------------|
| Age < 65 Not at-risk | Day 1 | Placebo | Positive | Anti N IgG (IU/ml) | 72 | 10 (10, 11) |
| Age < 65 Not at-risk | Day 1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 72 | 10 (10, 10) |
| Age < 65 Not at-risk | Day 1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 72 | 10 (10, 10) |
| Age < 65 Not at-risk | Day 1 | Placebo | Positive | Pseudovirus-nAb ID50 | 72 | 5 (5, 5) |
| Age < 65 Not at-risk | Day 1 | Placebo | Positive | Pseudovirus-nAb ID80 | 72 | 5 (5, 5) |
| Age < 65 Not at-risk | Day 29 | Vaccine | Negative | Anti N IgG (IU/ml) | 218 | 19467 (15117, 25069) |
| Age < 65 Not at-risk | Day 29 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 218 | 17639 (14174, 21953) |
| Age < 65 Not at-risk | Day 29 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 218 | 31500 (26782, 37050) |
| Age < 65 Not at-risk | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID50 | 218 | 90 (70, 115) |
| Age < 65 Not at-risk | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID80 | 218 | 157 (122, 200) |
| Age < 65 Not at-risk | Day 29 | Vaccine | Positive | Anti N IgG (IU/ml) | 73 | 31746 (21553, 46760) |
| Age < 65 Not at-risk | Day 29 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 73 | 23567 (16129, 34434) |
| Age < 65 Not at-risk | Day 29 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 73 | 58534 (42846, 79967) |
| Age < 65 Not at-risk | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID50 | 73 | 144 (97, 214) |
| Age < 65 Not at-risk | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID80 | 73 | 353 (229, 545) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|----------------------|--------|---------|---------------------|------------------------|-----|-------------------------------|
| Age < 65 Not at-risk | Day 29 | Placebo | Negative | Anti N IgG (IU/ml) | 40 | 10 (10, 10) |
| Age < 65 Not at-risk | Day 29 | Placebo | Negative | Anti RBD IgG (IU/ml) | 40 | 10 (10, 10) |
| Age < 65 Not at-risk | Day 29 | Placebo | Negative | Anti Spike IgG (IU/ml) | 40 | 10 (10, 10) |
| Age < 65 Not at-risk | Day 29 | Placebo | Negative | Pseudovirus-nAb ID50 | 40 | 5 (5, 5) |
| Age < 65 Not at-risk | Day 29 | Placebo | Negative | Pseudovirus-nAb ID80 | 40 | 5 (5, 5) |
| Age < 65 Not at-risk | Day 29 | Placebo | Positive | Anti N IgG (IU/ml) | 72 | 9421 (6230, 14246) |
| Age < 65 Not at-risk | Day 29 | Placebo | Positive | Anti RBD IgG (IU/ml) | 72 | 9616 (6788, 13622) |
| Age < 65 Not at-risk | Day 29 | Placebo | Positive | Anti Spike IgG (IU/ml) | 72 | 12751 (9770, 16642) |
| Age < 65 Not at-risk | Day 29 | Placebo | Positive | Pseudovirus-nAb ID50 | 72 | 38 (26, 55) |
| Age < 65 Not at-risk | Day 29 | Placebo | Positive | Pseudovirus-nAb ID80 | 72 | 101 (68, 150) |
| Age < 65 Not at-risk | Day 57 | Vaccine | Negative | Anti N IgG (IU/ml) | 218 | 260904 (193707, 351412) |
| Age < 65 Not at-risk | Day 57 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 218 | 730590 (572430, 932450) |
| Age < 65 Not at-risk | Day 57 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 218 | 1685764 (1382036, 2056240) |
| Age < 65 Not at-risk | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID50 | 218 | 1118 (830, 1506) |
| Age < 65 Not at-risk | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID80 | 218 | 1671 (1216, 2295) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|----------------------|--------|---------|---------------------|------------------------|----|-------------------------------|
| Age < 65 Not at-risk | Day 57 | Vaccine | Positive | Anti N IgG (IU/ml) | 73 | 712451 (424544, 1195605) |
| Age < 65 Not at-risk | Day 57 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 73 | 1679359 (1144789, 2463552) |
| Age < 65 Not at-risk | Day 57 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 73 | 4192147 (3040678, 5779665) |
| Age < 65 Not at-risk | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID50 | 73 | 4435 (2453, 8017) |
| Age < 65 Not at-risk | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID80 | 73 | 5833 (3464, 9821) |
| Age < 65 Not at-risk | Day 57 | Placebo | Negative | Anti N IgG (IU/ml) | 40 | 10 (10, 10) |
| Age < 65 Not at-risk | Day 57 | Placebo | Negative | Anti RBD IgG (IU/ml) | 40 | 10 (10, 10) |
| Age < 65 Not at-risk | Day 57 | Placebo | Negative | Anti Spike IgG (IU/ml) | 40 | 10 (10, 10) |
| Age < 65 Not at-risk | Day 57 | Placebo | Negative | Pseudovirus-nAb ID50 | 40 | 5 (5, 5) |
| Age < 65 Not at-risk | Day 57 | Placebo | Negative | Pseudovirus-nAb ID80 | 40 | 5 (5, 5) |
| Age < 65 Not at-risk | Day 57 | Placebo | Positive | Anti N IgG (IU/ml) | 72 | 88760 (53701, 146707) |
| Age < 65 Not at-risk | Day 57 | Placebo | Positive | Anti RBD IgG (IU/ml) | 72 | 241209 (168681, 344922) |
| Age < 65 Not at-risk | Day 57 | Placebo | Positive | Anti Spike IgG (IU/ml) | 72 | 463469 (322830, 665378) |
| Age < 65 Not at-risk | Day 57 | Placebo | Positive | Pseudovirus-nAb ID50 | 72 | 362 (224, 583) |
| Age < 65 Not at-risk | Day 57 | Placebo | Positive | Pseudovirus-nAb ID80 | 72 | 930 (559, 1549) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|-----------------------|-------|---------|---------------------|------------------------|-----|----------------|
| Age \geq 65 At-risk | Day 1 | Vaccine | Negative | Anti N IgG (IU/ml) | 255 | 10 (10, 10) |
| Age \geq 65 At-risk | Day 1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 255 | 10 (10, 10) |
| Age \geq 65 At-risk | Day 1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 255 | 10 (10, 10) |
| Age \geq 65 At-risk | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 255 | 5 (5, 5) |
| Age \geq 65 At-risk | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 255 | 5 (5, 5) |
| Age \geq 65 At-risk | Day 1 | Vaccine | Positive | Anti N IgG (IU/ml) | 52 | 10 (10, 10) |
| Age \geq 65 At-risk | Day 1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 52 | 10 (10, 10) |
| Age \geq 65 At-risk | Day 1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 52 | 10 (10, 10) |
| Age \geq 65 At-risk | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 52 | 5 (5, 6) |
| Age \geq 65 At-risk | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 52 | 5 (5, 5) |
| Age \geq 65 At-risk | Day 1 | Placebo | Negative | Anti N IgG (IU/ml) | 44 | 10 (10, 10) |
| Age \geq 65 At-risk | Day 1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 44 | 10 (10, 10) |
| Age \geq 65 At-risk | Day 1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 44 | 10 (10, 10) |
| Age \geq 65 At-risk | Day 1 | Placebo | Negative | Pseudovirus-nAb ID50 | 44 | 5 (5, 5) |
| Age \geq 65 At-risk | Day 1 | Placebo | Negative | Pseudovirus-nAb ID80 | 44 | 5 (5, 5) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|-----------------------|--------|---------|---------------------|------------------------|-----|----------------------------|
| Age \geq 65 At-risk | Day 1 | Placebo | Positive | Anti N IgG (IU/ml) | 48 | 10 (10, 10) |
| Age \geq 65 At-risk | Day 1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 48 | 10 (10, 11) |
| Age \geq 65 At-risk | Day 1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 48 | 10 (10, 10) |
| Age \geq 65 At-risk | Day 1 | Placebo | Positive | Pseudovirus-nAb ID50 | 48 | 5 (5, 5) |
| Age \geq 65 At-risk | Day 1 | Placebo | Positive | Pseudovirus-nAb ID80 | 48 | 5 (5, 5) |
| Age \geq 65 At-risk | Day 29 | Vaccine | Negative | Anti N IgG (IU/ml) | 255 | 48363 (38230, 61183) |
| Age \geq 65 At-risk | Day 29 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 255 | 54232 (44615, 65922) |
| Age \geq 65 At-risk | Day 29 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 255 | 84391 (70325, 101269) |
| Age \geq 65 At-risk | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID50 | 255 | 199 (157, 252) |
| Age \geq 65 At-risk | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID80 | 255 | 348 (276, 438) |
| Age \geq 65 At-risk | Day 29 | Vaccine | Positive | Anti N IgG (IU/ml) | 52 | 134756 (86047, 211040) |
| Age \geq 65 At-risk | Day 29 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 52 | 188670 (129392, 275106) |
| Age \geq 65 At-risk | Day 29 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 52 | 293282 (210942, 407763) |
| Age \geq 65 At-risk | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID50 | 52 | 541 (337, 870) |
| Age \geq 65 At-risk | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID80 | 52 | 1052 (680, 1627) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|-----------------------|--------|---------|---------------------|------------------------|-----|-------------------------------|
| Age \geq 65 At-risk | Day 29 | Placebo | Negative | Anti N IgG (IU/ml) | 44 | 10 (10, 10) |
| Age \geq 65 At-risk | Day 29 | Placebo | Negative | Anti RBD IgG (IU/ml) | 44 | 10 (10, 10) |
| Age \geq 65 At-risk | Day 29 | Placebo | Negative | Anti Spike IgG (IU/ml) | 44 | 10 (10, 10) |
| Age \geq 65 At-risk | Day 29 | Placebo | Negative | Pseudovirus-nAb ID50 | 44 | 5 (5, 5) |
| Age \geq 65 At-risk | Day 29 | Placebo | Negative | Pseudovirus-nAb ID80 | 44 | 5 (5, 5) |
| Age \geq 65 At-risk | Day 29 | Placebo | Positive | Anti N IgG (IU/ml) | 48 | 36017 (20724, 62595) |
| Age \geq 65 At-risk | Day 29 | Placebo | Positive | Anti RBD IgG (IU/ml) | 48 | 48060 (30237, 76388) |
| Age \geq 65 At-risk | Day 29 | Placebo | Positive | Anti Spike IgG (IU/ml) | 48 | 79058 (52125, 119908) |
| Age \geq 65 At-risk | Day 29 | Placebo | Positive | Pseudovirus-nAb ID50 | 48 | 155 (89, 270) |
| Age \geq 65 At-risk | Day 29 | Placebo | Positive | Pseudovirus-nAb ID80 | 48 | 378 (233, 613) |
| Age \geq 65 At-risk | Day 57 | Vaccine | Negative | Anti N IgG (IU/ml) | 255 | 614449 (455495, 828875) |
| Age \geq 65 At-risk | Day 57 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 255 | 2156196 (1736284, 2677662) |
| Age \geq 65 At-risk | Day 57 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 255 | 3754377 (3053564, 4616033) |
| Age \geq 65 At-risk | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID50 | 255 | 3359 (2423, 4656) |
| Age \geq 65 At-risk | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID80 | 255 | 4361 (3299, 5763) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|-----------------------|--------|---------|---------------------|------------------------|----|----------------------------------|
| Age \geq 65 At-risk | Day 57 | Vaccine | Positive | Anti N IgG (IU/ml) | 52 | 3325369 (2089439, 5292368) |
| Age \geq 65 At-risk | Day 57 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 52 | 7826271 (5853680, 10463591) |
| Age \geq 65 At-risk | Day 57 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 52 | 12884976 (10641883, 15600868) |
| Age \geq 65 At-risk | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID50 | 52 | 27431 (17819, 42227) |
| Age \geq 65 At-risk | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID80 | 52 | 22502 (13237, 38254) |
| Age \geq 65 At-risk | Day 57 | Placebo | Negative | Anti N IgG (IU/ml) | 44 | 10 (10, 10) |
| Age \geq 65 At-risk | Day 57 | Placebo | Negative | Anti RBD IgG (IU/ml) | 44 | 10 (10, 10) |
| Age \geq 65 At-risk | Day 57 | Placebo | Negative | Anti Spike IgG (IU/ml) | 44 | 10 (10, 10) |
| Age \geq 65 At-risk | Day 57 | Placebo | Negative | Pseudovirus-nAb ID50 | 44 | 5 (5, 5) |
| Age \geq 65 At-risk | Day 57 | Placebo | Negative | Pseudovirus-nAb ID80 | 44 | 5 (5, 6) |
| Age \geq 65 At-risk | Day 57 | Placebo | Positive | Anti N IgG (IU/ml) | 48 | 617829 (374065, 1020446) |
| Age \geq 65 At-risk | Day 57 | Placebo | Positive | Anti RBD IgG (IU/ml) | 48 | 1793880 (1112795, 2891824) |
| Age \geq 65 At-risk | Day 57 | Placebo | Positive | Anti Spike IgG (IU/ml) | 48 | 3402410 (2325361, 4978321) |
| Age \geq 65 At-risk | Day 57 | Placebo | Positive | Pseudovirus-nAb ID50 | 48 | 3501 (1863, 6577) |
| Age \geq 65 At-risk | Day 57 | Placebo | Positive | Pseudovirus-nAb ID80 | 48 | 5048 (2709, 9408) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|---------------------------|-------|---------|---------------------|------------------------|-----|----------------|
| Age \geq 65 Not at-risk | Day 1 | Vaccine | Negative | Anti N IgG (IU/ml) | 227 | 10 (10, 10) |
| Age \geq 65 Not at-risk | Day 1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 227 | 10 (10, 10) |
| Age \geq 65 Not at-risk | Day 1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 227 | 10 (10, 10) |
| Age \geq 65 Not at-risk | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 227 | 5 (5, 5) |
| Age \geq 65 Not at-risk | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 227 | 5 (5, 5) |
| Age \geq 65 Not at-risk | Day 1 | Vaccine | Positive | Anti N IgG (IU/ml) | 76 | 10 (10, 11) |
| Age \geq 65 Not at-risk | Day 1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 76 | 10 (10, 10) |
| Age \geq 65 Not at-risk | Day 1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 76 | 10 (10, 10) |
| Age \geq 65 Not at-risk | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 76 | 5 (5, 5) |
| Age \geq 65 Not at-risk | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 76 | 5 (5, 5) |
| Age \geq 65 Not at-risk | Day 1 | Placebo | Negative | Anti N IgG (IU/ml) | 39 | 10 (10, 10) |
| Age \geq 65 Not at-risk | Day 1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 39 | 10 (10, 10) |
| Age \geq 65 Not at-risk | Day 1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 39 | 10 (10, 10) |
| Age \geq 65 Not at-risk | Day 1 | Placebo | Negative | Pseudovirus-nAb ID50 | 39 | 5 (5, 5) |
| Age \geq 65 Not at-risk | Day 1 | Placebo | Negative | Pseudovirus-nAb ID80 | 39 | 5 (5, 5) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|---------------------------|--------|---------|---------------------|------------------------|-----|----------------------------|
| Age \geq 65 Not at-risk | Day 1 | Placebo | Positive | Anti N IgG (IU/ml) | 75 | 10 (10, 10) |
| Age \geq 65 Not at-risk | Day 1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 75 | 10 (10, 10) |
| Age \geq 65 Not at-risk | Day 1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 75 | 10 (10, 10) |
| Age \geq 65 Not at-risk | Day 1 | Placebo | Positive | Pseudovirus-nAb ID50 | 75 | 5 (5, 5) |
| Age \geq 65 Not at-risk | Day 1 | Placebo | Positive | Pseudovirus-nAb ID80 | 75 | 5 (5, 5) |
| Age \geq 65 Not at-risk | Day 29 | Vaccine | Negative | Anti N IgG (IU/ml) | 227 | 75305 (60091, 94371) |
| Age \geq 65 Not at-risk | Day 29 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 227 | 80069 (65707, 97571) |
| Age \geq 65 Not at-risk | Day 29 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 227 | 153593 (130667, 180543) |
| Age \geq 65 Not at-risk | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID50 | 227 | 332 (263, 418) |
| Age \geq 65 Not at-risk | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID80 | 227 | 421 (328, 540) |
| Age \geq 65 Not at-risk | Day 29 | Vaccine | Positive | Anti N IgG (IU/ml) | 76 | 127407 (81244, 199800) |
| Age \geq 65 Not at-risk | Day 29 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 76 | 139826 (99996, 195520) |
| Age \geq 65 Not at-risk | Day 29 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 76 | 241494 (182978, 318724) |
| Age \geq 65 Not at-risk | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID50 | 76 | 508 (317, 815) |
| Age \geq 65 Not at-risk | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID80 | 76 | 944 (626, 1422) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|---------------------------|--------|---------|---------------------|------------------------|-----|-------------------------------|
| Age \geq 65 Not at-risk | Day 29 | Placebo | Negative | Anti N IgG (IU/ml) | 39 | 10 (10, 10) |
| Age \geq 65 Not at-risk | Day 29 | Placebo | Negative | Anti RBD IgG (IU/ml) | 39 | 10 (10, 10) |
| Age \geq 65 Not at-risk | Day 29 | Placebo | Negative | Anti Spike IgG (IU/ml) | 39 | 10 (10, 10) |
| Age \geq 65 Not at-risk | Day 29 | Placebo | Negative | Pseudovirus-nAb ID50 | 39 | 5 (5, 5) |
| Age \geq 65 Not at-risk | Day 29 | Placebo | Negative | Pseudovirus-nAb ID80 | 39 | 5 (5, 5) |
| Age \geq 65 Not at-risk | Day 29 | Placebo | Positive | Anti N IgG (IU/ml) | 75 | 34367 (22390, 52751) |
| Age \geq 65 Not at-risk | Day 29 | Placebo | Positive | Anti RBD IgG (IU/ml) | 75 | 38048 (27669, 52321) |
| Age \geq 65 Not at-risk | Day 29 | Placebo | Positive | Anti Spike IgG (IU/ml) | 75 | 59664 (45819, 77691) |
| Age \geq 65 Not at-risk | Day 29 | Placebo | Positive | Pseudovirus-nAb ID50 | 75 | 156 (105, 232) |
| Age \geq 65 Not at-risk | Day 29 | Placebo | Positive | Pseudovirus-nAb ID80 | 75 | 257 (170, 390) |
| Age \geq 65 Not at-risk | Day 57 | Vaccine | Negative | Anti N IgG (IU/ml) | 227 | 1177109 (909148, 1524048) |
| Age \geq 65 Not at-risk | Day 57 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 227 | 3441017 (2860842, 4138850) |
| Age \geq 65 Not at-risk | Day 57 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 227 | 7365218 (6408010, 8465410) |
| Age \geq 65 Not at-risk | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID50 | 227 | 5534 (4137, 7404) |
| Age \geq 65 Not at-risk | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID80 | 227 | 7125 (5468, 9285) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|---------------------------|--------|---------|---------------------|------------------------|----|----------------------------------|
| Age \geq 65 Not at-risk | Day 57 | Vaccine | Positive | Anti N IgG (IU/ml) | 76 | 2806906 (1779671, 4427066) |
| Age \geq 65 Not at-risk | Day 57 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 76 | 7305563 (5522547, 9664247) |
| Age \geq 65 Not at-risk | Day 57 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 76 | 13343347 (11421210, 15588971) |
| Age \geq 65 Not at-risk | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID50 | 76 | 18240 (11134, 29880) |
| Age \geq 65 Not at-risk | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID80 | 76 | 17541 (10280, 29932) |
| Age \geq 65 Not at-risk | Day 57 | Placebo | Negative | Anti N IgG (IU/ml) | 39 | 10 (10, 10) |
| Age \geq 65 Not at-risk | Day 57 | Placebo | Negative | Anti RBD IgG (IU/ml) | 39 | 10 (10, 10) |
| Age \geq 65 Not at-risk | Day 57 | Placebo | Negative | Anti Spike IgG (IU/ml) | 39 | 10 (10, 10) |
| Age \geq 65 Not at-risk | Day 57 | Placebo | Negative | Pseudovirus-nAb ID50 | 39 | 5 (5, 6) |
| Age \geq 65 Not at-risk | Day 57 | Placebo | Negative | Pseudovirus-nAb ID80 | 39 | 5 (5, 5) |
| Age \geq 65 Not at-risk | Day 57 | Placebo | Positive | Anti N IgG (IU/ml) | 75 | 461295 (282331, 753702) |
| Age \geq 65 Not at-risk | Day 57 | Placebo | Positive | Anti RBD IgG (IU/ml) | 75 | 1599200 (1156266, 2211811) |
| Age \geq 65 Not at-risk | Day 57 | Placebo | Positive | Anti Spike IgG (IU/ml) | 75 | 2437171 (1815977, 3270859) |
| Age \geq 65 Not at-risk | Day 57 | Placebo | Positive | Pseudovirus-nAb ID50 | 75 | 2442 (1442, 4134) |
| Age \geq 65 Not at-risk | Day 57 | Placebo | Positive | Pseudovirus-nAb ID80 | 75 | 3681 (2278, 5949) |

Table 5e. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Sex

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|------------|-------|---------|---------------------|------------------------|-----|----------------|
| Sex | | | | | | |
| Male | Day 1 | Vaccine | Negative | Anti N IgG (IU/ml) | 395 | 10 (10, 10) |
| Male | Day 1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 395 | 10 (10, 10) |
| Male | Day 1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 395 | 10 (10, 10) |
| Male | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 395 | 5 (5, 5) |
| Male | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 395 | 5 (5, 5) |
| Male | Day 1 | Vaccine | Positive | Anti N IgG (IU/ml) | 121 | 10 (10, 10) |
| Male | Day 1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 121 | 10 (10, 10) |
| Male | Day 1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 121 | 10 (10, 10) |
| Male | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 121 | 5 (5, 5) |
| Male | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 121 | 5 (5, 5) |
| Male | Day 1 | Placebo | Negative | Anti N IgG (IU/ml) | 76 | 10 (10, 11) |
| Male | Day 1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 76 | 11 (9, 12) |
| Male | Day 1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 76 | 10 (10, 10) |
| Male | Day 1 | Placebo | Negative | Pseudovirus-nAb ID50 | 76 | 5 (5, 5) |
| Male | Day 1 | Placebo | Negative | Pseudovirus-nAb ID80 | 76 | 5 (5, 5) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|-------|--------|---------|---------------------|------------------------|-----|--------------------------|
| Male | Day 1 | Placebo | Positive | Anti N IgG (IU/ml) | 115 | 10 (10, 10) |
| Male | Day 1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 115 | 10 (10, 10) |
| Male | Day 1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 115 | 10 (10, 10) |
| Male | Day 1 | Placebo | Positive | Pseudovirus-nAb ID50 | 115 | 5 (5, 5) |
| Male | Day 1 | Placebo | Positive | Pseudovirus-nAb ID80 | 115 | 5 (5, 5) |
| Male | Day 29 | Vaccine | Negative | Anti N IgG (IU/ml) | 395 | 27118 (20803, 35351) |
| Male | Day 29 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 395 | 25738 (20110, 32941) |
| Male | Day 29 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 395 | 40290 (34397, 47193) |
| Male | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID50 | 395 | 121 (93, 157) |
| Male | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID80 | 395 | 207 (158, 272) |
| Male | Day 29 | Vaccine | Positive | Anti N IgG (IU/ml) | 121 | 52664 (36905, 75154) |
| Male | Day 29 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 121 | 43301 (30763, 60949) |
| Male | Day 29 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 121 | 83762 (65541, 107048) |
| Male | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID50 | 121 | 223 (158, 315) |
| Male | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID80 | 121 | 449 (303, 666) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|-------|--------|---------|---------------------|------------------------|-----|-------------------------------|
| Male | Day 29 | Placebo | Negative | Anti N IgG (IU/ml) | 76 | 10 (10, 10) |
| Male | Day 29 | Placebo | Negative | Anti RBD IgG (IU/ml) | 76 | 10 (10, 10) |
| Male | Day 29 | Placebo | Negative | Anti Spike IgG (IU/ml) | 76 | 10 (10, 10) |
| Male | Day 29 | Placebo | Negative | Pseudovirus-nAb ID50 | 76 | 5 (5, 5) |
| Male | Day 29 | Placebo | Negative | Pseudovirus-nAb ID80 | 76 | 5 (5, 5) |
| Male | Day 29 | Placebo | Positive | Anti N IgG (IU/ml) | 115 | 11707 (7655, 17903) |
| Male | Day 29 | Placebo | Positive | Anti RBD IgG (IU/ml) | 115 | 12838 (8743, 18852) |
| Male | Day 29 | Placebo | Positive | Anti Spike IgG (IU/ml) | 115 | 16359 (12044, 22219) |
| Male | Day 29 | Placebo | Positive | Pseudovirus-nAb ID50 | 115 | 43 (29, 63) |
| Male | Day 29 | Placebo | Positive | Pseudovirus-nAb ID80 | 115 | 100 (68, 146) |
| Male | Day 57 | Vaccine | Negative | Anti N IgG (IU/ml) | 395 | 358185 (259645, 494122) |
| Male | Day 57 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 395 | 1032572 (803692, 1326633) |
| Male | Day 57 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 395 | 2448348 (1992531, 3008439) |
| Male | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID50 | 395 | 1983 (1427, 2754) |
| Male | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID80 | 395 | 2322 (1694, 3181) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|-------|--------|---------|---------------------|------------------------|-----|-------------------------------|
| Male | Day 57 | Vaccine | Positive | Anti N IgG (IU/ml) | 121 | 1379076 (895389, 2124049) |
| Male | Day 57 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 121 | 2628794 (1842173, 3751308) |
| Male | Day 57 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 121 | 5518909 (4222583, 7213204) |
| Male | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID50 | 121 | 5567 (3235, 9581) |
| Male | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID80 | 121 | 9590 (6259, 14696) |
| Male | Day 57 | Placebo | Negative | Anti N IgG (IU/ml) | 76 | 10 (10, 10) |
| Male | Day 57 | Placebo | Negative | Anti RBD IgG (IU/ml) | 76 | 10 (10, 10) |
| Male | Day 57 | Placebo | Negative | Anti Spike IgG (IU/ml) | 76 | 10 (10, 10) |
| Male | Day 57 | Placebo | Negative | Pseudovirus-nAb ID50 | 76 | 5 (5, 5) |
| Male | Day 57 | Placebo | Negative | Pseudovirus-nAb ID80 | 76 | 5 (5, 5) |
| Male | Day 57 | Placebo | Positive | Anti N IgG (IU/ml) | 115 | 120405 (68919, 210356) |
| Male | Day 57 | Placebo | Positive | Anti RBD IgG (IU/ml) | 115 | 361345 (243436, 536364) |
| Male | Day 57 | Placebo | Positive | Anti Spike IgG (IU/ml) | 115 | 578439 (406742, 822616) |
| Male | Day 57 | Placebo | Positive | Pseudovirus-nAb ID50 | 115 | 606 (358, 1023) |
| Male | Day 57 | Placebo | Positive | Pseudovirus-nAb ID80 | 115 | 930 (554, 1559) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|--------|-------|---------|---------------------|------------------------|-----|----------------|
| Female | Day 1 | Vaccine | Negative | Anti N IgG (IU/ml) | 519 | 10 (10, 10) |
| Female | Day 1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 519 | 10 (10, 10) |
| Female | Day 1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 519 | 10 (10, 10) |
| Female | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 519 | 5 (5, 5) |
| Female | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 519 | 5 (5, 5) |
| Female | Day 1 | Vaccine | Positive | Anti N IgG (IU/ml) | 153 | 10 (10, 10) |
| Female | Day 1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 153 | 10 (10, 10) |
| Female | Day 1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 153 | 10 (10, 10) |
| Female | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 153 | 5 (5, 5) |
| Female | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 153 | 5 (5, 5) |
| Female | Day 1 | Placebo | Negative | Anti N IgG (IU/ml) | 87 | 10 (10, 10) |
| Female | Day 1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 87 | 10 (10, 10) |
| Female | Day 1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 87 | 10 (10, 10) |
| Female | Day 1 | Placebo | Negative | Pseudovirus-nAb ID50 | 87 | 5 (5, 5) |
| Female | Day 1 | Placebo | Negative | Pseudovirus-nAb ID80 | 87 | 5 (5, 6) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|--------|--------|---------|---------------------|------------------------|-----|--------------------------|
| Female | Day 1 | Placebo | Positive | Anti N IgG (IU/ml) | 155 | 10 (10, 11) |
| Female | Day 1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 155 | 10 (10, 10) |
| Female | Day 1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 155 | 10 (10, 10) |
| Female | Day 1 | Placebo | Positive | Pseudovirus-nAb ID50 | 155 | 5 (5, 5) |
| Female | Day 1 | Placebo | Positive | Pseudovirus-nAb ID80 | 155 | 5 (5, 5) |
| Female | Day 29 | Vaccine | Negative | Anti N IgG (IU/ml) | 519 | 21438 (17319, 26535) |
| Female | Day 29 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 519 | 21234 (17837, 25278) |
| Female | Day 29 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 519 | 41415 (35725, 48012) |
| Female | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID50 | 519 | 98 (80, 120) |
| Female | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID80 | 519 | 178 (145, 218) |
| Female | Day 29 | Vaccine | Positive | Anti N IgG (IU/ml) | 153 | 37697 (26222, 54193) |
| Female | Day 29 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 153 | 32117 (22658, 45526) |
| Female | Day 29 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 153 | 77611 (57216, 105276) |
| Female | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID50 | 153 | 165 (113, 242) |
| Female | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID80 | 153 | 401 (268, 602) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|--------|--------|---------|---------------------|------------------------|-----|-------------------------------|
| Female | Day 29 | Placebo | Negative | Anti N IgG (IU/ml) | 87 | 10 (10, 10) |
| Female | Day 29 | Placebo | Negative | Anti RBD IgG (IU/ml) | 87 | 10 (10, 10) |
| Female | Day 29 | Placebo | Negative | Anti Spike IgG (IU/ml) | 87 | 10 (10, 10) |
| Female | Day 29 | Placebo | Negative | Pseudovirus-nAb ID50 | 87 | 5 (5, 5) |
| Female | Day 29 | Placebo | Negative | Pseudovirus-nAb ID80 | 87 | 5 (5, 5) |
| Female | Day 29 | Placebo | Positive | Anti N IgG (IU/ml) | 155 | 13066 (8983, 19004) |
| Female | Day 29 | Placebo | Positive | Anti RBD IgG (IU/ml) | 155 | 12876 (9489, 17472) |
| Female | Day 29 | Placebo | Positive | Anti Spike IgG (IU/ml) | 155 | 19468 (15496, 24459) |
| Female | Day 29 | Placebo | Positive | Pseudovirus-nAb ID50 | 155 | 58 (42, 81) |
| Female | Day 29 | Placebo | Positive | Pseudovirus-nAb ID80 | 155 | 152 (105, 219) |
| Female | Day 57 | Vaccine | Negative | Anti N IgG (IU/ml) | 519 | 304934 (237911, 390840) |
| Female | Day 57 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 519 | 924524 (750510, 1138886) |
| Female | Day 57 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 519 | 1878895 (1586011, 2225864) |
| Female | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID50 | 519 | 1243 (972, 1588) |
| Female | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID80 | 519 | 2160 (1643, 2840) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|--------|--------|---------|---------------------|------------------------|-----|-------------------------------|
| Female | Day 57 | Vaccine | Positive | Anti N IgG (IU/ml) | 153 | 785331 (484933, 1271815) |
| Female | Day 57 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 153 | 2106655 (1490680, 2977161) |
| Female | Day 57 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 153 | 5236885 (3880756, 7066912) |
| Female | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID50 | 153 | 5754 (3356, 9868) |
| Female | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID80 | 153 | 6872 (4174, 11314) |
| Female | Day 57 | Placebo | Negative | Anti N IgG (IU/ml) | 87 | 10 (10, 10) |
| Female | Day 57 | Placebo | Negative | Anti RBD IgG (IU/ml) | 87 | 10 (10, 10) |
| Female | Day 57 | Placebo | Negative | Anti Spike IgG (IU/ml) | 87 | 10 (10, 10) |
| Female | Day 57 | Placebo | Negative | Pseudovirus-nAb ID50 | 87 | 5 (5, 5) |
| Female | Day 57 | Placebo | Negative | Pseudovirus-nAb ID80 | 87 | 5 (5, 5) |
| Female | Day 57 | Placebo | Positive | Anti N IgG (IU/ml) | 155 | 136546 (89268, 208864) |
| Female | Day 57 | Placebo | Positive | Anti RBD IgG (IU/ml) | 155 | 396863 (289955, 543189) |
| Female | Day 57 | Placebo | Positive | Anti Spike IgG (IU/ml) | 155 | 748414 (540245, 1036794) |
| Female | Day 57 | Placebo | Positive | Pseudovirus-nAb ID50 | 155 | 541 (355, 825) |
| Female | Day 57 | Placebo | Positive | Pseudovirus-nAb ID80 | 155 | 1659 (1064, 2588) |

Table 5f. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Age, sex

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|-----------------|-------|---------|---------------------|------------------------|-----|----------------|
| Age, sex | | | | | | |
| Age < 65 Female | Day 1 | Vaccine | Negative | Anti N IgG (IU/ml) | 269 | 10 (10, 10) |
| Age < 65 Female | Day 1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 269 | 10 (10, 10) |
| Age < 65 Female | Day 1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 269 | 10 (10, 10) |
| Age < 65 Female | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 269 | 5 (5, 5) |
| Age < 65 Female | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 269 | 5 (5, 5) |
| Age < 65 Female | Day 1 | Vaccine | Positive | Anti N IgG (IU/ml) | 79 | 10 (10, 10) |
| Age < 65 Female | Day 1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 79 | 10 (10, 10) |
| Age < 65 Female | Day 1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 79 | 10 (10, 10) |
| Age < 65 Female | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 79 | 5 (5, 5) |
| Age < 65 Female | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 79 | 5 (5, 5) |
| Age < 65 Female | Day 1 | Placebo | Negative | Anti N IgG (IU/ml) | 52 | 10 (10, 10) |
| Age < 65 Female | Day 1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 52 | 10 (10, 10) |
| Age < 65 Female | Day 1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 52 | 10 (10, 10) |
| Age < 65 Female | Day 1 | Placebo | Negative | Pseudovirus-nAb ID50 | 52 | 5 (5, 5) |
| Age < 65 Female | Day 1 | Placebo | Negative | Pseudovirus-nAb ID80 | 52 | 5 (5, 6) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|-----------------|--------|---------|---------------------|------------------------|-----|-------------------------|
| Age < 65 Female | Day 1 | Placebo | Positive | Anti N IgG (IU/ml) | 83 | 10 (10, 11) |
| Age < 65 Female | Day 1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 83 | 10 (10, 10) |
| Age < 65 Female | Day 1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 83 | 10 (10, 10) |
| Age < 65 Female | Day 1 | Placebo | Positive | Pseudovirus-nAb ID50 | 83 | 5 (5, 6) |
| Age < 65 Female | Day 1 | Placebo | Positive | Pseudovirus-nAb ID80 | 83 | 5 (5, 5) |
| Age < 65 Female | Day 29 | Vaccine | Negative | Anti N IgG (IU/ml) | 269 | 17005 (13156, 21980) |
| Age < 65 Female | Day 29 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 269 | 16543 (13418, 20396) |
| Age < 65 Female | Day 29 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 269 | 32705 (27399, 39039) |
| Age < 65 Female | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID50 | 269 | 79 (62, 101) |
| Age < 65 Female | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID80 | 269 | 150 (118, 191) |
| Age < 65 Female | Day 29 | Vaccine | Positive | Anti N IgG (IU/ml) | 79 | 27788 (17970, 42970) |
| Age < 65 Female | Day 29 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 79 | 21789 (14248, 33321) |
| Age < 65 Female | Day 29 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 79 | 56962 (39317, 82526) |
| Age < 65 Female | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID50 | 79 | 124 (78, 197) |
| Age < 65 Female | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID80 | 79 | 319 (195, 522) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|-----------------|--------|---------|---------------------|------------------------|-----|-------------------------------|
| Age < 65 Female | Day 29 | Placebo | Negative | Anti N IgG (IU/ml) | 52 | 10 (10, 10) |
| Age < 65 Female | Day 29 | Placebo | Negative | Anti RBD IgG (IU/ml) | 52 | 10 (10, 10) |
| Age < 65 Female | Day 29 | Placebo | Negative | Anti Spike IgG (IU/ml) | 52 | 10 (10, 10) |
| Age < 65 Female | Day 29 | Placebo | Negative | Pseudovirus-nAb ID50 | 52 | 5 (5, 5) |
| Age < 65 Female | Day 29 | Placebo | Negative | Pseudovirus-nAb ID80 | 52 | 5 (5, 5) |
| Age < 65 Female | Day 29 | Placebo | Positive | Anti N IgG (IU/ml) | 83 | 10603 (6760, 16631) |
| Age < 65 Female | Day 29 | Placebo | Positive | Anti RBD IgG (IU/ml) | 83 | 10100 (6984, 14608) |
| Age < 65 Female | Day 29 | Placebo | Positive | Anti Spike IgG (IU/ml) | 83 | 14961 (11369, 19689) |
| Age < 65 Female | Day 29 | Placebo | Positive | Pseudovirus-nAb ID50 | 83 | 46 (31, 69) |
| Age < 65 Female | Day 29 | Placebo | Positive | Pseudovirus-nAb ID80 | 83 | 133 (86, 207) |
| Age < 65 Female | Day 57 | Vaccine | Negative | Anti N IgG (IU/ml) | 269 | 240348 (178375, 323851) |
| Age < 65 Female | Day 57 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 269 | 725439 (563976, 933126) |
| Age < 65 Female | Day 57 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 269 | 1494002 (1218429, 1831901) |
| Age < 65 Female | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID50 | 269 | 946 (706, 1267) |
| Age < 65 Female | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID80 | 269 | 1691 (1216, 2352) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|-----------------|--------|---------|---------------------|------------------------|----|-------------------------------|
| Age < 65 Female | Day 57 | Vaccine | Positive | Anti N IgG (IU/ml) | 79 | 582852 (324144, 1048040) |
| Age < 65 Female | Day 57 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 79 | 1557246 (1019727, 2378101) |
| Age < 65 Female | Day 57 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 79 | 4234642 (2930914, 6118296) |
| Age < 65 Female | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID50 | 79 | 4195 (2173, 8100) |
| Age < 65 Female | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID80 | 79 | 5422 (2964, 9918) |
| Age < 65 Female | Day 57 | Placebo | Negative | Anti N IgG (IU/ml) | 52 | 10 (10, 10) |
| Age < 65 Female | Day 57 | Placebo | Negative | Anti RBD IgG (IU/ml) | 52 | 10 (10, 10) |
| Age < 65 Female | Day 57 | Placebo | Negative | Anti Spike IgG (IU/ml) | 52 | 10 (10, 10) |
| Age < 65 Female | Day 57 | Placebo | Negative | Pseudovirus-nAb ID50 | 52 | 5 (5, 5) |
| Age < 65 Female | Day 57 | Placebo | Negative | Pseudovirus-nAb ID80 | 52 | 5 (5, 5) |
| Age < 65 Female | Day 57 | Placebo | Positive | Anti N IgG (IU/ml) | 83 | 100999 (60463, 168711) |
| Age < 65 Female | Day 57 | Placebo | Positive | Anti RBD IgG (IU/ml) | 83 | 293632 (201048, 428852) |
| Age < 65 Female | Day 57 | Placebo | Positive | Anti Spike IgG (IU/ml) | 83 | 571578 (384900, 848795) |
| Age < 65 Female | Day 57 | Placebo | Positive | Pseudovirus-nAb ID50 | 83 | 387 (233, 641) |
| Age < 65 Female | Day 57 | Placebo | Positive | Pseudovirus-nAb ID80 | 83 | 1375 (804, 2349) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|---------------|-------|---------|---------------------|------------------------|-----|----------------|
| Age < 65 Male | Day 1 | Vaccine | Negative | Anti N IgG (IU/ml) | 163 | 10 (10, 10) |
| Age < 65 Male | Day 1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 163 | 10 (10, 10) |
| Age < 65 Male | Day 1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 163 | 10 (10, 10) |
| Age < 65 Male | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 163 | 5 (5, 5) |
| Age < 65 Male | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 163 | 5 (5, 5) |
| Age < 65 Male | Day 1 | Vaccine | Positive | Anti N IgG (IU/ml) | 67 | 10 (10, 10) |
| Age < 65 Male | Day 1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 67 | 10 (10, 10) |
| Age < 65 Male | Day 1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 67 | 10 (10, 10) |
| Age < 65 Male | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 67 | 5 (5, 5) |
| Age < 65 Male | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 67 | 5 (5, 5) |
| Age < 65 Male | Day 1 | Placebo | Negative | Anti N IgG (IU/ml) | 28 | 11 (9, 12) |
| Age < 65 Male | Day 1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 28 | 11 (9, 13) |
| Age < 65 Male | Day 1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 28 | 10 (10, 10) |
| Age < 65 Male | Day 1 | Placebo | Negative | Pseudovirus-nAb ID50 | 28 | 5 (5, 5) |
| Age < 65 Male | Day 1 | Placebo | Negative | Pseudovirus-nAb ID80 | 28 | 5 (5, 5) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|---------------|--------|---------|---------------------|------------------------|-----|-------------------------|
| Age < 65 Male | Day 1 | Placebo | Positive | Anti N IgG (IU/ml) | 64 | 10 (10, 10) |
| Age < 65 Male | Day 1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 64 | 10 (10, 10) |
| Age < 65 Male | Day 1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 64 | 10 (10, 10) |
| Age < 65 Male | Day 1 | Placebo | Positive | Pseudovirus-nAb ID50 | 64 | 5 (5, 5) |
| Age < 65 Male | Day 1 | Placebo | Positive | Pseudovirus-nAb ID80 | 64 | 5 (5, 5) |
| Age < 65 Male | Day 29 | Vaccine | Negative | Anti N IgG (IU/ml) | 163 | 20977 (14896, 29540) |
| Age < 65 Male | Day 29 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 163 | 18877 (13705, 26001) |
| Age < 65 Male | Day 29 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 163 | 29372 (24030, 35901) |
| Age < 65 Male | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID50 | 163 | 94 (67, 132) |
| Age < 65 Male | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID80 | 163 | 169 (118, 240) |
| Age < 65 Male | Day 29 | Vaccine | Positive | Anti N IgG (IU/ml) | 67 | 41875 (27088, 64734) |
| Age < 65 Male | Day 29 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 67 | 30884 (20281, 47031) |
| Age < 65 Male | Day 29 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 67 | 63477 (47023, 85688) |
| Age < 65 Male | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID50 | 67 | 180 (119, 274) |
| Age < 65 Male | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID80 | 67 | 372 (229, 604) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|---------------|--------|---------|---------------------|------------------------|-----|-------------------------------|
| Age < 65 Male | Day 29 | Placebo | Negative | Anti N IgG (IU/ml) | 28 | 10 (10, 10) |
| Age < 65 Male | Day 29 | Placebo | Negative | Anti RBD IgG (IU/ml) | 28 | 10 (10, 10) |
| Age < 65 Male | Day 29 | Placebo | Negative | Anti Spike IgG (IU/ml) | 28 | 10 (10, 10) |
| Age < 65 Male | Day 29 | Placebo | Negative | Pseudovirus-nAb ID50 | 28 | 5 (5, 5) |
| Age < 65 Male | Day 29 | Placebo | Negative | Pseudovirus-nAb ID80 | 28 | 5 (5, 5) |
| Age < 65 Male | Day 29 | Placebo | Positive | Anti N IgG (IU/ml) | 64 | 8697 (5222, 14483) |
| Age < 65 Male | Day 29 | Placebo | Positive | Anti RBD IgG (IU/ml) | 64 | 9188 (5784, 14598) |
| Age < 65 Male | Day 29 | Placebo | Positive | Anti Spike IgG (IU/ml) | 64 | 11210 (7775, 16161) |
| Age < 65 Male | Day 29 | Placebo | Positive | Pseudovirus-nAb ID50 | 64 | 31 (20, 50) |
| Age < 65 Male | Day 29 | Placebo | Positive | Pseudovirus-nAb ID80 | 64 | 73 (47, 115) |
| Age < 65 Male | Day 57 | Vaccine | Negative | Anti N IgG (IU/ml) | 163 | 276033 (182277, 418013) |
| Age < 65 Male | Day 57 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 163 | 756600 (546757, 1046981) |
| Age < 65 Male | Day 57 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 163 | 1920202 (1472176, 2504576) |
| Age < 65 Male | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID50 | 163 | 1532 (1004, 2337) |
| Age < 65 Male | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID80 | 163 | 1850 (1231, 2781) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|---------------|--------|---------|---------------------|------------------------|----|-------------------------------|
| Age < 65 Male | Day 57 | Vaccine | Positive | Anti N IgG (IU/ml) | 67 | 1079995 (633450, 1841326) |
| Age < 65 Male | Day 57 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 67 | 1977267 (1268954, 3080952) |
| Age < 65 Male | Day 57 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 67 | 4318054 (3077671, 6058343) |
| Age < 65 Male | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID50 | 67 | 3857 (1960, 7590) |
| Age < 65 Male | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID80 | 67 | 7789 (4625, 13117) |
| Age < 65 Male | Day 57 | Placebo | Negative | Anti N IgG (IU/ml) | 28 | 10 (10, 10) |
| Age < 65 Male | Day 57 | Placebo | Negative | Anti RBD IgG (IU/ml) | 28 | 10 (10, 11) |
| Age < 65 Male | Day 57 | Placebo | Negative | Anti Spike IgG (IU/ml) | 28 | 10 (10, 10) |
| Age < 65 Male | Day 57 | Placebo | Negative | Pseudovirus-nAb ID50 | 28 | 5 (5, 5) |
| Age < 65 Male | Day 57 | Placebo | Negative | Pseudovirus-nAb ID80 | 28 | 5 (5, 5) |
| Age < 65 Male | Day 57 | Placebo | Positive | Anti N IgG (IU/ml) | 64 | 83366 (42296, 164315) |
| Age < 65 Male | Day 57 | Placebo | Positive | Anti RBD IgG (IU/ml) | 64 | 236528 (146661, 381460) |
| Age < 65 Male | Day 57 | Placebo | Positive | Anti Spike IgG (IU/ml) | 64 | 373064 (243212, 572245) |
| Age < 65 Male | Day 57 | Placebo | Positive | Pseudovirus-nAb ID50 | 64 | 387 (206, 728) |
| Age < 65 Male | Day 57 | Placebo | Positive | Pseudovirus-nAb ID80 | 64 | 618 (331, 1154) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|--------------------|-------|---------|---------------------|------------------------|-----|----------------|
| Age \geq 65 Male | Day 1 | Vaccine | Negative | Anti N IgG (IU/ml) | 232 | 10 (10, 10) |
| Age \geq 65 Male | Day 1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 232 | 10 (10, 10) |
| Age \geq 65 Male | Day 1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 232 | 10 (10, 10) |
| Age \geq 65 Male | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 232 | 5 (5, 5) |
| Age \geq 65 Male | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 232 | 5 (5, 5) |
| Age \geq 65 Male | Day 1 | Vaccine | Positive | Anti N IgG (IU/ml) | 54 | 10 (10, 11) |
| Age \geq 65 Male | Day 1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 54 | 10 (10, 10) |
| Age \geq 65 Male | Day 1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 54 | 10 (10, 10) |
| Age \geq 65 Male | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 54 | 5 (5, 6) |
| Age \geq 65 Male | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 54 | 5 (5, 5) |
| Age \geq 65 Male | Day 1 | Placebo | Negative | Anti N IgG (IU/ml) | 48 | 10 (10, 10) |
| Age \geq 65 Male | Day 1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 48 | 10 (10, 10) |
| Age \geq 65 Male | Day 1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 48 | 10 (10, 10) |
| Age \geq 65 Male | Day 1 | Placebo | Negative | Pseudovirus-nAb ID50 | 48 | 5 (5, 5) |
| Age \geq 65 Male | Day 1 | Placebo | Negative | Pseudovirus-nAb ID80 | 48 | 5 (5, 5) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|--------------------|--------|---------|---------------------|------------------------|-----|----------------------------|
| Age \geq 65 Male | Day 1 | Placebo | Positive | Anti N IgG (IU/ml) | 51 | 10 (10, 10) |
| Age \geq 65 Male | Day 1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 51 | 10 (10, 10) |
| Age \geq 65 Male | Day 1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 51 | 10 (10, 10) |
| Age \geq 65 Male | Day 1 | Placebo | Positive | Pseudovirus-nAb ID50 | 51 | 5 (5, 6) |
| Age \geq 65 Male | Day 1 | Placebo | Positive | Pseudovirus-nAb ID80 | 51 | 5 (5, 5) |
| Age \geq 65 Male | Day 29 | Vaccine | Negative | Anti N IgG (IU/ml) | 232 | 59503 (46453, 76219) |
| Age \geq 65 Male | Day 29 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 232 | 66467 (53933, 81913) |
| Age \geq 65 Male | Day 29 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 232 | 105989 (87935, 127749) |
| Age \geq 65 Male | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID50 | 232 | 259 (203, 330) |
| Age \geq 65 Male | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID80 | 232 | 390 (306, 496) |
| Age \geq 65 Male | Day 29 | Vaccine | Positive | Anti N IgG (IU/ml) | 54 | 121492 (77083, 191487) |
| Age \geq 65 Male | Day 29 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 54 | 148457 (98119, 224620) |
| Age \geq 65 Male | Day 29 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 54 | 230231 (167261, 316907) |
| Age \geq 65 Male | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID50 | 54 | 482 (286, 812) |
| Age \geq 65 Male | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID80 | 54 | 895 (560, 1432) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|--------------------|--------|---------|---------------------|------------------------|-----|-------------------------------|
| Age \geq 65 Male | Day 29 | Placebo | Negative | Anti N IgG (IU/ml) | 48 | 10 (10, 10) |
| Age \geq 65 Male | Day 29 | Placebo | Negative | Anti RBD IgG (IU/ml) | 48 | 10 (10, 10) |
| Age \geq 65 Male | Day 29 | Placebo | Negative | Anti Spike IgG (IU/ml) | 48 | 10 (10, 10) |
| Age \geq 65 Male | Day 29 | Placebo | Negative | Pseudovirus-nAb ID50 | 48 | 5 (5, 5) |
| Age \geq 65 Male | Day 29 | Placebo | Negative | Pseudovirus-nAb ID80 | 48 | 5 (5, 5) |
| Age \geq 65 Male | Day 29 | Placebo | Positive | Anti N IgG (IU/ml) | 51 | 39245 (22100, 69691) |
| Age \geq 65 Male | Day 29 | Placebo | Positive | Anti RBD IgG (IU/ml) | 51 | 50082 (30542, 82125) |
| Age \geq 65 Male | Day 29 | Placebo | Positive | Anti Spike IgG (IU/ml) | 51 | 76189 (49115, 118188) |
| Age \geq 65 Male | Day 29 | Placebo | Positive | Pseudovirus-nAb ID50 | 51 | 147 (82, 263) |
| Age \geq 65 Male | Day 29 | Placebo | Positive | Pseudovirus-nAb ID80 | 51 | 350 (196, 626) |
| Age \geq 65 Male | Day 57 | Vaccine | Negative | Anti N IgG (IU/ml) | 232 | 794988 (585435, 1079548) |
| Age \geq 65 Male | Day 57 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 232 | 2674328 (2152728, 3322311) |
| Age \geq 65 Male | Day 57 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 232 | 5149990 (4231902, 6267253) |
| Age \geq 65 Male | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID50 | 232 | 4362 (3133, 6074) |
| Age \geq 65 Male | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID80 | 232 | 4649 (3501, 6173) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|--------------------|--------|---------|---------------------|------------------------|----|----------------------------------|
| Age \geq 65 Male | Day 57 | Vaccine | Positive | Anti N IgG (IU/ml) | 54 | 3362752 (2054881, 5503045) |
| Age \geq 65 Male | Day 57 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 54 | 7426127 (5296972, 10411111) |
| Age \geq 65 Male | Day 57 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 54 | 13502491 (11607977, 15706205) |
| Age \geq 65 Male | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID50 | 54 | 21221 (12633, 35647) |
| Age \geq 65 Male | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID80 | 54 | 20477 (11619, 36087) |
| Age \geq 65 Male | Day 57 | Placebo | Negative | Anti N IgG (IU/ml) | 48 | 10 (10, 10) |
| Age \geq 65 Male | Day 57 | Placebo | Negative | Anti RBD IgG (IU/ml) | 48 | 10 (10, 10) |
| Age \geq 65 Male | Day 57 | Placebo | Negative | Anti Spike IgG (IU/ml) | 48 | 10 (10, 10) |
| Age \geq 65 Male | Day 57 | Placebo | Negative | Pseudovirus-nAb ID50 | 48 | 5 (5, 5) |
| Age \geq 65 Male | Day 57 | Placebo | Negative | Pseudovirus-nAb ID80 | 48 | 5 (5, 5) |
| Age \geq 65 Male | Day 57 | Placebo | Positive | Anti N IgG (IU/ml) | 51 | 537607 (291471, 991596) |
| Age \geq 65 Male | Day 57 | Placebo | Positive | Anti RBD IgG (IU/ml) | 51 | 2027539 (1259961, 3262731) |
| Age \geq 65 Male | Day 57 | Placebo | Positive | Anti Spike IgG (IU/ml) | 51 | 3447429 (2322804, 5116559) |
| Age \geq 65 Male | Day 57 | Placebo | Positive | Pseudovirus-nAb ID50 | 51 | 3730 (1880, 7401) |
| Age \geq 65 Male | Day 57 | Placebo | Positive | Pseudovirus-nAb ID80 | 51 | 4892 (2560, 9348) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|----------------------|-------|---------|---------------------|------------------------|-----|----------------|
| Age \geq 65 Female | Day 1 | Vaccine | Negative | Anti N IgG (IU/ml) | 250 | 10 (10, 10) |
| Age \geq 65 Female | Day 1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 250 | 10 (10, 10) |
| Age \geq 65 Female | Day 1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 250 | 10 (10, 10) |
| Age \geq 65 Female | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 250 | 5 (5, 5) |
| Age \geq 65 Female | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 250 | 5 (5, 5) |
| Age \geq 65 Female | Day 1 | Vaccine | Positive | Anti N IgG (IU/ml) | 74 | 10 (10, 10) |
| Age \geq 65 Female | Day 1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 74 | 10 (10, 10) |
| Age \geq 65 Female | Day 1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 74 | 10 (10, 10) |
| Age \geq 65 Female | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 74 | 5 (5, 6) |
| Age \geq 65 Female | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 74 | 5 (5, 5) |
| Age \geq 65 Female | Day 1 | Placebo | Negative | Anti N IgG (IU/ml) | 35 | 10 (10, 10) |
| Age \geq 65 Female | Day 1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 35 | 10 (10, 10) |
| Age \geq 65 Female | Day 1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 35 | 10 (10, 10) |
| Age \geq 65 Female | Day 1 | Placebo | Negative | Pseudovirus-nAb ID50 | 35 | 5 (5, 5) |
| Age \geq 65 Female | Day 1 | Placebo | Negative | Pseudovirus-nAb ID80 | 35 | 5 (5, 5) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|----------------------|--------|---------|---------------------|------------------------|-----|----------------------------|
| Age \geq 65 Female | Day 1 | Placebo | Positive | Anti N IgG (IU/ml) | 72 | 10 (10, 10) |
| Age \geq 65 Female | Day 1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 72 | 10 (10, 10) |
| Age \geq 65 Female | Day 1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 72 | 10 (10, 10) |
| Age \geq 65 Female | Day 1 | Placebo | Positive | Pseudovirus-nAb ID50 | 72 | 5 (5, 5) |
| Age \geq 65 Female | Day 1 | Placebo | Positive | Pseudovirus-nAb ID80 | 72 | 5 (5, 5) |
| Age \geq 65 Female | Day 29 | Vaccine | Negative | Anti N IgG (IU/ml) | 250 | 59851 (47954, 74699) |
| Age \geq 65 Female | Day 29 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 250 | 64209 (53151, 77567) |
| Age \geq 65 Female | Day 29 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 250 | 117943 (99447, 139878) |
| Age \geq 65 Female | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID50 | 250 | 249 (197, 315) |
| Age \geq 65 Female | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID80 | 250 | 373 (294, 474) |
| Age \geq 65 Female | Day 29 | Vaccine | Positive | Anti N IgG (IU/ml) | 74 | 137448 (87797, 215179) |
| Age \geq 65 Female | Day 29 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 74 | 166523 (121761, 227741) |
| Age \geq 65 Female | Day 29 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 74 | 288235 (216852, 383115) |
| Age \geq 65 Female | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID50 | 74 | 553 (354, 864) |
| Age \geq 65 Female | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID80 | 74 | 1062 (720, 1566) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|-----------------|--------|---------|---------------------|------------------------|-----|-------------------------------|
| Age ≥ 65 Female | Day 29 | Placebo | Negative | Anti N IgG (IU/ml) | 35 | 10 (10, 10) |
| Age ≥ 65 Female | Day 29 | Placebo | Negative | Anti RBD IgG (IU/ml) | 35 | 10 (10, 10) |
| Age ≥ 65 Female | Day 29 | Placebo | Negative | Anti Spike IgG (IU/ml) | 35 | 10 (10, 10) |
| Age ≥ 65 Female | Day 29 | Placebo | Negative | Pseudovirus-nAb ID50 | 35 | 5 (5, 5) |
| Age ≥ 65 Female | Day 29 | Placebo | Negative | Pseudovirus-nAb ID80 | 35 | 5 (5, 5) |
| Age ≥ 65 Female | Day 29 | Placebo | Positive | Anti N IgG (IU/ml) | 72 | 32440 (21159, 49736) |
| Age ≥ 65 Female | Day 29 | Placebo | Positive | Anti RBD IgG (IU/ml) | 72 | 37051 (27449, 50013) |
| Age ≥ 65 Female | Day 29 | Placebo | Positive | Anti Spike IgG (IU/ml) | 72 | 61265 (47638, 78789) |
| Age ≥ 65 Female | Day 29 | Placebo | Positive | Pseudovirus-nAb ID50 | 72 | 162 (110, 238) |
| Age ≥ 65 Female | Day 29 | Placebo | Positive | Pseudovirus-nAb ID80 | 72 | 271 (188, 392) |
| Age ≥ 65 Female | Day 57 | Vaccine | Negative | Anti N IgG (IU/ml) | 250 | 875715 (670811, 1143209) |
| Age ≥ 65 Female | Day 57 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 250 | 2708471 (2228982, 3291105) |
| Age ≥ 65 Female | Day 57 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 250 | 5189777 (4355492, 6183867) |
| Age ≥ 65 Female | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID50 | 250 | 4169 (3097, 5612) |
| Age ≥ 65 Female | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID80 | 250 | 6397 (4907, 8340) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|----------------------|--------|---------|---------------------|------------------------|----|----------------------------------|
| Age \geq 65 Female | Day 57 | Vaccine | Positive | Anti N IgG (IU/ml) | 74 | 2781850 (1795669, 4309643) |
| Age \geq 65 Female | Day 57 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 74 | 7590360 (5921961, 9728799) |
| Age \geq 65 Female | Day 57 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 74 | 12894340 (10799304, 15395807) |
| Age \geq 65 Female | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID50 | 74 | 21984 (13986, 34558) |
| Age \geq 65 Female | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID80 | 74 | 18779 (11189, 31518) |
| Age \geq 65 Female | Day 57 | Placebo | Negative | Anti N IgG (IU/ml) | 35 | 10 (10, 10) |
| Age \geq 65 Female | Day 57 | Placebo | Negative | Anti RBD IgG (IU/ml) | 35 | 10 (10, 10) |
| Age \geq 65 Female | Day 57 | Placebo | Negative | Anti Spike IgG (IU/ml) | 35 | 10 (10, 10) |
| Age \geq 65 Female | Day 57 | Placebo | Negative | Pseudovirus-nAb ID50 | 35 | 5 (5, 5) |
| Age \geq 65 Female | Day 57 | Placebo | Negative | Pseudovirus-nAb ID80 | 35 | 5 (5, 6) |
| Age \geq 65 Female | Day 57 | Placebo | Positive | Anti N IgG (IU/ml) | 72 | 507512 (329028, 782814) |
| Age \geq 65 Female | Day 57 | Placebo | Positive | Anti RBD IgG (IU/ml) | 72 | 1473236 (1067157, 2033836) |
| Age \geq 65 Female | Day 57 | Placebo | Positive | Anti Spike IgG (IU/ml) | 72 | 2420004 (1820068, 3217693) |
| Age \geq 65 Female | Day 57 | Placebo | Positive | Pseudovirus-nAb ID50 | 72 | 2344 (1427, 3849) |
| Age \geq 65 Female | Day 57 | Placebo | Positive | Pseudovirus-nAb ID80 | 72 | 3767 (2352, 6032) |

Table 5g. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Hispanic or Latino ethnicity

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|-------------------------------------|-------|---------|---------------------|------------------------|-----|----------------|
| Hispanic or Latino ethnicity | | | | | | |
| Hispanic or Latino | Day 1 | Vaccine | Negative | Anti N IgG (IU/ml) | 136 | 10 (10, 10) |
| Hispanic or Latino | Day 1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 136 | 10 (10, 10) |
| Hispanic or Latino | Day 1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 136 | 10 (10, 10) |
| Hispanic or Latino | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 136 | 5 (5, 5) |
| Hispanic or Latino | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 136 | 5 (5, 6) |
| Hispanic or Latino | Day 1 | Vaccine | Positive | Anti N IgG (IU/ml) | 35 | 10 (10, 10) |
| Hispanic or Latino | Day 1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 35 | 10 (10, 10) |
| Hispanic or Latino | Day 1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 35 | 10 (10, 10) |
| Hispanic or Latino | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 35 | 5 (5, 5) |
| Hispanic or Latino | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 35 | 5 (5, 5) |
| Hispanic or Latino | Day 1 | Placebo | Negative | Anti N IgG (IU/ml) | 20 | 10 (10, 10) |
| Hispanic or Latino | Day 1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 20 | 10 (10, 10) |
| Hispanic or Latino | Day 1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 20 | 10 (10, 10) |
| Hispanic or Latino | Day 1 | Placebo | Negative | Pseudovirus-nAb ID50 | 20 | 5 (5, 5) |
| Hispanic or Latino | Day 1 | Placebo | Negative | Pseudovirus-nAb ID80 | 20 | 5 (5, 5) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|--------------------|--------|---------|---------------------|------------------------|-----|--------------------------|
| Hispanic or Latino | Day 1 | Placebo | Positive | Anti N IgG (IU/ml) | 38 | 10 (10, 10) |
| Hispanic or Latino | Day 1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 38 | 10 (10, 10) |
| Hispanic or Latino | Day 1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 38 | 10 (10, 10) |
| Hispanic or Latino | Day 1 | Placebo | Positive | Pseudovirus-nAb ID50 | 38 | 6 (5, 7) |
| Hispanic or Latino | Day 1 | Placebo | Positive | Pseudovirus-nAb ID80 | 38 | 5 (5, 5) |
| Hispanic or Latino | Day 29 | Vaccine | Negative | Anti N IgG (IU/ml) | 136 | 22074 (14121, 34506) |
| Hispanic or Latino | Day 29 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 136 | 22266 (15847, 31284) |
| Hispanic or Latino | Day 29 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 136 | 41773 (31562, 55289) |
| Hispanic or Latino | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID50 | 136 | 101 (67, 152) |
| Hispanic or Latino | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID80 | 136 | 190 (126, 284) |
| Hispanic or Latino | Day 29 | Vaccine | Positive | Anti N IgG (IU/ml) | 35 | 66150 (37538, 116570) |
| Hispanic or Latino | Day 29 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 35 | 57339 (30559, 107588) |
| Hispanic or Latino | Day 29 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 35 | 90332 (50343, 162084) |
| Hispanic or Latino | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID50 | 35 | 254 (155, 417) |
| Hispanic or Latino | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID80 | 35 | 498 (236, 1049) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|--------------------|--------|---------|---------------------|------------------------|-----|-------------------------------|
| Hispanic or Latino | Day 29 | Placebo | Negative | Anti N IgG (IU/ml) | 20 | 10 (10, 10) |
| Hispanic or Latino | Day 29 | Placebo | Negative | Anti RBD IgG (IU/ml) | 20 | 10 (10, 10) |
| Hispanic or Latino | Day 29 | Placebo | Negative | Anti Spike IgG (IU/ml) | 20 | 10 (10, 10) |
| Hispanic or Latino | Day 29 | Placebo | Negative | Pseudovirus-nAb ID50 | 20 | 5 (5, 5) |
| Hispanic or Latino | Day 29 | Placebo | Negative | Pseudovirus-nAb ID80 | 20 | 6 (4, 8) |
| Hispanic or Latino | Day 29 | Placebo | Positive | Anti N IgG (IU/ml) | 38 | 26345 (9909, 70041) |
| Hispanic or Latino | Day 29 | Placebo | Positive | Anti RBD IgG (IU/ml) | 38 | 34815 (16110, 75239) |
| Hispanic or Latino | Day 29 | Placebo | Positive | Anti Spike IgG (IU/ml) | 38 | 26708 (12585, 56680) |
| Hispanic or Latino | Day 29 | Placebo | Positive | Pseudovirus-nAb ID50 | 38 | 118 (42, 327) |
| Hispanic or Latino | Day 29 | Placebo | Positive | Pseudovirus-nAb ID80 | 38 | 351 (151, 818) |
| Hispanic or Latino | Day 57 | Vaccine | Negative | Anti N IgG (IU/ml) | 136 | 332872 (193115, 573771) |
| Hispanic or Latino | Day 57 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 136 | 1087406 (737091, 1604213) |
| Hispanic or Latino | Day 57 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 136 | 2082654 (1564176, 2772993) |
| Hispanic or Latino | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID50 | 136 | 1727 (1013, 2946) |
| Hispanic or Latino | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID80 | 136 | 2444 (1373, 4350) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|--------------------|--------|---------|---------------------|------------------------|----|--------------------------------|
| Hispanic or Latino | Day 57 | Vaccine | Positive | Anti N IgG (IU/ml) | 35 | 1420449 (558648, 3611715) |
| Hispanic or Latino | Day 57 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 35 | 2735111 (1368395, 5466868) |
| Hispanic or Latino | Day 57 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 35 | 7578287 (5040721, 11393296) |
| Hispanic or Latino | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID50 | 35 | 7727 (2908, 20532) |
| Hispanic or Latino | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID80 | 35 | 10208 (4492, 23195) |
| Hispanic or Latino | Day 57 | Placebo | Negative | Anti N IgG (IU/ml) | 20 | 10 (10, 10) |
| Hispanic or Latino | Day 57 | Placebo | Negative | Anti RBD IgG (IU/ml) | 20 | 10 (10, 10) |
| Hispanic or Latino | Day 57 | Placebo | Negative | Anti Spike IgG (IU/ml) | 20 | 10 (10, 10) |
| Hispanic or Latino | Day 57 | Placebo | Negative | Pseudovirus-nAb ID50 | 20 | 5 (5, 5) |
| Hispanic or Latino | Day 57 | Placebo | Negative | Pseudovirus-nAb ID80 | 20 | 5 (5, 5) |
| Hispanic or Latino | Day 57 | Placebo | Positive | Anti N IgG (IU/ml) | 38 | 452690 (158709, 1291220) |
| Hispanic or Latino | Day 57 | Placebo | Positive | Anti RBD IgG (IU/ml) | 38 | 747435 (391924, 1425424) |
| Hispanic or Latino | Day 57 | Placebo | Positive | Anti Spike IgG (IU/ml) | 38 | 1403460 (609038, 3234119) |
| Hispanic or Latino | Day 57 | Placebo | Positive | Pseudovirus-nAb ID50 | 38 | 1522 (466, 4976) |
| Hispanic or Latino | Day 57 | Placebo | Positive | Pseudovirus-nAb ID80 | 38 | 3063 (1057, 8877) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|------------------------|-------|---------|---------------------|------------------------|-----|----------------|
| Not Hispanic or Latino | Day 1 | Vaccine | Negative | Anti N IgG (IU/ml) | 690 | 10 (10, 10) |
| Not Hispanic or Latino | Day 1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 690 | 10 (10, 10) |
| Not Hispanic or Latino | Day 1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 690 | 10 (10, 10) |
| Not Hispanic or Latino | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 690 | 5 (5, 5) |
| Not Hispanic or Latino | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 690 | 5 (5, 5) |
| Not Hispanic or Latino | Day 1 | Vaccine | Positive | Anti N IgG (IU/ml) | 217 | 10 (10, 10) |
| Not Hispanic or Latino | Day 1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 217 | 10 (10, 10) |
| Not Hispanic or Latino | Day 1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 217 | 10 (10, 10) |
| Not Hispanic or Latino | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 217 | 5 (5, 5) |
| Not Hispanic or Latino | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 217 | 5 (5, 5) |
| Not Hispanic or Latino | Day 1 | Placebo | Negative | Anti N IgG (IU/ml) | 130 | 10 (10, 11) |
| Not Hispanic or Latino | Day 1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 130 | 10 (10, 10) |
| Not Hispanic or Latino | Day 1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 130 | 10 (10, 10) |
| Not Hispanic or Latino | Day 1 | Placebo | Negative | Pseudovirus-nAb ID50 | 130 | 5 (5, 5) |
| Not Hispanic or Latino | Day 1 | Placebo | Negative | Pseudovirus-nAb ID80 | 130 | 5 (5, 5) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|------------------------|--------|---------|---------------------|------------------------|-----|--------------------------|
| Not Hispanic or Latino | Day 1 | Placebo | Positive | Anti N IgG (IU/ml) | 214 | 10 (10, 10) |
| Not Hispanic or Latino | Day 1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 214 | 10 (10, 10) |
| Not Hispanic or Latino | Day 1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 214 | 10 (10, 10) |
| Not Hispanic or Latino | Day 1 | Placebo | Positive | Pseudovirus-nAb ID50 | 214 | 5 (5, 5) |
| Not Hispanic or Latino | Day 1 | Placebo | Positive | Pseudovirus-nAb ID80 | 214 | 5 (5, 5) |
| Not Hispanic or Latino | Day 29 | Vaccine | Negative | Anti N IgG (IU/ml) | 690 | 23655 (19521, 28664) |
| Not Hispanic or Latino | Day 29 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 690 | 23020 (19425, 27280) |
| Not Hispanic or Latino | Day 29 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 690 | 39694 (35055, 44946) |
| Not Hispanic or Latino | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID50 | 690 | 104 (86, 125) |
| Not Hispanic or Latino | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID80 | 690 | 191 (158, 230) |
| Not Hispanic or Latino | Day 29 | Vaccine | Positive | Anti N IgG (IU/ml) | 217 | 41747 (30714, 56743) |
| Not Hispanic or Latino | Day 29 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 217 | 35344 (26390, 47337) |
| Not Hispanic or Latino | Day 29 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 217 | 83383 (65546, 106075) |
| Not Hispanic or Latino | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID50 | 217 | 183 (133, 251) |
| Not Hispanic or Latino | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID80 | 217 | 411 (294, 575) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|------------------------|--------|---------|---------------------|------------------------|-----|-------------------------------|
| Not Hispanic or Latino | Day 29 | Placebo | Negative | Anti N IgG (IU/ml) | 130 | 10 (10, 10) |
| Not Hispanic or Latino | Day 29 | Placebo | Negative | Anti RBD IgG (IU/ml) | 130 | 10 (10, 10) |
| Not Hispanic or Latino | Day 29 | Placebo | Negative | Anti Spike IgG (IU/ml) | 130 | 10 (10, 10) |
| Not Hispanic or Latino | Day 29 | Placebo | Negative | Pseudovirus-nAb ID50 | 130 | 5 (5, 5) |
| Not Hispanic or Latino | Day 29 | Placebo | Negative | Pseudovirus-nAb ID80 | 130 | 5 (5, 5) |
| Not Hispanic or Latino | Day 29 | Placebo | Positive | Anti N IgG (IU/ml) | 214 | 12063 (8992, 16185) |
| Not Hispanic or Latino | Day 29 | Placebo | Positive | Anti RBD IgG (IU/ml) | 214 | 11608 (9046, 14896) |
| Not Hispanic or Latino | Day 29 | Placebo | Positive | Anti Spike IgG (IU/ml) | 214 | 18056 (14910, 21865) |
| Not Hispanic or Latino | Day 29 | Placebo | Positive | Pseudovirus-nAb ID50 | 214 | 48 (37, 63) |
| Not Hispanic or Latino | Day 29 | Placebo | Positive | Pseudovirus-nAb ID80 | 214 | 123 (92, 165) |
| Not Hispanic or Latino | Day 57 | Vaccine | Negative | Anti N IgG (IU/ml) | 690 | 334364 (266627, 419309) |
| Not Hispanic or Latino | Day 57 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 690 | 987977 (822264, 1187086) |
| Not Hispanic or Latino | Day 57 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 690 | 2063432 (1775937, 2397468) |
| Not Hispanic or Latino | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID50 | 690 | 1500 (1191, 1888) |
| Not Hispanic or Latino | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID80 | 690 | 2270 (1788, 2883) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|------------------------|--------|---------|---------------------|------------------------|-----|-------------------------------|
| Not Hispanic or Latino | Day 57 | Vaccine | Positive | Anti N IgG (IU/ml) | 217 | 968852 (654113, 1435033) |
| Not Hispanic or Latino | Day 57 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 217 | 2315554 (1731123, 3097290) |
| Not Hispanic or Latino | Day 57 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 217 | 5301268 (4150604, 6770929) |
| Not Hispanic or Latino | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID50 | 217 | 5224 (3348, 8151) |
| Not Hispanic or Latino | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID80 | 217 | 7937 (5300, 11886) |
| Not Hispanic or Latino | Day 57 | Placebo | Negative | Anti N IgG (IU/ml) | 130 | 10 (10, 10) |
| Not Hispanic or Latino | Day 57 | Placebo | Negative | Anti RBD IgG (IU/ml) | 130 | 10 (10, 10) |
| Not Hispanic or Latino | Day 57 | Placebo | Negative | Anti Spike IgG (IU/ml) | 130 | 10 (10, 10) |
| Not Hispanic or Latino | Day 57 | Placebo | Negative | Pseudovirus-nAb ID50 | 130 | 5 (5, 5) |
| Not Hispanic or Latino | Day 57 | Placebo | Negative | Pseudovirus-nAb ID80 | 130 | 5 (5, 5) |
| Not Hispanic or Latino | Day 57 | Placebo | Positive | Anti N IgG (IU/ml) | 214 | 129424 (89788, 186557) |
| Not Hispanic or Latino | Day 57 | Placebo | Positive | Anti RBD IgG (IU/ml) | 214 | 381696 (293138, 497006) |
| Not Hispanic or Latino | Day 57 | Placebo | Positive | Anti Spike IgG (IU/ml) | 214 | 648311 (505732, 831086) |
| Not Hispanic or Latino | Day 57 | Placebo | Positive | Pseudovirus-nAb ID50 | 214 | 555 (395, 782) |
| Not Hispanic or Latino | Day 57 | Placebo | Positive | Pseudovirus-nAb ID80 | 214 | 1324 (921, 1904) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|--------------------------|-------|---------|---------------------|------------------------|----|----------------|
| Not reported and unknown | Day 1 | Vaccine | Negative | Anti N IgG (IU/ml) | 88 | 10 (10, 10) |
| Not reported and unknown | Day 1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 88 | 10 (10, 10) |
| Not reported and unknown | Day 1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 88 | 10 (10, 10) |
| Not reported and unknown | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 88 | 5 (5, 5) |
| Not reported and unknown | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 88 | 5 (5, 5) |
| Not reported and unknown | Day 1 | Vaccine | Positive | Anti N IgG (IU/ml) | 22 | 10 (10, 10) |
| Not reported and unknown | Day 1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 22 | 10 (10, 10) |
| Not reported and unknown | Day 1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 22 | 10 (10, 10) |
| Not reported and unknown | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 22 | 6 (4, 7) |
| Not reported and unknown | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 22 | 5 (5, 5) |
| Not reported and unknown | Day 1 | Placebo | Negative | Anti N IgG (IU/ml) | 13 | 10 (10, 10) |
| Not reported and unknown | Day 1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 13 | 12 (8, 18) |
| Not reported and unknown | Day 1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 13 | 10 (10, 10) |
| Not reported and unknown | Day 1 | Placebo | Negative | Pseudovirus-nAb ID50 | 13 | 5 (5, 5) |
| Not reported and unknown | Day 1 | Placebo | Negative | Pseudovirus-nAb ID80 | 13 | 5 (5, 5) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|--------------------------|--------|---------|---------------------|------------------------|----|-------------------------|
| Not reported and unknown | Day 1 | Placebo | Positive | Anti N IgG (IU/ml) | 18 | 10 (10, 10) |
| Not reported and unknown | Day 1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 18 | 10 (10, 10) |
| Not reported and unknown | Day 1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 18 | 10 (10, 10) |
| Not reported and unknown | Day 1 | Placebo | Positive | Pseudovirus-nAb ID50 | 18 | 5 (5, 5) |
| Not reported and unknown | Day 1 | Placebo | Positive | Pseudovirus-nAb ID80 | 18 | 5 (5, 5) |
| Not reported and unknown | Day 29 | Vaccine | Negative | Anti N IgG (IU/ml) | 88 | 24172 (15240, 38338) |
| Not reported and unknown | Day 29 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 88 | 22876 (15904, 32905) |
| Not reported and unknown | Day 29 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 88 | 50488 (35885, 71034) |
| Not reported and unknown | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID50 | 88 | 133 (84, 213) |
| Not reported and unknown | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID80 | 88 | 174 (106, 287) |
| Not reported and unknown | Day 29 | Vaccine | Positive | Anti N IgG (IU/ml) | 22 | 34292 (18107, 64943) |
| Not reported and unknown | Day 29 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 22 | 25827 (18334, 36382) |
| Not reported and unknown | Day 29 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 22 | 46903 (33825, 65038) |
| Not reported and unknown | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID50 | 22 | 154 (91, 259) |
| Not reported and unknown | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID80 | 22 | 420 (198, 891) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|--------------------------|--------|---------|---------------------|------------------------|----|-------------------------------|
| Not reported and unknown | Day 29 | Placebo | Negative | Anti N IgG (IU/ml) | 13 | 10 (10, 10) |
| Not reported and unknown | Day 29 | Placebo | Negative | Anti RBD IgG (IU/ml) | 13 | 10 (10, 10) |
| Not reported and unknown | Day 29 | Placebo | Negative | Anti Spike IgG (IU/ml) | 13 | 10 (10, 10) |
| Not reported and unknown | Day 29 | Placebo | Negative | Pseudovirus-nAb ID50 | 13 | 5 (5, 5) |
| Not reported and unknown | Day 29 | Placebo | Negative | Pseudovirus-nAb ID80 | 13 | 5 (5, 5) |
| Not reported and unknown | Day 29 | Placebo | Positive | Anti N IgG (IU/ml) | 18 | 7067 (1907, 26192) |
| Not reported and unknown | Day 29 | Placebo | Positive | Anti RBD IgG (IU/ml) | 18 | 10750 (3611, 32001) |
| Not reported and unknown | Day 29 | Placebo | Positive | Anti Spike IgG (IU/ml) | 18 | 11909 (5649, 25107) |
| Not reported and unknown | Day 29 | Placebo | Positive | Pseudovirus-nAb ID50 | 18 | 37 (15, 93) |
| Not reported and unknown | Day 29 | Placebo | Positive | Pseudovirus-nAb ID80 | 18 | 58 (19, 177) |
| Not reported and unknown | Day 57 | Vaccine | Negative | Anti N IgG (IU/ml) | 88 | 259797 (148513, 454466) |
| Not reported and unknown | Day 57 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 88 | 735710 (462524, 1170251) |
| Not reported and unknown | Day 57 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 88 | 2279592 (1446853, 3591615) |
| Not reported and unknown | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID50 | 88 | 1291 (765, 2178) |
| Not reported and unknown | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID80 | 88 | 1748 (990, 3088) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|--------------------------|--------|---------|---------------------|------------------------|----|-------------------------------|
| Not reported and unknown | Day 57 | Vaccine | Positive | Anti N IgG (IU/ml) | 22 | 710026 (245263, 2055490) |
| Not reported and unknown | Day 57 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 22 | 1751283 (872333, 3515850) |
| Not reported and unknown | Day 57 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 22 | 3840709 (2197166, 6713669) |
| Not reported and unknown | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID50 | 22 | 8669 (2979, 25223) |
| Not reported and unknown | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID80 | 22 | 5104 (2140, 12175) |
| Not reported and unknown | Day 57 | Placebo | Negative | Anti N IgG (IU/ml) | 13 | 10 (10, 10) |
| Not reported and unknown | Day 57 | Placebo | Negative | Anti RBD IgG (IU/ml) | 13 | 10 (10, 10) |
| Not reported and unknown | Day 57 | Placebo | Negative | Anti Spike IgG (IU/ml) | 13 | 10 (10, 10) |
| Not reported and unknown | Day 57 | Placebo | Negative | Pseudovirus-nAb ID50 | 13 | 5 (5, 5) |
| Not reported and unknown | Day 57 | Placebo | Negative | Pseudovirus-nAb ID80 | 13 | 5 (5, 5) |
| Not reported and unknown | Day 57 | Placebo | Positive | Anti N IgG (IU/ml) | 18 | 26411 (10028, 69563) |
| Not reported and unknown | Day 57 | Placebo | Positive | Anti RBD IgG (IU/ml) | 18 | 162620 (55659, 475135) |
| Not reported and unknown | Day 57 | Placebo | Positive | Anti Spike IgG (IU/ml) | 18 | 417076 (107739, 1614570) |
| Not reported and unknown | Day 57 | Placebo | Positive | Pseudovirus-nAb ID50 | 18 | 188 (46, 766) |
| Not reported and unknown | Day 57 | Placebo | Positive | Pseudovirus-nAb ID80 | 18 | 437 (69, 2773) |

Table 5h. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Race

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|--------------------|-------|---------|---------------------|------------------------|-----|----------------|
| Race | | | | | | |
| White Non-Hispanic | Day 1 | Vaccine | Negative | Anti N IgG (IU/ml) | 362 | 10 (10, 10) |
| White Non-Hispanic | Day 1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 362 | 10 (10, 10) |
| White Non-Hispanic | Day 1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 362 | 10 (10, 10) |
| White Non-Hispanic | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 362 | 5 (5, 5) |
| White Non-Hispanic | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 362 | 5 (5, 5) |
| White Non-Hispanic | Day 1 | Vaccine | Positive | Anti N IgG (IU/ml) | 125 | 10 (10, 10) |
| White Non-Hispanic | Day 1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 125 | 10 (10, 10) |
| White Non-Hispanic | Day 1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 125 | 10 (10, 10) |
| White Non-Hispanic | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 125 | 5 (5, 5) |
| White Non-Hispanic | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 125 | 5 (5, 5) |
| White Non-Hispanic | Day 1 | Placebo | Negative | Anti N IgG (IU/ml) | 67 | 10 (10, 11) |
| White Non-Hispanic | Day 1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 67 | 10 (10, 10) |
| White Non-Hispanic | Day 1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 67 | 10 (10, 10) |
| White Non-Hispanic | Day 1 | Placebo | Negative | Pseudovirus-nAb ID50 | 67 | 5 (5, 5) |
| White Non-Hispanic | Day 1 | Placebo | Negative | Pseudovirus-nAb ID80 | 67 | 5 (5, 6) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|--------------------|--------|---------|---------------------|------------------------|-----|-------------------------|
| White Non-Hispanic | Day 1 | Placebo | Positive | Anti N IgG (IU/ml) | 121 | 10 (10, 10) |
| White Non-Hispanic | Day 1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 121 | 10 (10, 10) |
| White Non-Hispanic | Day 1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 121 | 10 (10, 10) |
| White Non-Hispanic | Day 1 | Placebo | Positive | Pseudovirus-nAb ID50 | 121 | 5 (5, 5) |
| White Non-Hispanic | Day 1 | Placebo | Positive | Pseudovirus-nAb ID80 | 121 | 5 (5, 5) |
| White Non-Hispanic | Day 29 | Vaccine | Negative | Anti N IgG (IU/ml) | 362 | 26952 (20883, 34784) |
| White Non-Hispanic | Day 29 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 362 | 23438 (18669, 29425) |
| White Non-Hispanic | Day 29 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 362 | 40376 (34349, 47460) |
| White Non-Hispanic | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID50 | 362 | 115 (90, 147) |
| White Non-Hispanic | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID80 | 362 | 188 (146, 241) |
| White Non-Hispanic | Day 29 | Vaccine | Positive | Anti N IgG (IU/ml) | 125 | 33909 (24023, 47863) |
| White Non-Hispanic | Day 29 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 125 | 30985 (21434, 44793) |
| White Non-Hispanic | Day 29 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 125 | 72481 (53061, 99008) |
| White Non-Hispanic | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID50 | 125 | 148 (104, 211) |
| White Non-Hispanic | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID80 | 125 | 348 (226, 535) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|--------------------|--------|---------|---------------------|------------------------|-----|-------------------------------|
| White Non-Hispanic | Day 29 | Placebo | Negative | Anti N IgG (IU/ml) | 67 | 10 (10, 10) |
| White Non-Hispanic | Day 29 | Placebo | Negative | Anti RBD IgG (IU/ml) | 67 | 10 (10, 10) |
| White Non-Hispanic | Day 29 | Placebo | Negative | Anti Spike IgG (IU/ml) | 67 | 10 (10, 10) |
| White Non-Hispanic | Day 29 | Placebo | Negative | Pseudovirus-nAb ID50 | 67 | 5 (5, 5) |
| White Non-Hispanic | Day 29 | Placebo | Negative | Pseudovirus-nAb ID80 | 67 | 5 (5, 5) |
| White Non-Hispanic | Day 29 | Placebo | Positive | Anti N IgG (IU/ml) | 121 | 12594 (8382, 18924) |
| White Non-Hispanic | Day 29 | Placebo | Positive | Anti RBD IgG (IU/ml) | 121 | 10931 (7560, 15804) |
| White Non-Hispanic | Day 29 | Placebo | Positive | Anti Spike IgG (IU/ml) | 121 | 18868 (14808, 24043) |
| White Non-Hispanic | Day 29 | Placebo | Positive | Pseudovirus-nAb ID50 | 121 | 52 (37, 74) |
| White Non-Hispanic | Day 29 | Placebo | Positive | Pseudovirus-nAb ID80 | 121 | 107 (76, 150) |
| White Non-Hispanic | Day 57 | Vaccine | Negative | Anti N IgG (IU/ml) | 362 | 328428 (241933, 445846) |
| White Non-Hispanic | Day 57 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 362 | 1035293 (809568, 1323956) |
| White Non-Hispanic | Day 57 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 362 | 2145772 (1770774, 2600184) |
| White Non-Hispanic | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID50 | 362 | 1376 (1010, 1874) |
| White Non-Hispanic | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID80 | 362 | 2011 (1465, 2761) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|--------------------|--------|---------|---------------------|------------------------|-----|-------------------------------|
| White Non-Hispanic | Day 57 | Vaccine | Positive | Anti N IgG (IU/ml) | 125 | 855574 (517613, 1414198) |
| White Non-Hispanic | Day 57 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 125 | 1943813 (1349835, 2799166) |
| White Non-Hispanic | Day 57 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 125 | 4608987 (3338577, 6362819) |
| White Non-Hispanic | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID50 | 125 | 4550 (2471, 8378) |
| White Non-Hispanic | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID80 | 125 | 7994 (4646, 13757) |
| White Non-Hispanic | Day 57 | Placebo | Negative | Anti N IgG (IU/ml) | 67 | 10 (10, 10) |
| White Non-Hispanic | Day 57 | Placebo | Negative | Anti RBD IgG (IU/ml) | 67 | 10 (10, 10) |
| White Non-Hispanic | Day 57 | Placebo | Negative | Anti Spike IgG (IU/ml) | 67 | 10 (10, 10) |
| White Non-Hispanic | Day 57 | Placebo | Negative | Pseudovirus-nAb ID50 | 67 | 5 (5, 5) |
| White Non-Hispanic | Day 57 | Placebo | Negative | Pseudovirus-nAb ID80 | 67 | 5 (5, 5) |
| White Non-Hispanic | Day 57 | Placebo | Positive | Anti N IgG (IU/ml) | 121 | 105260 (65764, 168478) |
| White Non-Hispanic | Day 57 | Placebo | Positive | Anti RBD IgG (IU/ml) | 121 | 393045 (287516, 537306) |
| White Non-Hispanic | Day 57 | Placebo | Positive | Anti Spike IgG (IU/ml) | 121 | 674526 (485396, 937351) |
| White Non-Hispanic | Day 57 | Placebo | Positive | Pseudovirus-nAb ID50 | 121 | 575 (371, 892) |
| White Non-Hispanic | Day 57 | Placebo | Positive | Pseudovirus-nAb ID80 | 121 | 1478 (953, 2292) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|---------------------------|-------|---------|---------------------|------------------------|-----|----------------|
| Black or African American | Day 1 | Vaccine | Negative | Anti N IgG (IU/ml) | 195 | 10 (10, 10) |
| Black or African American | Day 1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 195 | 10 (10, 11) |
| Black or African American | Day 1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 195 | 10 (10, 10) |
| Black or African American | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 195 | 5 (5, 5) |
| Black or African American | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 195 | 5 (5, 5) |
| Black or African American | Day 1 | Vaccine | Positive | Anti N IgG (IU/ml) | 52 | 10 (10, 10) |
| Black or African American | Day 1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 52 | 10 (10, 10) |
| Black or African American | Day 1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 52 | 10 (10, 10) |
| Black or African American | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 52 | 5 (5, 5) |
| Black or African American | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 52 | 5 (5, 5) |
| Black or African American | Day 1 | Placebo | Negative | Anti N IgG (IU/ml) | 39 | 10 (10, 10) |
| Black or African American | Day 1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 39 | 10 (10, 10) |
| Black or African American | Day 1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 39 | 10 (10, 10) |
| Black or African American | Day 1 | Placebo | Negative | Pseudovirus-nAb ID50 | 39 | 5 (5, 5) |
| Black or African American | Day 1 | Placebo | Negative | Pseudovirus-nAb ID80 | 39 | 5 (5, 5) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|---------------------------|--------|---------|---------------------|------------------------|-----|--------------------------|
| Black or African American | Day 1 | Placebo | Positive | Anti N IgG (IU/ml) | 60 | 10 (10, 10) |
| Black or African American | Day 1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 60 | 10 (10, 10) |
| Black or African American | Day 1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 60 | 10 (10, 10) |
| Black or African American | Day 1 | Placebo | Positive | Pseudovirus-nAb ID50 | 60 | 5 (5, 6) |
| Black or African American | Day 1 | Placebo | Positive | Pseudovirus-nAb ID80 | 60 | 5 (5, 5) |
| Black or African American | Day 29 | Vaccine | Negative | Anti N IgG (IU/ml) | 195 | 16417 (11437, 23568) |
| Black or African American | Day 29 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 195 | 18966 (14305, 25146) |
| Black or African American | Day 29 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 195 | 33478 (26923, 41629) |
| Black or African American | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID50 | 195 | 80 (57, 111) |
| Black or African American | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID80 | 195 | 168 (116, 244) |
| Black or African American | Day 29 | Vaccine | Positive | Anti N IgG (IU/ml) | 52 | 70405 (39637, 125057) |
| Black or African American | Day 29 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 52 | 49806 (32279, 76849) |
| Black or African American | Day 29 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 52 | 92510 (63827, 134083) |
| Black or African American | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID50 | 52 | 240 (126, 455) |
| Black or African American | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID80 | 52 | 595 (282, 1255) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|---------------------------|--------|---------|---------------------|------------------------|-----|-------------------------------|
| Black or African American | Day 29 | Placebo | Negative | Anti N IgG (IU/ml) | 39 | 10 (10, 10) |
| Black or African American | Day 29 | Placebo | Negative | Anti RBD IgG (IU/ml) | 39 | 10 (10, 10) |
| Black or African American | Day 29 | Placebo | Negative | Anti Spike IgG (IU/ml) | 39 | 10 (10, 10) |
| Black or African American | Day 29 | Placebo | Negative | Pseudovirus-nAb ID50 | 39 | 5 (5, 5) |
| Black or African American | Day 29 | Placebo | Negative | Pseudovirus-nAb ID80 | 39 | 5 (5, 5) |
| Black or African American | Day 29 | Placebo | Positive | Anti N IgG (IU/ml) | 60 | 9803 (5446, 17644) |
| Black or African American | Day 29 | Placebo | Positive | Anti RBD IgG (IU/ml) | 60 | 13142 (8909, 19387) |
| Black or African American | Day 29 | Placebo | Positive | Anti Spike IgG (IU/ml) | 60 | 17281 (11001, 27148) |
| Black or African American | Day 29 | Placebo | Positive | Pseudovirus-nAb ID50 | 60 | 44 (24, 81) |
| Black or African American | Day 29 | Placebo | Positive | Pseudovirus-nAb ID80 | 60 | 170 (88, 328) |
| Black or African American | Day 57 | Vaccine | Negative | Anti N IgG (IU/ml) | 195 | 270892 (186938, 392550) |
| Black or African American | Day 57 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 195 | 700976 (482795, 1017755) |
| Black or African American | Day 57 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 195 | 1698222 (1265203, 2279444) |
| Black or African American | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID50 | 195 | 1634 (1060, 2520) |
| Black or African American | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID80 | 195 | 2461 (1568, 3861) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|---------------------------|--------|---------|---------------------|------------------------|----|-------------------------------|
| Black or African American | Day 57 | Vaccine | Positive | Anti N IgG (IU/ml) | 52 | 1211651 (545292, 2692316) |
| Black or African American | Day 57 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 52 | 3863173 (2496394, 5978266) |
| Black or African American | Day 57 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 52 | 5233980 (3292870, 8319352) |
| Black or African American | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID50 | 52 | 9353 (5430, 16111) |
| Black or African American | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID80 | 52 | 10207 (5426, 19200) |
| Black or African American | Day 57 | Placebo | Negative | Anti N IgG (IU/ml) | 39 | 10 (10, 10) |
| Black or African American | Day 57 | Placebo | Negative | Anti RBD IgG (IU/ml) | 39 | 10 (10, 10) |
| Black or African American | Day 57 | Placebo | Negative | Anti Spike IgG (IU/ml) | 39 | 10 (10, 10) |
| Black or African American | Day 57 | Placebo | Negative | Pseudovirus-nAb ID50 | 39 | 5 (5, 5) |
| Black or African American | Day 57 | Placebo | Negative | Pseudovirus-nAb ID80 | 39 | 5 (5, 5) |
| Black or African American | Day 57 | Placebo | Positive | Anti N IgG (IU/ml) | 60 | 162243 (80633, 326450) |
| Black or African American | Day 57 | Placebo | Positive | Anti RBD IgG (IU/ml) | 60 | 304404 (168043, 551417) |
| Black or African American | Day 57 | Placebo | Positive | Anti Spike IgG (IU/ml) | 60 | 604842 (358324, 1020956) |
| Black or African American | Day 57 | Placebo | Positive | Pseudovirus-nAb ID50 | 60 | 572 (270, 1213) |
| Black or African American | Day 57 | Placebo | Positive | Pseudovirus-nAb ID80 | 60 | 1276 (599, 2723) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|-------|-------|---------|---------------------|------------------------|----|----------------|
| Asian | Day 1 | Vaccine | Negative | Anti N IgG (IU/ml) | 67 | 10 (10, 10) |
| Asian | Day 1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 67 | 10 (10, 10) |
| Asian | Day 1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 67 | 10 (10, 10) |
| Asian | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 67 | 5 (5, 5) |
| Asian | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 67 | 5 (5, 6) |
| Asian | Day 1 | Vaccine | Positive | Anti N IgG (IU/ml) | 24 | 10 (10, 11) |
| Asian | Day 1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 24 | 10 (10, 10) |
| Asian | Day 1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 24 | 10 (10, 10) |
| Asian | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 24 | 5 (5, 5) |
| Asian | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 24 | 6 (5, 7) |
| Asian | Day 1 | Placebo | Negative | Anti N IgG (IU/ml) | 12 | 10 (10, 10) |
| Asian | Day 1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 12 | 10 (10, 10) |
| Asian | Day 1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 12 | 10 (10, 10) |
| Asian | Day 1 | Placebo | Negative | Pseudovirus-nAb ID50 | 12 | 5 (5, 5) |
| Asian | Day 1 | Placebo | Negative | Pseudovirus-nAb ID80 | 12 | 5 (5, 5) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|-------|--------|---------|---------------------|------------------------|----|-------------------------|
| Asian | Day 1 | Placebo | Positive | Anti N IgG (IU/ml) | 13 | 10 (10, 10) |
| Asian | Day 1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 13 | 10 (10, 10) |
| Asian | Day 1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 13 | 10 (10, 10) |
| Asian | Day 1 | Placebo | Positive | Pseudovirus-nAb ID50 | 13 | 5 (5, 5) |
| Asian | Day 1 | Placebo | Positive | Pseudovirus-nAb ID80 | 13 | 5 (5, 5) |
| Asian | Day 29 | Vaccine | Negative | Anti N IgG (IU/ml) | 67 | 30141 (17403, 52204) |
| Asian | Day 29 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 67 | 33349 (22259, 49964) |
| Asian | Day 29 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 67 | 63758 (45931, 88504) |
| Asian | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID50 | 67 | 144 (92, 225) |
| Asian | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID80 | 67 | 330 (204, 534) |
| Asian | Day 29 | Vaccine | Positive | Anti N IgG (IU/ml) | 24 | 33316 (16935, 65545) |
| Asian | Day 29 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 24 | 24553 (12536, 48091) |
| Asian | Day 29 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 24 | 49522 (26709, 91821) |
| Asian | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID50 | 24 | 174 (94, 325) |
| Asian | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID80 | 24 | 368 (184, 735) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|-------|--------|---------|---------------------|------------------------|----|-------------------------------|
| Asian | Day 29 | Placebo | Negative | Anti N IgG (IU/ml) | 12 | 10 (10, 10) |
| Asian | Day 29 | Placebo | Negative | Anti RBD IgG (IU/ml) | 12 | 10 (10, 10) |
| Asian | Day 29 | Placebo | Negative | Anti Spike IgG (IU/ml) | 12 | 10 (10, 10) |
| Asian | Day 29 | Placebo | Negative | Pseudovirus-nAb ID50 | 12 | 5 (5, 6) |
| Asian | Day 29 | Placebo | Negative | Pseudovirus-nAb ID80 | 12 | 5 (5, 5) |
| Asian | Day 29 | Placebo | Positive | Anti N IgG (IU/ml) | 13 | 17273 (6186, 48234) |
| Asian | Day 29 | Placebo | Positive | Anti RBD IgG (IU/ml) | 13 | 27396 (5431, 138186) |
| Asian | Day 29 | Placebo | Positive | Anti Spike IgG (IU/ml) | 13 | 12500 (4740, 32962) |
| Asian | Day 29 | Placebo | Positive | Pseudovirus-nAb ID50 | 13 | 65 (17, 245) |
| Asian | Day 29 | Placebo | Positive | Pseudovirus-nAb ID80 | 13 | 146 (18, 1215) |
| Asian | Day 57 | Vaccine | Negative | Anti N IgG (IU/ml) | 67 | 759619 (426880, 1351718) |
| Asian | Day 57 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 67 | 1685637 (1167594, 2433528) |
| Asian | Day 57 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 67 | 2633046 (1864450, 3718486) |
| Asian | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID50 | 67 | 2850 (1578, 5149) |
| Asian | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID80 | 67 | 3805 (1835, 7889) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|-------|--------|---------|---------------------|------------------------|----|-------------------------------|
| Asian | Day 57 | Vaccine | Positive | Anti N IgG (IU/ml) | 24 | 639026 (148027, 2758648) |
| Asian | Day 57 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 24 | 2094481 (742718, 5906481) |
| Asian | Day 57 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 24 | 4848443 (2478358, 9485072) |
| Asian | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID50 | 24 | 6020 (2360, 15360) |
| Asian | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID80 | 24 | 8404 (2608, 27081) |
| Asian | Day 57 | Placebo | Negative | Anti N IgG (IU/ml) | 12 | 10 (10, 10) |
| Asian | Day 57 | Placebo | Negative | Anti RBD IgG (IU/ml) | 12 | 10 (10, 10) |
| Asian | Day 57 | Placebo | Negative | Anti Spike IgG (IU/ml) | 12 | 10 (10, 10) |
| Asian | Day 57 | Placebo | Negative | Pseudovirus-nAb ID50 | 12 | 5 (5, 5) |
| Asian | Day 57 | Placebo | Negative | Pseudovirus-nAb ID80 | 12 | 5 (5, 5) |
| Asian | Day 57 | Placebo | Positive | Anti N IgG (IU/ml) | 13 | 275834 (26204, 2903499) |
| Asian | Day 57 | Placebo | Positive | Anti RBD IgG (IU/ml) | 13 | 750472 (176753, 3186420) |
| Asian | Day 57 | Placebo | Positive | Anti Spike IgG (IU/ml) | 13 | 859200 (168867, 4371633) |
| Asian | Day 57 | Placebo | Positive | Pseudovirus-nAb ID50 | 13 | 482 (269, 862) |
| Asian | Day 57 | Placebo | Positive | Pseudovirus-nAb ID80 | 13 | 1167 (203, 6693) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|----------------------------------|-------|---------|---------------------|------------------------|----|----------------|
| American Indian or Alaska Native | Day 1 | Vaccine | Negative | Anti N IgG (IU/ml) | 13 | 10 (10, 10) |
| American Indian or Alaska Native | Day 1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 13 | 10 (10, 10) |
| American Indian or Alaska Native | Day 1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 13 | 10 (10, 10) |
| American Indian or Alaska Native | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 13 | 5 (5, 5) |
| American Indian or Alaska Native | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 13 | 5 (5, 5) |
| American Indian or Alaska Native | Day 1 | Vaccine | Positive | Anti N IgG (IU/ml) | 6 | 10 (10, 10) |
| American Indian or Alaska Native | Day 1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 6 | 10 (10, 10) |
| American Indian or Alaska Native | Day 1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 6 | 10 (10, 10) |
| American Indian or Alaska Native | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 6 | 5 (5, 5) |
| American Indian or Alaska Native | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 6 | 7 (4, 14) |
| American Indian or Alaska Native | Day 1 | Placebo | Negative | Anti N IgG (IU/ml) | 5 | 10 (10, 10) |
| American Indian or Alaska Native | Day 1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 5 | 10 (10, 10) |
| American Indian or Alaska Native | Day 1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 5 | 10 (10, 10) |
| American Indian or Alaska Native | Day 1 | Placebo | Negative | Pseudovirus-nAb ID50 | 5 | 5 (5, 5) |
| American Indian or Alaska Native | Day 1 | Placebo | Negative | Pseudovirus-nAb ID80 | 5 | 5 (5, 7) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|----------------------------------|--------|---------|---------------------|------------------------|----|--------------------------|
| American Indian or Alaska Native | Day 1 | Placebo | Positive | Anti N IgG (IU/ml) | 4 | 10 (10, 10) |
| American Indian or Alaska Native | Day 1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 4 | 10 (10, 10) |
| American Indian or Alaska Native | Day 1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 4 | 10 (10, 10) |
| American Indian or Alaska Native | Day 1 | Placebo | Positive | Pseudovirus-nAb ID50 | 4 | 5 (5, 5) |
| American Indian or Alaska Native | Day 1 | Placebo | Positive | Pseudovirus-nAb ID80 | 4 | 5 (5, 5) |
| American Indian or Alaska Native | Day 29 | Vaccine | Negative | Anti N IgG (IU/ml) | 13 | 45133 (16515, 123343) |
| American Indian or Alaska Native | Day 29 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 13 | 42283 (20288, 88120) |
| American Indian or Alaska Native | Day 29 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 13 | 30785 (13439, 70516) |
| American Indian or Alaska Native | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID50 | 13 | 186 (63, 554) |
| American Indian or Alaska Native | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID80 | 13 | 309 (55, 1753) |
| American Indian or Alaska Native | Day 29 | Vaccine | Positive | Anti N IgG (IU/ml) | 6 | 42543 (10105, 179112) |
| American Indian or Alaska Native | Day 29 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 6 | 22761 (8134, 63689) |
| American Indian or Alaska Native | Day 29 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 6 | 85898 (68138, 108288) |
| American Indian or Alaska Native | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID50 | 6 | 244 (182, 327) |
| American Indian or Alaska Native | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID80 | 6 | 1338 (620, 2888) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|----------------------------------|--------|---------|---------------------|------------------------|----|-------------------------------|
| American Indian or Alaska Native | Day 29 | Placebo | Negative | Anti N IgG (IU/ml) | 5 | 10 (10, 10) |
| American Indian or Alaska Native | Day 29 | Placebo | Negative | Anti RBD IgG (IU/ml) | 5 | 10 (10, 10) |
| American Indian or Alaska Native | Day 29 | Placebo | Negative | Anti Spike IgG (IU/ml) | 5 | 10 (10, 10) |
| American Indian or Alaska Native | Day 29 | Placebo | Negative | Pseudovirus-nAb ID50 | 5 | 5 (5, 5) |
| American Indian or Alaska Native | Day 29 | Placebo | Negative | Pseudovirus-nAb ID80 | 5 | 5 (5, 5) |
| American Indian or Alaska Native | Day 29 | Placebo | Positive | Anti N IgG (IU/ml) | 4 | 3080 (1115, 8510) |
| American Indian or Alaska Native | Day 29 | Placebo | Positive | Anti RBD IgG (IU/ml) | 4 | 7559 (3837, 14892) |
| American Indian or Alaska Native | Day 29 | Placebo | Positive | Anti Spike IgG (IU/ml) | 4 | 5348 (1735, 16488) |
| American Indian or Alaska Native | Day 29 | Placebo | Positive | Pseudovirus-nAb ID50 | 4 | 13 (4, 46) |
| American Indian or Alaska Native | Day 29 | Placebo | Positive | Pseudovirus-nAb ID80 | 4 | 79 (32, 190) |
| American Indian or Alaska Native | Day 57 | Vaccine | Negative | Anti N IgG (IU/ml) | 13 | 982833 (235813, 4096296) |
| American Indian or Alaska Native | Day 57 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 13 | 836025 (283249, 2467576) |
| American Indian or Alaska Native | Day 57 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 13 | 4760602 (2359191, 9606399) |
| American Indian or Alaska Native | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID50 | 13 | 3381 (548, 20856) |
| American Indian or Alaska Native | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID80 | 13 | 4097 (1137, 14766) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|----------------------------------|--------|---------|---------------------|------------------------|---|--------------------------------|
| American Indian or Alaska Native | Day 57 | Vaccine | Positive | Anti N IgG (IU/ml) | 6 | 2398314 (427206, 13464021) |
| American Indian or Alaska Native | Day 57 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 6 | 2320038 (501453, 10733961) |
| American Indian or Alaska Native | Day 57 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 6 | 7507181 (3379449, 16676615) |
| American Indian or Alaska Native | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID50 | 6 | 8919 (1502, 52953) |
| American Indian or Alaska Native | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID80 | 6 | 9789 (1020, 93964) |
| American Indian or Alaska Native | Day 57 | Placebo | Negative | Anti N IgG (IU/ml) | 5 | 10 (10, 10) |
| American Indian or Alaska Native | Day 57 | Placebo | Negative | Anti RBD IgG (IU/ml) | 5 | 10 (10, 10) |
| American Indian or Alaska Native | Day 57 | Placebo | Negative | Anti Spike IgG (IU/ml) | 5 | 10 (10, 10) |
| American Indian or Alaska Native | Day 57 | Placebo | Negative | Pseudovirus-nAb ID50 | 5 | 5 (5, 5) |
| American Indian or Alaska Native | Day 57 | Placebo | Negative | Pseudovirus-nAb ID80 | 5 | 5 (5, 5) |
| American Indian or Alaska Native | Day 57 | Placebo | Positive | Anti N IgG (IU/ml) | 4 | 36102 (4722, 276037) |
| American Indian or Alaska Native | Day 57 | Placebo | Positive | Anti RBD IgG (IU/ml) | 4 | 272152 (65917, 1123631) |
| American Indian or Alaska Native | Day 57 | Placebo | Positive | Anti Spike IgG (IU/ml) | 4 | 677711 (214540, 2140827) |
| American Indian or Alaska Native | Day 57 | Placebo | Positive | Pseudovirus-nAb ID50 | 4 | 126 (26, 608) |
| American Indian or Alaska Native | Day 57 | Placebo | Positive | Pseudovirus-nAb ID80 | 4 | 520 (61, 4436) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|---|-------|---------|---------------------|------------------------|----|----------------|
| Native Hawaiian or Other Pacific Islander | Day 1 | Vaccine | Negative | Anti N IgG (IU/ml) | 17 | 10 (10, 10) |
| Native Hawaiian or Other Pacific Islander | Day 1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 17 | 11 (9, 14) |
| Native Hawaiian or Other Pacific Islander | Day 1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 17 | 10 (10, 10) |
| Native Hawaiian or Other Pacific Islander | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 17 | 6 (4, 8) |
| Native Hawaiian or Other Pacific Islander | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 17 | 5 (5, 5) |
| Native Hawaiian or Other Pacific Islander | Day 1 | Vaccine | Positive | Anti N IgG (IU/ml) | 5 | 10 (10, 10) |
| Native Hawaiian or Other Pacific Islander | Day 1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 5 | 10 (10, 10) |
| Native Hawaiian or Other Pacific Islander | Day 1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 5 | 10 (10, 10) |
| Native Hawaiian or Other Pacific Islander | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 5 | 5 (5, 5) |
| Native Hawaiian or Other Pacific Islander | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 5 | 5 (5, 5) |
| Native Hawaiian or Other Pacific Islander | Day 1 | Placebo | Negative | Anti N IgG (IU/ml) | 1 | 10 (10, 10) |
| Native Hawaiian or Other Pacific Islander | Day 1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 1 | 10 (10, 10) |
| Native Hawaiian or Other Pacific Islander | Day 1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 1 | 10 (10, 10) |
| Native Hawaiian or Other Pacific Islander | Day 1 | Placebo | Negative | Pseudovirus-nAb ID50 | 1 | 5 (5, 5) |
| Native Hawaiian or Other Pacific Islander | Day 1 | Placebo | Negative | Pseudovirus-nAb ID80 | 1 | 5 (5, 5) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|---|--------|---------|---------------------|------------------------|----|---------------------------|
| Native Hawaiian or Other Pacific Islander | Day 1 | Placebo | Positive | Anti N IgG (IU/ml) | 1 | 10 (10, 10) |
| Native Hawaiian or Other Pacific Islander | Day 1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 1 | 10 (10, 10) |
| Native Hawaiian or Other Pacific Islander | Day 1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 1 | 10 (10, 10) |
| Native Hawaiian or Other Pacific Islander | Day 1 | Placebo | Positive | Pseudovirus-nAb ID50 | 1 | 5 (5, 5) |
| Native Hawaiian or Other Pacific Islander | Day 1 | Placebo | Positive | Pseudovirus-nAb ID80 | 1 | 5 (5, 5) |
| Native Hawaiian or Other Pacific Islander | Day 29 | Vaccine | Negative | Anti N IgG (IU/ml) | 17 | 114600 (47108, 278791) |
| Native Hawaiian or Other Pacific Islander | Day 29 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 17 | 114776 (53301, 247155) |
| Native Hawaiian or Other Pacific Islander | Day 29 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 17 | 116196 (67714, 199391) |
| Native Hawaiian or Other Pacific Islander | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID50 | 17 | 381 (198, 736) |
| Native Hawaiian or Other Pacific Islander | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID80 | 17 | 982 (339, 2849) |
| Native Hawaiian or Other Pacific Islander | Day 29 | Vaccine | Positive | Anti N IgG (IU/ml) | 5 | 55095 (9965, 304612) |
| Native Hawaiian or Other Pacific Islander | Day 29 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 5 | 44998 (2885, 701952) |
| Native Hawaiian or Other Pacific Islander | Day 29 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 5 | 107953 (71167, 163752) |
| Native Hawaiian or Other Pacific Islander | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID50 | 5 | 227 (17, 2989) |
| Native Hawaiian or Other Pacific Islander | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID80 | 5 | 489 (239, 1000) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|---|--------|---------|---------------------|------------------------|----|--------------------------------|
| Native Hawaiian or Other Pacific Islander | Day 29 | Placebo | Negative | Anti N IgG (IU/ml) | 1 | 10 (10, 10) |
| Native Hawaiian or Other Pacific Islander | Day 29 | Placebo | Negative | Anti RBD IgG (IU/ml) | 1 | 10 (10, 10) |
| Native Hawaiian or Other Pacific Islander | Day 29 | Placebo | Negative | Anti Spike IgG (IU/ml) | 1 | 10 (10, 10) |
| Native Hawaiian or Other Pacific Islander | Day 29 | Placebo | Negative | Pseudovirus-nAb ID50 | 1 | 5 (5, 5) |
| Native Hawaiian or Other Pacific Islander | Day 29 | Placebo | Negative | Pseudovirus-nAb ID80 | 1 | 5 (5, 5) |
| Native Hawaiian or Other Pacific Islander | Day 29 | Placebo | Positive | Anti N IgG (IU/ml) | 1 | 734 (734, 734) |
| Native Hawaiian or Other Pacific Islander | Day 29 | Placebo | Positive | Anti RBD IgG (IU/ml) | 1 | 6237 (6237, 6237) |
| Native Hawaiian or Other Pacific Islander | Day 29 | Placebo | Positive | Anti Spike IgG (IU/ml) | 1 | 10844 (10844, 10844) |
| Native Hawaiian or Other Pacific Islander | Day 29 | Placebo | Positive | Pseudovirus-nAb ID50 | 1 | 5 (5, 5) |
| Native Hawaiian or Other Pacific Islander | Day 29 | Placebo | Positive | Pseudovirus-nAb ID80 | 1 | 5 (5, 5) |
| Native Hawaiian or Other Pacific Islander | Day 57 | Vaccine | Negative | Anti N IgG (IU/ml) | 17 | 2236794 (700142, 7146051) |
| Native Hawaiian or Other Pacific Islander | Day 57 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 17 | 5533419 (2490433, 12294540) |
| Native Hawaiian or Other Pacific Islander | Day 57 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 17 | 7662810 (3323463, 17667914) |
| Native Hawaiian or Other Pacific Islander | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID50 | 17 | 10464 (2274, 48150) |
| Native Hawaiian or Other Pacific Islander | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID80 | 17 | 4635 (2089, 10284) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|---|--------|---------|---------------------|------------------------|---|-------------------------------|
| Native Hawaiian or Other Pacific Islander | Day 57 | Vaccine | Positive | Anti N IgG (IU/ml) | 5 | 513962 (93920, 2812583) |
| Native Hawaiian or Other Pacific Islander | Day 57 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 5 | 1828480 (947016, 3530396) |
| Native Hawaiian or Other Pacific Islander | Day 57 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 5 | 5139344 (595014, 44390337) |
| Native Hawaiian or Other Pacific Islander | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID50 | 5 | 2545 (185, 35084) |
| Native Hawaiian or Other Pacific Islander | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID80 | 5 | 1804 (213, 15248) |
| Native Hawaiian or Other Pacific Islander | Day 57 | Placebo | Negative | Anti N IgG (IU/ml) | 1 | 10 (10, 10) |
| Native Hawaiian or Other Pacific Islander | Day 57 | Placebo | Negative | Anti RBD IgG (IU/ml) | 1 | 10 (10, 10) |
| Native Hawaiian or Other Pacific Islander | Day 57 | Placebo | Negative | Anti Spike IgG (IU/ml) | 1 | 10 (10, 10) |
| Native Hawaiian or Other Pacific Islander | Day 57 | Placebo | Negative | Pseudovirus-nAb ID50 | 1 | 5 (5, 5) |
| Native Hawaiian or Other Pacific Islander | Day 57 | Placebo | Negative | Pseudovirus-nAb ID80 | 1 | 5 (5, 5) |
| Native Hawaiian or Other Pacific Islander | Day 57 | Placebo | Positive | Anti N IgG (IU/ml) | 1 | 969 (969, 969) |
| Native Hawaiian or Other Pacific Islander | Day 57 | Placebo | Positive | Anti RBD IgG (IU/ml) | 1 | 4780 (4780, 4780) |
| Native Hawaiian or Other Pacific Islander | Day 57 | Placebo | Positive | Anti Spike IgG (IU/ml) | 1 | 61376 (61376, 61376) |
| Native Hawaiian or Other Pacific Islander | Day 57 | Placebo | Positive | Pseudovirus-nAb ID50 | 1 | 44 (44, 44) |
| Native Hawaiian or Other Pacific Islander | Day 57 | Placebo | Positive | Pseudovirus-nAb ID80 | 1 | 144 (144, 144) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|-------------|-------|---------|---------------------|------------------------|----|----------------|
| Multiracial | Day 1 | Vaccine | Negative | Anti N IgG (IU/ml) | 52 | 10 (10, 10) |
| Multiracial | Day 1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 52 | 10 (10, 10) |
| Multiracial | Day 1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 52 | 10 (10, 10) |
| Multiracial | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 52 | 5 (5, 5) |
| Multiracial | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 52 | 5 (5, 5) |
| Multiracial | Day 1 | Vaccine | Positive | Anti N IgG (IU/ml) | 12 | 10 (10, 10) |
| Multiracial | Day 1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 12 | 10 (10, 10) |
| Multiracial | Day 1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 12 | 10 (10, 10) |
| Multiracial | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 12 | 5 (5, 5) |
| Multiracial | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 12 | 5 (5, 5) |
| Multiracial | Day 1 | Placebo | Negative | Anti N IgG (IU/ml) | 8 | 10 (10, 10) |
| Multiracial | Day 1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 8 | 10 (10, 10) |
| Multiracial | Day 1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 8 | 10 (10, 10) |
| Multiracial | Day 1 | Placebo | Negative | Pseudovirus-nAb ID50 | 8 | 5 (5, 5) |
| Multiracial | Day 1 | Placebo | Negative | Pseudovirus-nAb ID80 | 8 | 5 (5, 5) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|-------------|--------|---------|---------------------|------------------------|----|---------------------------|
| Multiracial | Day 1 | Placebo | Positive | Anti N IgG (IU/ml) | 19 | 10 (10, 10) |
| Multiracial | Day 1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 19 | 10 (10, 10) |
| Multiracial | Day 1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 19 | 10 (10, 10) |
| Multiracial | Day 1 | Placebo | Positive | Pseudovirus-nAb ID50 | 19 | 5 (5, 5) |
| Multiracial | Day 1 | Placebo | Positive | Pseudovirus-nAb ID80 | 19 | 5 (5, 5) |
| Multiracial | Day 29 | Vaccine | Negative | Anti N IgG (IU/ml) | 52 | 20542 (10447, 40388) |
| Multiracial | Day 29 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 52 | 21505 (13701, 33755) |
| Multiracial | Day 29 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 52 | 45067 (27165, 74765) |
| Multiracial | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID50 | 52 | 71 (38, 130) |
| Multiracial | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID80 | 52 | 135 (82, 222) |
| Multiracial | Day 29 | Vaccine | Positive | Anti N IgG (IU/ml) | 12 | 70589 (26321, 189314) |
| Multiracial | Day 29 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 12 | 55196 (16260, 187371) |
| Multiracial | Day 29 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 12 | 155885 (67996, 357377) |
| Multiracial | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID50 | 12 | 398 (197, 804) |
| Multiracial | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID80 | 12 | 277 (153, 502) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|-------------|--------|---------|---------------------|------------------------|----|-------------------------------|
| Multiracial | Day 29 | Placebo | Negative | Anti N IgG (IU/ml) | 8 | 10 (10, 10) |
| Multiracial | Day 29 | Placebo | Negative | Anti RBD IgG (IU/ml) | 8 | 10 (10, 10) |
| Multiracial | Day 29 | Placebo | Negative | Anti Spike IgG (IU/ml) | 8 | 10 (10, 10) |
| Multiracial | Day 29 | Placebo | Negative | Pseudovirus-nAb ID50 | 8 | 5 (5, 5) |
| Multiracial | Day 29 | Placebo | Negative | Pseudovirus-nAb ID80 | 8 | 5 (5, 5) |
| Multiracial | Day 29 | Placebo | Positive | Anti N IgG (IU/ml) | 19 | 15871 (7677, 32809) |
| Multiracial | Day 29 | Placebo | Positive | Anti RBD IgG (IU/ml) | 19 | 24792 (13458, 45670) |
| Multiracial | Day 29 | Placebo | Positive | Anti Spike IgG (IU/ml) | 19 | 25261 (11298, 56479) |
| Multiracial | Day 29 | Placebo | Positive | Pseudovirus-nAb ID50 | 19 | 51 (28, 93) |
| Multiracial | Day 29 | Placebo | Positive | Pseudovirus-nAb ID80 | 19 | 190 (60, 600) |
| Multiracial | Day 57 | Vaccine | Negative | Anti N IgG (IU/ml) | 52 | 214922 (107912, 428046) |
| Multiracial | Day 57 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 52 | 1262157 (710446, 2242309) |
| Multiracial | Day 57 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 52 | 2195866 (1476648, 3265387) |
| Multiracial | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID50 | 52 | 1524 (697, 3334) |
| Multiracial | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID80 | 52 | 1963 (778, 4953) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|-------------|--------|---------|---------------------|------------------------|----|--------------------------------|
| Multiracial | Day 57 | Vaccine | Positive | Anti N IgG (IU/ml) | 12 | 1276135 (551639, 2952150) |
| Multiracial | Day 57 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 12 | 3777504 (1786314, 7988255) |
| Multiracial | Day 57 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 12 | 8118223 (3167974, 20803689) |
| Multiracial | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID50 | 12 | 2411 (687, 8455) |
| Multiracial | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID80 | 12 | 10135 (6049, 16979) |
| Multiracial | Day 57 | Placebo | Negative | Anti N IgG (IU/ml) | 8 | 10 (10, 10) |
| Multiracial | Day 57 | Placebo | Negative | Anti RBD IgG (IU/ml) | 8 | 10 (10, 10) |
| Multiracial | Day 57 | Placebo | Negative | Anti Spike IgG (IU/ml) | 8 | 10 (10, 10) |
| Multiracial | Day 57 | Placebo | Negative | Pseudovirus-nAb ID50 | 8 | 5 (5, 5) |
| Multiracial | Day 57 | Placebo | Negative | Pseudovirus-nAb ID80 | 8 | 5 (5, 5) |
| Multiracial | Day 57 | Placebo | Positive | Anti N IgG (IU/ml) | 19 | 235861 (101669, 547174) |
| Multiracial | Day 57 | Placebo | Positive | Anti RBD IgG (IU/ml) | 19 | 693982 (285837, 1684912) |
| Multiracial | Day 57 | Placebo | Positive | Anti Spike IgG (IU/ml) | 19 | 791515 (327732, 1911609) |
| Multiracial | Day 57 | Placebo | Positive | Pseudovirus-nAb ID50 | 19 | 1034 (211, 5057) |
| Multiracial | Day 57 | Placebo | Positive | Pseudovirus-nAb ID80 | 19 | 2744 (676, 11140) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|-------|-------|---------|---------------------|------------------------|----|----------------|
| Other | Day 1 | Vaccine | Negative | Anti N IgG (IU/ml) | 34 | 10 (10, 10) |
| Other | Day 1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 34 | 10 (10, 10) |
| Other | Day 1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 34 | 10 (10, 10) |
| Other | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 34 | 5 (5, 5) |
| Other | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 34 | 6 (5, 7) |
| Other | Day 1 | Vaccine | Positive | Anti N IgG (IU/ml) | 7 | 10 (10, 10) |
| Other | Day 1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 7 | 10 (10, 10) |
| Other | Day 1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 7 | 10 (10, 10) |
| Other | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 7 | 5 (5, 5) |
| Other | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 7 | 5 (5, 5) |
| Other | Day 1 | Placebo | Negative | Anti N IgG (IU/ml) | 4 | 10 (10, 10) |
| Other | Day 1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 4 | 10 (10, 10) |
| Other | Day 1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 4 | 10 (10, 10) |
| Other | Day 1 | Placebo | Negative | Pseudovirus-nAb ID50 | 4 | 5 (5, 5) |
| Other | Day 1 | Placebo | Negative | Pseudovirus-nAb ID80 | 4 | 6 (4, 8) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|-------|--------|---------|---------------------|------------------------|----|--------------------------|
| Other | Day 1 | Placebo | Positive | Anti N IgG (IU/ml) | 5 | 10 (10, 10) |
| Other | Day 1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 5 | 10 (10, 10) |
| Other | Day 1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 5 | 10 (10, 10) |
| Other | Day 1 | Placebo | Positive | Pseudovirus-nAb ID50 | 5 | 5 (5, 5) |
| Other | Day 1 | Placebo | Positive | Pseudovirus-nAb ID80 | 5 | 5 (5, 5) |
| Other | Day 29 | Vaccine | Negative | Anti N IgG (IU/ml) | 34 | 21653 (9122, 51401) |
| Other | Day 29 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 34 | 22295 (11570, 42963) |
| Other | Day 29 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 34 | 38007 (21259, 67950) |
| Other | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID50 | 34 | 118 (54, 259) |
| Other | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID80 | 34 | 254 (100, 650) |
| Other | Day 29 | Vaccine | Positive | Anti N IgG (IU/ml) | 7 | 18596 (5457, 63367) |
| Other | Day 29 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 7 | 18039 (7489, 43449) |
| Other | Day 29 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 7 | 75844 (32129, 179037) |
| Other | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID50 | 7 | 63 (18, 221) |
| Other | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID80 | 7 | 283 (86, 936) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|-------|--------|---------|---------------------|------------------------|----|-------------------------------|
| Other | Day 29 | Placebo | Negative | Anti N IgG (IU/ml) | 4 | 10 (10, 10) |
| Other | Day 29 | Placebo | Negative | Anti RBD IgG (IU/ml) | 4 | 10 (10, 10) |
| Other | Day 29 | Placebo | Negative | Anti Spike IgG (IU/ml) | 4 | 10 (10, 10) |
| Other | Day 29 | Placebo | Negative | Pseudovirus-nAb ID50 | 4 | 5 (5, 5) |
| Other | Day 29 | Placebo | Negative | Pseudovirus-nAb ID80 | 4 | 5 (5, 5) |
| Other | Day 29 | Placebo | Positive | Anti N IgG (IU/ml) | 5 | 44670 (548, 3638655) |
| Other | Day 29 | Placebo | Positive | Anti RBD IgG (IU/ml) | 5 | 49870 (993, 2505753) |
| Other | Day 29 | Placebo | Positive | Anti Spike IgG (IU/ml) | 5 | 40496 (1871, 876366) |
| Other | Day 29 | Placebo | Positive | Pseudovirus-nAb ID50 | 5 | 221 (12, 4185) |
| Other | Day 29 | Placebo | Positive | Pseudovirus-nAb ID80 | 5 | 295 (27, 3229) |
| Other | Day 57 | Vaccine | Negative | Anti N IgG (IU/ml) | 34 | 460615 (152205, 1393948) |
| Other | Day 57 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 34 | 959325 (467189, 1969877) |
| Other | Day 57 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 34 | 2238776 (1221484, 4103302) |
| Other | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID50 | 34 | 1974 (715, 5452) |
| Other | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID80 | 34 | 3391 (1017, 11315) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|-------|--------|---------|---------------------|------------------------|---|--------------------------------|
| Other | Day 57 | Vaccine | Positive | Anti N IgG (IU/ml) | 7 | 506707 (112863, 2274911) |
| Other | Day 57 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 7 | 4612046 (1663462, 12787169) |
| Other | Day 57 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 7 | 5745695 (3340937, 9881364) |
| Other | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID50 | 7 | 2543 (573, 11275) |
| Other | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID80 | 7 | 4503 (1467, 13817) |
| Other | Day 57 | Placebo | Negative | Anti N IgG (IU/ml) | 4 | 10 (10, 10) |
| Other | Day 57 | Placebo | Negative | Anti RBD IgG (IU/ml) | 4 | 10 (10, 10) |
| Other | Day 57 | Placebo | Negative | Anti Spike IgG (IU/ml) | 4 | 10 (10, 10) |
| Other | Day 57 | Placebo | Negative | Pseudovirus-nAb ID50 | 4 | 5 (5, 5) |
| Other | Day 57 | Placebo | Negative | Pseudovirus-nAb ID80 | 4 | 5 (5, 5) |
| Other | Day 57 | Placebo | Positive | Anti N IgG (IU/ml) | 5 | 635834 (21972, 18400096) |
| Other | Day 57 | Placebo | Positive | Anti RBD IgG (IU/ml) | 5 | 390164 (12362, 12313729) |
| Other | Day 57 | Placebo | Positive | Anti Spike IgG (IU/ml) | 5 | 1950467 (62864, 60516607) |
| Other | Day 57 | Placebo | Positive | Pseudovirus-nAb ID50 | 5 | 6112 (27, 1395272) |
| Other | Day 57 | Placebo | Positive | Pseudovirus-nAb ID80 | 5 | 1609 (34, 75283) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|--------------------------|-------|---------|---------------------|------------------------|----|----------------|
| Not reported and unknown | Day 1 | Vaccine | Negative | Anti N IgG (IU/ml) | 87 | 10 (10, 10) |
| Not reported and unknown | Day 1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 87 | 10 (10, 10) |
| Not reported and unknown | Day 1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 87 | 10 (10, 10) |
| Not reported and unknown | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 87 | 5 (5, 5) |
| Not reported and unknown | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 87 | 5 (5, 5) |
| Not reported and unknown | Day 1 | Vaccine | Positive | Anti N IgG (IU/ml) | 20 | 10 (10, 10) |
| Not reported and unknown | Day 1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 20 | 10 (10, 10) |
| Not reported and unknown | Day 1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 20 | 10 (10, 10) |
| Not reported and unknown | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 20 | 6 (5, 7) |
| Not reported and unknown | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 20 | 5 (5, 5) |
| Not reported and unknown | Day 1 | Placebo | Negative | Anti N IgG (IU/ml) | 14 | 10 (10, 10) |
| Not reported and unknown | Day 1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 14 | 10 (10, 10) |
| Not reported and unknown | Day 1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 14 | 10 (10, 10) |
| Not reported and unknown | Day 1 | Placebo | Negative | Pseudovirus-nAb ID50 | 14 | 5 (5, 5) |
| Not reported and unknown | Day 1 | Placebo | Negative | Pseudovirus-nAb ID80 | 14 | 5 (5, 5) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|--------------------------|--------|---------|---------------------|------------------------|----|---------------------------|
| Not reported and unknown | Day 1 | Placebo | Positive | Anti N IgG (IU/ml) | 24 | 11 (9, 14) |
| Not reported and unknown | Day 1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 24 | 10 (10, 10) |
| Not reported and unknown | Day 1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 24 | 10 (10, 10) |
| Not reported and unknown | Day 1 | Placebo | Positive | Pseudovirus-nAb ID50 | 24 | 6 (5, 7) |
| Not reported and unknown | Day 1 | Placebo | Positive | Pseudovirus-nAb ID80 | 24 | 5 (5, 6) |
| Not reported and unknown | Day 29 | Vaccine | Negative | Anti N IgG (IU/ml) | 87 | 19313 (11899, 31347) |
| Not reported and unknown | Day 29 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 87 | 19972 (12070, 33047) |
| Not reported and unknown | Day 29 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 87 | 41499 (27382, 62895) |
| Not reported and unknown | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID50 | 87 | 85 (51, 144) |
| Not reported and unknown | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID80 | 87 | 167 (114, 245) |
| Not reported and unknown | Day 29 | Vaccine | Positive | Anti N IgG (IU/ml) | 20 | 67460 (18205, 249984) |
| Not reported and unknown | Day 29 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 20 | 57668 (23639, 140684) |
| Not reported and unknown | Day 29 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 20 | 112437 (52711, 239834) |
| Not reported and unknown | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID50 | 20 | 348 (94, 1295) |
| Not reported and unknown | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID80 | 20 | 581 (199, 1695) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|--------------------------|--------|---------|---------------------|------------------------|----|-------------------------------|
| Not reported and unknown | Day 29 | Placebo | Negative | Anti N IgG (IU/ml) | 14 | 10 (10, 10) |
| Not reported and unknown | Day 29 | Placebo | Negative | Anti RBD IgG (IU/ml) | 14 | 10 (10, 10) |
| Not reported and unknown | Day 29 | Placebo | Negative | Anti Spike IgG (IU/ml) | 14 | 10 (10, 10) |
| Not reported and unknown | Day 29 | Placebo | Negative | Pseudovirus-nAb ID50 | 14 | 5 (5, 6) |
| Not reported and unknown | Day 29 | Placebo | Negative | Pseudovirus-nAb ID80 | 14 | 5 (5, 5) |
| Not reported and unknown | Day 29 | Placebo | Positive | Anti N IgG (IU/ml) | 24 | 15732 (6215, 39822) |
| Not reported and unknown | Day 29 | Placebo | Positive | Anti RBD IgG (IU/ml) | 24 | 11890 (6465, 21867) |
| Not reported and unknown | Day 29 | Placebo | Positive | Anti Spike IgG (IU/ml) | 24 | 17779 (10512, 30069) |
| Not reported and unknown | Day 29 | Placebo | Positive | Pseudovirus-nAb ID50 | 24 | 46 (19, 111) |
| Not reported and unknown | Day 29 | Placebo | Positive | Pseudovirus-nAb ID80 | 24 | 168 (59, 476) |
| Not reported and unknown | Day 57 | Vaccine | Negative | Anti N IgG (IU/ml) | 87 | 313760 (169470, 580901) |
| Not reported and unknown | Day 57 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 87 | 958206 (602856, 1523015) |
| Not reported and unknown | Day 57 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 87 | 1898203 (1201387, 2999181) |
| Not reported and unknown | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID50 | 87 | 1331 (758, 2339) |
| Not reported and unknown | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID80 | 87 | 2345 (1156, 4755) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|--------------------------|--------|---------|---------------------|------------------------|----|--------------------------------|
| Not reported and unknown | Day 57 | Vaccine | Positive | Anti N IgG (IU/ml) | 20 | 1890562 (655546, 5452282) |
| Not reported and unknown | Day 57 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 20 | 3239260 (1199389, 8748461) |
| Not reported and unknown | Day 57 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 20 | 9280577 (5784309, 14890128) |
| Not reported and unknown | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID50 | 20 | 11045 (3104, 39295) |
| Not reported and unknown | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID80 | 20 | 5210 (1481, 18320) |
| Not reported and unknown | Day 57 | Placebo | Negative | Anti N IgG (IU/ml) | 14 | 10 (10, 10) |
| Not reported and unknown | Day 57 | Placebo | Negative | Anti RBD IgG (IU/ml) | 14 | 10 (10, 10) |
| Not reported and unknown | Day 57 | Placebo | Negative | Anti Spike IgG (IU/ml) | 14 | 10 (10, 10) |
| Not reported and unknown | Day 57 | Placebo | Negative | Pseudovirus-nAb ID50 | 14 | 5 (5, 5) |
| Not reported and unknown | Day 57 | Placebo | Negative | Pseudovirus-nAb ID80 | 14 | 5 (5, 5) |
| Not reported and unknown | Day 57 | Placebo | Positive | Anti N IgG (IU/ml) | 24 | 212439 (58037, 777613) |
| Not reported and unknown | Day 57 | Placebo | Positive | Anti RBD IgG (IU/ml) | 24 | 401782 (153583, 1051084) |
| Not reported and unknown | Day 57 | Placebo | Positive | Anti Spike IgG (IU/ml) | 24 | 645039 (295340, 1408800) |
| Not reported and unknown | Day 57 | Placebo | Positive | Pseudovirus-nAb ID50 | 24 | 485 (159, 1481) |
| Not reported and unknown | Day 57 | Placebo | Positive | Pseudovirus-nAb ID80 | 24 | 1124 (299, 4219) |

Table 5i. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Underrepresented minority status

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|---|-------|---------|---------------------|------------------------|-----|----------------|
| Underrepresented minority status | | | | | | |
| Communities of Color | Day 1 | Vaccine | Negative | Anti N IgG (IU/ml) | 420 | 10 (10, 10) |
| Communities of Color | Day 1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 420 | 10 (10, 10) |
| Communities of Color | Day 1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 420 | 10 (10, 10) |
| Communities of Color | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 420 | 5 (5, 5) |
| Communities of Color | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 420 | 5 (5, 5) |
| Communities of Color | Day 1 | Vaccine | Positive | Anti N IgG (IU/ml) | 120 | 10 (10, 10) |
| Communities of Color | Day 1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 120 | 10 (10, 10) |
| Communities of Color | Day 1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 120 | 10 (10, 10) |
| Communities of Color | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 120 | 5 (5, 5) |
| Communities of Color | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 120 | 5 (5, 6) |
| Communities of Color | Day 1 | Placebo | Negative | Anti N IgG (IU/ml) | 73 | 10 (10, 10) |
| Communities of Color | Day 1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 73 | 10 (10, 10) |
| Communities of Color | Day 1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 73 | 10 (10, 10) |
| Communities of Color | Day 1 | Placebo | Negative | Pseudovirus-nAb ID50 | 73 | 5 (5, 5) |
| Communities of Color | Day 1 | Placebo | Negative | Pseudovirus-nAb ID80 | 73 | 5 (5, 5) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|----------------------|--------|---------|---------------------|------------------------|-----|--------------------------|
| Communities of Color | Day 1 | Placebo | Positive | Anti N IgG (IU/ml) | 111 | 10 (10, 10) |
| Communities of Color | Day 1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 111 | 10 (10, 10) |
| Communities of Color | Day 1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 111 | 10 (10, 10) |
| Communities of Color | Day 1 | Placebo | Positive | Pseudovirus-nAb ID50 | 111 | 5 (5, 6) |
| Communities of Color | Day 1 | Placebo | Positive | Pseudovirus-nAb ID80 | 111 | 5 (5, 5) |
| Communities of Color | Day 29 | Vaccine | Negative | Anti N IgG (IU/ml) | 420 | 21539 (16824, 27575) |
| Communities of Color | Day 29 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 420 | 23355 (19242, 28347) |
| Communities of Color | Day 29 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 420 | 40216 (34320, 47124) |
| Communities of Color | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID50 | 420 | 99 (79, 124) |
| Communities of Color | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID80 | 420 | 208 (163, 266) |
| Communities of Color | Day 29 | Vaccine | Positive | Anti N IgG (IU/ml) | 120 | 59825 (42571, 84073) |
| Communities of Color | Day 29 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 120 | 44605 (32113, 61955) |
| Communities of Color | Day 29 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 120 | 90964 (70627, 117156) |
| Communities of Color | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID50 | 120 | 238 (171, 332) |
| Communities of Color | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID80 | 120 | 545 (371, 802) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|----------------------|--------|---------|---------------------|------------------------|-----|-------------------------------|
| Communities of Color | Day 29 | Placebo | Negative | Anti N IgG (IU/ml) | 73 | 10 (10, 10) |
| Communities of Color | Day 29 | Placebo | Negative | Anti RBD IgG (IU/ml) | 73 | 10 (10, 10) |
| Communities of Color | Day 29 | Placebo | Negative | Anti Spike IgG (IU/ml) | 73 | 10 (10, 10) |
| Communities of Color | Day 29 | Placebo | Negative | Pseudovirus-nAb ID50 | 73 | 5 (5, 5) |
| Communities of Color | Day 29 | Placebo | Negative | Pseudovirus-nAb ID80 | 73 | 5 (5, 6) |
| Communities of Color | Day 29 | Placebo | Positive | Anti N IgG (IU/ml) | 111 | 12076 (7763, 18784) |
| Communities of Color | Day 29 | Placebo | Positive | Anti RBD IgG (IU/ml) | 111 | 17596 (12331, 25109) |
| Communities of Color | Day 29 | Placebo | Positive | Anti Spike IgG (IU/ml) | 111 | 18884 (13334, 26743) |
| Communities of Color | Day 29 | Placebo | Positive | Pseudovirus-nAb ID50 | 111 | 54 (34, 84) |
| Communities of Color | Day 29 | Placebo | Positive | Pseudovirus-nAb ID80 | 111 | 178 (110, 288) |
| Communities of Color | Day 57 | Vaccine | Negative | Anti N IgG (IU/ml) | 420 | 358864 (270757, 475643) |
| Communities of Color | Day 57 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 420 | 977894 (775549, 1233031) |
| Communities of Color | Day 57 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 420 | 2083276 (1732503, 2505069) |
| Communities of Color | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID50 | 420 | 1903 (1416, 2557) |
| Communities of Color | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID80 | 420 | 2744 (2021, 3725) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|----------------------|--------|---------|---------------------|------------------------|-----|-------------------------------|
| Communities of Color | Day 57 | Vaccine | Positive | Anti N IgG (IU/ml) | 120 | 1149410 (702292, 1881190) |
| Communities of Color | Day 57 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 120 | 3146770 (2273084, 4356267) |
| Communities of Color | Day 57 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 120 | 5991417 (4527248, 7929117) |
| Communities of Color | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID50 | 120 | 7086 (4582, 10956) |
| Communities of Color | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID80 | 120 | 8885 (5903, 13374) |
| Communities of Color | Day 57 | Placebo | Negative | Anti N IgG (IU/ml) | 73 | 10 (10, 10) |
| Communities of Color | Day 57 | Placebo | Negative | Anti RBD IgG (IU/ml) | 73 | 10 (10, 10) |
| Communities of Color | Day 57 | Placebo | Negative | Anti Spike IgG (IU/ml) | 73 | 10 (10, 10) |
| Communities of Color | Day 57 | Placebo | Negative | Pseudovirus-nAb ID50 | 73 | 5 (5, 5) |
| Communities of Color | Day 57 | Placebo | Negative | Pseudovirus-nAb ID80 | 73 | 5 (5, 5) |
| Communities of Color | Day 57 | Placebo | Positive | Anti N IgG (IU/ml) | 111 | 193321 (112530, 332117) |
| Communities of Color | Day 57 | Placebo | Positive | Anti RBD IgG (IU/ml) | 111 | 397884 (256621, 616908) |
| Communities of Color | Day 57 | Placebo | Positive | Anti Spike IgG (IU/ml) | 111 | 734879 (489927, 1102301) |
| Communities of Color | Day 57 | Placebo | Positive | Pseudovirus-nAb ID50 | 111 | 684 (382, 1222) |
| Communities of Color | Day 57 | Placebo | Positive | Pseudovirus-nAb ID80 | 111 | 1409 (809, 2454) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|--------------------|-------|---------|---------------------|------------------------|-----|----------------|
| White Non-Hispanic | Day 1 | Vaccine | Negative | Anti N IgG (IU/ml) | 362 | 10 (10, 10) |
| White Non-Hispanic | Day 1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 362 | 10 (10, 10) |
| White Non-Hispanic | Day 1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 362 | 10 (10, 10) |
| White Non-Hispanic | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 362 | 5 (5, 5) |
| White Non-Hispanic | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 362 | 5 (5, 5) |
| White Non-Hispanic | Day 1 | Vaccine | Positive | Anti N IgG (IU/ml) | 125 | 10 (10, 10) |
| White Non-Hispanic | Day 1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 125 | 10 (10, 10) |
| White Non-Hispanic | Day 1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 125 | 10 (10, 10) |
| White Non-Hispanic | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 125 | 5 (5, 5) |
| White Non-Hispanic | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 125 | 5 (5, 5) |
| White Non-Hispanic | Day 1 | Placebo | Negative | Anti N IgG (IU/ml) | 67 | 10 (10, 11) |
| White Non-Hispanic | Day 1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 67 | 10 (10, 10) |
| White Non-Hispanic | Day 1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 67 | 10 (10, 10) |
| White Non-Hispanic | Day 1 | Placebo | Negative | Pseudovirus-nAb ID50 | 67 | 5 (5, 5) |
| White Non-Hispanic | Day 1 | Placebo | Negative | Pseudovirus-nAb ID80 | 67 | 5 (5, 6) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|--------------------|--------|---------|---------------------|------------------------|-----|-------------------------|
| White Non-Hispanic | Day 1 | Placebo | Positive | Anti N IgG (IU/ml) | 121 | 10 (10, 10) |
| White Non-Hispanic | Day 1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 121 | 10 (10, 10) |
| White Non-Hispanic | Day 1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 121 | 10 (10, 10) |
| White Non-Hispanic | Day 1 | Placebo | Positive | Pseudovirus-nAb ID50 | 121 | 5 (5, 5) |
| White Non-Hispanic | Day 1 | Placebo | Positive | Pseudovirus-nAb ID80 | 121 | 5 (5, 5) |
| White Non-Hispanic | Day 29 | Vaccine | Negative | Anti N IgG (IU/ml) | 362 | 26952 (20883, 34784) |
| White Non-Hispanic | Day 29 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 362 | 23438 (18669, 29425) |
| White Non-Hispanic | Day 29 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 362 | 40376 (34349, 47460) |
| White Non-Hispanic | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID50 | 362 | 115 (90, 147) |
| White Non-Hispanic | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID80 | 362 | 188 (146, 241) |
| White Non-Hispanic | Day 29 | Vaccine | Positive | Anti N IgG (IU/ml) | 125 | 33909 (24023, 47863) |
| White Non-Hispanic | Day 29 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 125 | 30985 (21434, 44793) |
| White Non-Hispanic | Day 29 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 125 | 72481 (53061, 99008) |
| White Non-Hispanic | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID50 | 125 | 148 (104, 211) |
| White Non-Hispanic | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID80 | 125 | 348 (226, 535) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|--------------------|--------|---------|---------------------|------------------------|-----|-------------------------------|
| White Non-Hispanic | Day 29 | Placebo | Negative | Anti N IgG (IU/ml) | 67 | 10 (10, 10) |
| White Non-Hispanic | Day 29 | Placebo | Negative | Anti RBD IgG (IU/ml) | 67 | 10 (10, 10) |
| White Non-Hispanic | Day 29 | Placebo | Negative | Anti Spike IgG (IU/ml) | 67 | 10 (10, 10) |
| White Non-Hispanic | Day 29 | Placebo | Negative | Pseudovirus-nAb ID50 | 67 | 5 (5, 5) |
| White Non-Hispanic | Day 29 | Placebo | Negative | Pseudovirus-nAb ID80 | 67 | 5 (5, 5) |
| White Non-Hispanic | Day 29 | Placebo | Positive | Anti N IgG (IU/ml) | 121 | 12594 (8382, 18924) |
| White Non-Hispanic | Day 29 | Placebo | Positive | Anti RBD IgG (IU/ml) | 121 | 10931 (7560, 15804) |
| White Non-Hispanic | Day 29 | Placebo | Positive | Anti Spike IgG (IU/ml) | 121 | 18868 (14808, 24043) |
| White Non-Hispanic | Day 29 | Placebo | Positive | Pseudovirus-nAb ID50 | 121 | 52 (37, 74) |
| White Non-Hispanic | Day 29 | Placebo | Positive | Pseudovirus-nAb ID80 | 121 | 107 (76, 150) |
| White Non-Hispanic | Day 57 | Vaccine | Negative | Anti N IgG (IU/ml) | 362 | 328428 (241933, 445846) |
| White Non-Hispanic | Day 57 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 362 | 1035293 (809568, 1323956) |
| White Non-Hispanic | Day 57 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 362 | 2145772 (1770774, 2600184) |
| White Non-Hispanic | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID50 | 362 | 1376 (1010, 1874) |
| White Non-Hispanic | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID80 | 362 | 2011 (1465, 2761) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|--------------------|--------|---------|---------------------|------------------------|-----|-------------------------------|
| White Non-Hispanic | Day 57 | Vaccine | Positive | Anti N IgG (IU/ml) | 125 | 855574 (517613, 1414198) |
| White Non-Hispanic | Day 57 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 125 | 1943813 (1349835, 2799166) |
| White Non-Hispanic | Day 57 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 125 | 4608987 (3338577, 6362819) |
| White Non-Hispanic | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID50 | 125 | 4550 (2471, 8378) |
| White Non-Hispanic | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID80 | 125 | 7994 (4646, 13757) |
| White Non-Hispanic | Day 57 | Placebo | Negative | Anti N IgG (IU/ml) | 67 | 10 (10, 10) |
| White Non-Hispanic | Day 57 | Placebo | Negative | Anti RBD IgG (IU/ml) | 67 | 10 (10, 10) |
| White Non-Hispanic | Day 57 | Placebo | Negative | Anti Spike IgG (IU/ml) | 67 | 10 (10, 10) |
| White Non-Hispanic | Day 57 | Placebo | Negative | Pseudovirus-nAb ID50 | 67 | 5 (5, 5) |
| White Non-Hispanic | Day 57 | Placebo | Negative | Pseudovirus-nAb ID80 | 67 | 5 (5, 5) |
| White Non-Hispanic | Day 57 | Placebo | Positive | Anti N IgG (IU/ml) | 121 | 105260 (65764, 168478) |
| White Non-Hispanic | Day 57 | Placebo | Positive | Anti RBD IgG (IU/ml) | 121 | 393045 (287516, 537306) |
| White Non-Hispanic | Day 57 | Placebo | Positive | Anti Spike IgG (IU/ml) | 121 | 674526 (485396, 937351) |
| White Non-Hispanic | Day 57 | Placebo | Positive | Pseudovirus-nAb ID50 | 121 | 575 (371, 892) |
| White Non-Hispanic | Day 57 | Placebo | Positive | Pseudovirus-nAb ID80 | 121 | 1478 (953, 2292) |

Table 5j. Geometric mean titers (GMTs) and geometric mean concentrations (GMCs) by Age, Underrepresented minority status

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|--|-------|---------|---------------------|------------------------|-----|----------------|
| Age, Underrepresented minority status | | | | | | |
| Age < 65 Communities of Color | Day 1 | Vaccine | Negative | Anti N IgG (IU/ml) | 192 | 10 (10, 10) |
| Age < 65 Communities of Color | Day 1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 192 | 10 (10, 10) |
| Age < 65 Communities of Color | Day 1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 192 | 10 (10, 10) |
| Age < 65 Communities of Color | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 192 | 5 (5, 5) |
| Age < 65 Communities of Color | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 192 | 5 (5, 5) |
| Age < 65 Communities of Color | Day 1 | Vaccine | Positive | Anti N IgG (IU/ml) | 69 | 10 (10, 10) |
| Age < 65 Communities of Color | Day 1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 69 | 10 (10, 10) |
| Age < 65 Communities of Color | Day 1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 69 | 10 (10, 10) |
| Age < 65 Communities of Color | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 69 | 5 (5, 5) |
| Age < 65 Communities of Color | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 69 | 5 (5, 6) |
| Age < 65 Communities of Color | Day 1 | Placebo | Negative | Anti N IgG (IU/ml) | 37 | 10 (10, 10) |
| Age < 65 Communities of Color | Day 1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 37 | 10 (10, 10) |
| Age < 65 Communities of Color | Day 1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 37 | 10 (10, 10) |
| Age < 65 Communities of Color | Day 1 | Placebo | Negative | Pseudovirus-nAb ID50 | 37 | 5 (5, 5) |
| Age < 65 Communities of Color | Day 1 | Placebo | Negative | Pseudovirus-nAb ID80 | 37 | 5 (5, 5) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|-------------------------------|--------|---------|---------------------|------------------------|-----|-------------------------|
| Age < 65 Communities of Color | Day 1 | Placebo | Positive | Anti N IgG (IU/ml) | 61 | 10 (10, 10) |
| Age < 65 Communities of Color | Day 1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 61 | 10 (10, 10) |
| Age < 65 Communities of Color | Day 1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 61 | 10 (10, 10) |
| Age < 65 Communities of Color | Day 1 | Placebo | Positive | Pseudovirus-nAb ID50 | 61 | 5 (5, 6) |
| Age < 65 Communities of Color | Day 1 | Placebo | Positive | Pseudovirus-nAb ID80 | 61 | 5 (5, 5) |
| Age < 65 Communities of Color | Day 29 | Vaccine | Negative | Anti N IgG (IU/ml) | 192 | 16236 (11950, 22060) |
| Age < 65 Communities of Color | Day 29 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 192 | 17593 (13852, 22344) |
| Age < 65 Communities of Color | Day 29 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 192 | 30531 (25113, 37119) |
| Age < 65 Communities of Color | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID50 | 192 | 76 (58, 101) |
| Age < 65 Communities of Color | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID80 | 192 | 174 (128, 236) |
| Age < 65 Communities of Color | Day 29 | Vaccine | Positive | Anti N IgG (IU/ml) | 69 | 50828 (33992, 76001) |
| Age < 65 Communities of Color | Day 29 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 69 | 34937 (23612, 51692) |
| Age < 65 Communities of Color | Day 29 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 69 | 70998 (52424, 96153) |
| Age < 65 Communities of Color | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID50 | 69 | 209 (141, 310) |
| Age < 65 Communities of Color | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID80 | 69 | 484 (305, 768) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|-------------------------------|--------|---------|---------------------|------------------------|-----|-------------------------------|
| Age < 65 Communities of Color | Day 29 | Placebo | Negative | Anti N IgG (IU/ml) | 37 | 10 (10, 10) |
| Age < 65 Communities of Color | Day 29 | Placebo | Negative | Anti RBD IgG (IU/ml) | 37 | 10 (10, 10) |
| Age < 65 Communities of Color | Day 29 | Placebo | Negative | Anti Spike IgG (IU/ml) | 37 | 10 (10, 10) |
| Age < 65 Communities of Color | Day 29 | Placebo | Negative | Pseudovirus-nAb ID50 | 37 | 5 (5, 5) |
| Age < 65 Communities of Color | Day 29 | Placebo | Negative | Pseudovirus-nAb ID80 | 37 | 5 (5, 6) |
| Age < 65 Communities of Color | Day 29 | Placebo | Positive | Anti N IgG (IU/ml) | 61 | 9484 (5617, 16014) |
| Age < 65 Communities of Color | Day 29 | Placebo | Positive | Anti RBD IgG (IU/ml) | 61 | 13618 (8923, 20783) |
| Age < 65 Communities of Color | Day 29 | Placebo | Positive | Anti Spike IgG (IU/ml) | 61 | 13717 (9065, 20756) |
| Age < 65 Communities of Color | Day 29 | Placebo | Positive | Pseudovirus-nAb ID50 | 61 | 42 (25, 72) |
| Age < 65 Communities of Color | Day 29 | Placebo | Positive | Pseudovirus-nAb ID80 | 61 | 150 (84, 267) |
| Age < 65 Communities of Color | Day 57 | Vaccine | Negative | Anti N IgG (IU/ml) | 192 | 292558 (206172, 415140) |
| Age < 65 Communities of Color | Day 57 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 192 | 741900 (555661, 990562) |
| Age < 65 Communities of Color | Day 57 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 192 | 1629402 (1297120, 2046806) |
| Age < 65 Communities of Color | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID50 | 192 | 1435 (996, 2067) |
| Age < 65 Communities of Color | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID80 | 192 | 2230 (1526, 3260) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|-------------------------------|--------|---------|---------------------|------------------------|----|-------------------------------|
| Age < 65 Communities of Color | Day 57 | Vaccine | Positive | Anti N IgG (IU/ml) | 69 | 930919 (513604, 1687309) |
| Age < 65 Communities of Color | Day 57 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 69 | 2542683 (1712040, 3776334) |
| Age < 65 Communities of Color | Day 57 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 69 | 5081700 (3610831, 7151727) |
| Age < 65 Communities of Color | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID50 | 69 | 5550 (3299, 9337) |
| Age < 65 Communities of Color | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID80 | 69 | 7380 (4562, 11940) |
| Age < 65 Communities of Color | Day 57 | Placebo | Negative | Anti N IgG (IU/ml) | 37 | 10 (10, 10) |
| Age < 65 Communities of Color | Day 57 | Placebo | Negative | Anti RBD IgG (IU/ml) | 37 | 10 (10, 10) |
| Age < 65 Communities of Color | Day 57 | Placebo | Negative | Anti Spike IgG (IU/ml) | 37 | 10 (10, 10) |
| Age < 65 Communities of Color | Day 57 | Placebo | Negative | Pseudovirus-nAb ID50 | 37 | 5 (5, 5) |
| Age < 65 Communities of Color | Day 57 | Placebo | Negative | Pseudovirus-nAb ID80 | 37 | 5 (5, 5) |
| Age < 65 Communities of Color | Day 57 | Placebo | Positive | Anti N IgG (IU/ml) | 61 | 145989 (76394, 278984) |
| Age < 65 Communities of Color | Day 57 | Placebo | Positive | Anti RBD IgG (IU/ml) | 61 | 277278 (163947, 468952) |
| Age < 65 Communities of Color | Day 57 | Placebo | Positive | Anti Spike IgG (IU/ml) | 61 | 543679 (333997, 884998) |
| Age < 65 Communities of Color | Day 57 | Placebo | Positive | Pseudovirus-nAb ID50 | 61 | 466 (233, 933) |
| Age < 65 Communities of Color | Day 57 | Placebo | Positive | Pseudovirus-nAb ID80 | 61 | 1073 (554, 2078) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|-----------------------------|-------|---------|---------------------|------------------------|-----|----------------|
| Age < 65 White Non-Hispanic | Day 1 | Vaccine | Negative | Anti N IgG (IU/ml) | 175 | 10 (10, 10) |
| Age < 65 White Non-Hispanic | Day 1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 175 | 10 (10, 10) |
| Age < 65 White Non-Hispanic | Day 1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 175 | 10 (10, 10) |
| Age < 65 White Non-Hispanic | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 175 | 5 (5, 5) |
| Age < 65 White Non-Hispanic | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 175 | 5 (5, 5) |
| Age < 65 White Non-Hispanic | Day 1 | Vaccine | Positive | Anti N IgG (IU/ml) | 59 | 10 (10, 10) |
| Age < 65 White Non-Hispanic | Day 1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 59 | 10 (10, 10) |
| Age < 65 White Non-Hispanic | Day 1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 59 | 10 (10, 10) |
| Age < 65 White Non-Hispanic | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 59 | 5 (5, 5) |
| Age < 65 White Non-Hispanic | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 59 | 5 (5, 5) |
| Age < 65 White Non-Hispanic | Day 1 | Placebo | Negative | Anti N IgG (IU/ml) | 31 | 10 (10, 11) |
| Age < 65 White Non-Hispanic | Day 1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 31 | 10 (10, 10) |
| Age < 65 White Non-Hispanic | Day 1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 31 | 10 (10, 10) |
| Age < 65 White Non-Hispanic | Day 1 | Placebo | Negative | Pseudovirus-nAb ID50 | 31 | 5 (5, 5) |
| Age < 65 White Non-Hispanic | Day 1 | Placebo | Negative | Pseudovirus-nAb ID80 | 31 | 5 (5, 6) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|-----------------------------|--------|---------|---------------------|------------------------|-----|-------------------------|
| Age < 65 White Non-Hispanic | Day 1 | Placebo | Positive | Anti N IgG (IU/ml) | 61 | 10 (10, 10) |
| Age < 65 White Non-Hispanic | Day 1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 61 | 10 (10, 10) |
| Age < 65 White Non-Hispanic | Day 1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 61 | 10 (10, 10) |
| Age < 65 White Non-Hispanic | Day 1 | Placebo | Positive | Pseudovirus-nAb ID50 | 61 | 5 (5, 5) |
| Age < 65 White Non-Hispanic | Day 1 | Placebo | Positive | Pseudovirus-nAb ID80 | 61 | 5 (5, 5) |
| Age < 65 White Non-Hispanic | Day 29 | Vaccine | Negative | Anti N IgG (IU/ml) | 175 | 22546 (16449, 30904) |
| Age < 65 White Non-Hispanic | Day 29 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 175 | 18239 (13758, 24181) |
| Age < 65 White Non-Hispanic | Day 29 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 175 | 31442 (25791, 38330) |
| Age < 65 White Non-Hispanic | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID50 | 175 | 98 (72, 132) |
| Age < 65 White Non-Hispanic | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID80 | 175 | 163 (120, 222) |
| Age < 65 White Non-Hispanic | Day 29 | Vaccine | Positive | Anti N IgG (IU/ml) | 59 | 22816 (14927, 34875) |
| Age < 65 White Non-Hispanic | Day 29 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 59 | 19045 (11981, 30275) |
| Age < 65 White Non-Hispanic | Day 29 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 59 | 50450 (34089, 74664) |
| Age < 65 White Non-Hispanic | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID50 | 59 | 100 (65, 155) |
| Age < 65 White Non-Hispanic | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID80 | 59 | 255 (148, 438) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|-----------------------------|--------|---------|---------------------|------------------------|-----|-------------------------------|
| Age < 65 White Non-Hispanic | Day 29 | Placebo | Negative | Anti N IgG (IU/ml) | 31 | 10 (10, 10) |
| Age < 65 White Non-Hispanic | Day 29 | Placebo | Negative | Anti RBD IgG (IU/ml) | 31 | 10 (10, 10) |
| Age < 65 White Non-Hispanic | Day 29 | Placebo | Negative | Anti Spike IgG (IU/ml) | 31 | 10 (10, 10) |
| Age < 65 White Non-Hispanic | Day 29 | Placebo | Negative | Pseudovirus-nAb ID50 | 31 | 5 (5, 5) |
| Age < 65 White Non-Hispanic | Day 29 | Placebo | Negative | Pseudovirus-nAb ID80 | 31 | 5 (5, 5) |
| Age < 65 White Non-Hispanic | Day 29 | Placebo | Positive | Anti N IgG (IU/ml) | 61 | 9218 (5562, 15276) |
| Age < 65 White Non-Hispanic | Day 29 | Placebo | Positive | Anti RBD IgG (IU/ml) | 61 | 7844 (4943, 12447) |
| Age < 65 White Non-Hispanic | Day 29 | Placebo | Positive | Anti Spike IgG (IU/ml) | 61 | 13337 (9897, 17972) |
| Age < 65 White Non-Hispanic | Day 29 | Placebo | Positive | Pseudovirus-nAb ID50 | 61 | 38 (25, 58) |
| Age < 65 White Non-Hispanic | Day 29 | Placebo | Positive | Pseudovirus-nAb ID80 | 61 | 78 (51, 118) |
| Age < 65 White Non-Hispanic | Day 57 | Vaccine | Negative | Anti N IgG (IU/ml) | 175 | 264562 (181376, 385898) |
| Age < 65 White Non-Hispanic | Day 57 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 175 | 821667 (605817, 1114423) |
| Age < 65 White Non-Hispanic | Day 57 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 175 | 1724310 (1360533, 2185355) |
| Age < 65 White Non-Hispanic | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID50 | 175 | 1085 (742, 1587) |
| Age < 65 White Non-Hispanic | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID80 | 175 | 1624 (1097, 2405) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|-----------------------------|--------|---------|---------------------|------------------------|----|-------------------------------|
| Age < 65 White Non-Hispanic | Day 57 | Vaccine | Positive | Anti N IgG (IU/ml) | 59 | 596002 (316557, 1122130) |
| Age < 65 White Non-Hispanic | Day 57 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 59 | 1330657 (839177, 2109982) |
| Age < 65 White Non-Hispanic | Day 57 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 59 | 3419951 (2265916, 5161739) |
| Age < 65 White Non-Hispanic | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID50 | 59 | 2838 (1308, 6159) |
| Age < 65 White Non-Hispanic | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID80 | 59 | 6125 (3095, 12121) |
| Age < 65 White Non-Hispanic | Day 57 | Placebo | Negative | Anti N IgG (IU/ml) | 31 | 10 (10, 10) |
| Age < 65 White Non-Hispanic | Day 57 | Placebo | Negative | Anti RBD IgG (IU/ml) | 31 | 10 (10, 10) |
| Age < 65 White Non-Hispanic | Day 57 | Placebo | Negative | Anti Spike IgG (IU/ml) | 31 | 10 (10, 10) |
| Age < 65 White Non-Hispanic | Day 57 | Placebo | Negative | Pseudovirus-nAb ID50 | 31 | 5 (5, 5) |
| Age < 65 White Non-Hispanic | Day 57 | Placebo | Negative | Pseudovirus-nAb ID80 | 31 | 5 (5, 5) |
| Age < 65 White Non-Hispanic | Day 57 | Placebo | Positive | Anti N IgG (IU/ml) | 61 | 69600 (38639, 125369) |
| Age < 65 White Non-Hispanic | Day 57 | Placebo | Positive | Anti RBD IgG (IU/ml) | 61 | 264698 (179593, 390131) |
| Age < 65 White Non-Hispanic | Day 57 | Placebo | Positive | Anti Spike IgG (IU/ml) | 61 | 451492 (299075, 681584) |
| Age < 65 White Non-Hispanic | Day 57 | Placebo | Positive | Pseudovirus-nAb ID50 | 61 | 376 (219, 646) |
| Age < 65 White Non-Hispanic | Day 57 | Placebo | Positive | Pseudovirus-nAb ID80 | 61 | 1102 (639, 1903) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|------------------------------------|-------|---------|---------------------|------------------------|-----|----------------|
| Age \geq 65 Communities of Color | Day 1 | Vaccine | Negative | Anti N IgG (IU/ml) | 228 | 10 (10, 10) |
| Age \geq 65 Communities of Color | Day 1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 228 | 10 (10, 10) |
| Age \geq 65 Communities of Color | Day 1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 228 | 10 (10, 10) |
| Age \geq 65 Communities of Color | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 228 | 5 (5, 5) |
| Age \geq 65 Communities of Color | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 228 | 5 (5, 5) |
| Age \geq 65 Communities of Color | Day 1 | Vaccine | Positive | Anti N IgG (IU/ml) | 51 | 10 (10, 11) |
| Age \geq 65 Communities of Color | Day 1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 51 | 10 (10, 10) |
| Age \geq 65 Communities of Color | Day 1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 51 | 10 (10, 10) |
| Age \geq 65 Communities of Color | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 51 | 5 (5, 6) |
| Age \geq 65 Communities of Color | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 51 | 5 (5, 5) |
| Age \geq 65 Communities of Color | Day 1 | Placebo | Negative | Anti N IgG (IU/ml) | 36 | 10 (10, 10) |
| Age \geq 65 Communities of Color | Day 1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 36 | 10 (10, 10) |
| Age \geq 65 Communities of Color | Day 1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 36 | 10 (10, 10) |
| Age \geq 65 Communities of Color | Day 1 | Placebo | Negative | Pseudovirus-nAb ID50 | 36 | 5 (5, 5) |
| Age \geq 65 Communities of Color | Day 1 | Placebo | Negative | Pseudovirus-nAb ID80 | 36 | 5 (5, 5) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|------------------------------------|--------|---------|---------------------|------------------------|-----|----------------------------|
| Age \geq 65 Communities of Color | Day 1 | Placebo | Positive | Anti N IgG (IU/ml) | 50 | 10 (10, 11) |
| Age \geq 65 Communities of Color | Day 1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 50 | 10 (10, 10) |
| Age \geq 65 Communities of Color | Day 1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 50 | 10 (10, 10) |
| Age \geq 65 Communities of Color | Day 1 | Placebo | Positive | Pseudovirus-nAb ID50 | 50 | 5 (5, 5) |
| Age \geq 65 Communities of Color | Day 1 | Placebo | Positive | Pseudovirus-nAb ID80 | 50 | 5 (5, 6) |
| Age \geq 65 Communities of Color | Day 29 | Vaccine | Negative | Anti N IgG (IU/ml) | 228 | 62158 (49075, 78729) |
| Age \geq 65 Communities of Color | Day 29 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 228 | 67566 (54928, 83111) |
| Age \geq 65 Communities of Color | Day 29 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 228 | 113000 (94968, 134457) |
| Age \geq 65 Communities of Color | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID50 | 228 | 263 (208, 334) |
| Age \geq 65 Communities of Color | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID80 | 228 | 409 (322, 520) |
| Age \geq 65 Communities of Color | Day 29 | Vaccine | Positive | Anti N IgG (IU/ml) | 51 | 120781 (72698, 200668) |
| Age \geq 65 Communities of Color | Day 29 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 51 | 127850 (82403, 198362) |
| Age \geq 65 Communities of Color | Day 29 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 51 | 264698 (193965, 361225) |
| Age \geq 65 Communities of Color | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID50 | 51 | 414 (254, 674) |
| Age \geq 65 Communities of Color | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID80 | 51 | 911 (557, 1491) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|------------------------------------|--------|---------|---------------------|------------------------|-----|-------------------------------|
| Age \geq 65 Communities of Color | Day 29 | Placebo | Negative | Anti N IgG (IU/ml) | 36 | 10 (10, 10) |
| Age \geq 65 Communities of Color | Day 29 | Placebo | Negative | Anti RBD IgG (IU/ml) | 36 | 10 (10, 10) |
| Age \geq 65 Communities of Color | Day 29 | Placebo | Negative | Anti Spike IgG (IU/ml) | 36 | 10 (10, 10) |
| Age \geq 65 Communities of Color | Day 29 | Placebo | Negative | Pseudovirus-nAb ID50 | 36 | 5 (5, 5) |
| Age \geq 65 Communities of Color | Day 29 | Placebo | Negative | Pseudovirus-nAb ID80 | 36 | 5 (5, 5) |
| Age \geq 65 Communities of Color | Day 29 | Placebo | Positive | Anti N IgG (IU/ml) | 50 | 36935 (21250, 64196) |
| Age \geq 65 Communities of Color | Day 29 | Placebo | Positive | Anti RBD IgG (IU/ml) | 50 | 57615 (37847, 87707) |
| Age \geq 65 Communities of Color | Day 29 | Placebo | Positive | Anti Spike IgG (IU/ml) | 50 | 82913 (55530, 123801) |
| Age \geq 65 Communities of Color | Day 29 | Placebo | Positive | Pseudovirus-nAb ID50 | 50 | 167 (101, 276) |
| Age \geq 65 Communities of Color | Day 29 | Placebo | Positive | Pseudovirus-nAb ID80 | 50 | 390 (234, 650) |
| Age \geq 65 Communities of Color | Day 57 | Vaccine | Negative | Anti N IgG (IU/ml) | 228 | 771969 (594098, 1003095) |
| Age \geq 65 Communities of Color | Day 57 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 228 | 2754587 (2268630, 3344640) |
| Age \geq 65 Communities of Color | Day 57 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 228 | 5234940 (4335352, 6321193) |
| Age \geq 65 Communities of Color | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID50 | 228 | 5478 (4015, 7473) |
| Age \geq 65 Communities of Color | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID80 | 228 | 5966 (4475, 7954) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|------------------------------------|--------|---------|---------------------|------------------------|----|---------------------------------|
| Age \geq 65 Communities of Color | Day 57 | Vaccine | Positive | Anti N IgG (IU/ml) | 51 | 2851970 (1691139, 4809619) |
| Age \geq 65 Communities of Color | Day 57 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 51 | 7886529 (5982602, 10396367) |
| Age \geq 65 Communities of Color | Day 57 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 51 | 12184499 (9858697, 15058989) |
| Age \geq 65 Communities of Color | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID50 | 51 | 20307 (11438, 36054) |
| Age \geq 65 Communities of Color | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID80 | 51 | 19769 (10376, 37665) |
| Age \geq 65 Communities of Color | Day 57 | Placebo | Negative | Anti N IgG (IU/ml) | 36 | 10 (10, 10) |
| Age \geq 65 Communities of Color | Day 57 | Placebo | Negative | Anti RBD IgG (IU/ml) | 36 | 10 (10, 10) |
| Age \geq 65 Communities of Color | Day 57 | Placebo | Negative | Anti Spike IgG (IU/ml) | 36 | 10 (10, 10) |
| Age \geq 65 Communities of Color | Day 57 | Placebo | Negative | Pseudovirus-nAb ID50 | 36 | 5 (5, 5) |
| Age \geq 65 Communities of Color | Day 57 | Placebo | Negative | Pseudovirus-nAb ID80 | 36 | 5 (5, 5) |
| Age \geq 65 Communities of Color | Day 57 | Placebo | Positive | Anti N IgG (IU/ml) | 50 | 709142 (413162, 1217155) |
| Age \geq 65 Communities of Color | Day 57 | Placebo | Positive | Anti RBD IgG (IU/ml) | 50 | 2116643 (1388474, 3226693) |
| Age \geq 65 Communities of Color | Day 57 | Placebo | Positive | Anti Spike IgG (IU/ml) | 50 | 2964324 (2089369, 4205680) |
| Age \geq 65 Communities of Color | Day 57 | Placebo | Positive | Pseudovirus-nAb ID50 | 50 | 4026 (2199, 7373) |
| Age \geq 65 Communities of Color | Day 57 | Placebo | Positive | Pseudovirus-nAb ID80 | 50 | 4985 (2691, 9234) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|----------------------------------|-------|---------|---------------------|------------------------|-----|----------------|
| Age \geq 65 White Non-Hispanic | Day 1 | Vaccine | Negative | Anti N IgG (IU/ml) | 187 | 10 (10, 10) |
| Age \geq 65 White Non-Hispanic | Day 1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 187 | 10 (10, 10) |
| Age \geq 65 White Non-Hispanic | Day 1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 187 | 10 (10, 10) |
| Age \geq 65 White Non-Hispanic | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 187 | 5 (5, 5) |
| Age \geq 65 White Non-Hispanic | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 187 | 5 (5, 5) |
| Age \geq 65 White Non-Hispanic | Day 1 | Vaccine | Positive | Anti N IgG (IU/ml) | 66 | 10 (10, 10) |
| Age \geq 65 White Non-Hispanic | Day 1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 66 | 10 (10, 10) |
| Age \geq 65 White Non-Hispanic | Day 1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 66 | 10 (10, 10) |
| Age \geq 65 White Non-Hispanic | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 66 | 5 (5, 6) |
| Age \geq 65 White Non-Hispanic | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 66 | 5 (5, 5) |
| Age \geq 65 White Non-Hispanic | Day 1 | Placebo | Negative | Anti N IgG (IU/ml) | 36 | 10 (10, 10) |
| Age \geq 65 White Non-Hispanic | Day 1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 36 | 10 (10, 10) |
| Age \geq 65 White Non-Hispanic | Day 1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 36 | 10 (10, 10) |
| Age \geq 65 White Non-Hispanic | Day 1 | Placebo | Negative | Pseudovirus-nAb ID50 | 36 | 5 (5, 5) |
| Age \geq 65 White Non-Hispanic | Day 1 | Placebo | Negative | Pseudovirus-nAb ID80 | 36 | 5 (5, 5) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|----------------------------------|--------|---------|---------------------|------------------------|-----|----------------------------|
| Age \geq 65 White Non-Hispanic | Day 1 | Placebo | Positive | Anti N IgG (IU/ml) | 60 | 10 (10, 10) |
| Age \geq 65 White Non-Hispanic | Day 1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 60 | 10 (10, 10) |
| Age \geq 65 White Non-Hispanic | Day 1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 60 | 10 (10, 10) |
| Age \geq 65 White Non-Hispanic | Day 1 | Placebo | Positive | Pseudovirus-nAb ID50 | 60 | 5 (5, 5) |
| Age \geq 65 White Non-Hispanic | Day 1 | Placebo | Positive | Pseudovirus-nAb ID80 | 60 | 5 (5, 5) |
| Age \geq 65 White Non-Hispanic | Day 29 | Vaccine | Negative | Anti N IgG (IU/ml) | 187 | 52931 (40926, 68456) |
| Age \geq 65 White Non-Hispanic | Day 29 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 187 | 60501 (48781, 75037) |
| Age \geq 65 White Non-Hispanic | Day 29 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 187 | 103956 (85919, 125780) |
| Age \geq 65 White Non-Hispanic | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID50 | 187 | 214 (164, 280) |
| Age \geq 65 White Non-Hispanic | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID80 | 187 | 317 (243, 412) |
| Age \geq 65 White Non-Hispanic | Day 29 | Vaccine | Positive | Anti N IgG (IU/ml) | 66 | 136437 (87480, 212792) |
| Age \geq 65 White Non-Hispanic | Day 29 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 66 | 171330 (122104, 240402) |
| Age \geq 65 White Non-Hispanic | Day 29 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 66 | 258922 (193660, 346179) |
| Age \geq 65 White Non-Hispanic | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID50 | 66 | 575 (355, 932) |
| Age \geq 65 White Non-Hispanic | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID80 | 66 | 1037 (709, 1518) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|-----------------------------|--------|---------|---------------------|------------------------|-----|-------------------------------|
| Age ≥ 65 White Non-Hispanic | Day 29 | Placebo | Negative | Anti N IgG (IU/ml) | 36 | 10 (10, 10) |
| Age ≥ 65 White Non-Hispanic | Day 29 | Placebo | Negative | Anti RBD IgG (IU/ml) | 36 | 10 (10, 10) |
| Age ≥ 65 White Non-Hispanic | Day 29 | Placebo | Negative | Anti Spike IgG (IU/ml) | 36 | 10 (10, 10) |
| Age ≥ 65 White Non-Hispanic | Day 29 | Placebo | Negative | Pseudovirus-nAb ID50 | 36 | 5 (5, 5) |
| Age ≥ 65 White Non-Hispanic | Day 29 | Placebo | Negative | Pseudovirus-nAb ID80 | 36 | 5 (5, 5) |
| Age ≥ 65 White Non-Hispanic | Day 29 | Placebo | Positive | Anti N IgG (IU/ml) | 60 | 37306 (22911, 60744) |
| Age ≥ 65 White Non-Hispanic | Day 29 | Placebo | Positive | Anti RBD IgG (IU/ml) | 60 | 34684 (23682, 50795) |
| Age ≥ 65 White Non-Hispanic | Day 29 | Placebo | Positive | Anti Spike IgG (IU/ml) | 60 | 63090 (45886, 86746) |
| Age ≥ 65 White Non-Hispanic | Day 29 | Placebo | Positive | Pseudovirus-nAb ID50 | 60 | 160 (99, 257) |
| Age ≥ 65 White Non-Hispanic | Day 29 | Placebo | Positive | Pseudovirus-nAb ID80 | 60 | 323 (207, 502) |
| Age ≥ 65 White Non-Hispanic | Day 57 | Vaccine | Negative | Anti N IgG (IU/ml) | 187 | 744013 (543887, 1017778) |
| Age ≥ 65 White Non-Hispanic | Day 57 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 187 | 2480906 (1963293, 3134986) |
| Age ≥ 65 White Non-Hispanic | Day 57 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 187 | 4905828 (4009921, 6001900) |
| Age ≥ 65 White Non-Hispanic | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID50 | 187 | 3376 (2393, 4763) |
| Age ≥ 65 White Non-Hispanic | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID80 | 187 | 4511 (3339, 6096) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | GMT/GMC |
|----------------------------------|--------|---------|---------------------|------------------------|----|----------------------------------|
| Age \geq 65 White Non-Hispanic | Day 57 | Vaccine | Positive | Anti N IgG (IU/ml) | 66 | 3047576 (1943331, 4779276) |
| Age \geq 65 White Non-Hispanic | Day 57 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 66 | 7361735 (5495760, 9861264) |
| Age \geq 65 White Non-Hispanic | Day 57 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 66 | 13150407 (11178796, 15469753) |
| Age \geq 65 White Non-Hispanic | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID50 | 66 | 23885 (15539, 36713) |
| Age \geq 65 White Non-Hispanic | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID80 | 66 | 20383 (12350, 33642) |
| Age \geq 65 White Non-Hispanic | Day 57 | Placebo | Negative | Anti N IgG (IU/ml) | 36 | 10 (10, 10) |
| Age \geq 65 White Non-Hispanic | Day 57 | Placebo | Negative | Anti RBD IgG (IU/ml) | 36 | 10 (10, 10) |
| Age \geq 65 White Non-Hispanic | Day 57 | Placebo | Negative | Anti Spike IgG (IU/ml) | 36 | 10 (10, 10) |
| Age \geq 65 White Non-Hispanic | Day 57 | Placebo | Negative | Pseudovirus-nAb ID50 | 36 | 5 (5, 5) |
| Age \geq 65 White Non-Hispanic | Day 57 | Placebo | Negative | Pseudovirus-nAb ID80 | 36 | 5 (5, 6) |
| Age \geq 65 White Non-Hispanic | Day 57 | Placebo | Positive | Anti N IgG (IU/ml) | 60 | 443960 (270210, 729435) |
| Age \geq 65 White Non-Hispanic | Day 57 | Placebo | Positive | Anti RBD IgG (IU/ml) | 60 | 1555275 (1070146, 2260326) |
| Age \geq 65 White Non-Hispanic | Day 57 | Placebo | Positive | Anti Spike IgG (IU/ml) | 60 | 2726537 (1931325, 3849174) |
| Age \geq 65 White Non-Hispanic | Day 57 | Placebo | Positive | Pseudovirus-nAb ID50 | 60 | 2516 (1427, 4435) |
| Age \geq 65 White Non-Hispanic | Day 57 | Placebo | Positive | Pseudovirus-nAb ID80 | 60 | 4096 (2471, 6792) |

Table 6a. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by All participants

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|-------------------------|-----------------------|---------|---------------------|------------------------|-----|------------------|-------------------------|-------------------------------|
| All participants | | | | | | | | |
| | D29 fold-rise over D1 | Vaccine | Negative | Anti N IgG (IU/ml) | 914 | 10 (10, 10) | 23543 (19945, 27790) | 2348.16 (1989.36, 2771.67) |
| | D29 fold-rise over D1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 914 | 10 (10, 10) | 22926 (19863, 26460) | 2279.09 (1975.09, 2629.88) |
| | D29 fold-rise over D1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 914 | 10 (10, 10) | 40963 (36741, 45671) | 4091.68 (3670.04, 4561.76) |
| | D29 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 914 | 5 (5, 5) | 106 (91, 125) | 21.01 (17.90, 24.67) |
| | D29 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 914 | 5 (5, 5) | 189 (161, 222) | 37.28 (31.71, 43.83) |
| | D29 fold-rise over D1 | Vaccine | Positive | Anti N IgG (IU/ml) | 274 | 10 (10, 10) | 43010 (33140, 55819) | 4284.83 (3302.19, 5559.89) |
| | D29 fold-rise over D1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 274 | 10 (10, 10) | 36133 (28182, 46328) | 3613.33 (2818.21, 4632.79) |
| | D29 fold-rise over D1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 274 | 10 (10, 10) | 79981 (65041, 98352) | 7998.08 (6504.13, 9835.19) |
| | D29 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 274 | 5 (5, 5) | 186 (142, 243) | 36.50 (27.92, 47.71) |
| | D29 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 274 | 5 (5, 5) | 420 (314, 560) | 82.61 (61.87, 110.32) |
| | D29 fold-rise over D1 | Placebo | Negative | Anti N IgG (IU/ml) | 163 | 10 (10, 10) | 10 (10, 10) | 0.98 (0.95, 1.02) |
| | D29 fold-rise over D1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 163 | 10 (10, 11) | 10 (10, 10) | 0.98 (0.95, 1.02) |
| | D29 fold-rise over D1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 163 | 10 (10, 10) | 10 (10, 10) | 0.99 (0.98, 1.01) |
| | D29 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID50 | 163 | 5 (5, 5) | 5 (5, 5) | 1.01 (0.99, 1.02) |
| | D29 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID80 | 163 | 5 (5, 5) | 5 (5, 5) | 0.99 (0.95, 1.04) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|-------|-----------------------|---------|---------------------|------------------------|-----|------------------|-------------------------------|-------------------------------------|
| | D29 fold-rise over D1 | Placebo | Positive | Anti N IgG (IU/ml) | 270 | 10 (10, 10) | 12518 (9458, 16567) | 1232.97 (937.69, 1621.23) |
| | D29 fold-rise over D1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 270 | 10 (10, 10) | 12861 (10150, 16296) | 1284.22 (1013.60, 1627.09) |
| | D29 fold-rise over D1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 270 | 10 (10, 10) | 18191 (15159, 21829) | 1819.07 (1515.87, 2182.92) |
| | D29 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID50 | 270 | 5 (5, 5) | 51 (40, 66) | 9.99 (7.85, 12.73) |
| | D29 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID80 | 270 | 5 (5, 5) | 129 (98, 169) | 25.46 (19.48, 33.27) |
| | D57 fold-rise over D1 | Vaccine | Negative | Anti N IgG (IU/ml) | 914 | 10 (10, 10) | 325136 (267241, 395574) | 32428.78 (26656.24, 39451.39) |
| | D57 fold-rise over D1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 914 | 10 (10, 10) | 966160 (823437, 1133621) | 96047.59 (81866.19, 112685.58) |
| | D57 fold-rise over D1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 914 | 10 (10, 10) | 2087965 (1831068, 2380904) | 208560.44 (182899.78, 237821.27) |
| | D57 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 914 | 5 (5, 5) | 1497 (1228, 1825) | 295.67 (242.59, 360.37) |
| | D57 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 914 | 5 (5, 5) | 2223 (1809, 2733) | 438.66 (357.19, 538.72) |
| | D57 fold-rise over D1 | Vaccine | Positive | Anti N IgG (IU/ml) | 274 | 10 (10, 10) | 980579 (697583, 1378379) | 97689.42 (69501.88, 137308.83) |
| | D57 fold-rise over D1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 274 | 10 (10, 10) | 2298869 (1785648, 2959596) | 229886.89 (178564.83, 295959.65) |
| | D57 fold-rise over D1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 274 | 10 (10, 10) | 5346334 (4339333, 6587023) | 534633.43 (433933.34, 658702.34) |
| | D57 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 274 | 5 (5, 5) | 5680 (3863, 8351) | 1114.53 (761.21, 1631.83) |
| | D57 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 274 | 5 (5, 5) | 7837 (5545, 11076) | 1542.78 (1091.92, 2179.81) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|-------|-----------------------|---------|---------------------|------------------------|-----|------------------|----------------------------|----------------------------------|
| | D57 fold-rise over D1 | Placebo | Negative | Anti N IgG (IU/ml) | 163 | 10 (10, 10) | 10 (10, 10) | 0.98 (0.95, 1.02) |
| | D57 fold-rise over D1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 163 | 10 (10, 11) | 10 (10, 10) | 0.99 (0.95, 1.02) |
| | D57 fold-rise over D1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 163 | 10 (10, 10) | 10 (10, 10) | 0.99 (0.98, 1.01) |
| | D57 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID50 | 163 | 5 (5, 5) | 5 (5, 5) | 1.00 (0.99, 1.02) |
| | D57 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID80 | 163 | 5 (5, 5) | 5 (5, 5) | 0.99 (0.95, 1.03) |
| | D57 fold-rise over D1 | Placebo | Positive | Anti N IgG (IU/ml) | 270 | 10 (10, 10) | 130008 (92643, 182444) | 12805.53 (9188.90, 17845.62) |
| | D57 fold-rise over D1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 270 | 10 (10, 10) | 382614 (299829, 488256) | 38205.28 (29939.10, 48753.76) |
| | D57 fold-rise over D1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 270 | 10 (10, 10) | 676872 (531354, 862241) | 67687.19 (53135.41, 86224.15) |
| | D57 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID50 | 270 | 5 (5, 5) | 566 (409, 783) | 109.82 (79.77, 151.19) |
| | D57 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID80 | 270 | 5 (5, 5) | 1324 (937, 1870) | 261.17 (185.46, 367.79) |

Table 6b. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Age

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|------------|-----------------------|---------|---------------------|------------------------|-----|------------------|-------------------------|-------------------------------|
| Age | | | | | | | | |
| Age < 65 | D29 fold-rise over D1 | Vaccine | Negative | Anti N IgG (IU/ml) | 432 | 10 (10, 10) | 18416 (15002, 22607) | 1838.80 (1497.94, 2257.21) |
| Age < 65 | D29 fold-rise over D1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 432 | 10 (10, 10) | 17393 (14565, 20770) | 1728.59 (1447.96, 2063.60) |
| Age < 65 | D29 fold-rise over D1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 432 | 10 (10, 10) | 31397 (27475, 35879) | 3139.72 (2747.52, 3587.91) |
| Age < 65 | D29 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 432 | 5 (5, 5) | 85 (69, 103) | 16.72 (13.72, 20.38) |
| Age < 65 | D29 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 432 | 5 (5, 5) | 157 (129, 192) | 31.07 (25.45, 37.94) |
| Age < 65 | D29 fold-rise over D1 | Vaccine | Positive | Anti N IgG (IU/ml) | 146 | 10 (10, 10) | 32567 (23744, 44670) | 3251.72 (2370.72, 4460.12) |
| Age < 65 | D29 fold-rise over D1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 146 | 10 (10, 10) | 24939 (18393, 33814) | 2493.88 (1839.31, 3381.39) |
| Age < 65 | D29 fold-rise over D1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 146 | 10 (10, 10) | 59400 (46119, 76506) | 5940.04 (4611.93, 7650.60) |
| Age < 65 | D29 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 146 | 5 (5, 5) | 144 (104, 198) | 28.34 (20.48, 39.21) |
| Age < 65 | D29 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 146 | 5 (5, 5) | 339 (238, 482) | 66.39 (46.61, 94.58) |
| Age < 65 | D29 fold-rise over D1 | Placebo | Negative | Anti N IgG (IU/ml) | 80 | 10 (10, 11) | 10 (10, 10) | 0.98 (0.94, 1.02) |
| Age < 65 | D29 fold-rise over D1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 80 | 10 (10, 11) | 10 (10, 10) | 0.98 (0.93, 1.02) |
| Age < 65 | D29 fold-rise over D1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 80 | 10 (10, 10) | 10 (10, 10) | 0.99 (0.98, 1.01) |
| Age < 65 | D29 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID50 | 80 | 5 (5, 5) | 5 (5, 5) | 1.00 (0.98, 1.03) |
| Age < 65 | D29 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID80 | 80 | 5 (5, 5) | 5 (5, 5) | 0.99 (0.93, 1.06) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|----------|-----------------------|---------|---------------------|------------------------|-----|------------------|-------------------------------|-------------------------------------|
| Age < 65 | D29 fold-rise over D1 | Placebo | Positive | Anti N IgG (IU/ml) | 147 | 10 (10, 10) | 9820 (7012, 13753) | 966.54 (695.88, 1342.48) |
| Age < 65 | D29 fold-rise over D1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 147 | 10 (10, 10) | 9737 (7318, 12957) | 973.73 (731.75, 1295.73) |
| Age < 65 | D29 fold-rise over D1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 147 | 10 (10, 10) | 13380 (10752, 16650) | 1337.99 (1075.18, 1665.05) |
| Age < 65 | D29 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID50 | 147 | 5 (5, 5) | 40 (29, 54) | 7.70 (5.77, 10.28) |
| Age < 65 | D29 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID80 | 147 | 5 (5, 5) | 106 (76, 147) | 20.88 (15.13, 28.82) |
| Age < 65 | D57 fold-rise over D1 | Vaccine | Negative | Anti N IgG (IU/ml) | 432 | 10 (10, 10) | 253319 (198848, 322710) | 25293.56 (19856.49, 32219.39) |
| Age < 65 | D57 fold-rise over D1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 432 | 10 (10, 10) | 737116 (604473, 898866) | 73258.07 (60080.95, 89325.22) |
| Age < 65 | D57 fold-rise over D1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 432 | 10 (10, 10) | 1643373 (1397160, 1932976) | 164337.35 (139715.98, 193297.60) |
| Age < 65 | D57 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 432 | 5 (5, 5) | 1136 (890, 1449) | 224.61 (176.12, 286.46) |
| Age < 65 | D57 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 432 | 5 (5, 5) | 1750 (1355, 2260) | 346.17 (268.34, 446.58) |
| Age < 65 | D57 fold-rise over D1 | Vaccine | Positive | Anti N IgG (IU/ml) | 146 | 10 (10, 10) | 739998 (487226, 1123907) | 73885.65 (48648.51, 112214.94) |
| Age < 65 | D57 fold-rise over D1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 146 | 10 (10, 10) | 1708031 (1250384, 2333179) | 170803.11 (125038.42, 233317.89) |
| Age < 65 | D57 fold-rise over D1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 146 | 10 (10, 10) | 4266733 (3292306, 5529560) | 426673.25 (329230.63, 552956.04) |
| Age < 65 | D57 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 146 | 5 (5, 5) | 4061 (2527, 6527) | 801.35 (501.10, 1281.50) |
| Age < 65 | D57 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 146 | 5 (5, 5) | 6238 (4090, 9513) | 1223.09 (802.31, 1864.58) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|----------|-----------------------|---------|---------------------|------------------------|-----|------------------|----------------------------|----------------------------------|
| Age < 65 | D57 fold-rise over D1 | Placebo | Negative | Anti N IgG (IU/ml) | 80 | 10 (10, 11) | 10 (10, 10) | 0.98 (0.94, 1.02) |
| Age < 65 | D57 fold-rise over D1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 80 | 10 (10, 11) | 10 (10, 10) | 0.98 (0.93, 1.03) |
| Age < 65 | D57 fold-rise over D1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 80 | 10 (10, 10) | 10 (10, 10) | 0.99 (0.98, 1.01) |
| Age < 65 | D57 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID50 | 80 | 5 (5, 5) | 5 (5, 5) | 1.00 (0.98, 1.01) |
| Age < 65 | D57 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID80 | 80 | 5 (5, 5) | 5 (5, 5) | 0.98 (0.93, 1.03) |
| Age < 65 | D57 fold-rise over D1 | Placebo | Positive | Anti N IgG (IU/ml) | 147 | 10 (10, 10) | 93772 (62211, 141344) | 9229.59 (6177.01, 13790.71) |
| Age < 65 | D57 fold-rise over D1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 147 | 10 (10, 10) | 270061 (201183, 362521) | 27006.13 (20118.30, 36252.12) |
| Age < 65 | D57 fold-rise over D1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 147 | 10 (10, 10) | 484596 (361146, 650244) | 48459.60 (36114.65, 65024.40) |
| Age < 65 | D57 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID50 | 147 | 5 (5, 5) | 387 (262, 572) | 75.13 (51.19, 110.26) |
| Age < 65 | D57 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID80 | 147 | 5 (5, 5) | 1009 (665, 1531) | 199.32 (131.81, 301.41) |
| Age ≥ 65 | D29 fold-rise over D1 | Vaccine | Negative | Anti N IgG (IU/ml) | 482 | 10 (10, 10) | 59687 (50609, 70395) | 5928.46 (5026.44, 6992.35) |
| Age ≥ 65 | D29 fold-rise over D1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 482 | 10 (10, 10) | 65260 (56734, 75068) | 6494.31 (5646.18, 7469.84) |
| Age ≥ 65 | D29 fold-rise over D1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 482 | 10 (10, 10) | 112166 (98902, 127209) | 11156.00 (9843.59, 12643.39) |
| Age ≥ 65 | D29 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 482 | 5 (5, 5) | 254 (214, 300) | 49.89 (42.15, 59.05) |
| Age ≥ 65 | D29 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 482 | 5 (5, 5) | 381 (321, 451) | 74.35 (62.85, 87.96) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|----------|-----------------------|---------|---------------------|------------------------|-----|------------------|----------------------------|----------------------------------|
| Age ≥ 65 | D29 fold-rise over D1 | Vaccine | Positive | Anti N IgG (IU/ml) | 128 | 10 (10, 10) | 130450 (94702, 179694) | 12881.38 (9387.70, 17675.25) |
| Age ≥ 65 | D29 fold-rise over D1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 128 | 10 (10, 10) | 158619 (123545, 203649) | 15861.86 (12354.53, 20364.88) |
| Age ≥ 65 | D29 fold-rise over D1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 128 | 10 (10, 10) | 262073 (211994, 323982) | 26207.29 (21199.35, 32398.25) |
| Age ≥ 65 | D29 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 128 | 5 (5, 5) | 522 (373, 731) | 100.15 (72.09, 139.12) |
| Age ≥ 65 | D29 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 128 | 5 (5, 5) | 988 (733, 1331) | 197.60 (146.66, 266.24) |
| Age ≥ 65 | D29 fold-rise over D1 | Placebo | Negative | Anti N IgG (IU/ml) | 83 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age ≥ 65 | D29 fold-rise over D1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 83 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age ≥ 65 | D29 fold-rise over D1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 83 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age ≥ 65 | D29 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID50 | 83 | 5 (5, 5) | 5 (5, 5) | 1.02 (0.99, 1.04) |
| Age ≥ 65 | D29 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID80 | 83 | 5 (5, 5) | 5 (5, 5) | 1.00 (0.98, 1.03) |
| Age ≥ 65 | D29 fold-rise over D1 | Placebo | Positive | Anti N IgG (IU/ml) | 123 | 10 (10, 10) | 35028 (24879, 49317) | 3460.86 (2457.33, 4874.22) |
| Age ≥ 65 | D29 fold-rise over D1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 123 | 10 (10, 10) | 41836 (32047, 54614) | 4151.56 (3184.55, 5412.22) |
| Age ≥ 65 | D29 fold-rise over D1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 123 | 10 (10, 10) | 66891 (53117, 84238) | 6689.12 (5311.68, 8423.77) |
| Age ≥ 65 | D29 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID50 | 123 | 5 (5, 5) | 156 (112, 216) | 30.24 (21.85, 41.85) |
| Age ≥ 65 | D29 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID80 | 123 | 5 (5, 5) | 301 (219, 413) | 59.03 (43.06, 80.92) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|----------|-----------------------|---------|---------------------|------------------------|-----|------------------|----------------------------------|--|
| Age ≥ 65 | D57 fold-rise over D1 | Vaccine | Negative | Anti N IgG (IU/ml) | 482 | 10 (10, 10) | 836805 (684275, 1023335) | 83115.94 (67970.66, 101635.90) |
| Age ≥ 65 | D57 fold-rise over D1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 482 | 10 (10, 10) | 2692372 (2329146, 3112243) | 267928.32 (231855.79, 309613.08) |
| Age ≥ 65 | D57 fold-rise over D1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 482 | 10 (10, 10) | 5171042 (4536102, 5894857) | 514311.17 (451159.38, 586302.75) |
| Age ≥ 65 | D57 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 482 | 5 (5, 5) | 4259 (3414, 5312) | 837.43 (671.41, 1044.49) |
| Age ≥ 65 | D57 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 482 | 5 (5, 5) | 5506 (4535, 6685) | 1075.58 (887.15, 1304.01) |
| Age ≥ 65 | D57 fold-rise over D1 | Vaccine | Positive | Anti N IgG (IU/ml) | 128 | 10 (10, 10) | 3014476 (2173987, 4179907) | 297666.07 (215032.46, 412054.47) |
| Age ≥ 65 | D57 fold-rise over D1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 128 | 10 (10, 10) | 7520373 (6146909, 9200723) | 752037.26 (614690.86, 920072.32) |
| Age ≥ 65 | D57 fold-rise over D1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 128 | 10 (10, 10) | 13148461 (11661345, 14825221) | 1314846.07 (1166134.50, 1482522.12) |
| Age ≥ 65 | D57 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 128 | 5 (5, 5) | 21658 (15437, 30385) | 4155.93 (2979.90, 5796.08) |
| Age ≥ 65 | D57 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 128 | 5 (5, 5) | 19480 (13318, 28494) | 3896.02 (2663.58, 5698.73) |
| Age ≥ 65 | D57 fold-rise over D1 | Placebo | Negative | Anti N IgG (IU/ml) | 83 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age ≥ 65 | D57 fold-rise over D1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 83 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age ≥ 65 | D57 fold-rise over D1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 83 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age ≥ 65 | D57 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID50 | 83 | 5 (5, 5) | 5 (5, 5) | 1.02 (0.99, 1.05) |
| Age ≥ 65 | D57 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID80 | 83 | 5 (5, 5) | 5 (5, 5) | 1.01 (0.97, 1.05) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|----------|-----------------------|---------|---------------------|------------------------|-----|------------------|-------------------------------|-------------------------------------|
| Age ≥ 65 | D57 fold-rise over D1 | Placebo | Positive | Anti N IgG (IU/ml) | 123 | 10 (10, 10) | 519433 (364323, 740581) | 51321.85 (36024.56, 73114.90) |
| Age ≥ 65 | D57 fold-rise over D1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 123 | 10 (10, 10) | 1675605 (1276999, 2198632) | 166277.45 (126741.57, 218146.20) |
| Age ≥ 65 | D57 fold-rise over D1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 123 | 10 (10, 10) | 2790960 (2209589, 3525298) | 279096.04 (220958.92, 352529.78) |
| Age ≥ 65 | D57 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID50 | 123 | 5 (5, 5) | 2827 (1887, 4233) | 549.05 (368.08, 818.99) |
| Age ≥ 65 | D57 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID80 | 123 | 5 (5, 5) | 4185 (2859, 6127) | 821.36 (562.39, 1199.58) |

Table 6c. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Risk for Severe Covid-19

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|---------------------------------|-----------------------|---------|---------------------|------------------------|-----|------------------|---------------------------|---------------------------------|
| Risk for Severe Covid-19 | | | | | | | | |
| At-risk | D29 fold-rise over D1 | Vaccine | Negative | Anti N IgG (IU/ml) | 469 | 10 (10, 10) | 23746 (19934, 28287) | 2359.08 (1981.02, 2809.29) |
| At-risk | D29 fold-rise over D1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 469 | 10 (10, 10) | 26276 (22610, 30535) | 2615.50 (2250.98, 3039.05) |
| At-risk | D29 fold-rise over D1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 469 | 10 (10, 10) | 45842 (40067, 52448) | 4565.75 (3992.37, 5221.47) |
| At-risk | D29 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 469 | 5 (5, 5) | 103 (87, 122) | 20.04 (16.98, 23.65) |
| At-risk | D29 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 469 | 5 (5, 5) | 215 (180, 258) | 42.59 (35.64, 50.91) |
| At-risk | D29 fold-rise over D1 | Vaccine | Positive | Anti N IgG (IU/ml) | 125 | 10 (10, 10) | 55180 (40419, 75332) | 5491.58 (4022.46, 7497.26) |
| At-risk | D29 fold-rise over D1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 125 | 10 (10, 10) | 55528 (43641, 70653) | 5552.80 (4364.10, 7065.28) |
| At-risk | D29 fold-rise over D1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 125 | 10 (10, 10) | 103862 (82479, 130788) | 10386.18 (8247.90, 13078.81) |
| At-risk | D29 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 125 | 5 (5, 5) | 220 (161, 302) | 43.07 (31.58, 58.75) |
| At-risk | D29 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 125 | 5 (5, 5) | 443 (318, 617) | 87.77 (62.95, 122.37) |
| At-risk | D29 fold-rise over D1 | Placebo | Negative | Anti N IgG (IU/ml) | 84 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| At-risk | D29 fold-rise over D1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 84 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| At-risk | D29 fold-rise over D1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 84 | 10 (10, 11) | 10 (10, 10) | 0.98 (0.94, 1.02) |
| At-risk | D29 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID50 | 84 | 5 (5, 5) | 5 (5, 5) | 1.02 (0.96, 1.08) |
| At-risk | D29 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID80 | 84 | 5 (5, 5) | 5 (5, 5) | 1.00 (0.98, 1.02) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|---------|-----------------------|---------|---------------------|------------------------|-----|------------------|-------------------------------|-------------------------------------|
| At-risk | D29 fold-rise over D1 | Placebo | Positive | Anti N IgG (IU/ml) | 123 | 10 (10, 10) | 16553 (12215, 22429) | 1648.35 (1215.87, 2234.65) |
| At-risk | D29 fold-rise over D1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 123 | 10 (10, 10) | 16713 (12642, 22096) | 1661.32 (1257.58, 2194.67) |
| At-risk | D29 fold-rise over D1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 123 | 10 (10, 10) | 26705 (21285, 33505) | 2670.50 (2128.48, 3350.54) |
| At-risk | D29 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID50 | 123 | 5 (5, 5) | 69 (52, 93) | 13.57 (10.16, 18.12) |
| At-risk | D29 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID80 | 123 | 5 (5, 5) | 180 (133, 243) | 35.50 (26.16, 48.18) |
| At-risk | D57 fold-rise over D1 | Vaccine | Negative | Anti N IgG (IU/ml) | 469 | 10 (10, 10) | 335374 (270080, 416453) | 33318.69 (26852.88, 41341.37) |
| At-risk | D57 fold-rise over D1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 469 | 10 (10, 10) | 1142597 (961925, 1357205) | 113734.61 (95775.71, 135060.99) |
| At-risk | D57 fold-rise over D1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 469 | 10 (10, 10) | 2144439 (1840509, 2498559) | 213582.55 (183324.98, 248834.09) |
| At-risk | D57 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 469 | 5 (5, 5) | 1796 (1424, 2264) | 349.12 (277.06, 439.92) |
| At-risk | D57 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 469 | 5 (5, 5) | 2766 (2265, 3377) | 546.96 (448.44, 667.12) |
| At-risk | D57 fold-rise over D1 | Vaccine | Positive | Anti N IgG (IU/ml) | 125 | 10 (10, 10) | 1327591 (937265, 1880469) | 132124.36 (93301.15, 187102.17) |
| At-risk | D57 fold-rise over D1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 125 | 10 (10, 10) | 2930270 (2216035, 3874704) | 293027.00 (221603.54, 387470.44) |
| At-risk | D57 fold-rise over D1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 125 | 10 (10, 10) | 6396516 (5214355, 7846688) | 639651.59 (521435.48, 784668.81) |
| At-risk | D57 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 125 | 5 (5, 5) | 6128 (4355, 8625) | 1197.37 (852.46, 1681.83) |
| At-risk | D57 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 125 | 5 (5, 5) | 11182 (7684, 16271) | 2214.72 (1523.03, 3220.55) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|-------------|-----------------------|---------|---------------------|------------------------|-----|------------------|------------------------------|------------------------------------|
| At-risk | D57 fold-rise over D1 | Placebo | Negative | Anti N IgG (IU/ml) | 84 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| At-risk | D57 fold-rise over D1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 84 | 10 (10, 10) | 10 (10, 10) | 1.01 (0.99, 1.04) |
| At-risk | D57 fold-rise over D1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 84 | 10 (10, 11) | 10 (10, 10) | 0.98 (0.94, 1.02) |
| At-risk | D57 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID50 | 84 | 5 (5, 5) | 5 (5, 5) | 0.99 (0.96, 1.03) |
| At-risk | D57 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID80 | 84 | 5 (5, 5) | 5 (5, 5) | 1.02 (0.98, 1.07) |
| At-risk | D57 fold-rise over D1 | Placebo | Positive | Anti N IgG (IU/ml) | 123 | 10 (10, 10) | 197242 (138403, 281094) | 19641.88 (13780.65, 27996.01) |
| At-risk | D57 fold-rise over D1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 123 | 10 (10, 10) | 663561 (492320, 894363) | 65958.42 (48940.12, 88894.61) |
| At-risk | D57 fold-rise over D1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 123 | 10 (10, 10) | 1012116 (794913, 1288669) | 101211.63 (79491.29, 128866.87) |
| At-risk | D57 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID50 | 123 | 5 (5, 5) | 931 (651, 1331) | 182.03 (127.42, 260.06) |
| At-risk | D57 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID80 | 123 | 5 (5, 5) | 2086 (1418, 3067) | 412.34 (280.42, 606.33) |
| Not at-risk | D29 fold-rise over D1 | Vaccine | Negative | Anti N IgG (IU/ml) | 445 | 10 (10, 10) | 23464 (18827, 29244) | 2343.90 (1880.63, 2921.30) |
| Not at-risk | D29 fold-rise over D1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 445 | 10 (10, 10) | 21736 (17965, 26298) | 2159.67 (1785.56, 2612.16) |
| Not at-risk | D29 fold-rise over D1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 445 | 10 (10, 10) | 39200 (34023, 45165) | 3920.03 (3402.34, 4516.49) |
| Not at-risk | D29 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 445 | 5 (5, 5) | 108 (87, 133) | 21.41 (17.29, 26.50) |
| Not at-risk | D29 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 445 | 5 (5, 5) | 180 (145, 223) | 35.39 (28.57, 43.84) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|-------------|-----------------------|---------|---------------------|------------------------|-----|------------------|-------------------------|-------------------------------|
| Not at-risk | D29 fold-rise over D1 | Vaccine | Positive | Anti N IgG (IU/ml) | 149 | 10 (10, 10) | 39449 (28242, 55103) | 3931.45 (2815.34, 5490.03) |
| Not at-risk | D29 fold-rise over D1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 149 | 10 (10, 10) | 31130 (22510, 43050) | 3113.00 (2251.05, 4305.00) |
| Not at-risk | D29 fold-rise over D1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 149 | 10 (10, 10) | 73051 (55946, 95386) | 7305.09 (5594.58, 9538.58) |
| Not at-risk | D29 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 149 | 5 (5, 5) | 175 (124, 247) | 34.46 (24.42, 48.63) |
| Not at-risk | D29 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 149 | 5 (5, 5) | 412 (284, 597) | 80.90 (55.76, 117.37) |
| Not at-risk | D29 fold-rise over D1 | Placebo | Negative | Anti N IgG (IU/ml) | 79 | 10 (10, 11) | 10 (10, 10) | 0.98 (0.93, 1.02) |
| Not at-risk | D29 fold-rise over D1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 79 | 10 (10, 11) | 10 (10, 10) | 0.97 (0.92, 1.03) |
| Not at-risk | D29 fold-rise over D1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 79 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Not at-risk | D29 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID50 | 79 | 5 (5, 5) | 5 (5, 5) | 1.00 (1.00, 1.00) |
| Not at-risk | D29 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID80 | 79 | 5 (5, 5) | 5 (5, 5) | 0.99 (0.92, 1.06) |
| Not at-risk | D29 fold-rise over D1 | Placebo | Positive | Anti N IgG (IU/ml) | 147 | 10 (10, 11) | 11438 (8001, 16352) | 1122.63 (792.35, 1590.58) |
| Not at-risk | D29 fold-rise over D1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 147 | 10 (10, 10) | 11818 (8756, 15950) | 1181.77 (875.58, 1595.05) |
| Not at-risk | D29 fold-rise over D1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 147 | 10 (10, 10) | 16070 (12770, 20222) | 1606.98 (1277.02, 2022.19) |
| Not at-risk | D29 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID50 | 147 | 5 (5, 5) | 47 (34, 64) | 9.06 (6.67, 12.30) |
| Not at-risk | D29 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID80 | 147 | 5 (5, 5) | 116 (82, 164) | 22.87 (16.28, 32.13) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|-------------|-----------------------|---------|---------------------|------------------------|-----|------------------|-------------------------------|-------------------------------------|
| Not at-risk | D57 fold-rise over D1 | Vaccine | Negative | Anti N IgG (IU/ml) | 445 | 10 (10, 10) | 321219 (247884, 416250) | 32087.38 (24761.78, 41580.21) |
| Not at-risk | D57 fold-rise over D1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 445 | 10 (10, 10) | 904842 (732112, 1118324) | 89906.29 (72750.39, 111107.87) |
| Not at-risk | D57 fold-rise over D1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 445 | 10 (10, 10) | 2066294 (1739231, 2454861) | 206629.43 (173923.14, 245486.15) |
| Not at-risk | D57 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 445 | 5 (5, 5) | 1394 (1075, 1808) | 277.07 (213.65, 359.32) |
| Not at-risk | D57 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 445 | 5 (5, 5) | 2041 (1549, 2690) | 402.41 (305.66, 529.78) |
| Not at-risk | D57 fold-rise over D1 | Vaccine | Positive | Anti N IgG (IU/ml) | 149 | 10 (10, 10) | 882754 (567083, 1374143) | 87975.05 (56520.81, 136933.81) |
| Not at-risk | D57 fold-rise over D1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 149 | 10 (10, 10) | 2113273 (1525010, 2928453) | 211327.27 (152501.04, 292845.31) |
| Not at-risk | D57 fold-rise over D1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 149 | 10 (10, 10) | 5023873 (3827375, 6594416) | 502387.34 (382737.50, 659441.62) |
| Not at-risk | D57 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 149 | 5 (5, 5) | 5532 (3337, 9171) | 1087.15 (659.48, 1792.15) |
| Not at-risk | D57 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 149 | 5 (5, 5) | 6928 (4429, 10838) | 1360.94 (870.25, 2128.30) |
| Not at-risk | D57 fold-rise over D1 | Placebo | Negative | Anti N IgG (IU/ml) | 79 | 10 (10, 11) | 10 (10, 10) | 0.98 (0.93, 1.02) |
| Not at-risk | D57 fold-rise over D1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 79 | 10 (10, 11) | 10 (10, 10) | 0.97 (0.92, 1.03) |
| Not at-risk | D57 fold-rise over D1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 79 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Not at-risk | D57 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID50 | 79 | 5 (5, 5) | 5 (5, 5) | 1.01 (1.00, 1.02) |
| Not at-risk | D57 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID80 | 79 | 5 (5, 5) | 5 (5, 5) | 0.97 (0.92, 1.03) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|-------------|-----------------------|---------|---------------------|------------------------|-----|------------------------------------|--------------------------------|----------------------------------|
| Not at-risk | D57 fold-rise over D1 | Placebo | Positive | Anti N IgG (IU/ml) | 147 | 10 (10, 11) (73666, 175296) | 113637 (7299.59, 17041.87) | 11153.41 (7299.59, 17041.87) |
| Not at-risk | D57 fold-rise over D1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 147 | 10 (10, 10) (235413, 435781) | 320294 (23541.29, 43578.07) | 32029.42 (23541.29, 43578.07) |
| Not at-risk | D57 fold-rise over D1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 147 | 10 (10, 10) (435730, 810886) | 594413 (43572.97, 81088.58) | 59441.32 (43572.97, 81088.58) |
| Not at-risk | D57 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID50 | 147 | 5 (5, 5) (318, 728) | 482 (62.10, 140.13) | 93.28 (62.10, 140.13) |
| Not at-risk | D57 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID80 | 147 | 5 (5, 5) (737, 1774) | 1143 (145.81, 348.33) | 225.36 (145.81, 348.33) |

Table 6d. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Age, Risk for Severe Covid-19

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|--------------------------------------|-----------------------|---------|---------------------|------------------------|-----|------------------|-------------------------|-------------------------------|
| Age, Risk for Severe Covid-19 | | | | | | | | |
| Age < 65 At-risk | D29 fold-rise over D1 | Vaccine | Negative | Anti N IgG (IU/ml) | 214 | 10 (10, 10) | 15066 (11800, 19236) | 1496.11 (1172.51, 1909.02) |
| Age < 65 At-risk | D29 fold-rise over D1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 214 | 10 (10, 10) | 16530 (13368, 20441) | 1647.12 (1332.23, 2036.44) |
| Age < 65 At-risk | D29 fold-rise over D1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 214 | 10 (10, 10) | 31028 (25725, 37423) | 3102.75 (2572.47, 3742.34) |
| Age < 65 At-risk | D29 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 214 | 5 (5, 5) | 68 (54, 85) | 13.04 (10.42, 16.32) |
| Age < 65 At-risk | D29 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 214 | 5 (5, 5) | 159 (123, 204) | 31.54 (24.49, 40.62) |
| Age < 65 At-risk | D29 fold-rise over D1 | Vaccine | Positive | Anti N IgG (IU/ml) | 73 | 10 (10, 10) | 35719 (23749, 53721) | 3546.51 (2357.97, 5334.12) |
| Age < 65 At-risk | D29 fold-rise over D1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 73 | 10 (10, 10) | 30603 (22501, 41623) | 3060.34 (2250.14, 4162.27) |
| Age < 65 At-risk | D29 fold-rise over D1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 73 | 10 (10, 10) | 62641 (46271, 84801) | 6264.08 (4627.13, 8480.14) |
| Age < 65 At-risk | D29 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 73 | 5 (5, 5) | 142 (95, 213) | 28.47 (19.00, 42.66) |
| Age < 65 At-risk | D29 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 73 | 5 (5, 5) | 291 (187, 453) | 57.32 (36.68, 89.56) |
| Age < 65 At-risk | D29 fold-rise over D1 | Placebo | Negative | Anti N IgG (IU/ml) | 40 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|------------------|-----------------------|---------|---------------------|------------------------|-----|------------------|-------------------------------|-------------------------------------|
| Age < 65 At-risk | D29 fold-rise over D1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 40 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age < 65 At-risk | D29 fold-rise over D1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 40 | 10 (10, 11) | 10 (10, 10) | 0.97 (0.91, 1.03) |
| Age < 65 At-risk | D29 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID50 | 40 | 5 (5, 5) | 5 (5, 6) | 1.01 (0.92, 1.11) |
| Age < 65 At-risk | D29 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID80 | 40 | 5 (5, 5) | 5 (5, 5) | 0.99 (0.96, 1.01) |
| Age < 65 At-risk | D29 fold-rise over D1 | Placebo | Positive | Anti N IgG (IU/ml) | 75 | 10 (10, 10) | 11526 (8014, 16577) | 1152.57 (801.38, 1657.66) |
| Age < 65 At-risk | D29 fold-rise over D1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 75 | 10 (10, 10) | 10221 (7219, 14470) | 1022.09 (721.94, 1447.04) |
| Age < 65 At-risk | D29 fold-rise over D1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 75 | 10 (10, 10) | 16112 (12299, 21107) | 1611.16 (1229.86, 2110.68) |
| Age < 65 At-risk | D29 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID50 | 75 | 5 (5, 5) | 48 (34, 67) | 9.40 (6.70, 13.17) |
| Age < 65 At-risk | D29 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID80 | 75 | 5 (5, 5) | 127 (87, 186) | 25.12 (17.07, 36.96) |
| Age < 65 At-risk | D57 fold-rise over D1 | Vaccine | Negative | Anti N IgG (IU/ml) | 214 | 10 (10, 10) | 227691 (168852, 307033) | 22610.51 (16792.97, 30443.42) |
| Age < 65 At-risk | D57 fold-rise over D1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 214 | 10 (10, 10) | 761200 (595277, 973370) | 75848.48 (59325.91, 96972.66) |
| Age < 65 At-risk | D57 fold-rise over D1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 214 | 10 (10, 10) | 1498825 (1211392, 1854460) | 149882.51 (121139.16, 185445.96) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|------------------|-----------------------|---------|---------------------|------------------------|-----|------------------|-------------------------------|-------------------------------------|
| Age < 65 At-risk | D57 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 214 | 5 (5, 5) | 1203 (876, 1652) | 231.86 (169.01, 318.08) |
| Age < 65 At-risk | D57 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 214 | 5 (5, 5) | 2067 (1571, 2720) | 411.15 (312.79, 540.45) |
| Age < 65 At-risk | D57 fold-rise over D1 | Vaccine | Positive | Anti N IgG (IU/ml) | 73 | 10 (10, 10) | 848831 (532838, 1352218) | 84280.25 (52926.74, 134207.39) |
| Age < 65 At-risk | D57 fold-rise over D1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 73 | 10 (10, 10) | 1815884 (1228679, 2683724) | 181588.39 (122867.87, 268372.40) |
| Age < 65 At-risk | D57 fold-rise over D1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 73 | 10 (10, 10) | 4547755 (3405518, 6073108) | 454775.50 (340551.75, 607310.79) |
| Age < 65 At-risk | D57 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 73 | 5 (5, 5) | 2953 (1859, 4690) | 590.64 (371.88, 938.10) |
| Age < 65 At-risk | D57 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 73 | 5 (5, 5) | 7954 (4852, 13039) | 1567.92 (957.49, 2567.49) |
| Age < 65 At-risk | D57 fold-rise over D1 | Placebo | Negative | Anti N IgG (IU/ml) | 40 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age < 65 At-risk | D57 fold-rise over D1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 40 | 10 (10, 10) | 10 (10, 11) | 1.02 (0.98, 1.07) |
| Age < 65 At-risk | D57 fold-rise over D1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 40 | 10 (10, 11) | 10 (10, 10) | 0.97 (0.91, 1.03) |
| Age < 65 At-risk | D57 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID50 | 40 | 5 (5, 5) | 5 (5, 5) | 0.99 (0.93, 1.05) |
| Age < 65 At-risk | D57 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID80 | 40 | 5 (5, 5) | 5 (5, 5) | 1.01 (0.96, 1.07) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|----------------------|-----------------------|---------|---------------------|------------------------|-----|------------------|-------------------------|-------------------------------|
| Age < 65 At-risk | D57 fold-rise over D1 | Placebo | Positive | Anti N IgG (IU/ml) | 75 | 10 (10, 10) | 115913 (72906, 184288) | 11591.25 (7290.61, 18428.80) |
| Age < 65 At-risk | D57 fold-rise over D1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 75 | 10 (10, 10) | 417627 (286526, 608715) | 41762.73 (28652.58, 60871.51) |
| Age < 65 At-risk | D57 fold-rise over D1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 75 | 10 (10, 10) | 575539 (423609, 781958) | 57553.86 (42360.90, 78195.85) |
| Age < 65 At-risk | D57 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID50 | 75 | 5 (5, 5) | 502 (325, 776) | 98.87 (64.02, 152.71) |
| Age < 65 At-risk | D57 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID80 | 75 | 5 (5, 5) | 1382 (851, 2245) | 273.33 (168.28, 443.96) |
| Age < 65 Not at-risk | D29 fold-rise over D1 | Vaccine | Negative | Anti N IgG (IU/ml) | 218 | 10 (10, 10) | 19467 (15117, 25069) | 1946.75 (1511.74, 2506.93) |
| Age < 65 Not at-risk | D29 fold-rise over D1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 218 | 10 (10, 10) | 17639 (14174, 21953) | 1751.83 (1408.13, 2179.42) |
| Age < 65 Not at-risk | D29 fold-rise over D1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 218 | 10 (10, 10) | 31500 (26782, 37050) | 3150.02 (2678.20, 3704.97) |
| Age < 65 Not at-risk | D29 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 218 | 5 (5, 5) | 90 (70, 115) | 17.91 (14.03, 22.88) |
| Age < 65 Not at-risk | D29 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 218 | 5 (5, 5) | 157 (122, 200) | 30.94 (24.21, 39.54) |
| Age < 65 Not at-risk | D29 fold-rise over D1 | Vaccine | Positive | Anti N IgG (IU/ml) | 73 | 10 (10, 10) | 31746 (21553, 46760) | 3174.64 (2155.33, 4675.99) |
| Age < 65 Not at-risk | D29 fold-rise over D1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 73 | 10 (10, 10) | 23567 (16129, 34434) | 2356.67 (1612.92, 3443.37) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|----------------------|-----------------------|---------|---------------------|------------------------|----|------------------|-------------------------|-------------------------------|
| Age < 65 Not at-risk | D29 fold-rise over D1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 73 | 10 (10, 10) | 58534 (42846, 79967) | 5853.44 (4284.64, 7996.66) |
| Age < 65 Not at-risk | D29 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 73 | 5 (5, 5) | 144 (97, 214) | 28.30 (18.99, 42.19) |
| Age < 65 Not at-risk | D29 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 73 | 5 (5, 5) | 353 (229, 545) | 69.15 (44.78, 106.78) |
| Age < 65 Not at-risk | D29 fold-rise over D1 | Placebo | Negative | Anti N IgG (IU/ml) | 40 | 10 (10, 11) | 10 (10, 10) | 0.97 (0.92, 1.03) |
| Age < 65 Not at-risk | D29 fold-rise over D1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 40 | 10 (10, 11) | 10 (10, 10) | 0.97 (0.91, 1.03) |
| Age < 65 Not at-risk | D29 fold-rise over D1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 40 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age < 65 Not at-risk | D29 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID50 | 40 | 5 (5, 5) | 5 (5, 5) | 1.00 (1.00, 1.00) |
| Age < 65 Not at-risk | D29 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID80 | 40 | 5 (5, 6) | 5 (5, 5) | 0.99 (0.91, 1.08) |
| Age < 65 Not at-risk | D29 fold-rise over D1 | Placebo | Positive | Anti N IgG (IU/ml) | 72 | 10 (10, 11) | 9421 (6230, 14246) | 923.44 (617.25, 1381.52) |
| Age < 65 Not at-risk | D29 fold-rise over D1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 72 | 10 (10, 10) | 9616 (6788, 13622) | 961.58 (678.78, 1362.18) |
| Age < 65 Not at-risk | D29 fold-rise over D1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 72 | 10 (10, 10) | 12751 (9770, 16642) | 1275.09 (976.97, 1664.19) |
| Age < 65 Not at-risk | D29 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID50 | 72 | 5 (5, 5) | 38 (26, 55) | 7.31 (5.13, 10.41) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|----------------------|-----------------------|---------|---------------------|------------------------|-----|------------------|----------------------------|----------------------------------|
| Age < 65 Not at-risk | D29 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID80 | 72 | 5 (5, 5) | 101 (68, 150) | 19.90 (13.43, 29.49) |
| Age < 65 Not at-risk | D57 fold-rise over D1 | Vaccine | Negative | Anti N IgG (IU/ml) | 218 | 10 (10, 10) | 260904 (193707, 351412) | 26090.40 (19370.69, 35141.19) |
| Age < 65 Not at-risk | D57 fold-rise over D1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 218 | 10 (10, 10) | 730590 (572430, 932450) | 72557.28 (56856.08, 92594.47) |
| Age < 65 Not at-risk | D57 fold-rise over D1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 218 | 10 (10, 10) | 1685764 (1382036, 2056240) | 168576.35 (138203.64, 205624.01) |
| Age < 65 Not at-risk | D57 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 218 | 5 (5, 5) | 1118 (830, 1506) | 222.65 (165.28, 299.92) |
| Age < 65 Not at-risk | D57 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 218 | 5 (5, 5) | 1671 (1216, 2295) | 330.08 (240.60, 452.85) |
| Age < 65 Not at-risk | D57 fold-rise over D1 | Vaccine | Positive | Anti N IgG (IU/ml) | 73 | 10 (10, 10) | 712451 (424544, 1195605) | 71245.12 (42454.38, 119560.51) |
| Age < 65 Not at-risk | D57 fold-rise over D1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 73 | 10 (10, 10) | 1679359 (1144789, 2463552) | 167935.92 (114478.90, 246355.20) |
| Age < 65 Not at-risk | D57 fold-rise over D1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 73 | 10 (10, 10) | 4192147 (3040678, 5779665) | 419214.74 (304067.80, 577966.50) |
| Age < 65 Not at-risk | D57 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 73 | 5 (5, 5) | 4435 (2453, 8017) | 871.87 (485.49, 1565.77) |
| Age < 65 Not at-risk | D57 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 73 | 5 (5, 5) | 5833 (3464, 9821) | 1141.93 (678.45, 1922.04) |
| Age < 65 Not at-risk | D57 fold-rise over D1 | Placebo | Negative | Anti N IgG (IU/ml) | 40 | 10 (10, 11) | 10 (10, 10) | 0.97 (0.92, 1.03) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|----------------------|-----------------------|---------|---------------------|------------------------|-----|------------------|----------------------------|----------------------------------|
| Age < 65 Not at-risk | D57 fold-rise over D1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 40 | 10 (10, 11) | 10 (10, 10) | 0.97 (0.91, 1.03) |
| Age < 65 Not at-risk | D57 fold-rise over D1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 40 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age < 65 Not at-risk | D57 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID50 | 40 | 5 (5, 5) | 5 (5, 5) | 1.00 (1.00, 1.00) |
| Age < 65 Not at-risk | D57 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID80 | 40 | 5 (5, 6) | 5 (5, 5) | 0.97 (0.90, 1.03) |
| Age < 65 Not at-risk | D57 fold-rise over D1 | Placebo | Positive | Anti N IgG (IU/ml) | 72 | 10 (10, 11) | 88760 (53701, 146707) | 8700.37 (5323.82, 14218.42) |
| Age < 65 Not at-risk | D57 fold-rise over D1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 72 | 10 (10, 10) | 241209 (168681, 344922) | 24120.91 (16868.12, 34492.19) |
| Age < 65 Not at-risk | D57 fold-rise over D1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 72 | 10 (10, 10) | 463469 (322830, 665378) | 46346.93 (32282.95, 66537.83) |
| Age < 65 Not at-risk | D57 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID50 | 72 | 5 (5, 5) | 362 (224, 583) | 69.97 (43.74, 111.92) |
| Age < 65 Not at-risk | D57 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID80 | 72 | 5 (5, 5) | 930 (559, 1549) | 183.66 (110.80, 304.42) |
| Age ≥ 65 At-risk | D29 fold-rise over D1 | Vaccine | Negative | Anti N IgG (IU/ml) | 255 | 10 (10, 10) | 48363 (38230, 61183) | 4808.12 (3800.84, 6082.35) |
| Age ≥ 65 At-risk | D29 fold-rise over D1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 255 | 10 (10, 10) | 54232 (44615, 65922) | 5389.56 (4435.12, 6549.39) |
| Age ≥ 65 At-risk | D29 fold-rise over D1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 255 | 10 (10, 10) | 84391 (70325, 101269) | 8352.45 (6975.06, 10001.82) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|------------------|-----------------------|---------|---------------------|------------------------|-----|------------------|----------------------------|----------------------------------|
| Age ≥ 65 At-risk | D29 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 255 | 5 (5, 5) | 199 (157, 252) | 39.22 (30.90, 49.78) |
| Age ≥ 65 At-risk | D29 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 255 | 5 (5, 5) | 348 (276, 438) | 68.12 (54.16, 85.68) |
| Age ≥ 65 At-risk | D29 fold-rise over D1 | Vaccine | Positive | Anti N IgG (IU/ml) | 52 | 10 (10, 10) | 134756 (86047, 211040) | 13475.64 (8604.68, 21103.95) |
| Age ≥ 65 At-risk | D29 fold-rise over D1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 52 | 10 (10, 10) | 188670 (129392, 275106) | 18867.03 (12939.21, 27510.55) |
| Age ≥ 65 At-risk | D29 fold-rise over D1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 52 | 10 (10, 10) | 293282 (210942, 407763) | 29328.19 (21094.20, 40776.26) |
| Age ≥ 65 At-risk | D29 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 52 | 5 (5, 6) | 541 (337, 870) | 100.78 (63.88, 159.01) |
| Age ≥ 65 At-risk | D29 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 52 | 5 (5, 5) | 1052 (680, 1627) | 210.47 (136.09, 325.50) |
| Age ≥ 65 At-risk | D29 fold-rise over D1 | Placebo | Negative | Anti N IgG (IU/ml) | 44 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age ≥ 65 At-risk | D29 fold-rise over D1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 44 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age ≥ 65 At-risk | D29 fold-rise over D1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 44 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age ≥ 65 At-risk | D29 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID50 | 44 | 5 (5, 5) | 5 (5, 5) | 1.03 (0.99, 1.08) |
| Age ≥ 65 At-risk | D29 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID80 | 44 | 5 (5, 5) | 5 (5, 5) | 1.02 (0.98, 1.06) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|------------------|-----------------------|---------|---------------------|------------------------|-----|------------------|--------------------------------|--------------------------------------|
| Age ≥ 65 At-risk | D29 fold-rise over D1 | Placebo | Positive | Anti N IgG (IU/ml) | 48 | 10 (10, 10) | 36017 (20724, 62595) | 3554.56 (2039.96, 6193.68) |
| Age ≥ 65 At-risk | D29 fold-rise over D1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 48 | 10 (10, 11) | 48060 (30237, 76388) | 4715.92 (2980.60, 7461.57) |
| Age ≥ 65 At-risk | D29 fold-rise over D1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 48 | 10 (10, 10) | 79058 (52125, 119908) | 7905.78 (5212.45, 11990.78) |
| Age ≥ 65 At-risk | D29 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID50 | 48 | 5 (5, 5) | 155 (89, 270) | 29.89 (17.24, 51.82) |
| Age ≥ 65 At-risk | D29 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID80 | 48 | 5 (5, 5) | 378 (233, 613) | 74.62 (45.91, 121.29) |
| Age ≥ 65 At-risk | D57 fold-rise over D1 | Vaccine | Negative | Anti N IgG (IU/ml) | 255 | 10 (10, 10) | 614449 (455495, 828875) | 61086.86 (45285.39, 82401.95) |
| Age ≥ 65 At-risk | D57 fold-rise over D1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 255 | 10 (10, 10) | 2156196 (1736284, 2677662) | 214282.06 (172705.04, 265868.34) |
| Age ≥ 65 At-risk | D57 fold-rise over D1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 255 | 10 (10, 10) | 3754377 (3053564, 4616033) | 371583.87 (302329.22, 456702.71) |
| Age ≥ 65 At-risk | D57 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 255 | 5 (5, 5) | 3359 (2423, 4656) | 662.04 (477.45, 917.99) |
| Age ≥ 65 At-risk | D57 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 255 | 5 (5, 5) | 4361 (3299, 5763) | 854.58 (648.16, 1126.74) |
| Age ≥ 65 At-risk | D57 fold-rise over D1 | Vaccine | Positive | Anti N IgG (IU/ml) | 52 | 10 (10, 10) | 3325369 (2089439, 5292368) | 332536.90 (208943.88, 529236.81) |
| Age ≥ 65 At-risk | D57 fold-rise over D1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 52 | 10 (10, 10) | 7826271 (5853680, 10463591) | 782627.11 (585368.05, 1046359.11) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|------------------|-----------------------|---------|---------------------|------------------------|----|------------------|----------------------------------|--|
| Age ≥ 65 At-risk | D57 fold-rise over D1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 52 | 10 (10, 10) | 12884976 (10641883, 15600868) | 1288497.62 (1064188.30, 1560086.81) |
| Age ≥ 65 At-risk | D57 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 52 | 5 (5, 6) | 27431 (17819, 42227) | 5108.47 (3366.93, 7750.83) |
| Age ≥ 65 At-risk | D57 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 52 | 5 (5, 5) | 22502 (13237, 38254) | 4500.48 (2647.36, 7650.76) |
| Age ≥ 65 At-risk | D57 fold-rise over D1 | Placebo | Negative | Anti N IgG (IU/ml) | 44 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age ≥ 65 At-risk | D57 fold-rise over D1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 44 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age ≥ 65 At-risk | D57 fold-rise over D1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 44 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age ≥ 65 At-risk | D57 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID50 | 44 | 5 (5, 5) | 5 (5, 5) | 1.00 (1.00, 1.00) |
| Age ≥ 65 At-risk | D57 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID80 | 44 | 5 (5, 5) | 5 (5, 6) | 1.04 (0.97, 1.11) |
| Age ≥ 65 At-risk | D57 fold-rise over D1 | Placebo | Positive | Anti N IgG (IU/ml) | 48 | 10 (10, 10) | 617829 (374065, 1020446) | 60974.99 (36881.21, 100808.77) |
| Age ≥ 65 At-risk | D57 fold-rise over D1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 48 | 10 (10, 11) | 1793880 (1112795, 2891824) | 176025.95 (109237.32, 283649.72) |
| Age ≥ 65 At-risk | D57 fold-rise over D1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 48 | 10 (10, 10) | 3402410 (2325361, 4978321) | 340240.98 (232536.09, 497832.07) |
| Age ≥ 65 At-risk | D57 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID50 | 48 | 5 (5, 5) | 3501 (1863, 6577) | 675.29 (361.89, 1260.11) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|----------------------|-----------------------|---------|---------------------|------------------------|-----|------------------|----------------------------|----------------------------------|
| Age ≥ 65 At-risk | D57 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID80 | 48 | 5 (5, 5) | 5048 (2709, 9408) | 997.20 (534.99, 1858.76) |
| Age ≥ 65 Not at-risk | D29 fold-rise over D1 | Vaccine | Negative | Anti N IgG (IU/ml) | 227 | 10 (10, 10) | 75305 (60091, 94371) | 7472.04 (5960.28, 9367.23) |
| Age ≥ 65 Not at-risk | D29 fold-rise over D1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 227 | 10 (10, 10) | 80069 (65707, 97571) | 7979.90 (6548.33, 9724.45) |
| Age ≥ 65 Not at-risk | D29 fold-rise over D1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 227 | 10 (10, 10) | 153593 (130667, 180543) | 15359.34 (13066.69, 18054.25) |
| Age ≥ 65 Not at-risk | D29 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 227 | 5 (5, 5) | 332 (263, 418) | 65.09 (51.60, 82.12) |
| Age ≥ 65 Not at-risk | D29 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 227 | 5 (5, 5) | 421 (328, 540) | 81.90 (63.99, 104.83) |
| Age ≥ 65 Not at-risk | D29 fold-rise over D1 | Vaccine | Positive | Anti N IgG (IU/ml) | 76 | 10 (10, 11) | 127407 (81244, 199800) | 12465.97 (8016.45, 19385.18) |
| Age ≥ 65 Not at-risk | D29 fold-rise over D1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 76 | 10 (10, 10) | 139826 (99996, 195520) | 13982.56 (9999.60, 19552.00) |
| Age ≥ 65 Not at-risk | D29 fold-rise over D1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 76 | 10 (10, 10) | 241494 (182978, 318724) | 24149.39 (18297.76, 31872.38) |
| Age ≥ 65 Not at-risk | D29 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 76 | 5 (5, 5) | 508 (317, 815) | 99.68 (62.60, 158.74) |
| Age ≥ 65 Not at-risk | D29 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 76 | 5 (5, 5) | 944 (626, 1422) | 188.75 (125.29, 284.35) |
| Age ≥ 65 Not at-risk | D29 fold-rise over D1 | Placebo | Negative | Anti N IgG (IU/ml) | 39 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|----------------------|-----------------------|---------|---------------------|------------------------|-----|------------------|----------------------------|----------------------------------|
| Age ≥ 65 Not at-risk | D29 fold-rise over D1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 39 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age ≥ 65 Not at-risk | D29 fold-rise over D1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 39 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age ≥ 65 Not at-risk | D29 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID50 | 39 | 5 (5, 5) | 5 (5, 5) | 1.00 (1.00, 1.00) |
| Age ≥ 65 Not at-risk | D29 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID80 | 39 | 5 (5, 5) | 5 (5, 5) | 0.99 (0.96, 1.01) |
| Age ≥ 65 Not at-risk | D29 fold-rise over D1 | Placebo | Positive | Anti N IgG (IU/ml) | 75 | 10 (10, 10) | 34367 (22390, 52751) | 3398.18 (2213.28, 5217.45) |
| Age ≥ 65 Not at-risk | D29 fold-rise over D1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 75 | 10 (10, 10) | 38048 (27669, 52321) | 3804.83 (2766.90, 5232.12) |
| Age ≥ 65 Not at-risk | D29 fold-rise over D1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 75 | 10 (10, 10) | 59664 (45819, 77691) | 5966.37 (4581.94, 7769.08) |
| Age ≥ 65 Not at-risk | D29 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID50 | 75 | 5 (5, 5) | 156 (105, 232) | 30.49 (20.53, 45.27) |
| Age ≥ 65 Not at-risk | D29 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID80 | 75 | 5 (5, 5) | 257 (170, 390) | 50.29 (33.38, 75.76) |
| Age ≥ 65 Not at-risk | D57 fold-rise over D1 | Vaccine | Negative | Anti N IgG (IU/ml) | 227 | 10 (10, 10) | 1177109 (909148, 1524048) | 116797.25 (90218.92, 151205.51) |
| Age ≥ 65 Not at-risk | D57 fold-rise over D1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 227 | 10 (10, 10) | 3441017 (2860842, 4138850) | 342939.68 (285103.95, 412507.88) |
| Age ≥ 65 Not at-risk | D57 fold-rise over D1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 227 | 10 (10, 10) | 7365218 (6408010, 8465410) | 736521.80 (640801.04, 846541.01) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|----------------------|-----------------------|---------|---------------------|------------------------|-----|------------------|----------------------------------|--|
| Age ≥ 65 Not at-risk | D57 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 227 | 5 (5, 5) | 5534 (4137, 7404) | 1085.68 (812.27, 1451.14) |
| Age ≥ 65 Not at-risk | D57 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 227 | 5 (5, 5) | 7125 (5468, 9285) | 1386.74 (1065.57, 1804.72) |
| Age ≥ 65 Not at-risk | D57 fold-rise over D1 | Vaccine | Positive | Anti N IgG (IU/ml) | 76 | 10 (10, 11) | 2806906 (1779671, 4427066) | 274637.99 (174793.56, 431514.90) |
| Age ≥ 65 Not at-risk | D57 fold-rise over D1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 76 | 10 (10, 10) | 7305563 (5522547, 9664247) | 730556.35 (552254.70, 966424.70) |
| Age ≥ 65 Not at-risk | D57 fold-rise over D1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 76 | 10 (10, 10) | 13343347 (11421210, 15588971) | 1334334.72 (1142121.04, 1558897.08) |
| Age ≥ 65 Not at-risk | D57 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 76 | 5 (5, 5) | 18240 (11134, 29880) | 3577.07 (2192.53, 5835.90) |
| Age ≥ 65 Not at-risk | D57 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 76 | 5 (5, 5) | 17541 (10280, 29932) | 3508.28 (2056.01, 5986.35) |
| Age ≥ 65 Not at-risk | D57 fold-rise over D1 | Placebo | Negative | Anti N IgG (IU/ml) | 39 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age ≥ 65 Not at-risk | D57 fold-rise over D1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 39 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age ≥ 65 Not at-risk | D57 fold-rise over D1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 39 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age ≥ 65 Not at-risk | D57 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID50 | 39 | 5 (5, 5) | 5 (5, 6) | 1.05 (0.98, 1.11) |
| Age ≥ 65 Not at-risk | D57 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID80 | 39 | 5 (5, 5) | 5 (5, 5) | 0.99 (0.96, 1.01) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|---------------------------|-----------------------|---------|---------------------|------------------------|----|------------------|-------------------------------|-------------------------------------|
| Age \geq 65 Not at-risk | D57 fold-rise over D1 | Placebo | Positive | Anti N IgG (IU/ml) | 75 | 10 (10, 10) | 461295 (282331, 753702) | 45612.82 (27970.09, 74384.08) |
| Age \geq 65 Not at-risk | D57 fold-rise over D1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 75 | 10 (10, 10) | 1599200 (1156266, 2211811) | 159920.02 (115626.58, 221181.10) |
| Age \geq 65 Not at-risk | D57 fold-rise over D1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 75 | 10 (10, 10) | 2437171 (1815977, 3270859) | 243717.12 (181597.68, 327085.88) |
| Age \geq 65 Not at-risk | D57 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID50 | 75 | 5 (5, 5) | 2442 (1442, 4134) | 476.56 (282.81, 803.04) |
| Age \geq 65 Not at-risk | D57 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID80 | 75 | 5 (5, 5) | 3681 (2278, 5949) | 719.25 (447.61, 1155.75) |

Table 6e. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Sex

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|------------|-----------------------|---------|---------------------|------------------------|-----|------------------|--------------------------|--------------------------------|
| Sex | | | | | | | | |
| Male | D29 fold-rise over D1 | Vaccine | Negative | Anti N IgG (IU/ml) | 395 | 10 (10, 10) | 27118 (20803, 35351) | 2707.97 (2077.28, 3530.15) |
| Male | D29 fold-rise over D1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 395 | 10 (10, 10) | 25738 (20110, 32941) | 2547.65 (1992.51, 3257.47) |
| Male | D29 fold-rise over D1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 395 | 10 (10, 10) | 40290 (34397, 47193) | 4021.73 (3433.73, 4710.40) |
| Male | D29 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 395 | 5 (5, 5) | 121 (93, 157) | 23.94 (18.44, 31.08) |
| Male | D29 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 395 | 5 (5, 5) | 207 (158, 272) | 41.19 (31.36, 54.12) |
| Male | D29 fold-rise over D1 | Vaccine | Positive | Anti N IgG (IU/ml) | 121 | 10 (10, 10) | 52664 (36905, 75154) | 5247.05 (3679.29, 7482.84) |
| Male | D29 fold-rise over D1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 121 | 10 (10, 10) | 43301 (30763, 60949) | 4330.07 (3076.26, 6094.90) |
| Male | D29 fold-rise over D1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 121 | 10 (10, 10) | 83762 (65541, 107048) | 8376.20 (6554.14, 10704.79) |
| Male | D29 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 121 | 5 (5, 5) | 223 (158, 315) | 44.26 (31.35, 62.49) |
| Male | D29 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 121 | 5 (5, 5) | 449 (303, 666) | 88.19 (59.60, 130.49) |
| Male | D29 fold-rise over D1 | Placebo | Negative | Anti N IgG (IU/ml) | 76 | 10 (10, 11) | 10 (10, 10) | 0.96 (0.88, 1.04) |
| Male | D29 fold-rise over D1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 76 | 11 (9, 12) | 10 (10, 10) | 0.95 (0.85, 1.05) |
| Male | D29 fold-rise over D1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 76 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Male | D29 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID50 | 76 | 5 (5, 5) | 5 (5, 5) | 1.02 (0.98, 1.07) |
| Male | D29 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID80 | 76 | 5 (5, 5) | 5 (5, 5) | 1.00 (0.99, 1.00) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|-------|-----------------------|---------|---------------------|------------------------|-----|------------------|-------------------------------|-------------------------------------|
| Male | D29 fold-rise over D1 | Placebo | Positive | Anti N IgG (IU/ml) | 115 | 10 (10, 10) | 11707 (7655, 17903) | 1170.65 (765.46, 1790.34) |
| Male | D29 fold-rise over D1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 115 | 10 (10, 10) | 12838 (8743, 18852) | 1283.80 (874.26, 1885.18) |
| Male | D29 fold-rise over D1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 115 | 10 (10, 10) | 16359 (12044, 22219) | 1635.88 (1204.42, 2221.91) |
| Male | D29 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID50 | 115 | 5 (5, 5) | 43 (29, 63) | 8.45 (5.76, 12.39) |
| Male | D29 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID80 | 115 | 5 (5, 5) | 100 (68, 146) | 19.80 (13.54, 28.93) |
| Male | D57 fold-rise over D1 | Vaccine | Negative | Anti N IgG (IU/ml) | 395 | 10 (10, 10) | 358185 (259645, 494122) | 35767.67 (25927.56, 49342.34) |
| Male | D57 fold-rise over D1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 395 | 10 (10, 10) | 1032572 (803692, 1326633) | 102207.86 (79582.66, 131265.36) |
| Male | D57 fold-rise over D1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 395 | 10 (10, 10) | 2448348 (1992531, 3008439) | 244392.84 (198889.12, 300307.33) |
| Male | D57 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 395 | 5 (5, 5) | 1983 (1427, 2754) | 392.99 (282.86, 546.00) |
| Male | D57 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 395 | 5 (5, 5) | 2322 (1694, 3181) | 461.27 (336.67, 631.96) |
| Male | D57 fold-rise over D1 | Vaccine | Positive | Anti N IgG (IU/ml) | 121 | 10 (10, 10) | 1379076 (895389, 2124049) | 137399.94 (89225.93, 211583.59) |
| Male | D57 fold-rise over D1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 121 | 10 (10, 10) | 2628794 (1842173, 3751308) | 262879.40 (184217.30, 375130.79) |
| Male | D57 fold-rise over D1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 121 | 10 (10, 10) | 5518909 (4222583, 7213204) | 551890.89 (422258.33, 721320.40) |
| Male | D57 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 121 | 5 (5, 5) | 5567 (3235, 9581) | 1105.10 (642.29, 1901.37) |
| Male | D57 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 121 | 5 (5, 5) | 9590 (6259, 14696) | 1881.91 (1235.71, 2866.05) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|--------|-----------------------|---------|---------------------|------------------------|-----|------------------|----------------------------|----------------------------------|
| Male | D57 fold-rise over D1 | Placebo | Negative | Anti N IgG (IU/ml) | 76 | 10 (10, 11) | 10 (10, 10) | 0.96 (0.88, 1.04) |
| Male | D57 fold-rise over D1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 76 | 11 (9, 12) | 10 (10, 10) | 0.96 (0.86, 1.07) |
| Male | D57 fold-rise over D1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 76 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Male | D57 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID50 | 76 | 5 (5, 5) | 5 (5, 5) | 1.01 (0.99, 1.02) |
| Male | D57 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID80 | 76 | 5 (5, 5) | 5 (5, 5) | 1.00 (0.99, 1.00) |
| Male | D57 fold-rise over D1 | Placebo | Positive | Anti N IgG (IU/ml) | 115 | 10 (10, 10) | 120405 (68919, 210356) | 12040.55 (6891.87, 21035.63) |
| Male | D57 fold-rise over D1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 115 | 10 (10, 10) | 361345 (243436, 536364) | 36134.52 (24343.59, 53636.45) |
| Male | D57 fold-rise over D1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 115 | 10 (10, 10) | 578439 (406742, 822616) | 57843.93 (40674.16, 82261.55) |
| Male | D57 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID50 | 115 | 5 (5, 5) | 606 (358, 1023) | 120.00 (71.07, 202.60) |
| Male | D57 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID80 | 115 | 5 (5, 5) | 930 (554, 1559) | 184.20 (109.85, 308.87) |
| Female | D29 fold-rise over D1 | Vaccine | Negative | Anti N IgG (IU/ml) | 519 | 10 (10, 10) | 21438 (17319, 26535) | 2136.48 (1726.18, 2644.32) |
| Female | D29 fold-rise over D1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 519 | 10 (10, 10) | 21234 (17837, 25278) | 2116.93 (1778.05, 2520.39) |
| Female | D29 fold-rise over D1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 519 | 10 (10, 10) | 41415 (35725, 48012) | 4138.70 (3570.16, 4797.78) |
| Female | D29 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 519 | 5 (5, 5) | 98 (80, 120) | 19.27 (15.73, 23.62) |
| Female | D29 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 519 | 5 (5, 5) | 178 (145, 218) | 34.90 (28.55, 42.66) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|--------|-----------------------|---------|---------------------|------------------------|-----|------------------|--------------------------|--------------------------------|
| Female | D29 fold-rise over D1 | Vaccine | Positive | Anti N IgG (IU/ml) | 153 | 10 (10, 10) | 37697 (26222, 54193) | 3755.35 (2612.56, 5398.02) |
| Female | D29 fold-rise over D1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 153 | 10 (10, 10) | 32117 (22658, 45526) | 3211.74 (2265.79, 4552.63) |
| Female | D29 fold-rise over D1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 153 | 10 (10, 10) | 77611 (57216, 105276) | 7761.12 (5721.63, 10527.59) |
| Female | D29 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 153 | 5 (5, 5) | 165 (113, 242) | 32.19 (21.92, 47.27) |
| Female | D29 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 153 | 5 (5, 5) | 401 (268, 602) | 79.18 (52.69, 118.97) |
| Female | D29 fold-rise over D1 | Placebo | Negative | Anti N IgG (IU/ml) | 87 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Female | D29 fold-rise over D1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 87 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Female | D29 fold-rise over D1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 87 | 10 (10, 10) | 10 (10, 10) | 0.99 (0.97, 1.01) |
| Female | D29 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID50 | 87 | 5 (5, 5) | 5 (5, 5) | 1.00 (0.98, 1.01) |
| Female | D29 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID80 | 87 | 5 (5, 6) | 5 (5, 5) | 0.99 (0.92, 1.07) |
| Female | D29 fold-rise over D1 | Placebo | Positive | Anti N IgG (IU/ml) | 155 | 10 (10, 11) | 13066 (8983, 19004) | 1274.54 (888.11, 1829.10) |
| Female | D29 fold-rise over D1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 155 | 10 (10, 10) | 12876 (9489, 17472) | 1284.49 (946.73, 1742.74) |
| Female | D29 fold-rise over D1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 155 | 10 (10, 10) | 19468 (15496, 24459) | 1946.81 (1549.59, 2445.85) |
| Female | D29 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID50 | 155 | 5 (5, 5) | 58 (42, 81) | 11.13 (8.13, 15.24) |
| Female | D29 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID80 | 155 | 5 (5, 5) | 152 (105, 219) | 29.90 (20.91, 42.76) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|--------|-----------------------|---------|---------------------|------------------------|-----|------------------|-------------------------------|-------------------------------------|
| Female | D57 fold-rise over D1 | Vaccine | Negative | Anti N IgG (IU/ml) | 519 | 10 (10, 10) | 304934 (237911, 390840) | 30389.88 (23713.90, 38945.28) |
| Female | D57 fold-rise over D1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 519 | 10 (10, 10) | 924524 (750510, 1138886) | 92171.55 (74822.64, 113543.10) |
| Female | D57 fold-rise over D1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 519 | 10 (10, 10) | 1878895 (1586011, 2225864) | 187761.05 (158494.70, 222431.47) |
| Female | D57 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 519 | 5 (5, 5) | 1243 (972, 1588) | 244.86 (191.72, 312.74) |
| Female | D57 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 519 | 5 (5, 5) | 2160 (1643, 2840) | 424.30 (323.30, 556.85) |
| Female | D57 fold-rise over D1 | Vaccine | Positive | Anti N IgG (IU/ml) | 153 | 10 (10, 10) | 785331 (484933, 1271815) | 78234.14 (48312.07, 126688.43) |
| Female | D57 fold-rise over D1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 153 | 10 (10, 10) | 2106655 (1490680, 2977161) | 210665.51 (149068.03, 297716.12) |
| Female | D57 fold-rise over D1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 153 | 10 (10, 10) | 5236885 (3880756, 7066912) | 523688.47 (388075.59, 706691.20) |
| Female | D57 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 153 | 5 (5, 5) | 5754 (3356, 9868) | 1120.71 (659.00, 1905.91) |
| Female | D57 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 153 | 5 (5, 5) | 6872 (4174, 11314) | 1355.55 (821.91, 2235.68) |
| Female | D57 fold-rise over D1 | Placebo | Negative | Anti N IgG (IU/ml) | 87 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Female | D57 fold-rise over D1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 87 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Female | D57 fold-rise over D1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 87 | 10 (10, 10) | 10 (10, 10) | 0.99 (0.97, 1.01) |
| Female | D57 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID50 | 87 | 5 (5, 5) | 5 (5, 5) | 1.00 (0.98, 1.02) |
| Female | D57 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID80 | 87 | 5 (5, 6) | 5 (5, 5) | 0.98 (0.92, 1.04) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|--------|-----------------------|---------|---------------------|------------------------|-----|--|--|--|
| Female | D57 fold-rise over D1 | Placebo | Positive | Anti N IgG (IU/ml) | 155 | 10 (10, 11) 10 (10, 10) 10 (10, 10) | 136546 (89268, 208864) 396863 (289955, 543189) 748414 (540245, 1036794) | 13319.90 (8844.86, 20059.09) 39591.01 (28926.67, 54186.94) 74841.37 (54024.52, 103679.41) |
| Female | D57 fold-rise over D1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 155 | 5 (5, 5) | 541 (355, 825) | 103.77 (68.77, 156.56) |
| Female | D57 fold-rise over D1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 155 | 5 (5, 5) | 1659 (1064, 2588) | 326.50 (210.44, 506.55) |
| Female | D57 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID50 | 155 | 5 (5, 5) | 541 (355, 825) | 103.77 (68.77, 156.56) |
| Female | D57 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID80 | 155 | 5 (5, 5) | 1659 (1064, 2588) | 326.50 (210.44, 506.55) |

Table 6f. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Age, sex

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|-----------------|-----------------------|---------|---------------------|------------------------|-----|------------------|-------------------------|-------------------------------|
| Age, sex | | | | | | | | |
| Age < 65 Female | D29 fold-rise over D1 | Vaccine | Negative | Anti N IgG (IU/ml) | 269 | 10 (10, 10) | 17005 (13156, 21980) | 1696.36 (1312.50, 2192.48) |
| Age < 65 Female | D29 fold-rise over D1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 269 | 10 (10, 10) | 16543 (13418, 20396) | 1649.23 (1337.49, 2033.63) |
| Age < 65 Female | D29 fold-rise over D1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 269 | 10 (10, 10) | 32705 (27399, 39039) | 3270.52 (2739.91, 3903.89) |
| Age < 65 Female | D29 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 269 | 5 (5, 5) | 79 (62, 101) | 15.62 (12.24, 19.92) |
| Age < 65 Female | D29 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 269 | 5 (5, 5) | 150 (118, 191) | 29.60 (23.28, 37.64) |
| Age < 65 Female | D29 fold-rise over D1 | Vaccine | Positive | Anti N IgG (IU/ml) | 79 | 10 (10, 10) | 27788 (17970, 42970) | 2771.79 (1792.45, 4286.21) |
| Age < 65 Female | D29 fold-rise over D1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 79 | 10 (10, 10) | 21789 (14248, 33321) | 2178.91 (1424.83, 3332.11) |
| Age < 65 Female | D29 fold-rise over D1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 79 | 10 (10, 10) | 56962 (39317, 82526) | 5696.22 (3931.72, 8252.62) |
| Age < 65 Female | D29 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 79 | 5 (5, 5) | 124 (78, 197) | 24.32 (15.30, 38.67) |
| Age < 65 Female | D29 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 79 | 5 (5, 5) | 319 (195, 522) | 62.74 (38.25, 102.90) |
| Age < 65 Female | D29 fold-rise over D1 | Placebo | Negative | Anti N IgG (IU/ml) | 52 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|-----------------|-----------------------|---------|---------------------|------------------------|-----|------------------|----------------------------|----------------------------------|
| Age < 65 Female | D29 fold-rise over D1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 52 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age < 65 Female | D29 fold-rise over D1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 52 | 10 (10, 10) | 10 (10, 10) | 0.99 (0.97, 1.01) |
| Age < 65 Female | D29 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID50 | 52 | 5 (5, 5) | 5 (5, 5) | 0.99 (0.97, 1.01) |
| Age < 65 Female | D29 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID80 | 52 | 5 (5, 6) | 5 (5, 5) | 0.99 (0.90, 1.08) |
| Age < 65 Female | D29 fold-rise over D1 | Placebo | Positive | Anti N IgG (IU/ml) | 83 | 10 (10, 11) | 10603 (6760, 16631) | 1033.17 (669.94, 1593.35) |
| Age < 65 Female | D29 fold-rise over D1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 83 | 10 (10, 10) | 10100 (6984, 14608) | 1010.05 (698.40, 1460.75) |
| Age < 65 Female | D29 fold-rise over D1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 83 | 10 (10, 10) | 14961 (11369, 19689) | 1496.11 (1136.86, 1968.90) |
| Age < 65 Female | D29 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID50 | 83 | 5 (5, 6) | 46 (31, 69) | 8.74 (6.00, 12.74) |
| Age < 65 Female | D29 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID80 | 83 | 5 (5, 5) | 133 (86, 207) | 26.17 (16.99, 40.31) |
| Age < 65 Female | D57 fold-rise over D1 | Vaccine | Negative | Anti N IgG (IU/ml) | 269 | 10 (10, 10) | 240348 (178375, 323851) | 23976.19 (17797.28, 32300.31) |
| Age < 65 Female | D57 fold-rise over D1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 269 | 10 (10, 10) | 725439 (563976, 933126) | 72323.27 (56225.78, 93029.48) |
| Age < 65 Female | D57 fold-rise over D1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 269 | 10 (10, 10) | 1494002 (1218429, 1831901) | 149400.21 (121842.92, 183190.15) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|-----------------|-----------------------|---------|---------------------|------------------------|-----|------------------|-------------------------------|-------------------------------------|
| Age < 65 Female | D57 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 269 | 5 (5, 5) | 946 (706, 1267) | 186.45 (139.19, 249.76) |
| Age < 65 Female | D57 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 269 | 5 (5, 5) | 1691 (1216, 2352) | 332.97 (239.88, 462.17) |
| Age < 65 Female | D57 fold-rise over D1 | Vaccine | Positive | Anti N IgG (IU/ml) | 79 | 10 (10, 10) | 582852 (324144, 1048040) | 58138.58 (32334.21, 104536.20) |
| Age < 65 Female | D57 fold-rise over D1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 79 | 10 (10, 10) | 1557246 (1019727, 2378101) | 155724.56 (101972.70, 237810.10) |
| Age < 65 Female | D57 fold-rise over D1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 79 | 10 (10, 10) | 4234642 (2930914, 6118296) | 423464.24 (293091.36, 611829.57) |
| Age < 65 Female | D57 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 79 | 5 (5, 5) | 4195 (2173, 8100) | 820.85 (429.44, 1568.99) |
| Age < 65 Female | D57 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 79 | 5 (5, 5) | 5422 (2964, 9918) | 1066.04 (581.49, 1954.38) |
| Age < 65 Female | D57 fold-rise over D1 | Placebo | Negative | Anti N IgG (IU/ml) | 52 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age < 65 Female | D57 fold-rise over D1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 52 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age < 65 Female | D57 fold-rise over D1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 52 | 10 (10, 10) | 10 (10, 10) | 0.99 (0.97, 1.01) |
| Age < 65 Female | D57 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID50 | 52 | 5 (5, 5) | 5 (5, 5) | 1.00 (0.97, 1.02) |
| Age < 65 Female | D57 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID80 | 52 | 5 (5, 6) | 5 (5, 5) | 0.97 (0.90, 1.04) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|-----------------|-----------------------|---------|---------------------|------------------------|-----|--------------------------------------|--------------------------------|--|
| Age < 65 Female | D57 fold-rise over D1 | Placebo | Positive | Anti N IgG (IU/ml) | 83 | 10 (10, 11) (60463, 168711) | 100999 (201048, 428852) | 9841.83 (6007.63, 16123.08) |
| Age < 65 Female | D57 fold-rise over D1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 83 | 10 (10, 10) (384900, 848795) | 293632 (20104.77, 42885.16) | 29363.18 (57157.76, 38489.96, 84879.54) |
| Age < 65 Female | D57 fold-rise over D1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 83 | 10 (10, 10) (233, 641) | 571578 (804, 2349) | 73.68 (45.02, 120.60) |
| Age < 65 Female | D57 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID50 | 83 | 5 (5, 6) (14896, 29540) | 387 (13705, 26001) | 270.38 (1866.53, 2937.19) |
| Age < 65 Female | D57 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID80 | 83 | 5 (5, 5) (24030, 35901) | 1375 (67, 132) | (2402.98, 3590.15) (18.70, 33.64) |
| Age < 65 Male | D29 fold-rise over D1 | Vaccine | Negative | Anti N IgG (IU/ml) | 163 | 10 (10, 10) (118, 240) | 20977 (27088, 64734) | 2097.68 (4187.48, 41874.8) |
| Age < 65 Male | D29 fold-rise over D1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 163 | 10 (10, 10) (20281, 47031) | 18877 (20281, 47031) | (1866.53, 3088.44) |
| Age < 65 Male | D29 fold-rise over D1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 163 | 10 (10, 10) (47023, 85688) | 29372 (4702.33, 8568.81) | (2937.19, 6347.70) |
| Age < 65 Male | D29 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 163 | 5 (5, 5) (5, 5) | 94 (119, 274) | (18.70, 33.64) |
| Age < 65 Male | D29 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 163 | 5 (5, 5) (119, 274) | 169 (118, 240) | (23.62, 47.90) |
| Age < 65 Male | D29 fold-rise over D1 | Vaccine | Positive | Anti N IgG (IU/ml) | 67 | 10 (10, 10) (2708.77, 6473.42) | 41875 (2708.77, 6473.42) | 4187.48 (3088.44, 6347.70) |
| Age < 65 Male | D29 fold-rise over D1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 67 | 10 (10, 10) (20281, 47031) | 30884 (47023, 85688) | (2028.11, 4703.13) |
| Age < 65 Male | D29 fold-rise over D1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 67 | 10 (10, 10) (119, 274) | 63477 (119, 274) | (4702.33, 8568.81) |
| Age < 65 Male | D29 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 67 | 5 (5, 5) (23.79, 54.76) | 180 (23.79, 54.76) | 36.09 |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|---------------|-----------------------|---------|---------------------|------------------------|-----|------------------|-------------------------------|-------------------------------------|
| Age < 65 Male | D29 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 67 | 5 (5, 5) | 372 (229, 604) | 72.62 (44.83, 117.63) |
| Age < 65 Male | D29 fold-rise over D1 | Placebo | Negative | Anti N IgG (IU/ml) | 28 | 11 (9, 12) | 10 (10, 10) | 0.93 (0.81, 1.07) |
| Age < 65 Male | D29 fold-rise over D1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 28 | 11 (9, 13) | 10 (10, 10) | 0.92 (0.78, 1.08) |
| Age < 65 Male | D29 fold-rise over D1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 28 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age < 65 Male | D29 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID50 | 28 | 5 (5, 5) | 5 (5, 5) | 1.03 (0.97, 1.10) |
| Age < 65 Male | D29 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID80 | 28 | 5 (5, 5) | 5 (5, 5) | 1.00 (1.00, 1.00) |
| Age < 65 Male | D29 fold-rise over D1 | Placebo | Positive | Anti N IgG (IU/ml) | 64 | 10 (10, 10) | 8697 (5222, 14483) | 869.66 (522.19, 1448.34) |
| Age < 65 Male | D29 fold-rise over D1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 64 | 10 (10, 10) | 9188 (5784, 14598) | 918.85 (578.36, 1459.77) |
| Age < 65 Male | D29 fold-rise over D1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 64 | 10 (10, 10) | 11210 (7775, 16161) | 1120.96 (777.52, 1616.12) |
| Age < 65 Male | D29 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID50 | 64 | 5 (5, 5) | 31 (20, 50) | 6.29 (3.99, 9.92) |
| Age < 65 Male | D29 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID80 | 64 | 5 (5, 5) | 73 (47, 115) | 14.60 (9.30, 22.92) |
| Age < 65 Male | D57 fold-rise over D1 | Vaccine | Negative | Anti N IgG (IU/ml) | 163 | 10 (10, 10) | 276033 (182277, 418013) | 27603.26 (18227.67, 41801.29) |
| Age < 65 Male | D57 fold-rise over D1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 163 | 10 (10, 10) | 756600 (546757, 1046981) | 74811.32 (54086.35, 103477.74) |
| Age < 65 Male | D57 fold-rise over D1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 163 | 10 (10, 10) | 1920202 (1472176, 2504576) | 192020.23 (147217.61, 250457.60) |
| Age < 65 Male | D57 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 163 | 5 (5, 5) | 1532 (1004, 2337) | 304.47 (199.53, 464.60) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|---------------|-----------------------|---------|---------------------|------------------------|-----|------------------|-------------------------------|-------------------------------------|
| Age < 65 Male | D57 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 163 | 5 (5, 5) | 1850 (1231, 2781) | 368.88 (245.44, 554.40) |
| Age < 65 Male | D57 fold-rise over D1 | Vaccine | Positive | Anti N IgG (IU/ml) | 67 | 10 (10, 10) | 1079995 (633450, 1841326) | 107999.49 (63345.04, 184132.65) |
| Age < 65 Male | D57 fold-rise over D1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 67 | 10 (10, 10) | 1977267 (1268954, 3080952) | 197726.73 (126895.40, 308095.19) |
| Age < 65 Male | D57 fold-rise over D1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 67 | 10 (10, 10) | 4318054 (3077671, 6058343) | 431805.36 (307767.09, 605834.32) |
| Age < 65 Male | D57 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 67 | 5 (5, 5) | 3857 (1960, 7590) | 771.41 (392.00, 1518.05) |
| Age < 65 Male | D57 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 67 | 5 (5, 5) | 7789 (4625, 13117) | 1520.50 (910.33, 2539.66) |
| Age < 65 Male | D57 fold-rise over D1 | Placebo | Negative | Anti N IgG (IU/ml) | 28 | 11 (9, 12) | 10 (10, 10) | 0.93 (0.81, 1.07) |
| Age < 65 Male | D57 fold-rise over D1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 28 | 11 (9, 13) | 10 (10, 11) | 0.94 (0.79, 1.11) |
| Age < 65 Male | D57 fold-rise over D1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 28 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age < 65 Male | D57 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID50 | 28 | 5 (5, 5) | 5 (5, 5) | 1.00 (1.00, 1.00) |
| Age < 65 Male | D57 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID80 | 28 | 5 (5, 5) | 5 (5, 5) | 1.00 (1.00, 1.00) |
| Age < 65 Male | D57 fold-rise over D1 | Placebo | Positive | Anti N IgG (IU/ml) | 64 | 10 (10, 10) | 83366 (42296, 164315) | 8336.56 (4229.57, 16431.52) |
| Age < 65 Male | D57 fold-rise over D1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 64 | 10 (10, 10) | 236528 (146661, 381460) | 23652.81 (14666.14, 38146.03) |
| Age < 65 Male | D57 fold-rise over D1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 64 | 10 (10, 10) | 373064 (243212, 572245) | 37306.38 (24321.16, 57224.48) |
| Age < 65 Male | D57 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID50 | 64 | 5 (5, 5) | 387 (206, 728) | 77.48 (41.21, 145.66) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|---------------|-----------------------|---------|---------------------|------------------------|-----|------------------|----------------------------|----------------------------------|
| Age < 65 Male | D57 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID80 | 64 | 5 (5, 5) | 618 (331, 1154) | 122.95 (65.86, 229.52) |
| Age ≥ 65 Male | D29 fold-rise over D1 | Vaccine | Negative | Anti N IgG (IU/ml) | 232 | 10 (10, 10) | 59503 (46453, 76219) | 5916.13 (4616.71, 7581.30) |
| Age ≥ 65 Male | D29 fold-rise over D1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 232 | 10 (10, 10) | 66467 (53933, 81913) | 6600.68 (5356.98, 8133.11) |
| Age ≥ 65 Male | D29 fold-rise over D1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 232 | 10 (10, 10) | 105989 (87935, 127749) | 10521.42 (8738.17, 12668.58) |
| Age ≥ 65 Male | D29 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 232 | 5 (5, 5) | 259 (203, 330) | 50.93 (39.90, 65.01) |
| Age ≥ 65 Male | D29 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 232 | 5 (5, 5) | 390 (306, 496) | 76.59 (60.31, 97.27) |
| Age ≥ 65 Male | D29 fold-rise over D1 | Vaccine | Positive | Anti N IgG (IU/ml) | 54 | 10 (10, 11) | 121492 (77083, 191487) | 11942.84 (7662.16, 18615.06) |
| Age ≥ 65 Male | D29 fold-rise over D1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 54 | 10 (10, 10) | 148457 (98119, 224620) | 14845.72 (9811.94, 22461.95) |
| Age ≥ 65 Male | D29 fold-rise over D1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 54 | 10 (10, 10) | 230231 (167261, 316907) | 23023.06 (16726.06, 31690.75) |
| Age ≥ 65 Male | D29 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 54 | 5 (5, 6) | 482 (286, 812) | 93.10 (56.09, 154.53) |
| Age ≥ 65 Male | D29 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 54 | 5 (5, 5) | 895 (560, 1432) | 179.10 (111.99, 286.42) |
| Age ≥ 65 Male | D29 fold-rise over D1 | Placebo | Negative | Anti N IgG (IU/ml) | 48 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age ≥ 65 Male | D29 fold-rise over D1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 48 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age ≥ 65 Male | D29 fold-rise over D1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 48 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age ≥ 65 Male | D29 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID50 | 48 | 5 (5, 5) | 5 (5, 5) | 1.01 (0.99, 1.04) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|---------------|-----------------------|---------|---------------------|------------------------|-----|------------------|----------------------------------|--|
| Age ≥ 65 Male | D29 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID80 | 48 | 5 (5, 5) | 5 (5, 5) | 0.99 (0.96, 1.01) |
| Age ≥ 65 Male | D29 fold-rise over D1 | Placebo | Positive | Anti N IgG (IU/ml) | 51 | 10 (10, 10) | 39245 (22100, 69691) | 3924.48 (2209.96, 6969.15) |
| Age ≥ 65 Male | D29 fold-rise over D1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 51 | 10 (10, 10) | 50082 (30542, 82125) | 5008.22 (3054.16, 8212.50) |
| Age ≥ 65 Male | D29 fold-rise over D1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 51 | 10 (10, 10) | 76189 (49115, 118188) | 7618.89 (4911.45, 11818.80) |
| Age ≥ 65 Male | D29 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID50 | 51 | 5 (5, 6) | 147 (82, 263) | 28.06 (15.81, 49.79) |
| Age ≥ 65 Male | D29 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID80 | 51 | 5 (5, 5) | 350 (196, 626) | 68.37 (38.37, 121.82) |
| Age ≥ 65 Male | D57 fold-rise over D1 | Vaccine | Negative | Anti N IgG (IU/ml) | 232 | 10 (10, 10) | 794988 (585435, 1079548) | 79042.03 (58202.65, 107342.91) |
| Age ≥ 65 Male | D57 fold-rise over D1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 232 | 10 (10, 10) | 2674328 (2152728, 3322311) | 265580.56 (213995.04, 329601.25) |
| Age ≥ 65 Male | D57 fold-rise over D1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 232 | 10 (10, 10) | 5149990 (4231902, 6267253) | 511235.06 (419941.28, 622375.80) |
| Age ≥ 65 Male | D57 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 232 | 5 (5, 5) | 4362 (3133, 6074) | 858.16 (615.90, 1195.72) |
| Age ≥ 65 Male | D57 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 232 | 5 (5, 5) | 4649 (3501, 6173) | 914.10 (689.08, 1212.60) |
| Age ≥ 65 Male | D57 fold-rise over D1 | Vaccine | Positive | Anti N IgG (IU/ml) | 54 | 10 (10, 11) | 3362752 (2054881, 5503045) | 330562.39 (202713.86, 539043.05) |
| Age ≥ 65 Male | D57 fold-rise over D1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 54 | 10 (10, 10) | 7426127 (5296972, 10411111) | 742612.73 (529697.25, 104111.05) |
| Age ≥ 65 Male | D57 fold-rise over D1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 54 | 10 (10, 10) | 13502491 (11607977, 15706205) | 1350249.15 (1160797.74, 1570620.53) |
| Age ≥ 65 Male | D57 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 54 | 5 (5, 6) | 21221 (12633, 35647) | 4098.51 (2451.98, 6850.70) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|-----------------|-----------------------|---------|---------------------|------------------------|-----|------------------|-------------------------------|-------------------------------------|
| Age ≥ 65 Male | D57 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 54 | 5 (5, 5) | 20477 (11619, 36087) | 4095.32 (2323.81, 7217.31) |
| Age ≥ 65 Male | D57 fold-rise over D1 | Placebo | Negative | Anti N IgG (IU/ml) | 48 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age ≥ 65 Male | D57 fold-rise over D1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 48 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age ≥ 65 Male | D57 fold-rise over D1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 48 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age ≥ 65 Male | D57 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID50 | 48 | 5 (5, 5) | 5 (5, 5) | 1.02 (0.98, 1.06) |
| Age ≥ 65 Male | D57 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID80 | 48 | 5 (5, 5) | 5 (5, 5) | 0.99 (0.96, 1.01) |
| Age ≥ 65 Male | D57 fold-rise over D1 | Placebo | Positive | Anti N IgG (IU/ml) | 51 | 10 (10, 10) | 537607 (291471, 991596) | 53760.68 (29147.06, 99159.60) |
| Age ≥ 65 Male | D57 fold-rise over D1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 51 | 10 (10, 10) | 2027539 (1259961, 3262731) | 202753.90 (125996.11, 326273.11) |
| Age ≥ 65 Male | D57 fold-rise over D1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 51 | 10 (10, 10) | 3447429 (2322804, 5116559) | 344742.86 (232280.42, 511655.88) |
| Age ≥ 65 Male | D57 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID50 | 51 | 5 (5, 6) | 3730 (1880, 7401) | 712.08 (364.28, 1391.96) |
| Age ≥ 65 Male | D57 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID80 | 51 | 5 (5, 5) | 4892 (2560, 9348) | 954.53 (501.47, 1816.94) |
| Age ≥ 65 Female | D29 fold-rise over D1 | Vaccine | Negative | Anti N IgG (IU/ml) | 250 | 10 (10, 10) | 59851 (47954, 74699) | 5939.41 (4759.85, 7411.27) |
| Age ≥ 65 Female | D29 fold-rise over D1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 250 | 10 (10, 10) | 64209 (53151, 77567) | 6401.45 (5299.06, 7733.16) |
| Age ≥ 65 Female | D29 fold-rise over D1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 250 | 10 (10, 10) | 117943 (99447, 139878) | 11750.53 (9917.62, 13922.19) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|-----------------|-----------------------|---------|---------------------|------------------------|-----|------------------|----------------------------|----------------------------------|
| Age ≥ 65 Female | D29 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 250 | 5 (5, 5) | 249 (197, 315) | 48.99 (38.78, 61.89) |
| Age ≥ 65 Female | D29 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 250 | 5 (5, 5) | 373 (294, 474) | 72.42 (57.16, 91.75) |
| Age ≥ 65 Female | D29 fold-rise over D1 | Vaccine | Positive | Anti N IgG (IU/ml) | 74 | 10 (10, 10) | 137448 (87797, 215179) | 13617.44 (8720.37, 21264.54) |
| Age ≥ 65 Female | D29 fold-rise over D1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 74 | 10 (10, 10) | 166523 (121761, 227741) | 16652.29 (12176.06, 22774.10) |
| Age ≥ 65 Female | D29 fold-rise over D1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 74 | 10 (10, 10) | 288235 (216852, 383115) | 28823.47 (21685.20, 38311.49) |
| Age ≥ 65 Female | D29 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 74 | 5 (5, 6) | 553 (354, 864) | 105.66 (68.26, 163.53) |
| Age ≥ 65 Female | D29 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 74 | 5 (5, 5) | 1062 (720, 1566) | 212.40 (144.04, 313.21) |
| Age ≥ 65 Female | D29 fold-rise over D1 | Placebo | Negative | Anti N IgG (IU/ml) | 35 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age ≥ 65 Female | D29 fold-rise over D1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 35 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age ≥ 65 Female | D29 fold-rise over D1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 35 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age ≥ 65 Female | D29 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID50 | 35 | 5 (5, 5) | 5 (5, 5) | 1.02 (0.98, 1.07) |
| Age ≥ 65 Female | D29 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID80 | 35 | 5 (5, 5) | 5 (5, 5) | 1.02 (0.98, 1.07) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|-----------------|-----------------------|---------|---------------------|------------------------|-----|------------------|-------------------------------|-------------------------------------|
| Age ≥ 65 Female | D29 fold-rise over D1 | Placebo | Positive | Anti N IgG (IU/ml) | 72 | 10 (10, 10) | 32440 (21159, 49736) | 3179.25 (2072.58, 4876.82) |
| Age ≥ 65 Female | D29 fold-rise over D1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 72 | 10 (10, 10) | 37051 (27449, 50013) | 3657.70 (2719.73, 4919.14) |
| Age ≥ 65 Female | D29 fold-rise over D1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 72 | 10 (10, 10) | 61265 (47638, 78789) | 6126.46 (4763.78, 7878.92) |
| Age ≥ 65 Female | D29 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID50 | 72 | 5 (5, 5) | 162 (110, 238) | 31.81 (21.63, 46.78) |
| Age ≥ 65 Female | D29 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID80 | 72 | 5 (5, 5) | 271 (188, 392) | 53.46 (37.23, 76.76) |
| Age ≥ 65 Female | D57 fold-rise over D1 | Vaccine | Negative | Anti N IgG (IU/ml) | 250 | 10 (10, 10) | 875715 (670811, 1143209) | 86902.97 (66586.59, 113418.14) |
| Age ≥ 65 Female | D57 fold-rise over D1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 250 | 10 (10, 10) | 2708471 (2228982, 3291105) | 270027.12 (222227.95, 328107.44) |
| Age ≥ 65 Female | D57 fold-rise over D1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 250 | 10 (10, 10) | 5189777 (4355492, 6183867) | 517053.81 (434090.43, 615873.16) |
| Age ≥ 65 Female | D57 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 250 | 5 (5, 5) | 4169 (3097, 5612) | 819.46 (609.36, 1102.00) |
| Age ≥ 65 Female | D57 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 250 | 5 (5, 5) | 6397 (4907, 8340) | 1242.43 (955.63, 1615.30) |
| Age ≥ 65 Female | D57 fold-rise over D1 | Vaccine | Positive | Anti N IgG (IU/ml) | 74 | 10 (10, 10) | 2781850 (1795669, 4309643) | 275607.01 (178109.07, 426475.89) |
| Age ≥ 65 Female | D57 fold-rise over D1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 74 | 10 (10, 10) | 7590360 (5921961, 9728799) | 759036.03 (592196.09, 972879.93) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|-----------------|-----------------------|---------|---------------------|------------------------|----|------------------|----------------------------------|--|
| Age ≥ 65 Female | D57 fold-rise over D1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 74 | 10 (10, 10) | 12894340 (10799304, 15395807) | 1289433.98 (1079930.42, 1539580.67) |
| Age ≥ 65 Female | D57 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 74 | 5 (5, 6) | 21984 (13986, 34558) | 4198.62 (2698.65, 6532.30) |
| Age ≥ 65 Female | D57 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 74 | 5 (5, 5) | 18779 (11189, 31518) | 3755.84 (2237.83, 6303.56) |
| Age ≥ 65 Female | D57 fold-rise over D1 | Placebo | Negative | Anti N IgG (IU/ml) | 35 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age ≥ 65 Female | D57 fold-rise over D1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 35 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age ≥ 65 Female | D57 fold-rise over D1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 35 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age ≥ 65 Female | D57 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID50 | 35 | 5 (5, 5) | 5 (5, 5) | 1.02 (0.98, 1.07) |
| Age ≥ 65 Female | D57 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID80 | 35 | 5 (5, 5) | 5 (5, 6) | 1.04 (0.96, 1.13) |
| Age ≥ 65 Female | D57 fold-rise over D1 | Placebo | Positive | Anti N IgG (IU/ml) | 72 | 10 (10, 10) | 507512 (329028, 782814) | 49738.19 (32306.17, 76576.34) |
| Age ≥ 65 Female | D57 fold-rise over D1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 72 | 10 (10, 10) | 1473236 (1067157, 2033836) | 145438.84 (105433.61, 200623.47) |
| Age ≥ 65 Female | D57 fold-rise over D1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 72 | 10 (10, 10) | 2420004 (1820068, 3217693) | 242000.40 (182006.75, 321769.35) |
| Age ≥ 65 Female | D57 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID50 | 72 | 5 (5, 5) | 2344 (1427, 3849) | 460.66 (280.22, 757.28) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|----------|-----------------------|---------|---------------------|----------------------|----|------------------|-----------------------|-----------------------------|
| Age ≥ 65 | D57 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID80 | 72 | 5 (5, 5) | 3767 (2352, 6032) | 742.12 (464.89, 1184.66) |
| Female | | | | | | | | |

MOCK

Table 6g. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Hispanic or Latino ethnicity

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|-------------------------------------|-----------------------|---------|---------------------|------------------------|-----|------------------|--------------------------|--------------------------------|
| Hispanic or Latino ethnicity | | | | | | | | |
| Hispanic or Latino | D29 fold-rise over D1 | Vaccine | Negative | Anti N IgG (IU/ml) | 136 | 10 (10, 10) | 22074 (14121, 34506) | 2207.38 (1412.06, 3450.64) |
| Hispanic or Latino | D29 fold-rise over D1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 136 | 10 (10, 10) | 22266 (15847, 31284) | 2226.58 (1584.75, 3128.36) |
| Hispanic or Latino | D29 fold-rise over D1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 136 | 10 (10, 10) | 41773 (31562, 55289) | 4177.34 (3156.18, 5528.90) |
| Hispanic or Latino | D29 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 136 | 5 (5, 5) | 101 (67, 152) | 20.07 (13.32, 30.26) |
| Hispanic or Latino | D29 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 136 | 5 (5, 6) | 190 (126, 284) | 35.82 (24.42, 52.53) |
| Hispanic or Latino | D29 fold-rise over D1 | Vaccine | Positive | Anti N IgG (IU/ml) | 35 | 10 (10, 10) | 66150 (37538, 116570) | 6614.98 (3753.79, 11657.02) |
| Hispanic or Latino | D29 fold-rise over D1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 35 | 10 (10, 10) | 57339 (30559, 107588) | 5733.92 (3055.89, 10758.85) |
| Hispanic or Latino | D29 fold-rise over D1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 35 | 10 (10, 10) | 90332 (50343, 162084) | 9033.16 (5034.32, 16208.37) |
| Hispanic or Latino | D29 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 35 | 5 (5, 5) | 254 (155, 417) | 50.85 (31.04, 83.31) |
| Hispanic or Latino | D29 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 35 | 5 (5, 5) | 498 (236, 1049) | 97.19 (45.87, 205.93) |
| Hispanic or Latino | D29 fold-rise over D1 | Placebo | Negative | Anti N IgG (IU/ml) | 20 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|--------------------|-----------------------|---------|---------------------|------------------------|-----|------------------|-------------------------------|-------------------------------------|
| Hispanic or Latino | D29 fold-rise over D1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 20 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Hispanic or Latino | D29 fold-rise over D1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 20 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Hispanic or Latino | D29 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID50 | 20 | 5 (5, 5) | 5 (5, 5) | 1.02 (0.98, 1.05) |
| Hispanic or Latino | D29 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID80 | 20 | 5 (5, 5) | 6 (4, 8) | 1.21 (0.87, 1.67) |
| Hispanic or Latino | D29 fold-rise over D1 | Placebo | Positive | Anti N IgG (IU/ml) | 38 | 10 (10, 10) | 26345 (9909, 70041) | 2607.33 (980.41, 6934.00) |
| Hispanic or Latino | D29 fold-rise over D1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 38 | 10 (10, 10) | 34815 (16110, 75239) | 3481.54 (1611.02, 7523.86) |
| Hispanic or Latino | D29 fold-rise over D1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 38 | 10 (10, 10) | 26708 (12585, 56680) | 2670.83 (1258.52, 5668.01) |
| Hispanic or Latino | D29 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID50 | 38 | 6 (5, 7) | 118 (42, 327) | 21.01 (8.52, 51.83) |
| Hispanic or Latino | D29 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID80 | 38 | 5 (5, 5) | 351 (151, 818) | 70.21 (30.13, 163.62) |
| Hispanic or Latino | D57 fold-rise over D1 | Vaccine | Negative | Anti N IgG (IU/ml) | 136 | 10 (10, 10) | 332872 (193115, 573771) | 33287.22 (19311.52, 57377.11) |
| Hispanic or Latino | D57 fold-rise over D1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 136 | 10 (10, 10) | 1087406 (737091, 1604213) | 108740.60 (73709.14, 160421.34) |
| Hispanic or Latino | D57 fold-rise over D1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 136 | 10 (10, 10) | 2082654 (1564176, 2772993) | 208265.41 (156417.59, 277299.26) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|--------------------|-----------------------|---------|---------------------|------------------------|-----|------------------|--------------------------------|--------------------------------------|
| Hispanic or Latino | D57 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 136 | 5 (5, 5) | 1727 (1013, 2946) | 344.71 (202.11, 587.93) |
| Hispanic or Latino | D57 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 136 | 5 (5, 6) | 2444 (1373, 4350) | 461.92 (266.06, 801.97) |
| Hispanic or Latino | D57 fold-rise over D1 | Vaccine | Positive | Anti N IgG (IU/ml) | 35 | 10 (10, 10) | 1420449 (558648, 3611715) | 142044.90 (55864.75, 361171.46) |
| Hispanic or Latino | D57 fold-rise over D1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 35 | 10 (10, 10) | 2735111 (1368395, 5466868) | 273511.13 (136839.49, 546686.78) |
| Hispanic or Latino | D57 fold-rise over D1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 35 | 10 (10, 10) | 7578287 (5040721, 11393296) | 757828.67 (504072.13, 1139329.58) |
| Hispanic or Latino | D57 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 35 | 5 (5, 5) | 7727 (2908, 20532) | 1545.45 (581.63, 4106.42) |
| Hispanic or Latino | D57 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 35 | 5 (5, 5) | 10208 (4492, 23195) | 1991.90 (877.85, 4519.79) |
| Hispanic or Latino | D57 fold-rise over D1 | Placebo | Negative | Anti N IgG (IU/ml) | 20 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Hispanic or Latino | D57 fold-rise over D1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 20 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Hispanic or Latino | D57 fold-rise over D1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 20 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Hispanic or Latino | D57 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID50 | 20 | 5 (5, 5) | 5 (5, 5) | 1.00 (1.00, 1.00) |
| Hispanic or Latino | D57 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID80 | 20 | 5 (5, 5) | 5 (5, 5) | 1.00 (1.00, 1.00) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|------------------------|-----------------------|---------|---------------------|------------------------|-----|------------------|------------------------------|------------------------------------|
| Hispanic or Latino | D57 fold-rise over D1 | Placebo | Positive | Anti N IgG (IU/ml) | 38 | 10 (10, 10) | 452690 (158709, 1291220) | 44802.56 (15709.89, 127771.11) |
| Hispanic or Latino | D57 fold-rise over D1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 38 | 10 (10, 10) | 747435 (391924, 1425424) | 74743.46 (39192.45, 142542.38) |
| Hispanic or Latino | D57 fold-rise over D1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 38 | 10 (10, 10) | 1403460 (609038, 3234119) | 140346.03 (60903.77, 323411.95) |
| Hispanic or Latino | D57 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID50 | 38 | 6 (5, 7) | 1522 (466, 4976) | 271.27 (88.81, 828.62) |
| Hispanic or Latino | D57 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID80 | 38 | 5 (5, 5) | 3063 (1057, 8877) | 612.54 (211.34, 1775.33) |
| Not Hispanic or Latino | D29 fold-rise over D1 | Vaccine | Negative | Anti N IgG (IU/ml) | 690 | 10 (10, 10) | 23655 (19521, 28664) | 2361.23 (1948.59, 2861.26) |
| Not Hispanic or Latino | D29 fold-rise over D1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 690 | 10 (10, 10) | 23020 (19425, 27280) | 2286.61 (1930.10, 2708.97) |
| Not Hispanic or Latino | D29 fold-rise over D1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 690 | 10 (10, 10) | 39694 (35055, 44946) | 3963.68 (3500.65, 4487.96) |
| Not Hispanic or Latino | D29 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 690 | 5 (5, 5) | 104 (86, 125) | 20.56 (17.07, 24.76) |
| Not Hispanic or Latino | D29 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 690 | 5 (5, 5) | 191 (158, 230) | 37.96 (31.48, 45.77) |
| Not Hispanic or Latino | D29 fold-rise over D1 | Vaccine | Positive | Anti N IgG (IU/ml) | 217 | 10 (10, 10) | 41747 (30714, 56743) | 4155.34 (3057.89, 5646.66) |
| Not Hispanic or Latino | D29 fold-rise over D1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 217 | 10 (10, 10) | 35344 (26390, 47337) | 3534.42 (2639.00, 4733.66) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|------------------------|-----------------------|---------|---------------------|------------------------|-----|------------------|--------------------------|--------------------------------|
| Not Hispanic or Latino | D29 fold-rise over D1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 217 | 10 (10, 10) | 83383 (65546, 106075) | 8338.33 (6554.59, 10607.48) |
| Not Hispanic or Latino | D29 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 217 | 5 (5, 5) | 183 (133, 251) | 36.13 (26.25, 49.73) |
| Not Hispanic or Latino | D29 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 217 | 5 (5, 5) | 411 (294, 575) | 80.81 (57.70, 113.17) |
| Not Hispanic or Latino | D29 fold-rise over D1 | Placebo | Negative | Anti N IgG (IU/ml) | 130 | 10 (10, 11) | 10 (10, 10) | 0.98 (0.94, 1.02) |
| Not Hispanic or Latino | D29 fold-rise over D1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 130 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Not Hispanic or Latino | D29 fold-rise over D1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 130 | 10 (10, 10) | 10 (10, 10) | 0.99 (0.98, 1.01) |
| Not Hispanic or Latino | D29 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID50 | 130 | 5 (5, 5) | 5 (5, 5) | 1.01 (0.98, 1.03) |
| Not Hispanic or Latino | D29 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID80 | 130 | 5 (5, 5) | 5 (5, 5) | 0.97 (0.93, 1.02) |
| Not Hispanic or Latino | D29 fold-rise over D1 | Placebo | Positive | Anti N IgG (IU/ml) | 214 | 10 (10, 10) | 12063 (8992, 16185) | 1185.92 (892.08, 1576.54) |
| Not Hispanic or Latino | D29 fold-rise over D1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 214 | 10 (10, 10) | 11608 (9046, 14896) | 1158.76 (903.07, 1486.86) |
| Not Hispanic or Latino | D29 fold-rise over D1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 214 | 10 (10, 10) | 18056 (14910, 21865) | 1805.57 (1490.99, 2186.53) |
| Not Hispanic or Latino | D29 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID50 | 214 | 5 (5, 5) | 48 (37, 63) | 9.40 (7.28, 12.15) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|------------------------|-----------------------|---------|---------------------|------------------------|-----|------------------|-------------------------------|-------------------------------------|
| Not Hispanic or Latino | D29 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID80 | 214 | 5 (5, 5) | 123 (92, 165) | 24.28 (18.23, 32.35) |
| Not Hispanic or Latino | D57 fold-rise over D1 | Vaccine | Negative | Anti N IgG (IU/ml) | 690 | 10 (10, 10) | 334364 (266627, 419309) | 33376.43 (26615.01, 41855.57) |
| Not Hispanic or Latino | D57 fold-rise over D1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 690 | 10 (10, 10) | 987977 (822264, 1187086) | 98137.11 (81690.28, 117895.20) |
| Not Hispanic or Latino | D57 fold-rise over D1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 690 | 10 (10, 10) | 2063432 (1775937, 2397468) | 206047.30 (177339.03, 239402.97) |
| Not Hispanic or Latino | D57 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 690 | 5 (5, 5) | 1500 (1191, 1888) | 296.84 (235.74, 373.77) |
| Not Hispanic or Latino | D57 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 690 | 5 (5, 5) | 2270 (1788, 2883) | 451.12 (355.29, 572.80) |
| Not Hispanic or Latino | D57 fold-rise over D1 | Vaccine | Positive | Anti N IgG (IU/ml) | 217 | 10 (10, 10) | 968852 (654113, 1435033) | 96436.92 (65115.44, 142824.48) |
| Not Hispanic or Latino | D57 fold-rise over D1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 217 | 10 (10, 10) | 2315554 (1731123, 3097290) | 231555.38 (173112.28, 309728.99) |
| Not Hispanic or Latino | D57 fold-rise over D1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 217 | 10 (10, 10) | 5301268 (4150604, 6770929) | 530126.82 (415060.39, 677092.90) |
| Not Hispanic or Latino | D57 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 217 | 5 (5, 5) | 5224 (3348, 8151) | 1034.14 (662.98, 1613.08) |
| Not Hispanic or Latino | D57 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 217 | 5 (5, 5) | 7937 (5300, 11886) | 1561.42 (1043.13, 2337.23) |
| Not Hispanic or Latino | D57 fold-rise over D1 | Placebo | Negative | Anti N IgG (IU/ml) | 130 | 10 (10, 11) | 10 (10, 10) | 0.98 (0.94, 1.02) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|--------------------------|-----------------------|---------|---------------------|------------------------|-----|------------------|----------------------------|----------------------------------|
| Not Hispanic or Latino | D57 fold-rise over D1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 130 | 10 (10, 10) | 10 (10, 10) | 1.01 (1.00, 1.02) |
| Not Hispanic or Latino | D57 fold-rise over D1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 130 | 10 (10, 10) | 10 (10, 10) | 0.99 (0.98, 1.01) |
| Not Hispanic or Latino | D57 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID50 | 130 | 5 (5, 5) | 5 (5, 5) | 1.00 (0.99, 1.02) |
| Not Hispanic or Latino | D57 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID80 | 130 | 5 (5, 5) | 5 (5, 5) | 0.98 (0.93, 1.03) |
| Not Hispanic or Latino | D57 fold-rise over D1 | Placebo | Positive | Anti N IgG (IU/ml) | 214 | 10 (10, 10) | 129424 (89788, 186557) | 12723.27 (8908.87, 18170.84) |
| Not Hispanic or Latino | D57 fold-rise over D1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 214 | 10 (10, 10) | 381696 (293138, 497006) | 38101.89 (29262.14, 49612.02) |
| Not Hispanic or Latino | D57 fold-rise over D1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 214 | 10 (10, 10) | 648311 (505732, 831086) | 64831.06 (50573.21, 83108.56) |
| Not Hispanic or Latino | D57 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID50 | 214 | 5 (5, 5) | 555 (395, 782) | 108.64 (77.40, 152.49) |
| Not Hispanic or Latino | D57 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID80 | 214 | 5 (5, 5) | 1324 (921, 1904) | 261.10 (182.28, 374.00) |
| Not reported and unknown | D29 fold-rise over D1 | Vaccine | Negative | Anti N IgG (IU/ml) | 88 | 10 (10, 10) | 24172 (15240, 38338) | 2390.80 (1508.53, 3789.06) |
| Not reported and unknown | D29 fold-rise over D1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 88 | 10 (10, 10) | 22876 (15904, 32905) | 2274.83 (1582.12, 3270.83) |
| Not reported and unknown | D29 fold-rise over D1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 88 | 10 (10, 10) | 50488 (35885, 71034) | 5048.79 (3588.47, 7103.37) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|--------------------------|-----------------------|---------|---------------------|------------------------|----|------------------|-------------------------|-------------------------------|
| Not reported and unknown | D29 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 88 | 5 (5, 5) | 133 (84, 213) | 25.71 (16.13, 40.96) |
| Not reported and unknown | D29 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 88 | 5 (5, 5) | 174 (106, 287) | 34.02 (20.65, 56.04) |
| Not reported and unknown | D29 fold-rise over D1 | Vaccine | Positive | Anti N IgG (IU/ml) | 22 | 10 (10, 10) | 34292 (18107, 64943) | 3429.17 (1810.69, 6494.31) |
| Not reported and unknown | D29 fold-rise over D1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 22 | 10 (10, 10) | 25827 (18334, 36382) | 2582.70 (1833.44, 3638.16) |
| Not reported and unknown | D29 fold-rise over D1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 22 | 10 (10, 10) | 46903 (33825, 65038) | 4690.32 (3382.48, 6503.83) |
| Not reported and unknown | D29 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 22 | 6 (4, 7) | 154 (91, 259) | 27.15 (16.58, 44.47) |
| Not reported and unknown | D29 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 22 | 5 (5, 5) | 420 (198, 891) | 83.98 (39.57, 178.24) |
| Not reported and unknown | D29 fold-rise over D1 | Placebo | Negative | Anti N IgG (IU/ml) | 13 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Not reported and unknown | D29 fold-rise over D1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 13 | 12 (8, 18) | 10 (10, 10) | 0.82 (0.56, 1.21) |
| Not reported and unknown | D29 fold-rise over D1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 13 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Not reported and unknown | D29 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID50 | 13 | 5 (5, 5) | 5 (5, 5) | 1.00 (1.00, 1.00) |
| Not reported and unknown | D29 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID80 | 13 | 5 (5, 5) | 5 (5, 5) | 1.00 (1.00, 1.00) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|--------------------------|-----------------------|---------|---------------------|------------------------|----|------------------|-------------------------------|-------------------------------------|
| Not reported and unknown | D29 fold-rise over D1 | Placebo | Positive | Anti N IgG (IU/ml) | 18 | 10 (10, 10) | 7067 (1907, 26192) | 706.66 (190.66, 2619.21) |
| Not reported and unknown | D29 fold-rise over D1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 18 | 10 (10, 10) | 10750 (3611, 32001) | 1075.02 (361.13, 3200.07) |
| Not reported and unknown | D29 fold-rise over D1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 18 | 10 (10, 10) | 11909 (5649, 25107) | 1190.89 (564.87, 2510.66) |
| Not reported and unknown | D29 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID50 | 18 | 5 (5, 5) | 37 (15, 93) | 7.39 (2.93, 18.63) |
| Not reported and unknown | D29 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID80 | 18 | 5 (5, 5) | 58 (19, 177) | 11.28 (3.70, 34.45) |
| Not reported and unknown | D57 fold-rise over D1 | Vaccine | Negative | Anti N IgG (IU/ml) | 88 | 10 (10, 10) | 259797 (148513, 454466) | 25696.00 (14717.82, 44862.93) |
| Not reported and unknown | D57 fold-rise over D1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 88 | 10 (10, 10) | 735710 (462524, 1170251) | 73159.15 (46013.55, 116319.24) |
| Not reported and unknown | D57 fold-rise over D1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 88 | 10 (10, 10) | 2279592 (1446853, 3591615) | 227959.19 (144685.30, 359161.52) |
| Not reported and unknown | D57 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 88 | 5 (5, 5) | 1291 (765, 2178) | 248.75 (147.56, 419.33) |
| Not reported and unknown | D57 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 88 | 5 (5, 5) | 1748 (990, 3088) | 341.31 (194.13, 600.06) |
| Not reported and unknown | D57 fold-rise over D1 | Vaccine | Positive | Anti N IgG (IU/ml) | 22 | 10 (10, 10) | 710026 (245263, 2055490) | 71002.57 (24526.34, 205549.00) |
| Not reported and unknown | D57 fold-rise over D1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 22 | 10 (10, 10) | 1751283 (872333, 3515850) | 175128.31 (87233.31, 351585.01) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|--------------------------|-----------------------|---------|---------------------|------------------------|----|------------------|-------------------------------|-------------------------------------|
| Not reported and unknown | D57 fold-rise over D1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 22 | 10 (10, 10) | 3840709 (2197166, 6713669) | 384070.92 (219716.64, 671366.86) |
| Not reported and unknown | D57 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 22 | 6 (4, 7) | 8669 (2979, 25223) | 1531.30 (641.99, 3652.47) |
| Not reported and unknown | D57 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 22 | 5 (5, 5) | 5104 (2140, 12175) | 1020.81 (427.96, 2434.92) |
| Not reported and unknown | D57 fold-rise over D1 | Placebo | Negative | Anti N IgG (IU/ml) | 13 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Not reported and unknown | D57 fold-rise over D1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 13 | 12 (8, 18) | 10 (10, 10) | 0.82 (0.56, 1.21) |
| Not reported and unknown | D57 fold-rise over D1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 13 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Not reported and unknown | D57 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID50 | 13 | 5 (5, 5) | 5 (5, 5) | 1.03 (0.97, 1.08) |
| Not reported and unknown | D57 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID80 | 13 | 5 (5, 5) | 5 (5, 5) | 1.00 (1.00, 1.00) |
| Not reported and unknown | D57 fold-rise over D1 | Placebo | Positive | Anti N IgG (IU/ml) | 18 | 10 (10, 10) | 26411 (10028, 69563) | 2641.13 (1002.77, 6956.29) |
| Not reported and unknown | D57 fold-rise over D1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 18 | 10 (10, 10) | 162620 (55659, 475135) | 16262.02 (5565.86, 47513.49) |
| Not reported and unknown | D57 fold-rise over D1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 18 | 10 (10, 10) | 417076 (107739, 1614570) | 41707.62 (10773.92, 161457.03) |
| Not reported and unknown | D57 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID50 | 18 | 5 (5, 5) | 188 (46, 766) | 37.59 (9.22, 153.25) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|--------------------------|-----------------------|---------|---------------------|----------------------|----|------------------|-----------------------|--------------------------|
| Not reported and unknown | D57 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID80 | 18 | 5 (5, 5) | 437 (69, 2773) | 85.21 (13.47, 538.99) |

MOCK

Table 6h. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Race

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|--------------------|-----------------------|---------|---------------------|------------------------|-----|------------------|-------------------------|-------------------------------|
| Race | | | | | | | | |
| White Non-Hispanic | D29 fold-rise over D1 | Vaccine | Negative | Anti N IgG (IU/ml) | 362 | 10 (10, 10) | 26952 (20883, 34784) | 2692.55 (2086.26, 3475.03) |
| White Non-Hispanic | D29 fold-rise over D1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 362 | 10 (10, 10) | 23438 (18669, 29425) | 2343.79 (1866.88, 2942.53) |
| White Non-Hispanic | D29 fold-rise over D1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 362 | 10 (10, 10) | 40376 (34349, 47460) | 4031.72 (3430.05, 4738.93) |
| White Non-Hispanic | D29 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 362 | 5 (5, 5) | 115 (90, 147) | 22.83 (17.82, 29.23) |
| White Non-Hispanic | D29 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 362 | 5 (5, 5) | 188 (146, 241) | 37.41 (29.16, 48.00) |
| White Non-Hispanic | D29 fold-rise over D1 | Vaccine | Positive | Anti N IgG (IU/ml) | 125 | 10 (10, 10) | 33909 (24023, 47863) | 3381.77 (2396.63, 4771.84) |
| White Non-Hispanic | D29 fold-rise over D1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 125 | 10 (10, 10) | 30985 (21434, 44793) | 3098.50 (2143.36, 4479.29) |
| White Non-Hispanic | D29 fold-rise over D1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 125 | 10 (10, 10) | 72481 (53061, 99008) | 7248.12 (5306.15, 9900.82) |
| White Non-Hispanic | D29 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 125 | 5 (5, 5) | 148 (104, 211) | 29.21 (20.49, 41.65) |
| White Non-Hispanic | D29 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 125 | 5 (5, 5) | 348 (226, 535) | 69.53 (45.18, 106.99) |
| White Non-Hispanic | D29 fold-rise over D1 | Placebo | Negative | Anti N IgG (IU/ml) | 67 | 10 (10, 11) | 10 (10, 10) | 0.97 (0.91, 1.03) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|--------------------|-----------------------|---------|---------------------|------------------------|-----|------------------|-------------------------------|-------------------------------------|
| White Non-Hispanic | D29 fold-rise over D1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 67 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| White Non-Hispanic | D29 fold-rise over D1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 67 | 10 (10, 10) | 10 (10, 10) | 0.99 (0.96, 1.01) |
| White Non-Hispanic | D29 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID50 | 67 | 5 (5, 5) | 5 (5, 5) | 1.01 (1.00, 1.02) |
| White Non-Hispanic | D29 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID80 | 67 | 5 (5, 6) | 5 (5, 5) | 0.96 (0.89, 1.04) |
| White Non-Hispanic | D29 fold-rise over D1 | Placebo | Positive | Anti N IgG (IU/ml) | 121 | 10 (10, 10) | 12594 (8382, 18924) | 1256.17 (836.02, 1887.47) |
| White Non-Hispanic | D29 fold-rise over D1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 121 | 10 (10, 10) | 10931 (7560, 15804) | 1089.81 (753.88, 1575.44) |
| White Non-Hispanic | D29 fold-rise over D1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 121 | 10 (10, 10) | 18868 (14808, 24043) | 1886.83 (1480.76, 2404.27) |
| White Non-Hispanic | D29 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID50 | 121 | 5 (5, 5) | 52 (37, 74) | 10.37 (7.32, 14.70) |
| White Non-Hispanic | D29 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID80 | 121 | 5 (5, 5) | 107 (76, 150) | 21.32 (15.15, 29.99) |
| White Non-Hispanic | D57 fold-rise over D1 | Vaccine | Negative | Anti N IgG (IU/ml) | 362 | 10 (10, 10) | 328428 (241933, 445846) | 32810.77 (24169.70, 44541.16) |
| White Non-Hispanic | D57 fold-rise over D1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 362 | 10 (10, 10) | 1035293 (809568, 1323956) | 103529.30 (80956.76, 132395.58) |
| White Non-Hispanic | D57 fold-rise over D1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 362 | 10 (10, 10) | 2145772 (1770774, 2600184) | 214266.04 (176817.71, 259645.59) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|--------------------|-----------------------|---------|---------------------|------------------------|-----|------------------|-------------------------------|-------------------------------------|
| White Non-Hispanic | D57 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 362 | 5 (5, 5) | 1376 (1010, 1874) | 273.04 (200.41, 371.99) |
| White Non-Hispanic | D57 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 362 | 5 (5, 5) | 2011 (1465, 2761) | 400.97 (292.11, 550.40) |
| White Non-Hispanic | D57 fold-rise over D1 | Vaccine | Positive | Anti N IgG (IU/ml) | 125 | 10 (10, 10) | 855574 (517613, 1414198) | 85327.48 (51627.40, 141025.47) |
| White Non-Hispanic | D57 fold-rise over D1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 125 | 10 (10, 10) | 1943813 (1349835, 2799166) | 194381.34 (134983.46, 279916.55) |
| White Non-Hispanic | D57 fold-rise over D1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 125 | 10 (10, 10) | 4608987 (3338577, 6362819) | 460898.73 (333857.72, 636281.94) |
| White Non-Hispanic | D57 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 125 | 5 (5, 5) | 4550 (2471, 8378) | 899.93 (488.90, 1656.55) |
| White Non-Hispanic | D57 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 125 | 5 (5, 5) | 7994 (4646, 13757) | 1598.88 (929.14, 2751.39) |
| White Non-Hispanic | D57 fold-rise over D1 | Placebo | Negative | Anti N IgG (IU/ml) | 67 | 10 (10, 11) | 10 (10, 10) | 0.97 (0.91, 1.03) |
| White Non-Hispanic | D57 fold-rise over D1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 67 | 10 (10, 10) | 10 (10, 10) | 1.01 (0.99, 1.03) |
| White Non-Hispanic | D57 fold-rise over D1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 67 | 10 (10, 10) | 10 (10, 10) | 0.99 (0.96, 1.01) |
| White Non-Hispanic | D57 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID50 | 67 | 5 (5, 5) | 5 (5, 5) | 1.00 (1.00, 1.00) |
| White Non-Hispanic | D57 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID80 | 67 | 5 (5, 6) | 5 (5, 5) | 0.98 (0.90, 1.06) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|---------------------------|-----------------------|---------|---------------------|------------------------|-----|------------------|----------------------------|----------------------------------|
| White Non-Hispanic | D57 fold-rise over D1 | Placebo | Positive | Anti N IgG (IU/ml) | 121 | 10 (10, 10) | 105260 (65764, 168478) | 10498.69 (6559.92, 16802.41) |
| White Non-Hispanic | D57 fold-rise over D1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 121 | 10 (10, 10) | 393045 (287516, 537306) | 39187.22 (28666.35, 53569.39) |
| White Non-Hispanic | D57 fold-rise over D1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 121 | 10 (10, 10) | 674526 (485396, 937351) | 67452.65 (48539.56, 93735.08) |
| White Non-Hispanic | D57 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID50 | 121 | 5 (5, 5) | 575 (371, 892) | 114.01 (73.52, 176.80) |
| White Non-Hispanic | D57 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID80 | 121 | 5 (5, 5) | 1478 (953, 2292) | 295.55 (190.57, 458.35) |
| Black or African American | D29 fold-rise over D1 | Vaccine | Negative | Anti N IgG (IU/ml) | 195 | 10 (10, 10) | 16417 (11437, 23568) | 1634.81 (1138.84, 2346.77) |
| Black or African American | D29 fold-rise over D1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 195 | 10 (10, 11) | 18966 (14305, 25146) | 1843.84 (1399.25, 2429.70) |
| Black or African American | D29 fold-rise over D1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 195 | 10 (10, 10) | 33478 (26923, 41629) | 3347.79 (2692.25, 4162.95) |
| Black or African American | D29 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 195 | 5 (5, 5) | 80 (57, 111) | 15.88 (11.38, 22.16) |
| Black or African American | D29 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 195 | 5 (5, 5) | 168 (116, 244) | 33.41 (23.02, 48.50) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|---------------------------|-----------------------|---------|---------------------|------------------------|----|------------------|--------------------------|--------------------------------|
| Black or African American | D29 fold-rise over D1 | Vaccine | Positive | Anti N IgG (IU/ml) | 52 | 10 (10, 10) | 70405 (39637, 125057) | 6985.30 (3937.62, 12391.85) |
| Black or African American | D29 fold-rise over D1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 52 | 10 (10, 10) | 49806 (32279, 76849) | 4980.58 (3227.90, 7684.92) |
| Black or African American | D29 fold-rise over D1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 52 | 10 (10, 10) | 92510 (63827, 134083) | 9251.02 (6382.72, 13408.29) |
| Black or African American | D29 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 52 | 5 (5, 5) | 240 (126, 455) | 47.20 (24.97, 89.23) |
| Black or African American | D29 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 52 | 5 (5, 5) | 595 (282, 1255) | 116.76 (55.14, 247.22) |
| Black or African American | D29 fold-rise over D1 | Placebo | Negative | Anti N IgG (IU/ml) | 39 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Black or African American | D29 fold-rise over D1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 39 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Black or African American | D29 fold-rise over D1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 39 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Black or African American | D29 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID50 | 39 | 5 (5, 5) | 5 (5, 5) | 0.97 (0.92, 1.03) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|---------------------------|-----------------------|---------|---------------------|------------------------|-----|------------------|-------------------------------|-------------------------------------|
| Black or African American | D29 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID80 | 39 | 5 (5, 5) | 5 (5, 5) | 1.00 (1.00, 1.00) |
| Black or African American | D29 fold-rise over D1 | Placebo | Positive | Anti N IgG (IU/ml) | 60 | 10 (10, 10) | 9803 (5446, 17644) | 975.15 (541.69, 1755.46) |
| Black or African American | D29 fold-rise over D1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 60 | 10 (10, 10) | 13142 (8909, 19387) | 1314.25 (890.92, 1938.73) |
| Black or African American | D29 fold-rise over D1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 60 | 10 (10, 10) | 17281 (11001, 27148) | 1728.13 (1100.06, 2714.79) |
| Black or African American | D29 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID50 | 60 | 5 (5, 6) | 44 (24, 81) | 8.34 (4.87, 14.28) |
| Black or African American | D29 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID80 | 60 | 5 (5, 5) | 170 (88, 328) | 33.37 (17.33, 64.24) |
| Black or African American | D57 fold-rise over D1 | Vaccine | Negative | Anti N IgG (IU/ml) | 195 | 10 (10, 10) | 270892 (186938, 392550) | 26974.76 (18614.75, 39089.32) |
| Black or African American | D57 fold-rise over D1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 195 | 10 (10, 11) | 700976 (482795, 1017755) | 68147.28 (47075.98, 98650.13) |
| Black or African American | D57 fold-rise over D1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 195 | 10 (10, 10) | 1698222 (1265203, 2279444) | 169822.23 (126520.28, 227944.40) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|---------------------------|-----------------------|---------|---------------------|------------------------|-----|------------------|-------------------------------|-------------------------------------|
| Black or African American | D57 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 195 | 5 (5, 5) | 1634 (1060, 2520) | 325.53 (211.14, 501.88) |
| Black or African American | D57 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 195 | 5 (5, 5) | 2461 (1568, 3861) | 488.47 (311.61, 765.72) |
| Black or African American | D57 fold-rise over D1 | Vaccine | Positive | Anti N IgG (IU/ml) | 52 | 10 (10, 10) | 1211651 (545292, 2692316) | 120214.66 (54113.01, 267062.68) |
| Black or African American | D57 fold-rise over D1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 52 | 10 (10, 10) | 3863173 (2496394, 5978266) | 386317.31 (249639.38, 597826.60) |
| Black or African American | D57 fold-rise over D1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 52 | 10 (10, 10) | 5233980 (3292870, 8319352) | 523397.96 (329286.96, 831935.23) |
| Black or African American | D57 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 52 | 5 (5, 5) | 9353 (5430, 16111) | 1839.68 (1070.22, 3162.36) |
| Black or African American | D57 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 52 | 5 (5, 5) | 10207 (5426, 19200) | 2004.31 (1066.53, 3766.66) |
| Black or African American | D57 fold-rise over D1 | Placebo | Negative | Anti N IgG (IU/ml) | 39 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Black or African American | D57 fold-rise over D1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 39 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|---------------------------|-----------------------|---------|---------------------|------------------------|----|------------------|-----------------------------|-----------------------------------|
| Black or African American | D57 fold-rise over D1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 39 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Black or African American | D57 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID50 | 39 | 5 (5, 5) | 5 (5, 5) | 0.99 (0.92, 1.06) |
| Black or African American | D57 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID80 | 39 | 5 (5, 5) | 5 (5, 5) | 1.00 (1.00, 1.00) |
| Black or African American | D57 fold-rise over D1 | Placebo | Positive | Anti N IgG (IU/ml) | 60 | 10 (10, 10) | 162243 (80633, 326450) | 16139.73 (8020.79, 32476.93) |
| Black or African American | D57 fold-rise over D1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 60 | 10 (10, 10) | 304404 (168043, 551417) | 30440.40 (16804.30, 55141.74) |
| Black or African American | D57 fold-rise over D1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 60 | 10 (10, 10) | 604842 (358324, 1020956) | 60484.17 (35832.44, 102095.63) |
| Black or African American | D57 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID50 | 60 | 5 (5, 6) | 572 (270, 1213) | 107.39 (52.57, 219.36) |
| Black or African American | D57 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID80 | 60 | 5 (5, 5) | 1276 (599, 2723) | 250.63 (117.65, 533.90) |
| Asian | D29 fold-rise over D1 | Vaccine | Negative | Anti N IgG (IU/ml) | 67 | 10 (10, 10) | 30141 (17403, 52204) | 2996.97 (1730.61, 5189.99) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|-------|-----------------------|---------|---------------------|------------------------|----|------------------|-------------------------|-------------------------------|
| Asian | D29 fold-rise over D1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 67 | 10 (10, 10) | 33349 (22259, 49964) | 3334.89 (2225.89, 4996.41) |
| Asian | D29 fold-rise over D1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 67 | 10 (10, 10) | 63758 (45931, 88504) | 6375.81 (4593.12, 8850.40) |
| Asian | D29 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 67 | 5 (5, 5) | 144 (92, 225) | 28.35 (18.13, 44.32) |
| Asian | D29 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 67 | 5 (5, 6) | 330 (204, 534) | 62.08 (38.25, 100.73) |
| Asian | D29 fold-rise over D1 | Vaccine | Positive | Anti N IgG (IU/ml) | 24 | 10 (10, 11) | 33316 (16935, 65545) | 3259.82 (1663.18, 6389.20) |
| Asian | D29 fold-rise over D1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 24 | 10 (10, 10) | 24553 (12536, 48091) | 2455.34 (1253.59, 4809.13) |
| Asian | D29 fold-rise over D1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 24 | 10 (10, 10) | 49522 (26709, 91821) | 4952.19 (2670.86, 9182.14) |
| Asian | D29 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 24 | 5 (5, 5) | 174 (94, 325) | 34.87 (18.71, 64.97) |
| Asian | D29 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 24 | 6 (5, 7) | 368 (184, 735) | 66.35 (30.44, 144.62) |
| Asian | D29 fold-rise over D1 | Placebo | Negative | Anti N IgG (IU/ml) | 12 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Asian | D29 fold-rise over D1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 12 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Asian | D29 fold-rise over D1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 12 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Asian | D29 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID50 | 12 | 5 (5, 5) | 5 (5, 6) | 1.03 (0.97, 1.11) |
| Asian | D29 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID80 | 12 | 5 (5, 5) | 5 (5, 5) | 1.00 (1.00, 1.00) |
| Asian | D29 fold-rise over D1 | Placebo | Positive | Anti N IgG (IU/ml) | 13 | 10 (10, 10) | 17273 (6186, 48234) | 1727.30 (618.56, 4823.36) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|-------|-----------------------|---------|---------------------|------------------------|----|------------------|-------------------------------|-------------------------------------|
| Asian | D29 fold-rise over D1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 13 | 10 (10, 10) | 27396 (5431, 138186) | 2739.55 (543.12, 13818.59) |
| Asian | D29 fold-rise over D1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 13 | 10 (10, 10) | 12500 (4740, 32962) | 1250.02 (474.04, 3296.21) |
| Asian | D29 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID50 | 13 | 5 (5, 5) | 65 (17, 245) | 12.91 (3.40, 49.02) |
| Asian | D29 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID80 | 13 | 5 (5, 5) | 146 (18, 1215) | 29.22 (3.51, 243.00) |
| Asian | D57 fold-rise over D1 | Vaccine | Negative | Anti N IgG (IU/ml) | 67 | 10 (10, 10) | 759619 (426880, 1351718) | 75529.70 (42469.21, 134326.40) |
| Asian | D57 fold-rise over D1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 67 | 10 (10, 10) | 1685637 (1167594, 2433528) | 168563.68 (116759.36, 243352.76) |
| Asian | D57 fold-rise over D1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 67 | 10 (10, 10) | 2633046 (1864450, 3718486) | 263304.56 (186444.95, 371848.60) |
| Asian | D57 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 67 | 5 (5, 5) | 2850 (1578, 5149) | 562.24 (311.66, 1014.28) |
| Asian | D57 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 67 | 5 (5, 6) | 3805 (1835, 7889) | 715.18 (348.74, 1466.64) |
| Asian | D57 fold-rise over D1 | Vaccine | Positive | Anti N IgG (IU/ml) | 24 | 10 (10, 11) | 639026 (148027, 2758648) | 62525.33 (14515.66, 269324.12) |
| Asian | D57 fold-rise over D1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 24 | 10 (10, 10) | 2094481 (742718, 5906481) | 209448.13 (74271.83, 590648.10) |
| Asian | D57 fold-rise over D1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 24 | 10 (10, 10) | 4848443 (2478358, 9485072) | 484844.34 (247835.80, 948507.20) |
| Asian | D57 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 24 | 5 (5, 5) | 6020 (2360, 15360) | 1204.08 (471.94, 3072.01) |
| Asian | D57 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 24 | 6 (5, 7) | 8404 (2608, 27081) | 1516.02 (420.28, 5468.58) |
| Asian | D57 fold-rise over D1 | Placebo | Negative | Anti N IgG (IU/ml) | 12 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|----------------------------------|-----------------------|---------|---------------------|------------------------|----|------------------|-----------------------------|-----------------------------------|
| Asian | D57 fold-rise over D1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 12 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Asian | D57 fold-rise over D1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 12 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Asian | D57 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID50 | 12 | 5 (5, 5) | 5 (5, 5) | 1.00 (1.00, 1.00) |
| Asian | D57 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID80 | 12 | 5 (5, 5) | 5 (5, 5) | 1.00 (1.00, 1.00) |
| Asian | D57 fold-rise over D1 | Placebo | Positive | Anti N IgG (IU/ml) | 13 | 10 (10, 10) | 275834 (26204, 2903499) | 27583.39 (2620.44, 290349.91) |
| Asian | D57 fold-rise over D1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 13 | 10 (10, 10) | 750472 (176753, 3186420) | 75047.23 (17675.28, 318642.03) |
| Asian | D57 fold-rise over D1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 13 | 10 (10, 10) | 859200 (168867, 4371633) | 85919.98 (16886.69, 437163.32) |
| Asian | D57 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID50 | 13 | 5 (5, 5) | 482 (269, 862) | 96.37 (53.86, 172.43) |
| Asian | D57 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID80 | 13 | 5 (5, 5) | 1167 (203, 6693) | 233.34 (40.67, 1338.57) |
| American Indian or Alaska Native | D29 fold-rise over D1 | Vaccine | Negative | Anti N IgG (IU/ml) | 13 | 10 (10, 10) | 45133 (16515, 123343) | 4513.35 (1651.52, 12334.31) |
| American Indian or Alaska Native | D29 fold-rise over D1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 13 | 10 (10, 10) | 42283 (20288, 88120) | 4228.26 (2028.84, 8812.00) |
| American Indian or Alaska Native | D29 fold-rise over D1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 13 | 10 (10, 10) | 30785 (13439, 70516) | 3078.46 (1343.94, 7051.60) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|----------------------------------|-----------------------|---------|---------------------|------------------------|----|------------------|--------------------------|--------------------------------|
| American Indian or Alaska Native | D29 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 13 | 5 (5, 5) | 186 (63, 554) | 37.27 (12.54, 110.76) |
| American Indian or Alaska Native | D29 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 13 | 5 (5, 5) | 309 (55, 1753) | 61.82 (10.90, 350.55) |
| American Indian or Alaska Native | D29 fold-rise over D1 | Vaccine | Positive | Anti N IgG (IU/ml) | 6 | 10 (10, 10) | 42543 (10105, 179112) | 4254.32 (1010.50, 17911.17) |
| American Indian or Alaska Native | D29 fold-rise over D1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 6 | 10 (10, 10) | 22761 (8134, 63689) | 2276.11 (813.43, 6368.93) |
| American Indian or Alaska Native | D29 fold-rise over D1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 6 | 10 (10, 10) | 85898 (68138, 108288) | 8589.81 (6813.79, 10828.76) |
| American Indian or Alaska Native | D29 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 6 | 5 (5, 5) | 244 (182, 327) | 48.86 (36.48, 65.43) |
| American Indian or Alaska Native | D29 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 6 | 7 (4, 14) | 1338 (620, 2888) | 189.36 (70.73, 506.98) |
| American Indian or Alaska Native | D29 fold-rise over D1 | Placebo | Negative | Anti N IgG (IU/ml) | 5 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| American Indian or Alaska Native | D29 fold-rise over D1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 5 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|----------------------------------|-----------------------|---------|---------------------|------------------------|----|------------------|-----------------------------|-----------------------------------|
| American Indian or Alaska Native | D29 fold-rise over D1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 5 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| American Indian or Alaska Native | D29 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID50 | 5 | 5 (5, 5) | 5 (5, 5) | 1.00 (1.00, 1.00) |
| American Indian or Alaska Native | D29 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID80 | 5 | 5 (5, 7) | 5 (5, 5) | 0.92 (0.76, 1.11) |
| American Indian or Alaska Native | D29 fold-rise over D1 | Placebo | Positive | Anti N IgG (IU/ml) | 4 | 10 (10, 10) | 3080 (1115, 8510) | 307.99 (111.47, 851.02) |
| American Indian or Alaska Native | D29 fold-rise over D1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 4 | 10 (10, 10) | 7559 (3837, 14892) | 755.89 (383.69, 1489.16) |
| American Indian or Alaska Native | D29 fold-rise over D1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 4 | 10 (10, 10) | 5348 (1735, 16488) | 534.82 (173.48, 1648.79) |
| American Indian or Alaska Native | D29 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID50 | 4 | 5 (5, 5) | 13 (4, 46) | 2.68 (0.78, 9.17) |
| American Indian or Alaska Native | D29 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID80 | 4 | 5 (5, 5) | 79 (32, 190) | 15.71 (6.48, 38.08) |
| American Indian or Alaska Native | D57 fold-rise over D1 | Vaccine | Negative | Anti N IgG (IU/ml) | 13 | 10 (10, 10) | 982833 (235813, 4096296) | 98283.35 (23581.35, 409629.55) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|----------------------------------|-----------------------|---------|---------------------|--|----|------------------|--------------------------------|--------------------------------------|
| American Indian or Alaska Native | D57 fold-rise over D1 | Vaccine | Negative | Anti RBD IgG (IU/ml) Anti Spike IgG (IU/ml) | 13 | 10 (10, 10) | 836025 (283249, 2467576) | 83602.47 (28324.85, 246757.62) |
| American Indian or Alaska Native | D57 fold-rise over D1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 13 | 10 (10, 10) | 4760602 (2359191, 9606399) | 476060.17 (235919.09, 960639.89) |
| American Indian or Alaska Native | D57 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 13 | 5 (5, 5) | 3381 (548, 20856) | 676.29 (109.65, 4171.15) |
| American Indian or Alaska Native | D57 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 13 | 5 (5, 5) | 4097 (1137, 14766) | 819.48 (227.39, 2953.28) |
| American Indian or Alaska Native | D57 fold-rise over D1 | Vaccine | Positive | Anti N IgG (IU/ml) | 6 | 10 (10, 10) | 2398314 (427206, 13464021) | 239831.36 (42720.58, 1346402.09) |
| American Indian or Alaska Native | D57 fold-rise over D1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 6 | 10 (10, 10) | 2320038 (501453, 10733961) | 232003.84 (50145.31, 1073396.08) |
| American Indian or Alaska Native | D57 fold-rise over D1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 6 | 10 (10, 10) | 7507181 (3379449, 16676615) | 750718.10 (337944.88, 1667661.53) |
| American Indian or Alaska Native | D57 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 6 | 5 (5, 5) | 8919 (1502, 52953) | 1783.72 (300.42, 10590.56) |
| American Indian or Alaska Native | D57 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 6 | 7 (4, 14) | 9789 (1020, 93964) | 1385.06 (263.35, 7284.52) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|----------------------------------|-----------------------|---------|---------------------|------------------------|---|------------------|-----------------------------|-----------------------------------|
| American Indian or Alaska Native | D57 fold-rise over D1 | Placebo | Negative | Anti N IgG (IU/ml) | 5 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| American Indian or Alaska Native | D57 fold-rise over D1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 5 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| American Indian or Alaska Native | D57 fold-rise over D1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 5 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| American Indian or Alaska Native | D57 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID50 | 5 | 5 (5, 5) | 5 (5, 5) | 1.00 (1.00, 1.00) |
| American Indian or Alaska Native | D57 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID80 | 5 | 5 (5, 7) | 5 (5, 5) | 0.92 (0.76, 1.11) |
| American Indian or Alaska Native | D57 fold-rise over D1 | Placebo | Positive | Anti N IgG (IU/ml) | 4 | 10 (10, 10) | 36102 (4722, 276037) | 3610.19 (472.16, 27603.67) |
| American Indian or Alaska Native | D57 fold-rise over D1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 4 | 10 (10, 10) | 272152 (65917, 1123631) | 27215.15 (6591.71, 112363.10) |
| American Indian or Alaska Native | D57 fold-rise over D1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 4 | 10 (10, 10) | 677711 (214540, 2140827) | 67771.11 (21453.97, 214082.67) |
| American Indian or Alaska Native | D57 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID50 | 4 | 5 (5, 5) | 126 (26, 608) | 25.11 (5.18, 121.64) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|---|-----------------------|---------|---------------------|------------------------|----|------------------|---------------------------|---------------------------------|
| American Indian or Alaska Native | D57 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID80 | 4 | 5 (5, 5) | 520 (61, 4436) | 104.04 (12.20, 887.23) |
| Native Hawaiian or Other Pacific Islander | D29 fold-rise over D1 | Vaccine | Negative | Anti N IgG (IU/ml) | 17 | 10 (10, 10) | 114600 (47108, 278791) | 11460.05 (4710.80, 27879.06) |
| Native Hawaiian or Other Pacific Islander | D29 fold-rise over D1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 17 | 11 (9, 14) | 114776 (53301, 247155) | 10095.55 (4569.91, 22302.43) |
| Native Hawaiian or Other Pacific Islander | D29 fold-rise over D1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 17 | 10 (10, 10) | 116196 (67714, 199391) | 11619.59 (6771.36, 19939.11) |
| Native Hawaiian or Other Pacific Islander | D29 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 17 | 6 (4, 8) | 381 (198, 736) | 66.42 (37.70, 117.02) |
| Native Hawaiian or Other Pacific Islander | D29 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 17 | 5 (5, 5) | 982 (339, 2849) | 196.48 (67.76, 569.73) |
| Native Hawaiian or Other Pacific Islander | D29 fold-rise over D1 | Vaccine | Positive | Anti N IgG (IU/ml) | 5 | 10 (10, 10) | 55095 (9965, 304612) | 5509.47 (996.49, 30461.20) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|---|-----------------------|---------|---------------------|------------------------|---|------------------|---------------------------|---------------------------------|
| Native Hawaiian or Other Pacific Islander | D29 fold-rise over D1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 5 | 10 (10, 10) | 44998 (2885, 701952) | 4499.84 (288.46, 70195.19) |
| Native Hawaiian or Other Pacific Islander | D29 fold-rise over D1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 5 | 10 (10, 10) | 107953 (71167, 163752) | 10795.26 (7116.74, 16375.16) |
| Native Hawaiian or Other Pacific Islander | D29 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 5 | 5 (5, 5) | 227 (17, 2989) | 45.50 (3.46, 597.82) |
| Native Hawaiian or Other Pacific Islander | D29 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 5 | 5 (5, 5) | 489 (239, 1000) | 97.88 (47.90, 200.01) |
| Native Hawaiian or Other Pacific Islander | D29 fold-rise over D1 | Placebo | Negative | Anti N IgG (IU/ml) | 1 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Native Hawaiian or Other Pacific Islander | D29 fold-rise over D1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 1 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Native Hawaiian or Other Pacific Islander | D29 fold-rise over D1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 1 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|---|-----------------------|---------|---------------------|------------------------|---|------------------|-------------------------|-------------------------------|
| Native Hawaiian or Other Pacific Islander | D29 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID50 | 1 | 5 (5, 5) | 5 (5, 5) | 1.00 (1.00, 1.00) |
| Native Hawaiian or Other Pacific Islander | D29 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID80 | 1 | 5 (5, 5) | 5 (5, 5) | 1.00 (1.00, 1.00) |
| Native Hawaiian or Other Pacific Islander | D29 fold-rise over D1 | Placebo | Positive | Anti N IgG (IU/ml) | 1 | 10 (10, 10) | 734 (734, 734) | 73.38 (73.38, 73.38) |
| Native Hawaiian or Other Pacific Islander | D29 fold-rise over D1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 1 | 10 (10, 10) | 6237 (6237, 6237) | 623.73 (623.73, 623.73) |
| Native Hawaiian or Other Pacific Islander | D29 fold-rise over D1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 1 | 10 (10, 10) | 10844 (10844, 10844) | 1084.43 (1084.43, 1084.43) |
| Native Hawaiian or Other Pacific Islander | D29 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID50 | 1 | 5 (5, 5) | 5 (5, 5) | 1.00 (1.00, 1.00) |
| Native Hawaiian or Other Pacific Islander | D29 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID80 | 1 | 5 (5, 5) | 5 (5, 5) | 1.00 (1.00, 1.00) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|---|-----------------------|---------|---------------------|------------------------|----|------------------|--------------------------------|--------------------------------------|
| Native Hawaiian or Other Pacific Islander | D57 fold-rise over D1 | Vaccine | Negative | Anti N IgG (IU/ml) | 17 | 10 (10, 10) | 2236794 (700142, 7146051) | 223679.40 (70014.16, 714605.11) |
| Native Hawaiian or Other Pacific Islander | D57 fold-rise over D1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 17 | 11 (9, 14) | 5533419 (2490433, 12294540) | 486710.15 (203427.87, 1164475.48) |
| Native Hawaiian or Other Pacific Islander | D57 fold-rise over D1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 17 | 10 (10, 10) | 7662810 (3323463, 17667914) | 766281.01 (332346.29, 1766791.43) |
| Native Hawaiian or Other Pacific Islander | D57 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 17 | 6 (4, 8) | 10464 (2274, 48150) | 1821.72 (378.83, 8760.18) |
| Native Hawaiian or Other Pacific Islander | D57 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 17 | 5 (5, 5) | 4635 (2089, 10284) | 927.06 (417.84, 2056.86) |
| Native Hawaiian or Other Pacific Islander | D57 fold-rise over D1 | Vaccine | Positive | Anti N IgG (IU/ml) | 5 | 10 (10, 10) | 513962 (93920, 2812583) | 51396.21 (9391.97, 281258.27) |
| Native Hawaiian or Other Pacific Islander | D57 fold-rise over D1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 5 | 10 (10, 10) | 1828480 (947016, 3530396) | 182848.03 (94701.55, 353039.63) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|---|-----------------------|---------|---------------------|--|---|------------------|-------------------------------|-------------------------------------|
| Native Hawaiian or Other Pacific Islander | D57 fold-rise over D1 | Vaccine | Positive | Anti Spike IgG (IU/ml) Pseudovirus-nAb ID50 | 5 | 10 (10, 10) | 5139344 (595014, 44390337) | 513934.43 (59501.37, 4439033.72) |
| Native Hawaiian or Other Pacific Islander | D57 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 5 | 5 (5, 5) | 2545 (185, 35084) | 509.01 (36.92, 7016.90) |
| Native Hawaiian or Other Pacific Islander | D57 fold-rise over D1 | Vaccine | Positive | Anti N IgG (IU/ml) | 1 | 10 (10, 10) | 1804 (213, 15248) | 360.81 (42.69, 3049.51) |
| Native Hawaiian or Other Pacific Islander | D57 fold-rise over D1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 1 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Native Hawaiian or Other Pacific Islander | D57 fold-rise over D1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 1 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Native Hawaiian or Other Pacific Islander | D57 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID50 | 1 | 5 (5, 5) | 5 (5, 5) | 1.00 (1.00, 1.00) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|---|-----------------------|---------|---------------------|------------------------|----|------------------|-------------------------|-------------------------------|
| Native Hawaiian or Other Pacific Islander | D57 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID80 | 1 | 5 (5, 5) | 5 (5, 5) | 1.00 (1.00, 1.00) |
| Native Hawaiian or Other Pacific Islander | D57 fold-rise over D1 | Placebo | Positive | Anti N IgG (IU/ml) | 1 | 10 (10, 10) | 969 (969, 969) | 96.94 (96.94, 96.94) |
| Native Hawaiian or Other Pacific Islander | D57 fold-rise over D1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 1 | 10 (10, 10) | 4780 (4780, 4780) | 477.97 (477.97, 477.97) |
| Native Hawaiian or Other Pacific Islander | D57 fold-rise over D1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 1 | 10 (10, 10) | 61376 (61376, 61376) | 6137.62 (6137.62, 6137.62) |
| Native Hawaiian or Other Pacific Islander | D57 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID50 | 1 | 5 (5, 5) | 44 (44, 44) | 8.78 (8.78, 8.78) |
| Native Hawaiian or Other Pacific Islander | D57 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID80 | 1 | 5 (5, 5) | 144 (144, 144) | 28.88 (28.88, 28.88) |
| Multiracial | D29 fold-rise over D1 | Vaccine | Negative | Anti N IgG (IU/ml) | 52 | 10 (10, 10) | 20542 (10447, 40388) | 2054.15 (1044.75, 4038.82) |
| Multiracial | D29 fold-rise over D1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 52 | 10 (10, 10) | 21505 (13701, 33755) | 2150.54 (1370.10, 3375.53) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|-------------|-----------------------|---------|---------------------|------------------------|----|------------------|---------------------------|---------------------------------|
| Multiracial | D29 fold-rise over D1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 52 | 10 (10, 10) | 45067 (27165, 74765) | 4506.67 (2716.51, 7476.53) |
| Multiracial | D29 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 52 | 5 (5, 5) | 71 (38, 130) | 14.15 (7.67, 26.10) |
| Multiracial | D29 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 52 | 5 (5, 5) | 135 (82, 222) | 27.01 (16.44, 44.37) |
| Multiracial | D29 fold-rise over D1 | Vaccine | Positive | Anti N IgG (IU/ml) | 12 | 10 (10, 10) | 70589 (26321, 189314) | 7058.93 (2632.06, 18931.39) |
| Multiracial | D29 fold-rise over D1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 12 | 10 (10, 10) | 55196 (16260, 187371) | 5519.61 (1625.98, 18737.06) |
| Multiracial | D29 fold-rise over D1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 12 | 10 (10, 10) | 155885 (67996, 357377) | 15588.50 (6799.58, 35737.70) |
| Multiracial | D29 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 12 | 5 (5, 5) | 398 (197, 804) | 79.65 (39.46, 160.77) |
| Multiracial | D29 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 12 | 5 (5, 5) | 277 (153, 502) | 55.46 (30.62, 100.45) |
| Multiracial | D29 fold-rise over D1 | Placebo | Negative | Anti N IgG (IU/ml) | 8 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Multiracial | D29 fold-rise over D1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 8 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Multiracial | D29 fold-rise over D1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 8 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Multiracial | D29 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID50 | 8 | 5 (5, 5) | 5 (5, 5) | 1.00 (1.00, 1.00) |
| Multiracial | D29 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID80 | 8 | 5 (5, 5) | 5 (5, 5) | 1.00 (1.00, 1.00) |
| Multiracial | D29 fold-rise over D1 | Placebo | Positive | Anti N IgG (IU/ml) | 19 | 10 (10, 10) | 15871 (7677, 32809) | 1587.06 (767.70, 3280.89) |
| Multiracial | D29 fold-rise over D1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 19 | 10 (10, 10) | 24792 (13458, 45670) | 2479.22 (1345.85, 4567.01) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|-------------|-----------------------|---------|---------------------|------------------------|----|------------------|--------------------------------|--------------------------------------|
| Multiracial | D29 fold-rise over D1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 19 | 10 (10, 10) | 25261 (11298, 56479) | 2526.08 (1129.81, 5647.92) |
| Multiracial | D29 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID50 | 19 | 5 (5, 5) | 51 (28, 93) | 10.28 (5.69, 18.57) |
| Multiracial | D29 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID80 | 19 | 5 (5, 5) | 190 (60, 600) | 38.04 (12.06, 119.98) |
| Multiracial | D57 fold-rise over D1 | Vaccine | Negative | Anti N IgG (IU/ml) | 52 | 10 (10, 10) | 214922 (107912, 428046) | 21492.16 (10791.19, 42804.62) |
| Multiracial | D57 fold-rise over D1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 52 | 10 (10, 10) | 1262157 (710446, 2242309) | 126215.68 (71044.61, 224230.92) |
| Multiracial | D57 fold-rise over D1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 52 | 10 (10, 10) | 2195866 (1476648, 3265387) | 219586.59 (147664.79, 326538.73) |
| Multiracial | D57 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 52 | 5 (5, 5) | 1524 (697, 3334) | 304.82 (139.36, 666.71) |
| Multiracial | D57 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 52 | 5 (5, 5) | 1963 (778, 4953) | 392.69 (155.66, 990.65) |
| Multiracial | D57 fold-rise over D1 | Vaccine | Positive | Anti N IgG (IU/ml) | 12 | 10 (10, 10) | 1276135 (551639, 2952150) | 127613.54 (55163.92, 295214.95) |
| Multiracial | D57 fold-rise over D1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 12 | 10 (10, 10) | 3777504 (1786314, 7988255) | 377750.36 (178631.43, 798825.46) |
| Multiracial | D57 fold-rise over D1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 12 | 10 (10, 10) | 8118223 (3167974, 20803689) | 811822.28 (316797.37, 2080368.91) |
| Multiracial | D57 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 12 | 5 (5, 5) | 2411 (687, 8455) | 482.14 (137.47, 1690.96) |
| Multiracial | D57 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 12 | 5 (5, 5) | 10135 (6049, 16979) | 2026.93 (1209.86, 3395.82) |
| Multiracial | D57 fold-rise over D1 | Placebo | Negative | Anti N IgG (IU/ml) | 8 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Multiracial | D57 fold-rise over D1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 8 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|-------------|-----------------------|---------|---------------------|------------------------|----|------------------|-----------------------------|-----------------------------------|
| Multiracial | D57 fold-rise over D1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 8 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Multiracial | D57 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID50 | 8 | 5 (5, 5) | 5 (5, 5) | 1.00 (1.00, 1.00) |
| Multiracial | D57 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID80 | 8 | 5 (5, 5) | 5 (5, 5) | 1.00 (1.00, 1.00) |
| Multiracial | D57 fold-rise over D1 | Placebo | Positive | Anti N IgG (IU/ml) | 19 | 10 (10, 10) | 235861 (101669, 547174) | 23586.11 (10166.87, 54717.37) |
| Multiracial | D57 fold-rise over D1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 19 | 10 (10, 10) | 693982 (285837, 1684912) | 69398.16 (28583.71, 168491.21) |
| Multiracial | D57 fold-rise over D1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 19 | 10 (10, 10) | 791515 (327732, 1911609) | 79151.46 (32773.19, 191160.91) |
| Multiracial | D57 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID50 | 19 | 5 (5, 5) | 1034 (211, 5057) | 206.71 (42.25, 1011.44) |
| Multiracial | D57 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID80 | 19 | 5 (5, 5) | 2744 (676, 11140) | 548.80 (135.18, 2227.99) |
| Other | D29 fold-rise over D1 | Vaccine | Negative | Anti N IgG (IU/ml) | 34 | 10 (10, 10) | 21653 (9122, 51401) | 2165.33 (912.17, 5140.10) |
| Other | D29 fold-rise over D1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 34 | 10 (10, 10) | 22295 (11570, 42963) | 2229.51 (1156.96, 4296.34) |
| Other | D29 fold-rise over D1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 34 | 10 (10, 10) | 38007 (21259, 67950) | 3800.73 (2125.91, 6794.99) |
| Other | D29 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 34 | 5 (5, 5) | 118 (54, 259) | 23.46 (10.69, 51.49) |
| Other | D29 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 34 | 6 (5, 7) | 254 (100, 650) | 45.07 (19.22, 105.68) |
| Other | D29 fold-rise over D1 | Vaccine | Positive | Anti N IgG (IU/ml) | 7 | 10 (10, 10) | 18596 (5457, 63367) | 1859.60 (545.72, 6336.73) |
| Other | D29 fold-rise over D1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 7 | 10 (10, 10) | 18039 (7489, 43449) | 1803.88 (748.91, 4344.93) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|-------|-----------------------|---------|---------------------|------------------------|----|------------------|-----------------------------|-----------------------------------|
| Other | D29 fold-rise over D1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 7 | 10 (10, 10) | 75844 (32129, 179037) | 7584.42 (3212.93, 17903.73) |
| Other | D29 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 7 | 5 (5, 5) | 63 (18, 221) | 12.67 (3.62, 44.29) |
| Other | D29 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 7 | 5 (5, 5) | 283 (86, 936) | 56.63 (17.13, 187.20) |
| Other | D29 fold-rise over D1 | Placebo | Negative | Anti N IgG (IU/ml) | 4 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Other | D29 fold-rise over D1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 4 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Other | D29 fold-rise over D1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 4 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Other | D29 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID50 | 4 | 5 (5, 5) | 5 (5, 5) | 1.00 (1.00, 1.00) |
| Other | D29 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID80 | 4 | 6 (4, 8) | 5 (5, 5) | 0.87 (0.67, 1.14) |
| Other | D29 fold-rise over D1 | Placebo | Positive | Anti N IgG (IU/ml) | 5 | 10 (10, 10) | 44670 (548, 3638655) | 4466.95 (54.84, 363865.54) |
| Other | D29 fold-rise over D1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 5 | 10 (10, 10) | 49870 (993, 2505753) | 4987.05 (99.25, 250575.29) |
| Other | D29 fold-rise over D1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 5 | 10 (10, 10) | 40496 (1871, 876366) | 4049.58 (187.13, 87636.61) |
| Other | D29 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID50 | 5 | 5 (5, 5) | 221 (12, 4185) | 44.21 (2.34, 836.92) |
| Other | D29 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID80 | 5 | 5 (5, 5) | 295 (27, 3229) | 58.92 (5.37, 645.90) |
| Other | D57 fold-rise over D1 | Vaccine | Negative | Anti N IgG (IU/ml) | 34 | 10 (10, 10) | 460615 (152205, 1393948) | 46061.47 (15220.51, 139394.78) |
| Other | D57 fold-rise over D1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 34 | 10 (10, 10) | 959325 (467189, 1969877) | 95932.51 (46718.88, 196987.75) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|-------|-----------------------|---------|---------------------|------------------------|----|------------------|--------------------------------|--------------------------------------|
| Other | D57 fold-rise over D1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 34 | 10 (10, 10) | 2238776 (1221484, 4103302) | 223877.62 (122148.43, 410330.20) |
| Other | D57 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 34 | 5 (5, 5) | 1974 (715, 5452) | 392.38 (142.10, 1083.45) |
| Other | D57 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 34 | 6 (5, 7) | 3391 (1017, 11315) | 600.81 (201.25, 1793.66) |
| Other | D57 fold-rise over D1 | Vaccine | Positive | Anti N IgG (IU/ml) | 7 | 10 (10, 10) | 506707 (112863, 2274911) | 50670.72 (11286.25, 227491.09) |
| Other | D57 fold-rise over D1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 7 | 10 (10, 10) | 4612046 (1663462, 12787169) | 461204.60 (166346.19, 1278716.85) |
| Other | D57 fold-rise over D1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 7 | 10 (10, 10) | 5745695 (3340937, 9881364) | 574569.52 (334093.70, 988136.36) |
| Other | D57 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 7 | 5 (5, 5) | 2543 (573, 11275) | 508.53 (114.67, 2255.10) |
| Other | D57 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 7 | 5 (5, 5) | 4503 (1467, 13817) | 900.51 (293.45, 2763.40) |
| Other | D57 fold-rise over D1 | Placebo | Negative | Anti N IgG (IU/ml) | 4 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Other | D57 fold-rise over D1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 4 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Other | D57 fold-rise over D1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 4 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Other | D57 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID50 | 4 | 5 (5, 5) | 5 (5, 5) | 1.00 (1.00, 1.00) |
| Other | D57 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID80 | 4 | 6 (4, 8) | 5 (5, 5) | 0.87 (0.67, 1.14) |
| Other | D57 fold-rise over D1 | Placebo | Positive | Anti N IgG (IU/ml) | 5 | 10 (10, 10) | 635834 (21972, 18400096) | 63583.42 (2197.19, 1840009.60) |
| Other | D57 fold-rise over D1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 5 | 10 (10, 10) | 390164 (12362, 12313729) | 39016.41 (1236.25, 1231372.90) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|--------------------------|-----------------------|---------|---------------------|------------------------|----|------------------|------------------------------|------------------------------------|
| Other | D57 fold-rise over D1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 5 | 10 (10, 10) | 1950467 (62864, 60516607) | 195046.73 (6286.41, 6051660.72) |
| Other | D57 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID50 | 5 | 5 (5, 5) | 6112 (27, 1395272) | 1222.45 (5.36, 279054.32) |
| Other | D57 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID80 | 5 | 5 (5, 5) | 1609 (34, 75283) | 321.73 (6.87, 15056.61) |
| Not reported and unknown | D29 fold-rise over D1 | Vaccine | Negative | Anti N IgG (IU/ml) | 87 | 10 (10, 10) | 19313 (11899, 31347) | 1931.33 (1189.92, 3134.71) |
| Not reported and unknown | D29 fold-rise over D1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 87 | 10 (10, 10) | 19972 (12070, 33047) | 1984.44 (1199.39, 3283.33) |
| Not reported and unknown | D29 fold-rise over D1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 87 | 10 (10, 10) | 41499 (27382, 62895) | 4133.86 (2728.77, 6262.46) |
| Not reported and unknown | D29 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 87 | 5 (5, 5) | 85 (51, 144) | 16.41 (9.71, 27.74) |
| Not reported and unknown | D29 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 87 | 5 (5, 5) | 167 (114, 245) | 32.87 (22.41, 48.19) |
| Not reported and unknown | D29 fold-rise over D1 | Vaccine | Positive | Anti N IgG (IU/ml) | 20 | 10 (10, 10) | 67460 (18205, 249984) | 6745.99 (1820.46, 24998.37) |
| Not reported and unknown | D29 fold-rise over D1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 20 | 10 (10, 10) | 57668 (23639, 140684) | 5766.80 (2363.88, 14068.40) |
| Not reported and unknown | D29 fold-rise over D1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 20 | 10 (10, 10) | 112437 (52711, 239834) | 11243.65 (5271.13, 23983.41) |
| Not reported and unknown | D29 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 20 | 6 (5, 7) | 348 (94, 1295) | 63.04 (16.08, 247.10) |
| Not reported and unknown | D29 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 20 | 5 (5, 5) | 581 (199, 1695) | 116.20 (39.84, 338.93) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|--------------------------|-----------------------|---------|---------------------|------------------------|----|------------------|-----------------------------|-----------------------------------|
| Not reported and unknown | D29 fold-rise over D1 | Placebo | Negative | Anti N IgG (IU/ml) | 14 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Not reported and unknown | D29 fold-rise over D1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 14 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Not reported and unknown | D29 fold-rise over D1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 14 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Not reported and unknown | D29 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID50 | 14 | 5 (5, 5) | 5 (5, 6) | 1.07 (0.93, 1.23) |
| Not reported and unknown | D29 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID80 | 14 | 5 (5, 5) | 5 (5, 5) | 1.00 (1.00, 1.00) |
| Not reported and unknown | D29 fold-rise over D1 | Placebo | Positive | Anti N IgG (IU/ml) | 24 | 11 (9, 14) | 15732 (6215, 39822) | 1415.94 (642.37, 3121.07) |
| Not reported and unknown | D29 fold-rise over D1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 24 | 10 (10, 10) | 11890 (6465, 21867) | 1188.99 (646.49, 2186.73) |
| Not reported and unknown | D29 fold-rise over D1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 24 | 10 (10, 10) | 17779 (10512, 30069) | 1777.89 (1051.21, 3006.90) |
| Not reported and unknown | D29 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID50 | 24 | 6 (5, 7) | 46 (19, 111) | 8.22 (3.79, 17.84) |
| Not reported and unknown | D29 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID80 | 24 | 5 (5, 6) | 168 (59, 476) | 31.45 (11.89, 83.22) |
| Not reported and unknown | D57 fold-rise over D1 | Vaccine | Negative | Anti N IgG (IU/ml) | 87 | 10 (10, 10) | 313760 (169470, 580901) | 31376.01 (16947.01, 58090.14) |
| Not reported and unknown | D57 fold-rise over D1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 87 | 10 (10, 10) | 958206 (602856, 1523015) | 95207.62 (59917.16, 151283.72) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|--------------------------|-----------------------|---------|---------------------|------------------------|----|------------------|--------------------------------|--------------------------------------|
| Not reported and unknown | D57 fold-rise over D1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 87 | 10 (10, 10) | 1898203 (1201387, 2999181) | 189087.45 (119691.94, 298717.41) |
| Not reported and unknown | D57 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 87 | 5 (5, 5) | 1331 (758, 2339) | 256.28 (146.58, 448.08) |
| Not reported and unknown | D57 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 87 | 5 (5, 5) | 2345 (1156, 4755) | 461.94 (227.90, 936.32) |
| Not reported and unknown | D57 fold-rise over D1 | Vaccine | Positive | Anti N IgG (IU/ml) | 20 | 10 (10, 10) | 1890562 (655546, 5452282) | 189056.18 (65554.64, 545228.19) |
| Not reported and unknown | D57 fold-rise over D1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 20 | 10 (10, 10) | 3239260 (1199389, 8748461) | 323926.04 (119938.90, 874846.13) |
| Not reported and unknown | D57 fold-rise over D1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 20 | 10 (10, 10) | 9280577 (5784309, 14890128) | 928057.68 (578430.93, 1489012.80) |
| Not reported and unknown | D57 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 20 | 6 (5, 7) | 11045 (3104, 39295) | 2000.02 (606.29, 6597.67) |
| Not reported and unknown | D57 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 20 | 5 (5, 5) | 5210 (1481, 18320) | 1041.90 (296.28, 3663.93) |
| Not reported and unknown | D57 fold-rise over D1 | Placebo | Negative | Anti N IgG (IU/ml) | 14 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Not reported and unknown | D57 fold-rise over D1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 14 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Not reported and unknown | D57 fold-rise over D1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 14 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Not reported and unknown | D57 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID50 | 14 | 5 (5, 5) | 5 (5, 5) | 1.02 (0.98, 1.07) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|--------------------------|-----------------------|---------|---------------------|------------------------|----|------------------|-----------------------------|-----------------------------------|
| Not reported and unknown | D57 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID80 | 14 | 5 (5, 5) | 5 (5, 5) | 1.00 (1.00, 1.00) |
| Not reported and unknown | D57 fold-rise over D1 | Placebo | Positive | Anti N IgG (IU/ml) | 24 | 11 (9, 14) | 212439 (58037, 777613) | 19119.79 (5831.21, 62691.28) |
| Not reported and unknown | D57 fold-rise over D1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 24 | 10 (10, 10) | 401782 (153583, 1051084) | 40178.22 (15358.33, 105108.37) |
| Not reported and unknown | D57 fold-rise over D1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 24 | 10 (10, 10) | 645039 (295340, 1408800) | 64503.88 (29533.99, 140880.03) |
| Not reported and unknown | D57 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID50 | 24 | 6 (5, 7) | 485 (159, 1481) | 87.38 (29.73, 256.78) |
| Not reported and unknown | D57 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID80 | 24 | 5 (5, 6) | 1124 (299, 4219) | 209.99 (58.57, 752.84) |

Table 6i. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Underrepresented minority status

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|---|-----------------------|---------|---------------------|------------------------|-----|------------------|-----------------------|-----------------------------|
| Underrepresented minority status | | | | | | | | |
| Communities of Color | D29 fold-rise over D1 | Vaccine | Negative | Anti N IgG (IU/ml) | 420 | 10 (10, 10) | 21539 (16824, 27575) | 2147.71 (1677.60, 2749.55) |
| Communities of Color | D29 fold-rise over D1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 420 | 10 (10, 10) | 23355 (19242, 28347) | 2298.01 (1896.26, 2784.86) |
| Communities of Color | D29 fold-rise over D1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 420 | 10 (10, 10) | 40216 (34320, 47124) | 4021.60 (3432.03, 4712.44) |
| Communities of Color | D29 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 420 | 5 (5, 5) | 99 (79, 124) | 19.66 (15.68, 24.64) |
| Communities of Color | D29 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 420 | 5 (5, 5) | 208 (163, 266) | 40.35 (31.69, 51.38) |
| Communities of Color | D29 fold-rise over D1 | Vaccine | Positive | Anti N IgG (IU/ml) | 120 | 10 (10, 10) | 59825 (42571, 84073) | 5939.85 (4228.47, 8343.87) |
| Communities of Color | D29 fold-rise over D1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 120 | 10 (10, 10) | 44605 (32113, 61955) | 4460.46 (3211.32, 6195.47) |
| Communities of Color | D29 fold-rise over D1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 120 | 10 (10, 10) | 90964 (70627, 117156) | 9096.36 (7062.72, 11715.57) |
| Communities of Color | D29 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 120 | 5 (5, 5) | 238 (171, 332) | 47.22 (33.91, 65.75) |
| Communities of Color | D29 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 120 | 5 (5, 6) | 545 (371, 802) | 103.86 (70.31, 153.42) |
| Communities of Color | D29 fold-rise over D1 | Placebo | Negative | Anti N IgG (IU/ml) | 73 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|----------------------|-----------------------|---------|---------------------|------------------------|-----|------------------|----------------------------|----------------------------------|
| Communities of Color | D29 fold-rise over D1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 73 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Communities of Color | D29 fold-rise over D1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 73 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Communities of Color | D29 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID50 | 73 | 5 (5, 5) | 5 (5, 5) | 0.99 (0.96, 1.02) |
| Communities of Color | D29 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID80 | 73 | 5 (5, 5) | 5 (5, 6) | 1.04 (0.95, 1.15) |
| Communities of Color | D29 fold-rise over D1 | Placebo | Positive | Anti N IgG (IU/ml) | 111 | 10 (10, 10) | 12076 (7763, 18784) | 1203.77 (773.81, 1872.63) |
| Communities of Color | D29 fold-rise over D1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 111 | 10 (10, 10) | 17596 (12331, 25109) | 1759.61 (1233.11, 2510.90) |
| Communities of Color | D29 fold-rise over D1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 111 | 10 (10, 10) | 18884 (13334, 26743) | 1888.39 (1333.43, 2674.32) |
| Communities of Color | D29 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID50 | 111 | 5 (5, 6) | 54 (34, 84) | 10.35 (6.82, 15.71) |
| Communities of Color | D29 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID80 | 111 | 5 (5, 5) | 178 (110, 288) | 35.18 (21.73, 56.94) |
| Communities of Color | D57 fold-rise over D1 | Vaccine | Negative | Anti N IgG (IU/ml) | 420 | 10 (10, 10) | 358864 (270757, 475643) | 35783.11 (26998.45, 47426.08) |
| Communities of Color | D57 fold-rise over D1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 420 | 10 (10, 10) | 977894 (775549, 1233031) | 96220.17 (76347.07, 121266.24) |
| Communities of Color | D57 fold-rise over D1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 420 | 10 (10, 10) | 2083276 (1732503, 2505069) | 208327.61 (173250.30, 250506.88) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|----------------------|-----------------------|---------|---------------------|------------------------|-----|------------------|-------------------------------|-------------------------------------|
| Communities of Color | D57 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 420 | 5 (5, 5) | 1903 (1416, 2557) | 377.51 (280.96, 507.24) |
| Communities of Color | D57 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 420 | 5 (5, 5) | 2744 (2021, 3725) | 531.46 (393.63, 717.56) |
| Communities of Color | D57 fold-rise over D1 | Vaccine | Positive | Anti N IgG (IU/ml) | 120 | 10 (10, 10) | 1149410 (702292, 1881190) | 114120.94 (69745.73, 186729.57) |
| Communities of Color | D57 fold-rise over D1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 120 | 10 (10, 10) | 3146770 (2273084, 4356267) | 314676.99 (227308.38, 435626.74) |
| Communities of Color | D57 fold-rise over D1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 120 | 10 (10, 10) | 5991417 (4527248, 7929117) | 599141.71 (452724.79, 792911.71) |
| Communities of Color | D57 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 120 | 5 (5, 5) | 7086 (4582, 10956) | 1407.15 (910.55, 2174.59) |
| Communities of Color | D57 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 120 | 5 (5, 6) | 8885 (5903, 13374) | 1691.75 (1126.45, 2540.74) |
| Communities of Color | D57 fold-rise over D1 | Placebo | Negative | Anti N IgG (IU/ml) | 73 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Communities of Color | D57 fold-rise over D1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 73 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Communities of Color | D57 fold-rise over D1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 73 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Communities of Color | D57 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID50 | 73 | 5 (5, 5) | 5 (5, 5) | 0.99 (0.96, 1.03) |
| Communities of Color | D57 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID80 | 73 | 5 (5, 5) | 5 (5, 5) | 0.99 (0.97, 1.01) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|----------------------|-----------------------|---------|---------------------|------------------------|-----|------------------|--------------------------|--------------------------------|
| Communities of Color | D57 fold-rise over D1 | Placebo | Positive | Anti N IgG (IU/ml) | 111 | 10 (10, 10) | 193321 (112530, 332117) | 19271.20 (11217.36, 33107.55) |
| Communities of Color | D57 fold-rise over D1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 111 | 10 (10, 10) | 397884 (256621, 616908) | 39788.42 (25662.15, 61690.79) |
| Communities of Color | D57 fold-rise over D1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 111 | 10 (10, 10) | 734879 (489927, 1102301) | 73487.92 (48992.72, 110230.12) |
| Communities of Color | D57 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID50 | 111 | 5 (5, 6) | 684 (382, 1222) | 131.54 (74.79, 231.36) |
| Communities of Color | D57 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID80 | 111 | 5 (5, 5) | 1409 (809, 2454) | 278.73 (160.13, 485.18) |
| White Non-Hispanic | D29 fold-rise over D1 | Vaccine | Negative | Anti N IgG (IU/ml) | 362 | 10 (10, 10) | 26952 (20883, 34784) | 2692.55 (2086.26, 3475.03) |
| White Non-Hispanic | D29 fold-rise over D1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 362 | 10 (10, 10) | 23438 (18669, 29425) | 2343.79 (1866.88, 2942.53) |
| White Non-Hispanic | D29 fold-rise over D1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 362 | 10 (10, 10) | 40376 (34349, 47460) | 4031.72 (3430.05, 4738.93) |
| White Non-Hispanic | D29 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 362 | 5 (5, 5) | 115 (90, 147) | 22.83 (17.82, 29.23) |
| White Non-Hispanic | D29 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 362 | 5 (5, 5) | 188 (146, 241) | 37.41 (29.16, 48.00) |
| White Non-Hispanic | D29 fold-rise over D1 | Vaccine | Positive | Anti N IgG (IU/ml) | 125 | 10 (10, 10) | 33909 (24023, 47863) | 3381.77 (2396.63, 4771.84) |
| White Non-Hispanic | D29 fold-rise over D1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 125 | 10 (10, 10) | 30985 (21434, 44793) | 3098.50 (2143.36, 4479.29) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|--------------------|-----------------------|---------|---------------------|------------------------|-----|------------------|-------------------------|-------------------------------|
| White Non-Hispanic | D29 fold-rise over D1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 125 | 10 (10, 10) | 72481 (53061, 99008) | 7248.12 (5306.15, 9900.82) |
| White Non-Hispanic | D29 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 125 | 5 (5, 5) | 148 (104, 211) | 29.21 (20.49, 41.65) |
| White Non-Hispanic | D29 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 125 | 5 (5, 5) | 348 (226, 535) | 69.53 (45.18, 106.99) |
| White Non-Hispanic | D29 fold-rise over D1 | Placebo | Negative | Anti N IgG (IU/ml) | 67 | 10 (10, 11) | 10 (10, 10) | 0.97 (0.91, 1.03) |
| White Non-Hispanic | D29 fold-rise over D1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 67 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| White Non-Hispanic | D29 fold-rise over D1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 67 | 10 (10, 10) | 10 (10, 10) | 0.99 (0.96, 1.01) |
| White Non-Hispanic | D29 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID50 | 67 | 5 (5, 5) | 5 (5, 5) | 1.01 (1.00, 1.02) |
| White Non-Hispanic | D29 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID80 | 67 | 5 (5, 6) | 5 (5, 5) | 0.96 (0.89, 1.04) |
| White Non-Hispanic | D29 fold-rise over D1 | Placebo | Positive | Anti N IgG (IU/ml) | 121 | 10 (10, 10) | 12594 (8382, 18924) | 1256.17 (836.02, 1887.47) |
| White Non-Hispanic | D29 fold-rise over D1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 121 | 10 (10, 10) | 10931 (7560, 15804) | 1089.81 (753.88, 1575.44) |
| White Non-Hispanic | D29 fold-rise over D1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 121 | 10 (10, 10) | 18868 (14808, 24043) | 1886.83 (1480.76, 2404.27) |
| White Non-Hispanic | D29 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID50 | 121 | 5 (5, 5) | 52 (37, 74) | 10.37 (7.32, 14.70) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|--------------------|-----------------------|---------|---------------------|------------------------|-----|------------------|-------------------------------|-------------------------------------|
| White Non-Hispanic | D29 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID80 | 121 | 5 (5, 5) | 107 (76, 150) | 21.32 (15.15, 29.99) |
| White Non-Hispanic | D57 fold-rise over D1 | Vaccine | Negative | Anti N IgG (IU/ml) | 362 | 10 (10, 10) | 328428 (241933, 445846) | 32810.77 (24169.70, 44541.16) |
| White Non-Hispanic | D57 fold-rise over D1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 362 | 10 (10, 10) | 1035293 (809568, 1323956) | 103529.30 (80956.76, 132395.58) |
| White Non-Hispanic | D57 fold-rise over D1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 362 | 10 (10, 10) | 2145772 (1770774, 2600184) | 214266.04 (176817.71, 259645.59) |
| White Non-Hispanic | D57 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 362 | 5 (5, 5) | 1376 (1010, 1874) | 273.04 (200.41, 371.99) |
| White Non-Hispanic | D57 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 362 | 5 (5, 5) | 2011 (1465, 2761) | 400.97 (292.11, 550.40) |
| White Non-Hispanic | D57 fold-rise over D1 | Vaccine | Positive | Anti N IgG (IU/ml) | 125 | 10 (10, 10) | 855574 (517613, 1414198) | 85327.48 (51627.40, 141025.47) |
| White Non-Hispanic | D57 fold-rise over D1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 125 | 10 (10, 10) | 1943813 (1349835, 2799166) | 194381.34 (134983.46, 279916.55) |
| White Non-Hispanic | D57 fold-rise over D1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 125 | 10 (10, 10) | 4608987 (3338577, 6362819) | 460898.73 (333857.72, 636281.94) |
| White Non-Hispanic | D57 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 125 | 5 (5, 5) | 4550 (2471, 8378) | 899.93 (488.90, 1656.55) |
| White Non-Hispanic | D57 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 125 | 5 (5, 5) | 7994 (4646, 13757) | 1598.88 (929.14, 2751.39) |
| White Non-Hispanic | D57 fold-rise over D1 | Placebo | Negative | Anti N IgG (IU/ml) | 67 | 10 (10, 11) | 10 (10, 10) | 0.97 (0.91, 1.03) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|--------------------|-----------------------|---------|---------------------|------------------------|-----|------------------|----------------------------|----------------------------------|
| White Non-Hispanic | D57 fold-rise over D1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 67 | 10 (10, 10) | 10 (10, 10) | 1.01 (0.99, 1.03) |
| White Non-Hispanic | D57 fold-rise over D1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 67 | 10 (10, 10) | 10 (10, 10) | 0.99 (0.96, 1.01) |
| White Non-Hispanic | D57 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID50 | 67 | 5 (5, 5) | 5 (5, 5) | 1.00 (1.00, 1.00) |
| White Non-Hispanic | D57 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID80 | 67 | 5 (5, 6) | 5 (5, 5) | 0.98 (0.90, 1.06) |
| White Non-Hispanic | D57 fold-rise over D1 | Placebo | Positive | Anti N IgG (IU/ml) | 121 | 10 (10, 10) | 105260 (65764, 168478) | 10498.69 (6559.92, 16802.41) |
| White Non-Hispanic | D57 fold-rise over D1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 121 | 10 (10, 10) | 393045 (287516, 537306) | 39187.22 (28666.35, 53569.39) |
| White Non-Hispanic | D57 fold-rise over D1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 121 | 10 (10, 10) | 674526 (485396, 937351) | 67452.65 (48539.56, 93735.08) |
| White Non-Hispanic | D57 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID50 | 121 | 5 (5, 5) | 575 (371, 892) | 114.01 (73.52, 176.80) |
| White Non-Hispanic | D57 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID80 | 121 | 5 (5, 5) | 1478 (953, 2292) | 295.55 (190.57, 458.35) |

Table 6j. Geometric mean titer ratios (GMTRs) or geometric mean concentration ratios (GMCRs) between post-vaccinations/pre-vaccination by Age, Underrepresented minority status

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|--|-----------------------|---------|---------------------|------------------------|-----|------------------|-------------------------|-------------------------------|
| Age, Underrepresented minority status | | | | | | | | |
| Age < 65 Communities of Color | D29 fold-rise over D1 | Vaccine | Negative | Anti N IgG (IU/ml) | 192 | 10 (10, 10) | 16236 (11950, 22060) | 1623.60 (1194.98, 2205.96) |
| Age < 65 Communities of Color | D29 fold-rise over D1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 192 | 10 (10, 10) | 17593 (13852, 22344) | 1725.89 (1361.64, 2187.59) |
| Age < 65 Communities of Color | D29 fold-rise over D1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 192 | 10 (10, 10) | 30531 (25113, 37119) | 3053.10 (2511.25, 3711.87) |
| Age < 65 Communities of Color | D29 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 192 | 5 (5, 5) | 76 (58, 101) | 15.18 (11.48, 20.07) |
| Age < 65 Communities of Color | D29 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 192 | 5 (5, 5) | 174 (128, 236) | 33.64 (24.93, 45.38) |
| Age < 65 Communities of Color | D29 fold-rise over D1 | Vaccine | Positive | Anti N IgG (IU/ml) | 69 | 10 (10, 10) | 50828 (33992, 76001) | 5058.85 (3383.17, 7564.49) |
| Age < 65 Communities of Color | D29 fold-rise over D1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 69 | 10 (10, 10) | 34937 (23612, 51692) | 3493.66 (2361.25, 5169.16) |
| Age < 65 Communities of Color | D29 fold-rise over D1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 69 | 10 (10, 10) | 70998 (52424, 96153) | 7099.81 (5242.39, 9615.33) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|----------------------------------|-----------------------|---------|---------------------|------------------------|----|------------------|------------------------|------------------------------|
| Age < 65 Communities of Color | D29 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 69 | 5 (5, 5) | 209 (141, 310) | 41.82 (28.22, 61.98) |
| Age < 65 Communities of Color | D29 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 69 | 5 (5, 6) | 484 (305, 768) | 91.16 (57.15, 145.40) |
| Age < 65 Communities of Color | D29 fold-rise over D1 | Placebo | Negative | Anti N IgG (IU/ml) | 37 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age < 65 Communities of Color | D29 fold-rise over D1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 37 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age < 65 Communities of Color | D29 fold-rise over D1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 37 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age < 65 Communities of Color | D29 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID50 | 37 | 5 (5, 5) | 5 (5, 5) | 0.98 (0.94, 1.02) |
| Age < 65 Communities of Color | D29 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID80 | 37 | 5 (5, 5) | 5 (5, 6) | 1.05 (0.93, 1.19) |
| Age < 65 Communities of Color | D29 fold-rise over D1 | Placebo | Positive | Anti N IgG (IU/ml) | 61 | 10 (10, 10) | 9484 (5617, 16014) | 948.43 (561.72, 1601.39) |
| Age < 65 Communities of Color | D29 fold-rise over D1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 61 | 10 (10, 10) | 13618 (8923, 20783) | 1361.81 (892.33, 2078.29) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|-------------------------------|-----------------------|---------|---------------------|------------------------|-----|------------------|-------------------------------|-------------------------------------|
| Age < 65 Communities of Color | D29 fold-rise over D1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 61 | 10 (10, 10) | 13717 (9065, 20756) | 1371.71 (906.53, 2075.61) |
| Age < 65 Communities of Color | D29 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID50 | 61 | 5 (5, 6) | 42 (25, 72) | 8.09 (4.93, 13.29) |
| Age < 65 Communities of Color | D29 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID80 | 61 | 5 (5, 5) | 150 (84, 267) | 30.02 (16.87, 53.39) |
| Age < 65 Communities of Color | D57 fold-rise over D1 | Vaccine | Negative | Anti N IgG (IU/ml) | 192 | 10 (10, 10) | 292558 (206172, 415140) | 29255.76 (20617.15, 41513.96) |
| Age < 65 Communities of Color | D57 fold-rise over D1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 192 | 10 (10, 10) | 741900 (555661, 990562) | 72781.13 (54544.47, 97115.13) |
| Age < 65 Communities of Color | D57 fold-rise over D1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 192 | 10 (10, 10) | 1629402 (1297120, 2046806) | 162940.23 (129711.97, 204680.56) |
| Age < 65 Communities of Color | D57 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 192 | 5 (5, 5) | 1435 (996, 2067) | 285.33 (198.09, 411.00) |
| Age < 65 Communities of Color | D57 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 192 | 5 (5, 5) | 2230 (1526, 3260) | 431.29 (297.10, 626.08) |
| Age < 65 Communities of Color | D57 fold-rise over D1 | Vaccine | Positive | Anti N IgG (IU/ml) | 69 | 10 (10, 10) | 930919 (513604, 1687309) | 92654.09 (51125.98, 167914.24) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|----------------------------------|-----------------------|---------|---------------------|------------------------|----|------------------|-------------------------------|-------------------------------------|
| Age < 65 Communities of Color | D57 fold-rise over D1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 69 | 10 (10, 10) | 2542683 (1712040, 3776334) | 254268.26 (171204.01, 377633.36) |
| Age < 65 Communities of Color | D57 fold-rise over D1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 69 | 10 (10, 10) | 5081700 (3610831, 7151727) | 508170.01 (361083.05, 715172.74) |
| Age < 65 Communities of Color | D57 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 69 | 5 (5, 5) | 5550 (3299, 9337) | 1109.99 (659.78, 1867.40) |
| Age < 65 Communities of Color | D57 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 69 | 5 (5, 6) | 7380 (4562, 11940) | 1389.33 (861.24, 2241.22) |
| Age < 65 Communities of Color | D57 fold-rise over D1 | Placebo | Negative | Anti N IgG (IU/ml) | 37 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age < 65 Communities of Color | D57 fold-rise over D1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 37 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age < 65 Communities of Color | D57 fold-rise over D1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 37 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age < 65 Communities of Color | D57 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID50 | 37 | 5 (5, 5) | 5 (5, 5) | 0.99 (0.95, 1.04) |
| Age < 65 Communities of Color | D57 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID80 | 37 | 5 (5, 5) | 5 (5, 5) | 0.99 (0.97, 1.01) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|-------------------------------|-----------------------|---------|---------------------|------------------------|-----|------------------|----------------------------|----------------------------------|
| Age < 65 Communities of Color | D57 fold-rise over D1 | Placebo | Positive | Anti N IgG (IU/ml) | 61 | 10 (10, 10) | 145989 (76394, 278984) | 14598.87 (7639.41, 27898.36) |
| Age < 65 Communities of Color | D57 fold-rise over D1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 61 | 10 (10, 10) | 277278 (163947, 468952) | 27727.83 (16394.70, 46895.20) |
| Age < 65 Communities of Color | D57 fold-rise over D1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 61 | 10 (10, 10) | 543679 (333997, 884998) | 54367.88 (33399.71, 88499.76) |
| Age < 65 Communities of Color | D57 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID50 | 61 | 5 (5, 6) | 466 (233, 933) | 89.60 (45.67, 175.78) |
| Age < 65 Communities of Color | D57 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID80 | 61 | 5 (5, 5) | 1073 (554, 2078) | 214.52 (110.72, 415.67) |
| Age < 65 White Non-Hispanic | D29 fold-rise over D1 | Vaccine | Negative | Anti N IgG (IU/ml) | 175 | 10 (10, 10) | 22546 (16449, 30904) | 2254.62 (1644.88, 3090.40) |
| Age < 65 White Non-Hispanic | D29 fold-rise over D1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 175 | 10 (10, 10) | 18239 (13758, 24181) | 1823.94 (1375.79, 2418.07) |
| Age < 65 White Non-Hispanic | D29 fold-rise over D1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 175 | 10 (10, 10) | 31442 (25791, 38330) | 3144.18 (2579.11, 3833.04) |
| Age < 65 White Non-Hispanic | D29 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 175 | 5 (5, 5) | 98 (72, 132) | 19.42 (14.32, 26.34) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|-----------------------------------|-----------------------|---------|---------------------|------------------------|-----|------------------|-------------------------|-------------------------------|
| Age < 65 White Non-Hispanic | D29 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 175 | 5 (5, 5) | 163 (120, 222) | 32.68 (24.04, 44.44) |
| Age < 65 White Non-Hispanic | D29 fold-rise over D1 | Vaccine | Positive | Anti N IgG (IU/ml) | 59 | 10 (10, 10) | 22816 (14927, 34875) | 2281.61 (1492.66, 3487.54) |
| Age < 65 White Non-Hispanic | D29 fold-rise over D1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 59 | 10 (10, 10) | 19045 (11981, 30275) | 1904.54 (1198.08, 3027.54) |
| Age < 65 White Non-Hispanic | D29 fold-rise over D1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 59 | 10 (10, 10) | 50450 (34089, 74664) | 5044.99 (3408.87, 7466.38) |
| Age < 65 White Non-Hispanic | D29 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 59 | 5 (5, 5) | 100 (65, 155) | 20.06 (12.98, 31.00) |
| Age < 65 White Non-Hispanic | D29 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 59 | 5 (5, 5) | 255 (148, 438) | 50.94 (29.59, 87.68) |
| Age < 65 White Non-Hispanic | D29 fold-rise over D1 | Placebo | Negative | Anti N IgG (IU/ml) | 31 | 10 (10, 11) | 10 (10, 10) | 0.96 (0.88, 1.04) |
| Age < 65 White Non-Hispanic | D29 fold-rise over D1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 31 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age < 65 White Non-Hispanic | D29 fold-rise over D1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 31 | 10 (10, 10) | 10 (10, 10) | 0.98 (0.95, 1.02) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|-----------------------------------|-----------------------|---------|---------------------|------------------------|-----|------------------|-----------------------------|-----------------------------------|
| Age < 65 White Non-Hispanic | D29 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID50 | 31 | 5 (5, 5) | 5 (5, 5) | 1.00 (1.00, 1.00) |
| Age < 65 White Non-Hispanic | D29 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID80 | 31 | 5 (5, 6) | 5 (5, 5) | 0.95 (0.85, 1.05) |
| Age < 65 White Non-Hispanic | D29 fold-rise over D1 | Placebo | Positive | Anti N IgG (IU/ml) | 61 | 10 (10, 10) | 9218 (5562, 15276) | 921.79 (556.25, 1527.56) |
| Age < 65 White Non-Hispanic | D29 fold-rise over D1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 61 | 10 (10, 10) | 7844 (4943, 12447) | 784.36 (494.26, 1244.74) |
| Age < 65 White Non-Hispanic | D29 fold-rise over D1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 61 | 10 (10, 10) | 13337 (9897, 17972) | 1333.71 (989.74, 1797.23) |
| Age < 65 White Non-Hispanic | D29 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID50 | 61 | 5 (5, 5) | 38 (25, 58) | 7.54 (4.91, 11.57) |
| Age < 65 White Non-Hispanic | D29 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID80 | 61 | 5 (5, 5) | 78 (51, 118) | 15.51 (10.18, 23.62) |
| Age < 65 White Non-Hispanic | D57 fold-rise over D1 | Vaccine | Negative | Anti N IgG (IU/ml) | 175 | 10 (10, 10) | 264562 (181376, 385898) | 26456.16 (18137.64, 38589.80) |
| Age < 65 White Non-Hispanic | D57 fold-rise over D1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 175 | 10 (10, 10) | 821667 (605817, 1114423) | 82166.69 (60581.70, 111442.32) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|-----------------------------------|-----------------------|---------|---------------------|------------------------|-----|------------------|-------------------------------|-------------------------------------|
| Age < 65 White Non-Hispanic | D57 fold-rise over D1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 175 | 10 (10, 10) | 1724310 (1360533, 2185355) | 172431.05 (136053.26, 218535.49) |
| Age < 65 White Non-Hispanic | D57 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 175 | 5 (5, 5) | 1085 (742, 1587) | 215.99 (147.67, 315.94) |
| Age < 65 White Non-Hispanic | D57 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 175 | 5 (5, 5) | 1624 (1097, 2405) | 324.87 (219.40, 481.06) |
| Age < 65 White Non-Hispanic | D57 fold-rise over D1 | Vaccine | Positive | Anti N IgG (IU/ml) | 59 | 10 (10, 10) | 596002 (316557, 1122130) | 59600.20 (31655.74, 112212.97) |
| Age < 65 White Non-Hispanic | D57 fold-rise over D1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 59 | 10 (10, 10) | 1330657 (839177, 2109982) | 133065.71 (83917.71, 210998.18) |
| Age < 65 White Non-Hispanic | D57 fold-rise over D1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 59 | 10 (10, 10) | 3419951 (2265916, 5161739) | 341995.14 (226591.60, 516173.95) |
| Age < 65 White Non-Hispanic | D57 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 59 | 5 (5, 5) | 2838 (1308, 6159) | 567.69 (261.64, 1231.71) |
| Age < 65 White Non-Hispanic | D57 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 59 | 5 (5, 5) | 6125 (3095, 12121) | 1224.99 (619.02, 2424.13) |
| Age < 65 White Non-Hispanic | D57 fold-rise over D1 | Placebo | Negative | Anti N IgG (IU/ml) | 31 | 10 (10, 11) | 10 (10, 10) | 0.96 (0.88, 1.04) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|-----------------------------------|-----------------------|---------|---------------------|------------------------|----|------------------|----------------------------|----------------------------------|
| Age < 65 White Non-Hispanic | D57 fold-rise over D1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 31 | 10 (10, 10) | 10 (10, 10) | 1.01 (0.99, 1.03) |
| Age < 65 White Non-Hispanic | D57 fold-rise over D1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 31 | 10 (10, 10) | 10 (10, 10) | 0.98 (0.95, 1.02) |
| Age < 65 White Non-Hispanic | D57 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID50 | 31 | 5 (5, 5) | 5 (5, 5) | 1.00 (1.00, 1.00) |
| Age < 65 White Non-Hispanic | D57 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID80 | 31 | 5 (5, 6) | 5 (5, 5) | 0.96 (0.86, 1.07) |
| Age < 65 White Non-Hispanic | D57 fold-rise over D1 | Placebo | Positive | Anti N IgG (IU/ml) | 61 | 10 (10, 10) | 69600 (38639, 125369) | 6959.96 (3863.88, 12536.92) |
| Age < 65 White Non-Hispanic | D57 fold-rise over D1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 61 | 10 (10, 10) | 264698 (179593, 390131) | 26469.79 (17959.33, 39013.14) |
| Age < 65 White Non-Hispanic | D57 fold-rise over D1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 61 | 10 (10, 10) | 451492 (299075, 681584) | 45149.17 (29907.49, 68158.43) |
| Age < 65 White Non-Hispanic | D57 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID50 | 61 | 5 (5, 5) | 376 (219, 646) | 74.74 (43.50, 128.41) |
| Age < 65 White Non-Hispanic | D57 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID80 | 61 | 5 (5, 5) | 1102 (639, 1903) | 220.47 (127.72, 380.58) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|----------------------------------|-----------------------|---------|---------------------|------------------------|-----|------------------|----------------------------|----------------------------------|
| Age ≥ 65 Communities of Color | D29 fold-rise over D1 | Vaccine | Negative | Anti N IgG (IU/ml) | 228 | 10 (10, 10) | 62158 (49075, 78729) | 6131.29 (4841.75, 7764.28) |
| Age ≥ 65 Communities of Color | D29 fold-rise over D1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 228 | 10 (10, 10) | 67566 (54928, 83111) | 6723.29 (5465.75, 8270.15) |
| Age ≥ 65 Communities of Color | D29 fold-rise over D1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 228 | 10 (10, 10) | 113000 (94968, 134457) | 11300.05 (9496.80, 13445.69) |
| Age ≥ 65 Communities of Color | D29 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 228 | 5 (5, 5) | 263 (208, 334) | 51.85 (40.91, 65.71) |
| Age ≥ 65 Communities of Color | D29 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 228 | 5 (5, 5) | 409 (322, 520) | 79.83 (63.06, 101.06) |
| Age ≥ 65 Communities of Color | D29 fold-rise over D1 | Vaccine | Positive | Anti N IgG (IU/ml) | 51 | 10 (10, 11) | 120781 (72698, 200668) | 11866.15 (7200.38, 19555.30) |
| Age ≥ 65 Communities of Color | D29 fold-rise over D1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 51 | 10 (10, 10) | 127850 (82403, 198362) | 12784.98 (8240.28, 19836.18) |
| Age ≥ 65 Communities of Color | D29 fold-rise over D1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 51 | 10 (10, 10) | 264698 (193965, 361225) | 26469.82 (19396.51, 36122.55) |
| Age ≥ 65 Communities of Color | D29 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 51 | 5 (5, 6) | 414 (254, 674) | 79.73 (50.17, 126.69) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|----------------------------------|-----------------------|---------|---------------------|------------------------|----|------------------|--------------------------|--------------------------------|
| Age ≥ 65 Communities of Color | D29 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 51 | 5 (5, 5) | 911 (557, 1491) | 182.23 (111.38, 298.14) |
| Age ≥ 65 Communities of Color | D29 fold-rise over D1 | Placebo | Negative | Anti N IgG (IU/ml) | 36 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age ≥ 65 Communities of Color | D29 fold-rise over D1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 36 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age ≥ 65 Communities of Color | D29 fold-rise over D1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 36 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age ≥ 65 Communities of Color | D29 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID50 | 36 | 5 (5, 5) | 5 (5, 5) | 1.02 (0.98, 1.06) |
| Age ≥ 65 Communities of Color | D29 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID80 | 36 | 5 (5, 5) | 5 (5, 5) | 1.01 (0.94, 1.09) |
| Age ≥ 65 Communities of Color | D29 fold-rise over D1 | Placebo | Positive | Anti N IgG (IU/ml) | 50 | 10 (10, 11) | 36935 (21250, 64196) | 3628.46 (2082.95, 6320.71) |
| Age ≥ 65 Communities of Color | D29 fold-rise over D1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 50 | 10 (10, 10) | 57615 (37847, 87707) | 5761.48 (3784.71, 8770.72) |
| Age ≥ 65 Communities of Color | D29 fold-rise over D1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 50 | 10 (10, 10) | 82913 (55530, 123801) | 8291.33 (5552.97, 12380.06) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|----------------------------------|-----------------------|---------|---------------------|------------------------|-----|------------------|--------------------------------|--------------------------------------|
| Age ≥ 65 Communities of Color | D29 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID50 | 50 | 5 (5, 5) | 167 (101, 276) | 32.28 (19.55, 53.29) |
| Age ≥ 65 Communities of Color | D29 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID80 | 50 | 5 (5, 6) | 390 (234, 650) | 73.32 (44.82, 119.94) |
| Age ≥ 65 Communities of Color | D57 fold-rise over D1 | Vaccine | Negative | Anti N IgG (IU/ml) | 228 | 10 (10, 10) | 771969 (594098, 1003095) | 76147.19 (58640.43, 98880.49) |
| Age ≥ 65 Communities of Color | D57 fold-rise over D1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 228 | 10 (10, 10) | 2754587 (2268630, 3344640) | 274100.63 (225748.76, 332808.72) |
| Age ≥ 65 Communities of Color | D57 fold-rise over D1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 228 | 10 (10, 10) | 5234940 (4335352, 6321193) | 523493.98 (433535.17, 632119.29) |
| Age ≥ 65 Communities of Color | D57 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 228 | 5 (5, 5) | 5478 (4015, 7473) | 1078.45 (791.36, 1469.70) |
| Age ≥ 65 Communities of Color | D57 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 228 | 5 (5, 5) | 5966 (4475, 7954) | 1163.05 (875.98, 1544.19) |
| Age ≥ 65 Communities of Color | D57 fold-rise over D1 | Vaccine | Positive | Anti N IgG (IU/ml) | 51 | 10 (10, 11) | 2851970 (1691139, 4809619) | 280191.41 (166781.09, 470720.20) |
| Age ≥ 65 Communities of Color | D57 fold-rise over D1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 51 | 10 (10, 10) | 7886529 (5982602, 10396367) | 788652.86 (598260.24, 1039636.74) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|-------------------------------|-----------------------|---------|---------------------|------------------------|----|------------------|---------------------------------|---------------------------------------|
| Age ≥ 65 Communities of Color | D57 fold-rise over D1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 51 | 10 (10, 10) | 12184499 (9858697, 15058989) | 1218449.89 (985869.74, 1505898.89) |
| Age ≥ 65 Communities of Color | D57 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 51 | 5 (5, 6) | 20307 (11438, 36054) | 3912.01 (2231.34, 6858.57) |
| Age ≥ 65 Communities of Color | D57 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 51 | 5 (5, 5) | 19769 (10376, 37665) | 3953.73 (2075.11, 7533.05) |
| Age ≥ 65 Communities of Color | D57 fold-rise over D1 | Placebo | Negative | Anti N IgG (IU/ml) | 36 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age ≥ 65 Communities of Color | D57 fold-rise over D1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 36 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age ≥ 65 Communities of Color | D57 fold-rise over D1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 36 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age ≥ 65 Communities of Color | D57 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID50 | 36 | 5 (5, 5) | 5 (5, 5) | 1.00 (1.00, 1.00) |
| Age ≥ 65 Communities of Color | D57 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID80 | 36 | 5 (5, 5) | 5 (5, 5) | 0.98 (0.94, 1.02) |
| Age ≥ 65 Communities of Color | D57 fold-rise over D1 | Placebo | Positive | Anti N IgG (IU/ml) | 50 | 10 (10, 11) | 709142 (413162, 1217155) | 69666.09 (40572.33, 119622.51) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|------------------------------------|-----------------------|---------|---------------------|------------------------|-----|------------------|-------------------------------|-------------------------------------|
| Age \geq 65 Communities of Color | D57 fold-rise over D1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 50 | 10 (10, 10) | 2116643 (1388474, 3226693) | 211664.33 (138847.41, 322669.26) |
| Age \geq 65 Communities of Color | D57 fold-rise over D1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 50 | 10 (10, 10) | 2964324 (2089369, 4205680) | 296432.41 (208936.91, 420567.97) |
| Age \geq 65 Communities of Color | D57 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID50 | 50 | 5 (5, 5) | 4026 (2199, 7373) | 777.87 (423.25, 1429.59) |
| Age \geq 65 Communities of Color | D57 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID80 | 50 | 5 (5, 6) | 4985 (2691, 9234) | 936.31 (513.96, 1705.72) |
| Age \geq 65 White Non-Hispanic | D29 fold-rise over D1 | Vaccine | Negative | Anti N IgG (IU/ml) | 187 | 10 (10, 10) | 52931 (40926, 68456) | 5268.42 (4072.81, 6815.00) |
| Age \geq 65 White Non-Hispanic | D29 fold-rise over D1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 187 | 10 (10, 10) | 60501 (48781, 75037) | 6050.09 (4878.07, 7503.69) |
| Age \geq 65 White Non-Hispanic | D29 fold-rise over D1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 187 | 10 (10, 10) | 103956 (85919, 125780) | 10323.75 (8540.15, 12479.85) |
| Age \geq 65 White Non-Hispanic | D29 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 187 | 5 (5, 5) | 214 (164, 280) | 42.04 (32.14, 54.99) |
| Age \geq 65 White Non-Hispanic | D29 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 187 | 5 (5, 5) | 317 (243, 412) | 62.39 (47.99, 81.11) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|-----------------------------------|-----------------------|---------|---------------------|--|----|------------------|----------------------------|----------------------------------|
| Age ≥ 65 White Non-Hispanic | D29 fold-rise over D1 | Vaccine | Positive | Anti N IgG (IU/ml) Anti RBD IgG (IU/ml) Anti Spike IgG (IU/ml) | 66 | 10 (10, 10) | 136437 (87480, 212792) | 13478.95 (8689.60, 20908.00) |
| Age ≥ 65 White Non-Hispanic | D29 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 66 | 10 (10, 10) | 171330 (122104, 240402) | 17133.00 (12210.38, 24040.16) |
| Age ≥ 65 White Non-Hispanic | D29 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 66 | 5 (5, 6) | 258922 (193660, 346179) | 25892.24 (19365.96, 34617.87) |
| Age ≥ 65 White Non-Hispanic | D29 fold-rise over D1 | Vaccine | Positive | Anti N IgG (IU/ml) | 36 | 10 (10, 10) | 575 (355, 932) | 109.39 (68.12, 175.65) |
| Age ≥ 65 White Non-Hispanic | D29 fold-rise over D1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 36 | 10 (10, 10) | 1037 (709, 1518) | 207.43 (141.72, 303.60) |
| Age ≥ 65 White Non-Hispanic | D29 fold-rise over D1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 36 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age ≥ 65 White Non-Hispanic | D29 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID50 | 36 | 5 (5, 5) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age ≥ 65 White Non-Hispanic | D29 fold-rise over D1 | Placebo | Negative | Anti N IgG (IU/ml) | 36 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age ≥ 65 White Non-Hispanic | D29 fold-rise over D1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 36 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age ≥ 65 White Non-Hispanic | D29 fold-rise over D1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 36 | 5 (5, 5) | 5 (5, 5) | 1.02 (0.98, 1.06) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|-----------------------------------|-----------------------|---------|---------------------|------------------------|-----|------------------|-------------------------------|-------------------------------------|
| Age ≥ 65 White Non-Hispanic | D29 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID80 | 36 | 5 (5, 5) | 5 (5, 5) | 1.00 (1.00, 1.00) |
| Age ≥ 65 White Non-Hispanic | D29 fold-rise over D1 | Placebo | Positive | Anti N IgG (IU/ml) | 60 | 10 (10, 10) | 37306 (22911, 60744) | 3687.38 (2264.32, 6004.81) |
| Age ≥ 65 White Non-Hispanic | D29 fold-rise over D1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 60 | 10 (10, 10) | 34684 (23682, 50795) | 3422.26 (2343.82, 4996.92) |
| Age ≥ 65 White Non-Hispanic | D29 fold-rise over D1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 60 | 10 (10, 10) | 63090 (45886, 86746) | 6309.04 (4588.59, 8674.56) |
| Age ≥ 65 White Non-Hispanic | D29 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID50 | 60 | 5 (5, 5) | 160 (99, 257) | 31.48 (19.58, 50.61) |
| Age ≥ 65 White Non-Hispanic | D29 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID80 | 60 | 5 (5, 5) | 323 (207, 502) | 64.50 (41.47, 100.34) |
| Age ≥ 65 White Non-Hispanic | D57 fold-rise over D1 | Vaccine | Negative | Anti N IgG (IU/ml) | 187 | 10 (10, 10) | 744013 (543887, 1017778) | 74055.02 (54135.35, 101304.35) |
| Age ≥ 65 White Non-Hispanic | D57 fold-rise over D1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 187 | 10 (10, 10) | 2480906 (1963293, 3134986) | 248090.62 (196329.26, 313498.63) |
| Age ≥ 65 White Non-Hispanic | D57 fold-rise over D1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 187 | 10 (10, 10) | 4905828 (4009921, 6001900) | 487190.64 (398077.65, 596252.31) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|-----------------------------------|-----------------------|---------|---------------------|------------------------|-----|------------------|----------------------------------|--|
| Age ≥ 65 White Non-Hispanic | D57 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 187 | 5 (5, 5) | 3376 (2393, 4763) | 662.37 (469.40, 934.65) |
| Age ≥ 65 White Non-Hispanic | D57 fold-rise over D1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 187 | 5 (5, 5) | 4511 (3339, 6096) | 888.68 (657.99, 1200.26) |
| Age ≥ 65 White Non-Hispanic | D57 fold-rise over D1 | Vaccine | Positive | Anti N IgG (IU/ml) | 66 | 10 (10, 10) | 3047576 (1943331, 4779276) | 301077.79 (192430.18, 471068.71) |
| Age ≥ 65 White Non-Hispanic | D57 fold-rise over D1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 66 | 10 (10, 10) | 7361735 (5495760, 9861264) | 736173.49 (549575.99, 986126.43) |
| Age ≥ 65 White Non-Hispanic | D57 fold-rise over D1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 66 | 10 (10, 10) | 13150407 (11178796, 15469753) | 1315040.71 (1117879.58, 1546975.29) |
| Age ≥ 65 White Non-Hispanic | D57 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 66 | 5 (5, 6) | 23885 (15539, 36713) | 4542.74 (2980.14, 6924.67) |
| Age ≥ 65 White Non-Hispanic | D57 fold-rise over D1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 66 | 5 (5, 5) | 20383 (12350, 33642) | 4076.69 (2470.01, 6728.46) |
| Age ≥ 65 White Non-Hispanic | D57 fold-rise over D1 | Placebo | Negative | Anti N IgG (IU/ml) | 36 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age ≥ 65 White Non-Hispanic | D57 fold-rise over D1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 36 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |

(continued)

| Group | Visit | Arm | Baseline SARS-CoV-2 | Marker | N | Baseline GMT/GMC | Post Baseline GMT/GMC | GMTR/GMCR |
|-----------------------------------|-----------------------|---------|---------------------|------------------------|----|------------------|-------------------------------|-------------------------------------|
| Age ≥ 65 White Non-Hispanic | D57 fold-rise over D1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 36 | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age ≥ 65 White Non-Hispanic | D57 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID50 | 36 | 5 (5, 5) | 5 (5, 5) | 1.00 (1.00, 1.00) |
| Age ≥ 65 White Non-Hispanic | D57 fold-rise over D1 | Placebo | Negative | Pseudovirus-nAb ID80 | 36 | 5 (5, 5) | 5 (5, 6) | 1.04 (0.96, 1.12) |
| Age ≥ 65 White Non-Hispanic | D57 fold-rise over D1 | Placebo | Positive | Anti N IgG (IU/ml) | 60 | 10 (10, 10) | 443960 (270210, 729435) | 43882.05 (26757.87, 71965.14) |
| Age ≥ 65 White Non-Hispanic | D57 fold-rise over D1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 60 | 10 (10, 10) | 1555275 (1070146, 2260326) | 153460.09 (105621.81, 222965.32) |
| Age ≥ 65 White Non-Hispanic | D57 fold-rise over D1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 60 | 10 (10, 10) | 2726537 (1931325, 3849174) | 272653.70 (193132.47, 384917.37) |
| Age ≥ 65 White Non-Hispanic | D57 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID50 | 60 | 5 (5, 5) | 2516 (1427, 4435) | 495.52 (282.39, 869.51) |
| Age ≥ 65 White Non-Hispanic | D57 fold-rise over D1 | Placebo | Positive | Pseudovirus-nAb ID80 | 60 | 5 (5, 5) | 4096 (2471, 6792) | 819.28 (494.12, 1358.43) |

Table 7. The ratios of GMTs/GMCs between groups

| Group 1 vs 2 | Visit | Arm | Baseline SARS-CoV-2 | Marker | Group 1 GMT/GMC | Group 2 GMT/GMC | Ratios of GMT/GMC |
|---------------------------|-------|---------|---------------------|------------------------|-----------------|-----------------|----------------------|
| Age \geq 65 vs Age < 65 | Day 1 | Vaccine | Negative | Anti N IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.01 (1.00, 1.01) |
| Age \geq 65 vs Age < 65 | Day 1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (0.99, 1.01) |
| Age \geq 65 vs Age < 65 | Day 1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.01 (1.00, 1.01) |
| Age \geq 65 vs Age < 65 | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 5 (5, 5) | 5 (5, 5) | 1.01 (0.99, 1.02) |
| Age \geq 65 vs Age < 65 | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 5 (5, 5) | 5 (5, 5) | 1.01 (0.99, 1.04) |
| Age \geq 65 vs Age < 65 | Day 1 | Vaccine | Positive | Anti N IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.01 (0.99, 1.03) |
| Age \geq 65 vs Age < 65 | Day 1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age \geq 65 vs Age < 65 | Day 1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age \geq 65 vs Age < 65 | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 5 (5, 5) | 5 (5, 5) | 1.03 (0.98, 1.08) |
| Age \geq 65 vs Age < 65 | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 5 (5, 5) | 5 (5, 5) | 0.98 (0.96, 1.00) |
| Age \geq 65 vs Age < 65 | Day 1 | Placebo | Negative | Anti N IgG (IU/ml) | 10 (10, 10) | 10 (10, 11) | 0.98 (0.94, 1.02) |
| Age \geq 65 vs Age < 65 | Day 1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 10 (10, 10) | 10 (10, 11) | 0.98 (0.93, 1.02) |

(continued)

| Group 1 vs 2 | Visit | Arm | Baseline SARS-CoV-2 | Marker | Group 1 GMT/GMC | Group 2 GMT/GMC | Ratios of GMT/GMC |
|---------------------------|--------|---------|---------------------|------------------------|---------------------------|-------------------------|----------------------|
| Age \geq 65 vs Age < 65 | Day 1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 0.99 (0.98, 1.01) |
| Age \geq 65 vs Age < 65 | Day 1 | Placebo | Negative | Pseudovirus-nAb ID50 | 5 (5, 5) | 5 (5, 5) | 0.99 (0.98, 1.01) |
| Age \geq 65 vs Age < 65 | Day 1 | Placebo | Negative | Pseudovirus-nAb ID80 | 5 (5, 5) | 5 (5, 5) | 0.98 (0.93, 1.03) |
| Age \geq 65 vs Age < 65 | Day 1 | Placebo | Positive | Anti N IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (0.96, 1.03) |
| Age \geq 65 vs Age < 65 | Day 1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.01 (0.99, 1.02) |
| Age \geq 65 vs Age < 65 | Day 1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age \geq 65 vs Age < 65 | Day 1 | Placebo | Positive | Pseudovirus-nAb ID50 | 5 (5, 5) | 5 (5, 5) | 1.00 (0.95, 1.05) |
| Age \geq 65 vs Age < 65 | Day 1 | Placebo | Positive | Pseudovirus-nAb ID80 | 5 (5, 5) | 5 (5, 5) | 1.01 (0.98, 1.04) |
| Age \geq 65 vs Age < 65 | Day 29 | Vaccine | Negative | Anti N IgG (IU/ml) | 59687 (50609, 70395) | 18416 (15002, 22607) | 3.24 (2.49, 4.22) |
| Age \geq 65 vs Age < 65 | Day 29 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 65260 (56734, 75068) | 17393 (14565, 20770) | 3.75 (2.99, 4.70) |
| Age \geq 65 vs Age < 65 | Day 29 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 112166 (98902, 127209) | 31397 (27475, 35879) | 3.57 (2.97, 4.29) |
| Age \geq 65 vs Age < 65 | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID50 | 254 (214, 300) | 85 (69, 103) | 3.00 (2.32, 3.89) |

(continued)

| Group 1 vs 2 | Visit | Arm | Baseline SARS-CoV-2 | Marker | Group 1 GMT/GMC | Group 2 GMT/GMC | Ratios of GMT/GMC |
|---------------------------|--------|---------|---------------------|------------------------|----------------------------|-------------------------|----------------------|
| Age \geq 65 vs Age < 65 | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID80 | 381 (321, 451) | 157 (129, 192) | 2.42 (1.86, 3.15) |
| Age \geq 65 vs Age < 65 | Day 29 | Vaccine | Positive | Anti N IgG (IU/ml) | 130450 (94702, 179694) | 32567 (23744, 44670) | 4.01 (2.55, 6.28) |
| Age \geq 65 vs Age < 65 | Day 29 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 158619 (123545, 203649) | 24939 (18393, 33814) | 6.36 (4.29, 9.43) |
| Age \geq 65 vs Age < 65 | Day 29 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 262073 (211994, 323982) | 59400 (46119, 76506) | 4.41 (3.17, 6.14) |
| Age \geq 65 vs Age < 65 | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID50 | 522 (373, 731) | 144 (104, 198) | 3.63 (2.28, 5.80) |
| Age \geq 65 vs Age < 65 | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID80 | 988 (733, 1331) | 339 (238, 482) | 2.92 (1.84, 4.63) |
| Age \geq 65 vs Age < 65 | Day 29 | Placebo | Negative | Anti N IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age \geq 65 vs Age < 65 | Day 29 | Placebo | Negative | Anti RBD IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age \geq 65 vs Age < 65 | Day 29 | Placebo | Negative | Anti Spike IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age \geq 65 vs Age < 65 | Day 29 | Placebo | Negative | Pseudovirus-nAb ID50 | 5 (5, 5) | 5 (5, 5) | 1.01 (0.98, 1.04) |
| Age \geq 65 vs Age < 65 | Day 29 | Placebo | Negative | Pseudovirus-nAb ID80 | 5 (5, 5) | 5 (5, 5) | 0.99 (0.95, 1.03) |
| Age \geq 65 vs Age < 65 | Day 29 | Placebo | Positive | Anti N IgG (IU/ml) | 35028 (24879, 49317) | 9820 (7012, 13753) | 3.57 (2.21, 5.77) |

(continued)

| Group 1 vs 2 | Visit | Arm | Baseline SARS-CoV-2 | Marker | Group 1 GMT/GMC | Group 2 GMT/GMC | Ratios of GMT/GMC |
|---------------------------|--------|---------|---------------------|------------------------|----------------------------------|-------------------------------|----------------------|
| Age \geq 65 vs Age < 65 | Day 29 | Placebo | Positive | Anti RBD IgG (IU/ml) | 41836 (32047, 54614) | 9737 (7318, 12957) | 4.30 (2.91, 6.35) |
| Age \geq 65 vs Age < 65 | Day 29 | Placebo | Positive | Anti Spike IgG (IU/ml) | 66891 (53117, 84238) | 13380 (10752, 16650) | 5.00 (3.64, 6.87) |
| Age \geq 65 vs Age < 65 | Day 29 | Placebo | Positive | Pseudovirus-nAb ID50 | 156 (112, 216) | 40 (29, 54) | 3.93 (2.51, 6.13) |
| Age \geq 65 vs Age < 65 | Day 29 | Placebo | Positive | Pseudovirus-nAb ID80 | 301 (219, 413) | 106 (76, 147) | 2.85 (1.80, 4.49) |
| Age \geq 65 vs Age < 65 | Day 57 | Vaccine | Negative | Anti N IgG (IU/ml) | 836805 (684275, 1023335) | 253319 (198848, 322710) | 3.30 (2.41, 4.53) |
| Age \geq 65 vs Age < 65 | Day 57 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 2692372 (2329146, 3112243) | 737116 (604473, 898866) | 3.65 (2.86, 4.67) |
| Age \geq 65 vs Age < 65 | Day 57 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 5171042 (4536102, 5894857) | 1643373 (1397160, 1932976) | 3.15 (2.55, 3.88) |
| Age \geq 65 vs Age < 65 | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID50 | 4259 (3414, 5312) | 1136 (890, 1449) | 3.75 (2.70, 5.21) |
| Age \geq 65 vs Age < 65 | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID80 | 5506 (4535, 6685) | 1750 (1355, 2260) | 3.15 (2.28, 4.34) |
| Age \geq 65 vs Age < 65 | Day 57 | Vaccine | Positive | Anti N IgG (IU/ml) | 3014476 (2173987, 4179907) | 739998 (487226, 1123907) | 4.07 (2.40, 6.92) |
| Age \geq 65 vs Age < 65 | Day 57 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 7520373 (6146909, 9200723) | 1708031 (1250384, 2333179) | 4.40 (3.04, 6.38) |
| Age \geq 65 vs Age < 65 | Day 57 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 13148461 (11661345, 14825221) | 4266733 (3292306, 5529560) | 3.08 (2.32, 4.10) |

(continued)

| Group 1 vs 2 | Visit | Arm | Baseline SARS-CoV-2 | Marker | Group 1 GMT/GMC | Group 2 GMT/GMC | Ratios of GMT/GMC |
|---------------------------|--------|---------|---------------------|------------------------|-------------------------------|----------------------------|-----------------------|
| Age \geq 65 vs Age < 65 | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID50 | 21658 (15437, 30385) | 4061 (2527, 6527) | 5.33 (2.98, 9.55) |
| Age \geq 65 vs Age < 65 | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID80 | 19480 (13318, 28494) | 6238 (4090, 9513) | 3.12 (1.77, 5.51) |
| Age \geq 65 vs Age < 65 | Day 57 | Placebo | Negative | Anti N IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age \geq 65 vs Age < 65 | Day 57 | Placebo | Negative | Anti RBD IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 0.99 (0.98, 1.01) |
| Age \geq 65 vs Age < 65 | Day 57 | Placebo | Negative | Anti Spike IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age \geq 65 vs Age < 65 | Day 57 | Placebo | Negative | Pseudovirus-nAb ID50 | 5 (5, 5) | 5 (5, 5) | 1.02 (0.99, 1.05) |
| Age \geq 65 vs Age < 65 | Day 57 | Placebo | Negative | Pseudovirus-nAb ID80 | 5 (5, 5) | 5 (5, 5) | 1.01 (0.97, 1.05) |
| Age \geq 65 vs Age < 65 | Day 57 | Placebo | Positive | Anti N IgG (IU/ml) | 519433 (364323, 740581) | 93772 (62211, 141344) | 5.54 (3.22, 9.53) |
| Age \geq 65 vs Age < 65 | Day 57 | Placebo | Positive | Anti RBD IgG (IU/ml) | 1675605 (1276999, 2198632) | 270061 (201183, 362521) | 6.20 (4.16, 9.26) |
| Age \geq 65 vs Age < 65 | Day 57 | Placebo | Positive | Anti Spike IgG (IU/ml) | 2790960 (2209589, 3525298) | 484596 (361146, 650244) | 5.76 (3.96, 8.38) |
| Age \geq 65 vs Age < 65 | Day 57 | Placebo | Positive | Pseudovirus-nAb ID50 | 2827 (1887, 4233) | 387 (262, 572) | 7.30 (4.17, 12.81) |
| Age \geq 65 vs Age < 65 | Day 57 | Placebo | Positive | Pseudovirus-nAb ID80 | 4185 (2859, 6127) | 1009 (665, 1531) | 4.15 (2.36, 7.30) |

(continued)

| Group 1 vs 2 | Visit | Arm | Baseline SARS-CoV-2 | Marker | Group 1 GMT/GMC | Group 2 GMT/GMC | Ratios of GMT/GMC |
|------------------------|-------|---------|---------------------|------------------------|-----------------|-----------------|----------------------|
| At-risk vs Not at-risk | Day 1 | Vaccine | Negative | Anti N IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.01 (1.00, 1.01) |
| At-risk vs Not at-risk | Day 1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (0.99, 1.01) |
| At-risk vs Not at-risk | Day 1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.01) |
| At-risk vs Not at-risk | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 5 (5, 5) | 5 (5, 5) | 1.02 (1.00, 1.04) |
| At-risk vs Not at-risk | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 5 (5, 5) | 5 (5, 5) | 1.00 (0.98, 1.02) |
| At-risk vs Not at-risk | Day 1 | Vaccine | Positive | Anti N IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (0.99, 1.01) |
| At-risk vs Not at-risk | Day 1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| At-risk vs Not at-risk | Day 1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| At-risk vs Not at-risk | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 5 (5, 5) | 5 (5, 5) | 1.01 (0.97, 1.05) |
| At-risk vs Not at-risk | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 5 (5, 5) | 5 (5, 5) | 0.99 (0.96, 1.02) |
| At-risk vs Not at-risk | Day 1 | Placebo | Negative | Anti N IgG (IU/ml) | 10 (10, 10) | 10 (10, 11) | 0.98 (0.93, 1.02) |
| At-risk vs Not at-risk | Day 1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 10 (10, 10) | 10 (10, 11) | 0.97 (0.92, 1.03) |

(continued)

| Group 1 vs 2 | Visit | Arm | Baseline SARS-CoV-2 | Marker | Group 1 GMT/GMC | Group 2 GMT/GMC | Ratios of GMT/GMC |
|------------------------|--------|---------|---------------------|------------------------|-------------------------|-------------------------|----------------------|
| At-risk vs Not at-risk | Day 1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 10 (10, 11) | 10 (10, 10) | 1.02 (0.98, 1.06) |
| At-risk vs Not at-risk | Day 1 | Placebo | Negative | Pseudovirus-nAb ID50 | 5 (5, 5) | 5 (5, 5) | 1.02 (0.98, 1.05) |
| At-risk vs Not at-risk | Day 1 | Placebo | Negative | Pseudovirus-nAb ID80 | 5 (5, 5) | 5 (5, 5) | 0.98 (0.92, 1.04) |
| At-risk vs Not at-risk | Day 1 | Placebo | Positive | Anti N IgG (IU/ml) | 10 (10, 10) | 10 (10, 11) | 0.99 (0.95, 1.02) |
| At-risk vs Not at-risk | Day 1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.01 (0.99, 1.02) |
| At-risk vs Not at-risk | Day 1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| At-risk vs Not at-risk | Day 1 | Placebo | Positive | Pseudovirus-nAb ID50 | 5 (5, 5) | 5 (5, 5) | 0.99 (0.94, 1.04) |
| At-risk vs Not at-risk | Day 1 | Placebo | Positive | Pseudovirus-nAb ID80 | 5 (5, 5) | 5 (5, 5) | 1.00 (0.97, 1.03) |
| At-risk vs Not at-risk | Day 29 | Vaccine | Negative | Anti N IgG (IU/ml) | 23746 (19934, 28287) | 23464 (18827, 29244) | 1.01 (0.76, 1.34) |
| At-risk vs Not at-risk | Day 29 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 26276 (22610, 30535) | 21736 (17965, 26298) | 1.21 (0.95, 1.55) |
| At-risk vs Not at-risk | Day 29 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 45842 (40067, 52448) | 39200 (34023, 45165) | 1.17 (0.96, 1.43) |
| At-risk vs Not at-risk | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID50 | 103 (87, 122) | 108 (87, 133) | 0.96 (0.73, 1.26) |

(continued)

| Group 1 vs 2 | Visit | Arm | Baseline SARS-CoV-2 | Marker | Group 1 GMT/GMC | Group 2 GMT/GMC | Ratios of GMT/GMC |
|------------------------|--------|---------|---------------------|------------------------|---------------------------|-------------------------|----------------------|
| At-risk vs Not at-risk | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID80 | 215 (180, 258) | 180 (145, 223) | 1.20 (0.91, 1.59) |
| At-risk vs Not at-risk | Day 29 | Vaccine | Positive | Anti N IgG (IU/ml) | 55180 (40419, 75332) | 39449 (28242, 55103) | 1.40 (0.88, 2.23) |
| At-risk vs Not at-risk | Day 29 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 55528 (43641, 70653) | 31130 (22510, 43050) | 1.78 (1.17, 2.72) |
| At-risk vs Not at-risk | Day 29 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 103862 (82479, 130788) | 73051 (55946, 95386) | 1.42 (0.99, 2.05) |
| At-risk vs Not at-risk | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID50 | 220 (161, 302) | 175 (124, 247) | 1.26 (0.78, 2.02) |
| At-risk vs Not at-risk | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID80 | 443 (318, 617) | 412 (284, 597) | 1.08 (0.65, 1.78) |
| At-risk vs Not at-risk | Day 29 | Placebo | Negative | Anti N IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| At-risk vs Not at-risk | Day 29 | Placebo | Negative | Anti RBD IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| At-risk vs Not at-risk | Day 29 | Placebo | Negative | Anti Spike IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| At-risk vs Not at-risk | Day 29 | Placebo | Negative | Pseudovirus-nAb ID50 | 5 (5, 5) | 5 (5, 5) | 1.04 (0.99, 1.09) |
| At-risk vs Not at-risk | Day 29 | Placebo | Negative | Pseudovirus-nAb ID80 | 5 (5, 5) | 5 (5, 5) | 0.99 (0.94, 1.03) |
| At-risk vs Not at-risk | Day 29 | Placebo | Positive | Anti N IgG (IU/ml) | 16553 (12215, 22429) | 11438 (8001, 16352) | 1.45 (0.90, 2.33) |

(continued)

| Group 1 vs 2 | Visit | Arm | Baseline SARS-CoV-2 | Marker | Group 1 GMT/GMC | Group 2 GMT/GMC | Ratios of GMT/GMC |
|------------------------|--------|---------|---------------------|------------------------|-------------------------------|-------------------------------|----------------------|
| At-risk vs Not at-risk | Day 29 | Placebo | Positive | Anti RBD IgG (IU/ml) | 16713 (12642, 22096) | 11818 (8756, 15950) | 1.41 (0.93, 2.16) |
| At-risk vs Not at-risk | Day 29 | Placebo | Positive | Anti Spike IgG (IU/ml) | 26705 (21285, 33505) | 16070 (12770, 20222) | 1.66 (1.18, 2.33) |
| At-risk vs Not at-risk | Day 29 | Placebo | Positive | Pseudovirus-nAb ID50 | 69 (52, 93) | 47 (34, 64) | 1.48 (0.96, 2.30) |
| At-risk vs Not at-risk | Day 29 | Placebo | Positive | Pseudovirus-nAb ID80 | 180 (133, 243) | 116 (82, 164) | 1.55 (0.97, 2.47) |
| At-risk vs Not at-risk | Day 57 | Vaccine | Negative | Anti N IgG (IU/ml) | 335374 (270080, 416453) | 321219 (247884, 416250) | 1.04 (0.74, 1.47) |
| At-risk vs Not at-risk | Day 57 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 1142597 (961925, 1357205) | 904842 (732112, 1118324) | 1.26 (0.96, 1.66) |
| At-risk vs Not at-risk | Day 57 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 2144439 (1840509, 2498559) | 2066294 (1739231, 2454861) | 1.04 (0.82, 1.31) |
| At-risk vs Not at-risk | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID50 | 1796 (1424, 2264) | 1394 (1075, 1808) | 1.29 (0.91, 1.83) |
| At-risk vs Not at-risk | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID80 | 2766 (2265, 3377) | 2041 (1549, 2690) | 1.35 (0.96, 1.91) |
| At-risk vs Not at-risk | Day 57 | Vaccine | Positive | Anti N IgG (IU/ml) | 1327591 (937265, 1880469) | 882754 (567083, 1374143) | 1.50 (0.85, 2.66) |
| At-risk vs Not at-risk | Day 57 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 2930270 (2216035, 3874704) | 2113273 (1525010, 2928453) | 1.39 (0.89, 2.15) |
| At-risk vs Not at-risk | Day 57 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 6396516 (5214355, 7846688) | 5023873 (3827375, 6594416) | 1.27 (0.90, 1.80) |

(continued)

| Group 1 vs 2 | Visit | Arm | Baseline SARS-CoV-2 | Marker | Group 1 GMT/GMC | Group 2 GMT/GMC | Ratios of GMT/GMC |
|------------------------|--------|---------|---------------------|------------------------|------------------------------|----------------------------|----------------------|
| At-risk vs Not at-risk | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID50 | 6128 (4355, 8625) | 5532 (3337, 9171) | 1.11 (0.59, 2.07) |
| At-risk vs Not at-risk | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID80 | 11182 (7684, 16271) | 6928 (4429, 10838) | 1.61 (0.90, 2.90) |
| At-risk vs Not at-risk | Day 57 | Placebo | Negative | Anti N IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| At-risk vs Not at-risk | Day 57 | Placebo | Negative | Anti RBD IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.01 (0.99, 1.04) |
| At-risk vs Not at-risk | Day 57 | Placebo | Negative | Anti Spike IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| At-risk vs Not at-risk | Day 57 | Placebo | Negative | Pseudovirus-nAb ID50 | 5 (5, 5) | 5 (5, 5) | 1.00 (0.98, 1.02) |
| At-risk vs Not at-risk | Day 57 | Placebo | Negative | Pseudovirus-nAb ID80 | 5 (5, 5) | 5 (5, 5) | 1.03 (0.99, 1.07) |
| At-risk vs Not at-risk | Day 57 | Placebo | Positive | Anti N IgG (IU/ml) | 197242 (138403, 281094) | 113637 (73666, 175296) | 1.74 (0.98, 3.07) |
| At-risk vs Not at-risk | Day 57 | Placebo | Positive | Anti RBD IgG (IU/ml) | 663561 (492320, 894363) | 320294 (235413, 435781) | 2.07 (1.33, 3.22) |
| At-risk vs Not at-risk | Day 57 | Placebo | Positive | Anti Spike IgG (IU/ml) | 1012116 (794913, 1288669) | 594413 (435730, 810886) | 1.70 (1.13, 2.56) |
| At-risk vs Not at-risk | Day 57 | Placebo | Positive | Pseudovirus-nAb ID50 | 931 (651, 1331) | 482 (318, 728) | 1.93 (1.10, 3.39) |
| At-risk vs Not at-risk | Day 57 | Placebo | Positive | Pseudovirus-nAb ID80 | 2086 (1418, 3067) | 1143 (737, 1774) | 1.82 (1.01, 3.29) |

(continued)

| Group 1 vs 2 | Visit | Arm | Baseline SARS-CoV-2 | Marker | Group 1 GMT/GMC | Group 2 GMT/GMC | Ratios of GMT/GMC |
|--|-------|---------|---------------------|------------------------|-----------------|-----------------|----------------------|
| Age < 65 At-risk vs Age < 65 Not at-risk | Day 1 | Vaccine | Negative | Anti N IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.01 (0.99, 1.02) |
| Age < 65 At-risk vs Age < 65 Not at-risk | Day 1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (0.98, 1.01) |
| Age < 65 At-risk vs Age < 65 Not at-risk | Day 1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age < 65 At-risk vs Age < 65 Not at-risk | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 5 (5, 5) | 5 (5, 5) | 1.03 (1.00, 1.07) |
| Age < 65 At-risk vs Age < 65 Not at-risk | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 5 (5, 5) | 5 (5, 5) | 0.99 (0.98, 1.01) |
| Age < 65 At-risk vs Age < 65 Not at-risk | Day 1 | Vaccine | Positive | Anti N IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.01 (0.99, 1.02) |
| Age < 65 At-risk vs Age < 65 Not at-risk | Day 1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age < 65 At-risk vs Age < 65 Not at-risk | Day 1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |

(continued)

| Group 1 vs 2 | Visit | Arm | Baseline SARS-CoV-2 | Marker | Group 1 GMT/GMC | Group 2 GMT/GMC | Ratios of GMT/GMC |
|--|-------|---------|---------------------|------------------------|-----------------|-----------------|----------------------|
| Age < 65 At-risk vs Age < 65 Not at-risk | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 5 (5, 5) | 5 (5, 5) | 0.98 (0.95, 1.02) |
| Age < 65 At-risk vs Age < 65 Not at-risk | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 5 (5, 5) | 5 (5, 5) | 0.99 (0.95, 1.03) |
| Age < 65 At-risk vs Age < 65 Not at-risk | Day 1 | Placebo | Negative | Anti N IgG (IU/ml) | 10 (10, 10) | 10 (10, 11) | 0.97 (0.92, 1.03) |
| Age < 65 At-risk vs Age < 65 Not at-risk | Day 1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 10 (10, 10) | 10 (10, 11) | 0.97 (0.91, 1.03) |
| Age < 65 At-risk vs Age < 65 Not at-risk | Day 1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 10 (10, 11) | 10 (10, 10) | 1.03 (0.97, 1.10) |
| Age < 65 At-risk vs Age < 65 Not at-risk | Day 1 | Placebo | Negative | Pseudovirus-nAb ID50 | 5 (5, 5) | 5 (5, 5) | 1.03 (0.97, 1.08) |
| Age < 65 At-risk vs Age < 65 Not at-risk | Day 1 | Placebo | Negative | Pseudovirus-nAb ID80 | 5 (5, 5) | 5 (5, 6) | 0.98 (0.91, 1.05) |
| Age < 65 At-risk vs Age < 65 Not at-risk | Day 1 | Placebo | Positive | Anti N IgG (IU/ml) | 10 (10, 10) | 10 (10, 11) | 0.98 (0.94, 1.02) |

(continued)

| Group 1 vs 2 | Visit | Arm | Baseline SARS-CoV-2 | Marker | Group 1 GMT/GMC | Group 2 GMT/GMC | Ratios of GMT/GMC |
|--|--------|---------|---------------------|------------------------|-------------------------|-------------------------|----------------------|
| Age < 65 At-risk vs Age < 65 Not at-risk | Day 1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age < 65 At-risk vs Age < 65 Not at-risk | Day 1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age < 65 At-risk vs Age < 65 Not at-risk | Day 1 | Placebo | Positive | Pseudovirus-nAb ID50 | 5 (5, 5) | 5 (5, 5) | 0.98 (0.93, 1.04) |
| Age < 65 At-risk vs Age < 65 Not at-risk | Day 1 | Placebo | Positive | Pseudovirus-nAb ID80 | 5 (5, 5) | 5 (5, 5) | 1.00 (0.97, 1.03) |
| Age < 65 At-risk vs Age < 65 Not at-risk | Day 29 | Vaccine | Negative | Anti N IgG (IU/ml) | 15066 (11800, 19236) | 19467 (15117, 25069) | 0.77 (0.54, 1.10) |
| Age < 65 At-risk vs Age < 65 Not at-risk | Day 29 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 16530 (13368, 20441) | 17639 (14174, 21953) | 0.94 (0.69, 1.27) |
| Age < 65 At-risk vs Age < 65 Not at-risk | Day 29 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 31028 (25725, 37423) | 31500 (26782, 37050) | 0.98 (0.77, 1.26) |
| Age < 65 At-risk vs Age < 65 Not at-risk | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID50 | 68 (54, 85) | 90 (70, 115) | 0.75 (0.54, 1.05) |

(continued)

| Group 1 vs 2 | Visit | Arm | Baseline SARS-CoV-2 | Marker | Group 1 GMT/GMC | Group 2 GMT/GMC | Ratios of GMT/GMC |
|--|--------|---------|---------------------|------------------------|-------------------------|-------------------------|----------------------|
| Age < 65 At-risk vs Age < 65 Not at-risk | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID80 | 159 (123, 204) | 157 (122, 200) | 1.01 (0.71, 1.44) |
| Age < 65 At-risk vs Age < 65 Not at-risk | Day 29 | Vaccine | Positive | Anti N IgG (IU/ml) | 35719 (23749, 53721) | 31746 (21553, 46760) | 1.13 (0.64, 1.97) |
| Age < 65 At-risk vs Age < 65 Not at-risk | Day 29 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 30603 (22501, 41623) | 23567 (16129, 34434) | 1.30 (0.80, 2.12) |
| Age < 65 At-risk vs Age < 65 Not at-risk | Day 29 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 62641 (46271, 84801) | 58534 (42846, 79967) | 1.07 (0.69, 1.65) |
| Age < 65 At-risk vs Age < 65 Not at-risk | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID50 | 142 (95, 213) | 144 (97, 214) | 0.99 (0.56, 1.74) |
| Age < 65 At-risk vs Age < 65 Not at-risk | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID80 | 291 (187, 453) | 353 (229, 545) | 0.82 (0.44, 1.53) |
| Age < 65 At-risk vs Age < 65 Not at-risk | Day 29 | Placebo | Negative | Anti N IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age < 65 At-risk vs Age < 65 Not at-risk | Day 29 | Placebo | Negative | Anti RBD IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |

(continued)

| Group 1 vs 2 | Visit | Arm | Baseline SARS-CoV-2 | Marker | Group 1 GMT/GMC | Group 2 GMT/GMC | Ratios of GMT/GMC |
|--|--------|---------|---------------------|------------------------|-------------------------|------------------------|----------------------|
| Age < 65 At-risk vs Age < 65 Not at-risk | Day 29 | Placebo | Negative | Anti Spike IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age < 65 At-risk vs Age < 65 Not at-risk | Day 29 | Placebo | Negative | Pseudovirus-nAb ID50 | 5 (5, 6) | 5 (5, 5) | 1.04 (0.96, 1.12) |
| Age < 65 At-risk vs Age < 65 Not at-risk | Day 29 | Placebo | Negative | Pseudovirus-nAb ID80 | 5 (5, 5) | 5 (5, 5) | 0.97 (0.93, 1.03) |
| Age < 65 At-risk vs Age < 65 Not at-risk | Day 29 | Placebo | Positive | Anti N IgG (IU/ml) | 11526 (8014, 16577) | 9421 (6230, 14246) | 1.22 (0.71, 2.12) |
| Age < 65 At-risk vs Age < 65 Not at-risk | Day 29 | Placebo | Positive | Anti RBD IgG (IU/ml) | 10221 (7219, 14470) | 9616 (6788, 13622) | 1.06 (0.65, 1.74) |
| Age < 65 At-risk vs Age < 65 Not at-risk | Day 29 | Placebo | Positive | Anti Spike IgG (IU/ml) | 16112 (12299, 21107) | 12751 (9770, 16642) | 1.26 (0.86, 1.85) |
| Age < 65 At-risk vs Age < 65 Not at-risk | Day 29 | Placebo | Positive | Pseudovirus-nAb ID50 | 48 (34, 67) | 38 (26, 55) | 1.26 (0.77, 2.08) |
| Age < 65 At-risk vs Age < 65 Not at-risk | Day 29 | Placebo | Positive | Pseudovirus-nAb ID80 | 127 (87, 186) | 101 (68, 150) | 1.26 (0.72, 2.19) |

(continued)

| Group 1 vs 2 | Visit | Arm | Baseline SARS-CoV-2 | Marker | Group 1 GMT/GMC | Group 2 GMT/GMC | Ratios of GMT/GMC |
|--|--------|---------|---------------------|------------------------|-------------------------------|-------------------------------|----------------------|
| Age < 65 At-risk vs Age < 65 Not at-risk | Day 57 | Vaccine | Negative | Anti N IgG (IU/ml) | 227691 (168852, 307033) | 260904 (193707, 351412) | 0.87 (0.57, 1.33) |
| Age < 65 At-risk vs Age < 65 Not at-risk | Day 57 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 761200 (595277, 973370) | 730590 (572430, 932450) | 1.04 (0.74, 1.47) |
| Age < 65 At-risk vs Age < 65 Not at-risk | Day 57 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 1498825 (1211392, 1854460) | 1685764 (1382036, 2056240) | 0.89 (0.66, 1.19) |
| Age < 65 At-risk vs Age < 65 Not at-risk | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID50 | 1203 (876, 1652) | 1118 (830, 1506) | 1.08 (0.70, 1.66) |
| Age < 65 At-risk vs Age < 65 Not at-risk | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID80 | 2067 (1571, 2720) | 1671 (1216, 2295) | 1.24 (0.81, 1.88) |
| Age < 65 At-risk vs Age < 65 Not at-risk | Day 57 | Vaccine | Positive | Anti N IgG (IU/ml) | 848831 (532838, 1352218) | 712451 (424544, 1195605) | 1.19 (0.59, 2.39) |
| Age < 65 At-risk vs Age < 65 Not at-risk | Day 57 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 1815884 (1228679, 2683724) | 1679359 (1144789, 2463552) | 1.08 (0.63, 1.87) |
| Age < 65 At-risk vs Age < 65 Not at-risk | Day 57 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 4547755 (3405518, 6073108) | 4192147 (3040678, 5779665) | 1.08 (0.70, 1.67) |

(continued)

| Group 1 vs 2 | Visit | Arm | Baseline SARS-CoV-2 | Marker | Group 1 GMT/GMC | Group 2 GMT/GMC | Ratios of GMT/GMC |
|--|--------|---------|---------------------|------------------------|---------------------------|--------------------------|----------------------|
| Age < 65 At-risk vs Age < 65 Not at-risk | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID50 | 2953 (1859, 4690) | 4435 (2453, 8017) | 0.67 (0.31, 1.41) |
| Age < 65 At-risk vs Age < 65 Not at-risk | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID80 | 7954 (4852, 13039) | 5833 (3464, 9821) | 1.36 (0.66, 2.80) |
| Age < 65 At-risk vs Age < 65 Not at-risk | Day 57 | Placebo | Negative | Anti N IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age < 65 At-risk vs Age < 65 Not at-risk | Day 57 | Placebo | Negative | Anti RBD IgG (IU/ml) | 10 (10, 11) | 10 (10, 10) | 1.02 (0.98, 1.07) |
| Age < 65 At-risk vs Age < 65 Not at-risk | Day 57 | Placebo | Negative | Anti Spike IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age < 65 At-risk vs Age < 65 Not at-risk | Day 57 | Placebo | Negative | Pseudovirus-nAb ID50 | 5 (5, 5) | 5 (5, 5) | 1.02 (0.98, 1.05) |
| Age < 65 At-risk vs Age < 65 Not at-risk | Day 57 | Placebo | Negative | Pseudovirus-nAb ID80 | 5 (5, 5) | 5 (5, 5) | 1.02 (0.98, 1.07) |
| Age < 65 At-risk vs Age < 65 Not at-risk | Day 57 | Placebo | Positive | Anti N IgG (IU/ml) | 115913 (72906, 184288) | 88760 (53701, 146707) | 1.31 (0.66, 2.59) |

(continued)

| Group 1 vs 2 | Visit | Arm | Baseline SARS-CoV-2 | Marker | Group 1 GMT/GMC | Group 2 GMT/GMC | Ratios of GMT/GMC |
|--|--------|---------|---------------------|------------------------|----------------------------|----------------------------|----------------------|
| Age < 65 At-risk vs Age < 65 Not at-risk | Day 57 | Placebo | Positive | Anti RBD IgG (IU/ml) | 417627 (286526, 608715) | 241209 (168681, 344922) | 1.73 (1.03, 2.91) |
| Age < 65 At-risk vs Age < 65 Not at-risk | Day 57 | Placebo | Positive | Anti Spike IgG (IU/ml) | 575539 (423609, 781958) | 463469 (322830, 665378) | 1.24 (0.77, 1.99) |
| Age < 65 At-risk vs Age < 65 Not at-risk | Day 57 | Placebo | Positive | Pseudovirus-nAb ID50 | 502 (325, 776) | 362 (224, 583) | 1.39 (0.73, 2.65) |
| Age < 65 At-risk vs Age < 65 Not at-risk | Day 57 | Placebo | Positive | Pseudovirus-nAb ID80 | 1382 (851, 2245) | 930 (559, 1549) | 1.49 (0.73, 3.00) |
| Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk | Day 1 | Vaccine | Negative | Anti N IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (0.98, 1.01) |
| Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk | Day 1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (0.99, 1.02) |
| Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk | Day 1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.01 (1.00, 1.03) |
| Age ≥ 65 At-risk vs Age ≥ 65 Not at-risk | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 5 (5, 5) | 5 (5, 5) | 1.00 (0.97, 1.02) |

(continued)

| Group 1 vs 2 | Visit | Arm | Baseline SARS-CoV-2 | Marker | Group 1 GMT/GMC | Group 2 GMT/GMC | Ratios of GMT/GMC |
|--|-------|---------|---------------------|------------------------|-----------------|-----------------|----------------------|
| Age \geq 65 At-risk vs Age \geq 65 Not at-risk | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 5 (5, 5) | 5 (5, 5) | 0.99 (0.96, 1.03) |
| Age \geq 65 At-risk vs Age \geq 65 Not at-risk | Day 1 | Vaccine | Positive | Anti N IgG (IU/ml) | 10 (10, 10) | 10 (10, 11) | 0.98 (0.95, 1.01) |
| Age \geq 65 At-risk vs Age \geq 65 Not at-risk | Day 1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age \geq 65 At-risk vs Age \geq 65 Not at-risk | Day 1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age \geq 65 At-risk vs Age \geq 65 Not at-risk | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 5 (5, 6) | 5 (5, 5) | 1.05 (0.96, 1.15) |
| Age \geq 65 At-risk vs Age \geq 65 Not at-risk | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 5 (5, 5) | 5 (5, 5) | 1.00 (1.00, 1.00) |
| Age \geq 65 At-risk vs Age \geq 65 Not at-risk | Day 1 | Placebo | Negative | Anti N IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age \geq 65 At-risk vs Age \geq 65 Not at-risk | Day 1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |

(continued)

| Group 1 vs 2 | Visit | Arm | Baseline SARS-CoV-2 | Marker | Group 1 GMT/GMC | Group 2 GMT/GMC | Ratios of GMT/GMC |
|--|-------|---------|---------------------|------------------------|-----------------|-----------------|----------------------|
| Age \geq 65 At-risk vs Age \geq 65 Not at-risk | Day 1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age \geq 65 At-risk vs Age \geq 65 Not at-risk | Day 1 | Placebo | Negative | Pseudovirus-nAb ID50 | 5 (5, 5) | 5 (5, 5) | 1.00 (1.00, 1.00) |
| Age \geq 65 At-risk vs Age \geq 65 Not at-risk | Day 1 | Placebo | Negative | Pseudovirus-nAb ID80 | 5 (5, 5) | 5 (5, 5) | 0.99 (0.96, 1.01) |
| Age \geq 65 At-risk vs Age \geq 65 Not at-risk | Day 1 | Placebo | Positive | Anti N IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (0.97, 1.04) |
| Age \geq 65 At-risk vs Age \geq 65 Not at-risk | Day 1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 10 (10, 11) | 10 (10, 10) | 1.02 (0.98, 1.06) |
| Age \geq 65 At-risk vs Age \geq 65 Not at-risk | Day 1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age \geq 65 At-risk vs Age \geq 65 Not at-risk | Day 1 | Placebo | Positive | Pseudovirus-nAb ID50 | 5 (5, 5) | 5 (5, 5) | 1.01 (0.95, 1.08) |
| Age \geq 65 At-risk vs Age \geq 65 Not at-risk | Day 1 | Placebo | Positive | Pseudovirus-nAb ID80 | 5 (5, 5) | 5 (5, 5) | 0.99 (0.95, 1.03) |

(continued)

| Group 1 vs 2 | Visit | Arm | Baseline SARS-CoV-2 | Marker | Group 1 GMT/GMC | Group 2 GMT/GMC | Ratios of GMT/GMC |
|--|--------|---------|---------------------|------------------------|----------------------------|----------------------------|----------------------|
| Age \geq 65 At-risk vs Age \geq 65 Not at-risk | Day 29 | Vaccine | Negative | Anti N IgG (IU/ml) | 48363 (38230, 61183) | 75305 (60091, 94371) | 0.64 (0.46, 0.89) |
| Age \geq 65 At-risk vs Age \geq 65 Not at-risk | Day 29 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 54232 (44615, 65922) | 80069 (65707, 97571) | 0.68 (0.51, 0.89) |
| Age \geq 65 At-risk vs Age \geq 65 Not at-risk | Day 29 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 84391 (70325, 101269) | 153593 (130667, 180543) | 0.55 (0.43, 0.70) |
| Age \geq 65 At-risk vs Age \geq 65 Not at-risk | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID50 | 199 (157, 252) | 332 (263, 418) | 0.60 (0.43, 0.84) |
| Age \geq 65 At-risk vs Age \geq 65 Not at-risk | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID80 | 348 (276, 438) | 421 (328, 540) | 0.83 (0.59, 1.16) |
| Age \geq 65 At-risk vs Age \geq 65 Not at-risk | Day 29 | Vaccine | Positive | Anti N IgG (IU/ml) | 134756 (86047, 211040) | 127407 (81244, 199800) | 1.06 (0.56, 1.99) |
| Age \geq 65 At-risk vs Age \geq 65 Not at-risk | Day 29 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 188670 (129392, 275106) | 139826 (99996, 195520) | 1.35 (0.82, 2.23) |
| Age \geq 65 At-risk vs Age \geq 65 Not at-risk | Day 29 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 293282 (210942, 407763) | 241494 (182978, 318724) | 1.21 (0.79, 1.86) |

(continued)

| Group 1 vs 2 | Visit | Arm | Baseline SARS-CoV-2 | Marker | Group 1 GMT/GMC | Group 2 GMT/GMC | Ratios of GMT/GMC |
|--|--------|---------|---------------------|------------------------|-------------------------|-------------------------|----------------------|
| Age \geq 65 At-risk vs Age \geq 65 Not at-risk | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID50 | 541 (337, 870) | 508 (317, 815) | 1.06 (0.55, 2.08) |
| Age \geq 65 At-risk vs Age \geq 65 Not at-risk | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID80 | 1052 (680, 1627) | 944 (626, 1422) | 1.12 (0.62, 2.02) |
| Age \geq 65 At-risk vs Age \geq 65 Not at-risk | Day 29 | Placebo | Negative | Anti N IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age \geq 65 At-risk vs Age \geq 65 Not at-risk | Day 29 | Placebo | Negative | Anti RBD IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age \geq 65 At-risk vs Age \geq 65 Not at-risk | Day 29 | Placebo | Negative | Anti Spike IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age \geq 65 At-risk vs Age \geq 65 Not at-risk | Day 29 | Placebo | Negative | Pseudovirus-nAb ID50 | 5 (5, 5) | 5 (5, 5) | 1.03 (0.99, 1.08) |
| Age \geq 65 At-risk vs Age \geq 65 Not at-risk | Day 29 | Placebo | Negative | Pseudovirus-nAb ID80 | 5 (5, 5) | 5 (5, 5) | 1.02 (0.98, 1.06) |
| Age \geq 65 At-risk vs Age \geq 65 Not at-risk | Day 29 | Placebo | Positive | Anti N IgG (IU/ml) | 36017 (20724, 62595) | 34367 (22390, 52751) | 1.05 (0.52, 2.11) |

(continued)

| Group 1 vs 2 | Visit | Arm | Baseline SARS-CoV-2 | Marker | Group 1 GMT/GMC | Group 2 GMT/GMC | Ratios of GMT/GMC |
|--|--------|---------|---------------------|------------------------|-------------------------------|-------------------------------|----------------------|
| Age \geq 65 At-risk vs Age \geq 65 Not at-risk | Day 29 | Placebo | Positive | Anti RBD IgG (IU/ml) | 48060 (30237, 76388) | 38048 (27669, 52321) | 1.26 (0.72, 2.22) |
| Age \geq 65 At-risk vs Age \geq 65 Not at-risk | Day 29 | Placebo | Positive | Anti Spike IgG (IU/ml) | 79058 (52125, 119908) | 59664 (45819, 77691) | 1.33 (0.81, 2.17) |
| Age \geq 65 At-risk vs Age \geq 65 Not at-risk | Day 29 | Placebo | Positive | Pseudovirus-nAb ID50 | 155 (89, 270) | 156 (105, 232) | 0.99 (0.50, 1.96) |
| Age \geq 65 At-risk vs Age \geq 65 Not at-risk | Day 29 | Placebo | Positive | Pseudovirus-nAb ID80 | 378 (233, 613) | 257 (170, 390) | 1.47 (0.77, 2.79) |
| Age \geq 65 At-risk vs Age \geq 65 Not at-risk | Day 57 | Vaccine | Negative | Anti N IgG (IU/ml) | 614449 (455495, 828875) | 1177109 (909148, 1524048) | 0.52 (0.35, 0.77) |
| Age \geq 65 At-risk vs Age \geq 65 Not at-risk | Day 57 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 2156196 (1736284, 2677662) | 3441017 (2860842, 4138850) | 0.63 (0.47, 0.83) |
| Age \geq 65 At-risk vs Age \geq 65 Not at-risk | Day 57 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 3754377 (3053564, 4616033) | 7365218 (6408010, 8465410) | 0.51 (0.40, 0.65) |
| Age \geq 65 At-risk vs Age \geq 65 Not at-risk | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID50 | 3359 (2423, 4656) | 5534 (4137, 7404) | 0.61 (0.39, 0.94) |

(continued)

| Group 1 vs 2 | Visit | Arm | Baseline SARS-CoV-2 | Marker | Group 1 GMT/GMC | Group 2 GMT/GMC | Ratios of GMT/GMC |
|--|--------|---------|---------------------|------------------------|----------------------------------|----------------------------------|----------------------|
| Age \geq 65 At-risk vs Age \geq 65 Not at-risk | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID80 | 4361 (3299, 5763) | 7125 (5468, 9285) | 0.61 (0.42, 0.90) |
| Age \geq 65 At-risk vs Age \geq 65 Not at-risk | Day 57 | Vaccine | Positive | Anti N IgG (IU/ml) | 3325369 (2089439, 5292368) | 2806906 (1779671, 4427066) | 1.18 (0.62, 2.26) |
| Age \geq 65 At-risk vs Age \geq 65 Not at-risk | Day 57 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 7826271 (5853680, 10463591) | 7305563 (5522547, 9664247) | 1.07 (0.72, 1.60) |
| Age \geq 65 At-risk vs Age \geq 65 Not at-risk | Day 57 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 12884976 (10641883, 15600868) | 13343347 (11421210, 15588971) | 0.97 (0.76, 1.23) |
| Age \geq 65 At-risk vs Age \geq 65 Not at-risk | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID50 | 27431 (17819, 42227) | 18240 (11134, 29880) | 1.50 (0.78, 2.88) |
| Age \geq 65 At-risk vs Age \geq 65 Not at-risk | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID80 | 22502 (13237, 38254) | 17541 (10280, 29932) | 1.28 (0.61, 2.71) |
| Age \geq 65 At-risk vs Age \geq 65 Not at-risk | Day 57 | Placebo | Negative | Anti N IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age \geq 65 At-risk vs Age \geq 65 Not at-risk | Day 57 | Placebo | Negative | Anti RBD IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |

(continued)

| Group 1 vs 2 | Visit | Arm | Baseline SARS-CoV-2 | Marker | Group 1 GMT/GMC | Group 2 GMT/GMC | Ratios of GMT/GMC |
|--|--------|---------|---------------------|------------------------|-------------------------------|-------------------------------|----------------------|
| Age \geq 65 At-risk vs Age \geq 65 Not at-risk | Day 57 | Placebo | Negative | Anti Spike IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Age \geq 65 At-risk vs Age \geq 65 Not at-risk | Day 57 | Placebo | Negative | Pseudovirus-nAb ID50 | 5 (5, 5) | 5 (5, 6) | 0.96 (0.90, 1.02) |
| Age \geq 65 At-risk vs Age \geq 65 Not at-risk | Day 57 | Placebo | Negative | Pseudovirus-nAb ID80 | 5 (5, 6) | 5 (5, 5) | 1.04 (0.97, 1.11) |
| Age \geq 65 At-risk vs Age \geq 65 Not at-risk | Day 57 | Placebo | Positive | Anti N IgG (IU/ml) | 617829 (374065, 1020446) | 461295 (282331, 753702) | 1.34 (0.66, 2.70) |
| Age \geq 65 At-risk vs Age \geq 65 Not at-risk | Day 57 | Placebo | Positive | Anti RBD IgG (IU/ml) | 1793880 (1112795, 2891824) | 1599200 (1156266, 2211811) | 1.12 (0.63, 1.99) |
| Age \geq 65 At-risk vs Age \geq 65 Not at-risk | Day 57 | Placebo | Positive | Anti Spike IgG (IU/ml) | 3402410 (2325361, 4978321) | 2437171 (1815977, 3270859) | 1.40 (0.87, 2.25) |
| Age \geq 65 At-risk vs Age \geq 65 Not at-risk | Day 57 | Placebo | Positive | Pseudovirus-nAb ID50 | 3501 (1863, 6577) | 2442 (1442, 4134) | 1.43 (0.63, 3.27) |
| Age \geq 65 At-risk vs Age \geq 65 Not at-risk | Day 57 | Placebo | Positive | Pseudovirus-nAb ID80 | 5048 (2709, 9408) | 3681 (2278, 5949) | 1.37 (0.63, 3.00) |
| Male vs Female | Day 1 | Vaccine | Negative | Anti N IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (0.99, 1.00) |

(continued)

| Group 1 vs 2 | Visit | Arm | Baseline SARS-CoV-2 | Marker | Group 1 GMT/GMC | Group 2 GMT/GMC | Ratios of GMT/GMC |
|----------------|-------|---------|---------------------|------------------------|-----------------|-----------------|----------------------|
| Male vs Female | Day 1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.01 (0.99, 1.02) |
| Male vs Female | Day 1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Male vs Female | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 5 (5, 5) | 5 (5, 5) | 0.99 (0.98, 1.01) |
| Male vs Female | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 5 (5, 5) | 5 (5, 5) | 0.99 (0.97, 1.01) |
| Male vs Female | Day 1 | Vaccine | Positive | Anti N IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (0.99, 1.01) |
| Male vs Female | Day 1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Male vs Female | Day 1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Male vs Female | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 5 (5, 5) | 5 (5, 5) | 0.98 (0.94, 1.02) |
| Male vs Female | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 5 (5, 5) | 5 (5, 5) | 1.01 (0.96, 1.05) |
| Male vs Female | Day 1 | Placebo | Negative | Anti N IgG (IU/ml) | 10 (10, 11) | 10 (10, 10) | 1.05 (0.96, 1.14) |
| Male vs Female | Day 1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 11 (9, 12) | 10 (10, 10) | 1.05 (0.95, 1.17) |
| Male vs Female | Day 1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 0.99 (0.97, 1.01) |
| Male vs Female | Day 1 | Placebo | Negative | Pseudovirus-nAb ID50 | 5 (5, 5) | 5 (5, 5) | 0.99 (0.98, 1.01) |
| Male vs Female | Day 1 | Placebo | Negative | Pseudovirus-nAb ID80 | 5 (5, 5) | 5 (5, 6) | 0.97 (0.91, 1.03) |
| Male vs Female | Day 1 | Placebo | Positive | Anti N IgG (IU/ml) | 10 (10, 10) | 10 (10, 11) | 0.98 (0.94, 1.02) |

(continued)

| Group 1 vs 2 | Visit | Arm | Baseline SARS-CoV-2 | Marker | Group 1 GMT/GMC | Group 2 GMT/GMC | Ratios of GMT/GMC |
|----------------|--------|---------|---------------------|------------------------|--------------------------|--------------------------|----------------------|
| Male vs Female | Day 1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (0.99, 1.00) |
| Male vs Female | Day 1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Male vs Female | Day 1 | Placebo | Positive | Pseudovirus-nAb ID50 | 5 (5, 5) | 5 (5, 5) | 0.97 (0.92, 1.02) |
| Male vs Female | Day 1 | Placebo | Positive | Pseudovirus-nAb ID80 | 5 (5, 5) | 5 (5, 5) | 0.99 (0.96, 1.02) |
| Male vs Female | Day 29 | Vaccine | Negative | Anti N IgG (IU/ml) | 27118 (20803, 35351) | 21438 (17319, 26535) | 1.26 (0.90, 1.78) |
| Male vs Female | Day 29 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 25738 (20110, 32941) | 21234 (17837, 25278) | 1.21 (0.89, 1.65) |
| Male vs Female | Day 29 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 40290 (34397, 47193) | 41415 (35725, 48012) | 0.97 (0.78, 1.22) |
| Male vs Female | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID50 | 121 (93, 157) | 98 (80, 120) | 1.23 (0.89, 1.72) |
| Male vs Female | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID80 | 207 (158, 272) | 178 (145, 218) | 1.17 (0.83, 1.64) |
| Male vs Female | Day 29 | Vaccine | Positive | Anti N IgG (IU/ml) | 52664 (36905, 75154) | 37697 (26222, 54193) | 1.40 (0.84, 2.33) |
| Male vs Female | Day 29 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 43301 (30763, 60949) | 32117 (22658, 45526) | 1.35 (0.81, 2.24) |
| Male vs Female | Day 29 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 83762 (65541, 107048) | 77611 (57216, 105276) | 1.08 (0.72, 1.62) |
| Male vs Female | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID50 | 223 (158, 315) | 165 (113, 242) | 1.35 (0.80, 2.27) |
| Male vs Female | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID80 | 449 (303, 666) | 401 (268, 602) | 1.12 (0.64, 1.97) |
| Male vs Female | Day 29 | Placebo | Negative | Anti N IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |

(continued)

| Group 1 vs 2 | Visit | Arm | Baseline SARS-CoV-2 | Marker | Group 1 GMT/GMC | Group 2 GMT/GMC | Ratios of GMT/GMC |
|----------------|--------|---------|---------------------|------------------------|-------------------------------|-------------------------------|----------------------|
| Male vs Female | Day 29 | Placebo | Negative | Anti RBD IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Male vs Female | Day 29 | Placebo | Negative | Anti Spike IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Male vs Female | Day 29 | Placebo | Negative | Pseudovirus-nAb ID50 | 5 (5, 5) | 5 (5, 5) | 1.02 (0.98, 1.06) |
| Male vs Female | Day 29 | Placebo | Negative | Pseudovirus-nAb ID80 | 5 (5, 5) | 5 (5, 5) | 0.97 (0.93, 1.02) |
| Male vs Female | Day 29 | Placebo | Positive | Anti N IgG (IU/ml) | 11707 (7655, 17903) | 13066 (8983, 19004) | 0.90 (0.51, 1.58) |
| Male vs Female | Day 29 | Placebo | Positive | Anti RBD IgG (IU/ml) | 12838 (8743, 18852) | 12876 (9489, 17472) | 1.00 (0.60, 1.65) |
| Male vs Female | Day 29 | Placebo | Positive | Anti Spike IgG (IU/ml) | 16359 (12044, 22219) | 19468 (15496, 24459) | 0.84 (0.56, 1.26) |
| Male vs Female | Day 29 | Placebo | Positive | Pseudovirus-nAb ID50 | 43 (29, 63) | 58 (42, 81) | 0.73 (0.44, 1.23) |
| Male vs Female | Day 29 | Placebo | Positive | Pseudovirus-nAb ID80 | 100 (68, 146) | 152 (105, 219) | 0.66 (0.38, 1.14) |
| Male vs Female | Day 57 | Vaccine | Negative | Anti N IgG (IU/ml) | 358185 (259645, 494122) | 304934 (237911, 390840) | 1.17 (0.78, 1.77) |
| Male vs Female | Day 57 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 1032572 (803692, 1326633) | 924524 (750510, 1138886) | 1.12 (0.80, 1.56) |
| Male vs Female | Day 57 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 2448348 (1992531, 3008439) | 1878895 (1586011, 2225864) | 1.30 (0.99, 1.71) |
| Male vs Female | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID50 | 1983 (1427, 2754) | 1243 (972, 1588) | 1.60 (1.05, 2.41) |
| Male vs Female | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID80 | 2322 (1694, 3181) | 2160 (1643, 2840) | 1.07 (0.70, 1.64) |
| Male vs Female | Day 57 | Vaccine | Positive | Anti N IgG (IU/ml) | 1379076 (895389, 2124049) | 785331 (484933, 1271815) | 1.76 (0.92, 3.34) |

(continued)

| Group 1 vs 2 | Visit | Arm | Baseline SARS-CoV-2 | Marker | Group 1 GMT/GMC | Group 2 GMT/GMC | Ratios of GMT/GMC |
|----------------|--------|---------|---------------------|------------------------|-------------------------------|-------------------------------|----------------------|
| Male vs Female | Day 57 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 2628794 (1842173, 3751308) | 2106655 (1490680, 2977161) | 1.25 (0.76, 2.06) |
| Male vs Female | Day 57 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 5518909 (4222583, 7213204) | 5236885 (3880756, 7066912) | 1.05 (0.70, 1.59) |
| Male vs Female | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID50 | 5567 (3235, 9581) | 5754 (3356, 9868) | 0.97 (0.45, 2.07) |
| Male vs Female | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID80 | 9590 (6259, 14696) | 6872 (4174, 11314) | 1.40 (0.73, 2.67) |
| Male vs Female | Day 57 | Placebo | Negative | Anti N IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Male vs Female | Day 57 | Placebo | Negative | Anti RBD IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.01 (0.99, 1.03) |
| Male vs Female | Day 57 | Placebo | Negative | Anti Spike IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Male vs Female | Day 57 | Placebo | Negative | Pseudovirus-nAb ID50 | 5 (5, 5) | 5 (5, 5) | 1.00 (0.98, 1.02) |
| Male vs Female | Day 57 | Placebo | Negative | Pseudovirus-nAb ID80 | 5 (5, 5) | 5 (5, 5) | 0.99 (0.97, 1.01) |
| Male vs Female | Day 57 | Placebo | Positive | Anti N IgG (IU/ml) | 120405 (68919, 210356) | 136546 (89268, 208864) | 0.88 (0.43, 1.79) |
| Male vs Female | Day 57 | Placebo | Positive | Anti RBD IgG (IU/ml) | 361345 (243436, 536364) | 396863 (289955, 543189) | 0.91 (0.54, 1.55) |
| Male vs Female | Day 57 | Placebo | Positive | Anti Spike IgG (IU/ml) | 578439 (406742, 822616) | 748414 (540245, 1036794) | 0.77 (0.47, 1.28) |
| Male vs Female | Day 57 | Placebo | Positive | Pseudovirus-nAb ID50 | 606 (358, 1023) | 541 (355, 825) | 1.12 (0.56, 2.23) |
| Male vs Female | Day 57 | Placebo | Positive | Pseudovirus-nAb ID80 | 930 (554, 1559) | 1659 (1064, 2588) | 0.56 (0.28, 1.12) |

(continued)

| Group 1 vs 2 | Visit | Arm | Baseline SARS-CoV-2 | Marker | Group 1 GMT/GMC | Group 2 GMT/GMC | Ratios of GMT/GMC |
|--|-------|---------|---------------------|------------------------|-----------------|-----------------|----------------------|
| Hispanic or Latino vs Not Hispanic or Latino | Day 1 | Vaccine | Negative | Anti N IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Hispanic or Latino vs Not Hispanic or Latino | Day 1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 0.99 (0.99, 1.00) |
| Hispanic or Latino vs Not Hispanic or Latino | Day 1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Hispanic or Latino vs Not Hispanic or Latino | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 5 (5, 5) | 5 (5, 5) | 0.99 (0.98, 1.00) |
| Hispanic or Latino vs Not Hispanic or Latino | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 5 (5, 6) | 5 (5, 5) | 1.05 (0.97, 1.14) |
| Hispanic or Latino vs Not Hispanic or Latino | Day 1 | Vaccine | Positive | Anti N IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (0.99, 1.00) |

(continued)

| Group 1 vs 2 | Visit | Arm | Baseline SARS-CoV-2 | Marker | Group 1 GMT/GMC | Group 2 GMT/GMC | Ratios of GMT/GMC |
|--|-------|---------|---------------------|------------------------|-----------------|-----------------|----------------------|
| Hispanic or Latino vs Not Hispanic or Latino | Day 1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Hispanic or Latino vs Not Hispanic or Latino | Day 1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Hispanic or Latino vs Not Hispanic or Latino | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 5 (5, 5) | 5 (5, 5) | 0.99 (0.98, 1.00) |
| Hispanic or Latino vs Not Hispanic or Latino | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 5 (5, 5) | 5 (5, 5) | 1.01 (0.96, 1.06) |
| Hispanic or Latino vs Not Hispanic or Latino | Day 1 | Placebo | Negative | Anti N IgG (IU/ml) | 10 (10, 10) | 10 (10, 11) | 0.98 (0.94, 1.02) |
| Hispanic or Latino vs Not Hispanic or Latino | Day 1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |

(continued)

| Group 1 vs 2 | Visit | Arm | Baseline SARS-CoV-2 | Marker | Group 1 GMT/GMC | Group 2 GMT/GMC | Ratios of GMT/GMC |
|--|-------|---------|---------------------|------------------------|-----------------|-----------------|----------------------|
| Hispanic or Latino vs Not Hispanic or Latino | Day 1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 0.99 (0.98, 1.01) |
| Hispanic or Latino vs Not Hispanic or Latino | Day 1 | Placebo | Negative | Pseudovirus-nAb ID50 | 5 (5, 5) | 5 (5, 5) | 0.99 (0.98, 1.01) |
| Hispanic or Latino vs Not Hispanic or Latino | Day 1 | Placebo | Negative | Pseudovirus-nAb ID80 | 5 (5, 5) | 5 (5, 5) | 0.97 (0.93, 1.02) |
| Hispanic or Latino vs Not Hispanic or Latino | Day 1 | Placebo | Positive | Anti N IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 0.99 (0.96, 1.03) |
| Hispanic or Latino vs Not Hispanic or Latino | Day 1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (0.99, 1.00) |
| Hispanic or Latino vs Not Hispanic or Latino | Day 1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |

(continued)

| Group 1 vs 2 | Visit | Arm | Baseline SARS-CoV-2 | Marker | Group 1 GMT/GMC | Group 2 GMT/GMC | Ratios of GMT/GMC |
|--|--------|---------|---------------------|------------------------|-------------------------|-------------------------|----------------------|
| Hispanic or Latino vs Not Hispanic or Latino | Day 1 | Placebo | Positive | Pseudovirus-nAb ID50 | 6 (5, 7) | 5 (5, 5) | 1.10 (0.90, 1.34) |
| Hispanic or Latino vs Not Hispanic or Latino | Day 1 | Placebo | Positive | Pseudovirus-nAb ID80 | 5 (5, 5) | 5 (5, 5) | 0.99 (0.97, 1.01) |
| Hispanic or Latino vs Not Hispanic or Latino | Day 29 | Vaccine | Negative | Anti N IgG (IU/ml) | 22074 (14121, 34506) | 23655 (19521, 28664) | 0.93 (0.57, 1.52) |
| Hispanic or Latino vs Not Hispanic or Latino | Day 29 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 22266 (15847, 31284) | 23020 (19425, 27280) | 0.97 (0.66, 1.42) |
| Hispanic or Latino vs Not Hispanic or Latino | Day 29 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 41773 (31562, 55289) | 39694 (35055, 44946) | 1.05 (0.77, 1.44) |
| Hispanic or Latino vs Not Hispanic or Latino | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID50 | 101 (67, 152) | 104 (86, 125) | 0.97 (0.62, 1.52) |

(continued)

| Group 1 vs 2 | Visit | Arm | Baseline SARS-CoV-2 | Marker | Group 1 GMT/GMC | Group 2 GMT/GMC | Ratios of GMT/GMC |
|--|--------|---------|---------------------|------------------------|--------------------------|--------------------------|----------------------|
| Hispanic or Latino vs Not Hispanic or Latino | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID80 | 190 (126, 284) | 191 (158, 230) | 0.99 (0.63, 1.55) |
| Hispanic or Latino vs Not Hispanic or Latino | Day 29 | Vaccine | Positive | Anti N IgG (IU/ml) | 66150 (37538, 116570) | 41747 (30714, 56743) | 1.58 (0.84, 2.98) |
| Hispanic or Latino vs Not Hispanic or Latino | Day 29 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 57339 (30559, 107588) | 35344 (26390, 47337) | 1.62 (0.82, 3.20) |
| Hispanic or Latino vs Not Hispanic or Latino | Day 29 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 90332 (50343, 162084) | 83383 (65546, 106075) | 1.08 (0.58, 2.02) |
| Hispanic or Latino vs Not Hispanic or Latino | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID50 | 254 (155, 417) | 183 (133, 251) | 1.39 (0.78, 2.48) |
| Hispanic or Latino vs Not Hispanic or Latino | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID80 | 498 (236, 1049) | 411 (294, 575) | 1.21 (0.55, 2.69) |

(continued)

| Group 1 vs 2 | Visit | Arm | Baseline SARS-CoV-2 | Marker | Group 1 GMT/GMC | Group 2 GMT/GMC | Ratios of GMT/GMC |
|--|--------|---------|---------------------|------------------------|------------------------|------------------------|----------------------|
| Hispanic or Latino vs Not Hispanic or Latino | Day 29 | Placebo | Negative | Anti N IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Hispanic or Latino vs Not Hispanic or Latino | Day 29 | Placebo | Negative | Anti RBD IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Hispanic or Latino vs Not Hispanic or Latino | Day 29 | Placebo | Negative | Anti Spike IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Hispanic or Latino vs Not Hispanic or Latino | Day 29 | Placebo | Negative | Pseudovirus-nAb ID50 | 5 (5, 5) | 5 (5, 5) | 1.00 (0.97, 1.04) |
| Hispanic or Latino vs Not Hispanic or Latino | Day 29 | Placebo | Negative | Pseudovirus-nAb ID80 | 6 (4, 8) | 5 (5, 5) | 1.21 (0.89, 1.64) |
| Hispanic or Latino vs Not Hispanic or Latino | Day 29 | Placebo | Positive | Anti N IgG (IU/ml) | 26345 (9909, 70041) | 12063 (8992, 16185) | 2.18 (0.81, 5.85) |

(continued)

| Group 1 vs 2 | Visit | Arm | Baseline SARS-CoV-2 | Marker | Group 1 GMT/GMC | Group 2 GMT/GMC | Ratios of GMT/GMC |
|--|--------|---------|---------------------|------------------------|------------------------------|-----------------------------|----------------------|
| Hispanic or Latino vs Not Hispanic or Latino | Day 29 | Placebo | Positive | Anti RBD IgG (IU/ml) | 34815 (16110, 75239) | 11608 (9046, 14896) | 3.00 (1.35, 6.66) |
| Hispanic or Latino vs Not Hispanic or Latino | Day 29 | Placebo | Positive | Anti Spike IgG (IU/ml) | 26708 (12585, 56680) | 18056 (14910, 21865) | 1.48 (0.70, 3.14) |
| Hispanic or Latino vs Not Hispanic or Latino | Day 29 | Placebo | Positive | Pseudovirus-nAb ID50 | 118 (42, 327) | 48 (37, 63) | 2.45 (0.88, 6.82) |
| Hispanic or Latino vs Not Hispanic or Latino | Day 29 | Placebo | Positive | Pseudovirus-nAb ID80 | 351 (151, 818) | 123 (92, 165) | 2.85 (1.19, 6.80) |
| Hispanic or Latino vs Not Hispanic or Latino | Day 57 | Vaccine | Negative | Anti N IgG (IU/ml) | 332872 (193115, 573771) | 334364 (266627, 419309) | 1.00 (0.55, 1.79) |
| Hispanic or Latino vs Not Hispanic or Latino | Day 57 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 1087406 (737091, 1604213) | 987977 (822264, 1187086) | 1.10 (0.71, 1.70) |

(continued)

| Group 1 vs 2 | Visit | Arm | Baseline SARS-CoV-2 | Marker | Group 1 GMT/GMC | Group 2 GMT/GMC | Ratios of GMT/GMC |
|--|--------|---------|---------------------|------------------------|--------------------------------|-------------------------------|----------------------|
| Hispanic or Latino vs Not Hispanic or Latino | Day 57 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 2082654 (1564176, 2772993) | 2063432 (1775937, 2397468) | 1.01 (0.73, 1.40) |
| Hispanic or Latino vs Not Hispanic or Latino | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID50 | 1727 (1013, 2946) | 1500 (1191, 1888) | 1.15 (0.64, 2.06) |
| Hispanic or Latino vs Not Hispanic or Latino | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID80 | 2444 (1373, 4350) | 2270 (1788, 2883) | 1.08 (0.58, 2.00) |
| Hispanic or Latino vs Not Hispanic or Latino | Day 57 | Vaccine | Positive | Anti N IgG (IU/ml) | 1420449 (558648, 3611715) | 968852 (654113, 1435033) | 1.47 (0.54, 3.95) |
| Hispanic or Latino vs Not Hispanic or Latino | Day 57 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 2735111 (1368395, 5466868) | 2315554 (1731123, 3097290) | 1.18 (0.56, 2.47) |
| Hispanic or Latino vs Not Hispanic or Latino | Day 57 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 7578287 (5040721, 11393296) | 5301268 (4150604, 6770929) | 1.43 (0.90, 2.28) |

(continued)

| Group 1 vs 2 | Visit | Arm | Baseline SARS-CoV-2 | Marker | Group 1 GMT/GMC | Group 2 GMT/GMC | Ratios of GMT/GMC |
|--|--------|---------|---------------------|------------------------|------------------------|-----------------------|----------------------|
| Hispanic or Latino vs Not Hispanic or Latino | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID50 | 7727 (2908, 20532) | 5224 (3348, 8151) | 1.48 (0.52, 4.24) |
| Hispanic or Latino vs Not Hispanic or Latino | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID80 | 10208 (4492, 23195) | 7937 (5300, 11886) | 1.29 (0.53, 3.14) |
| Hispanic or Latino vs Not Hispanic or Latino | Day 57 | Placebo | Negative | Anti N IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Hispanic or Latino vs Not Hispanic or Latino | Day 57 | Placebo | Negative | Anti RBD IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 0.99 (0.98, 1.00) |
| Hispanic or Latino vs Not Hispanic or Latino | Day 57 | Placebo | Negative | Anti Spike IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Hispanic or Latino vs Not Hispanic or Latino | Day 57 | Placebo | Negative | Pseudovirus-nAb ID50 | 5 (5, 5) | 5 (5, 5) | 0.99 (0.98, 1.00) |

(continued)

| Group 1 vs 2 | Visit | Arm | Baseline SARS-CoV-2 | Marker | Group 1 GMT/GMC | Group 2 GMT/GMC | Ratios of GMT/GMC |
|--|--------|---------|---------------------|------------------------|------------------------------|----------------------------|-----------------------|
| Hispanic or Latino vs Not Hispanic or Latino | Day 57 | Placebo | Negative | Pseudovirus-nAb ID80 | 5 (5, 5) | 5 (5, 5) | 0.99 (0.97, 1.00) |
| Hispanic or Latino vs Not Hispanic or Latino | Day 57 | Placebo | Positive | Anti N IgG (IU/ml) | 452690 (158709, 1291220) | 129424 (89788, 186557) | 3.50 (1.19, 10.30) |
| Hispanic or Latino vs Not Hispanic or Latino | Day 57 | Placebo | Positive | Anti RBD IgG (IU/ml) | 747435 (391924, 1425424) | 381696 (293138, 497006) | 1.96 (0.99, 3.89) |
| Hispanic or Latino vs Not Hispanic or Latino | Day 57 | Placebo | Positive | Anti Spike IgG (IU/ml) | 1403460 (609038, 3234119) | 648311 (505732, 831086) | 2.16 (0.93, 5.02) |
| Hispanic or Latino vs Not Hispanic or Latino | Day 57 | Placebo | Positive | Pseudovirus-nAb ID50 | 1522 (466, 4976) | 555 (395, 782) | 2.74 (0.84, 8.96) |
| Hispanic or Latino vs Not Hispanic or Latino | Day 57 | Placebo | Positive | Pseudovirus-nAb ID80 | 3063 (1057, 8877) | 1324 (921, 1904) | 2.31 (0.78, 6.86) |
| Communities of Color vs White Non-Hispanic | Day 1 | Vaccine | Negative | Anti N IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.01) |

(continued)

| Group 1 vs 2 | Visit | Arm | Baseline SARS-CoV-2 | Marker | Group 1 GMT/GMC | Group 2 GMT/GMC | Ratios of GMT/GMC |
|--|-------|---------|---------------------|------------------------|-----------------|-----------------|----------------------|
| Communities of Color vs White Non-Hispanic | Day 1 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.02 (1.00, 1.04) |
| Communities of Color vs White Non-Hispanic | Day 1 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Communities of Color vs White Non-Hispanic | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID50 | 5 (5, 5) | 5 (5, 5) | 1.00 (0.99, 1.01) |
| Communities of Color vs White Non-Hispanic | Day 1 | Vaccine | Negative | Pseudovirus-nAb ID80 | 5 (5, 5) | 5 (5, 5) | 1.03 (1.00, 1.06) |
| Communities of Color vs White Non-Hispanic | Day 1 | Vaccine | Positive | Anti N IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (0.99, 1.02) |
| Communities of Color vs White Non-Hispanic | Day 1 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Communities of Color vs White Non-Hispanic | Day 1 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Communities of Color vs White Non-Hispanic | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID50 | 5 (5, 5) | 5 (5, 5) | 1.00 (0.98, 1.02) |

(continued)

| Group 1 vs 2 | Visit | Arm | Baseline SARS-CoV-2 | Marker | Group 1 GMT/GMC | Group 2 GMT/GMC | Ratios of GMT/GMC |
|--|-------|---------|---------------------|------------------------|-----------------|-----------------|----------------------|
| Communities of Color vs White Non-Hispanic | Day 1 | Vaccine | Positive | Pseudovirus-nAb ID80 | 5 (5, 6) | 5 (5, 5) | 1.05 (0.99, 1.11) |
| Communities of Color vs White Non-Hispanic | Day 1 | Placebo | Negative | Anti N IgG (IU/ml) | 10 (10, 10) | 10 (10, 11) | 0.97 (0.91, 1.03) |
| Communities of Color vs White Non-Hispanic | Day 1 | Placebo | Negative | Anti RBD IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Communities of Color vs White Non-Hispanic | Day 1 | Placebo | Negative | Anti Spike IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 0.99 (0.96, 1.01) |
| Communities of Color vs White Non-Hispanic | Day 1 | Placebo | Negative | Pseudovirus-nAb ID50 | 5 (5, 5) | 5 (5, 5) | 1.02 (0.99, 1.05) |
| Communities of Color vs White Non-Hispanic | Day 1 | Placebo | Negative | Pseudovirus-nAb ID80 | 5 (5, 5) | 5 (5, 6) | 0.97 (0.90, 1.05) |
| Communities of Color vs White Non-Hispanic | Day 1 | Placebo | Positive | Anti N IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (0.99, 1.01) |
| Communities of Color vs White Non-Hispanic | Day 1 | Placebo | Positive | Anti RBD IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (0.99, 1.00) |

(continued)

| Group 1 vs 2 | Visit | Arm | Baseline SARS-CoV-2 | Marker | Group 1 GMT/GMC | Group 2 GMT/GMC | Ratios of GMT/GMC |
|--|--------|---------|---------------------|------------------------|-------------------------|-------------------------|----------------------|
| Communities of Color vs White Non-Hispanic | Day 1 | Placebo | Positive | Anti Spike IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Communities of Color vs White Non-Hispanic | Day 1 | Placebo | Positive | Pseudovirus-nAb ID50 | 5 (5, 6) | 5 (5, 5) | 1.03 (0.97, 1.10) |
| Communities of Color vs White Non-Hispanic | Day 1 | Placebo | Positive | Pseudovirus-nAb ID80 | 5 (5, 5) | 5 (5, 5) | 1.01 (1.00, 1.02) |
| Communities of Color vs White Non-Hispanic | Day 29 | Vaccine | Negative | Anti N IgG (IU/ml) | 21539 (16824, 27575) | 26952 (20883, 34784) | 0.80 (0.56, 1.14) |
| Communities of Color vs White Non-Hispanic | Day 29 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 23355 (19242, 28347) | 23438 (18669, 29425) | 1.00 (0.74, 1.34) |
| Communities of Color vs White Non-Hispanic | Day 29 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 40216 (34320, 47124) | 40376 (34349, 47460) | 1.00 (0.79, 1.25) |
| Communities of Color vs White Non-Hispanic | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID50 | 99 (79, 124) | 115 (90, 147) | 0.86 (0.62, 1.20) |
| Communities of Color vs White Non-Hispanic | Day 29 | Vaccine | Negative | Pseudovirus-nAb ID80 | 208 (163, 266) | 188 (146, 241) | 1.11 (0.78, 1.57) |

(continued)

| Group 1 vs 2 | Visit | Arm | Baseline SARS-CoV-2 | Marker | Group 1 GMT/GMC | Group 2 GMT/GMC | Ratios of GMT/GMC |
|--|--------|---------|---------------------|------------------------|--------------------------|-------------------------|----------------------|
| Communities of Color vs White Non-Hispanic | Day 29 | Vaccine | Positive | Anti N IgG (IU/ml) | 59825 (42571, 84073) | 33909 (24023, 47863) | 1.76 (1.09, 2.86) |
| Communities of Color vs White Non-Hispanic | Day 29 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 44605 (32113, 61955) | 30985 (21434, 44793) | 1.44 (0.88, 2.36) |
| Communities of Color vs White Non-Hispanic | Day 29 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 90964 (70627, 117156) | 72481 (53061, 99008) | 1.25 (0.84, 1.88) |
| Communities of Color vs White Non-Hispanic | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID50 | 238 (171, 332) | 148 (104, 211) | 1.61 (0.99, 2.62) |
| Communities of Color vs White Non-Hispanic | Day 29 | Vaccine | Positive | Pseudovirus-nAb ID80 | 545 (371, 802) | 348 (226, 535) | 1.57 (0.88, 2.80) |
| Communities of Color vs White Non-Hispanic | Day 29 | Placebo | Negative | Anti N IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Communities of Color vs White Non-Hispanic | Day 29 | Placebo | Negative | Anti RBD IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Communities of Color vs White Non-Hispanic | Day 29 | Placebo | Negative | Anti Spike IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |

(continued)

| Group 1 vs 2 | Visit | Arm | Baseline SARS-CoV-2 | Marker | Group 1 GMT/GMC | Group 2 GMT/GMC | Ratios of GMT/GMC |
|--|--------|---------|---------------------|------------------------|----------------------------|----------------------------|----------------------|
| Communities of Color vs White Non-Hispanic | Day 29 | Placebo | Negative | Pseudovirus-nAb ID50 | 5 (5, 5) | 5 (5, 5) | 1.00 (0.99, 1.01) |
| Communities of Color vs White Non-Hispanic | Day 29 | Placebo | Negative | Pseudovirus-nAb ID80 | 5 (5, 6) | 5 (5, 5) | 1.06 (0.96, 1.16) |
| Communities of Color vs White Non-Hispanic | Day 29 | Placebo | Positive | Anti N IgG (IU/ml) | 12076 (7763, 18784) | 12594 (8382, 18924) | 0.96 (0.53, 1.75) |
| Communities of Color vs White Non-Hispanic | Day 29 | Placebo | Positive | Anti RBD IgG (IU/ml) | 17596 (12331, 25109) | 10931 (7560, 15804) | 1.61 (0.96, 2.69) |
| Communities of Color vs White Non-Hispanic | Day 29 | Placebo | Positive | Anti Spike IgG (IU/ml) | 18884 (13334, 26743) | 18868 (14808, 24043) | 1.00 (0.65, 1.53) |
| Communities of Color vs White Non-Hispanic | Day 29 | Placebo | Positive | Pseudovirus-nAb ID50 | 54 (34, 84) | 52 (37, 74) | 1.03 (0.58, 1.81) |
| Communities of Color vs White Non-Hispanic | Day 29 | Placebo | Positive | Pseudovirus-nAb ID80 | 178 (110, 288) | 107 (76, 150) | 1.67 (0.92, 3.01) |
| Communities of Color vs White Non-Hispanic | Day 57 | Vaccine | Negative | Anti N IgG (IU/ml) | 358864 (270757, 475643) | 328428 (241933, 445846) | 1.09 (0.72, 1.66) |

(continued)

| Group 1 vs 2 | Visit | Arm | Baseline SARS-CoV-2 | Marker | Group 1 GMT/GMC | Group 2 GMT/GMC | Ratios of GMT/GMC |
|--|--------|---------|---------------------|------------------------|-------------------------------|-------------------------------|----------------------|
| Communities of Color vs White Non-Hispanic | Day 57 | Vaccine | Negative | Anti RBD IgG (IU/ml) | 977894 (775549, 1233031) | 1035293 (809568, 1323956) | 0.94 (0.67, 1.32) |
| Communities of Color vs White Non-Hispanic | Day 57 | Vaccine | Negative | Anti Spike IgG (IU/ml) | 2083276 (1732503, 2505069) | 2145772 (1770774, 2600184) | 0.97 (0.74, 1.27) |
| Communities of Color vs White Non-Hispanic | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID50 | 1903 (1416, 2557) | 1376 (1010, 1874) | 1.38 (0.90, 2.12) |
| Communities of Color vs White Non-Hispanic | Day 57 | Vaccine | Negative | Pseudovirus-nAb ID80 | 2744 (2021, 3725) | 2011 (1465, 2761) | 1.36 (0.88, 2.12) |
| Communities of Color vs White Non-Hispanic | Day 57 | Vaccine | Positive | Anti N IgG (IU/ml) | 1149410 (702292, 1881190) | 855574 (517613, 1414198) | 1.34 (0.66, 2.72) |
| Communities of Color vs White Non-Hispanic | Day 57 | Vaccine | Positive | Anti RBD IgG (IU/ml) | 3146770 (2273084, 4356267) | 1943813 (1349835, 2799166) | 1.62 (0.99, 2.64) |
| Communities of Color vs White Non-Hispanic | Day 57 | Vaccine | Positive | Anti Spike IgG (IU/ml) | 5991417 (4527248, 7929117) | 4608987 (3338577, 6362819) | 1.30 (0.85, 1.99) |
| Communities of Color vs White Non-Hispanic | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID50 | 7086 (4582, 10956) | 4550 (2471, 8378) | 1.56 (0.74, 3.30) |

(continued)

| Group 1 vs 2 | Visit | Arm | Baseline SARS-CoV-2 | Marker | Group 1 GMT/GMC | Group 2 GMT/GMC | Ratios of GMT/GMC |
|--|--------|---------|---------------------|------------------------|----------------------------|----------------------------|----------------------|
| Communities of Color vs White Non-Hispanic | Day 57 | Vaccine | Positive | Pseudovirus-nAb ID80 | 8885 (5903, 13374) | 7994 (4646, 13757) | 1.11 (0.56, 2.19) |
| Communities of Color vs White Non-Hispanic | Day 57 | Placebo | Negative | Anti N IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Communities of Color vs White Non-Hispanic | Day 57 | Placebo | Negative | Anti RBD IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 0.99 (0.98, 1.01) |
| Communities of Color vs White Non-Hispanic | Day 57 | Placebo | Negative | Anti Spike IgG (IU/ml) | 10 (10, 10) | 10 (10, 10) | 1.00 (1.00, 1.00) |
| Communities of Color vs White Non-Hispanic | Day 57 | Placebo | Negative | Pseudovirus-nAb ID50 | 5 (5, 5) | 5 (5, 5) | 1.01 (0.99, 1.03) |
| Communities of Color vs White Non-Hispanic | Day 57 | Placebo | Negative | Pseudovirus-nAb ID80 | 5 (5, 5) | 5 (5, 5) | 0.98 (0.96, 1.01) |
| Communities of Color vs White Non-Hispanic | Day 57 | Placebo | Positive | Anti N IgG (IU/ml) | 193321 (112530, 332117) | 105260 (65764, 168478) | 1.84 (0.90, 3.76) |
| Communities of Color vs White Non-Hispanic | Day 57 | Placebo | Positive | Anti RBD IgG (IU/ml) | 397884 (256621, 616908) | 393045 (287516, 537306) | 1.01 (0.59, 1.73) |

(continued)

| Group 1 vs 2 | Visit | Arm | Baseline SARS-CoV-2 | Marker | Group 1 GMT/GMC | Group 2 GMT/GMC | Ratios of GMT/GMC |
|--|--------|---------|---------------------|------------------------|-----------------------------|----------------------------|----------------------|
| Communities of Color vs White Non-Hispanic | Day 57 | Placebo | Positive | Anti Spike IgG (IU/ml) | 734879 (489927, 1102301) | 674526 (485396, 937351) | 1.09 (0.65, 1.84) |
| Communities of Color vs White Non-Hispanic | Day 57 | Placebo | Positive | Pseudovirus-nAb ID50 | 684 (382, 1222) | 575 (371, 892) | 1.19 (0.57, 2.46) |
| Communities of Color vs White Non-Hispanic | Day 57 | Placebo | Positive | Pseudovirus-nAb ID80 | 1409 (809, 2454) | 1478 (953, 2292) | 0.95 (0.47, 1.93) |

Table 8a. Differences in the responder rates, 2FRs, 4FRs between the vaccine arm and the placebo arm by All participants

| Group | Visit | Baseline SARS-CoV-2 | Marker | Comparison | Responder | % 2-Fold Rise | % 4-Fold Rise |
|--------|----------|---------------------|------------------------|--------------------|-------------------------|-------------------------|-------------------------|
| Day 29 | Negative | | Anti N IgG (IU/ml) | Vaccine vs Placebo | 100% (100%, 100%) | 100% (100%, 100%) | 99.8% (98.6%, 100%) |
| | Negative | | Anti RBD IgG (IU/ml) | Vaccine vs Placebo | 100% (100%, 100%) | 100% (100%, 100%) | 100% (100%, 100%) |
| | Negative | | Anti Spike IgG (IU/ml) | Vaccine vs Placebo | 100% (100%, 100%) | 100% (100%, 100%) | 100% (100%, 100%) |
| | Negative | | Pseudovirus-nAb ID50 | Vaccine vs Placebo | 87.1% (82.7%, 90%) | 87.5% (83.2%, 90.4%) | 81.8% (77.9%, 85.1%) |
| | Negative | | Pseudovirus-nAb ID80 | Vaccine vs Placebo | 93% (87.4%, 95.1%) | 93% (87.4%, 95.1%) | 87.3% (80.6%, 90.2%) |
| | Positive | | Anti N IgG (IU/ml) | Vaccine vs Placebo | 0% (0%, 0%) | 0% (0%, 0%) | 0% (0%, 0%) |
| | Positive | | Anti RBD IgG (IU/ml) | Vaccine vs Placebo | 0% (0%, 0%) | 0% (0%, 0%) | 0% (0%, 0%) |
| | Positive | | Anti Spike IgG (IU/ml) | Vaccine vs Placebo | 0% (0%, 0%) | 0% (0%, 0%) | 0% (0%, 0%) |
| | Positive | | Pseudovirus-nAb ID50 | Vaccine vs Placebo | 12.6% (5.3%, 20.1%) | 12.3% (5.1%, 19.9%) | 23.2% (13.3%, 32.3%) |
| | Positive | | Pseudovirus-nAb ID80 | Vaccine vs Placebo | 5.5% (-0.1%, 11.6%) | 5.4% (-0.4%, 11.5%) | 9.9% (3.5%, 17%) |
| Day 57 | Negative | | Anti N IgG (IU/ml) | Vaccine vs Placebo | 100% (100%, 100%) | 100% (100%, 100%) | 100% (100%, 100%) |
| | Negative | | Anti RBD IgG (IU/ml) | Vaccine vs Placebo | 99.4% (96%, 99.9%) | 99.4% (96%, 99.9%) | 100% (100%, 100%) |
| | Negative | | Anti Spike IgG (IU/ml) | Vaccine vs Placebo | 100% (100%, 100%) | 100% (100%, 100%) | 100% (100%, 100%) |
| | Negative | | Pseudovirus-nAb ID50 | Vaccine vs Placebo | 98% (95.7%, 98.8%) | 98% (95.7%, 98.8%) | 97.4% (95.6%, 98.5%) |
| | Negative | | Pseudovirus-nAb ID80 | Vaccine vs Placebo | 98.2% (94.7%, 99.1%) | 98.2% (94.7%, 99.1%) | 98.3% (96.4%, 99.2%) |

(continued)

| Group | Visit | Baseline SARS-CoV-2 | Marker | Comparison | Responder | % 2-Fold Rise | % 4-Fold Rise |
|-------|--------|---------------------|------------------------|--------------------|----------------------|----------------------|----------------------|
| | Day 57 | Positive | Anti N IgG (IU/ml) | Vaccine vs Placebo | 0% (0%, 0%) | 0% (0%, 0%) | 0% (0%, 0%) |
| | Day 57 | Positive | Anti RBD IgG (IU/ml) | Vaccine vs Placebo | 0% (0%, 0%) | 0% (0%, 0%) | 0% (0%, 0%) |
| | Day 57 | Positive | Anti Spike IgG (IU/ml) | Vaccine vs Placebo | 0% (0%, 0%) | 0% (0%, 0%) | 0% (0%, 0%) |
| | Day 57 | Positive | Pseudovirus-nAb ID50 | Vaccine vs Placebo | 4.1% (1.7%, 9.4%) | 4.1% (1.7%, 9.4%) | 7.7% (4.1%, 14%) |
| | Day 57 | Positive | Pseudovirus-nAb ID80 | Vaccine vs Placebo | 2% (0.6%, 6.8%) | 2% (0.6%, 6.8%) | 2.5% (0.9%, 6.8%) |

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 9. Antibody levels in the baseline SARS-CoV-2 negative per-protocol cohort (vaccine vs. placebo)

| Visit | Marker | Baseline SARS-CoV-2 Negative | | | | | | | |
|--------|------------------------|---|-------------------------------|---|----------------|-------------------------|-------------------------------------|--|--|
| | | Vaccine | | | | Placebo | | | |
| N | Resp rate | GMT/GMC | N | Resp rate | GMT/GMC | Resp Rate Difference | GMTR/GMCR | | |
| Day 29 | Anti N IgG (IU/ml) | 914 13295/13295 = 100.0% (100.0%, 100.0%) | 23543 (19945, 27790) | 163 0/13359 = 0.0% (0.0%, 0.0%) | 10 (10, 10) | 100% (100%, 100%) | 2354.30 (1994.51, 2778.99) | | |
| Day 29 | Anti RBD IgG (IU/ml) | 914 13295/13295 = 100.0% (100.0%, 100.0%) | 22926 (19863, 26460) | 163 0/13359 = 0.0% (0.0%, 0.0%) | 10 (10, 10) | 100% (100%, 100%) | 2292.58 (1986.35, 2646.03) | | |
| Day 29 | Anti Spike IgG (IU/ml) | 914 13295/13295 = 100.0% (100.0%, 100.0%) | 40963 (36741, 45671) | 163 0/13359 = 0.0% (0.0%, 0.0%) | 10 (10, 10) | 100% (100%, 100%) | 4096.31 (3674.06, 4567.08) | | |
| Day 29 | Pseudovirus-nAb ID50 | 914 11733.1/13295 = 88.3% (84.7%, 91.0%) | 106 (91, 125) | 163 149.5/13359 = 1.1% (0.3%, 3.8%) | 5 (5, 5) | 87.1% (82.7%, 90%) | 21.04 (17.92, 24.71) | | |
| Day 29 | Pseudovirus-nAb ID80 | 914 12521.7/13295 = 94.2% (91.6%, 96.0%) | 189 (161, 222) | 163 160.7/13359 = 1.2% (0.2%, 6.1%) | 5 (5, 5) | 93% (87.4%, 95.1%) | 37.14 (31.48, 43.81) | | |
| Day 57 | Anti N IgG (IU/ml) | 914 13295/13295 = 100.0% (100.0%, 100.0%) | 325136 (267241, 395574) | 163 0/13359 = 0.0% (0.0%, 0.0%) | 10 (10, 10) | 100% (100%, 100%) | 32513.59 (26724.06, 39557.36) | | |
| Day 57 | Anti RBD IgG (IU/ml) | 914 13295/13295 = 100.0% (100.0%, 100.0%) | 966160 (823437, 1133621) | 163 76.3/13359 = 0.6% (0.1%, 4.0%) | 10 (10, 10) | 99.4% (96%, 99.9%) | 96216.76 (81986.55, 112916.89) | | |
| Day 57 | Anti Spike IgG (IU/ml) | 914 13295/13295 = 100.0% (100.0%, 100.0%) | 2087965 (1831068, 2380904) | 163 0/13359 = 0.0% (0.0%, 0.0%) | 10 (10, 10) | 100% (100%, 100%) | 208796.50 (183106.81, 238090.43) | | |
| Day 57 | Pseudovirus-nAb ID50 | 914 13159.4/13295 = 99.0% (98.0%, 99.5%) | 1497 (1228, 1825) | 163 131.9/13359 = 1.0% (0.3%, 3.0%) | 5 (5, 5) | 98% (95.7%, 98.8%) | 297.04 (243.64, 362.15) | | |
| Day 57 | Pseudovirus-nAb ID80 | 914 13174.8/13295 = 99.1% (97.1%, 99.7%) | 2223 (1809, 2733) | 163 120.7/13359 = 0.9% (0.2%, 3.8%) | 5 (5, 5) | 98.2% (94.7%, 99.1%) | 440.71 (358.41, 541.91) | | |

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 10. Antibody levels in the baseline SARS-CoV-2 positive per-protocol cohort (vaccine vs. placebo)

| Visit | Marker | Baseline SARS-CoV-2 Positive | | | | | | | |
|--------|------------------------|------------------------------|--|-------------------------------|---------|--|----------------------------|------------------------|------------------------|
| | | Vaccine | | | | Placebo | | | |
| N | Resp rate | GMT/GMC | N | Resp rate | GMT/GMC | Resp Rate Difference | GMTR/GMCR | | |
| Day 29 | Anti N IgG (IU/ml) | 274 | 1432/1432 = 100.0% (100.0%, 100.0%) | 43010 (33140, 55819) | 270 | 1357/1357 = 100.0% (100.0%, 100.0%) | 12518 (9458, 16567) | 0% (0%, 0%) | 3.44 (2.34, 5.04) |
| Day 29 | Anti RBD IgG (IU/ml) | 274 | 1432/1432 = 100.0% (100.0%, 100.0%) | 36133 (28182, 46328) | 270 | 1357/1357 = 100.0% (100.0%, 100.0%) | 12861 (10150, 16296) | 0% (0%, 0%) | 2.81 (1.99, 3.96) |
| Day 29 | Anti Spike IgG (IU/ml) | 274 | 1432/1432 = 100.0% (100.0%, 100.0%) | 79981 (65041, 98352) | 270 | 1357/1357 = 100.0% (100.0%, 100.0%) | 18191 (15159, 21829) | 0% (0%, 0%) | 4.40 (3.34, 5.79) |
| Day 29 | Pseudovirus-nAb ID50 | 274 | 1383.1/1432 = 96.6% (91.6%, 98.7%) | 186 (142, 243) | 270 | 1139.8/1357 = 84.0% (76.8%, 89.3%) | 51 (40, 66) | 12.6% (5.3%, 20.1%) | 3.61 (2.50, 5.22) |
| Day 29 | Pseudovirus-nAb ID80 | 274 | 1407.2/1432 = 98.3% (93.8%, 99.5%) | 420 (314, 560) | 270 | 1258.5/1357 = 92.7% (86.8%, 96.1%) | 129 (98, 169) | 5.5% (-0.1%, 11.6%) | 3.25 (2.19, 4.83) |
| Day 57 | Anti N IgG (IU/ml) | 274 | 1432/1432 = 100.0% (100.0%, 100.0%) | 980579 (697583, 1378379) | 270 | 1357/1357 = 100.0% (100.0%, 100.0%) | 130008 (92643, 182444) | 0% (0%, 0%) | 7.54 (4.67, 12.19) |
| Day 57 | Anti RBD IgG (IU/ml) | 274 | 1432/1432 = 100.0% (100.0%, 100.0%) | 2298869 (1785648, 2959596) | 270 | 1357/1357 = 100.0% (100.0%, 100.0%) | 382614 (299829, 488256) | 0% (0%, 0%) | 6.01 (4.23, 8.54) |
| Day 57 | Anti Spike IgG (IU/ml) | 274 | 1432/1432 = 100.0% (100.0%, 100.0%) | 5346334 (4339333, 6587023) | 270 | 1357/1357 = 100.0% (100.0%, 100.0%) | 676872 (531354, 862241) | 0% (0%, 0%) | 7.90 (5.74, 10.87) |
| Day 57 | Pseudovirus-nAb ID50 | 274 | 1432/1432 = 100.0% (100.0%, 100.0%) | 5680 (3863, 8351) | 270 | 1301.8/1357 = 95.9% (90.6%, 98.3%) | 566 (409, 783) | 4.1% (1.7%, 9.4%) | 10.04 (6.07, 16.62) |
| Day 57 | Pseudovirus-nAb ID80 | 274 | 1432/1432 = 100.0% (100.0%, 100.0%) | 7837 (5545, 11076) | 270 | 1330.1/1357 = 98.0% (93.2%, 99.4%) | 1324 (937, 1870) | 2% (0.6%, 6.8%) | 5.92 (3.63, 9.65) |

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 11. Antibody levels in the per-protocol cohort (vaccine recipients)

| Visit | Marker | Vaccine Recipients | | | | | | | |
|--------|------------------------|---|-------------------------------|---|-------------------------------|------------------------------|----------------------|--|------------|
| | | Baseline SARS-CoV-2 Positive | | | | Baseline SARS-CoV-2 Negative | | | Comparison |
| N | Resp rate | GMT/GMC | N | Resp rate | GMT/GMC | Resp Rate Difference | GMTR/GMCR | | |
| Day 29 | Anti N IgG (IU/ml) | 274 1432/1432 = 100.0% (100.0%, 100.0%) | 43010 (33140, 55819) | 914 13295/13295 = 100.0% (100.0%, 100.0%) | 23543 (19945, 27790) | 0% (0%, 0%) | 1.83 (1.34, 2.49) | | |
| Day 29 | Anti RBD IgG (IU/ml) | 274 1432/1432 = 100.0% (100.0%, 100.0%) | 36133 (28182, 46328) | 914 13295/13295 = 100.0% (100.0%, 100.0%) | 22926 (19863, 26460) | 0% (0%, 0%) | 1.58 (1.18, 2.10) | | |
| Day 29 | Anti Spike IgG (IU/ml) | 274 1432/1432 = 100.0% (100.0%, 100.0%) | 79981 (65041, 98352) | 914 13295/13295 = 100.0% (100.0%, 100.0%) | 40963 (36741, 45671) | 0% (0%, 0%) | 1.95 (1.55, 2.47) | | |
| Day 29 | Pseudovirus-nAb ID50 | 274 1383.1/1432 = 96.6% (91.6%, 98.7%) | 186 (142, 243) | 914 11733.1/13295 = 88.3% (84.7%, 91.0%) | 106 (91, 125) | 8.3% (2.6%, 12.4%) | 1.75 (1.28, 2.39) | | |
| Day 29 | Pseudovirus-nAb ID80 | 274 1407.2/1432 = 98.3% (93.8%, 99.5%) | 420 (314, 560) | 914 12521.7/13295 = 94.2% (91.6%, 96.0%) | 189 (161, 222) | 4.1% (-0.8%, 7%) | 2.22 (1.59, 3.09) | | |
| Day 57 | Anti N IgG (IU/ml) | 274 1432/1432 = 100.0% (100.0%, 100.0%) | 980579 (697583, 1378379) | 914 13295/13295 = 100.0% (100.0%, 100.0%) | 325136 (267241, 395574) | 0% (0%, 0%) | 3.02 (2.04, 4.47) | | |
| Day 57 | Anti RBD IgG (IU/ml) | 274 1432/1432 = 100.0% (100.0%, 100.0%) | 2298869 (1785648, 2959596) | 914 13295/13295 = 100.0% (100.0%, 100.0%) | 966160 (823437, 1133621) | 0% (0%, 0%) | 2.38 (1.76, 3.21) | | |
| Day 57 | Anti Spike IgG (IU/ml) | 274 1432/1432 = 100.0% (100.0%, 100.0%) | 5346334 (4339333, 6587023) | 914 13295/13295 = 100.0% (100.0%, 100.0%) | 2087965 (1831068, 2380904) | 0% (0%, 0%) | 2.56 (2.00, 3.28) | | |
| Day 57 | Pseudovirus-nAb ID50 | 274 1432/1432 = 100.0% (100.0%, 100.0%) | 5680 (3863, 8351) | 914 13159.4/13295 = 99.0% (98.0%, 99.5%) | 1497 (1228, 1825) | 1% (0.5%, 2%) | 3.79 (2.46, 5.85) | | |
| Day 57 | Pseudovirus-nAb ID80 | 274 1432/1432 = 100.0% (100.0%, 100.0%) | 7837 (5545, 11076) | 914 13174.8/13295 = 99.1% (97.1%, 99.7%) | 2223 (1809, 2733) | 0.9% (0.3%, 2.9%) | 3.53 (2.36, 5.27) | | |

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Table 12. Antibody levels in the per-protocol cohort (placebo recipients)

| Visit | Marker | Placebo Recipients | | | | | | | |
|--------|------------------------|------------------------------|--|----------------------------|---------|------------------------------------|----------------|-------------------------|----------------------------------|
| | | Baseline SARS-CoV-2 Positive | | | | Baseline SARS-CoV-2 Negative | | | Comparison |
| N | Resp rate | GMT/GMC | N | Resp rate | GMT/GMC | Resp Rate Difference | GMTR/GMCR | | |
| Day 29 | Anti N IgG (IU/ml) | 270 | 1357/1357 = 100.0% (100.0%, 100.0%) | 12518 (9458, 16567) | 163 | 0/13359 = 0.0% (0.0%, 0.0%) | 10 (10, 10) | 100% (100%, 100%) | 1251.77 (945.80, 1656.72) |
| Day 29 | Anti RBD IgG (IU/ml) | 270 | 1357/1357 = 100.0% (100.0%, 100.0%) | 12861 (10150, 16296) | 163 | 0/13359 = 0.0% (0.0%, 0.0%) | 10 (10, 10) | 100% (100%, 100%) | 1286.10 (1015.03, 1629.57) |
| Day 29 | Anti Spike IgG (IU/ml) | 270 | 1357/1357 = 100.0% (100.0%, 100.0%) | 18191 (15159, 21829) | 163 | 0/13359 = 0.0% (0.0%, 0.0%) | 10 (10, 10) | 100% (100%, 100%) | 1819.07 (1515.87, 2182.92) |
| Day 29 | Pseudovirus-nAb ID50 | 270 | 1139.8/1357 = 84.0% (76.8%, 89.3%) | 51 (40, 66) | 163 | 149.5/13359 = 1.1% (0.3%, 3.8%) | 5 (5, 5) | 82.9% (75.2%, 88.2%) | 10.18 (7.90, 13.11) |
| Day 29 | Pseudovirus-nAb ID80 | 270 | 1258.5/1357 = 92.7% (86.8%, 96.1%) | 129 (98, 169) | 163 | 160.7/13359 = 1.2% (0.2%, 6.1%) | 5 (5, 5) | 91.5% (83.8%, 95.1%) | 25.36 (19.29, 33.34) |
| Day 57 | Anti N IgG (IU/ml) | 270 | 1357/1357 = 100.0% (100.0%, 100.0%) | 130008 (92643, 182444) | 163 | 0/13359 = 0.0% (0.0%, 0.0%) | 10 (10, 10) | 100% (100%, 100%) | 13000.84 (9264.31, 18244.40) |
| Day 57 | Anti RBD IgG (IU/ml) | 270 | 1357/1357 = 100.0% (100.0%, 100.0%) | 382614 (299829, 488256) | 163 | 76.3/13359 = 0.6% (0.1%, 4.0%) | 10 (10, 10) | 99.4% (96%, 99.9%) | 38103.25 (29854.93, 48630.43) |
| Day 57 | Anti Spike IgG (IU/ml) | 270 | 1357/1357 = 100.0% (100.0%, 100.0%) | 676872 (531354, 862241) | 163 | 0/13359 = 0.0% (0.0%, 0.0%) | 10 (10, 10) | 100% (100%, 100%) | 67687.19 (53135.41, 86224.15) |
| Day 57 | Pseudovirus-nAb ID50 | 270 | 1301.8/1357 = 95.9% (90.6%, 98.3%) | 566 (409, 783) | 163 | 131.9/13359 = 1.0% (0.3%, 3.0%) | 5 (5, 5) | 94.9% (89.3%, 97.4%) | 112.24 (81.10, 155.32) |
| Day 57 | Pseudovirus-nAb ID80 | 270 | 1330.1/1357 = 98.0% (93.2%, 99.4%) | 1324 (937, 1870) | 163 | 120.7/13359 = 0.9% (0.2%, 3.8%) | 5 (5, 5) | 97.1% (91.5%, 98.7%) | 262.45 (185.80, 370.71) |

Percentages are calculated for the whole per-protocol group/subgroup, using inverse probability weighting.

Chapter 2

Graphical Description of Immunogenicity Data

2.1 Pairs plots of antibody markers for overall per-protocol cohort

2.1.1 Baseline SARS-CoV-2 Negative




Figure 2.1: Pair plots of D29 Ab markers: baseline negative vaccine arm




Figure 2.2: Pair plots of D57 Ab markers: baseline negative vaccine arm

D29 Fold-rise over D1 Ab markers: baseline negative, vaccine arm




Figure 2.3: Pair plots of D29 fold-rise over D1 Ab markers: baseline negative vaccine arm




Figure 2.4: Pair plots of D57 fold-rise over D1 Ab markers: baseline negative vaccine arm




Figure 2.5: Pair plots of D1, D29 and D57 Binding Antibody to Spike: baseline negative vaccine arm




Figure 2.6: Pair plots of D1, D29 and D57 Binding Antibody to RBD: baseline negative vaccine arm




Figure 2.7: Pair plots of D1, D29 and D57 PsV Neutralization 50% Titer: baseline negative vaccine arm




Figure 2.8: Pair plots of D1, D29 and D57 PsV Neutralization 80% Titer: Baseline negative vaccine arm

2.1.2 Baseline SARS-CoV-2 Positive




Figure 2.9: Pair plots of D29 Ab markers: baseline negative vaccine arm




Figure 2.10: Pair plots of D57 Ab markers: baseline negative vaccine arm




Figure 2.11: Pair plots of D29 fold-rise over D1 Ab markers: baseline negative vaccine arm

D57 Fold-rise over D1 Ab markers: baseline positive, vaccine arm




Figure 2.12: Pair plots of D57 fold-rise over D1 Ab markers: baseline negative vaccine arm




Figure 2.13: Pair plots of D1, D29 and D57 Binding Antibody to Spike: baseline negative vaccine arm




Figure 2.14: Pair plots of D1, D29 and D57 Binding Antibody to RBD: baseline negative vaccine arm

PsV Neutralization 50% Titer: baseline positive vaccine arm




Figure 2.15: Pair plots of D1, D29 and D57 PsV Neutralization 50% Titer: baseline negative vaccine arm




Figure 2.16: Pair plots of D1, D29 and D57 PsV Neutralization 80% Titer: Baseline negative vaccine arm

2.2 RCDF plots of antibody markers for overall per-protocol cohort




Figure 2.17: RCDF plots for D29 Ab markers: by baseline status x randomization arm




Figure 2.18: RCDF plots for D57 Ab markers: by baseline status x randomization arm




Figure 2.19: RCDF plots for D29 fold-rise over D1 Ab markers: by baseline status x randomization arm




Figure 2.20: RCDF plots for D57 fold-rise over D1 Ab markers: by baseline status x randomization arm




Figure 2.21: RCDF plots for D29 Ab markers: by baseline status for the vaccine arm




Figure 2.22: RCDF plots for D57 Ab markers: by baseline status for the vaccine arm




Figure 2.23: RCDF plots for D29 over D1 fold-rise Ab markers: by baseline status for the vaccine arm




Figure 2.24: RCDF plots for D57 fold-rise over D1 Ab markers: by baseline status for the vaccine arm




Figure 2.25: RCDF plots for D29 Ab markers: baseline negative vaccine arm




Figure 2.26: RCDF plots for D57 Ab markers: baseline negative vaccine arm




Figure 2.27: RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm




Figure 2.28: RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm

2.3 Scatter plots of antibody markers versus age for overall per-protocol cohort

2.3.1 Baseline SARS-CoV-2 negative




Figure 2.29: Scatter plots for D29 Ab markers vs. age: baseline negative vaccine arm

2.3. SCATTER PLOTS OF ANTIBODY MARKERS VERSUS AGE FOR OVERALL PER-PROTOCOL COHORT443




Figure 2.30: Scatter plots for D57 Ab markers vs. age: baseline negative vaccine arm

2.3.2 Baseline SARS-CoV-2 positive




Figure 2.31: Scatter plots for D29 Ab markers vs. age: baseline positive vaccine arm

2.3. SCATTER PLOTS OF ANTIBODY MARKERS VERSUS AGE FOR OVERALL PER-PROTOCOL COHORT445




Figure 2.32: Scatter plots for D57 Ab markers vs. age: baseline positive vaccine arm

2.4 Box plots of antibody markers for overall per-protocol cohort

2.4.1 Baseline SARS-CoV-2 negative




Figure 2.33: Boxplots of D29 Ab markers: baseline negative vaccine + placebo arms




Figure 2.34: Boxplots of D57 Ab markers: baseline negative vaccine + placebo arms




Figure 2.35: Boxplots of D29 fold-rise over D1 Ab markers: baseline negative vaccine + placebo arms




Figure 2.36: Boxplots of D57 fold-rise over D1 Ab markers: baseline negative vaccine + placebo arms

2.4.2 Baseline SARS-CoV-2 positive




Figure 2.37: Boxplots of D29 Ab markers: baseline positive vaccine + placebo arms




Figure 2.38: Boxplots of D57 Ab markers: baseline positive vaccine + placebo arms




Figure 2.39: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine + placebo arms




Figure 2.40: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine + placebo arms

2.4.3 Baseline negative vs. positive vaccine recipients




Figure 2.41: Boxplots of D29 Ab markers: baseline positive + negative vaccine arm




Figure 2.42: Boxplots of D57 Ab markers: baseline positive + negative vaccine arm




Figure 2.43: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive + negative vaccine arm




Figure 2.44: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive + negative vaccine arm

2.4.4 Baseline negative vs. positive placebo recipients




Figure 2.45: Boxplots of D29 Ab markers: baseline positive + negative placebo arm




Figure 2.46: Boxplots of D57 Ab markers: baseline positive + negative placebo arm




Figure 2.47: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive + negative placebo arm




Figure 2.48: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive + negative placebo arm

2.5 Spaghetti plots of antibody markers over time for the overall per-protocol cohort

2.5.1 Baseline SARS-CoV-2 negative




Figure 2.49: Spaghetti plots of Ab markers over time: baseline negative vaccine + placebo arm

2.5. SPAGHETTI PLOTS OF ANTIBODY MARKERS OVER TIME FOR THE OVERALL PER-PROTOCOL COHORT40

2.5.2 Baseline SARS-CoV-2 positive




Figure 2.50: Spaghetti plots of Ab markers over time: baseline positive vaccine + placebo arm

2.6 RCDF plots of antibody markers by demographics for per-protocol cohort

2.6.1 Baseline SARS-CoV-2 negative




Figure 2.51: RCDF plots for D29 Ab markers: baseline negative vaccine arm by age groups.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT465




Figure 2.52: RCDF plots for D57 Ab markers: baseline negative vaccine arm by age groups.




Figure 2.53: RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by age groups.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT467




Figure 2.54: RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by age groups.




Figure 2.55: RCDF plots for D29 Ab markers: baseline negative vaccine arm by high-risk condition.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT469




Figure 2.56: RCDF plots for D57 Ab markers: baseline negative vaccine arm by high-risk condition.




Figure 2.57: RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by high-risk condition.




Figure 2.58: RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by high-risk condition.




Figure 2.59: RCDF plots for D29 Ab markers: baseline negative vaccine arm by age and high-risk condition.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT473




Figure 2.60: RCDF plots for D57 Ab markers: baseline negative vaccine arm by age and high-risk condition.




Figure 2.61: RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and high-risk condition.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT475




Figure 2.62: RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and high-risk condition.




Figure 2.63: RCDF plots for D29 Ab markers: baseline negative vaccine arm by sex assigned at birth.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT477




Figure 2.64: RCDF plots for D57 Ab markers: baseline negative vaccine arm by sex assigned at birth.




Figure 2.65: RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by sex assigned at birth.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT479




Figure 2.66: RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by sex assigned at birth.




Figure 2.67: RCDF plots for D29 Ab markers: baseline negative vaccine arm by age and sex assigned at birth.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT481




Figure 2.68: RCDF plots for D57 Ab markers: baseline negative vaccine arm by age and sex assigned at birth.




Figure 2.69: RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and sex assigned at birth.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT483




Figure 2.70: RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and sex at birth.




Figure 2.71: RCDF plots for D29 Ab markers: baseline negative vaccine arm by ethnicity.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT485




Figure 2.72: RCDF plots for D57 Ab markers: baseline negative vaccine arm by ethnicity.




Figure 2.73: RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by ethnicity.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT487




Figure 2.74: RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by ethnicity.




Figure 2.75: RCDF plots for D29 Ab markers: baseline negative vaccine arm by race.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT489




Figure 2.76: RCDF plots for D57 Ab markers: baseline negative vaccine arm by race.




Figure 2.77: RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by race.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT491




Figure 2.78: RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by race.




Figure 2.79: RCDF plots for D29 Ab markers: baseline negative vaccine arm by dichotomous classification of race and ethnic group.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT493




Figure 2.80: RCDF plots for D57 Ab markers: baseline negative vaccine arm by dichotomous classification of race and ethnic group.




Figure 2.81: RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by dichotomous classification of race and ethnic group.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT495




Figure 2.82: RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by dichotomous classification of race and ethnic group.




Figure 2.83: RCDF plots for D29 Ab markers: baseline negative vaccine arm by age and dichotomous classification of race and ethnic group.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT497




Figure 2.84: RCDF plots for D57 Ab markers: baseline negative vaccine arm by age and dichotomous classification of race and ethnic group.




Figure 2.85: RCDF plots for D29 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and dichotomous classification of race and ethnic group.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT499




Figure 2.86: RCDF plots for D57 fold-rise over D1 Ab markers: baseline negative vaccine arm by age and dichotomous classification of race and ethnic group.

2.6.2 Baseline SARS-CoV-2 positive




Figure 2.87: RCDF plots for D29 Ab markers: baseline positive vaccine arm by age groups.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT501




Figure 2.88: RCDF plots for D57 Ab markers: baseline positive vaccine arm by age groups.




Figure 2.89: RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age groups.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT503




Figure 2.90: RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age groups.




Figure 2.91: RCDF plots for D29 Ab markers: baseline positive vaccine arm by high-risk condition.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT505




Figure 2.92: RCDF plots for D57 Ab markers: baseline positive vaccine arm by high-risk condition.




Figure 2.93: RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by high-risk condition.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT507




Figure 2.94: RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by high-risk condition.




Figure 2.95: RCDF plots for D29 Ab markers: baseline positive vaccine arm by age and high-risk condition.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT509




Figure 2.96: RCDF plots for D57 Ab markers: baseline positive vaccine arm by age and high-risk condition.




Figure 2.97: RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and high-risk condition.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT511




Figure 2.98: RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and high-risk condition.




Figure 2.99: RCDF plots for D29 Ab markers: baseline positive vaccine arm by sex assigned at birth.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT513




Figure 2.100: RCDF plots for D57 Ab markers: baseline positive vaccine arm by sex assigned at birth.




Figure 2.101: RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by sex assigned at birth.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT515




Figure 2.102: RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by sex assigned at birth.




Figure 2.103: RCDF plots for D29 Ab markers: baseline positive vaccine arm by age and sex assigned at birth.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT517




Figure 2.104: RCDF plots for D57 Ab markers: baseline positive vaccine arm by age and sex assigned at birth.




Figure 2.105: RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and sex assigned at birth.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT519




Figure 2.106: RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and sex assigned at birth.




Figure 2.107: RCDF plots for D29 Ab markers: baseline positive vaccine arm by ethnicity.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT521




Figure 2.108: RCDF plots for D57 Ab markers: baseline positive vaccine arm by ethnicity.




Figure 2.109: RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by ethnicity.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT523




Figure 2.110: RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by ethnicity.




Figure 2.111: RCDF plots for D29 Ab markers: baseline positive vaccine arm by race.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT525




Figure 2.112: RCDF plots for D57 Ab markers: baseline positive vaccine arm by race.




Figure 2.113: RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by race.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT527




Figure 2.114: RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by race.




Figure 2.115: RCDF plots for D29 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT529




Figure 2.116: RCDF plots for D57 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group.




Figure 2.117: RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group.




Figure 2.118: RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group.




Figure 2.119: RCDF plots for D29 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT533




Figure 2.120: RCDF plots for D57 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group.




Figure 2.121: RCDF plots for D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group.

2.6. RCDF PLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT535




Figure 2.122: RCDF plots for D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group.

2.7 Boxplots of antibody markers by demographics for per-protocol cohort

2.7.1 Baseline SARS-CoV-2 negative




Figure 2.123: Boxplots of D29 Ab markers: Baseline negative vaccine arm by age group.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT537




Figure 2.124: Boxplots of D57 Ab markers: Baseline negative vaccine arm by age group.




Figure 2.125: Boxplots of D29 fold-rise over D1 Ab markers: Baseline negative vaccine arm by age and sex assigned at birth.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT539




Figure 2.126: Boxplots of D57 fold-rise over D1 Ab markers: Baseline negative vaccine arm by age and sex assigned at birth.




Figure 2.127: Boxplots of D29 fold-rise over D1 Ab markers: Baseline negative vaccine arm by ethnicity.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT541




Figure 2.128: Boxplots of D57 fold-rise over D1 Ab markers: Baseline negative vaccine arm by ethnicity.




Figure 2.129: Boxplots of D29 fold-rise over D1 Ab markers: Baseline negative vaccine arm by race.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT543




Figure 2.130: Boxplots of D57 fold-rise over D1 Ab markers: Baseline negative vaccine arm by race.




Figure 2.131: Boxplots of D29 fold-rise over D1 Ab markers: Baseline negative vaccine arm by dichotomous classification of race and ethnic group.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT545




Figure 2.132: Boxplots of D57 fold-rise over D1 Ab markers: Baseline negative vaccine arm by dichotomous classification of race and ethnic group.




Figure 2.133: Boxplots of D29 fold-rise over D1 Ab markers: Baseline negative vaccine arm by age and dichotomous classification of race and ethnic group.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT547




Figure 2.134: Boxplots of D57 fold-rise over D1 Ab markers: Baseline negative vaccine arm by age and dichotomous classification of race and ethnic group.

2.7.2 Baseline SARS-CoV-2 positive

MOCK

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT549




Figure 2.135: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age group.




Figure 2.136: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age group.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT551




Figure 2.137: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by high-risk condition.




Figure 2.138: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by high-risk condition.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT553




Figure 2.139: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and high-risk condition.




Figure 2.140: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and high-risk condition.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT555




Figure 2.141: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by sex assigned at birth.




Figure 2.142: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by sex assigned at birth.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT557




Figure 2.143: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and sex assigned at birth.




Figure 2.144: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and sex assigned at birth.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT559




Figure 2.145: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by ethnicity.




Figure 2.146: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by ethnicity.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT561




Figure 2.147: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by race.




Figure 2.148: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by race.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT563




Figure 2.149: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group.




Figure 2.150: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by dichotomous classification of race and ethnic group.

2.7. BOXPLOTS OF ANTIBODY MARKERS BY DEMOGRAPHICS FOR PER-PROTOCOL COHORT565




Figure 2.151: Boxplots of D29 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group.




Figure 2.152: Boxplots of D57 fold-rise over D1 Ab markers: baseline positive vaccine arm by age and dichotomous classification of race and ethnic group.